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Preface 
Although the basic principles of liver transplantation have not changed, the field of 
liver transplantation is still young, evolving, and dynamic. In this book, the authors
are pioneers in different aspects of liver transplantation and come from many centers
across the world. The contributions resulted in a valuable reference to anyone
interested in developing a global view on liver transplantation, including medical 
students, residents, fellows, nurses, and practicing physicians and surgeons, as well as 
researchers in the field of liver transplantation. This book covers a wide spectrum of
topics including, but not limited to, the technical issues in living and deceased donor
liver transplant procedures, cell and experimental liver transplantation, as well as the 
complications of liver transplantation. Some of the very important topics such as the
arterial reconstruction in living donor liver transplantation, biliary complications, and 
the post-transplant-lymphoprolifrative disorders (PTLD), have been covered in more 
than one chapter. 
As the editor, I wish to thank all of the authors for their co-operation and desire to 
share their precious experience with the medical community. On their behalf, I wish to
express hope that our publication will facilitate access to the latest scientific 
achievements in the field of liver transplantation all across the world. 
To all my colleagues at the National Liver Institute in Egypt who supported and 
embraced me with their warm feelings: I love you all. To all my professors who so
generously guided me by their example, wisdom, and insights: thank you. Finally, to 
Ms. Romana Vukelic, the publishing manager, with whom editing this book was a real 
pleasure: thank you.
Hesham Abdeldayem, MD.
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Living Donor Liver Transplantation 
Hesham Abdeldayem 
Professor of Surgery, National Liver Institute, Menoufeyia University, 
Egypt 
"As to diseases, make a habit of two things: to help, or at least, to do no harm." 
Hippocrates (460 - 377 BC) 
1. Introduction 
Living donor liver transplantation (LDLT) is probably the most high-profile of all surgical 
enterprises. At the same time, it is an amazing act of altruism. It requires hard work of 
dedicated multidisciplinary medical teams coupled with the courage of the patients and 
their families. The concept of LDLT is based on the following two factors: (1) the remarkable 
regenerative capacity of the liver, and (2) the shortage of cadaveric organs (Olthoff K, 2003). 
LDLT has become an acceptable alternative for patients in need of liver transplantation (LT) 
who are not likely to receive a deceased donor liver transplant (DDLT) in a timely fashion. 
This is seen especially in countries where cadaveric donation is limited by religious and 
cultural beliefs, as in Japan, Egypt, Korea, and India (Abdeldayem H, 2010). 
This chapter outlines the advantages and disadvantages of LDLT, addresses the moral and 
ethical issues surrounding this procedure, reviews the evaluation process of the recipient 
and the donor candidates, highlights controversial indication for LDLT, outlines technical 
aspects of LDLT, and the middle hepatic vein controversy and reviews donor and recipient 
outcomes and complications. Where possible, emphasis is placed on the differences in LDLT 
compared to whole organ DDLT. At the end, the author addresses the issue of living donor 
mortality and highlights the importance of transparency in LDLT.  
2. Historical perspective 
Liver transplantation utilizing a partial-liver graft was theoretically proposed for children 
by Smith in 1969. On 8 December 1988, Raia et al. made the first attempt at LDLT in a four 
and a half-year-old girl suffering from biliary atresia. In July 1989, Strong et al. performed 
the first LDLT with long-term success in an 11-month-old boy using segments II and III 
graft. Broelsch et al. soon followed with publication of the first series of 20 successful cases 
of LDLT in children at the University of Chicago (Broelsch et al.,1991).  
In 1991, Habib et al performed the first LDLT procedure in Africa and the Middle East at the 
National Liver Institute, in Egypt. They reported the success of their first case in 1993 (Habib 
et al, 1993). In the same year, Haberal et al. extended LDLT to adult recipients. In their 
series, they transplanted left-liver grafts to eight patients. In 1994, Yamaoka et al. reported 
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unplanned adult-to-child LDLT using right liver .In this particular case, the operative 
procedure was changed from left hepatectomy to right hepatectomy because of unfavorable 
anatomy of the left hepatic artery. 
3. Advantages and disadvantages  
In LDLT, the waiting time is reduced, with the ability to perform transplantation when it is 
medically indicated and the recipient is in the most optimal condition. This ensures better 
outcome before serious decompensation, disease progression (e.g., hepatocellular carcinoma) 
or death occurs (Russo M et al., 2004).  
LDLT is usually is scheduled on an elective basis, allowing time for completing 
pretransplant work-up of the recipient and donor. The entire surgical team is more rested 
since the surgery is planned electively. Extensive workup to exclude other diseases in the 
donor is made. Details of vascular and liver anatomy are known well before transplant. 
There will be an opportunity to treat, or at least control, viral hepatitis B or C infection prior 
to transplantation (in those who can tolerate the medication pretransplant). Bacteremia or 
sepsis, if present, can be cleared with appropriate antibiotic therapy prior to the procedure 
(Olthoff K, et al., 2005).  
Since the graft is transported between adjacent operating rooms, the cold ischemia time is 
short. The complications associated with organ preservation are minimized, and primary 
nonfunction is rare. Another advantage may be related to avoiding the activation of the 
inflammatory cascade seen in cadaveric livers obtained from brain dead donors, which has 
been implicated in up-regulation of inflammatory cytokines, adhesion molecules, class II 
presentation and in affecting microcirculatory flow to the, liver with resultant hepatocellular 
damage and allograft dysfunction. The age of the living donor is usually young. This avoids 
the usage of organs procured from terminally ill patient with the possibility of end-organ 
damage. (Jassem W et al., 2003) In LDLT, there is a potential for better human leukocyte 
antigen (HLA) matching. Improved matching may have an immunological advantage 
similar to that observed in living donor kidney transplantation. However, this was not 
proved (Neumann U et al., 2003). 
These advantages, though, need to be weighed against the fact that a healthy person is being 
exposed to an extensive abdominal surgery with its potential for morbidity and mortality. 
The incidence of biliary complications in the recipient are said to occur more frequently than 
in DDLT. LDLT recipients are also exposed to slightly higher risk of hepatic artery 
thrombosis. The so called “small-for-size syndrome”, may occur if careful size-matching 
between the donor and the recipient is not made. Additionally the donor has to face 
financial and emotional consequences. The donation will limit the functionality of the donor 
for weeks or months after the surgery (Abdeldayem H et al., 2009). 
4. Moral and ethical issues 
Primum non nocere "First do no harm”, a fundamental medical precept of Hippocrates, is 
an important philosophy believed in medicine. LDLT challenges this tenet, because a 
healthy individual undergoes a major operation for no physical benefit to himself or herself. 
Perhaps there is no greater ethical dilemma than to operate and remove an organ from a 
perfectly healthy individual to help another (Abdeldayem H et al., 2009). It seems that the  
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general public strongly believes that it is the donor’s sole right to donate an organ and this 
decision should rest with the donor. In liberal societies everyone has the right to participate 
in dangerous activities according to his or her will, but the transplant procedure involves an 
‘accomplice’; the transplant surgeon. Yet, for surgeons the principle according to the 
Hippocratic Oath is to ‘do no harm’. Does a surgeon have an obligation to remove a person’s 
organ upon request? (Mazaris E; Papalois V, 2006) 
4.1 Donor’s motivation 
It is important that donors feel they are gaining something by donation so as to be 
sufficiently motivated and that their profit is of an emotional or moral nature (Sauer P et 
al., 2004). Donor motivation may be influenced by the type of relationship to the recipient 
and personal and religious beliefs and values. Donor motivations may include, a desire to 
help, a feeling of moral duty, a perception that donation is something that he or she is 
expected to do, and an increase in self-esteem from doing good deeds. Donors may 
imagine themselves in the recipient’s situation, especially siblings, who are sure that the 
latter would act accordingly if they were in a similar state. That may be the case for 
parents as well. Spouses may be motivated by self-benefit from their companion’s 
improved health and the improvement of the couple’s quality of life (Lennerling A, et al, 
2004). The reasons for donation must be thoroughly explored by the team and the donor. 
The social worker must assess whether the volunteer’s decision is made freely without 
any undo pressure or coercion, and whether motivation is consistent with the donor’s 
values and previous behaviors. Pressure may be more likely when the recipient’s death is 
imminent without a transplant and when no other donor options exist (Lennerling A, et 
al, 2004).  
4.2 Informed consent 
Individuals considering living donation must be free to decide how much and what sort of 
risk is acceptable for them. Potential donors cannot make such decisions if they are not first 
provided with proper informed consent regarding the risks they are undertaking and 
potential implications their decision may have on the recipient. The person who consents 
to be a live donor should be competent, willing to donate, free from coercion, medically 
and psychosocially suitable, fully informed of the risks, benefits and alternative treatment 
available to the recipient. The professional who provides informed consent for donation 
should be a neutral third person. A transplant centre may have reasons for wanting an 
organ donation to go ahead: transplants are their source of income; they are able to 
increase their prestige and conduct research (Abdeldayem H. et al., 2009; Steiner R & Gert 
B 2000).  
Issues to be fully explained to the potential donor include: 
1. The technical elements of the evaluation process, surgery and recovery, short- and long-
term follow-up care. 
2. The risk for complications and death to both the donor and the recipient.  
3. Medical uncertainties, including the potential for long-term donor complications.  
4. Unforeseeable consequences that might change the donor’s life, e.g. employment, and 
insurability, and expenses to be borne by the donor.  
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general public strongly believes that it is the donor’s sole right to donate an organ and this 
decision should rest with the donor. In liberal societies everyone has the right to participate 
in dangerous activities according to his or her will, but the transplant procedure involves an 
‘accomplice’; the transplant surgeon. Yet, for surgeons the principle according to the 
Hippocratic Oath is to ‘do no harm’. Does a surgeon have an obligation to remove a person’s 
organ upon request? (Mazaris E; Papalois V, 2006) 
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expected to do, and an increase in self-esteem from doing good deeds. Donors may 
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parents as well. Spouses may be motivated by self-benefit from their companion’s 
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values and previous behaviors. Pressure may be more likely when the recipient’s death is 
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4.2 Informed consent 
Individuals considering living donation must be free to decide how much and what sort of 
risk is acceptable for them. Potential donors cannot make such decisions if they are not first 
provided with proper informed consent regarding the risks they are undertaking and 
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and psychosocially suitable, fully informed of the risks, benefits and alternative treatment 
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should be a neutral third person. A transplant centre may have reasons for wanting an 
organ donation to go ahead: transplants are their source of income; they are able to 
increase their prestige and conduct research (Abdeldayem H. et al., 2009; Steiner R & Gert 
B 2000).  
Issues to be fully explained to the potential donor include: 
1. The technical elements of the evaluation process, surgery and recovery, short- and long-
term follow-up care. 
2. The risk for complications and death to both the donor and the recipient.  
3. Medical uncertainties, including the potential for long-term donor complications.  
4. Unforeseeable consequences that might change the donor’s life, e.g. employment, and 
insurability, and expenses to be borne by the donor.  
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5. Expected outcome of transplantation for the recipient. 
6. Any alternative therapies available to the recipient.  
7. The specific experience and statistics of the transplant centre. 
4.2.1 Informed understanding 
The donor must demonstrate informed understanding. This is best achieved with written 
and verbal presentation of the necessary information in lay language and in accordance with 
the person’s educational level. The potential donor must demonstrate their understanding 
of the essential elements of the donation process, particularly the risks of the procedure. 
Adequate time should be allowed for the potential donor to absorb the information, and ask 
questions. This may require several consultations. The donor’s family/ loved ones are given 
the opportunity to discuss their concerns (Trotter J et al., 2007). The donor should be given a 
period of time to review the decision to donate (Abdullah K et al, 2005). It is very important 
to inform the prospective donor that he or she can choose not to proceed with the surgery 
without the risks of coercion or consequences. If the donor is not accepted, the reasons are 
kept confidential. Most transplant centers will inform the recipient that the donor is not 
suitable on medical grounds, even when the actual reason may be different. This is done to 
protect the donor and to avoid any deterioration in the relationship with the recipient 
(Trotter J et al., 2007). The team must establish that there is no donor monetary compensation 
and no coercion to donate by family or others. The potential donor’s disclosure and consent 
process should be completely documented. 
4.3 Donor advocate 
In many transplant centers, a donor advocate evaluates the donor independent of the 
transplantation team. The advocate should not be in contact with the potential recipient and 
should not be influenced by the severity of the recipient’s illness. The donor advocate could 
be a social worker, psychiatrist, or physician. The primary role of the donor advocate is to 
protect and promote the interests and well-being of the donor, and to help the donor 
through the entire process. The advocate should not pre-empt the donor’s decision, since the 
donor continues to possess the ethical and legal right to decide to proceed with LDLT (Chen 
Y et al., 2003). The donor advocate should be able to answer the following questions. Is the 
donor adequately informed about the transplant procedure? Is consent truly informed? Is 
the donor vulnerable in any way to exploitation? Is the donor aware of alternative options 
for the recipient? Does the donor recognize the possibility of future health problems related 
to donation? (Trotter J 2000) 
4.4 Relationship to the recipient 
Reasons for donation are more understandable when there is a close bond between the pair. 
For genetically unrelated prospective living donors, questions must be tailored to the 
specific situation to fully understand why the individual wishes to donate. 
4.4.1 Live unrelated donation 
It has been well established that live genetically-unrelated emotionally-related donors 
such as spouses, partners or friends can be potential donors for LDLT. There are surgeons 
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against spousal donation advising that since a good percentage of marriages end in 
divorce there is no guarantee of a long-lasting loving relationship as a motive for such 
donation. Friends have been accepted reluctantly as potential donors, despite the fact that 
they might feel less pressure to donate compared to a family member (Terasaki P. et al., 
1997). 
4.4.2 Donation by strangers and good samaritan donors 
Occasionally, an unrelated (so-called “altruistic”) donor may volunteer to be assessed for 
LDLT, but such a practice is best avoided if possible. The intrinsic reasons for such 
unreserved altruism, especially in the adult-to-adult LDLT setting, are usually ill-defined 
prior to the surgery, and may only surface afterward, leading to serious unforeseen 
problems (Choudhry et al., 2003). The majority of transplant centers disapprove living 
donation between strangers, expressing doubts about their motivation and commitment to 
donation, their understanding of the potential risks and their psychological stability. 
Such donors may benefit from their act with increased self-esteem and may experience great 
satisfaction without being coerced by any sense of obligation. It has been proposed that in 
non-directed donation, the donor and recipient should remain anonymous to each other and 
probably meet only after the transplant, if they both agree. It has been suggested that true 
altruists do not need the name of those they help. Yet, the donors might want to see the 
results of their good deed, and the recipients might want to express their gratitude to the 
donor. It seems unethical to allow potential donors to specify particular characteristics of the 
recipient (e.g. sex, religion or race) (Levinsky N, 2000).  
4.5 Commercialization of organ donation 
It may be said that, living related donation involves a ‘highly artificial altruism’ according to 
which everyone is paid, including the transplant team as well as the recipient who gains an 
important benefit and only the donor is required to be altruistic. On the other hand, 
shortage of cadaveric organs has led to a worldwide black market for living-donor organs. 
Of course, it is unethical to sell human organs. A poor donor may be compelled by their 
financial status to donate, thus making the action non-voluntary. Yet, on the contrary, the 
donor may be choosing the best from a list of bad options, since it carries significantly less 
risk than working, for example, under harsh and dangerous conditions. Paid donors are, in 
their majority, poor and less educated, thus possibly unable to understand the risks 
involved (Choudhry et al., 2003).  
4.6 Paired-exchange programs 
A possible way to increase the live-donor pool is the paired exchange programs. In such 
programs, pairs of potential donors who are incompatible with their recipients donate 
eventually to each other’s recipient. Some have suggested that strict confidentiality should 
be maintained for each donor-recipient pair because there is a possibility of frustration, 
anger or resentment between the two pairs, in case one recipient does not have such a good 
outcome as the other. It is also suggested that both procedures should be performed 
simultaneously in order to avoid the possibility of one donor refusing after the other donor 
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procedure had already been performed (Park K et al, 1999). Psychological evaluation should 
be more meticulous to ensure that the donors are acting voluntarily. With the advances in 
immunosuppression and plasma-exchange techniques, such programs may be unnecessary, 
since ABO- incompatible transplants may be possible. 
4.7 Orphan graft 
The possibility of being unable to transplant a liver graft (orphan graft) into the intended 
recipient because of intraoperative death or other causes should be included in a prospective 
protocol at all institutions performing LDLT. Recommendations for handling an orphan 
liver graft include, (1) before donation, informed consent should be obtained from all donors 
indicating what the donor would want to have done with the orphan graft, (2) the sequence 
of steps in the operation should be structured to avoid removal of the donor graft until the 
recipient hepatectomy has been performed and the recipient’s survival is likely, and (3) the 
orphan graft is allocated according to preestablished institutional guidelines (Siegler J et al., 
2004). If the recipient dies intraoperatively and this possibility has not been covered in the 
preoperative consent discussion, the surgical team must obtain oral and written consent 
from the donor or the donor’s family to reallocate the organ. 
5. Evaluation and selection of the potential recipient 
5.1 Selection of the potential recipient 
Given the potential risks to the living donor, only recipients with a reasonably favorable 
post-transplant outcome should be considered for LDLT. Thus, before proceeding to work 
up any potential donor, the recipient candidate should first be deemed suitable for the 
LDLT operation both medically as well as surgically (Abdullah K et al, 2007). 
All potential LDLT recipients must first be listed for DDLT. This ensures the following, (1) 
the recipient is an appropriate candidate for liver transplant and avoids LDLT being done 
in futile situations (e.g., inoperable hepatocellular carcinoma), (2) should there be any 
post-LDLT complications including poor- or nonfunctioning graft, the recipient can be 
immediately upgraded to a top priority status to obtain a DDLT, and (3) third-party 
payers may require listing for DDLT before approving a patient for LDLT (Tan et al., 
2007). 
It has been suggested that a MELD score of 18 may be a reasonably good cutoff level 
above which LDLT is indicated, because a patient with a MELD score above 18 has a 
greater than 10% risk of 90-day mortality without transplantation; this exceeds the 1-year 
mortality after LDLT (10%). On the other hand, for patients with a MELD score below 17, 
the risk of transplant surgery is said to outweigh the risk of death from liver disease (Li C 
et al, 2010). 
Whether there is an upper limit for the MELD score above which LDLT may not be a viable 
option is unclear. Poorly decompensated patients have a comparatively poor prognosis and 
may not tolerate LDLT very well. It is thought that small grafts are unable to meet the needs 
of patients experiencing severe and prolonged illness. Some experts argue that a MELD 
score greater than 25 precludes LDLT, since a whole allograft, rather than a partial liver, is 
required to ensure adequate post-transplant recovery (Li C et al., 2010).  
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On the other hand, some of the patients with a low MELD score (below 18) may have other 
medically compelling reasons that prompt to consider LDLT (Li C et al., 2010; Trotter J et al., 
2005). These cases may include: 
1. Patients with HCC who may benefit from an expeditious LDLT before tumor 
progression occurs while on the waiting list (see later).  
2. Patients with a low MELD score that does not truly reflect their illness e.g. those with 
cholestatic liver diseases such as primary biliary cirrhosis or primary sclerosing 
cholangitis. These patients may have significant refractory symptoms or complications, 
e.g. severe pruritus, intractable ascites, infections, or hepatic encephalopathy. 
3. Patients with symptomatic benign hepatic masses, e.g. huge hemangioma, 
hemangioendothelioma, polycystic liver disease.  
4. Patients with metabolic disorders, e.g. familial amyloidosis, hyperoxaluria, tyrosinemia, 
and glycogen storage disease.  
5. Patients where LDLT can help prevent life-threatening complications, e.g. 
cholangiocarcinoma in primary sclerosing cholangitis. 
5.2 Evaluation of the potential recipient 
The evaluation of potential recipients for LDLT involves a multidisciplinary team approach 
which includes transplant surgeons, hepatologists, psychologists/psychiatrists, social 
workers, nurse coordinators, and other consultants (anesthesiologist, cardiologist, 
pulmonologist, infectious disease, neurologist, gynecologist, nutritionist, dentist, etc) 
(Abdullah K et al., 2005). Although the pretransplant workup varies with transplant centers, 
it should not differ from that of those accepted for DDLT. Most programs require a basic 
battery of laboratory tests, imaging studies, EKG, upper GI endoscopy and thorough 
evaluation of the general medical condition and fitness for major surgery (see Table 1).  
5.2.1 Psychosocial evaluation of the potential recipient 
The pretransplant period can be extremely stressful. Declining health, uncertainty about the 
possibility of LT, and inability to continue working and participating in daily activities all 
may increase the risk of depression and/or anxiety for the transplant candidate. Those 
patients who experience psychological distress prior to transplantation are likely to experience 
increased distress after transplantation, which may ultimately impact their recovery from 
transplantation (Walter M et al., 2002). Patients with chronic hepatitis C hepatitis have a 
greater incidence of depression and anxiety than patients with other forms of liver disease; 
thus, these patients in particular should be carefully screened and monitored. Patients who 
experience depression or anxiety are encouraged to seek psychiatric treatment prior to LT to 
improve their emotional and physical functioning. Some patients experience psychological 
distress or impairment that interferes with their health behavior to an extent that it may 
prevent them from adhering to medical directives. These patients should be required to 
pursue psychiatric services until their functioning is stable enough to be evaluated and 
satisfactorily listed for LT (Walter M et al., 2002). 
5.2.2 Social support 
Patients cannot and should not undergo stressful LT without considerable social support. 
Depending on the severity of the patient’s illness at the time of LT evaluation, many family 
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members and/or close friends may already have assumed care giving duties, including 
overseeing medication and dietary regimens and coordinating the patient’s medical 
appointments. Specifically, the caregiver’s relationship with the patient, current functioning, 
availability, and willingness to provide perioperative care should be assessed, as patients 
will rely heavily upon their caregivers during the perioperative period. 
 
Laboratory tests 
1. ABO blood grouping. 
2. Complete blood count, serum electrolytes, BUN, creatinine, liver biochemistry, 
alpha-fetoprotein and coagulation panel. 
3. Serology (hepatitis markers, RPR, HIV, CMV, EBV, etc). 
4. Stool and urine analysis and cultures. 
5. Others (serum alfa-1 antitrypsin, ferritin, ceruloplasmin, antinuclear antibody, 
antismooth muscle antibody etc.) 
Imaging studies 
1. Chest x-ray. 
2. Abdominal ultrasound to assess the patency of hepatic vasculature, presence of 
ascites, and to exclude focal lesions. 
3. Abdominal CT/MRI to exclude HCC, and to clarify abnormalities seen in ultrasound. 
EKG 
Endoscopy: Upper GI endoscopy to evaluate and treat varices. 
For selected patients 
1. Mammography, pap smear and pregnancy tests for female patients. 
2. Dental and dermatology evaluation.  
3. Cardiac stress test if EKG is abnormal.  
4. Coronary angiogram if cardiac stress test is positive. 
5. Carotid duplex. 
6. Pulmonary function tests and arterial blood gas. 
7. Bone scan and bone density. 
8. Liver biopsy. 
9. ERCP.  
10. Colonoscopy. 
11. PPD skin test. 
Table 1. list of investigations required for evaluation of a potential LDLT recipient 
5.2.3 Readiness for transplantation 
Certain patients may be in denial regarding the severity of their liver disease. It is important 
to ensure that patients possess a good understanding of the transplant process. When 
assessing readiness for transplantation, patients are reminded of the importance of continued 
adherence to all medical directives. 
5.3 Contraindications for recipient listing for LDLT 
Contraindications to LDLT are becoming fewer. Absolute contraindications for LDLT are 
similar to those for DDLT and include multisystem organ failure, severe and uncontrolled 
sepsis, irreversible brain damage, extrahepatic malignancy, advanced cardiopulmonary 
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disease, active substance abuse, and medical noncompliance. Common relative 
contraindications include thrombosis of multiple visceral veins, multiple significan 
abdominal surgeries, morbid obesity, uncontrolled diabetes, HIV, adverse psychosocial 
factors, and advanced age. Budd-Chiari syndrome and portal vein thrombosis are not 
usually deemed to be absolute contraindications (Trotter J et al., 2005).   
6. Controversial indication for LDLT 
6.1 Hepatitis C infection 
At present, patients with HCV should not be denied live donor transplants. Large number 
of studies has been published supporting differing views including that LDLT for patients 
with hepatitis C yields worse results, equivalent results, and even better results than those 
of DDLT. The majority of studies, however, have suggested the outcome is not different for 
HCV-positive recipients undergoing LDLT (Gallegos-Orozco J 2009). The benefits of LDLT 
in HCV-positive patients include: younger donors, less cold ischemia time, and the 
possibility of successfully treating patients with antiviral therapy prior to transplantation. It 
is not certain whether the regeneration of a partial liver graft, particularly in small-for-size 
grafts may stimulate and increase the rate of reactivation of the latent infection. Previous 
concerns about a higher frequency of cholestatic hepatitis or more aggressive fibrogenesis 
with live donors have not turned out to be true (Kuo A; Terrault NA 2009.). 
6.2 Hepatocellular carcinoma (HCC) 
Success in treating HCC with transplantation has been complicated by the supply and 
demand issues. LDLT was developed as a solution to this imbalance between cadaveric 
donor graft availability and the growing number of potential recipients. Changes in organ 
allocation systems giving priority to specific HCC patients have raised questions to the use 
of LDLT as a treatment for HCC. From an operative standpoint, the HCC patient is an ideal 
LDLT recipient, because the MELD priority points assigned to HCC patients mean that they 
have a much lower calculated MELD score. HCC patients generally have preserved liver 
function and less portal hypertension, and they are better able to tolerate implantation of a 
relatively undersized graft (Takada Y et al., 2010). 
6.2.1 Indications for LDLT for patients with HCC 
6.2.1.1 Long time on the waiting-list for DDLT 
A main indication for LDLT in HCC is when the patient will not likely receive a deceased 
donor organ in a timely fashion with the resulting potential for tumor progression to an 
untransplantable state. Therefore, in regions where cadaveric donation is limited by 
religious and cultural beliefs or there is a prolonged waiting time for deceased organs, the 
use of LDLT to curb tumor progression and increase survival is indicated. Even in areas 
where the waiting time is moderate, LDLT may still be valuable, if it can be determined 
that tumor progression is accelerated. Independent predictors of tumor progression may be 
useful to define aggressive tumors that are more sensitive to waiting list time. Thus, in 
those patients with large and multiple tumors, and those with high AFP levels, LDLT may 
still be indicated in those settings with short to moderate waiting time (Bhangui P et al., 
2011). 
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6.2.1.2 HCC exceeding the Milan criteria 
A second potential indication for LDLT in HCC patients is the presence of tumors exceeding 
the Milan Criteria. There is evidence to suggest, that Milan criteria may be too restrictive, 
and that there may be patients with potentially curable tumors that go untreated because of 
their exclusion from DDLT listing. The idea of using LDLT to transplant those patients with 
HCC exceeding the Milan Criteria requires a reasonable possibility of long-term survival 
(Shirabe K et al., 2011). 
6.2.2 Impact of LDLT on HCC recurrence 
Some centers have noted an increase in the recurrence of HCC when examined on a stage-
for-stage basis in those patients who have had their transplant waiting time shortened by 
using expanded donor options (LDLT, split liver transplants, domino liver transplants). In 
contrast, other centers have described no difference in recurrence rates between LDLT and 
cadaveric transplant for HCC. The explanations offered by the groups that report a higher 
rate of recurrence are: (1) the release of growth factors and cytokines that induce hepatic 
regeneration in LDLT. These factors have tumor-promoting effects (2) the biological 
aggressiveness of the tumor. Prolonged waiting time allows a tumor to declare its biological 
aggressiveness. Using LDLT to shorten the time on the waiting list may result in 
transplanting very aggressive tumors that have already metastasized on a microscopic level 
but are not yet apparent. A short waitlist time may prevent identification of these aggressive 
tumors, so that LDLT may result in transplanting those patients that are likely to have 
recurrent HCC. Preoperative microdissection genotyping of the HCC, with measurements of 
DCP levels, may identify HCC with a high certainty of recurrence and allow judicious use of 
LDLT minimizing recurrence attributed to “fast-tracking.” (Kaido T et al., 2011) 
6.2.3 Ethical concerns 
Because the donor safety is the paramount concern in LDLT, it is important to consider 
ethical issues related to LDLT specific to HCC. The potential risks and complications to the 
donor mean that LDLT should only take place when there is an acceptable survival. 
However, some will argue that survival outcomes for LDLT for HCC should be compared to 
nonsurgical/no-treatment outcomes rather than compared to outcomes from transplanting 
non-HCC patients (Mazzaferro V et al, 2008). 
LDLT is ethically justified in those cases where waiting time is disproportionately long and 
the prolonged waitlist increases the risk of the HCC progression to a nontransplantable state. 
The risk to the donor can be justified because acceptable survival results can be expected. 
On the other hand, when LDLT is performed for HCC that exceeds the Milan Criteria it is 
ethically less clear, because the LDLT is being done due the recipient’s exclusion from a 
possible cadaveric transplant. It is difficult to justify the potential risks to the donor in such a 
situation where the society prohibits a transplant because it is unlikely to be of benefit. As 
stated above, there is accumulating evidence, however, that slightly exceeding the Milan 
Criteria can still yield acceptable survival and for this situation LDLT may be ethically 
acceptable. Beyond this, there is poor survival, and it is not acceptable to expose the donor 
to the risks in this situation. Normally if a graft acutely fails, it requires an urgent 
retransplant (Shirabe K et al., 2011). If LDLT were used in a situation where a cadaveric  
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donor is contraindicated, such as exceeding the Milan Criteria, the urgent retransplant 
would require a cadaveric organ, even though the patient was originally contraindicated. In 
these situations, the patient should not be retransplanted (Takada Y et al., 2010). 
6.3 Acute liver failure 
Patients with fulminant hepatic failure (FHF) rarely recover spontaneously, and there is a 
limited interval between the onset and irreversible complications and death. Despite 
advances in medical management, including hemodiafiltration and plasma exchange, the 
survival rate of patients with FHF under these treatments is low. Liver transplantation is the 
only available effective treatment for this group of patients. Timely access to an organ is 
paramount, to ensure reversibility of the condition. Although the outcomes of LDLT are 
fairly acceptable despite severe general conditions and emergent transplant settings, the use 
of LDLT for patients with FHF is a matter of controversy and raises significant ethical issues. 
The major advantage of LDLT for FHF is the timely availability of a liver graft. This has 
beneficial effects on the neurological outcomes (Matsui Y et al., 2008).  
But LDLT also has major disadvantages. The donor needs to be selected in a timely fashion, 
under medical and social pressures. In addition, there is the possibility of acquiring an extra 
small graft, which cannot support the metabolic demand of a recipient. Some physicians 
have expressed concern that the expedited evaluation in the setting of acute liver failure 
potentially could preclude the potential donor from making a careful reasoned decision 
about donation. Because of these concerns, some centers have elected to exclude acute liver 
failure as an indication for LDLT (Rudow D et al, 2003). 
In countries where DD transplants are limited, LDLT is the only chance to rescue patients 
suffering from highly urgent conditions like FHF, with satisfactory overall patient and graft 
survival rates. On the other hand, in countries where DDLT is available, such patients are 
listed as high priority and thus have a good chance to receive a DDLT in a short time. 
However, even programs with good access to DDLT, LDLT should be kept as a viable 
option in emergency situations, when any wait increases the risk to the potential recipient.  
6.3.1 Ethical concerns 
The emergency nature of FHF could preclude the potential donor from making a careful 
decision about donation. The process of informed consent by the donor could also be 
influenced by coercion from family members or from the medical team. Autocoercion is also 
a strong possibility. In the context of extending elective LDLT to the more urgent situation 
of FHF, transplant programs must pay special attention to the autonomy of the potential 
donor and must ensure truly informed consent (Rudow D et al., 2003). 
7. Donor evaluation  
Donor evaluation consists of comprehensive examinations evaluating medical suitability for 
major surgery, psychological suitability, and liver-related suitability. The two fundamental 
purposes of the donor evaluation are to ensure (1) donor safety and (2) that the donor is able 
to yield a suitable graft for the recipient. Members of the evaluation team should include 
hepatologist, surgeon, psychologist, social worker, and transplant coordinator (Marcos A et 
al., 2000). 
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Guidelines for evaluating potential living liver donors are not standardized. There is a great 
deal of variability among individual centers regarding components of their living donor 
evaluation protocols. Variability exists in the performance of some diagnostic studies, such 
as liver biopsy, hepatic angiography, and cholangiography (Totter J et al., 2002). The most 
frequently used model is a process that involves phases that are progressively more invasive 
and expensive (see table 2). In principle, one should try to limit the number of invasive 
investigations and reserve them for the later part of the evaluation. In an effort to limit the 
cost, more expensive tests are generally performed later in the evaluation process (Abdullah 
K et al., 2007). Another advantage of such a process includes several opportunities for the 
donor candidate to re-evaluate and reaffirm the decision to donate. The entire process 
usually takes a period of 1 to 2 months. In emergent situations, it can be shortened to less 
than 24 hours.  
The initial phase is designed to determine that the potential donor meets all the appropriate 
inclusion criteria for donation: appropriate blood type, age, body size, and relationship to 
the recipient. The initial screening history may be performed by an experienced transplant 
coordinator, or the donor is asked to fill out an information sheet. Questions regarding age; 
height; weight; blood type (if known); past and current medical, surgical, or psychosocial 
problems (including a history of alcohol use); and current medication use are included in 
the questionnaire (Totter J et al., 2002). The lower limit of age for donation is determined by 
the ability to give legal consent. The potential donor must be between the ages of 18 and 55 
years. However, some extend the upper limit to 60 years. Most centers require that the 
potential donor should show a significant long-term relationship with the recipient. Body 
size compatibility between the donor and recipient is an important preliminary 
consideration in the donor evaluation. The potential donor should have an identical or 
compatible blood type and no significant medical problems. Surgical history is documented, 
along with current medications. Serum electrolyte levels, blood count, liver function tests, 
and hepatitis serological tests are performed. Relative contraindications for donor 
evaluation are discovered frequently in this phase and include, previous significant 
abdominal surgery, hypertension, hypercholesterolemia, and obesity (Chen Y et al., 2003).  
The next phase, involves a thorough history and physical examination to determine 
eligibility for the operation. Female potential donors of reproductive age should undergo a 
pregnancy test. The use of oral contraceptive pills or hormonal devices indicates 
perioperative deep vein thrombosis prophylaxis by subcutaneous heparin in addition to 
physical means. This phase involves evaluation of the donor liver. This can be subdivided 
into three components, which include assessment of the (1) hepatic parenchyma, (2) liver 
volume, and (3) vascular and biliary anatomy (Bradhagen D, et al., 2003). 
7.1 Evaluation of hepatic parenchyma 
The presence of chronic liver disease and steatosis could have potential implications for both 
the donor and recipient. This begins with liver biochemistry tests, including aspartate 
aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, albumin, and 
international normalized ratio (Chen Y et al., 2003). Blood tests to exclude chronic liver 
disease often are performed early in the course of the evaluation. These tests include serum 
transferrin saturation, ferritin, ceruloplasmin, alfa-1-antitrypsin phenotype, antinuclear 
antibody, smooth muscle antibody, antimitochondrial antibody, and hepatitis serological  
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Phase 1  
The potential donor should satisfy the following before proceeding to the next phases 
1. Clinical evaluation:  
• Age: between 18 and 55 years. 
• Identical or compatible blood type with recipient. 
• Body weight, height and Body mass index. 
• Absence of previous significant abdominal surgery and/or medical problems. 
• Significant long-term relationship with recipient. 
2. Normal liver function test results, serum electrolyte levels, complete blood count 
with differential cell count, and negative hepatitis B surface antigen and hepatitis C 
antibody results. 
3. Informed consent (for testing and surgery). 
 
Phase 2 
1. Complete and thorough medical history and physical examination. 
2. Laboratory tests: 
• Serology: hepatitis A, B and C (surface antigen, core antibody, surface antibody), 
rapid plasmin reagin, cytomegalovirus antibody (immunoglobulin G), Epstein-
Barr virus antibody (immunoglobulin G), antinuclear antibody, human 
immunodeficiency antibody, toxicology/substance abuse screen.  
• Serum ferritin, iron, transferrin, ceruloplasmin, alpha-1-antitrypsin, transferring, 
alpha fetoprotein, carcinoembryonic antigen. 
• Urinalysis. 
• Coagulation profile; protein C; antithrombin III; factor V, VII, and VIII. 
• C-reactive protein. 
• Thyroid function tests . 
• Pregnancy test for female donors. 
3. Imaging studies:  
• Chest X-ray.  
• Abdominal ultrasound scan. 
• CT scan and magnetic resonance imaging to assess the liver volume, the biliary 




1. Psychological evaluation, and informed consent. 
2. Other tests or consultations to clarify any potential problems uncovered during 
evaluation: e.g., endoscopic retrograde cholangiopancreatography, hepatic angiogram, 
liver biopsy, echocardiogram, and stress echocardiogram (some centers routinely 
perform some or all of these tests as part of the donor evaluation). 
 
Step 4 
1. Planning of OR date and availability of intensive care unit facilities. 
2. Blood bank: autologous blood donation. 
3. Second informed consent (for blood and surgery). 
Table 2. Suggested protocol for living donor evaluation  
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tests (hepatitis B surface antigen and antibody, hepatitis B core antibody, and hepatitis C 
antibody). Donors with evidence of underlying chronic liver disease or a positive hepatitis C 
antibody or, hepatitis B surface antigen result are excluded from further consideration. 
There is no consensus on the use of donors who are alfa-1-antitrypsin phenotype MZ or 
hemochromatosis C282Y heterozygotes. (Bradhagen D, et al., 2003)  
7.1.1 Steatosis 
Hepatic steatosis can be characterized histologically as microvesicular or macrovesicular. In 
general, macrovesicular steatosis is regarded as a benign lesion and often is asymptomatic, 
whereas microvesicular steatosis often is more serious. Hepatic steatosis can adversely affect 
both of the recipient and the donor. Steatotic livers may not function well because they are 
more susceptible to injury from general anesthesia and ischemia-reperfusion. In addition, 
steatosis has been shown to increase cold ischemic injury and impair hepatic regeneration. 
Several studies have shown that the risk for primary allograft nonfunction increases with 
increasing severity of steatosis. Because steatosis reduces functional hepatic mass, some 
advocate subtracting the percentage of steatosis from the estimated liver mass before 
calculating the final mass of the hepatic allograft and remnant (Bradhagen D, et al., 2003). 
There is currently no agreed cutoff value on the percentage of steatosis that is safe for 
performance of LDLT. The maximal acceptable amount of steatosis in the donor liver varies 
among LDLT programs and ranges from 10% to 30%. Several studies have shown that livers 
from deceased donors with less than 30% steatosis can be transplanted with results similar 
to organs without fat. Additional studies are needed to better define the acceptable amount 
of steatosis in the donor liver that will ensure a safe and successful operation for both the 
donor and recipient. There are some data to suggest that steatosis identified on a 
predonation biopsy can be reversed with a program of dieting and exercise, and rebiopsy in 
this situation may show the potential donor to be suitable (Chen Y et al., 2003). 
7.1.1.1 Liver biochemistry tests  
Liver biochemistry tests are not sensitive or specific and may even show normal results in 
those with advanced hepatic fibrosis. Other methods, such as body topography and lipid 
levels, have shown a weak correlation with hepatic steatosis. Of all biochemical parameters, 
serum triglyceride level appears to have the strongest correlation.  
7.1.1.2 Anthropometric measures 
Waist-hip ratio seems to be a good predictor of steatosis. An increased waist-hip ratio, 
which is present more commonly in men, is associated with a greater risk for hepatic 
steatosis. Of all noninvasive methods for assessment of hepatic steatosis, body mass index 
(BMI) may have the greatest utility. Several studies have shown a correlation between 
hepatic steatosis and increasing BMI. In addition, obese patients are more likely to have 
comorbid conditions (hypertension, hypercholesterolemia, and diabetes), which could 
increase the risk for postoperative complications after donor hepatectomy. Studies from the 
general surgery literature, suggest an increased incidence of surgical complications such as 
bleeding and wound problems in obese individuals. Obesity is also a risk factor for 
underlying cardiovascular problems, which could lead to an increased chance for medical 
complications posttransplant. Because of these risk factors, most obese donors will not be 
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suitable donors. In general, obese individuals (BMI > 28 kg/m2) are unsuitable for donation. 
Certainly a BMI of > 35 would be a contraindication. Many centers exclude donors with  
BMI > 30, but others will selectively evaluate these donors and perform a liver biopsy to rule 
out the possibility of liver steatosis (Bradhagen D, et al., 2003). 
7.1.1.3 Abdominal imaging 
Ultrasound, CT, and MRI, may detect the presence of hepatic steatosis. Their sensitivity and 
specificity are technique and operator dependent and also may vary based on degree of 
steatosis. The imaging modalities are not able to quantify the amount of steatosis or 
distinguish between simple steatosis and steatohepatitis. Iwasaki and colleagues (2004) have 
demonstrated that liver-to-spleen CT alternation values ratios using noncontrast CT scan are 
useful to detect appreciable hepatic macrovesicular steatosis. Newer imaging modalities, 
such as dual-echo and gradient-echo MR sequences, may provide increasing accuracy for 
the detection and quantification of hepatic steatosis. At present, the available abdominal 
imaging studies do not appear to be sufficiently sensitive or specific to replace liver biopsy 
in most situations (Iwasaki et al, 2004) . 
7.1.1.4 Liver biopsy 
Liver biopsy is the gold standard for the assessment of hepatic parenchymal disease, 
including steatosis. In general, liver biopsy is a safe procedure with a low risk for serious 
complications. Liver biopsy also is useful in excluding occult chronic liver disease. The 
appropriate use of liver biopsy in the evaluation of living donor candidates is an area of 
continuing controversy (Bradhagen D, et al., 2003). The role of liver biopsy in the donor 
evaluation process varies greatly from center to center. Some centers perform liver biopsy 
on all potential donors, whereas others perform liver biopsy based only on clinical findings 
that suggest some degree of concern e.g., significant history of alcohol intake, BMI greater 
than 28 kg/m2, elevated serum ferritin level, presence of steatosis on imaging studies, and 
so on. Liver biopsy may be avoided is patients with a BMI less than 25 who do not have 
diabetes, hypertension, or a history of excess alcohol consumption. In addition, they also 
should have normal liver test results and lipid levels and undergo tests to exclude chronic 
liver disease and hepatic imaging studies. Liver biopsy results that would preclude donation 
include fibrosis, nonalcoholic steatohepatitis (NASH), steatosis > 30% and histologic 
abnormalities such as inflammatory changes (Nadalin S et al, 2005). 
7.2 Volumetric assessment 
Donor safety is of primary concern, and the smallest resection that provides adequate actual 
and functional mass for the recipient is selected. Determination of adequate hepatic mass is 
critical for successful outcomes for both donor and recipient. Height and weight of the 
donor and recipient pair can be useful in excluding a very small donor when the intended 
recipient is large, but is not accurate enough in most other situations. Volumetric assessment 
of the hepatic segments can be performed using either CT or MRI. In general, hepatic mass 
estimated by volumetric imaging correlates well with actual hepatic mass determined at the 
time of hepatectomy. It is helpful for the surgeon to work with the radiologist in making the 
planned line of liver transection and to provide the most accurate assessment of graft 
volume (Hill MJ, et al., 2009).  
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tests (hepatitis B surface antigen and antibody, hepatitis B core antibody, and hepatitis C 
antibody). Donors with evidence of underlying chronic liver disease or a positive hepatitis C 
antibody or, hepatitis B surface antigen result are excluded from further consideration. 
There is no consensus on the use of donors who are alfa-1-antitrypsin phenotype MZ or 
hemochromatosis C282Y heterozygotes. (Bradhagen D, et al., 2003)  
7.1.1 Steatosis 
Hepatic steatosis can be characterized histologically as microvesicular or macrovesicular. In 
general, macrovesicular steatosis is regarded as a benign lesion and often is asymptomatic, 
whereas microvesicular steatosis often is more serious. Hepatic steatosis can adversely affect 
both of the recipient and the donor. Steatotic livers may not function well because they are 
more susceptible to injury from general anesthesia and ischemia-reperfusion. In addition, 
steatosis has been shown to increase cold ischemic injury and impair hepatic regeneration. 
Several studies have shown that the risk for primary allograft nonfunction increases with 
increasing severity of steatosis. Because steatosis reduces functional hepatic mass, some 
advocate subtracting the percentage of steatosis from the estimated liver mass before 
calculating the final mass of the hepatic allograft and remnant (Bradhagen D, et al., 2003). 
There is currently no agreed cutoff value on the percentage of steatosis that is safe for 
performance of LDLT. The maximal acceptable amount of steatosis in the donor liver varies 
among LDLT programs and ranges from 10% to 30%. Several studies have shown that livers 
from deceased donors with less than 30% steatosis can be transplanted with results similar 
to organs without fat. Additional studies are needed to better define the acceptable amount 
of steatosis in the donor liver that will ensure a safe and successful operation for both the 
donor and recipient. There are some data to suggest that steatosis identified on a 
predonation biopsy can be reversed with a program of dieting and exercise, and rebiopsy in 
this situation may show the potential donor to be suitable (Chen Y et al., 2003). 
7.1.1.1 Liver biochemistry tests  
Liver biochemistry tests are not sensitive or specific and may even show normal results in 
those with advanced hepatic fibrosis. Other methods, such as body topography and lipid 
levels, have shown a weak correlation with hepatic steatosis. Of all biochemical parameters, 
serum triglyceride level appears to have the strongest correlation.  
7.1.1.2 Anthropometric measures 
Waist-hip ratio seems to be a good predictor of steatosis. An increased waist-hip ratio, 
which is present more commonly in men, is associated with a greater risk for hepatic 
steatosis. Of all noninvasive methods for assessment of hepatic steatosis, body mass index 
(BMI) may have the greatest utility. Several studies have shown a correlation between 
hepatic steatosis and increasing BMI. In addition, obese patients are more likely to have 
comorbid conditions (hypertension, hypercholesterolemia, and diabetes), which could 
increase the risk for postoperative complications after donor hepatectomy. Studies from the 
general surgery literature, suggest an increased incidence of surgical complications such as 
bleeding and wound problems in obese individuals. Obesity is also a risk factor for 
underlying cardiovascular problems, which could lead to an increased chance for medical 
complications posttransplant. Because of these risk factors, most obese donors will not be 
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suitable donors. In general, obese individuals (BMI > 28 kg/m2) are unsuitable for donation. 
Certainly a BMI of > 35 would be a contraindication. Many centers exclude donors with  
BMI > 30, but others will selectively evaluate these donors and perform a liver biopsy to rule 
out the possibility of liver steatosis (Bradhagen D, et al., 2003). 
7.1.1.3 Abdominal imaging 
Ultrasound, CT, and MRI, may detect the presence of hepatic steatosis. Their sensitivity and 
specificity are technique and operator dependent and also may vary based on degree of 
steatosis. The imaging modalities are not able to quantify the amount of steatosis or 
distinguish between simple steatosis and steatohepatitis. Iwasaki and colleagues (2004) have 
demonstrated that liver-to-spleen CT alternation values ratios using noncontrast CT scan are 
useful to detect appreciable hepatic macrovesicular steatosis. Newer imaging modalities, 
such as dual-echo and gradient-echo MR sequences, may provide increasing accuracy for 
the detection and quantification of hepatic steatosis. At present, the available abdominal 
imaging studies do not appear to be sufficiently sensitive or specific to replace liver biopsy 
in most situations (Iwasaki et al, 2004) . 
7.1.1.4 Liver biopsy 
Liver biopsy is the gold standard for the assessment of hepatic parenchymal disease, 
including steatosis. In general, liver biopsy is a safe procedure with a low risk for serious 
complications. Liver biopsy also is useful in excluding occult chronic liver disease. The 
appropriate use of liver biopsy in the evaluation of living donor candidates is an area of 
continuing controversy (Bradhagen D, et al., 2003). The role of liver biopsy in the donor 
evaluation process varies greatly from center to center. Some centers perform liver biopsy 
on all potential donors, whereas others perform liver biopsy based only on clinical findings 
that suggest some degree of concern e.g., significant history of alcohol intake, BMI greater 
than 28 kg/m2, elevated serum ferritin level, presence of steatosis on imaging studies, and 
so on. Liver biopsy may be avoided is patients with a BMI less than 25 who do not have 
diabetes, hypertension, or a history of excess alcohol consumption. In addition, they also 
should have normal liver test results and lipid levels and undergo tests to exclude chronic 
liver disease and hepatic imaging studies. Liver biopsy results that would preclude donation 
include fibrosis, nonalcoholic steatohepatitis (NASH), steatosis > 30% and histologic 
abnormalities such as inflammatory changes (Nadalin S et al, 2005). 
7.2 Volumetric assessment 
Donor safety is of primary concern, and the smallest resection that provides adequate actual 
and functional mass for the recipient is selected. Determination of adequate hepatic mass is 
critical for successful outcomes for both donor and recipient. Height and weight of the 
donor and recipient pair can be useful in excluding a very small donor when the intended 
recipient is large, but is not accurate enough in most other situations. Volumetric assessment 
of the hepatic segments can be performed using either CT or MRI. In general, hepatic mass 
estimated by volumetric imaging correlates well with actual hepatic mass determined at the 
time of hepatectomy. It is helpful for the surgeon to work with the radiologist in making the 
planned line of liver transection and to provide the most accurate assessment of graft 
volume (Hill MJ, et al., 2009).  
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Two formulas are used to assess graft size adequacy: (1) graft-recipient body weight ratio 
(GRBWR) and (2) graft weight as a percentage of standard liver mass. There is an excellent 
linear correlation between the two, and either is acceptable. It probably is reasonable to 
correct the GRBWR for steatosis by subtracting the percentage of steatosis noted on liver 
biopsy from the functional hepatic mass (Hill MJ, et al., 2009). 
Resection should not exceed 70% of the total liver volume; that is, the donor should be left 
with at least 30% of the measured total liver volume. Liver failure has been reported 
postdonation, with at least one donor requiring an urgent liver transplant because of liver 
failure after donation. As a result, LDLT has limited applicability in large patients because of 
the inability to identify a suitable donor (Nadalin S et al, 2004). 
A GRBWR of 1% is approximately equal to 50% of standard liver mass. The consensus is 
that the GRBWR should be equal or greater than 0.8 % (equivalent to about 40 % of the 
standard liver volume). It should be stressed, however, that these values are based upon 
LDLT performed in noncritically ill patients. Patients with significant decompensation of 
chronic liver disease will have excessive metabolic demands and require the maximum liver 
volume available. On the other hand, some authorities ( Selzner et al, 2009) suggest that, 
patients with Child’s class A cirrhosis or those without portal hypertension could receive an 
allograft with a GRBWR greater than 0.6%. Marcos A (2000) summarized the issue of hepatic 
mass by stating, “Neither the minimum transplantable hepatic mass nor the optimal mass 
have been accurately determined. In all likelihood, these values are dependent on both 
donor- and recipient-specific characteristics and could never be determined with precision”. 
For physically large recipients greater than 100 kg, the likelihood of finding a donor 
physically large enough to yield a sufficiently large graft is small. For a pediatric recipient, 
the main issue is not usually whether the liver volume may be too small; rather the issue is 
whether it may be too large; this may lead to problems with closure of the abdomen in the 
recipient. Usually the GRBWR should not exceed 5%(Bradhagen D, et al., 2003). 
7.3 Donor liver anatomy 
Variations in vascular and biliary anatomy can be quite common. Preoperative knowledge 
of the anatomical variations is important for planning the operative procedure and for 
maximizing the chances of a safe and successful operation for both donor and recipient. 
Preoperative imaging studies include MR angiography and cholangiography, CT 
angiography, ERCP, and mesenteric angiography. The choice of the imaging modalities is 
dependent on institutional experience and expertise. Most centers have abandoned the use 
of invasive tests such as angiogram, and routinely use CT or MRI with 3-D reconstructions 
(Tsang Let al, 2008).  
Common arterial variations include replaced right and left hepatic arteries with and without 
the presence of proper, right, and left hepatic arteries. These variations are usually 
detectable by CT or MR angiography. A replaced left hepatic artery increases donor safety 
because the artery is away from the surgical field and less prone to injury during right 
hepatectomy (Takatsuki M et al,2006). A completely replaced right hepatic artery is a 
favorable situation for both donor and recipient. It is longer than a right hepatic artery, 
remote from the left liver arterial in-flow, and more amenable to dissection from 
surrounding tissue. The presence of both replaced and standard right hepatic arteries 
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introduces more complexity. Reconstruction before implantation is possible with a 
bifurcated recipient proper hepatic artery graft, or the arteries can be sewn separately to the 
recipient right and left hepatic arteries. Nevertheless, the presence of two arteries increases 
the risk for thrombosis. Occasionally, a right hepatic branch may arise from the left hepatic 
artery or a left hepatic branch may arise from the right hepatic artery; both situations may 
preclude donation (Sugawara Y, et al. 2003). 
The most common portal venous variation is separate right anterior and posterior portal 
venous trunks which may require reconstruction before implantation (most commonly with 
a bifurcated venous graft) or separate anastomoses during implantation to the recipient 
right and left portal veins. A sizable left portal branch arising from the right portal system or 
a right branch from the left system may preclude donation (Xu M, et al, 2008 ). 
Hepatic venous anatomy is also variable. Most commonly, there are two tributaries to the 
middle hepatic vein (MHV) within the anterior segments of the right liver, segments V and 
VIII. The need for reconstruction of these tributaries in the recipient remains controversial. 
Some centers routinely reconstruct both veins, others reconstruct them when large, and 
others never do (see later). Large caudate veins also are common. Most centers reimplant 
caudate veins larger than 0.5 cm. Intraoperative ultrasonography is helpful, as well (Radtke 
A et al., 2010).  
The biliary anatomy may be difficult to evaluate accurately preoperatively. Some centers 
routinely perform MRCP or ERCP as part of the evaluation process. The latter is an invasive 
test, whereas the former may not provide the degree of accuracy and clarity required to be 
of value. As a result many centers choose to perform an intraoperative cholangiogram, 
rather than preoperative biliary imaging. However, ongoing improvements in imaging 
modalities may soon allow for preoperative noninvasive imaging that is equivalent to the 
intraoperative cholangiogram with regards to its detail and clarity. The most common 
variations are multiple right hepatic ducts that require separate anastomoses in the 
recipient, but. Occasionally, a left duct arises from the right system, but these ducts usually 
are small and can be safely divided during right hepatectomy (Limanond P et al, 2004).  
7.4 Evaluation for thrombophilia 
Deep venous thrombosis with subsequent pulmonary embolism represents a serious 
postoperative complication to the living donor. Several cases of pulmonary embolism have 
been reported with at least one donor mortality due to this complication. Known risk factors 
for thromboembolic complications include obesity, use of oral hormone therapy, old age, 
smoking, positive family history, and an identified underlying procoagulation disorder. 
These risk factors should be addressed during the evaluation process, including screening 
tests to identify a procoagulation disorder. Tests include, protein C and S and alfa-1-
antitrypsin deficiency, checking for factor VIII elevation, evaluating for the presence of 
antiphospholipid or anticardiolipin antibodies, and screening for the factor V Leiden and 
prothrombin gene mutations (Ogawa H, et al., 2011). 
7.5 Psychosocial evaluation 
This part of the evaluation assesses the donor’s mental fitness and willingness to donate, 
ensuring that consent is obtained in a voluntary manner with the absence of coercion. A 
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Two formulas are used to assess graft size adequacy: (1) graft-recipient body weight ratio 
(GRBWR) and (2) graft weight as a percentage of standard liver mass. There is an excellent 
linear correlation between the two, and either is acceptable. It probably is reasonable to 
correct the GRBWR for steatosis by subtracting the percentage of steatosis noted on liver 
biopsy from the functional hepatic mass (Hill MJ, et al., 2009). 
Resection should not exceed 70% of the total liver volume; that is, the donor should be left 
with at least 30% of the measured total liver volume. Liver failure has been reported 
postdonation, with at least one donor requiring an urgent liver transplant because of liver 
failure after donation. As a result, LDLT has limited applicability in large patients because of 
the inability to identify a suitable donor (Nadalin S et al, 2004). 
A GRBWR of 1% is approximately equal to 50% of standard liver mass. The consensus is 
that the GRBWR should be equal or greater than 0.8 % (equivalent to about 40 % of the 
standard liver volume). It should be stressed, however, that these values are based upon 
LDLT performed in noncritically ill patients. Patients with significant decompensation of 
chronic liver disease will have excessive metabolic demands and require the maximum liver 
volume available. On the other hand, some authorities ( Selzner et al, 2009) suggest that, 
patients with Child’s class A cirrhosis or those without portal hypertension could receive an 
allograft with a GRBWR greater than 0.6%. Marcos A (2000) summarized the issue of hepatic 
mass by stating, “Neither the minimum transplantable hepatic mass nor the optimal mass 
have been accurately determined. In all likelihood, these values are dependent on both 
donor- and recipient-specific characteristics and could never be determined with precision”. 
For physically large recipients greater than 100 kg, the likelihood of finding a donor 
physically large enough to yield a sufficiently large graft is small. For a pediatric recipient, 
the main issue is not usually whether the liver volume may be too small; rather the issue is 
whether it may be too large; this may lead to problems with closure of the abdomen in the 
recipient. Usually the GRBWR should not exceed 5%(Bradhagen D, et al., 2003). 
7.3 Donor liver anatomy 
Variations in vascular and biliary anatomy can be quite common. Preoperative knowledge 
of the anatomical variations is important for planning the operative procedure and for 
maximizing the chances of a safe and successful operation for both donor and recipient. 
Preoperative imaging studies include MR angiography and cholangiography, CT 
angiography, ERCP, and mesenteric angiography. The choice of the imaging modalities is 
dependent on institutional experience and expertise. Most centers have abandoned the use 
of invasive tests such as angiogram, and routinely use CT or MRI with 3-D reconstructions 
(Tsang Let al, 2008).  
Common arterial variations include replaced right and left hepatic arteries with and without 
the presence of proper, right, and left hepatic arteries. These variations are usually 
detectable by CT or MR angiography. A replaced left hepatic artery increases donor safety 
because the artery is away from the surgical field and less prone to injury during right 
hepatectomy (Takatsuki M et al,2006). A completely replaced right hepatic artery is a 
favorable situation for both donor and recipient. It is longer than a right hepatic artery, 
remote from the left liver arterial in-flow, and more amenable to dissection from 
surrounding tissue. The presence of both replaced and standard right hepatic arteries 
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introduces more complexity. Reconstruction before implantation is possible with a 
bifurcated recipient proper hepatic artery graft, or the arteries can be sewn separately to the 
recipient right and left hepatic arteries. Nevertheless, the presence of two arteries increases 
the risk for thrombosis. Occasionally, a right hepatic branch may arise from the left hepatic 
artery or a left hepatic branch may arise from the right hepatic artery; both situations may 
preclude donation (Sugawara Y, et al. 2003). 
The most common portal venous variation is separate right anterior and posterior portal 
venous trunks which may require reconstruction before implantation (most commonly with 
a bifurcated venous graft) or separate anastomoses during implantation to the recipient 
right and left portal veins. A sizable left portal branch arising from the right portal system or 
a right branch from the left system may preclude donation (Xu M, et al, 2008 ). 
Hepatic venous anatomy is also variable. Most commonly, there are two tributaries to the 
middle hepatic vein (MHV) within the anterior segments of the right liver, segments V and 
VIII. The need for reconstruction of these tributaries in the recipient remains controversial. 
Some centers routinely reconstruct both veins, others reconstruct them when large, and 
others never do (see later). Large caudate veins also are common. Most centers reimplant 
caudate veins larger than 0.5 cm. Intraoperative ultrasonography is helpful, as well (Radtke 
A et al., 2010).  
The biliary anatomy may be difficult to evaluate accurately preoperatively. Some centers 
routinely perform MRCP or ERCP as part of the evaluation process. The latter is an invasive 
test, whereas the former may not provide the degree of accuracy and clarity required to be 
of value. As a result many centers choose to perform an intraoperative cholangiogram, 
rather than preoperative biliary imaging. However, ongoing improvements in imaging 
modalities may soon allow for preoperative noninvasive imaging that is equivalent to the 
intraoperative cholangiogram with regards to its detail and clarity. The most common 
variations are multiple right hepatic ducts that require separate anastomoses in the 
recipient, but. Occasionally, a left duct arises from the right system, but these ducts usually 
are small and can be safely divided during right hepatectomy (Limanond P et al, 2004).  
7.4 Evaluation for thrombophilia 
Deep venous thrombosis with subsequent pulmonary embolism represents a serious 
postoperative complication to the living donor. Several cases of pulmonary embolism have 
been reported with at least one donor mortality due to this complication. Known risk factors 
for thromboembolic complications include obesity, use of oral hormone therapy, old age, 
smoking, positive family history, and an identified underlying procoagulation disorder. 
These risk factors should be addressed during the evaluation process, including screening 
tests to identify a procoagulation disorder. Tests include, protein C and S and alfa-1-
antitrypsin deficiency, checking for factor VIII elevation, evaluating for the presence of 
antiphospholipid or anticardiolipin antibodies, and screening for the factor V Leiden and 
prothrombin gene mutations (Ogawa H, et al., 2011). 
7.5 Psychosocial evaluation 
This part of the evaluation assesses the donor’s mental fitness and willingness to donate, 
ensuring that consent is obtained in a voluntary manner with the absence of coercion. A 
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trained transplant psychiatrist, psychologist, clinical social worker, and psychiatric nurse 
perform this psychological assessment. The professional(s) responsible for psychological 
assessment should be part of the transplant team and must be experienced in the assessment 
of liver transplant recipients, so that they understand the particular context and unique 
psychological demands of liver transplants (Walter M, et al, 2002). 
No strict guidelines exist for psychological assessment of prospective donor. However, most 
transplant centers have adopted formal psychological assessment as an integral part of their 
donor evaluation. There are several components to this part of the evaluation, but basically 
the following issues should be addressed: (1) mental, psychological, emotional, and social 
stability, (2) motivation for donation including a careful assessment to ensure that there is 
no coercion or inducement involved and competency to give informed consent, and (3) full 
understanding of, the donation process, the surgery involved, the potential complications, 
and the recovery involved (Walter M, et al, 2002). 
The presence of underlying mental illness, cognitive impairments, aberrant personality 
traits, or other factors that may interfere with the potential donor’s ability to make a 
reasoned decision may preclude donation. A history of anxiety, depression, or other 
concerns are discussed to determine whether donation could exacerbate underlying 
symptoms. Present and past behaviors are explored because they may be predictors to 
coping with potential donor outcomes. Donors must understand how donation could 
impact on their mental health (Noma et al., 2010). 
The clinical psychologist makes an independent recommendation as to whether the donor 
is suitable to undergo donation. Informed consent to proceed with the necessary tests and 
surgery is discussed in detail with the prospective donor. After all the donor candidate’s 
questions are answered to his or her satisfaction, written consent is obtained, and a copy of 
the consent form is given to the candidate to keep; this is separate from a second written 
informed consent, which is obtained prior to the LDLT surgery itself. Upon completion of 
this step, a decision regarding donor acceptability needs to be made by a multidisciplinary 
committee, which takes into consideration both the medical and ethical aspects of each 
case. 
8. Hepatitis B virus core antibody positive donors 
The presence of antibody to hepatitis B core antigen (anti-HBc) in the absence of hepatitis B 
surface antigen (HBsAg) signifies past exposure to hepatitis B virus (HBV) and may 
represent a state of resolved infection with immunity or recent clearance of HbsAg and yet 
persistent low-grade hepatitis activity. The use of live donors who are anti-HBc positive 
involves consideration of two factors: risk to the donor and potential risk of transmission to 
the recipient. With regard to the recipient, the issues are no different from those for a 
deceased donor who is core positive (Suehiro T et al., 2005). 
8.1 Risks to the recipient 
Experience with the use of anti-HBc-positive livers from deceased donors indicated that the 
risk of HBV reactivation varies with the recipient’s HBV serology status. A variety of terms 
such as de novo hepatitis B, recurrent hepatitis B, transmission of hepatitis B, or reactivation 
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of hepatitis B have been used to describe HBV infection in this setting. The presence of anti-
HBs in the recipient has been reported to protect against reactivation. Anti-HBc 
seropositivity has also been shown to be associated with a lower risk of HBV reactivation. 
On the other hand, the concomitant presence of anti-HBs in the donor’s serum does not offer 
any protective effect. Other factors as the Child-Pugh score and the type of 
immunosuppressive therapy, have been suggested to affect the rate of HBV reactivation 
through its effect on the host immune response (Munoz S, 2002).  
8.1.1 Strategies to minimize the risks to the recipient  
a. Matching: In DDLT. anti-HBc-positive liver graft from a deceased donor is usually 
allocated first to HBsAg-positive recipients who would in any case need prophylaxis 
against recurrence. Unfortunately, a matching policy has little role in the practice of 
LDLT. A living donor is evaluated for the possibility of donation to a specific recipient 
(Fontana R & Merion R, 2003). 
b. Prophylaxis against HBV reactivation: Strategies including hepatitis- B-immune 
globulin (HBIG) and/or lamivudine to prevent recurrent hepatitis B in HBsAg-negative 
recipients have been used (Suehiro T et al., 2005). 
8.2 Risks to the donor 
Theoretically, the potential problems in anti-HBc-positive donors include, (1) the underlying 
hepatitis infection may delay the recovery and regeneration of the liver remnant. (2) 
reactivation of integrated HBV virus in the postoperative period, (3) on the long-term, the 
occult hepatitis infection may progress to the development of cirrhosis or HCC and the 
previous hepatic resection for liver donation may compromise the prospects for appropriate 
treatment (Suehiro T et al., 2005). Whether the risk is significant in patients with 
biochemically and histologically normal liver is controversial. Transplant centers that accept 
living donors positive for anti-HBc are obliged to continue lifelong follow-up of these 
donors in order to assess these potential long-term sequels. 
8.3 Recommendations 
a. Detailed preoperative assessment is mandatory for both the donor and the recipient.  
b. Donors with ongoing chronic hepatitis and viremia as indicated by abnormal liver 
biochemistry and positive serum HBV DNA should be excluded.  
c. A routine preoperative liver biopsy is mandatory in the HB c antibody-positive donor. 
The presence of hepatic fibrosis would preclude donor hepatectomy. 
d. Donors seronegative for anti-HBs should receive HBV vaccination to protect against the 
risk of future HBV reactivation.  
e. For the HBsAg-positive recipients, there is no need for any adjustment to the 
appropriate prophylaxis against HBV recurrence.  
f. All HBsAg-negative recipients should receive prophylactic treatment with lamivudine 
alone or in combination with HBIG after transplantation.  
g. Both the donor and the recipient should receive regular and lifelong follow-up. Any 
episode of liver dysfunction should be investigated for HBV reactivation with 
serological and virological testing. (Suehiro T et al., 2005; Fontana R; Merion R, 2003) 
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trained transplant psychiatrist, psychologist, clinical social worker, and psychiatric nurse 
perform this psychological assessment. The professional(s) responsible for psychological 
assessment should be part of the transplant team and must be experienced in the assessment 
of liver transplant recipients, so that they understand the particular context and unique 
psychological demands of liver transplants (Walter M, et al, 2002). 
No strict guidelines exist for psychological assessment of prospective donor. However, most 
transplant centers have adopted formal psychological assessment as an integral part of their 
donor evaluation. There are several components to this part of the evaluation, but basically 
the following issues should be addressed: (1) mental, psychological, emotional, and social 
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involves consideration of two factors: risk to the donor and potential risk of transmission to 
the recipient. With regard to the recipient, the issues are no different from those for a 
deceased donor who is core positive (Suehiro T et al., 2005). 
8.1 Risks to the recipient 
Experience with the use of anti-HBc-positive livers from deceased donors indicated that the 
risk of HBV reactivation varies with the recipient’s HBV serology status. A variety of terms 
such as de novo hepatitis B, recurrent hepatitis B, transmission of hepatitis B, or reactivation 
 
Living Donor Liver Transplantation 
 
21 
of hepatitis B have been used to describe HBV infection in this setting. The presence of anti-
HBs in the recipient has been reported to protect against reactivation. Anti-HBc 
seropositivity has also been shown to be associated with a lower risk of HBV reactivation. 
On the other hand, the concomitant presence of anti-HBs in the donor’s serum does not offer 
any protective effect. Other factors as the Child-Pugh score and the type of 
immunosuppressive therapy, have been suggested to affect the rate of HBV reactivation 
through its effect on the host immune response (Munoz S, 2002).  
8.1.1 Strategies to minimize the risks to the recipient  
a. Matching: In DDLT. anti-HBc-positive liver graft from a deceased donor is usually 
allocated first to HBsAg-positive recipients who would in any case need prophylaxis 
against recurrence. Unfortunately, a matching policy has little role in the practice of 
LDLT. A living donor is evaluated for the possibility of donation to a specific recipient 
(Fontana R & Merion R, 2003). 
b. Prophylaxis against HBV reactivation: Strategies including hepatitis- B-immune 
globulin (HBIG) and/or lamivudine to prevent recurrent hepatitis B in HBsAg-negative 
recipients have been used (Suehiro T et al., 2005). 
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Theoretically, the potential problems in anti-HBc-positive donors include, (1) the underlying 
hepatitis infection may delay the recovery and regeneration of the liver remnant. (2) 
reactivation of integrated HBV virus in the postoperative period, (3) on the long-term, the 
occult hepatitis infection may progress to the development of cirrhosis or HCC and the 
previous hepatic resection for liver donation may compromise the prospects for appropriate 
treatment (Suehiro T et al., 2005). Whether the risk is significant in patients with 
biochemically and histologically normal liver is controversial. Transplant centers that accept 
living donors positive for anti-HBc are obliged to continue lifelong follow-up of these 
donors in order to assess these potential long-term sequels. 
8.3 Recommendations 
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b. Donors with ongoing chronic hepatitis and viremia as indicated by abnormal liver 
biochemistry and positive serum HBV DNA should be excluded.  
c. A routine preoperative liver biopsy is mandatory in the HB c antibody-positive donor. 
The presence of hepatic fibrosis would preclude donor hepatectomy. 
d. Donors seronegative for anti-HBs should receive HBV vaccination to protect against the 
risk of future HBV reactivation.  
e. For the HBsAg-positive recipients, there is no need for any adjustment to the 
appropriate prophylaxis against HBV recurrence.  
f. All HBsAg-negative recipients should receive prophylactic treatment with lamivudine 
alone or in combination with HBIG after transplantation.  
g. Both the donor and the recipient should receive regular and lifelong follow-up. Any 
episode of liver dysfunction should be investigated for HBV reactivation with 
serological and virological testing. (Suehiro T et al., 2005; Fontana R; Merion R, 2003) 
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9. Technical aspects of LDLT 
Timing of the donor procedure in relation to the recipient procedure is very important. 
Recipients with nonmalignant disorders are usually brought to the operating room after the 
anatomy in the donor has been assessed and found to be suitable for donation. Recipients 
with potentially malignant lesions should be explored through a relatively small right 
subcostal incision before the donor is anesthetized. If enlarged lymph nodes are found, 
biopsies are sent for frozen section (Henrik P et al., 2009; Polak W et al., 2009).  
9.1 Recipient hepatectomy  
A generous bilateral subcostal incision and upward midline extension is made. Native 
hepatectomy with caval flow preservation is performed in a standard fashion except for 
vascular and biliary management. Hilar dissection is made to free the right and left hepatic 
artery, the common hepatic duct, the right and left portal vein and its main trunk. The tissue 
around the common hepatic duct is preserved as far as possible in order to retain its blood 
supply (Soejima Y, et al., 2008). It is then divided close to the liver hilum so as to retain 
enough length for subsequent duct-to-duct anastomosis. The left and right portal veins must 
be free for the full length (Kim B et al., 2009). The portal vein is not divided until the liver 
graft is available. Then, the main portal vein is clamped and the right and left portal veins 
are divided close to the liver hilum. The hepatic veins are clamped and divided. The hepatic 
vein stump intended for venous outflow reconstruction is slit open to fashion a triangular 
venotomy opening that matches in size and shape with the hepatic vein opening of the liver 
graft (Henrik P et al., 2009; Polak W et al., 2009).  
9.2 Donor right hepatectomy 
9.2.1 Access 
Access is gained through a bilateral subcostal incision with upper midline extension. The 
ligamentum teres is ligated and divided, and the falciform ligament severed toward the 
suprahepatic vena cava to reveal the border between the RHV and the MHV. The right liver 
is then mobilized by dissection of the triangular ligament (Cipe G, et al., 2011). 
9.2.2 Intraoperative cholangiogram and Doppler ultrasound 
Cholecystectomy is performed and a tube for cholangiogram is inserted through the cystic 
duct. Cholangiogram can be postponed until the right hepatic duct is roughly dissected and 
marked with a clip. Intraoperative Doppler ultrasound is performed to map the position 
and direction of the MHV. The route of the MHV can be drawn on the anterior surface of the 
liver with electrocautery (Haberal M et al,2011).  
9.2.3 Mobilization 
The liver is rotated to expose the retrohepatic cava. Tiny, short hepatic veins are 
meticulously divided. Posterior hepatic veins with a diameter larger than 0.5 cm should be 
eventually reanastomosed to the cava of the recipient. The caval side of the vein is 
oversewn, and the venous stump is temporarily clipped. The IVC ligament just below the 
RHV usually contains vessels of significant caliber and should be oversewn after 
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transection. The RHV is fully exposed and encircled. The extent of the dissection of the 
retrohepatic-cava plane can be pictured as a longitudinal line drawn from the space between 
RHV and MHV to the midportion of the process of the caudate lobe. It usually corresponds 
to half to two thirds of the anterior surface of the IVC (Cipe G, et al., 2011). 
9.2.4 Hilar time 
Hilar dissection is started from the right side of the CBD. The RHA is identified first, 
followed by the portal vein. The RHA is dissected from its origin to the liver parenchyma. 
All large branches to segment IV should be spared. The posterior aspect of the RPV is then 
exposed with division of caudate lobe branches, if necessary. The RPV and RHA are 
temporarily clamped, with a noncrushing vascular clip, to visualize the demarcation line of 
the liver. The space between the right hepatic artery and the right hepatic duct should not be 
disrupted in order to preserve the blood supply of the latter (Soejima Y, et al., 2008).  
9.2.5 Parenchymal transection 
No matter whether CUSA, Water Jet Dissector, Monopolar and Bipolar Coagulator, Tissue 
Link or Staple Devices are used, the ultimate goal is to transect the parenchyma with the 
minimal blood loss possible, respecting the anatomical structures vital to the graft and to the 
donor. Individual preferences dictate the level of comfort in relying on the aforementioned 
devices (Cipe G, et al., 2011). Under a low central venous pressure and complete muscle 
relaxation, bleeding during liver transection would not be excessive. The plane of 
transection is dictated by the position of the MHV and whether it will be taken with the 
graft or not. (Humar A et al., 2006; Tanaka K et al., 2010; Belghiti J; R Kianmanesh 2003).  
The control and transection of the posterior plane above the vena cava can be facilitated by 
passing the umbilical tape between the hilar structures and the space between the RHV and 
MHV and pulling it by both ends ”the hanging maneuver”. In this way the liver is lifted 
upward and the resection is greatly facilitated.. To include the MHV in the graft during the 
hanging maneuver, the origin of the MHV is rounded and a tape is passed to the space 
between the LHV and MHV (Ogata S, 2007; Cipe G, et al., 2011).  
Some surgeons routinely give heparin before vascular clamping. The RHA, RPV, and RHV 
in sequence are separately clamped and divided, and the liver segment is immediately 
removed. The vascular stumps are oversewn with Prolene sutures. The donor side of the 
bile duct is closed after the graft is removed and the vascular stumps are oversewn (Henrik 
P et al., 2009; Polak W et al., 2009; Humar A et al., 2006).  
To shorten the cold ischemic time, the graft is not delivered until the recipient is almost ready for 
graft implantation. Precise communication between the two teams is vital in this regard (Cipe G, et 
al., 2011). 
9.2.6 Back-table procedure 
Once delivered, the graft is flushed with cold preservative solution either, University of 
Wisconsin (UW) (Via Span, Duramed Pharmaceuticals) or histidine-tryptophane-
ketoglutarate (HTK; Custodial, Odyssey Pharmaceuticals). The flushing is continued 
through the portal vein until the effluent from the hepatic vein is completely clear. This 
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usually requires 3 mL/g of liver weight (Henrik P et al., 2009; Polak W et al., 2009; Humar A 
et al., 2006; Tanaka K et al., 2010).  
Back-table reconstruction may be required as follows:  
a. Tributaries of the donor MHV may require extensions with an autologous vein grafts. 
b. The RHV may require a venoplasty using an autologous (portal) vein graft. If two right 
hepatic veins are present, and if they are not too far apart, they can be sewn together.  
c. If two portal vein orifices are present, and are not too far apart, they can be sewn 
together; alternatively, a venous Y-graft (of autologous portal vein branches from the 
recipient’s resected native liver) can be used.  
d. The orifices of the bile duct(s), if they are not too far apart, are sewn together; they can 
also be incised to create a larger anastomosis.  
e. The liver’s cut surface is inspected. Leaks identified during flushing are oversewn.  
9.3 Right liver implantation 
The liver graft is placed in a natural position. The implantation starts with the hepatic vein 
anastomosis performed in a triangular fashion using 5-0 Prolene. Attention should be paid to 
prevent inversion, especially of the posterior wall. There should be no tension on the suture 
(Polak W et al., 2009; Humar A et al., 2006; Tan H et al., 2007; Tanaka K et al., 2010).  
Portal vein anastomosis is completed using running 6-0 sutures to the RPV, portal bifurcation, 
or portal trunk of the recipient, depending on its diameter and distance. The running 
sutures are taken on the anterior wall from the medial to the lateral aspects of the recipient 
and donor portal veins. The suture is tied at the lateral side with incorporation of a “growth 
factor.” to prevent portal vein narrowing at the anastomotic site itself (Starzl TE et al., 1984; 
Xu MQ et al., 2008). 
The vascular clamp is removed from the recipient portal vein and the liver is reperfused. 
About 500 mL of blood are vented through the (untied) medial aspect of the vena cava 
anastomosis. The portal vein is clamped again, and the running suture of the medial aspect 
of the caval anastomosis is tied to the corner stitch. The clamps on the vena cava and the 
portal vein are now removed, and the liver graft is reperfused (Humar A et al., 2006; Tan H 
et al., 2007; Tanaka K et al., 2010 ). The surgeon assesses the quality of liver perfusion and 
stops any significant bleeding with suture ligation. Usually, the liver pinks up immediately. 
If the MHV was not included in the graft or if venous tributaries were not reconstructed, the 
medial aspects of segments 5 and 8 (right anterior or paramedian segments) may be dusky-
blue and are frequently swollen. The cut surface is assessed for bleeding and hemostasis is 
obtained (Henrik P et al., 2009; Polak W et al., 2009; Tan H 2007; Tanaka K et al., 2010).  
The arterial anastomosis is usually tedious because of its small size. The arterial anastomosis is 
usually performed end-to-end with 7-0 or 8-0 nonabsorbable sutures in interrupted fashion 
and the use of surgical loop magnification. Alternatively, an operating microscope can be 
used. After revascularization is complete, flow velocity and signal patterns are checked by 
Doppler ultrasonography (Henrik P et al., 2009; Polak W et al., 2009).  
Biliary reconstruction is technically demanding because of the small diameter and short 
length. More frequently, multiple small ducts are cut flush in the donor’s hilar plate are 
present. As a consequence, the incidence of technical complications, such as leaks and 
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strictures, is significantly higher with LDDT (vs. DDLT). The requirements are a tension-free 
anastomosis and preserving periductal connective tissue to maintain the bile ducts’ 
ascending axial vascular circulation (which originates from the RHA and the superior 
posterior pancreaticoduodenal artery). Biliary reconstruction is by direct anastomosis or 
hepaticojejunostomy (Kim B et al., 2009). Direct duct-to-duct anastomosis is now 
increasingly performed. In general, a duct-to-duct anastomosis is advantageous because it 
reduces operative time, represents a simpler biliary anastomosis, preserves physiologic 
bilioenteric and bowel continuity, preserves the physiologic sphincter mechanism with a 
decreased risk of ascending or reflux cholangitis, eliminates the need for bowel 
manipulation with a decreased risk of intraabdominal contamination and of postoperative 
ileus, results in earlier return of gastrointestinal function, allows easy radiologic access to 
the biliary tract. The decision to stent the biliary anastomosis is controversia (Kim B et al., 
2009). 
Possible options if more than one duct orifice is encountered (Haberal M et al., 2011): 
a. If the ducts are in close proximity or share a common wall, they can be joined together 
and only 1 anastomosis needs to be done.  
b. If the distance between the bile ducts is > 1 cm, two enterotomies may need to be made. 
c. Multiple orifices can be anastomosed to RHD, LHD, or the cystic duct of the recipient.  
d. If only one recipient bile duct is available for anastomosis, the remaining ducts require 
construction of a Roux-en-Y loop.  
e. Very small (< 1mm), distant biliary orifices are sometimes sacrificed and oversewn.  
9.4 Donor left hepatectomy 
Donor left hepatectomy consists of either full left, or left lateral hepatectomy depending on 
the relative donor–recipient size ratio(Humar A et al., 2006; Tanaka K et al., 2010).  
9.4.1 Exposure 
The abdomen is entered through a bilateral subcostal incision and a midline extension. After 
division of the round and falciform ligament, the LHV and MHV are exposed to their 
insertion to the IVC. The left triangular and coronary ligaments are excised to reveal the left 
surface of the LHV. Any accessory or replaced left hepatic artery from the left gastric artery 
is carefully preserved as the gastrohepatic ligament is divided (Humar A et al., 2006).  
9.4.2 Intraoperative cholangiography and Doppler ultrasound 
Intraoperative ultrasonography is performed to study the anatomy of the MHV and the 
LHV. Doppler study is also performed to locate the site of hepatic artery. Cholecystectomy 
is then performed and the cystic duct cannulated for operative cholangiography. The 
location of the proposed division of the left hepatic duct is marked by a large size metal clip 
(Henrik P et al., 2009; Polak W et al., 2009; Humar A et al., 2006).  
9.4.3 Mobilization 
The retrohepatic cava is defined after incising the overlying peritoneum along its lateral 
aspect, exposing the cava up to the LHV junction. Smaller draining veins are ligated or 
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aspect, exposing the cava up to the LHV junction. Smaller draining veins are ligated or 
 
Liver Transplantation – Technical Issues and Complications 
 
26 
clipped as the entire left lobe and caudate lobe are retracted to the LHV, MHV and RHV are 
isolated as they drain into the cava (Humar A et al., 2006; Tanaka K et al., 2010).  
9.4.4 Hilar time 
Hilar dissection is confined to the left side to free the LHA and LPV. Attention should be 
paid to the caudate branches of the LPV when moved back to its origin. The LPV is usually 
longer than the right, and a reasonable segment is isolated and looped. Some surgeons 
advocate preserving the caudate lobe and its dominant vein draining into the vena cava. If a 
large branch of the LHA arising from the left gastric artery is encountered, it must be 
preserved for subsequent reconstruction if needed (Soejima Y, et al., 2008).  
9.4.5 Parenchymal transection 
The Cantlie line is marked at the anterior surface of the liver by diathermy at a plane 
demarcated after temporary occlusion of the LHA and LPV. At the inferior surface of the 
liver, the division plane deviates to the left side of gallbladder fossa to meet the proposed 
dividing line of the LHD. The transection plane is angled to the left after identification of 
tributaries to the MHV. The LHD is cut sharply and the donor side is oversewn (Tan H et 
al., 2007 & Tanaka K et al., 2010). Further transection of the parenchyma is performed along 
the plane of the ligamentum venosus. Once parenchymal transection is complete, 
hemostasis and absence of bile leak are confirmed on both surfaces. The LHA, LPV, and 
LHV in sequence are separately clamped and divided, and the liver segment is immediately 
removed. Some surgeons routinely give heparin before vascular clamping. The vascular 
stumps are oversewn with Prolene sutures and the donor side of the bile duct is closed 
(Henrik P et al., 2009; Polak W et al., 2009).  
9.4.6 Left-sided liver implantation 
The implantation starts with the hepatic vein anastomosis performed in a triangular fashion 
using 5-0 Prolene. Attention should be paid to prevent inversion, especially of the posterior 
wall. There should be no tension on the suture. Depending on its length and diameter, the 
graft portal vein is anastomosed with the LPV, the portal bifurcation, or the portal trunk of 
the recipient, using running 6-0 sutures. At this point, the hepatic vein and portal vein are 
declamped. Arterial anastomosis is performed using interrupted 8-0 sutures . Sharp edges, 
adequate removal of surrounding tissue, and absence of tension or kinks in the anastomosis 
contribute to the success of this procedure. When two significant arteries are present within 
the graft, a good back flow in the second one after the reperfusion of the major one can be a 
good reason to ligate the second one. After revascularization is complete, flow velocity and 
signal patterns are checked by Doppler ultrasonography. Biliary reconstruction is by duct-
to-duct anastomosis or hepaticojejunostomy. Previously, hepatico-jejunostomy was thought 
to be the only reconstruction method for left-liver graft. Recently, more and more surgeons 
perform duct-to-duct anastomosis (Kim B et al., 2009).  
The liver graft is fixed by suturing the falciform ligament to the anterior abdominal wall to 
prevent rotation into the right subphrenic cavity. The latter may lead to graft congestion (as 
a result of MHV kinking) or poor vascular inflow (as a result of folding of the portal vein) 
and ultimately graft failure (Henrik P et al., 2009; Humar A et al., 2006).  
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10. The middle hepatic vein controversy 
The construction of an optimal venous outflow determines the outcome of LDLT. The 
routine anastomosis of the accessory inferior hepatic veins with a diameter larger than 0.5 
cm was accepted by almost all centers. However, there are no defined standards for the 
reconstruction of MHV or its tributaries (Chan SC et al, 2011). 
The MHV is responsible for the drainage segment 4 together with variable part of the 
anterior sector of the right liver (segments 5 and 8) in the great majority of the cases. 
Transection of the drainage territory of the MHV at the time of procurement leads to venous 
congestion of “marginal zones” in both graft and donor remnant (Radtke A et al., 2010).  
Poor venous outflow has been associated with increased sinusoidal pressure, disruption of 
sinusoidal epithelium, hepatic artery thrombosis, impaired liver regeneration, and dismal 
outcome. Such physiologic harm can be particularly detrimental in recipients with relatively 
small grafts and significant portal hypertension, in whom an underlying SFSS situation can 
turn into graft failure or at least lead to severe biliary and/or vascular complications. A 
triangular interrelationship between inflow, outflow, and GRBW ratio has been proposed to 
determine the fate of the graft (Humar A et al., 2006; Tan H et al., 2007).  
When the MHV is not taken with the graft, a variable portion of the anterior sector of the 
right liver remains congested. The relief of the congestion may occur either through 
intraparenchymal communication between the venous outflow of the anterior sector and 
the posterior sector drained by the RHV or by reversal of flow in the anterior branch of 
the portal vein into the posterior branch. The percentage of the congested portion relative 
to the overall volume of the graft, the GRBWR, the presence and the degree of portal 
hypertension, and the compliance of the liver determine the magnitude of graft 
malfunction after transplantation. If the functional mass of the right-lobe graft is adequate 
without the MHV (high GRWR), some degree of congestion may be tolerated early 
posttransplant, until the graft has regenerated or the anterior sector drainage is rerouted 
(Chan SC et al, 2011). 
10.1 Available options for the surgical management of the MHV 
(1) Exclusion of the MHV from the graft: The rationale is that not all right grafts present 
with congestion after reperfusion, and simple RHV anastomosis is sufficient in many cases. 
Obviously, if venous drainage from segments 5 and 8 is predominately via the RHV, 
including the MHV with the right-lobe graft is unnecessary. With the donor MHV clamped 
and reversal of flow in the anterior branch of the portal vein detected by Doppler, the 
temporary occlusion of the right hepatic artery will determine the portion of right liver 
affected by congestion (Chan SC et al, 2011). 
(2) Inclusion of the MHV with the right-lobe graft: This guarantees the most complete 
drainage of the anterior sector of the right graft. Contraindications are a small predicted 
residual liver volume (< 30%) in the donor as this may pose the donor at a higher risk of 
postoperative complications because the regeneration of segment 4 is stunned by the lack of 
adequate venous drainage (Radtke A et al., 2010).  
(3) Inclusion of the distal part of the MHV with the right-lobe graft (leaving the proximal 
remnant in the donor): This technique preserves large segment 4a venous tributaries into the 
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clipped as the entire left lobe and caudate lobe are retracted to the LHV, MHV and RHV are 
isolated as they drain into the cava (Humar A et al., 2006; Tanaka K et al., 2010).  
9.4.4 Hilar time 
Hilar dissection is confined to the left side to free the LHA and LPV. Attention should be 
paid to the caudate branches of the LPV when moved back to its origin. The LPV is usually 
longer than the right, and a reasonable segment is isolated and looped. Some surgeons 
advocate preserving the caudate lobe and its dominant vein draining into the vena cava. If a 
large branch of the LHA arising from the left gastric artery is encountered, it must be 
preserved for subsequent reconstruction if needed (Soejima Y, et al., 2008).  
9.4.5 Parenchymal transection 
The Cantlie line is marked at the anterior surface of the liver by diathermy at a plane 
demarcated after temporary occlusion of the LHA and LPV. At the inferior surface of the 
liver, the division plane deviates to the left side of gallbladder fossa to meet the proposed 
dividing line of the LHD. The transection plane is angled to the left after identification of 
tributaries to the MHV. The LHD is cut sharply and the donor side is oversewn (Tan H et 
al., 2007 & Tanaka K et al., 2010). Further transection of the parenchyma is performed along 
the plane of the ligamentum venosus. Once parenchymal transection is complete, 
hemostasis and absence of bile leak are confirmed on both surfaces. The LHA, LPV, and 
LHV in sequence are separately clamped and divided, and the liver segment is immediately 
removed. Some surgeons routinely give heparin before vascular clamping. The vascular 
stumps are oversewn with Prolene sutures and the donor side of the bile duct is closed 
(Henrik P et al., 2009; Polak W et al., 2009).  
9.4.6 Left-sided liver implantation 
The implantation starts with the hepatic vein anastomosis performed in a triangular fashion 
using 5-0 Prolene. Attention should be paid to prevent inversion, especially of the posterior 
wall. There should be no tension on the suture. Depending on its length and diameter, the 
graft portal vein is anastomosed with the LPV, the portal bifurcation, or the portal trunk of 
the recipient, using running 6-0 sutures. At this point, the hepatic vein and portal vein are 
declamped. Arterial anastomosis is performed using interrupted 8-0 sutures . Sharp edges, 
adequate removal of surrounding tissue, and absence of tension or kinks in the anastomosis 
contribute to the success of this procedure. When two significant arteries are present within 
the graft, a good back flow in the second one after the reperfusion of the major one can be a 
good reason to ligate the second one. After revascularization is complete, flow velocity and 
signal patterns are checked by Doppler ultrasonography. Biliary reconstruction is by duct-
to-duct anastomosis or hepaticojejunostomy. Previously, hepatico-jejunostomy was thought 
to be the only reconstruction method for left-liver graft. Recently, more and more surgeons 
perform duct-to-duct anastomosis (Kim B et al., 2009).  
The liver graft is fixed by suturing the falciform ligament to the anterior abdominal wall to 
prevent rotation into the right subphrenic cavity. The latter may lead to graft congestion (as 
a result of MHV kinking) or poor vascular inflow (as a result of folding of the portal vein) 
and ultimately graft failure (Henrik P et al., 2009; Humar A et al., 2006).  
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10. The middle hepatic vein controversy 
The construction of an optimal venous outflow determines the outcome of LDLT. The 
routine anastomosis of the accessory inferior hepatic veins with a diameter larger than 0.5 
cm was accepted by almost all centers. However, there are no defined standards for the 
reconstruction of MHV or its tributaries (Chan SC et al, 2011). 
The MHV is responsible for the drainage segment 4 together with variable part of the 
anterior sector of the right liver (segments 5 and 8) in the great majority of the cases. 
Transection of the drainage territory of the MHV at the time of procurement leads to venous 
congestion of “marginal zones” in both graft and donor remnant (Radtke A et al., 2010).  
Poor venous outflow has been associated with increased sinusoidal pressure, disruption of 
sinusoidal epithelium, hepatic artery thrombosis, impaired liver regeneration, and dismal 
outcome. Such physiologic harm can be particularly detrimental in recipients with relatively 
small grafts and significant portal hypertension, in whom an underlying SFSS situation can 
turn into graft failure or at least lead to severe biliary and/or vascular complications. A 
triangular interrelationship between inflow, outflow, and GRBW ratio has been proposed to 
determine the fate of the graft (Humar A et al., 2006; Tan H et al., 2007).  
When the MHV is not taken with the graft, a variable portion of the anterior sector of the 
right liver remains congested. The relief of the congestion may occur either through 
intraparenchymal communication between the venous outflow of the anterior sector and 
the posterior sector drained by the RHV or by reversal of flow in the anterior branch of 
the portal vein into the posterior branch. The percentage of the congested portion relative 
to the overall volume of the graft, the GRBWR, the presence and the degree of portal 
hypertension, and the compliance of the liver determine the magnitude of graft 
malfunction after transplantation. If the functional mass of the right-lobe graft is adequate 
without the MHV (high GRWR), some degree of congestion may be tolerated early 
posttransplant, until the graft has regenerated or the anterior sector drainage is rerouted 
(Chan SC et al, 2011). 
10.1 Available options for the surgical management of the MHV 
(1) Exclusion of the MHV from the graft: The rationale is that not all right grafts present 
with congestion after reperfusion, and simple RHV anastomosis is sufficient in many cases. 
Obviously, if venous drainage from segments 5 and 8 is predominately via the RHV, 
including the MHV with the right-lobe graft is unnecessary. With the donor MHV clamped 
and reversal of flow in the anterior branch of the portal vein detected by Doppler, the 
temporary occlusion of the right hepatic artery will determine the portion of right liver 
affected by congestion (Chan SC et al, 2011). 
(2) Inclusion of the MHV with the right-lobe graft: This guarantees the most complete 
drainage of the anterior sector of the right graft. Contraindications are a small predicted 
residual liver volume (< 30%) in the donor as this may pose the donor at a higher risk of 
postoperative complications because the regeneration of segment 4 is stunned by the lack of 
adequate venous drainage (Radtke A et al., 2010).  
(3) Inclusion of the distal part of the MHV with the right-lobe graft (leaving the proximal 
remnant in the donor): This technique preserves large segment 4a venous tributaries into the 
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MHV in its most proximal portion. Inclusion of the distal MHV improves segment V 
drainage but not that of segment VIII (Chan SC et al, 2011). 
(4) Anastomosing the major tributaries draining the anterior sector of the right liver into the 
MHV to the vena cava leaving the MHV with the donor rest liver. Doppler waveform 
characteristics may identify tributaries that could benefit from separate anastomosis. Reversed 
flow in the MHV tributaries may indicate that reconstruction is not required. Reconstructing 
MHV tributaries according to diameter (> 5 mm) has also been recommended. The 
tributaries from segments 5 and 8 are anastomosed to venous conduits of various origins 
that serve as jump grafts. This has been accomplished with the donor inferior mesenteric 
vein, iliac vein, ovarian vein, cryopreserved iliac vein, recipient saphenous vein, umbilical 
vein, LPV, superficial femoral vein, and internal jugular vein. Reconstruction of 
interposition grafts is, preferably, done on the back table; it can also be done after restoration 
of portal flow, in order to first assess the degree of venous congestion. 
Reconstruction of these branches with interposition grafts results in a more complex 
operation, longer operating time, and longer warm ischemia time. Also, a relatively long 
segment of interposition graft makes it more prone to thrombosis (Radtke A et al., 2010). 
Whether one technical approach is sounder than the other is probably not possible to decide. 
Thus, individualized planning is mandatory for the optimal outcome of both donors and 
recipients in the setting of the high degree of variability of MHV, RHV, and IHV drainage. A 
selective approach based on GRBWR, greater or less than 1; graft/recipient standard liver, 
greater or less than 50%; and size of the MHV tributaries, greater or less than 5 mm in 
diameter; is used by the some groups to decide whether the graft will be harvested with or 
without the middle hepatic vein (Chan SC et al, 2011). 
11. Double liver transplant 
If the donor has a large right lobe (> 70% of total liver volume), the remaining left lobe will 
be small (< 30% of total liver volume) and thus will threaten donor safety. An alternative is 
to simultaneously transplant two small liver grafts (left lobe or left lateral segment) from 
two different donors; that is, a double or dual-graft transplant, to solve graft-size 
insufficiency and provide donor safety. The recipient and two donor operations are started 
simultaneously. The first graft is orthotopically positioned in the original left position. The 
second graft is heterotopically positioned to the right-upper-quadrant fossa, rotating it 180°, 
so that the graft’s hilar structures are at the same level as the recipient’s right hilar structures 
(Lu Q, et al., 2010).  
12. Retransplantation  
The only therapeutic option for failing hepatic allograft is a liver retransplant. The most 
common causes are chronic rejection, chronic cholangitis, and vascular complications, small 
for size graft and primary nonfunction. In Re-LDLTs, ethical problems and the timing of the 
retransplant are controversial. Furthermore, availability of LDLT and DDLT for 
retransplants differs in each country or region. Donor selection for Re-LDLTs is difficult. 
The probability of retransplants (with either DDLT or LDLT) is low because of the lack of 
donors. Thus, serious posttransplant complications after LDLT often lead to death, with no 
chance of a retransplant. During the procedure, surgeons encounter difficulty in dissecting 
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surrounding tissues and identifying the important vessels due to the relatively small size 
and short length of vessels in LDLT grafts (Lerner S et al., 2005).  
13. Recipient outcomes and complications of LDLT 
The spectrum of posttransplant complications is not different for LDLT versus DDLT. 
However, the incidence of biliary, and vascular complications may be more common and 
severe in nature than in DDLT. In addition, new problems such as small-for-size syndrome 
have been introduced (Soin A et al., 2010 ).  
13.1 Hepatic artery complications 
13.1.1 Hepatic artery thrombosis (HAT) 
Risk Factors include, recipients body weight < 10 kg or age < 3 years, reconstructing arteries 
with diameters < 3 mm, ABO incompatibility, excessive intraoperative fresh frozen plasma 
transfusion, and elevated hematocrite levels. Doppler ultrasonography has high sensitivity 
for the diagnosis of HAT. By performing serial examinations at frequent intervals during the 
first 1 to 2 weeks posttransplant, HAT can be detected before it becomes clinically obvious. 
Early diagnosis permits immediate thrombectomy and revascularization before the patient 
deteriorates. If there is suspicion for HAT, one can choose to delineate the anatomy with 
angiography or proceed urgent re-exploration. Angiography offers nonoperative method to 
diagnose and potentially treat with balloon angioplasty (Steinbrück K, et al., 2011). 
Management depends on the timing and the clinical condition . Early HAT, once diagnosed 
by ultrasound, the patient is immediately taken to the operating room. The anastomosis is 
taken down. The vessel is cleared of all clot, inspected for intimal injury, and assessed for 
adequate inflow. If good inflow is present, a primary anastomosis is attempted. If adequate 
inflow is not provided, an arterial conduit is anastomosed to the aorta. Postoperatively, the 
patient is closely watched with frequent Doppler. Systemic heparinization is used according 
to coagulation parameters (Steinbrück K, et al., 2011).  
If there is a delay in the diagnosis, or if ultrasound is questionable, selective arteriography 
may be employed to diagnose the site of thrombosis and to begin therapeutic thrombolysis. 
Decisions on retransplantation are made based on the clinical condition, patency of the 
vessels, and appearance of late complications as biliary stricture (Steinbrück K et al., 2011). 
Late HAT is often asymptomatic because of the development of a rich collateral network. 
Attempts at operative revision should not be undertaken, as a large majority survive with 
normal allograft function, and any operative procedure carries the risk of destroying the 
graft-sustaining collaterals. Significant late allograft dysfunction needs careful monitoring 
for septic complications, biloma and cholangitis. Attempts at graft salvage in this population 
are universally unsuccessful (Henrik P et al., 2009; Polak W et al., 2009).  
13.1.2 Hepatic Artery Stenosis (HAS) 
HAS, although usually asymptomatic, will eventually progress to HAT. Frequently, patients 
develop biliary strictures and bile leaks. HAS may be detected on surveillance Doppler. 
Dampened waveforms with decreased resistive indices (RI) and slow peak velocities 
suggest HAS. Stenosis should be suspected when the RI is <0.5 or the systolic ascending  
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MHV in its most proximal portion. Inclusion of the distal MHV improves segment V 
drainage but not that of segment VIII (Chan SC et al, 2011). 
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MHV to the vena cava leaving the MHV with the donor rest liver. Doppler waveform 
characteristics may identify tributaries that could benefit from separate anastomosis. Reversed 
flow in the MHV tributaries may indicate that reconstruction is not required. Reconstructing 
MHV tributaries according to diameter (> 5 mm) has also been recommended. The 
tributaries from segments 5 and 8 are anastomosed to venous conduits of various origins 
that serve as jump grafts. This has been accomplished with the donor inferior mesenteric 
vein, iliac vein, ovarian vein, cryopreserved iliac vein, recipient saphenous vein, umbilical 
vein, LPV, superficial femoral vein, and internal jugular vein. Reconstruction of 
interposition grafts is, preferably, done on the back table; it can also be done after restoration 
of portal flow, in order to first assess the degree of venous congestion. 
Reconstruction of these branches with interposition grafts results in a more complex 
operation, longer operating time, and longer warm ischemia time. Also, a relatively long 
segment of interposition graft makes it more prone to thrombosis (Radtke A et al., 2010). 
Whether one technical approach is sounder than the other is probably not possible to decide. 
Thus, individualized planning is mandatory for the optimal outcome of both donors and 
recipients in the setting of the high degree of variability of MHV, RHV, and IHV drainage. A 
selective approach based on GRBWR, greater or less than 1; graft/recipient standard liver, 
greater or less than 50%; and size of the MHV tributaries, greater or less than 5 mm in 
diameter; is used by the some groups to decide whether the graft will be harvested with or 
without the middle hepatic vein (Chan SC et al, 2011). 
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If the donor has a large right lobe (> 70% of total liver volume), the remaining left lobe will 
be small (< 30% of total liver volume) and thus will threaten donor safety. An alternative is 
to simultaneously transplant two small liver grafts (left lobe or left lateral segment) from 
two different donors; that is, a double or dual-graft transplant, to solve graft-size 
insufficiency and provide donor safety. The recipient and two donor operations are started 
simultaneously. The first graft is orthotopically positioned in the original left position. The 
second graft is heterotopically positioned to the right-upper-quadrant fossa, rotating it 180°, 
so that the graft’s hilar structures are at the same level as the recipient’s right hilar structures 
(Lu Q, et al., 2010).  
12. Retransplantation  
The only therapeutic option for failing hepatic allograft is a liver retransplant. The most 
common causes are chronic rejection, chronic cholangitis, and vascular complications, small 
for size graft and primary nonfunction. In Re-LDLTs, ethical problems and the timing of the 
retransplant are controversial. Furthermore, availability of LDLT and DDLT for 
retransplants differs in each country or region. Donor selection for Re-LDLTs is difficult. 
The probability of retransplants (with either DDLT or LDLT) is low because of the lack of 
donors. Thus, serious posttransplant complications after LDLT often lead to death, with no 
chance of a retransplant. During the procedure, surgeons encounter difficulty in dissecting 
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surrounding tissues and identifying the important vessels due to the relatively small size 
and short length of vessels in LDLT grafts (Lerner S et al., 2005).  
13. Recipient outcomes and complications of LDLT 
The spectrum of posttransplant complications is not different for LDLT versus DDLT. 
However, the incidence of biliary, and vascular complications may be more common and 
severe in nature than in DDLT. In addition, new problems such as small-for-size syndrome 
have been introduced (Soin A et al., 2010 ).  
13.1 Hepatic artery complications 
13.1.1 Hepatic artery thrombosis (HAT) 
Risk Factors include, recipients body weight < 10 kg or age < 3 years, reconstructing arteries 
with diameters < 3 mm, ABO incompatibility, excessive intraoperative fresh frozen plasma 
transfusion, and elevated hematocrite levels. Doppler ultrasonography has high sensitivity 
for the diagnosis of HAT. By performing serial examinations at frequent intervals during the 
first 1 to 2 weeks posttransplant, HAT can be detected before it becomes clinically obvious. 
Early diagnosis permits immediate thrombectomy and revascularization before the patient 
deteriorates. If there is suspicion for HAT, one can choose to delineate the anatomy with 
angiography or proceed urgent re-exploration. Angiography offers nonoperative method to 
diagnose and potentially treat with balloon angioplasty (Steinbrück K, et al., 2011). 
Management depends on the timing and the clinical condition . Early HAT, once diagnosed 
by ultrasound, the patient is immediately taken to the operating room. The anastomosis is 
taken down. The vessel is cleared of all clot, inspected for intimal injury, and assessed for 
adequate inflow. If good inflow is present, a primary anastomosis is attempted. If adequate 
inflow is not provided, an arterial conduit is anastomosed to the aorta. Postoperatively, the 
patient is closely watched with frequent Doppler. Systemic heparinization is used according 
to coagulation parameters (Steinbrück K, et al., 2011).  
If there is a delay in the diagnosis, or if ultrasound is questionable, selective arteriography 
may be employed to diagnose the site of thrombosis and to begin therapeutic thrombolysis. 
Decisions on retransplantation are made based on the clinical condition, patency of the 
vessels, and appearance of late complications as biliary stricture (Steinbrück K et al., 2011). 
Late HAT is often asymptomatic because of the development of a rich collateral network. 
Attempts at operative revision should not be undertaken, as a large majority survive with 
normal allograft function, and any operative procedure carries the risk of destroying the 
graft-sustaining collaterals. Significant late allograft dysfunction needs careful monitoring 
for septic complications, biloma and cholangitis. Attempts at graft salvage in this population 
are universally unsuccessful (Henrik P et al., 2009; Polak W et al., 2009).  
13.1.2 Hepatic Artery Stenosis (HAS) 
HAS, although usually asymptomatic, will eventually progress to HAT. Frequently, patients 
develop biliary strictures and bile leaks. HAS may be detected on surveillance Doppler. 
Dampened waveforms with decreased resistive indices (RI) and slow peak velocities 
suggest HAS. Stenosis should be suspected when the RI is <0.5 or the systolic ascending  
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time (SAT) is >10 msec. The diagnosis should be confirmed by angiography. If diagnosed in 
the immediate postoperative period, planned exploration and revision of the arterial 
anastomosis should be undertaken. Although conventional treatment is either surgical 
repair or a retransplant, percutaneous transluminal angioplasty (PTA) or stent placement is 
becoming predominant (Polak W et al., 2009; Humar A et al., 2006; Tanaka K et al., 2010). 
13.2 Biliary complications 
Biliary complications remain the most common cause of postoperative morbidity and the 
most challenging complications in LDLT recipients, and occasionally graft loss and death. 
Risk factors include, small size or multiple bile duct anastomoses, delayed arterial 
revascularization, HAT, extensive periductal dissection and biliary leaks from the cut-
surface of liver tissue., cytomegalovirus infection, and rejection (Yuan Y & Gotoh M, 2010). 
13.2.1 Biliary leaks 
The sources of biliary leaks could be from (1) The cut surface of the liver, (2) The site of the 
biliary anastomosis, (3) The site of the intestinal anastomosis, and (4) The exit site of a T tube 
(or other types of external stents). Anastomotic leaks are caused either by ischemic necrosis 
of the end of the bile duct or by a technically unsatisfactory anastomosis. Leaks can manifest 
as sudden onset of biliary drainage from the abdominal drain, or they may present by 
intraabdominal collection, referred to as “biloma”. Biloma can be detected by 
ultrasonography or CT scan before the recipient becomes symptomatic (Khalaf H et al., 
2011).  
Leaks from the cut-surface can be managed expectantly as long as it is adequately drained. 
Leaks from the anastomosis also can be successfully managed with nonsurgical treatment if 
they are small and localized. Stenting with percutaneous transhepatic cholangiography 
(PTC) or ERCP at the anastomotic site can resolve minor leaks. If the anastomosis is 
seriously disrupted, surgical revision is the safest approach (Kohler S et al. 2009).  
For bilomas, percutaneous drainage is performed. Once the patient is stabilized, ERCP or 
PTC is performed, and a stent is placed to bypass the flow of bile through the leak. If 
excessive leak is diagnosed in the immediate post operative period, operative exploration, 
drainage, and revision of the anastomosis may be warranted (Khalaf H et al., 2011).  
13.2.2 Biliary strictures 
Risk factors include, CMV infection, hepatic artery complications, ABO incompatible 
transplantation, and prior anastomotic leak. The patient may present with asymptomatic 
elevation of cholestatic liver enzymes or may present with manifestations of cholangitis: 
fever, jaundice abdominal pain. Ultrasound scan is the initial imaging technique, however, 
ductal dilatation is often late. Direct cholangiogram is the gold-standard for diagnosing 
biliary strictures. Any patient with biliary stenosis, especially with multiple strictures, 
should be evaluated for HAT (Kohler S et al. 2009). Early strictures are often amenable to 
endoscopic or transhepatic intervention with good long-term results. Operative treatment is 
indicated for complications of percutaneous therapies and intractable strictures. Patients 
with strictures associated with HAT should continue to undergo percutaneous treatment. 
Operative exploration should be avoided, as it disrupts the arterial collaterals supplying the  
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graft. Evaluation for retransplantation should occur if the strictures affect graft function, 
associated with bilomas and frequent bouts of cholangitis (Yuan Y and Gotoh M, 2010). 
13.3 Portal vein thrombosis (PVT) 
Risk factors include, native PVT, the use of interposition grafts, extensive collaterals, 
portosystemic shunts and splenectomy. The patient may present with ascites, elevated LFTs, 
and splenomegaly, and gastrointestinal hemorrhage. Diagnosis is made with Doppler and 
confirmed by venography. Early PVT is treated with surgical thrombectomy and revision of 
the anastomosis. Late PVT may require surgical shunting to decompress the portal system 
as treatment of the complications of portal hypertension (Kyoden Y, et al., 2008). 
13.4 Hepatic venous outflow block (HVOB) 
Risk factors include, technical causes, graft rotation and kinking of the anastomosis and 
graft regeneration with subsequent rotation. HVOB is occasionally diagnosed during 
transplant surgery on the basis of swelling and congestion of the graft. The diagnosis is 
confirmed if intraoperative ultrasonography detects a flat waveform in the hepatic vein. 
Postoperatively, the clinical presentation includes ascites, elevated liver function test results, 
splenomegaly, variceal bleeding, lower-extremity edema, and kidney dysfunction. A 
persistent monophasic wave pattern from the hepatic vein on Doppler ultrasonography 
suggests substantial stenosis. Subsequent angiography with direct contrast can confirm the 
diagnosis; the pressure gradient across the stenosis is typically > 3 to 10 mm Hg. 
Management is by percutaneous balloon venoplasty. Multiple procedures are often 
required. Stent placement may be required for cases that do not respond to simple 
dilatation. In severe cases, HVOB may cause graft dysfunction or failure, requiring a 
retransplantion (Ikeda O, et al., 2010). 
13.5 Abdominal compartment syndrome 
Causes include, oversized allograft as in adult to pediatric LDLT, closure with considerable 
intra-abdominal tension, and intestinal edema due to prolonged portal vein clamping. The 
patient presents with, respiratory compromise, renal insufficiency, hemodynamic instability, 
and allograft thrombosis because of excessive pressure and positional kinking of the graft.  
13.6 The ‘small for size’ liver graft syndrome (SFSS) 
SFSS is a clinical syndrome, which occurs in the presence of a reduced mass of liver 
insufficient to maintain normal liver function. It is characterized by a combination of early 
postoperative progressive cholestasis, persistent portal hypertension, ascites, kidney failure, 
and coagulopathy. Microscopic features include cholestasis with hepatocyte ballooning, 
vacuolar degeneration, sinusoidal disruption, steatosis, and centrilobular necrosis. SFSS 
reduces the graft survival rate and increases the mortality rate (Selvaggi G& Tzakis A, 2009). 
13.6.1 Pathophysiology 
A partial liver graft transplanted into an adult recipient is, by definition, a small-for-size 
graft. Such a graft is, however, well tolerated when it is not under a critical size. The 
pathogenesis of the syndrome is primarily tied to graft volume, but three other factors have 
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time (SAT) is >10 msec. The diagnosis should be confirmed by angiography. If diagnosed in 
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graft. Evaluation for retransplantation should occur if the strictures affect graft function, 
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patient presents with, respiratory compromise, renal insufficiency, hemodynamic instability, 
and allograft thrombosis because of excessive pressure and positional kinking of the graft.  
13.6 The ‘small for size’ liver graft syndrome (SFSS) 
SFSS is a clinical syndrome, which occurs in the presence of a reduced mass of liver 
insufficient to maintain normal liver function. It is characterized by a combination of early 
postoperative progressive cholestasis, persistent portal hypertension, ascites, kidney failure, 
and coagulopathy. Microscopic features include cholestasis with hepatocyte ballooning, 
vacuolar degeneration, sinusoidal disruption, steatosis, and centrilobular necrosis. SFSS 
reduces the graft survival rate and increases the mortality rate (Selvaggi G& Tzakis A, 2009). 
13.6.1 Pathophysiology 
A partial liver graft transplanted into an adult recipient is, by definition, a small-for-size 
graft. Such a graft is, however, well tolerated when it is not under a critical size. The 
pathogenesis of the syndrome is primarily tied to graft volume, but three other factors have 
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been proved to contribute to its occurrence, (1) functional liver mass (graft volume, steatosis, 
donor age), (2) recipient status and the severity of hepatic disease at the time of the 
transplant, and (3) graft perfusion (portal hypertension, impaired venous outflow, and 
immune-mediated cellular infiltration) (Dahm F et al., 2005). 
Reduced intrahepatic vascular bed with higher portal flow per gram of remnant liver results 
in increased portal pressure. Following reperfusion, portal vein flow (PVF) is inversely 
related to graft size, while hepatic artery flow is reduced proportionately to graft size. 
Impaired HA flow is results from increased PVF. Enhanced PVF induces shear stress and 
endothelial injury with progressive alterations of hepatic microcirculation. Shear stress is 
responsible for up-and-down regulation of vasoregulatory genes, alteration of tissue repair 
mechanisms, and imbalance of intracellular homeostasis. Liver regeneration may be 
hindered by increased hepatic portal resistance (Selvaggi G & Tzakis A, 2009).  
13.6.2 Prevention and treatment  
Different strategies have been proposed (Selvaggi G& Tzakis A, 2009; Dahm F et al., 2005): 
a. Pharmacologic approach aiming to reduce the portal pressure. 
b. Ischemic preconditioning of the liver to protect the parenchyma against prolonged 
ischemic periods. 
c. Extracorporeal liver support to enhance of liver regeneration. 
d. Surgical techniques to control high PVF and PVP after graft reperfusion: 
• Splenic artery ligation (SAL) with or without splenectomy. 
• Meso-caval shunt with downstream ligation of the superior mesenteric vein.  
• Graded porto-caval shunt, portal vein band, or porto-mesenteric disconnection. 
e. Retransplantation  
14. Donor outcomes and complications 
14.1 Recovery of the liver function after donor hepatectomy 
Early aminotransferase elevation is common after donor hepatectomy. Liver enzymes peak 
early, in the first 48 hours, whereas bilirubin tends to peak later, approximately 
postoperative day 3. Exaggerated enzyme leak in the absence of synthetic dysfunction 
suggests focal ischemia, which can occur for example with a devascularized segment 4 
following lateral segmentectomy. Prolonged or exaggerated cholestasis in the absence of a 
biliary complication suggests ischemia or a small residual volume. Unusual clinical patterns 
of liver function should be investigated with ultrasound scanning, duplex sonography 
and/or computed tomography (Dindo D et al., 2004). 
14.2 Donor complications 
In worldwide reports donor morbidity ranged between 0% and 67%, depending on the 
individual definition and recognition of morbidity. Donor morbidity is influenced by 
variables including center experience, extent and technique of hepatic resection, anatomic 
factors, and general health of the donor (Fernandes R, et al., 2010). The lack of a standardized 
assessment of perioperative complications is a limitation to the analysis of donor-related 
morbidity. A universally accepted classification system for living donor complications 
would be ideal. This would allow accurate comparisons and help establish trends in the 
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assessment of morbidity. In this regard, modifications of the Clavien scale for LDLT is 
gaining acceptance as the standard for reporting surgical morbidity. This system consists of 
four grades of severity (Clavien P et al. 1994; Dindo D et al., 2004). 
Grade I consists of complications that are not life threatening and do not result in any 
significant morbidity, such as superficial wound infections or transient bile leaks.  
Grade II includes complications that have the potential to be life threatening or those 
requiring drug therapy or <1 foreign blood unit, but does not require therapeutic invasive 
therapy and does not result in residual disability. An example is any infectious sequelae 
requiring antimicrobial treatment, postoperative bleeding without requiring relaparotomy 
and local controlled deep venous thrombosis without thrombembolic complications. 
Grade III complications are potentially life threatening, requiring invasive intervention, 
blood transfusions and/or leads to readmission into the ICU, but does not lead to residual 
disability. For example, postoperative bleeding requiring relaparotomy, bile leak requiring 
endoscopic or surgical procedures, deep wound infections requiring relaparotomy or 
interventional drainage and deep venous thrombosis with pulmonary embolism 
Grade IV includes any complication with residual or lasting disability or that leads to death. 
Examples include liver failure requiring liver transplantation.  
The majority of donor morbidity are Grades I and II, with Grade III complications less 
frequent. The most commonly reported complications are listed in Table 3. 
 
Medical complications 
1. Transient cholestasis  
2. Pulmonary complications: atelectasis, pneumonia, pleural effusion, and pneumothorax 
3. Hypophosphatemia  
4. Thrombocytopenia 
5. Psychiatric complications 
6. Urinary infection  
General Surgical complications 
1. Wound infection 
2. Postoperative bleeding 
3. Deep vein thrombosis and pulmonary embolism 
4. Incisional hernia  
5. Nerve palsy  
6. Bowel obstruction, ileus  
Hepatectomy related complications 
1. Aborted donation  
2. Portal vein thrombosis 
3. Biliary tract complications: leaks, biloma, strictures 
4. Liver failure, hepatic encephalopathy  
Table 3. The most commonly reported complications in living donors 
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assessment of perioperative complications is a limitation to the analysis of donor-related 
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assessment of morbidity. In this regard, modifications of the Clavien scale for LDLT is 
gaining acceptance as the standard for reporting surgical morbidity. This system consists of 
four grades of severity (Clavien P et al. 1994; Dindo D et al., 2004). 
Grade I consists of complications that are not life threatening and do not result in any 
significant morbidity, such as superficial wound infections or transient bile leaks.  
Grade II includes complications that have the potential to be life threatening or those 
requiring drug therapy or <1 foreign blood unit, but does not require therapeutic invasive 
therapy and does not result in residual disability. An example is any infectious sequelae 
requiring antimicrobial treatment, postoperative bleeding without requiring relaparotomy 
and local controlled deep venous thrombosis without thrombembolic complications. 
Grade III complications are potentially life threatening, requiring invasive intervention, 
blood transfusions and/or leads to readmission into the ICU, but does not lead to residual 
disability. For example, postoperative bleeding requiring relaparotomy, bile leak requiring 
endoscopic or surgical procedures, deep wound infections requiring relaparotomy or 
interventional drainage and deep venous thrombosis with pulmonary embolism 
Grade IV includes any complication with residual or lasting disability or that leads to death. 
Examples include liver failure requiring liver transplantation.  
The majority of donor morbidity are Grades I and II, with Grade III complications less 
frequent. The most commonly reported complications are listed in Table 3. 
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14.2.1 Biliary complications 
Biliary leaks after left lateral segment donation range from 5% to 10%, with a higher rate (up 
to 13%) in right hepatectomy. The source of leaks are typically the cut surface of the liver, 
however, the stump of the bile duct could be the source. Most leaks are diagnosed in the 
early postoperative period during the initial hospitalization by assessment of postoperative 
drain fluid, though late leaks are also reported. For most cases, observation and simple 
external drainage of the otherwise asymptomatic patient will be sufficient to avoid sepsis 
until the leak spontaneously resolves. More severe leaks require an interventional radiology 
procedure, endoscopic biliary, or reoperation (Yuan Y & Gotoh M. 2010). 
Strictures are reported less commonly but will more likely require invasive intervention. 
Bile duct strictures result from injury to the right, left or common hepatic duct during 
hepatectomy. Bile duct strictures may increase the lifetime risk of the donor for developing 
secondary biliary cirrhosis (Yuan Y, & Gotoh M. 2010). 
14.2.2 Acute liver failure 
Early postoperative acute liver failure suggests a vascular event like portal vein or arterial 
thrombosis, or acute outflow obstruction. Although acute vascular events can be reversible 
with immediate intervention (usually surgical), the patient should be listed for 
transplantation because survival in acute liver failure is directly related to the timing of liver 
replacement before the development of multiorgan failure or neurological injury (Fernandes 
R, et al, 2010; Dindo D et al., 2004).  
14.2.3 Small-for-size remnant liver 
Liver failure in the absence of an early technical complication like arterial or portal venous 
thrombosis is likely to be caused by a small-for-size remnant liver. Remnant liver volumes 
less than 30%, especially if there is underlying steatosis have been associated with 
prolonged cholestasis, portal hypertension, and normal or near enzymes and synthetic 
function after hepatectomy (“small-for size-syndrome”), especially in the presence of 
moderate steatosis. Outcome data for small for size syndrome in donors are sparse. The 
presence of a concomitant complication like bile leak, infection, or bleeding may exacerbate 
the poor recovery in a small-for-size liver. Treatment of small-for-size syndrome is 
supportive care and avoidance of further injury to the remnant (Fernandes R et al., 2010). 
15. Living donor mortality  
Liver donation puts the donor at risk of medical and surgical complications and even death. 
Unfortunately, the actual risk of death after a donor hepatectomy is unknown, because of 
the absence of sufficient database to allow an accurate determination of this infrequent but 
devastating outcome. When death occurs in a healthy donor, there are exceptional 
consequences. A donor death will have a devastating effect not only on the families and 
friends of the donor and recipient but also on all the clinical staff involved in the procedure. 
The impact of death may spread to other potential donors and recipients, and brings 
negative publicity and potential economic damage to the transplant center (Trotter J, 2006; 
Hashikura Y et al., 2009).  
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Placing a healthy individual at risk of death for a procedure that does not directly benefit 
him or her needs to be balanced by the autonomy and the psychological benefit to the 
donor. If a donor gives informed consent and if the transplant team is prepared to undertake 
the procedure, where is the problem?(Akabayashi A et al., 2004; B Ringe & R Strong 2008) 
The estimated donor mortality rate is 0.5%. The causes of death include, pulmonary 
embolism, pulmonary infection due to uncommon pathogen, emphysematous gastritis, liver 
failure due to congenital lipodystrophy and non-alcoholic steatohepatitis, acute pancreatitis 
and cerebral hemorrhage. Donor suicide was also reported. The exact number of live liver 
donor mortality in the world is not available because no central reporting agency exists. 
Current estimates of donor death rates are derived from either survey data or single-center 
reports. The use of survey data (in which transplant programs are retrospectively queried 
regarding clinical outcomes) is inexact because of incomplete follow-up of all donor 
outcomes and bias toward reporting favorable results (Trotter, J. et al., 2006). Single-center 
reports are likely to provide more complete follow-up data but, may be biased and are 
limited by the relatively small numbers of cases. In the absence of a definitive means to 
record all donor deaths, the medical literature has included reports of deaths that in many 
cases are based on verbal communications, circular references, or frankly unsubstantiated 
outcomes. As a result, the actual number of donor deaths after LDLT is difficult to ascertain 
and is a subject of considerable speculation (Trotter J 2006; Akabayashi A et al., 2004) 
The first donor death reported in the world was related to a fatal pulmonary embolus 
occurring in an adult-to-child living donor liver transplantation and was reported in the 
literature in detail. The first reported death in the United States was related to anaphylaxis 
secondary to medication, also in a left lateral segment donor (Trotter J 2006 B Ringe &R 
Strong 2008). The first death reported from Asia occurred in Kyoto, Japan (Akabayashi A et 
al., 2004). The donor was a mother in her late forties donated the right lobe of her liver to her 
daughter with biliary atresia. The mother fell into liver failure and underwent an 
unsuccessful domino liver transplant from a donor with a metabolic disease. Histological 
examination of the donor liver revealed that she had nonalcoholic steatohepatitis (NASH).  
In Egypt, the number of LDLT procedures performed annually has increased rapidly in the 
past few years (Abdeldayem H et al., 2008 & 2009). In January, 2010, the number of LDLT 
procedures performed in Egypt topped out to more than one thousand procedures, done in 
11 centers. The case number 1000 had been performed at the National Liver Institute in 
Menoufeyia. Although the author is aware of at least 6 deaths among living donors in 
Egypt. the reported deaths were only two. While one case has apparently been fully 
reported in the literature, the second death was reported in brief in the proceedings of the 
international congress of organ transplantation, in November 2008 (Abdeldayem H et al., 
2008 ) The first death was a 45 year-old male who donated the right hepatic lobe to his 
brother and died of sepsis from bile leak 1 month after donation (El-Meteini M et al., 2010). 
The second donor was a 22 year-old male who donated his right lobe to his father, suffered 
from massive intraoperative bleeding from the stump of the portal vein and died of 
multisystem organ failure after 10 days (Abdeldayem H et al., 2009).  
15.1 What is the acceptable risk of mortality to the donor? 
The main issue is what the acceptable risk of mortality to the donor is and, who should 
determine if this risk is acceptable? ? Donors may be willing to accept high rates of mortality 
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14.2.1 Biliary complications 
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procedure, endoscopic biliary, or reoperation (Yuan Y & Gotoh M. 2010). 
Strictures are reported less commonly but will more likely require invasive intervention. 
Bile duct strictures result from injury to the right, left or common hepatic duct during 
hepatectomy. Bile duct strictures may increase the lifetime risk of the donor for developing 
secondary biliary cirrhosis (Yuan Y, & Gotoh M. 2010). 
14.2.2 Acute liver failure 
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thrombosis, or acute outflow obstruction. Although acute vascular events can be reversible 
with immediate intervention (usually surgical), the patient should be listed for 
transplantation because survival in acute liver failure is directly related to the timing of liver 
replacement before the development of multiorgan failure or neurological injury (Fernandes 
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thrombosis is likely to be caused by a small-for-size remnant liver. Remnant liver volumes 
less than 30%, especially if there is underlying steatosis have been associated with 
prolonged cholestasis, portal hypertension, and normal or near enzymes and synthetic 
function after hepatectomy (“small-for size-syndrome”), especially in the presence of 
moderate steatosis. Outcome data for small for size syndrome in donors are sparse. The 
presence of a concomitant complication like bile leak, infection, or bleeding may exacerbate 
the poor recovery in a small-for-size liver. Treatment of small-for-size syndrome is 
supportive care and avoidance of further injury to the remnant (Fernandes R et al., 2010). 
15. Living donor mortality  
Liver donation puts the donor at risk of medical and surgical complications and even death. 
Unfortunately, the actual risk of death after a donor hepatectomy is unknown, because of 
the absence of sufficient database to allow an accurate determination of this infrequent but 
devastating outcome. When death occurs in a healthy donor, there are exceptional 
consequences. A donor death will have a devastating effect not only on the families and 
friends of the donor and recipient but also on all the clinical staff involved in the procedure. 
The impact of death may spread to other potential donors and recipients, and brings 
negative publicity and potential economic damage to the transplant center (Trotter J, 2006; 
Hashikura Y et al., 2009).  
 
Living Donor Liver Transplantation 
 
35 
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donor mortality in the world is not available because no central reporting agency exists. 
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reports. The use of survey data (in which transplant programs are retrospectively queried 
regarding clinical outcomes) is inexact because of incomplete follow-up of all donor 
outcomes and bias toward reporting favorable results (Trotter, J. et al., 2006). Single-center 
reports are likely to provide more complete follow-up data but, may be biased and are 
limited by the relatively small numbers of cases. In the absence of a definitive means to 
record all donor deaths, the medical literature has included reports of deaths that in many 
cases are based on verbal communications, circular references, or frankly unsubstantiated 
outcomes. As a result, the actual number of donor deaths after LDLT is difficult to ascertain 
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occurring in an adult-to-child living donor liver transplantation and was reported in the 
literature in detail. The first reported death in the United States was related to anaphylaxis 
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al., 2004). The donor was a mother in her late forties donated the right lobe of her liver to her 
daughter with biliary atresia. The mother fell into liver failure and underwent an 
unsuccessful domino liver transplant from a donor with a metabolic disease. Histological 
examination of the donor liver revealed that she had nonalcoholic steatohepatitis (NASH).  
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from massive intraoperative bleeding from the stump of the portal vein and died of 
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if the life of a loved one is in jeopardy. But what mortality rate is acceptable when the donor 
understands the risks and coercion has been excluded? There has to be a balance between 
the risk incurred by the donor and what is acceptable to the recipient, the society, and. the 
medical community (Trotter J 2006; Hashikura Y et al., 2009; Akabayashi A et al., 2004;  
B Ringe & R Strong 2008; Abdeldayem H et al., 2008 & 2010, Abdullah K et al., 2005, 2007) 
16. Transparency and LDLT 
Many, including the author, believe that, the true death, and complication rates among both 
the donors and the recipients in LDLT are underestimated. As clinicians involved in the 
evaluation of LDLT, we strive to present accurate information on the risks of the procedure. 
Because of the discrepancy found between published and unpublished data, the dilemma 
between reporting rumor vs. reporting facts currently prevails. The reluctance to publish 
any death or serious complication, although understandable in a fraught medicolegal 
environment, is not good for patient care or the procedure of LDLT itself. Potential liver 
transplant donors and recipients are best served by accurate information derived from 
genuine transparency. To maintain truly informed consent, it is imperative that all serious 
complications and deaths be reported. Transplant centers must be fully aware of their own 
responsibility: being honest to themselves and their patients. Secrecy is unacceptable, as it leads to 
gossip and speculation by others. If the mortality of this surgery is truly as high as reported 
by some editorialists, a very different message needs to be conveyed to the patients (Ringe & 
R Strong 2008; Abdeldayem H et al., 2008, 2009 &2010; Abdullah K et al., 2005& 2007). To be 
“transparent” or not to be? That’s the question!, … and the answer is clear. 
17. Conclusions 
LDLT will continue to play an important role for many patients who have no chance of 
receiving an organ from a deceased donor in timely fashion. This procedure demands 
technical expertise in both hepatobiliary surgery and whole-liver transplantation and hard 
work of multidisciplinary medical team. Every step requires attention and should be 
planned and performed meticulously. The main drawback with LDLT is the potential for 
donor morbidity and mortality. In order to promote living donation, absolute transparency 
about the risks and benefits of this procedure is mandatory.  
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1. Introduction 
Since the first successful operation in 1989, living donor liver transplantation (LDLT) for 
children with end-stage liver diseases has emerged as an alternative to cadaveric liver 
transplantation. (Strong et al., 1990) The applicability of LDLT was extended to adult 
patients in 1994. (Kiuchi et al., 1999) Justification of LDLT has evolved from increased organ-
waiting times, wait-list morbidity and mortality of transplant candidates. (Renz & Busuttil, 
2000) The left lobe or the left lateral segment of an adult liver is most often of adequate size 
for donation to a child recipient. However in the adult, the right hepatic lobe transplantation 
is usually the procedure of choice to provide adequate liver volume to the recipient. 
(Nakamura et al., 2002) 
By having a thorough and accurate knowledge of vascular variants, the transplant surgeon 
can adopt the optimal techniques for vascular reconstruction, with the intent to provide an 
adequate inflow and outflow through liver parenchyma and to avoid postoperative vascular 
complications.  
The present chapter reviews the surgical anatomy of the hepatic artery (HA), arterial 
reconstruction techniques as applied to LDLT, and postoperative arterial complications. 
2. Preoperative assessment of hepatic arterial anatomy  
Hepatic arterial anomalies are present in almost half of the living donors. (Macdonald et al., 
2005) To accomplish a successful and uncomplicated operation, preoperative assessment of 
anatomy of hepatic vasculature is of paramount importance for both donor and recipient. 
Preoperative work-up may involve computed tomography (CT), ultrasonography (US) 
including Doppler imaging, magnetic resonance (MR) imaging, and catheter angiography. 
Conventional angiography was substituted by three-dimensional computer tomography (3D 
CT) angiography which is a safer, more convenient, cheaper, and better-tolerated procedure 
for determination of hepatic arterial anatomy. (Winter et al., 1995; Coskun et al., 2005)  
CT has progressed from dual slice CT to 64-Multidetector Computed Tomography (MDCT) 
(Johnson & Fishman, 2006), which represents a non-invasive technological advance that 
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permits high-speed and high-resolution helical imaging of the entire liver volume during a 
single breath-hold. (Johnson & Fishman, 2006)  
CT angiography has become a key component of state-of-the-art imaging. The 
reconstruction of CT angiographic data sets obtained on 16- and 64-section scanners may 
result in 1000–5000 images per examination. The large size of the data set makes it 
impractical to extract all the information present by using standard two-dimensional 
techniques and makes clear the importance of volume imaging and 3D image display. 
(Fishman et al., 2006) The 3D high-quality reconstruction images are easy for post editing, 
and make possible to observe the origin, flow pattern and branches of the hepatic artery in 
fine anatomic details, from multiple angles, positions and layers, as well as adjacent 
structures. (Huang et al., 2009) Although 2D data sets show small arteries to better 
advantage than 3D multidetector CT angiography  (MDCTA), the 3D MDCT angiograms 
provide a useful overview of hepatic anatomy. (Stemmler et al., 2004) 
Radiologists now have workstations that provide capabilities for evaluation of these data 
sets by using a range of software programs and processing tools. Although different systems 
have unique capabilities and functionality, all provide the options of volume rendering (VR) 
and maximum intensity projection (MIP) for image display and analysis. In the MIP 
technique, only the pixel of highest intensity is used to calculate each line of pixel data 
through the viewed object and about 90% of data is discarded. A cine loop of multiple MIP 
images can be incorporated to facilitate determination of the vascular interrelations. In 
contrast, in the VR technique, all the helical CT data set is used for image reconstruction, 
thus multiple overlapping vessels, spatial relations between the arteries and the viscera, and 
arteries with small diameters can be displayed. (Fishman et al., 2006)  
MDCT is a valuable evaluation of potential living liver donors because it provides an 
excellent pre-operative mapping of the hepatic arterial, hepatic, and portal venous systems 
of the potential donors prior LDLT, a comprehensive assessment of the liver parenchyma 
(e.g. fatty infiltration) and of many other intra-abdominal diseases or abnormalities, an 
accurate measurement of graft and remnant liver volume, and an excellent defining of the 
curved virtual hepatectomy plane that provides sufficient volume to satisfy the metabolic 
demands of both donors and recipients. (Alonso-Torres et al., 2005; Stemmler et al., 2004) 
The most critical aspect of imaging potential liver donors is the accurate depiction of the 
origin and course of the artery to segment IV. Unlike currently available conventional 
helical scanners, MDCTA results in 1.25-mm resolution. If the acquisition parameters and 
timing of the contrast bolus are optimized, this resolution allows even a tiny artery to be 
viewed with minor interruption in adjacent slices or with no interruption in 3D models. 
MR volumetry, venography, angiography, and cholangiography with 3D reconstruction is 
considered by some authors to be sufficient for all major imaging evaluation for LDLT. 
(Cheng et al., 2001, Sahani et al., 2004) 
With the advantage of advanced imaging techniques used pretransplant, now it is possible 
to identify the anatomical type of hepatic artery (HA) according to Michels classification 
(Tabel 1). 
There was no significant difference observed in the overall incidence of arterial 
complications between grafts with normal and abnormal anatomy. (Soin et al., 1996) 
Anomalies of hepatic arterial vasculature occur in one-third of all livers and do not 
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compromise graft outcome unless multiple anastomoses or direct anastomosis to the 
recipient aorta are required for arterial reconstruction. (Soin et al., 1996) 
Type Description 
I Entire hepatic trunk arising from CHA 
II Replaced LHA arising from LGA 
III Replaced RHA arising from SMA 
IV Replaced LHA and replaced RHA 
V Accessory LHA arising from LGA 
VI Accessory RHA arising from SMA 
VII Accessory LHA and accessory RHA 
VIII Replaced RHA and accessory LHA or replaced LHA and accessory RHA 
IX Entire hepatic trunk arising from SMA 
X Entire hepatic trunk arising from LGA 
Table 1. Michels classification of the anatomical types of hepatic artery. (Michels, 1955 as 
cited in Coskun et al., 2005) 
Hepatic arterial branching patterns do not correlate well with the presence of anomalous 
biliary drainage. In patients with normal hepatic vascular anatomy, biliary anomalies are 
more frequent than in those with anomalous vascular anatomy (50% versus 30%). 
(Macdonald et al., 2005) Arterial blood supply to the left lobe often shows variations such as 
multiple branches, aberrant left hepatic artery (Sakamoto et al., 2002), whereas the right 
hepatic artery is often unique. (Kishi et al., 2004) Anatomic variations in graft hepatic 
arteries are classified by Takatsuki et al. into 3 types (Figure 1): Type I, single pedicle with 
(Ia) or without (Ib) aberrant artery (left hepatic artery (HA) from the left gastric artery or 
right HA from the superior mesenteric artery); Type II, double pedicles with (2a) or without 
(2b) aberrant artery; and Type III, equal to or more than three pedicles. (Takatsuki et al., 
2006) The arterial reconstruction is anticipated based on this classification. Type I of arterial 
vasculature will allow the reconstruction of only one artery. Type II and III will necessitate a 
very careful intraoperative assessment of the arterial flow and an elaborated decision for the 
arterial reconstruction.  
 
Fig. 1. Type I, single pedicle; Type II, double pedicles; and Type III, equal to or more than 
three pedicles. RL – right lobe, LL – left liver (modified after Takatsuki et al., 2006) 
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compromise graft outcome unless multiple anastomoses or direct anastomosis to the 
recipient aorta are required for arterial reconstruction. (Soin et al., 1996) 
Type Description 
I Entire hepatic trunk arising from CHA 
II Replaced LHA arising from LGA 
III Replaced RHA arising from SMA 
IV Replaced LHA and replaced RHA 
V Accessory LHA arising from LGA 
VI Accessory RHA arising from SMA 
VII Accessory LHA and accessory RHA 
VIII Replaced RHA and accessory LHA or replaced LHA and accessory RHA 
IX Entire hepatic trunk arising from SMA 
X Entire hepatic trunk arising from LGA 
Table 1. Michels classification of the anatomical types of hepatic artery. (Michels, 1955 as 
cited in Coskun et al., 2005) 
Hepatic arterial branching patterns do not correlate well with the presence of anomalous 
biliary drainage. In patients with normal hepatic vascular anatomy, biliary anomalies are 
more frequent than in those with anomalous vascular anatomy (50% versus 30%). 
(Macdonald et al., 2005) Arterial blood supply to the left lobe often shows variations such as 
multiple branches, aberrant left hepatic artery (Sakamoto et al., 2002), whereas the right 
hepatic artery is often unique. (Kishi et al., 2004) Anatomic variations in graft hepatic 
arteries are classified by Takatsuki et al. into 3 types (Figure 1): Type I, single pedicle with 
(Ia) or without (Ib) aberrant artery (left hepatic artery (HA) from the left gastric artery or 
right HA from the superior mesenteric artery); Type II, double pedicles with (2a) or without 
(2b) aberrant artery; and Type III, equal to or more than three pedicles. (Takatsuki et al., 
2006) The arterial reconstruction is anticipated based on this classification. Type I of arterial 
vasculature will allow the reconstruction of only one artery. Type II and III will necessitate a 
very careful intraoperative assessment of the arterial flow and an elaborated decision for the 
arterial reconstruction.  
 
Fig. 1. Type I, single pedicle; Type II, double pedicles; and Type III, equal to or more than 
three pedicles. RL – right lobe, LL – left liver (modified after Takatsuki et al., 2006) 
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A rare anatomical variant is worth mentioning. In Fig. 2 it is depicted a communication 
between a normal right medial arterial branch emerging from proper hepatic artery and a 
replaced right lateral arterial branch emerging from superior mesenteric artery. This 
communication is favorable by avoiding the reconstruction of both branches. Both branches 
are cut proximal to the interconnection. Only the larger donor’s artery is used to perform the 
arterial anastomosis with the receptor’s proper hepatic artery.  
  
Fig. 2. A) Dissection of hepatic hilum with the identification of a communication between a 
normal right medial arterial branch emerging from proper hepatic artery and a replaced 
right lateral arterial branch emerging from superior mesenteric artery. B) Arterial 
anastomosis is completed between the donor’s hepatic branch from superior mesenteric 
artery and recipient’s proper hepatic artery 
3. Reconstruction techniques of the liver arterial vasculature 
During hilar dissection in donor operation, the HA and portal vein of the donor are 
individually exposed and carefully divided. In left grafts, the proper HA is exposed up to 
the bifurcation of the left (or middle) HA and the right HA. In right grafts, the right HA is 
identified and isolated to the right side of the hepatic duct. The division point of HA is 
determined by the length and size of the artery, its relationship with the cutting plane of the 
liver, and the position of the arteries. (Takatsuki et al., 2006) Division of the donor vessels at 
a point further distal to the main trunk than would be considered ideal for donor protection. 
Anastomosis of first- or second-order vascular branches is a requirement of LDLT. (Marcos 
et al., 2001) 
The reconstruction technique of the liver arterial vasculature is selected by the surgeon 
based on the anatomical arterial variants, differences in vessel caliber, length and quality of 
recipient HA (i.e. aneurysm, stenosis, intimal dissection, inflammation of the porta hepatis, 
inadvertent injury of donor or recipient HA).  
In the recipient, HA reconstruction is carried out after reconstructing of both hepatic and 
portal veins followed by the reperfusion of the implanted graft. In liver transplantation 
arterial reconstruction is essential to ensure a good blood inflow for proper graft function. 
The absence of an adequate hepatic arterial supply usually results in graft loss due to biliary 
ischemia and parenchymal complications. Hepatic arterial reconstruction in LDLT is 
technically more difficult and troublesome than in orthotopic liver transplantation (OLT),  
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mainly because of the need to reconstruct thin, short, and/or multiple arterial branches in 
limited surgical fields. Moreover the hilar structures lie in a different plane than native 
vessels, and optimal realignment for anastomosis is sometimes impossible to achieve. 
Reconstruction under these circumstances requires an unusual degree of precision. (Marcos 
et al., 2001) 
Microsurgical reconstruction of the liver vasculature in LDLT rises significant challenges to 
the surgeon. There are various aspects to be addressed: (1) difficulty in obtaining a good 
operative field and a sufficient view through the microscope due to the deep location of the 
liver in the abdominal cavity; (2) the respiratory movement and heart pulsation; (3) vessel-
size discrepancy between the graft and recipient hepatic arterial stumps; (4) possible intimal 
dissection and atheromatosis, small caliber, and/or short stalk of the donor hepatic 
artery/arteries.  
Longer microsurgical instruments are required to get an easier access. One or two soft 
suction tubes are placed at both sides of the HA to provide a bloodless operative field. 
When an operating microscope is used, it is draped with a sterile plastic bag and adjusted 
as the operator stand at the patient’s right side and the assistant stand at patient’s left side. 
HA in LDLT can also be safely reconstructed with microsurgical techniques without 
microscope using, with 6x loupe magnification. (Enne et al., 2010; Guarrera et al., 2004) To 
provide a wide anastomosis and consecutively to avoid microscope usage, native and graft 
hepatic arteries can be spatulated from both the anterior and posterior walls. (Haberal et 
al., 2007) 
To overcome large movement caused by respiration, the suturing of the hepatic arteries 
should be synchronized according to the rhythmic chest wall up-and-down movement. If 
this has not the expected result, a decrease of the tidal volume to 300–400 mL/min may 
help. An alternative stabilization of the operative field is to use smooth manual bagging 
technique instead of mechanical ventilation.  
In most cases the caliber discrepancy is dealt with simple methods such as gently dilatation 
of the vessel edge, enlargement of the circumference of the smaller lumen by cutting artery 
obliquely or in fish-mouth, making a longitudinal side-cut, funnelization, suturing with 
wider bites on the larger vessel. (Inomoto et al., 1996) When the size mismatch is greater 
than 1:3, the alternatives are: the interposition of an arterial graft (e.g. superior rectal artery, 
ovarian artery, radial artery (Kamei et al., 2006)) or venous conduct, the construction of an 
end-to-side anastomosis or anastomosis with a side branch of the larger vessel. When a 
discrepancy in the thickness of the vessel walls is encountered, full bites of the thinner 
vessel and only inner layers of the thicker vessel should be taken in the sutures.  
 Multiple arterial tributaries in right liver graft procurement are rare. Due to its anatomic 
characteristics RHA anastomosis is relatively straightforward (Marcos et al., 2000) with no 
complications and is often aided only by loupe magnification, sometimes using an artifice. 
(Di Benedetto et al., 2004) In case of a very short right arterial stump in the graft, there are 
two options: (1) the use of microsurgical techniques with double needle threads; (2) the 
interposition technique proposed as a reversed extension graft. Harvesting an arterial graft 
for interposition will subject either the donors or recipients to an additional incision or more 
extensive dissection and prolonged operation time with consecutive increased risk of 
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A rare anatomical variant is worth mentioning. In Fig. 2 it is depicted a communication 
between a normal right medial arterial branch emerging from proper hepatic artery and a 
replaced right lateral arterial branch emerging from superior mesenteric artery. This 
communication is favorable by avoiding the reconstruction of both branches. Both branches 
are cut proximal to the interconnection. Only the larger donor’s artery is used to perform the 
arterial anastomosis with the receptor’s proper hepatic artery.  
  
Fig. 2. A) Dissection of hepatic hilum with the identification of a communication between a 
normal right medial arterial branch emerging from proper hepatic artery and a replaced 
right lateral arterial branch emerging from superior mesenteric artery. B) Arterial 
anastomosis is completed between the donor’s hepatic branch from superior mesenteric 
artery and recipient’s proper hepatic artery 
3. Reconstruction techniques of the liver arterial vasculature 
During hilar dissection in donor operation, the HA and portal vein of the donor are 
individually exposed and carefully divided. In left grafts, the proper HA is exposed up to 
the bifurcation of the left (or middle) HA and the right HA. In right grafts, the right HA is 
identified and isolated to the right side of the hepatic duct. The division point of HA is 
determined by the length and size of the artery, its relationship with the cutting plane of the 
liver, and the position of the arteries. (Takatsuki et al., 2006) Division of the donor vessels at 
a point further distal to the main trunk than would be considered ideal for donor protection. 
Anastomosis of first- or second-order vascular branches is a requirement of LDLT. (Marcos 
et al., 2001) 
The reconstruction technique of the liver arterial vasculature is selected by the surgeon 
based on the anatomical arterial variants, differences in vessel caliber, length and quality of 
recipient HA (i.e. aneurysm, stenosis, intimal dissection, inflammation of the porta hepatis, 
inadvertent injury of donor or recipient HA).  
In the recipient, HA reconstruction is carried out after reconstructing of both hepatic and 
portal veins followed by the reperfusion of the implanted graft. In liver transplantation 
arterial reconstruction is essential to ensure a good blood inflow for proper graft function. 
The absence of an adequate hepatic arterial supply usually results in graft loss due to biliary 
ischemia and parenchymal complications. Hepatic arterial reconstruction in LDLT is 
technically more difficult and troublesome than in orthotopic liver transplantation (OLT),  
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mainly because of the need to reconstruct thin, short, and/or multiple arterial branches in 
limited surgical fields. Moreover the hilar structures lie in a different plane than native 
vessels, and optimal realignment for anastomosis is sometimes impossible to achieve. 
Reconstruction under these circumstances requires an unusual degree of precision. (Marcos 
et al., 2001) 
Microsurgical reconstruction of the liver vasculature in LDLT rises significant challenges to 
the surgeon. There are various aspects to be addressed: (1) difficulty in obtaining a good 
operative field and a sufficient view through the microscope due to the deep location of the 
liver in the abdominal cavity; (2) the respiratory movement and heart pulsation; (3) vessel-
size discrepancy between the graft and recipient hepatic arterial stumps; (4) possible intimal 
dissection and atheromatosis, small caliber, and/or short stalk of the donor hepatic 
artery/arteries.  
Longer microsurgical instruments are required to get an easier access. One or two soft 
suction tubes are placed at both sides of the HA to provide a bloodless operative field. 
When an operating microscope is used, it is draped with a sterile plastic bag and adjusted 
as the operator stand at the patient’s right side and the assistant stand at patient’s left side. 
HA in LDLT can also be safely reconstructed with microsurgical techniques without 
microscope using, with 6x loupe magnification. (Enne et al., 2010; Guarrera et al., 2004) To 
provide a wide anastomosis and consecutively to avoid microscope usage, native and graft 
hepatic arteries can be spatulated from both the anterior and posterior walls. (Haberal et 
al., 2007) 
To overcome large movement caused by respiration, the suturing of the hepatic arteries 
should be synchronized according to the rhythmic chest wall up-and-down movement. If 
this has not the expected result, a decrease of the tidal volume to 300–400 mL/min may 
help. An alternative stabilization of the operative field is to use smooth manual bagging 
technique instead of mechanical ventilation.  
In most cases the caliber discrepancy is dealt with simple methods such as gently dilatation 
of the vessel edge, enlargement of the circumference of the smaller lumen by cutting artery 
obliquely or in fish-mouth, making a longitudinal side-cut, funnelization, suturing with 
wider bites on the larger vessel. (Inomoto et al., 1996) When the size mismatch is greater 
than 1:3, the alternatives are: the interposition of an arterial graft (e.g. superior rectal artery, 
ovarian artery, radial artery (Kamei et al., 2006)) or venous conduct, the construction of an 
end-to-side anastomosis or anastomosis with a side branch of the larger vessel. When a 
discrepancy in the thickness of the vessel walls is encountered, full bites of the thinner 
vessel and only inner layers of the thicker vessel should be taken in the sutures.  
 Multiple arterial tributaries in right liver graft procurement are rare. Due to its anatomic 
characteristics RHA anastomosis is relatively straightforward (Marcos et al., 2000) with no 
complications and is often aided only by loupe magnification, sometimes using an artifice. 
(Di Benedetto et al., 2004) In case of a very short right arterial stump in the graft, there are 
two options: (1) the use of microsurgical techniques with double needle threads; (2) the 
interposition technique proposed as a reversed extension graft. Harvesting an arterial graft 
for interposition will subject either the donors or recipients to an additional incision or more 
extensive dissection and prolonged operation time with consecutive increased risk of 
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thrombosis in the recipient. Thus the arterial conduct interposition should be avoided as 
much as possible. 
It is still debated in LDLT whether all arterial stumps should be anastomosed. However a 
simple method of only one anastomosis is sufficient if backflow from another tributary is 
confirmed, indicating that a compensation of arterial perfusion exists in both left (Ikegami et 
al., 1996) and right liver grafts (Kishi et al., 2004). When backflow from the second tributary 
is absent, this artery should be reconstructed. (Marcos et al., 2001)  
Different from the right lobe, multiple arteries to the left lobe are rather common, and care 
must be taken when harvesting the graft in such cases. Incidence of HA thrombosis was 
showed to be four times higher in the grafts with multiple arteries than those with a single 
artery. When encountering dual arteries during donor surgery, there are three options to be 
considered: (1) division of both arteries and reconstruction of only one; (2) division and 
reconstruction of both arteries; (3) 2-in-1 segmental resection followed by donor HA 
reconstruction.  
The arterial reconstruction is sometimes needed in the donor when a 2-in-1 segmental 
resection is performed and, as in the recipient, it is of paramount concern. The incidence of 
arterial occlusion after reconstruction in the donor HA must be lower than in the recipient in 
order to address the most important ethical issue of LDLT - donor safety.  
The average diameters of the stump of the graft and recipient’s arteries are 2.5-0.5 mm and 
the average of these caliber differences are 0.3-0.5 mm. The end-to-end arterial anastomosis 
is the choice whenever possible. Depending on the diameter of the vessels, the surgeon has 
to choose between loupe and microscope. The use of microvascular techniques has 
revolutionized reconstruction and expanded the range of options for reconstructing small 
and incongruent arteries. Microsurgery is complex and technically demanding, but with 
careful preparation and proper execution, it has been proved beneficial to the patient and 
rewarding to the surgeon. (Inomoto et al., 1996)  
Arterial anastomoses in the left lobe and left lateral segment living donor transplantation 
incur a relative frequent complication rate when performed by loupe magnification but a 
significant lower incidence of these when microvascular techniques are used. By using the 
microscope, a fine hepatic artery less than 2 mm in diameter is no longer regarded as a 
contraindication for LDLT due to the potential arterial complications. (Inomoto et al., 1995) 
The graft should be prepared in such a way that only one arterial anastomosis is performed 
in order to avoid the risk of thrombosis. The single independent arterial anastomosis 
technique is most commonly used for arterial anastomosis in LVLT.  
After preparing the graft for anastomosis, the fitness of each arterial branch should be assess 
for microvascular reconstruction. In this assessment the quality of the recipient hepatic 
artery should be inspected carefully using the high power of microscope. The interior of 
vessel should be observed for signs of intimal irregularity such as separation from the media 
due to preexisting conditions (e.g. atherosclerosis, previous surgical trauma). Any sign of 
damage indicates the need for further debridement. After adequate debridement, there 
should be a strong pulsatile flow from the recipient artery. After assessment of quality of 
arteries, the length and caliber matching should be carefully observed.  
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The difficulty related to correct match of vessels diameter is present mostly in pediatric 
LDLA cases where the caliber of the graft artery is smaller than that of the recipient hepatic 
artery. In most cases the caliber difference is dealt with simple methods such as gently 
dilatation of the vessel edge, oblique cutting of the graft artery, fish-mouth method, and 
short longitudinal incision. Funnelization is an appropriate method to accommodate a much 
wider size disparity by enlarging the circumference of the smaller lumen. 
In LDLT graft HAs are usually reconstructed with a recipient HA branch (anatomical HA 
reconstruction). Surgeons often encounter difficulties in extra-anatomical HA reconstruction, 
when a recipient artery other than a HA branch must be used. When biliary reconstruction 
is chosen to be performed by duct-to-duct anastomosis, recipient's left HAs should be 
selected for HA reconstruction in right liver LDLT in order to decrease the rate of septic and 
biliary complication. (Uchiyama et al., 2010) In extra-anatomical HA reconstructions, the 
arteries used are right gastroepiplooic artery, gastric artery, gastroduodenal artery, left 
gastric artery, splenic artery, cystic artery (Lee et al., 2008), and infrarenal abdominal aorta 
(Uchiyama et al., 2010).  
The single independent arterial anastomosis can be performed with or without interposition 
graft depending on the condition of arteries that are to be anastomosed. When the intimal 
condition, length, and diameter of the recipient and donor artery are appropriate to each 
other then the single independent arterial anastomosis without interposition graft is 
performed in an end-to-end fashion in LDLT.  
In almost all the situations vessel anastomosis in recipient is performed in end-to-end 
fashion using interrupted sutures. For a HA with a diameter of at least 3.0 mm, 8-0 suture is 
indicated. For a HA with a diameter less than 3.0 mm, 9-0 suture is indicated (Okochi M et 
al., 2010). The monofilament suture can be nylon (Ethilon; Ehicon Inc, Somerville, NJ) or 
polypropylene (Prolene; Ehicon Inc, Somerville, NJ). Less frequently, arterial anastomoses 
are performed using continuous suturing. The reason to avoid continuous suturing is to 
minimize narrowing of the arterial lumen. Some authors describe the placement of 
continuous suture on the posterior wall and interrupted sutures on the anterior wall. 
(Okochi M et al., 2010) 
An alternative surgical technique that avoids interpositional vessel grafts or tension on the 
connection is successfully used by some authors. An end-to-side anastomosis is performed 
between allograft hepatic vein and recipient inferior vena cava in a more caudate location. 
The level of venotomy on the recipient vena cava is decided according to the pre-
anastomotic placement of the allograft in the recipient hepatectomy site with sufficient 
width to have a hepatic artery anastomosis without tension or need for an interposition graft 
during hepatic artery and portal vein anastomoses. (Ersozet et al., 2003) 
There are various techniques applicable for hepatic arterial reconstruction.  
1. The double clip-fixation technique is feasible when the donor arterial stump is long 
enough to allow to turn over the vessels after the completion of the anterior wall of the 
anastomosis. The double micro-clamp is applied first to the donor HA then the recipient 
HA and a silastic background is placed behind the hepatic vessels. 
2. The two stay suture technique is performed without using a double clip. Two stay 
sutures are placed 180° apart at the center of the anterior and posterior walls, left untied,  
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thrombosis in the recipient. Thus the arterial conduct interposition should be avoided as 
much as possible. 
It is still debated in LDLT whether all arterial stumps should be anastomosed. However a 
simple method of only one anastomosis is sufficient if backflow from another tributary is 
confirmed, indicating that a compensation of arterial perfusion exists in both left (Ikegami et 
al., 1996) and right liver grafts (Kishi et al., 2004). When backflow from the second tributary 
is absent, this artery should be reconstructed. (Marcos et al., 2001)  
Different from the right lobe, multiple arteries to the left lobe are rather common, and care 
must be taken when harvesting the graft in such cases. Incidence of HA thrombosis was 
showed to be four times higher in the grafts with multiple arteries than those with a single 
artery. When encountering dual arteries during donor surgery, there are three options to be 
considered: (1) division of both arteries and reconstruction of only one; (2) division and 
reconstruction of both arteries; (3) 2-in-1 segmental resection followed by donor HA 
reconstruction.  
The arterial reconstruction is sometimes needed in the donor when a 2-in-1 segmental 
resection is performed and, as in the recipient, it is of paramount concern. The incidence of 
arterial occlusion after reconstruction in the donor HA must be lower than in the recipient in 
order to address the most important ethical issue of LDLT - donor safety.  
The average diameters of the stump of the graft and recipient’s arteries are 2.5-0.5 mm and 
the average of these caliber differences are 0.3-0.5 mm. The end-to-end arterial anastomosis 
is the choice whenever possible. Depending on the diameter of the vessels, the surgeon has 
to choose between loupe and microscope. The use of microvascular techniques has 
revolutionized reconstruction and expanded the range of options for reconstructing small 
and incongruent arteries. Microsurgery is complex and technically demanding, but with 
careful preparation and proper execution, it has been proved beneficial to the patient and 
rewarding to the surgeon. (Inomoto et al., 1996)  
Arterial anastomoses in the left lobe and left lateral segment living donor transplantation 
incur a relative frequent complication rate when performed by loupe magnification but a 
significant lower incidence of these when microvascular techniques are used. By using the 
microscope, a fine hepatic artery less than 2 mm in diameter is no longer regarded as a 
contraindication for LDLT due to the potential arterial complications. (Inomoto et al., 1995) 
The graft should be prepared in such a way that only one arterial anastomosis is performed 
in order to avoid the risk of thrombosis. The single independent arterial anastomosis 
technique is most commonly used for arterial anastomosis in LVLT.  
After preparing the graft for anastomosis, the fitness of each arterial branch should be assess 
for microvascular reconstruction. In this assessment the quality of the recipient hepatic 
artery should be inspected carefully using the high power of microscope. The interior of 
vessel should be observed for signs of intimal irregularity such as separation from the media 
due to preexisting conditions (e.g. atherosclerosis, previous surgical trauma). Any sign of 
damage indicates the need for further debridement. After adequate debridement, there 
should be a strong pulsatile flow from the recipient artery. After assessment of quality of 
arteries, the length and caliber matching should be carefully observed.  
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The difficulty related to correct match of vessels diameter is present mostly in pediatric 
LDLA cases where the caliber of the graft artery is smaller than that of the recipient hepatic 
artery. In most cases the caliber difference is dealt with simple methods such as gently 
dilatation of the vessel edge, oblique cutting of the graft artery, fish-mouth method, and 
short longitudinal incision. Funnelization is an appropriate method to accommodate a much 
wider size disparity by enlarging the circumference of the smaller lumen. 
In LDLT graft HAs are usually reconstructed with a recipient HA branch (anatomical HA 
reconstruction). Surgeons often encounter difficulties in extra-anatomical HA reconstruction, 
when a recipient artery other than a HA branch must be used. When biliary reconstruction 
is chosen to be performed by duct-to-duct anastomosis, recipient's left HAs should be 
selected for HA reconstruction in right liver LDLT in order to decrease the rate of septic and 
biliary complication. (Uchiyama et al., 2010) In extra-anatomical HA reconstructions, the 
arteries used are right gastroepiplooic artery, gastric artery, gastroduodenal artery, left 
gastric artery, splenic artery, cystic artery (Lee et al., 2008), and infrarenal abdominal aorta 
(Uchiyama et al., 2010).  
The single independent arterial anastomosis can be performed with or without interposition 
graft depending on the condition of arteries that are to be anastomosed. When the intimal 
condition, length, and diameter of the recipient and donor artery are appropriate to each 
other then the single independent arterial anastomosis without interposition graft is 
performed in an end-to-end fashion in LDLT.  
In almost all the situations vessel anastomosis in recipient is performed in end-to-end 
fashion using interrupted sutures. For a HA with a diameter of at least 3.0 mm, 8-0 suture is 
indicated. For a HA with a diameter less than 3.0 mm, 9-0 suture is indicated (Okochi M et 
al., 2010). The monofilament suture can be nylon (Ethilon; Ehicon Inc, Somerville, NJ) or 
polypropylene (Prolene; Ehicon Inc, Somerville, NJ). Less frequently, arterial anastomoses 
are performed using continuous suturing. The reason to avoid continuous suturing is to 
minimize narrowing of the arterial lumen. Some authors describe the placement of 
continuous suture on the posterior wall and interrupted sutures on the anterior wall. 
(Okochi M et al., 2010) 
An alternative surgical technique that avoids interpositional vessel grafts or tension on the 
connection is successfully used by some authors. An end-to-side anastomosis is performed 
between allograft hepatic vein and recipient inferior vena cava in a more caudate location. 
The level of venotomy on the recipient vena cava is decided according to the pre-
anastomotic placement of the allograft in the recipient hepatectomy site with sufficient 
width to have a hepatic artery anastomosis without tension or need for an interposition graft 
during hepatic artery and portal vein anastomoses. (Ersozet et al., 2003) 
There are various techniques applicable for hepatic arterial reconstruction.  
1. The double clip-fixation technique is feasible when the donor arterial stump is long 
enough to allow to turn over the vessels after the completion of the anterior wall of the 
anastomosis. The double micro-clamp is applied first to the donor HA then the recipient 
HA and a silastic background is placed behind the hepatic vessels. 
2. The two stay suture technique is performed without using a double clip. Two stay 
sutures are placed 180° apart at the center of the anterior and posterior walls, left untied,  
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3. and retracted gently to keep the anastomotic site in the best position. Some sutures are 
placed on one lateral side between the stay sutures, and left untied to ensure precise 
placement of the sutures in the direct view of the lumen. After all these side sutures are 
placed, they are tied. Next, the two stay sutures are turned over 180° and retracted in 
the opposite direction, and the other lateral side sutures are placed in the same manner. 
The anastomosis is completed by tying the stay sutures.  
4. The doubly-armed microsuture technique or back wall support suture technique is 
recommended to avoid the twisting during suturing and thus to overcome the 
drawbacks of the conventional method performed in a deep abdominal cavity and/or 
on a short hepatic artery with no possibility for turning of the microclamps. (Ikegamiet 
et al., 2000) Microvascular anastomosis without turning over the clamp is considered by 
some authors superior to the conventional method in terms of reducing intimal damage 
to the vessels. (Yamamoto et al., 1999) Back wall-first approach should be favored 
especially when dealing with a fragile HA due to age, liver disease, atherosclerosis or 
post-transcatheter interventions such as arterial embolization in hepatocellular 
carcinoma before transplant. (Takatsuki et al, 2006) The recipient and graft arteries are 
clamped with single microclamps. The first double needle 9-0 monofilament 
microsuture is placed at the most difficult point (usually at the middle of the posterior 
wall) in the artery to be visualized through the microscope. Each stitch is always placed 
from the inner side of the arterial wall to the outer side. The posterior stitch is tied 
pulling toward the back. The subsequent sutures are advanced anteriorly on either side 
adjacent to the previous suture. The anterior vessel wall is sutured with a regular 
microsuture with a single needle. (Miyagi et al, 2008) 
5. The branch patch anastomosis for hepatic arteries uses the bifurcation of hepatic arterial 
branches. The bifurcation of the arteries are cut longitudinally and then the plasty is 
performed to make a patch. To create a large orifice for the arterial anastomosis, the 
short part of the patch is wrapped with a long flap of the arteries from the other side. 
Cystic artery bifurcation from right hepatic artery can also be used to prepare a patch to 
be anastomosed to the recipient right branch of the hepatic artery. (Di Benedetto et al., 
2004) During the procedure, a small vascular catheter can be used as a guide inside the 
gastroduodenal artery (GDA) which then is removed at the end of the anastomosis, as 
the GDA itself is sutured. 
6. The technique of the ex situ reconstruction with a Y-extension graft is suited for the 
complex situation of double hepatic arteries. In the case of a donor graft with two 
arteries, the Y-extension graft procedure appears to be necessary. (Marcos et al., 2001, 
2003) The recipient’s HA is dissected well beyond both the right and left hepatic arteries 
which are transected to obtain the Y-extension graft. The artery is transected just distal 
to the takeoff of the gastroduodenal artery while the recipient liver continues to be 
perfused by portal blood flow during ex situ reconstruction of the arteries. Because 
arterial inflow to the recipient common bile duct may be sacrificed, duct-to-duct biliary 
reconstruction is contraindicated.  
On back table the right and left hepatic arteries are anastomosed with interrupted 
sutures to the dual arterial system on the donor right lobe under loupe magnification. 
The patency and integrity of the anastomoses are reassessed through the free end of the 
vascular conduit before engraftment. The free end of the Y-extension graft (proper 
hepatic artery) is sutured in situ to the recipient hepatic artery branched cuff of the 
common hepatic artery and gastroduodenal artery. The wide lumen created by branch 
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patching usually allows for running anastomosis with 5-0 or 6-0 prolene suture (Figure 
3). (Marcos et al., 2001) 
  
                                    (a)                                                                                      (b) 
Fig. 3. Reconstruction of two right hepatic branches. A. Recipient’ s right, left, and proper 
hepatic arteries are sectioned to obtain a Y-vascular graft. The level of section of proper 
hepatic artery is at the takeoff of gastroduodenal artery. B. The arterial branches of the 
hepatic graft are anastomosed on table using the bifurcation of Y-graft. The free end of the 
Y-graft is anastomosed at the bifurcation of common hepatic artery 
  
                                   (a)                                                                                           (b) 
Fig. 4. Reconstruction of a short right hepatic artery. A. Right, left, and proper hepatic 
arteries are sectioned to obtain a Y-vascular graft. The level of section of proper hepatic 
artery is at the takeoff of gastroduodenal artery. B. The free end of Y-graft is anastomosed 
with the right hepatic artery of the graft on back table. The branches of Y-graft are cut at the 
bifurcation to obtain a larger lumen that will be anastomosed with the bifurcation of 
recipient’s common hepatic artery 
 
Liver Transplantation – Technical Issues and Complications 
 
50 
3. and retracted gently to keep the anastomotic site in the best position. Some sutures are 
placed on one lateral side between the stay sutures, and left untied to ensure precise 
placement of the sutures in the direct view of the lumen. After all these side sutures are 
placed, they are tied. Next, the two stay sutures are turned over 180° and retracted in 
the opposite direction, and the other lateral side sutures are placed in the same manner. 
The anastomosis is completed by tying the stay sutures.  
4. The doubly-armed microsuture technique or back wall support suture technique is 
recommended to avoid the twisting during suturing and thus to overcome the 
drawbacks of the conventional method performed in a deep abdominal cavity and/or 
on a short hepatic artery with no possibility for turning of the microclamps. (Ikegamiet 
et al., 2000) Microvascular anastomosis without turning over the clamp is considered by 
some authors superior to the conventional method in terms of reducing intimal damage 
to the vessels. (Yamamoto et al., 1999) Back wall-first approach should be favored 
especially when dealing with a fragile HA due to age, liver disease, atherosclerosis or 
post-transcatheter interventions such as arterial embolization in hepatocellular 
carcinoma before transplant. (Takatsuki et al, 2006) The recipient and graft arteries are 
clamped with single microclamps. The first double needle 9-0 monofilament 
microsuture is placed at the most difficult point (usually at the middle of the posterior 
wall) in the artery to be visualized through the microscope. Each stitch is always placed 
from the inner side of the arterial wall to the outer side. The posterior stitch is tied 
pulling toward the back. The subsequent sutures are advanced anteriorly on either side 
adjacent to the previous suture. The anterior vessel wall is sutured with a regular 
microsuture with a single needle. (Miyagi et al, 2008) 
5. The branch patch anastomosis for hepatic arteries uses the bifurcation of hepatic arterial 
branches. The bifurcation of the arteries are cut longitudinally and then the plasty is 
performed to make a patch. To create a large orifice for the arterial anastomosis, the 
short part of the patch is wrapped with a long flap of the arteries from the other side. 
Cystic artery bifurcation from right hepatic artery can also be used to prepare a patch to 
be anastomosed to the recipient right branch of the hepatic artery. (Di Benedetto et al., 
2004) During the procedure, a small vascular catheter can be used as a guide inside the 
gastroduodenal artery (GDA) which then is removed at the end of the anastomosis, as 
the GDA itself is sutured. 
6. The technique of the ex situ reconstruction with a Y-extension graft is suited for the 
complex situation of double hepatic arteries. In the case of a donor graft with two 
arteries, the Y-extension graft procedure appears to be necessary. (Marcos et al., 2001, 
2003) The recipient’s HA is dissected well beyond both the right and left hepatic arteries 
which are transected to obtain the Y-extension graft. The artery is transected just distal 
to the takeoff of the gastroduodenal artery while the recipient liver continues to be 
perfused by portal blood flow during ex situ reconstruction of the arteries. Because 
arterial inflow to the recipient common bile duct may be sacrificed, duct-to-duct biliary 
reconstruction is contraindicated.  
On back table the right and left hepatic arteries are anastomosed with interrupted 
sutures to the dual arterial system on the donor right lobe under loupe magnification. 
The patency and integrity of the anastomoses are reassessed through the free end of the 
vascular conduit before engraftment. The free end of the Y-extension graft (proper 
hepatic artery) is sutured in situ to the recipient hepatic artery branched cuff of the 
common hepatic artery and gastroduodenal artery. The wide lumen created by branch 
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patching usually allows for running anastomosis with 5-0 or 6-0 prolene suture (Figure 
3). (Marcos et al., 2001) 
  
                                    (a)                                                                                      (b) 
Fig. 3. Reconstruction of two right hepatic branches. A. Recipient’ s right, left, and proper 
hepatic arteries are sectioned to obtain a Y-vascular graft. The level of section of proper 
hepatic artery is at the takeoff of gastroduodenal artery. B. The arterial branches of the 
hepatic graft are anastomosed on table using the bifurcation of Y-graft. The free end of the 
Y-graft is anastomosed at the bifurcation of common hepatic artery 
  
                                   (a)                                                                                           (b) 
Fig. 4. Reconstruction of a short right hepatic artery. A. Right, left, and proper hepatic 
arteries are sectioned to obtain a Y-vascular graft. The level of section of proper hepatic 
artery is at the takeoff of gastroduodenal artery. B. The free end of Y-graft is anastomosed 
with the right hepatic artery of the graft on back table. The branches of Y-graft are cut at the 
bifurcation to obtain a larger lumen that will be anastomosed with the bifurcation of 
recipient’s common hepatic artery 
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7. The reversed extension bifurcated graft technique is a standard technique for single 
arterial anastomosis in the recipients. The modification begins with the dissection of the 
recipient hepatic artery well beyond the bifurcation of the RHA and LHA. 
The proper hepatic artery is transected just distal to the takeoff of the gastroduodenal 
artery from the common hepatic artery while the recipient liver continues to receive 
portal perfusion. The bifurcation of the RHA and LHA is opened to create a wider 
bifurcated cuff. Then the arterial segment is reversed so that the once-proximal end of 
the PHA is sutured to the donor graft RHA under direct vision ex situ, and tension free, 
with interrupted 7-0 prolene. The reversed bifurcated (RHA/LHA) graft, with its new 
arterial extension, is then anastomosed to the larger branched cuff of the CHA and 
GDA using standard branch-patch technique (Figure 4). (Marcos et al., 2003) 
8. The ex situ graft extension is another feasible and alternative technique for 
reconstruction of hepatic artery in LDLT if there are issues regarding length, size 
discrepancy or reconstruction of more than one artery. (Marcos et al., 2003) From 
cadaveric grafts it can be used internal and external iliac artery, splenic artery, reversed 
saphenous vein, and superior mesenteric artery. The SMA has proved particularly 
useful to overcome large size discrepancies and also reconstruct multiple arteries into a 
single vessel. Splenic artery can be ligated because the short gastrosplenic vessels and 
the left gastric artery maintain the vascularization of the spleen. However the risk of 
splenic infarction exists especially in case of a large spleen. (Lehar et al., 1990) The right 
gastroepiplooic artery can be dissected free from the greater curvature of the stomach 
and the surrounding tissue without causing ischemia of the stomach. An end-to-end 
anastomosis between this artery and the donor hepatic artery can be performed. The 
major disadvantage of any interpositional graft is that it needs two anastomosis to be 
performed which may lead toward increased risk of HAT. Anastomosis to the 
recipient's common hepatic artery resulted in a high incidence of thrombosis, whereas 
anastomosis to the infrarenal aorta nearly always remained patent, regardless of the 
length of the interposition of the saphenous vein. The inferior mesenteric vein can also 
be used for the arterial reconstruction. (Margreiter et al., 2008) There is a high risk for 
the inferior mesenteric vein to become ectatic when exposed to arterial pressure, which 
causes turbulence, and thrombosis may result. (Broelsch et al., 1999)  
9. The superior mesenteric artery branch of Roux-en-Y limb technique is an alternative 
when porta hepatis inflammation makes difficult to use the hepatic, gastroduodenal or 
right gastroepiplooic artery for hepatic arterial reconstruction, or when a subintimal 
dissection or atheromatosis extends to all tributaries of the celiac arterial trunk. 
(Kasahara et al., 2005) A jejunal arterial arcade of Roux-en-Y limb mobilized for biliary 
reconstruction is anastomosed to the donor hepatic artery in end-to-end fashion. 
(Ikegami, et al., 2008) The arterial reconstruction in Roux-en-Y hepaticojejunostomy 
technique is performed before biliary reconstruction (Figure 5). 
10. When multiple graft arteries are encountered, the dominant artery is reconstructed first. 
The dominant HA in grafts with multiple hepatic arteries can be determined by 
comparing arterial flows during intraoperative DUS after temporary occlusion of each 
artery using microvascular clips in the donor operation. This is followed by careful 
check-up on back-bleeding from the other arteries. If back-bleeding is insufficient both 
arteries must be reconstructed. Despite the fact that complex HA reconstructions are 
needed in such circumstances, with technical advancement, HA-related complications 
can be avoided in most cases. (Uchiyama et al., 2010) If back-bleeding is sufficient, the 
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unreconstructed arteries can be ligated. The blood flow through the vessel anastomosis 




anastomosis between donor right hepatic artery
and a branch of recipient superior mesenteric artery
right portal vein
 
Fig. 5. A segment of jejunum is mobilized. An arterial branch of superior mesenteric artery 
of Roux-en-Y limb is anastomosed with the arterial stump of the liver graft. Biliary 
anastomosis is performed after arterial reconstructions 
In rare case of right graft dual arterial supply the anastomosis of the larger branch is made 
first, then the backflow is checked from the smaller branch. If not good, the smaller branch 
must be reconstructed. The cystic artery can be used as a conduit for the reconstruction. The 
length of cystic artery is preserved as long as possible. The cystic arterial stump is 
anastomosed to the stump of the posterior branch the of RHA under microscopic guidance 
on the back table. Patency is checked through the stump of the anterior branch of the RHA. 
With this technique, only one orifice, the stump of right anterior hepatic artery, is used for 
hepatic artery reconstruction. (Lee et al., 2008) 
In case of left graft dual arterial supply Douard et al. use a two-step strategy for the 
development of flow-induced enlargement of a small diameter artery. The smaller arterial 
branch is ligated during a laparoscopic first-step procedure to induce a 30% enlargement of 
the remaining branch. The second-step donor hepatectomy is performed one week later 
using a larger artery for successful vascular anastomosis. (Douard et al., 2002) It is worth 
underlining the importance of preoperative imaging for the identification of anatomic 
vascular variants which can be addressed in two-step strategy. The same authors reported a 
case with angiographic revealed celiac trunk compression by the median arcuate ligament 
and reverse vascularization of the middle hepatic artery via the gastroduodenal artery, a 
proper hepatic artery 2 mm in diameter irrigating the left lateral segment exclusively, and a 
right hepatic artery irrigating the right lobe and segment IV. First-step division of the 
median arcuate ligament and gastroduodenal artery ligation was followed by a repeat 
angiography at the third week showing a 50% enlargement of the middle hepatic artery  
(3 mm) and the second-step left lobectomy performed at the fifth week. (Douard et al., 2002)  
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7. The reversed extension bifurcated graft technique is a standard technique for single 
arterial anastomosis in the recipients. The modification begins with the dissection of the 
recipient hepatic artery well beyond the bifurcation of the RHA and LHA. 
The proper hepatic artery is transected just distal to the takeoff of the gastroduodenal 
artery from the common hepatic artery while the recipient liver continues to receive 
portal perfusion. The bifurcation of the RHA and LHA is opened to create a wider 
bifurcated cuff. Then the arterial segment is reversed so that the once-proximal end of 
the PHA is sutured to the donor graft RHA under direct vision ex situ, and tension free, 
with interrupted 7-0 prolene. The reversed bifurcated (RHA/LHA) graft, with its new 
arterial extension, is then anastomosed to the larger branched cuff of the CHA and 
GDA using standard branch-patch technique (Figure 4). (Marcos et al., 2003) 
8. The ex situ graft extension is another feasible and alternative technique for 
reconstruction of hepatic artery in LDLT if there are issues regarding length, size 
discrepancy or reconstruction of more than one artery. (Marcos et al., 2003) From 
cadaveric grafts it can be used internal and external iliac artery, splenic artery, reversed 
saphenous vein, and superior mesenteric artery. The SMA has proved particularly 
useful to overcome large size discrepancies and also reconstruct multiple arteries into a 
single vessel. Splenic artery can be ligated because the short gastrosplenic vessels and 
the left gastric artery maintain the vascularization of the spleen. However the risk of 
splenic infarction exists especially in case of a large spleen. (Lehar et al., 1990) The right 
gastroepiplooic artery can be dissected free from the greater curvature of the stomach 
and the surrounding tissue without causing ischemia of the stomach. An end-to-end 
anastomosis between this artery and the donor hepatic artery can be performed. The 
major disadvantage of any interpositional graft is that it needs two anastomosis to be 
performed which may lead toward increased risk of HAT. Anastomosis to the 
recipient's common hepatic artery resulted in a high incidence of thrombosis, whereas 
anastomosis to the infrarenal aorta nearly always remained patent, regardless of the 
length of the interposition of the saphenous vein. The inferior mesenteric vein can also 
be used for the arterial reconstruction. (Margreiter et al., 2008) There is a high risk for 
the inferior mesenteric vein to become ectatic when exposed to arterial pressure, which 
causes turbulence, and thrombosis may result. (Broelsch et al., 1999)  
9. The superior mesenteric artery branch of Roux-en-Y limb technique is an alternative 
when porta hepatis inflammation makes difficult to use the hepatic, gastroduodenal or 
right gastroepiplooic artery for hepatic arterial reconstruction, or when a subintimal 
dissection or atheromatosis extends to all tributaries of the celiac arterial trunk. 
(Kasahara et al., 2005) A jejunal arterial arcade of Roux-en-Y limb mobilized for biliary 
reconstruction is anastomosed to the donor hepatic artery in end-to-end fashion. 
(Ikegami, et al., 2008) The arterial reconstruction in Roux-en-Y hepaticojejunostomy 
technique is performed before biliary reconstruction (Figure 5). 
10. When multiple graft arteries are encountered, the dominant artery is reconstructed first. 
The dominant HA in grafts with multiple hepatic arteries can be determined by 
comparing arterial flows during intraoperative DUS after temporary occlusion of each 
artery using microvascular clips in the donor operation. This is followed by careful 
check-up on back-bleeding from the other arteries. If back-bleeding is insufficient both 
arteries must be reconstructed. Despite the fact that complex HA reconstructions are 
needed in such circumstances, with technical advancement, HA-related complications 
can be avoided in most cases. (Uchiyama et al., 2010) If back-bleeding is sufficient, the 
 
Arterial Anastomosis in Living Donor Liver Transplantation 
 
53 
unreconstructed arteries can be ligated. The blood flow through the vessel anastomosis 




anastomosis between donor right hepatic artery
and a branch of recipient superior mesenteric artery
right portal vein
 
Fig. 5. A segment of jejunum is mobilized. An arterial branch of superior mesenteric artery 
of Roux-en-Y limb is anastomosed with the arterial stump of the liver graft. Biliary 
anastomosis is performed after arterial reconstructions 
In rare case of right graft dual arterial supply the anastomosis of the larger branch is made 
first, then the backflow is checked from the smaller branch. If not good, the smaller branch 
must be reconstructed. The cystic artery can be used as a conduit for the reconstruction. The 
length of cystic artery is preserved as long as possible. The cystic arterial stump is 
anastomosed to the stump of the posterior branch the of RHA under microscopic guidance 
on the back table. Patency is checked through the stump of the anterior branch of the RHA. 
With this technique, only one orifice, the stump of right anterior hepatic artery, is used for 
hepatic artery reconstruction. (Lee et al., 2008) 
In case of left graft dual arterial supply Douard et al. use a two-step strategy for the 
development of flow-induced enlargement of a small diameter artery. The smaller arterial 
branch is ligated during a laparoscopic first-step procedure to induce a 30% enlargement of 
the remaining branch. The second-step donor hepatectomy is performed one week later 
using a larger artery for successful vascular anastomosis. (Douard et al., 2002) It is worth 
underlining the importance of preoperative imaging for the identification of anatomic 
vascular variants which can be addressed in two-step strategy. The same authors reported a 
case with angiographic revealed celiac trunk compression by the median arcuate ligament 
and reverse vascularization of the middle hepatic artery via the gastroduodenal artery, a 
proper hepatic artery 2 mm in diameter irrigating the left lateral segment exclusively, and a 
right hepatic artery irrigating the right lobe and segment IV. First-step division of the 
median arcuate ligament and gastroduodenal artery ligation was followed by a repeat 
angiography at the third week showing a 50% enlargement of the middle hepatic artery  
(3 mm) and the second-step left lobectomy performed at the fifth week. (Douard et al., 2002)  
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Upon completion of the arterial anastomosis the distal clamp is released first and any major 
leaks should be dealt with by reapplying the clamp, irrigating, and inserting additional 
sutures. 
4. Posttransplant arterial complications 
In the early days of LDLT, the primary cause of postsurgical hepatic ischemia and failure 
used to be acute thrombosis of the HA with consecutive ischemia of the bile ducts and patch 
necrosis of the graft. Later, anastomotic stenosis of the HA has also been recognized as an 
important cause of posttransplant liver ischemia. An additional cause of graft ischemia is 
arterial steal syndrome, in which liver ischemia is caused by reduced blood flow through 
the HA rather than by obstruction. Other arterial complications are arterio-venous fistulas, 
anastomotic leakage, and intimal dissection. 
Multivariate analysis of cases revealed that microsurgical experience was the only 
significant factor in reducing the incidence of HA complications in LDLT. (Matsuda et al., 
2006) 
In the face of donor organ shortage and high mortality related to liver re-transplantation, 
earlier detection of arterial complications using various imaging techniques followed by 
prompt revascularization as an alternative to re-transplant is very important. 
4.1 Hepatic artery thrombosis (HAT) 
Hepatic artery thrombosis (HAT) still remains the most devastating event that may occur in 
patients after LDLT, with a higher incidence than in patients with OLT. HAT most 
commonly occurs within the first postoperative week. There are three clinical presentations 
of the patient with HAT. The first one is fulminant hepatic necrosis with rapid clinical 
deterioration. In this situation HAT is the primary concern and the diagnosis should be 
actively pursued even when the US finding is negative. If focal parenchymal alterations 
such as infarcts or abscesses are seen with US, the diagnosis is certain in 90% cases. This is 
invariably fatal without transplantation. The second clinical presentation is the development 
of a delayed bile leak due to ischemic necrosis of the bile duct, a direct result of the HAT. 
Subhepatic fluid collections, frank bile peritonitis, bacteremia, and sepsis may occur. In 
milder cases, episodes of cholangitis, bile duct strictures, or segmental biliary dilatation are 
encountered. The third clinical presentation consists in relapsing bacteremia, 
gastrointestinal bleeding, fever of unknown origin, coagulopathy, or unexplained increase 
in liver enzymes.  
When compared to adults, children have been reported to be at greater risk for HAT after 
pediatric LDLT due to small arterial size, nonuse of intraoperative microscope, and 
postoperative hypercoagulable state. LT recipients diagnosed with HAT have a relative risk 
of 90% for developing biliary complications. Up to 50% of patients with HAT may require 
retransplantation.  
Surgical technique remains the primary cause for HAT, especially if thrombosis occurs 
within 2 months since transplantation. Surgical risk factors include small volume of graft or 
small arterial size in donor and/or recipient [specifically small recipient (< 10 kg or < 15 kg) 
or recipient artery (< 3 mm)], disparity in hepatic artery diameter between donor and 
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recipient, the use of interposition, and tight anastomosis. In this category are also mentioned 
changes in hepatic arterial flow caused by tension, twisting, kinking, or compression of the 
vascular pedicle. Incriminated non-surgical causes for HAT are ABO-incompatible graft, 
anticardiolipin antibody in the recipient, cigarette smoking, prolonged cold ischemic time, 
acute rejection episodes, excessive intraoperative transfusion of clotting factor, coagulation 
abnormalities including heritable thrombophilia, absence of postoperative prophylactic 
anticoagulation, over-transfusion of fresh frozen plasma, high hematocrit levels, low 
donor/recipient age ratio, re-transplantation, and CMV infection. 
The incidence of HAT has been reduced not only with the use of new and innovative 
surgical and microsurgical techniques (Aramaki et al., 2006) (Uchiyama et al., 2002), but also 
with posttransplantation administration of heparin, aspirin, alprostadil (PGE) (Heffron, et 
al., 2003), and/or gabexate mesilate (Miyagi et al., 2010). Overtransfusion of fresh-frozen 
plasma in high-risk patients (ABO incompatible) may be a critical factor in the development 
of HAT in LDLT. (Hatano et al., 1997) Although HA thrombosis is not always due to 
technical causes, some authors believe that when anastomosis is done correctly, no 
additional medication is necessary. (Takatsuki et al., 2006) 
A proposed administration regime for heparin is 200 U/ kg of body weight per day for a 
period of 14 days. Administration of single dose of aspirin as low as 3 mg/kg will inactivate 
circulating platelets by acetylating the enzyme cyclooxigenase present in platelet wall and 
has a beneficial effect on anastomosis patency. Some authors proved that anticoagulation 
utilizing ASA and alprostadil is sufficient to avoid HAT in pediatric recepients. (Heffron et 
al., 2003) Dextran can be administered as 500 mL over 5 to 6 hours once daily for 3 to 5 days 
or 500 mL slowly over a 24 hour period. The allergic reactions can be avoided by 
administration of dextran 1 instead of dextran 40. When gabexate mesilate was administered 
as full-dose of 40 mg/kg/day no HAT occured. (Miyagi et al., 2010)  
Doppler ultrasound (DUS) has been accepted as the best diagnostic tool for HAT and has 
surpassed angiography, which is invasive and time-consuming. Upon the completion of 
arterial anastomosis in LDLT an immediate intraoperative ultrasonography (IOUS) with 8-
12-MHz linear transducer is mandatory both on gray-scale and Doppler study. HA 
anastomosis is identified on gray-scale US, and the diameter and percentage of stenosis of 
the anastomosis is measured. The HA is also evaluated to detect thrombus or dissection in 
the region of anastomosis. Doppler study of the graft HA is performed to search for the 
abnormal parameters (e.g. peak systolic velocity < 30 cm/s or > 2 m/s, resistive index (RI) < 
0.5, and systolic acceleration time > 80 msec). (Mun et al., 2010) Intraoperative identification 
of arterial complication may impose arterial reanastomosis (Figure 6). 
The sonographist must know the details of arterial anastomosis. In patients making an 
uneventful recovery, the arterial velocity tended to increase and the resistive index to 
decrease during the first postoperative week. (Stell et al., 2004) The peak systolic velocities, 
end-diastolic velocities, and resistive indices are associated with the length and caliber of the 
type of hepatic artery anastomosis used. End-to-end anastomoses are short and have a 
uniform small caliber; aortohepatic bypasses are longer and have a progressively by smaller 
caliber. (De Candia et al., 2002)  
The normal hepatic artery shows a hepatopedal flow, with a systolic flow maximum greater 
than 30 cm/sec (Broering et al., 2004), a rapid systolic upstroke with an acceleration time 
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Upon completion of the arterial anastomosis the distal clamp is released first and any major 
leaks should be dealt with by reapplying the clamp, irrigating, and inserting additional 
sutures. 
4. Posttransplant arterial complications 
In the early days of LDLT, the primary cause of postsurgical hepatic ischemia and failure 
used to be acute thrombosis of the HA with consecutive ischemia of the bile ducts and patch 
necrosis of the graft. Later, anastomotic stenosis of the HA has also been recognized as an 
important cause of posttransplant liver ischemia. An additional cause of graft ischemia is 
arterial steal syndrome, in which liver ischemia is caused by reduced blood flow through 
the HA rather than by obstruction. Other arterial complications are arterio-venous fistulas, 
anastomotic leakage, and intimal dissection. 
Multivariate analysis of cases revealed that microsurgical experience was the only 
significant factor in reducing the incidence of HA complications in LDLT. (Matsuda et al., 
2006) 
In the face of donor organ shortage and high mortality related to liver re-transplantation, 
earlier detection of arterial complications using various imaging techniques followed by 
prompt revascularization as an alternative to re-transplant is very important. 
4.1 Hepatic artery thrombosis (HAT) 
Hepatic artery thrombosis (HAT) still remains the most devastating event that may occur in 
patients after LDLT, with a higher incidence than in patients with OLT. HAT most 
commonly occurs within the first postoperative week. There are three clinical presentations 
of the patient with HAT. The first one is fulminant hepatic necrosis with rapid clinical 
deterioration. In this situation HAT is the primary concern and the diagnosis should be 
actively pursued even when the US finding is negative. If focal parenchymal alterations 
such as infarcts or abscesses are seen with US, the diagnosis is certain in 90% cases. This is 
invariably fatal without transplantation. The second clinical presentation is the development 
of a delayed bile leak due to ischemic necrosis of the bile duct, a direct result of the HAT. 
Subhepatic fluid collections, frank bile peritonitis, bacteremia, and sepsis may occur. In 
milder cases, episodes of cholangitis, bile duct strictures, or segmental biliary dilatation are 
encountered. The third clinical presentation consists in relapsing bacteremia, 
gastrointestinal bleeding, fever of unknown origin, coagulopathy, or unexplained increase 
in liver enzymes.  
When compared to adults, children have been reported to be at greater risk for HAT after 
pediatric LDLT due to small arterial size, nonuse of intraoperative microscope, and 
postoperative hypercoagulable state. LT recipients diagnosed with HAT have a relative risk 
of 90% for developing biliary complications. Up to 50% of patients with HAT may require 
retransplantation.  
Surgical technique remains the primary cause for HAT, especially if thrombosis occurs 
within 2 months since transplantation. Surgical risk factors include small volume of graft or 
small arterial size in donor and/or recipient [specifically small recipient (< 10 kg or < 15 kg) 
or recipient artery (< 3 mm)], disparity in hepatic artery diameter between donor and 
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recipient, the use of interposition, and tight anastomosis. In this category are also mentioned 
changes in hepatic arterial flow caused by tension, twisting, kinking, or compression of the 
vascular pedicle. Incriminated non-surgical causes for HAT are ABO-incompatible graft, 
anticardiolipin antibody in the recipient, cigarette smoking, prolonged cold ischemic time, 
acute rejection episodes, excessive intraoperative transfusion of clotting factor, coagulation 
abnormalities including heritable thrombophilia, absence of postoperative prophylactic 
anticoagulation, over-transfusion of fresh frozen plasma, high hematocrit levels, low 
donor/recipient age ratio, re-transplantation, and CMV infection. 
The incidence of HAT has been reduced not only with the use of new and innovative 
surgical and microsurgical techniques (Aramaki et al., 2006) (Uchiyama et al., 2002), but also 
with posttransplantation administration of heparin, aspirin, alprostadil (PGE) (Heffron, et 
al., 2003), and/or gabexate mesilate (Miyagi et al., 2010). Overtransfusion of fresh-frozen 
plasma in high-risk patients (ABO incompatible) may be a critical factor in the development 
of HAT in LDLT. (Hatano et al., 1997) Although HA thrombosis is not always due to 
technical causes, some authors believe that when anastomosis is done correctly, no 
additional medication is necessary. (Takatsuki et al., 2006) 
A proposed administration regime for heparin is 200 U/ kg of body weight per day for a 
period of 14 days. Administration of single dose of aspirin as low as 3 mg/kg will inactivate 
circulating platelets by acetylating the enzyme cyclooxigenase present in platelet wall and 
has a beneficial effect on anastomosis patency. Some authors proved that anticoagulation 
utilizing ASA and alprostadil is sufficient to avoid HAT in pediatric recepients. (Heffron et 
al., 2003) Dextran can be administered as 500 mL over 5 to 6 hours once daily for 3 to 5 days 
or 500 mL slowly over a 24 hour period. The allergic reactions can be avoided by 
administration of dextran 1 instead of dextran 40. When gabexate mesilate was administered 
as full-dose of 40 mg/kg/day no HAT occured. (Miyagi et al., 2010)  
Doppler ultrasound (DUS) has been accepted as the best diagnostic tool for HAT and has 
surpassed angiography, which is invasive and time-consuming. Upon the completion of 
arterial anastomosis in LDLT an immediate intraoperative ultrasonography (IOUS) with 8-
12-MHz linear transducer is mandatory both on gray-scale and Doppler study. HA 
anastomosis is identified on gray-scale US, and the diameter and percentage of stenosis of 
the anastomosis is measured. The HA is also evaluated to detect thrombus or dissection in 
the region of anastomosis. Doppler study of the graft HA is performed to search for the 
abnormal parameters (e.g. peak systolic velocity < 30 cm/s or > 2 m/s, resistive index (RI) < 
0.5, and systolic acceleration time > 80 msec). (Mun et al., 2010) Intraoperative identification 
of arterial complication may impose arterial reanastomosis (Figure 6). 
The sonographist must know the details of arterial anastomosis. In patients making an 
uneventful recovery, the arterial velocity tended to increase and the resistive index to 
decrease during the first postoperative week. (Stell et al., 2004) The peak systolic velocities, 
end-diastolic velocities, and resistive indices are associated with the length and caliber of the 
type of hepatic artery anastomosis used. End-to-end anastomoses are short and have a 
uniform small caliber; aortohepatic bypasses are longer and have a progressively by smaller 
caliber. (De Candia et al., 2002)  
The normal hepatic artery shows a hepatopedal flow, with a systolic flow maximum greater 
than 30 cm/sec (Broering et al., 2004), a rapid systolic upstroke with an acceleration time 
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(time from end diastole to the first systolic peak) of less than 100 msec, and a continuous 
flow through diastole with a resistive index between 0.5 and 0.7 (Muradali & Wilson, 2005) 
(Figure 7).  
 
Fig. 6. IOUS with Doppler study. Resistive index (RI) 0.72 indicates stenosis of hepatic 
arterial anastomosis on a patient with right hepatic lobe transplantation. The intraoperator 
correction of arterial anastomosis was performed 
 
Fig. 7. Percutaneous DUS performed on a patient with right hepatic lobe transplantation on 
the third postoperative day shows a resistive index (RI) of hepatic artery at the upper limit 
of the normal. The outcome was favorable after i.v. infusion of Iloprost (Ilomedin®) 
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DUS has become the best diagnostic tool for HAT, thus surpassing angiography, which is 
invasive and time-consuming. Ultrasound can detect the absence of flow up to 92% of cases 
of hepatic artery thrombosis. Occasionally, a blunted waveform (tardus parvus arterial 
waveform) with resistive index < 0.5 and acceleration time > 100 ms may be obtained within 
the hepatic parenchyma. (Muradali & Wilson, 2005) This waveform is produced by 
collateral arterial vessels, which may develop as early as two weeks posttransplant. A false 
positive diagnostic of HAT may occur with severe hepatic edema, systemic hypotension, 
and high-grade hepatic artery stenosis. A diminished resistance index is an indication for an 
arteriogram.   
Percutaneous DUS follow-up is scheduled daily during the first 2 weeks posttransplant, every 
other day on the third week, and twice a week thereafter until discharge. After discharge DUS 
should be done at intervals between 6 and 12 months. A diagnosis of vessel obstruction or 
thrombosis made by DUS (Figure 8) had to be confirmed by 3D CT angiography (Figure 9). 
(Okochi et al., 2010) In donors who underwent 2-in-1 segmental resection of the hepatic 
arteries, DUS is carried out on the second postoperative day and before discharge. 
 
Fig. 8. Percutaneous DUS performed on a patient with right liver transplantation shows RI 
of 0.76 which is higher than normal suggesting HAT 
DUS criteria for HAT include the following features: total absence of hepatic artery signal, 
absence of extrahepatic signal with intrahepatic low amplitude, delayed upstroke signal 
suggesting thrombosis with collateralization, direct visualization of abrupt loss of arterial 
signal in the extrahepatic arterial branches, visualization of arterial collaterals in the porta 
hepatis. Ancillary ultrasound findings that suggest HAT include parenchymal infarcts, 
intrahepatic bilomas or abscesses, or multifocal biliary dilatation.  
Angiographic confirmation of HAT is needed if DUS diagnosis is equivocal.  
Early detection of HAT by DUS with no suggestion of underlying clinical or biological 
factors is an indication for emergency revascularization with thrombectomy, which has  
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Fig. 9. 3D CT angiography confirmed complete stenosis of hepatic artery on a patient with 
right hepatic lobe transplantation 
replaced retransplantation as the first treatment strategy for early HAT, with good rates of 
graft salvage and patient survival. (Nishida et al., 2002; Sakamoto et al., 1999) If recipient 
HA cannot be reanastomosed to the graft hepatic artery, other revascularization methods 
should be contemplated (e.g. anastomosis of hepatic artery with right gastroepiplooic artery 
(Tannuri et al., 2006), usage of a vein graft from the common iliac artery (Asakura et al., 
2000) or recipient sigmoid artery (Inomoto et al., 1995). 
In the past, early HAT after undergoing LT was considered uniformly fatal if the patient did 
not undergo urgent re-transplantation. Recently, the importance of urgent thrombectomy 
and revascularization has been reported. However, biliary complications, graft loss and late 
re-transplantation have tempered enthusiasm for this approach. The success of urgent 
revascularization clearly depends on early diagnosis and prompt intervention before the 
development of irreversible hepatic or biliary ischemia. The optimum treatment modality 
depends mostly on the condition of the patient, viability of the liver, availability of specific 
medical expertise, and availability of organ for re-transplantation, surgical revascularization, 
thrombolytic treatment, thrombectomy, and percutaneous transluminal balloon angioplasty 
with stent placement. 
4.2 Hepatic arterial stenosis 
Hepatic arterial stenosis (HAS) is the second most common arterial complication that occurs 
between few days to several months posttransplant. Critical hepatic artery stenosis (HAS) is 
considered mainly as a result of technical error and is characterized by 30% reduction in the 
diameter of the HA. HAS frequently progresses to thrombosis. In most cases it is caused by 
a technical failure. The incidence of HAS after LTx is reported to be 3 – 11%, although the 
introduction of microsurgery has significantly lowered the incidence of hepatic artery 
complications in the field of LDLT (Ulusal et al., 2006). More than 50% of HAS involve 
arterial anastomosis or graft artery (donor), while recipient artery stenosis is extremely rare.  
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The etiological factors for HAS are poor surgical technique, inappropriate angulation at the 
anastomotic site, clamp injury, excessive removal of the adventitia, intimal dissection, 
allograft rejection, or preservation injury, or the result of underlying liver disease. The risk 
factors for the development of HAS are a recipient weighing less than 10 kg, a long cold 
ischemic time, an insufficient inflow, a small diameter of the artery lumen, anatomic arterial 
variant, or repeated anastomosis. 
The diagnostic procedure for HAS is DUS. Direct evidence of HAS involves identifying and 
localizing a hemodynamically significant narrowing within vessel. If the stenosis is 
significant, peak systolic velocities will be greater than 2-3 m/sec), with associated turbulent 
flow distally. Indirect evidence of HAS includes a tardus parvus waveform anywhere 
within the HA (resistive index < 0.5, acceleration time > 100 msec) and is more common 
seen in clinical practice. (Muradali & Wilson, 2005) 
Angiographic confirmation is needed if DUS shows signs of HAS because therapy for HAS 
depends mainly on the location and length of the stenotic segment. Angiography is also 
needed if clinic suspicion of HAS is high despite a normal Doppler study. 
Early diagnosis of HAS with deliberated follow-up of graft arterial circulation using DUS 
contributes to graft salvage by preventing graft infarction or devastating biliary ischemia, 
and thus the compensatory growth of abundant collateral arterial flow into the liver effects 
better outcome of the patient, even if the HA is stenosed. Angiographic confirmation is 
needed in cases where DUS screening shows signs of HAS. Management of HAS depends 
mainly on the location and length of the stenotic segment. The initial therapy for HAS 
should be medical treatment with anti-coagulants, vasodilators, hyperbaric oxygen 
administration and correction of dehydration until collateral vessels grow in the graft. If 
conservative treatment fails, an interventional procedure should be considered. In the first 
few days posttransplant, direct surgical re-anastomosis of the HA is occasionally possible. 
After the first postoperative week surgical reanastomosis is often difficult and unsuccessful 
because of fragile artery wall tissue. A substitute for surgery in relatively short HAS is 
percutaneous transluminal angioplasty (PTA) and stenting. Interventional radiology can be 
safely and successfully applied to the treatment of vascular complications using balloon 
dilatation (Tanaka et al., 1993) and/or stent placement techniques before graft dysfunction 
becomes irreversible. (Egawa, 2004) However major complications can occur (e.g. dehiscence 
of the surgical anastomoses if an inappropriate size of balloon catheter is used). Moreover 
the long-term results remain to be evaluated in the future with such approach of treatment. 
Untreated HAS carries a high morbidity rate. HA PTA have better patency rates than those 
associated with hepatic artery stent placement. (Saad et al., 2005) If the treatment with PTA 
is ineffective or stenosis is extensive, surgical revision should be performed. Retransplantation 
is the last resort and is indicated if there are biliary complications. 
4.3 Pseudoaneurysm of hepatic artery 
Pseudoaneurysm of hepatic artery is seldom encountered, but when occurs, it may lead to 
serious life threatening complications of liver transplant, especially when it ruptures. It 
usually develops at the site of the arterial anastomosis as result of a technical error or 
bacterial or fungal infection. If located intrahepatic, it indicates a relation to a needle biopsy 
of the transplanted liver. The rupture of an intrahepatic false aneurysm may lead toward the 
formation of an arterio-portal fistula with subsequent development of hyperkinetic portal 
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hypertension. If a pseudoaneurysm perforates into the bile ducts, it can cause hematobilia, 
severe shock, or even death. Consequently, bacterial and fungal infections are also a serious 
threat. Diagnosis of pseudoaneurysm of hepatic artery requires a high degree of suspicion. 
On gray-scale ultrasound, pseudoaneurysm appears as a cystic (anechoic) periportal 
structure, with intense swirling flow on DUS and a disorganized spectral waveform. DUS 
and CT may miss the diagnosis. (Tobben et al., 1988) Any suspicion of a hepatic aneurysm 
mandates arteriography during which a stent placement or transcatheter arterial coil 
embolization of the aneurysm can be performed. (Maleux et al., 2005)  
The surgical therapeutic options include: (1) resection of the pseudoaneurysm and ligation 
of the hepatic artery, as long as sufficient collateral circulation into the graft within 1 month 
after transplantation can be anticipated; (2) reconstruction of the hepatic artery using autograft 
interposition or bypass (e.g. cadaveric iliac artery conduit between the donor hepatic artery 
and the recipient aorta) (Jarzembowski et al., 2008) only if the perioperative site is not 
contaminated; (3) retransplantation. In anticipation of such unpredictable complication, it 
might be useful to preserve both hepatic arteries of the recipient in adequate length and shape. 
4.4 Arterial steal syndrome 
Arterial steal syndrome is a significant problem after liver transplantation and is 
characterized by arterial hypoperfusion of the graft, which is caused by a shift in blood flow 
into other arteries that originate from the same trunk. Most cases of steal syndrome are 
associated with the splenic artery which has been reported in 3.2-4% of patients. The onset 
of the splenic artery steal syndrome, which varies among patients, may occur either during 
the first few hours after liver transplantation or as late as several weeks after 
transplantation. If the hyperdynamic state does not improve immediately after liver 
transplantation, reduced splenic arterial resistance and increased splenic arterial flow may 
divert celiac blood flow into the spleen. In some patients, swelling of the liver develops as a 
result of preservation injury, which usually causes increased intrahepatic arterial resistance 
and further diversion of blood flow away from the hepatic artery into the splenic artery. In 
other patients it may be more related to the progressive increase in splenic arterial flow 
caused by the pre-surgical hyperdynamic state, with or without the development of clinical 
hypersplenism. Development of splenic artery steal syndrome might also be related to pre-
surgical increased splenic arterial flow that is not clinically significant at the time of 
transplantation but is exacerbated by the rejection of the graft or by viral hepatitis. Cases of 
gastroduodenal artery steal syndrome have also been reported.  
Dramatic recovery of the graft and LFTs after cessation of the steal makes it mandatory to 
consider this condition in the differential diagnosis of postoperative hepatic dysfunction.  
Arterial steal syndrome is suggested by elevated levels of liver enzymes and the results of 
DUS and computed tomographic angiography. In steal syndrome hepatic artery is patent 
but characterized by sluggish flow. The filling of the intrahepatic arterial branches by 
contrast material is delayed in comparison with the filling of other branches of the celiac 
trunk. Poor peripheral hepatic parenchymal perfusion is associated with early and abundant 
filling of the splenic or left gastric artery, which also shows increased size and flow. The 
diagnosis is confirmed by angiography.  
Angiography offers the possibility of therapy by transcatheter splenic or left gastric artery 
occlusion with metallic coils or by placement of an endoluminal narrowing stent. The result 
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is checked by angiography. In each patient, vital signs should be monitored, LFTs 
reassessed, and DUS scheduled twice a day for 2 days and then once a day for 1 week. 
Significant recovery of the graft and LFTs after cessation of the steal syndrome makes 
mandatory to consider it in the differential diagnosis of postoperative hepatic dysfunction.  
5. Conclusions 
Anatomical variability is the rule rather than the exception in liver transplantation. Hepatic 
arterial reconstruction is one of the most difficult procedures in LDLT. HA reconstruction in 
LDLT is more complex in left grafts when compared with right grafts due to a higher 
incidence of multiple arteries in the former. This problem is surmounted by meticulous 
perioperative planning, intraoperative surgical innovations, and postoperative close follow-
up. Currently, dynamic contrast material–enhanced CT and MR imaging have replaced 
other imaging tests for preoperative evaluation. Surgeons who perform hepatic arterial 
reconstruction in LDLT should be highly trained in microvascular techniques. In LDLT with 
right lobe microvascular arterial anastomosis is not necessary, and vascular complications 
should be infrequent. In LDLT with left liver microsurgical techniques are a requisite that 
enables the reconstruction of arteries with reduced diameter or caliber difference, and thus 
decreases arterial complications. With the implementation of broadly applicable, practical, 
surgical techniques for arterial reconstruction, LDLT would be less laborious and with more 
consistent results and no contraindication for LDLT should be affirmed based on anatomical 
variants of arterial vasculature of the liver. Close surveillance of the vascular anastomoses 
and multidisciplinary approach to the treatment of vascular complication after LRLT 
considerably reduces graft loss and patient mortality. Gray-scale sonography coupled with 
color Doppler is the best first intention screening examination to be performed after hepatic 
transplantation. Arteriography not only remains the key examination for the diagnosis and 
evaluation of these complications but also has proved to be a graft-saving approach in the 
treatment of arterial complications.  
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Even with the recent technical advances in the surgical procedures used for living donor 
liver transplantation (LDLT), hepatic artery reconstruction is still one of the most difficult 
procedures in LDLT (Matsuda et al., 2006; Eguchi et al., 2008). Because hepatic artery 
complications in liver transplantation, such as hepatic artery thrombosis (HAT) or hepatic 
artery dissection (HAD), often lead to devastating consequences, such as graft loss or patient 
death (Yanaga et al., 1990a; Settmacher et al., 2000; Stange et al., 2003), hepatic artery 
reconstruction should be performed using the most reliable procedure. A graft hepatic 
artery to be reconstructed in LDLT usually has a narrower caliber and a shorter stump 
compared to the arteries used during cadaveric liver transplantation. We introduced 
microvascular surgery for hepatic artery reconstruction in LDLT at the beginning of our 
LDLT program (Uchiyama et al., 2002). The use of microvascular surgery in LDLT was first 
reported in 1992 (Mori et al., 1992). Thereafter, many transplant centers introduced this 
technique for hepatic artery reconstruction in LDLT and confirmed that its application to 
hepatic artery reconstruction in LDLT decreased the number of hepatic artery complications 
(Inomoto, et al., 1996; Millis et al., 2000; Wei et al., 2004; Takatsuki et al., 2006; Panossian et 
al., 2009). We performed 401 cases of LDLT between October 1996 and June 2011 and almost 
all hepatic artery reconstructions were performed by microvascular surgery under a 
microscope. Microvascular surgery for hepatic artery reconstruction has been performed by 
general surgeons in our department. In this chapter, we present our microvascular surgical 
techniques used for hepatic artery reconstructions in LDLT and the outcomes of these 
reconstructions in 401 LDLT cases. 
2. Preoperative anatomical evaluation of graft hepatic arteries 
In our early experience, the donors underwent invasive conventional angiography to assess 
the anatomy of the hepatic arteries. Now, we use only CT angiography for the assessment of 
the donor’s hepatic artery anatomy. Current CT angiography methods can be used to assess 
the donor’s hepatic artery anatomy preoperatively with almost 100% accuracy (Saylisoy et 
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al., 2005; Apisarnthanarak et al., 2011). Graft hepatic arteries are usually reconstructed using 
the recipient hepatic arterial branches (Fig. 1). 
 
Fig. 1. A schematic diagram of hepatic artery reconstruction. dLHA, left hepatic artery of the 
donor; dRHA, right hepatic artery of the donor; rLHA, left hepatic artery of the recipient; 
rRHA, right hepatic artery of the recipient 
When assessing the donor’s hepatic artery anatomy, the most important consideration is to 
precisely predict how many hepatic arterial stumps there will be on a graft (Fig. 2). 
Sometimes, a hepatic graft has multiple hepatic arterial stumps, which usually have a very 
narrow caliber (Uchiyama et al., 2010a). Thus, LDLT using such graft makes hepatic artery 
reconstruction difficult. Some transplant surgeons regard such a graft as a contraindication 
for LDLT (Broelsch et al., 1991; Kostelic et al., 1996), and others have reported various 
arterial manipulations in donors that can be used to make the hepatic artery reconstruction 
easier (Takatsuki et al., 2006; Douard et al., 2002). On rare occasions, a hepatic graft is 
expected to have three or more hepatic arterial stumps by CT angiography, in which hepatic 
artery reconstructions are extremely difficult. In such cases, the other side graft (i.e., right 
lobe) or a graft from another donor may be selected.  
 
Fig. 2. The results of a CT angiographic examination of a donor. The arrow (A) indicates the 
dividing point of the middle and left hepatic arteries when the left lobe graft is selected, 
while the arrow (B) indicates the dividing point of the right hepatic artery. LHA, left hepatic 
artery; MHA, middle hepatic artery; RHA, right hepatic artery 
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3. Preparation of graft hepatic arteries for hepatic artery reconstruction 
The arterial flows into the donor’s remnant liver should never be compromised. In procuring a 
graft liver, special care should be paid not to make wall dissections of graft arteries by 
ligating the proximal site of the hepatic artery with excessive force, because wall dissection 
of the arterial stump is usually irreparable. On the backtable, it is not necessary to flush the 
graft artery with preservation solution because the preservation time is very short in LDLT. 
In fact, cannulating a flushing tube into the narrow graft artery increases the risk of making 
a wall dissection. Furthermore, there is no need to trim the graft artery on the backtable.  
After the portal vein is reperfused and hemostasis is obtained to a certain degree, 
microvascular hepatic artery reconstruction is started. The micro-instruments and the 
microscope we usually use are shown in Figs. 3 and 4, respectively. Microvascular hepatic 
artery reconstruction is performed by 3 surgeons (Fig. 5). The primary surgeon and the first 
assistant face each other looking into the lens of the microscope. The second assistant 
exposes the surgical field. 
First, the hepatic graft is brought up or rotated in a proper position to fully visualize the 
graft hepatic arteries (Fig. 6). The graft hepatic arteries in a right lobe graft usually exist 
deep in the right subdiaphragmatic space. By putting several piles of folded gauze under 
the graft liver, the graft artery is brought up, which makes the hepatic artery reconstruction 
easier. The graft hepatic arteries in a left lobe graft are usually covered by the graft itself. By 
pulling the round ligament upward or using a brain retractor, the graft hepatic artery can be 
exposed. It is very difficult to expose the graft hepatic arteries on a lateral graft used for 
small infants because of the very small abdominal cavity relative to the hepatic graft. 
However, by rotating the graft liver clockwise and pushing it into the left subdiaphragmatic 
space made by pulling down the spleen, the graft hepatic artery can be exposed.  
 
Fig. 3. Instruments used for microvascular hepatic artery reconstruction (A) Needle holder 
(Aesculap, FD245R).  (B) Micro scissors (Aesculap, FD023R). (C) Angulated micro forceps (S 
& T, JFAL-3-18). (D) Straight micro forceps (S & T, JF-3-18) 
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Fig. 4. The surgical microscope used for microvascular hepatic artery reconstruction (Carl 
Zeiss, OPMI VARIO S88). This microscope has a foot pedal. The surgeon can adjust the 
microscope using this foot pedal without interrupting the procedure 
 
Fig. 5. The positioning of the microvascular surgeons. The primary surgeon stands on the 
right side of the recipient. The first assistant stands on the left side of a recipient, looking 
into the other lens of a microscope. The second assistant stands next to the first assistant and 
exposes the surgical field 
 




Fig. 6. The positioning of the hepatic grafts required to visualize the graft hepatic artery. 
Hepatic grafts are positioned in order to fully expose the graft arteries 
In preparing the graft hepatic arteries for anastomosis, they should be gently manipulated 
so as not to injure the arterial wall (Fig. 7). When a surgeon wants to move the arterial 
stump, only the surrounding connective tissue should be grasped.  
 
Fig. 7. Preparation of the graft hepatic artery. (A) The outer surrounding connective tissue is 
removed from the artery. (B) Sometimes, small branches are encountered. These are ligated 
with 8-0 ProleneTM string and cut. (C) The edge of the arterial stump is trimmed off. (D) 
Then, the graft hepatic artery is ready to be anastomosed 
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4. Preparation of recipient hepatic arteries for hepatic artery reconstruction 
The recipient arteries to be used for hepatic artery reconstruction are usually hepatic arterial 
branches, such as the left hepatic artery, the middle hepatic artery, and the right hepatic 
artery. First, we determine how many graft hepatic arteries should be reconstructed. In our 
experience, 28% of hepatic grafts have two or more graft hepatic arteries (Table 1).  
Most of them are left hepatic grafts. Despite the greater difficulty of hepatic artery 
reconstruction when selecting left hepatic grafts with multiple hepatic arteries, we prefer to 
use a left hepatic graft because it increases donor’s safety (Nishizaki et al., 2001; Soejima et 
al., 2006; Taketomi et al., 2009). 
 
Table 1. A summary of hepatic artery reconstruction. Note: Because one recipient received 
dual grafts, the total number of hepatic grafts is 402 in 401 LDLTs 
 
Microvascular Hepatic Artery Reconstruction in Living Donor Liver Transplantation 
 
71 
Most of the reported donor deaths are the result of right hepatic lobe donation (Miller et al., 
2004; Akabayashi et al., 2004; Trotter et al., 2006; Ghobrial et al., 2008). Although some 
surgeons have stated that it is not always necessary for all graft hepatic arteries to be 
reconstructed when backflows are observed from the second graft hepatic artery after 
reconstruction of the first artery (Ikegami et al., 1996; Kubota et al., 2000) because of the 
collateral arterial blood supply of the liver (Plengvanit et al., 1972), our policy for a graft 
with two or more graft hepatic arteries is that all graft hepatic arteries should be 
reconstructed if it is technically feasible (Uchiyama, 2010a). Incomplete hepatic artery 
reconstruction may result in relative arterial ischemia in a hepatic graft, which leads to 
biliary stricture, abscess formation, and so on (Yanaga, et al. 1990b; Suehiro, et al. 2002).  
To increase the number of candidate recipient hepatic arteries and in cases of very short 
graft hepatic arteries, the recipient hepatic arterial branches must be divided as peripherally 
as possible. When dividing hepatic arterial branches, a surgeon should pay special attention 
not to make a wall dissection. Patients with end-stage liver disease have enlarged hepatic 
arteries to compensate for their decreased portal venous flow, and as a result, they tend to 
have fragile hepatic arterial walls. Once an arterial wall dissection occurs, it often extends to 
the proximal celiac trunk and none of the tributary arteries of the celiac trunk can then be 
used for hepatic artery reconstruction. To avoid this devastating complication, we first 
gently tie a hepatic artery, then we place the second knot with a relatively secure force just 
above the first knot. The artery is then divided just above the second knot.  
In selecting which hepatic arterial branch to use as an inflow artery, we prefer to use the left 
hepatic artery (Uchiyama et al., 2010b). Patients with end-stage liver disease usually have a 
relatively large left hepatic arteries, of the proper size for hepatic artery reconstruction, 
because of the compensation for the decreased portal venous flow. Furthermore, our first 
choice for biliary reconstruction is currently duct-to-duct biliary reconstruction, which 
makes hepatic artery reconstructions using the recipient right hepatic artery relatively 
difficult. The recipient bile duct is partly nourished by small branches of the right hepatic 
artery. To make the right hepatic artery easy to use for reconstruction, the connective tissues 
between the common hepatic duct and the right hepatic artery are somewhat divided, 
which may disrupt those small nourishing arteries flowing into the common hepatic duct 
(Chen et al., 1999; Gunji et al., 2006). The ischemia of the bile duct is considered to be one of 
the leading causes of anastomotic biliary stricture (Fan et al., 2002). On the other hand, if the 
connective tissue is untouched for fear of disrupting the nourishing arteries, not only is it 
more difficult to reconstruct the hepatic artery using the right hepatic artery because the 
right hepatic artery does not have good flexibility, but also there will be a kink at the 
anastomosis site after performing duct-to-duct anastomosis. 
When the recipient hepatic arterial branches cannot be used for an inflow artery, as in the 
case of a stiff arterial wall caused by repeated transarterial chemoembolization for 
hepatocellular carcinoma (Lin et al., 2009), or intraoperative arterial injury, a surgeon should 
use any recipient arteries other than hepatic arterial branches, such as the gastric arteries 
(Wang et al., 2008; Ikegami et al., 2000), as an inflow artery because a hepatic graft without 
any arterial flow may often succumb to graft failure or sepsis. We call this mode of hepatic 
artery reconstruction extra-anatomical hepatic artery reconstruction (Uchiyama et al., 2010c). In 
reconstructing graft hepatic arteries extra-anatomically, we use the right gastroepiploic 
artery, the right gastric artery, the gastroduodenal artery, and so on (Table 2). 
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Table 2. A summary of the recipient inflow arteries used in hepatic artery reconstructions 
So far, we have used only 3 interposition vessel grafts for hepatic artery reconstruction, 
namely one right gastric vein graft (Uchiyama et al., 2007), one splenic artery graft and one 
superior rectal artery graft. The right gastric vein graft was used to fill a gap between the 
graft artery and the recipient inflow artery. The Y-shaped splenic artery graft was used to 
reconstruct two graft arteries from one inflow artery. The superior rectal artery graft was 
used to taper the caliber of a large recipient inflow artery. Because the use of an 
interposition graft necessitates at least two anastomoses, which may increase the rate of 
hepatic artery complications, it should be considered a last resort for hepatic artery 
reconstruction.  
In preparing the recipient arteries, the outer surrounding tissue around the recipient 
candidate hepatic arteries has to be meticulously removed (Fig. 8).  
Recipients with end-stage liver disease often have dense nerve fibers and lymphatic vessels 
around the hepatic arteries. These fibers and vessels are obstacles for hepatic artery 
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reconstruction and should be removed. Adequate blood flow is confirmed by releasing the 
proximal forceps. 
 
Fig. 8. Preparation of the recipient hepatic artery. (A) The outer surrounding tissue is 
removed from the recipient hepatic artery. (B) Sometimes, nerve fibers are firmly attached to 
the artery. These are dissected from the artery and divided. (C) After the proximal portion of 
the artery is clamped, the distal end of the artery is cut open. (D) The intact arterial flow is 
confirmed by temporary declamping of the artery, and the recipient artery is ready to be 
anastomosed 
 
Fig. 9. Hepatic artery reconstruction using a double-clip. (A) After removal of the outer 
connective tissue surrounding both the donor and recipient arteries, these are secured by a 
double-clip. Angle stitches (8-0 or 9-0 non-absorbable sutures) are placed on both edges of 
the arteries. (B) After the clips are moved inward so that both arteries are attached to each 
other, the angle stitches are tied. (C) Several stitches (usually 4 or 5 stitches) are placed 
between the angle stitches. The number of stitches is determined according to the diameter 
of the arteries. These stitches are left untied until all stitches are placed, because it is easier to 
place each stitch correctly before they are tied, which is called the untied suture technique 
(Harashina, 1977). (D) These stitches are tied one-by-one. Then, the double-clip is turned 
over. (E, F) Several stitches are placed on the other side of the arteries in the same manner 
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5. Hepatic artery anastomosis 
After the preparation of both the donor and recipient hepatic arteries is complete, then the 
final step is to actually reconstruct the graft hepatic arteries. When considering the 
hemodynamics of the arterial flow, a direct end-to-end anastomosis is the preferred mode of 
reconstruction. All hepatic artery reconstructions we experienced were done by a direct end-
to-end anastomosis. A size-discrepancy up to 2 times is usually acceptable. However, 
anastomosing so large a recipient artery to a thin graft artery may lead to a rupture of the 
anastomosis. In such cases, another recipient artery should be selected. So far, we have 
never experienced a case that required end-to-side anastomosis.  
5.1 Hepatic artery anastomosis using a double-clip 
We prefer to use a disposable double-clip for performing anastomosis (Fig. 9). The desired 
grasp force is 45 to 60 grams. By fixing both the graft and recipient arteries, excessive forces 
at the anastomosis can be avoided. 
 
Fig. 10. Hepatic artery reconstruction without a double-clip. (A) After removal of the outer 
connective tissue surrounding both the donor and recipient arteries, angle stitches are 
placed on the 6 o’clock and the 12 o’clock positions. (B) After the angle stitches are tied, 
these stitches are pulled in opposite directions using light clamps so that the arterial walls 
between the angle stitches are held horizontal with appropriate tension. (C) Several stitches 
(usually 4 or 5 stitches) are placed between the angle stitches. The number of stitches is 
determined according to the diameter of the arteries. These stitches are left untied until all 
stitches are placed, because it is easier to place each stitch correctly before they are tied, 
which is called the untied suture technique (Harashina, 1977). (D) These stitches are tied 
one-by-one. The arteries being anastomosed are turned over by pulling each angle stitch in 
the opposite direction. (E, F) Several stitches are placed on the other side of the arteries in 
the same manner 
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5.2 Hepatic artery anastomosis without a double-clip 
Sometimes, surgeons encounter a situation where a double-clip cannot grasp the arteries to 
be anastomosed because of the stiffness of the arteries or because the stump is too short. In 
such situations, hepatic arteries are reconstructed using two tension stitches placed at the 6 
o’clock and 12 o’clock positions (Fig. 10). 
6. Posttransplant management 
Daily Doppler ultrasound should be performed to check for intact hepatic arterial flows for 
7 days after transplantation (Fig. 11). We use neither anti-coagulant nor anti-platelet agents 
for the purpose of preventing hepatic artery thrombosis. Current Doppler ultrasound 
machines are so accurate (Kaneko et al., 2004) that they rarely give false positive results 
(good pulsatile hepatic arterial flows in the graft are detected even when there is a hepatic 
arterial problem). Whenever there is no pulsatile hepatic arterial flow on Doppler 
ultrasonography, the patient should immediately undergo contrast-enhanced CT. If there is 
a suspicion of hepatic artery complications, invasive angiography should be performed, and 
any attempts to restore the hepatic arterial flow into the graft need to be made within 
several hours, or devastating consequences (graft failure, sepsis, etc.) will occur.  
With regard to repairing hepatic artery complications, our first choice is surgical revision of 
the HA anastomosis, although there have been some reports regarding non-surgical 
interventional therapy or retransplantation (Maleux et al., 2005; Kodama et al., 2006; 
Fistouris et al., 2006).  
 
Fig. 11. Doppler ultrasonography is used to detect the intact hepatic arterial flow in the graft 
liver 
7. Hepatic artery complications after living donor liver transplantation 
So far, we have experienced 6 hepatic artery complications (Table 3, Fig. 12). Most of them 
occurred in our early experience. 
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reconstruction. All hepatic artery reconstructions we experienced were done by a direct end-
to-end anastomosis. A size-discrepancy up to 2 times is usually acceptable. However, 
anastomosing so large a recipient artery to a thin graft artery may lead to a rupture of the 
anastomosis. In such cases, another recipient artery should be selected. So far, we have 
never experienced a case that required end-to-side anastomosis.  
5.1 Hepatic artery anastomosis using a double-clip 
We prefer to use a disposable double-clip for performing anastomosis (Fig. 9). The desired 
grasp force is 45 to 60 grams. By fixing both the graft and recipient arteries, excessive forces 
at the anastomosis can be avoided. 
 
Fig. 10. Hepatic artery reconstruction without a double-clip. (A) After removal of the outer 
connective tissue surrounding both the donor and recipient arteries, angle stitches are 
placed on the 6 o’clock and the 12 o’clock positions. (B) After the angle stitches are tied, 
these stitches are pulled in opposite directions using light clamps so that the arterial walls 
between the angle stitches are held horizontal with appropriate tension. (C) Several stitches 
(usually 4 or 5 stitches) are placed between the angle stitches. The number of stitches is 
determined according to the diameter of the arteries. These stitches are left untied until all 
stitches are placed, because it is easier to place each stitch correctly before they are tied, 
which is called the untied suture technique (Harashina, 1977). (D) These stitches are tied 
one-by-one. The arteries being anastomosed are turned over by pulling each angle stitch in 
the opposite direction. (E, F) Several stitches are placed on the other side of the arteries in 
the same manner 
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5.2 Hepatic artery anastomosis without a double-clip 
Sometimes, surgeons encounter a situation where a double-clip cannot grasp the arteries to 
be anastomosed because of the stiffness of the arteries or because the stump is too short. In 
such situations, hepatic arteries are reconstructed using two tension stitches placed at the 6 
o’clock and 12 o’clock positions (Fig. 10). 
6. Posttransplant management 
Daily Doppler ultrasound should be performed to check for intact hepatic arterial flows for 
7 days after transplantation (Fig. 11). We use neither anti-coagulant nor anti-platelet agents 
for the purpose of preventing hepatic artery thrombosis. Current Doppler ultrasound 
machines are so accurate (Kaneko et al., 2004) that they rarely give false positive results 
(good pulsatile hepatic arterial flows in the graft are detected even when there is a hepatic 
arterial problem). Whenever there is no pulsatile hepatic arterial flow on Doppler 
ultrasonography, the patient should immediately undergo contrast-enhanced CT. If there is 
a suspicion of hepatic artery complications, invasive angiography should be performed, and 
any attempts to restore the hepatic arterial flow into the graft need to be made within 
several hours, or devastating consequences (graft failure, sepsis, etc.) will occur.  
With regard to repairing hepatic artery complications, our first choice is surgical revision of 
the HA anastomosis, although there have been some reports regarding non-surgical 
interventional therapy or retransplantation (Maleux et al., 2005; Kodama et al., 2006; 
Fistouris et al., 2006).  
 
Fig. 11. Doppler ultrasonography is used to detect the intact hepatic arterial flow in the graft 
liver 
7. Hepatic artery complications after living donor liver transplantation 
So far, we have experienced 6 hepatic artery complications (Table 3, Fig. 12). Most of them 
occurred in our early experience. 
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Patient #17 underwent an auxiliary partial orthotopic LDLT. The case was previously 
reported as a case report (Uchiyama et al., 2007). The left hepatic graft had a single left 
hepatic artery, which was reconstructed using the right gastric artery interposed by the right 
gastric vein graft. There was a restriction on the use of recipient inflow arteries because the 
native residual liver also had to receive arterial inflows. The patient underwent a follow-up 
CT examination at 4 years after the LDLT without any symptoms, and an aneurysm at the 
vein graft was found incidentally. Six months later, the patient underwent a follow-up CT 
examination again, and the aneurysm was found to be growing. We performed an 
aneurysm resection and hepatic artery re-reconstruction using the right gastroepiploic 
artery. The patient is now alive and still doing well at 12 years and 3 months post-
transplant. 
Patient #18 suffered refractory anastomotic bile leakage after the first LDLT and had to 
undergo repeated drainage tube insertions to drain infected biloma. On posttransplant day 
28, the serous transaminases were steeply elevated and the pulsatile hepatic arterial flows 
disappeared on Doppler ultrasonography. Emergency angiography was performed which 
revealed that there was no hepatic artery inflow into the hepatic graft. Although we tried to 
re-reconstruct the hepatic artery, the tissues around the hepatic hilum had become very 
fragile because of the infected biloma and we could not perform hepatic artery re-
reconstruction. The patient underwent re-LDLT and is still alive at 12 years and 2 months 
posttransplant. 
Patient #39 experienced an unstable clinical course after LDLT, in which hypotension, atrial 
fibrillation, and oliguria persisted. On posttransplant day 7, the serum transaminases were 
steeply elevated and no pulsatile arterial flows in the hepatic graft could be detected. 
Emergency angiography revealed that there was a hepatic artery thrombosis at the 
anastomosis. An emergency operation was performed to restore the hepatic arterial flows 
into the graft. The thrombus partially extended into the graft from the origin at the 
anastomosis. After the thrombus was removed from the graft hepatic artery as much as 
possible, the arterial re-reconstruction was accomplished using the recipient gastroduodenal 
artery. Nevertheless, the patient died of multiple organ failure with intact hepatic arterial 
flows on postransplant day 10. 
Patient #73 received a right hepatic graft and the right hepatic artery was anastomosed to 
the right hepatic artery of the recipient. On posttransplant day 7, the pulsatile flows on 
Doppler ultrasonography were shown to be weakened, and emergency angiography 
revealed there was an arterial wall dissection which extended 3 cm proximally from the 
anastomosis. The dissected wall was resected, and the graft hepatic artery was re-
reconstructed using the left gastric artery. 
Patient #203 received a right hepatic graft with two hepatic arterial stumps. The main right 
hepatic artery and the accessory A6 artery were each reconstructed using the anterior 
branch of the right hepatic artery and the posterior branch of the posterior branch of the 
right hepatic artery, respectively. This was an ABO-incompatible case, and a cannulation 
tube was inserted into the hepatic artery for local graft infusion therapy (Egawa et al., 2008), 
which was considered to have caused the later hepatic artery complication. On the 
posttransplant day 10, the pulsatile flows on Doppler ultrasonography were shown to be 
weakened, and emergency angiography revealed there was an arterial wall dissection which 
extended proximally from the anastomosis with intact A6 arterial flow. We considered that  
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this tiny A6 artery could not sustain the right hepatic graft, and a reoperation was 
performed. The dissected wall was resected, and the graft main right hepatic artery was re-
reconstructed using the recipient right gastroepiploic artery. 
Patient #292 received a left lobe graft with two graft hepatic arteries. The graft replaced left 
hepatic artery and the graft middle hepatic artery were anastomosed to the recipient left 
hepatic artery and the recipient middle hepatic artery, respectively. The patient was 
incidentally found to have an aneurysm at the anastomosis between the graft replaced left 
hepatic artery and the recipient left hepatic artery. The aneurysm was resected and the graft 
replaced left hepatic artery was re-reconstructed. 
8. Conclusion 
With the technical advances made in hepatic artery reconstruction, plus our experience with 
the procedures, we have not recently encountered any hepatic artery-related complications. 
Although mastering microvascular surgical techniques is time-consuming, we think that this 
is the most reliable procedure for hepatic artery reconstruction, especially in LDLT for small 
recipients. The next issue that must be addressed is how to securely pass these techniques to 
the next generation. 
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1. Introduction 
Patients scheduled for liver transplantation frequently have portal hypertension and 
consequently they are likely to have a high portal blood flow in the transplanted graft. 
When the graft volume is small in adult living donor liver transplantation with partial liver 
transplantation, various problems that may affect the prognosis often occur because the 
partial graft cannot sustain excessive portal blood perfusion. It is widely known that liver 
transplant recipients can potentially develop a specific syndrome known as “small-for-size 
syndrome”, when a small for size graft causes size mismatch in the presence of portal 
hypertension. The small-for-size syndrome can result in large-volume ascites, 
hyperbilirubinemia, and coagulopathy. The pathologic mechanism of small-for-size 
syndrome includes graft failure caused by excessive and destructive portal inflow into the 
small for size graft. The small-for-size syndrome is widely recognized by transplant surgeon 
as one of the important post-transplant events. Thus, sufficient graft volume is one of the 
important determinants of successful transplant and clinically satisfactory outcome. 
Particularly in the case of living donor liver transplantation, there is the added problem of 
insufficient donor pool and donor safety, but it is essential to maintain graft function under 
the given circumstances. The decision on the type of liver graft depends on various factors, 
such as recipients’ status and donor safety: a small for size graft tends to be selected due to 
problems related to donor selection and to ensure the safety of the donor. In this regard, 
many centers stipulate the absolute lack of various pre-transplant risk factors and a minimal 
graft size in order to prevent the development of this syndrome and good outcome.  
2. Pathophysiological mechanisms of small-for-size syndrome 
Small-for-size syndrome can occur in the special situation of partial liver graft 
transplantation, especially in adult living donor liver transplantation, with resultant size 
mismatching between graft size and recipient hepato-portal circulation. Once the partial 
liver volume graft is subjected to excessive portal inflow, portal hyperperfusion results in 
the development of the small-for-size syndrome. The basic pathophysiology in this 
syndrome relates to graft injury after transplantation, which is caused by graft size 
mismatch and portal hypertension, followed by the appearance of various clinical 
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abnormalities such as excessive ascites, hyperbilirubinemia, coagulopathy, encephalopathy, 
and renal dysfunction. Transplant recipients develop symptoms related to the above 
abnormalities after transplantation and post-transplant prognosis is reported to be less than 
ideal.  
To understand the pathophysiological mechanism of the small-for-size syndrome, several 
studies examined post-transplant biopsies. These studies reported histopathological 
evidence of mechanical injury and graft failure caused by destructive portal hyperperfusion. 
The main histopathological findings are: (1) Portal vein and periportal sinusoidal 
endothelial denudation and focal hemorrhage into the portal tract connective tissue; and (2) 
poor arterial flow and vasospasm, resulting in ischemic cholangitis and parenchymal infarct. 
Furthermore, electron microscopic examination showed sinusoidal congestion, excessive 
swelling of the mitochondria in hepatocytes, irregular large gaps of sinusoidal lining cells, 
and collapse of the space of Disse. These findings are considered to represent progressive 
damage of the graft resulting from microcirculatory failure due to irreversible endothelial 
injury after reperfusion. On the other hand, other studies examined the molecular basis of 
graft damage by analyzing intragraft gene expression. The results of these studies provided 
evidence for sinusoidal damage. Cases of small-for-size syndrome and associated graft 
dysfunction due to portal hyperperfusion, showed intragraft upregulation of endothelin-1 
and down regulation of heme-oxigenase-1 and heat shock protein-70. Others showed low 
portal venous plasma nitric oxide levels. In addition, experimental studies using animal 
models of the small-for-size syndrome showed intragraft over-expression of endothelin-1, 
early growth response -1 (Egr-1) and endotherin-1A receptor and significant changes in 
intragraft mRNA levels as well as plasma levels of inflammatory cytokines (interleukin [IL]-
6, IL-15, tumor necrosis factor [TNF]-alpha). Furthermore, the small for size isografts and 
allografts, with volumes measuring 50% or 30% of the liver graft volume, demonstrated 
higher expression levels of vascular endothelial growth factor (VEGF) and fetal liver kinase 
(Flk)-1 than the whole isograft and allograft.  In addition, Flk-1-positive activated 
macrophages were also detected in small for size isografts and allografts, which were 
probably induced by VEGF. In this regard, the expression of VEGF and its interaction with 
Flk-1 could mediate the inflammatory response, early activation of macrophages. Thus, the 
above changes in the small for size graft injury likely play important roles in the accelerated 
acute rejection process of the small for size allograft. 
Previous studies indicated that liver regeneration begins in the early period after partial 
liver transplantation. Although the detailed mechanism remains unknown at present, the 
high portal flow rate and high portal pressure are considered important triggers of liver 
regeneration. In partial liver transplantation, a high level of liver regeneration is observed 
when the graft size is small, or when portal pressure is high in cirrhotic patients. On the 
other hand, liver tissue damage and ischemic reperfusion injury caused by high portal 
pressure in small-for-size syndrome result in serious interference with the process of liver 
regeneration. Interestingly, IL-6 and TNF-alpha play key roles in liver regeneration, though 
they are also considered to represent markers of acute-phase tissue damage. Local activation 
and excessive production of these cytokines is associated with poor liver regeneration, since 
they can act as negative regulators of cell proliferation. In fact, TNF-alpha could trigger the 
cell death pathway after binding to the TNF-receptor. Thus, although the role of these 
cytokines remains controversial, they are considered to function as inflammatory cytokines, 
rather than as liver regenerative factors, in patients with small-for-size syndrome. 
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Furthermore, accumulation of oxygen free radicals in the graft could possibly contribute to 
graft dysfunction. 
3. Treatment strategy for small-for-size syndrome 
The most important step is prevention of small-for-size syndrome through perioperative 
treatment strategies that include approaches aimed at reducing excessive portal inflow as 
the major cause of small-for-size syndrome, and lowering the graft perfusion pressure. 
Furthermore, efforts should be made to prevent hepatic venous congestion due to 
insufficient vascular orifices or mechanical stenosis and kinking.  
An important factor in determining portal inflow volume and pressure is the blood 
perfusion level in the spleen, thus highlighting the benefits of splenectomy and ligation of 
the splenic artery. However, patients with end-stage hepatic failure exhibit a 
hyperdynamic state of splanchnic blood flow, compared with normal state, and are at 
increased risk of hemorrhage associated with seriously invasive surgical procedures. Thus, 
careful attention should be paid to the expansion of the dissection area during surgery, 
especially in patients with collateral circulation around the splenic artery, such as gastric 
coronary vein and spleno-renal shunt. However, the development of new surgical 
technique and advances in medical devices have allowed a reduction in blood loss during 
surgical dissection procedures and splenectomy. Although the invasiveness of surgical 
procedure such as splenectomy and splenic artery ligation could be diminished further, 
adverse events such as increased susceptibility to infection caused by low immunity and 
portal vein thrombosis, may occur after splenectomy. Thus, patients should be carefully 
selected for splenectomy and splenic artery ligation. 
Portosystemic shunt is currently considered an efficacious procedure in the treatment of 
portal hypertension. Especially adequate portosystemic shunt, which achieves favorable 
portal decompression to below 15 mmHg, could dramatically improve the post-transplant 
prognosis of patients with small for size graft. The procedure has allowed lowering the cut-
off value for graft weight-to-recipient body weight ratio from 0.8% to 0.6%. This procedure 
is anticipated to become the main strategy in the future to prevent the development of the 
small-for-size syndrome. However, the separation of the graft portal route, as seen in 
portosystemic shunt, may result in portal steal to the extrahepatic route, which sometimes 
leads to fatal events especially in cases with decreased graft portal vascular compliance, 
such as the case of steatotic liver graft or accute cellular rejection. Based on this potential 
complication, some centers have adopted certain precautionary measures against such 
complications using modifications of the shunt closing technique. 
The recently introduced approach of splenic artery embolization could be an effective 
procedure for portal decompression instead of the conventional treatment. Splenic artery 
embolization is described by some investigators as a rescue treatment for post-transplant 
small-for-size syndrome. In this regard, we previously reported that preoperative portal 
decompression by splenic artery embolization efficaciously reduced blood loss during 
operation and shortened the operating time, and that it contributed to favorable prognosis 
without serious complications related to the procedure itself. In our institution, preoperative 
embolization is selected for patients considered at risk of development of shunt in the  
peri-celiac trunk. The risk assessment is based on preoperative radiography showing 
possible problems with safety of splenic artery ligation. In each patient scheduled  
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The recently introduced approach of splenic artery embolization could be an effective 
procedure for portal decompression instead of the conventional treatment. Splenic artery 
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for preoperative splenic artery embolization, abdominal angiography was performed 12 to 
18 hours before transplantation. As a rule, a metallic coil was placed in the area adjacent to 
the root of the splenic artery and proximal to the bifurcation of the major pancreatic artery, 
to produce total embolization of the splenic artery trunk (Figure 1). Evaluation of post-
transplantation graft hemodynamics by Doppler ultrasonography showed a significant 
reduction in the level of graft portal perfusion following splenic artery ligation and splenic 
artery embolization in the portal modulation group, compared with the non-portal 
modulation group (Figure 2). In the portal modulation group, the efficacy of portal 
decompression following splenic artery embolization was equivalent to that after splenic 
artery ligation. Furthermore, hepatic arterial flow was significantly higher during the 
postoperative phase in the portal modulation group, reflecting arterial flow shift from the 
spleen to the hepatic artery or hepatic arterial buffer response (Figure. 1). 
 
Fig. 1. Preoperative splenic artery embolization as a prophylactic procedure for the 
prevention of small-for-size syndrome. Splenic artery was totally embolized adjacent to the 
root of celiac artery, 12-18 hours before liver transplantation. Splenic artery embolization 
reduced portal flow and increased hepatic arterial flow. Preoperative portal decompression 
also decreased blood loss and shortened operative time 
As a result, such change in arterial blood flow could also contribute to the prevention of 
splenic artery steal syndrome, which causes poor arterial blood supply. Based on this 
procedure, none of the patients developed portal vein thrombosis or septicemia, which are 
sometimes observed after splenectomy. 
Another issue related to liver transplantation is the post-transplant course. In this regard, 
high level liver regeneration is observed when the graft size is small, or when portal 
pressure is high in cirrhotic patients. Importantly, high serum IL-6 concentrations are 
considered to reflect high hemodynamic shear stress, which could lead to regenerative 
signaling pathway. However, in patients with extra small for size graft, regeneration of the 
graft liver does not occur sometimes, and liver tissue damage and ischemic reperfusion 
injury could result in increased release of inflammatory cytokines, such as IL-6 and TNF-
alpha, which lead to poor liver regeneration, i.e., these cytokines act as negative regulators 
of cell proliferation. Thus, although the role of these cytokines remains controversial, they 
are considered to function as inflammatory cytokines, rather than as liver regenerative 
factors, in patients with small-for-size syndrome, and thus, are considered as markers of 
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graft injury. The postoperative outcome depends on the extent of graft injury immediately 
after the transplantation and portal decompression can protect the liver graft from 
destructive portal hyperperfusion and reduce the levels of these inflammatory cytokines. 
Our previous study reported that prophylactic splenic artery embolization and ligation 
decreased serum IL-6 and TNF-alpha after graft reperfusion and resulted in certain graft 
liver regeneration and favorable outcome. Based on these new findings, in terms of 
treatment strategy in small-for-size syndrome, prophylactic treatment would be favorable 
compared with rescue therapy.  
 
Fig. 2. Box-and-whisker plots of portal vein flow and hepatic artery flow in patients of the 
non-portal modulation (PM) and PM groups during postoperative days (POD) 1, 3, 5 and 7  
Any decision regarding the treatment strategy for small-for-size syndrome, flexible stance is 
often needed. Among the various approaches, either decision could be suitable depending 
on the individual patient. For example, the patient characteristics and institutional operative 
policies could influence the final decision. While portosystemic shunt is widely used for the 
prevention of small-for-size syndrome, there is no doubt that splenectomy and splenic 
artery ligation are also suitable and effective techniques to produce portal decompression. 
Furthermore, splenic artery embolization prior to transplantation could be an alternative 
effective treatment modality especially in patients with severe portal hypertension, and with 
established collateral circulation in the peri-celiac trunk, which makes it difficult to perform 
splenic artery ligation or splenectomy. In this regard, when sufficient portal decompression 
cannot be achieved through a single technique, a combination of two or more procedures 
should be applied. In essence, a proper portal decompression therapy can inhibit portal 
overperfusion injury and prevent small-for-size syndrome and also have beneficial effects 
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on liver generation as well as improvement of post-transplantation prognosis. In addition to 
the reduction in the mortality rate after the development of the technique of living donor 
liver transplantation, from medical and economic standpoints, the cost benefits of liver 
transplantation can be fully expected based on the reduced use of blood products, and 
shorter hospitalization through improvement of perioperative clinical condition.  
4. Prediction of small-for-size syndrome and hospital mortality  
Theoretically, small-for-size syndrome is expected in cases of small for size graft with high 
portal inflow. However, several studies have demonstrated that small-for-size syndrome 
does not necessarily occur even in such situations. In other words, the development of small 
for size syndrome and post-transplant graft function could not be predicted from the graft 
size only. We hypothesized that early graft function does not only depend on graft size, but 
also on portal hypertension, donor age and recipient status. To test our hypothesis, we 
determined the perioperative risk factors in small-for-size syndrome and post-transplant 
hospital death. In this regard, there are only a few studies that have dealt with the 
prediction of small-for-size syndrome in living donor liver transplantation.  
We analyzed retrospectively 200 consecutive adult patients who underwent living donor 
liver transplantation in our hospital during the period from August 1998 to January 2010. 
We used multivariate analysis of hospital deaths for this purpose and various clinical, 
pathological and surgical parameters, after employment of cut-off values for these 
parameters using ROC analysis. Patients were divided into two groups according to the 
treatment protocol for the prevention of small-for-size syndrome. The first 50 patients had 
not received any prophylactic portal decompression. There were significant differences in 
the clinical parameters based on the time trend between the groups with and without 
prophylactic portal decompression. Interestingly, an aggressive operative stance was 
identified in the late time group and this correlated with the recipient age, donor age, 
MELD, and graft volume. Meanwhile, there was a significant learning curve, which seemed 
to reflect the development of the operative procedure, including the cold ischemic time, 
blood loss, and operative time (Figure 3). In the first 50 cases, the in-hospital mortality rate 
and 1-year survival rates of patients with a graft weight (GW)/recipient body weight (RBW) 
rate less than 0.8% were 27.3% and 63.6%, respectively (Figure 4). Multivariate analysis 
identified a single factor, which was a graft weight (GW)/recipient body weight (RBW) rate 
less than 0.8%, as a significant determinant of post-transplant hospital death (Table 1). From 
the 51th patients onward, prophylactic portal decompression was used in 70 of the 150 
patients in order to prevent small-for-size syndrome. The prophylactic portal 
decompression consisted of splenic artery embolization in 50 patients, splenic arterial 
ligation in 14, splenectomy in 5, and portocaval shunt in 1 patient. After the introduction of 
the prophylactic portal decompression in the later 150 cases, the hospital mortality rate and 
1-year survival rate of patients with GW/RBW less than 0.8% were 7.2% and 86%, 
respectively. After the introduction of prophylactic portal decompression, post-transplant 
prognosis did not correlate with a cut-off value of 0.8% for the GW/RBW ratio (Figure 4). 
Multivariate analysis of post-transplant hospital mortality rate in the later 150 cases 
identified donor age more than 54 years and MELD score more than 23, but not the 
GW/RBW, as significant perioperative risk factors (Table 2). In other words, the minimum 
GW/RBW ratio could be safely lowered to 0.68% with adequate portal modulation. 
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Variables n Odds ratio P-Value 
Recipient factors     
Age ≥ 50 (vs < 50 years)  22 / 28 23.4 0.99 
MELD ≥ 20 (vs < 20)  2 / 48 6.29 0.23 
Disease     
Cholestatic disease vs PLC 22 / 19 0.34 0.21 
Acute liver failure vs PLC 9 / 19 1.39 - 
Donor factors    
Age ≥ 53 (vs < 53 years) 10 / 40 1.15 0.92 
Graft type (right lobe vs left lobe graft) 38 / 12 0.29 0.46 
GW/RBW < 0.8% (vs ≥ 0.8%)  12 / 38 8.44 0.02 
Treatment and Operative factors    
Blood loss ≥ 50 (vs < 50ml/kg) 39 / 11 3.59 0.99 
CIT ≥ 80 (vs < 80min) 16 / 34 1.16 0.91 
WIT ≥ 50 (vs < 50min) 14 / 36 1.92 0.40 
Operating time ≥10 (vs <10 hrs) 38 / 12 4.56 0.74 
Table 1. Logistic regression analysis of post-transplant hospital mortality (the first 50 cases). 
PLC, Post-necrotic Liver cirrhosis; MELD, Model for End-stage Liver Disease; GW/RBW, 
Graft weight to recipient body weight ratio; CIT, Cold ischemic time; WIT, Warm ischemic 
time 
 
Fig. 3. Box-and-whisker plots of clinical factors in the first 50 cases (right side) and the later 
150 cases (left side) 
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Fig. 5. Correlation between graft size, MELD, and donor age in cases of small-for-size 
syndrome and hospital death 
To evaluate the impact of small for size graft on the outcome, we defined small-for-size 
syndrome as both prolonged functional cholestasis and intractable ascites. Prolonged 
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functional cholestasis was defined as total bilirubin >10 mg/dL at postoperative day 14, 
without any other cause of cholestasis. Intractable ascites was defined as daily production of 
ascites of more than one liter at postoperative day 14 or >500 mL at postoperative day 28. 
Production of ascites represented the daily volume of ascites estimated by discharge from 
the abdominal drain. According to this diagnostic criterion, small-for-size syndrome occurred 
in 21 of 200 cases (10.5%) and 5 cases had fatal outcome. Patients with the small-for-size 
syndrome consisted of 11 cases (22%) in the first 50 cases and 10 cases (6.7%) in the later 150 
cases, respectively. Furthermore, early hospital death was noted in 16 of 200 cases (8%). 
 
Fig. 6. Decision tree analysis of post-transplant hospital mortality (175 cases). MELD, model 
for end-stage liver disease; GRWR, graft weight to recipient body weight ratio; SAM, splenic 
artery embolization as portal modulation 
The occurrence of small-for-size syndrome and hospital death depends on the specific 
combination of graft size, donor age, and MELD. Even using large-size graft, the use of 
grafts with high MELD and from old-age donors tended to result in the development of 
small-for-size syndrome and hospital mortality (Figure 5). These results indicated that the 
use if sufficient graft volume does not prevent the development of small-for-size syndrome 
graft, and that the incidence of this syndrome depends on other risk factors, which affect the 
post-transplant prognosis. Concerning the prediction of small-for-size syndrome or post-
transplant prognosis, none of the analyses used could find significant risk factors. The 
decision tree analysis for hospital mortality indicated that the value of any one risk factor 
should affect the cut-off values of other risk factors (Figure 6). Thus, early graft function and 
hospital mortality are determined not only by graft size, but also by donor age and recipient 
status. Donor age and graft size should be matched to the recipient status when possible, 
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and when not possible, portal modulation should be considered. Splenic artery embolization 
could help reduce the morbidity and mortality rates, as well as increase the survival rates, 
and should be considered along with the other perioperative risk factors. 
Variable n Odds ratio P-Value 
Recipient factors    
Age ≥ 54 (vs < 54 years) 78 / 72 1.54 0.59 
MELD ≥ 23 (vs < 23) 24 / 126 3.66 0.001 
Disease    
Cholestatic disease vs PLC 21 / 115 0.61 0.73 
Acute liver failure vs PLC 14 / 115 1.39  
Donor factors    
Age ≥ 53 (vs < 53 years) 33 / 117 6.84 0.03 
Graft type (Right lobe vs Left lobe graft) 80 / 70 0.47 0.44 
GW/RBW < 0.68% (vs ≥ 0.68%) 26 / 124 1.41 0.72 
Treatment and Operative factor    
Portal modulation 70 / 80 0.61 0.54 
Blood loss ≥ 50 (vs < 50ml/kg) 101 / 49 1.90 0.61 
CIT ≥ 80 (vs < 80min) 35 / 115 1.91 0.40 
WIT ≥ 50 (vs < 50min) 42 / 108 1.87 0.74 
Operating time ≥ 10 (vs < 10hrs) 59 / 91 3.98 0.39 
Table 2. Logistic regression analysis of post-transplant hospital mortality (the later 150 cases). 
LC, post-necrotic liver cirrhosis; MELD, model for end-stage liver disease; GW/RBW, graft 
weight to recipient body weight ratio; CIT, cold ischemic time; WIT, warm ischemic time 
5. Conclusion 
Recently published clinical trials and basic research conducted by several groups have 
uncovered the mechanism of small-for-size syndrome, allowing the design and 
implementation of new treatment strategies. These advances have resulted in significant 
improvement in prognosis after living donor transplantation. Further improvement of liver 
transplantation and liver surgery techniques should result in better outcome of patients with 
small for size syndrome. 
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and when not possible, portal modulation should be considered. Splenic artery embolization 
could help reduce the morbidity and mortality rates, as well as increase the survival rates, 
and should be considered along with the other perioperative risk factors. 
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Treatment and Operative factor    
Portal modulation 70 / 80 0.61 0.54 
Blood loss ≥ 50 (vs < 50ml/kg) 101 / 49 1.90 0.61 
CIT ≥ 80 (vs < 80min) 35 / 115 1.91 0.40 
WIT ≥ 50 (vs < 50min) 42 / 108 1.87 0.74 
Operating time ≥ 10 (vs < 10hrs) 59 / 91 3.98 0.39 
Table 2. Logistic regression analysis of post-transplant hospital mortality (the later 150 cases). 
LC, post-necrotic liver cirrhosis; MELD, model for end-stage liver disease; GW/RBW, graft 
weight to recipient body weight ratio; CIT, cold ischemic time; WIT, warm ischemic time 
5. Conclusion 
Recently published clinical trials and basic research conducted by several groups have 
uncovered the mechanism of small-for-size syndrome, allowing the design and 
implementation of new treatment strategies. These advances have resulted in significant 
improvement in prognosis after living donor transplantation. Further improvement of liver 
transplantation and liver surgery techniques should result in better outcome of patients with 
small for size syndrome. 
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1. Introduction 
The purpose of this chapter is to review the various techniques of implantation for deceased 
donor liver transplants (DDLT). Given the overall broad nature of the topic, the focus will be 
exclusively on adult DDLT, without including split liver and living donor liver transplants.  
There are a total of five structures that have to be reconstructed in DDLT. These include the 
suprahepatic and infrahepatic vena cava, the portal vein, the hepatic artery and the bile 
duct. Prior to describing the various methods of implantation of the donor liver, we will 
briefly review the different options available for the recipient hepatectomy, as the surgeon’s 
choice of reconstruction of the vena cava will dictate the type of hepatectomy performed. 
For a bicaval anastomosis, the hepatectomy involves completely dissecting out the supra- 
and infrahepatic vena cava, mobilizing the inferior vena cava (IVC) off of the retroperitoneum, 
achieving full vascular isolation and subsequently removing the intrahepatic portion of the 
IVC with the native liver. In this scenario, the use of venovenous bypass may be required for 
hemodynamic stability of the patient. The traditional method involves reconstruction of the 
suprahepatic and infrahepatic donor cava to the corresponding structures in the recipient. 
A second option is to preserve the vena cava by dissecting the native liver off of the IVC 
completely. Subsequently, we describe several ways in which the cava is reanastomosed in 
the setting of caval preservation. One method is commonly known as the “piggyback” 
technique where two or all three recipient hepatic veins are joined together into a common 
orifice which is used as the site of anastomosis. Other configurations of caval anastomosis 
are also used, including side-to-side and end-to-side techniques. Finally, we discuss a 
modification of the lateral cavo-cavostomy. 
The remainder of the implantation is similar regardless of the method chosen for caval 
reconstruction. The next anastomosis is usually the portal vein (PV). For the most part, 
portal vein reconstruction is straightforward unless there is partial or complete thrombosis 
of the recipient portal vein. If thrombectomy fails, then a venous conduit may be necessary. 
Other salvage maneuvers are used if even a conduit is not possible. 
At this point, the liver is usually reperfused. In some situations, hepatic arterial reperfusion 
is performed simultaneously with portal, or even precedes portal reconstruction. Close 
cooperation between the surgical and anesthesia team is necessary at this critical time as 
reperfusion instability may result. 
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Hepatic arterial reconstruction probably has the most options, as anatomic variations are 
common, and depending on surgeon preference, different techniques of reconstruction are 
available. If there is inadequate inflow from the recipient’s hepatic artery or its branches, an 
arterial conduit between the recipient aorta and donor artery may be necessary.  
The last anastomosis is the biliary, which has been dubbed the “Achilles heel” of DDLT. 
Options for reconstructing the bile duct include common duct to common duct anastomosis 
for the donor and recipient. The second method is a Roux-en-Y hepaticojejunostomy. We 
will discuss the indications for a Roux reconstruction, and mention some controversies 
regarding biliary reconstruction. 
While an attempt is made to mention many variations in technique, the reader should bear 
in mind the fact that there are numerous small modifications that are done on a case by case 
basis based upon the surgeon’s preference and personal experience. 
2. Recipient hepatectomy 
Deceased donor liver transplantation (DDLT) can be divided into several distinct steps. The 
first is the recipient hepatectomy, followed by the anhepatic phase, and finally reperfusion 
of the donor graft and completion of the arterial and biliary reconstruction. It would be 
difficult to simply focus on the implantation of the donor graft without mentioning the 
recipient hepatectomy, as the choice of vascular reconstruction during the implantation 
essentially dictates the type of hepatectomy performed. 
A key factor to improving outcomes in DDLT is minimizing the cold ischemic time 
especially in marginal donors or in donation after cardiac death. Therefore, we prefer to 
have two surgical teams. Once the procurement team has visualized the donor liver and 
reviewed any biopsies if indicated, the decision is made to proceed or abort the recipient 
case. If the donor liver is deemed suitable, the recipient is brought to the operating room in 
preparation for the procedure. Our preference is to have both a pulmonary artery catheter 
placed for close hemodynamic monitoring, as well as a large bore bypass line placed in the 
right internal jugular vein in case of need for venovenous bypass. 
The hepatectomy can be quite challenging depending on factors such as the degree of 
portal hypertension, presence of adhesions, and clinical stability of the recipient. Typically, 
it is started by a bilateral subcostal incision with a vertical midline incision (Figure 1). 
Previous incisions or anatomy (e.g. presence of ostomy) may dictate where the incision is 
made. Also, if a combined liver and kidney transplant is planned, the subcostal portion can 
be made lower on the abdominal wall to facilitate placement of the kidney. With the 
standard incision, the right side is extended laterally to at least to the mid-axillary line to 
allow for adequate exposure for both dissection and placement of clamps on the IVC. The 
upper midline extension is carried to the xiphoid process, and, if necessary, the xiphoid is 
removed for better exposure of the suprahepatic IVC. The falciform ligament is then taken 
down and the coronary ligament is dissected until the anterior border of the suprahepatic 
IVC is identified. Next the left triangular ligament is divided and the left lateral lobe is 
mobilized. The next step is to mobilize the gastro-hepatic ligament, which would expose 
the left side of the IVC and the caudate lobe. If there is a replaced left hepatic artery it is 
ligated at this time. 
 




Fig. 1. Typical bilateral subcostal incision with upper midline extension 
Dissection of the portal structures proceeds from the left or right side depending on the 
surgeon’s preference. From the left, the gastro-hepatic ligament is divided anterior to the 
caudate lobe, and the lateral aspect of the portal vein is identified. Staying anterior to the 
PV, the proper hepatic artery is dissected out and transected. We do not routinely dissect 
out and divide the right and left hepatic artery individually high up in the hilum. However, 
some teams prefer to maintain length on the native artery if their preference is to use the 
bifurcation of the proper hepatic artery for reconstruction. Once the hepatic artery is 
divided, the only structure anterior to the PV is the common bile duct. This structure is 
taken down immediately distal to the insertion of the cystic duct. Finally, the only remaining 
structure in the hilum is the portal vein. At this time the PV is completely skeletonized from 
its bifurcation distally to near the first pancreatic branch proximally. One needs to ensure 
that the PV is completely mobilized circumferentially from the surrounding lymphatic and 
loose areolar tissue. 
The next step is mobilization of the IVC. The initial step is to dissect out and obtain control 
of the infrahepatic IVC. Once the plane of the IVC is established, we continue to the left and 
mobilize the lateral aspect of the caudate lobe off of the IVC. This is carried in a cephalad 
direction until the lateral aspect of the suprahepatic IVC is identified immediately above the 
insertion of the left hepatic vein. When the left side of the IVC is exposed, attention is then 
directed toward mobilizing the right lobe of the liver. The right triangular and hepatorenal 
ligaments are taken down and the right lobe is mobilized fully until the suprahepatic IVC is 
exposed immediately superior to the insertion of right hepatic vein. 
At this point, the dissection differs between the standard and caval sparing technique.  
2.1 Bicaval hepatectomy 
 For the standard bicaval technique, both the suprahepatic and infrahepatic IVC are 
circumferentially dissected out. Generally, the right adrenal vein has to be taken down to 
provide for adequate infrahepatic exposure. Care is taken near the right renal vein, adrenal 
gland, and right hepatic vein. Gently, the surgeon’s index finger is passed behind the 
suprahepatic IVC and the soft tissue posterior to the IVC is ensnared and retracted forward 
(Figure 2). This tissue is taken down either with electrocautery or tied off with silk tie if 
there is any concern for bleeding or retroperitoneal varices. 
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Once the intrahepatic cava is fully mobilized a test clamp is performed. For this, the surgeon 
manually compresses both the infrahepatic IVC and the PV, then checks with the anesthesia 
team to ensure patient stability. If the patient remains hemodynamically stable, then we 
proceed with the hepatectomy. Initially a clamp is placed on the PV proximally and the 
distal aspect of the PV is tied off with a silk tie at the level of its bifurcation and transected. 
Subsequently a vascular clamp is place on the infrahepatic IVC. This clamp can be either 
placed in a horizontal or vertical position. Finally, a clamp is placed on the suprahepatic 
IVC. The recipient’s IVC is transected between the clamps and the liver is passed off the field. 
 
Fig. 2. Hepatectomy with mobilization of retrohepatic vena cava 
While this technique avoids the extra time for going on venovenous bypass, two concerns 
arise. First, is that the recipient may initially be hemodynamically stable, but may become 
unstable during the anhepatic phase. Second, if there is concern for lack of exposure, such as 
edematous viscera, small recipient, or a large donor liver, proceeding in the anhepatic phase 
without bypass can lead to significantly worsening bowel edema and a more technically 
challenging implantation. For these reasons, we have a very low threshold for going on 
bypass. In general, however, venovenous bypass is used selectively nowadays depending 
on the recipient status and the bias of the surgical team (Reddy, 2005). 
 
Fig. 3. Venovenous Scheme: Systemic and mesenteric flow travels out of patient through 
centrifugal pump, and is reintroduced into systemic circulation through either the axillary 
or jugular vein 
To start systemic bypass, a femoral cannula is placed by cut-down or percutaneous 
technique in either groin, and the infrarenal cava is cannulated. Systemic return is through a 
cannula placed through cutdown in the axillary vein, or (as we prefer) through a 
percutaneously placed jugular cannula. Systemic bypass is then initiated while leaving the 
portal cannula of the circuit still clamped. Subsequently, the PV is clamped and taken down, 
and the PV cannula is then inserted and full venovenous bypass initiated (Figure 3). In 
certain situations,only the systemic and/or portal bypass portion of the venovenous circuit 
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is utilized. Once on venovenous bypass, the infrahepatic and suprahepatic IVC are clamped 
and the liver is explanted. Rarely, as with a very large liver (e.g. polycystic liver), the 
hepatectomy is facilitated by removing the left lateral segment of the liver first. 
2.2 Caval sparing hepatectomy 
For the caval sparing technique, the caudate and right lobes are mobilized as before. 
However, the right adrenal vein is left alone, and no dissection is carried out behind the 
cava. Instead, starting from the region of the infrahepatic cava, the liver is mobilized off the 
anterior surface of the IVC. Dissection proceeds either from left to right (or visa versa) 
depending on the anatomy. All short hepatic veins are dissected out and either tied with silk 
ties or oversewn with 5-0 prolene for larger branches. Larger retrohepatic veins may also be 
stapled.  
While the PV can be left intact during most of the piggyback dissection, many surgeons 
prefer to create a temporary end-to-side portacaval shunt to minimize mesenteric congestion 
and improve hemodynamic stability (Cherqui et al., 1994; Llado´ & Figueras, 2004). Other 
reasons to use a shunt include decreased bleeding, improved renal function, reduced liver 
congestion,and improved exposure and mobility of the liver.. Shunting is more important 
when the patient has not developed chronic mesenteric collateralization (e.g. fulminant 
hepatitis). When partial clamping of the cava is used in conjunction with a shunt, both 
systemic and mesenteric flow are preserved without the need for venovenous bypass. If no 
portal decompression is used, the portal vein is left intact as long as possible prior to 
removing the liver in order to prevent splanchnic congestion (Lerut, 2003). 
 
Fig. 4. Caval preservation: Liver is mobilized off retrohepatic cava in a caudal to cephalad 
direction. Shown above right renal vein is a temporary end-to-side portal caval shunt 
 The dissection is carried cephalad anterior to the IVC until the IVC ligament is identified, 
dissected out, and transected. We prefer to use an endovascular stapler on “thick” caval 
ligaments however one can clamp and cut the IVC ligament, and subsequently suture the 
remnant stump (large caudate lobes may increase the difficulty). Finally, the hepatic veins 
are isolated and completely dissected out. Many times, it helps to divide the right hepatic 
vein which facilitates exposure of the common middle and left trunk.  
If a portacaval shunt has not been created, at this time the PV is taken down, and depending 
on the reconstruction technique, the hepatic veins are either taken with a stapler or a 
Satinsky clamp is placed on the caval side of the hepatic veins, and the liver is removed. If 
the hepatic vein cuffs are to be used as part of the recipient anastomosis, the veins are 
transected intrahepatically to preserve length. The liver is now removed.  
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or jugular vein 
To start systemic bypass, a femoral cannula is placed by cut-down or percutaneous 
technique in either groin, and the infrarenal cava is cannulated. Systemic return is through a 
cannula placed through cutdown in the axillary vein, or (as we prefer) through a 
percutaneously placed jugular cannula. Systemic bypass is then initiated while leaving the 
portal cannula of the circuit still clamped. Subsequently, the PV is clamped and taken down, 
and the PV cannula is then inserted and full venovenous bypass initiated (Figure 3). In 
certain situations,only the systemic and/or portal bypass portion of the venovenous circuit 
 
Vascular and Biliary Anastomoses in Deceased Donor Orthotopic Liver Transplantation 
 
101 
is utilized. Once on venovenous bypass, the infrahepatic and suprahepatic IVC are clamped 
and the liver is explanted. Rarely, as with a very large liver (e.g. polycystic liver), the 
hepatectomy is facilitated by removing the left lateral segment of the liver first. 
2.2 Caval sparing hepatectomy 
For the caval sparing technique, the caudate and right lobes are mobilized as before. 
However, the right adrenal vein is left alone, and no dissection is carried out behind the 
cava. Instead, starting from the region of the infrahepatic cava, the liver is mobilized off the 
anterior surface of the IVC. Dissection proceeds either from left to right (or visa versa) 
depending on the anatomy. All short hepatic veins are dissected out and either tied with silk 
ties or oversewn with 5-0 prolene for larger branches. Larger retrohepatic veins may also be 
stapled.  
While the PV can be left intact during most of the piggyback dissection, many surgeons 
prefer to create a temporary end-to-side portacaval shunt to minimize mesenteric congestion 
and improve hemodynamic stability (Cherqui et al., 1994; Llado´ & Figueras, 2004). Other 
reasons to use a shunt include decreased bleeding, improved renal function, reduced liver 
congestion,and improved exposure and mobility of the liver.. Shunting is more important 
when the patient has not developed chronic mesenteric collateralization (e.g. fulminant 
hepatitis). When partial clamping of the cava is used in conjunction with a shunt, both 
systemic and mesenteric flow are preserved without the need for venovenous bypass. If no 
portal decompression is used, the portal vein is left intact as long as possible prior to 
removing the liver in order to prevent splanchnic congestion (Lerut, 2003). 
 
Fig. 4. Caval preservation: Liver is mobilized off retrohepatic cava in a caudal to cephalad 
direction. Shown above right renal vein is a temporary end-to-side portal caval shunt 
 The dissection is carried cephalad anterior to the IVC until the IVC ligament is identified, 
dissected out, and transected. We prefer to use an endovascular stapler on “thick” caval 
ligaments however one can clamp and cut the IVC ligament, and subsequently suture the 
remnant stump (large caudate lobes may increase the difficulty). Finally, the hepatic veins 
are isolated and completely dissected out. Many times, it helps to divide the right hepatic 
vein which facilitates exposure of the common middle and left trunk.  
If a portacaval shunt has not been created, at this time the PV is taken down, and depending 
on the reconstruction technique, the hepatic veins are either taken with a stapler or a 
Satinsky clamp is placed on the caval side of the hepatic veins, and the liver is removed. If 
the hepatic vein cuffs are to be used as part of the recipient anastomosis, the veins are 
transected intrahepatically to preserve length. The liver is now removed.  
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Caval sparing techniques are used in large part to maintain systemic (and portal flow, if a 
temporary portal caval shunt is used) without requiring venovenous bypass. Thus, the 
dissection is carried out without disturbing systemic flow of the cava. Sometimes, however, 
either a partially occluding clamp, or complete caval clamping is necessary if troublesome 
bleeding ensues. (Belghiti et al., 2001). Also, if necessary, venovenous bypass can be used, 
although proponents of caval preservation usually are striving to avoid systemic bypass. 
During the anhepatic phase, once the liver is explanted, the operative field is meticulously 
examined to ensure adequate hemostasis. This is the best opportunity to visualize the 
retrohepatic space before the new liver is implanted. 
3. Anhepatic phase 
The anhepatic phase consists of the IVC and PV reconstruction. 
The initial anastomosis in the implantation of the donor liver is the IVC reconstruction. 
There are several different techniques which we will discuss here. These include the 
standard bicaval method, the piggyback technique, the lateral cavocavostomy and a 
modification of the cavocavostomy technique. 
3.1 Bicaval technique 
For the standard bicaval reconstruction, both the suprahepatic and infrahepatic IVC of the 
recipient are already fully clamped. Depending on the patient’s clinical status and the 
surgeon’s preference, the patient may already be on venovenous bypass. The donor liver is 
brought onto the operative field. Some teams prefer to maintain a slow, continuous 
antegrade flush through the portal vein to keep the liver cold. For the suprahepatic IVC, 3-0 
prolene suture is used. Initially the corner stitches are placed on both the donor and 
recipient suprahepatic IVC and the liver is gently lowered into the surgical field. Both ends 
are tied and the posterior wall o f the IVC is anastomosed first from inside the lumen of both 
veins. An imbrication technique is used to prevent posterior leaks, and to exclude 
potentially thrombogenic adventitial surfaces. Subsequently the anterior wall is sutured.  
After the suprahepatic IVC anastomosis is complete, attention is turned to the infrahepatic 
IVC. The anastomosis is created with 4-0 prolene in similar fashion to the suprahepatic IVC. 
Prior to completing the lower caval anastomoses, the liver needs to be flushed with 
approximately 1 liter of cold crystalloid solution to remove by products of metabolism, air, 
and preservation solution. This is especially true if using University of Wisconsin solution 
which is high in potassium and can cause arrhythmias post-reperfusion. The crystalloid is 
flushed through the donor’s PV and the effluent is drained via the infrahepatic IVC.  
When the drainage is complete, the lower IVC anastomosis is completed. Sometimes the 
lower caval anastomosis is left untied to allow egress of blood if the surgical team prefers to 
also vent the liver with blood prior to final reperfusion. (Figure 5). 
3.2 Classic piggyback technique 
In the case of the piggyback technique, there is no infrahepatic IVC reconstruction. In this 
case the orifice of the right hepatic vein can be tied or stapled off, and the common opening 
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of the middle and left hepatic veins of the recipient are sewn to the donor’s suprahepatic 
IVC. However, joining all three hepatic veins and using a common orifice may be associated 
with less incidence of venous outflow obstruction (Parrilla et al., 1999; Tayar et al, 2011). 
Usually, it is technically difficult to place a clamp that will include all three veins during the 
hepatectomy phase. Therefore, in most instances, the orifice of the right hepatic vein and the 
common orifice of the left and middle hepatic veins are initially clamped separately. Once 
the liver is removed, a second clamp is placed to include all three veins The initial clamps 
are removed and the opening of all three veins are joined together. (Figure 6). Another 
technique described involves making a horizontal enlargement of the middle/left trunk to 
decrease outflow obstruction (Lerut et al, 1997). 
            
Fig. 5. Bicaval reconstruction: Suprahepatic anastomosis preceedes infrahepatic anastomosis 
              
Fig. 6. Classic piggyback reconstruction: Recipient hepatic veins are joined together (all three 
in this picture), and anastomosed to donor cava 
The donor liver is brought onto the operative field. Using 3-0 prolene, the donor’s 
suprahepatic cava is anastomosed to the common orifice of all three hepatic veins of the 
recipient. Similar to the bicaval technique the posterior wall is created first. Once the 
suprahepatic anastomoses is complete, one liter of cold crystalloid solution is flushed 
through the donor’s PV and the effluent is drained through the donor infrahepatic cava. 
Once the flush is complete, the orifice of the donor infrahepatic IVC is stapled off with a TA 
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stapler, or double tied off with 0 silk ties. Once again, some teams leave the infrahepatic side 
open for further blood venting prior to reperfusion. 
3.3 Piggyback modifications 
As surgeons gained more experience with the original piggyback concept, other variations 
of the caval reconstruction evolved ((Belghiti et al., 1992; Bismuth et al., 1992; Cherqui et al., 
1994,Lerut et al, 1997). These were developed to allow preservation of caval flow, and to 
decrease venous outflow complications. Configurations include lateral side-to-side 
cavocavostomy and end-to-side cavocavostomy (Figure 7).  
         
                                                 (a)                                                                   (b) 
Fig. 7. Piggyback modifications: (a) side-to-side and (b) end-to-side. The recipient hepatic 
veins have been stapled closed 
The hepatectomy for these techniques is similar to that described above for the classic 
piggyback technique. A portacaval shunt can be created depending on the operating team’s 
preference and the patient’s clinical status. To perform the side-to-side anastomosis, the 
recipient hepatic veins are transected and the donor cava’s suprahepatic and infrahepatic 
openings are eventually closed. A partially occluding clamp is placed on the recipient’s 
cava, and a longitudinal cavotomy is created (approximately 6 cm). A corresponding 
cavotomy is made on the donor cava, and a side-to-side anastomosis is carried out between 
the recipient and donor (Figure 8). This anastomosis is usually done from the left side of the 
table using an intraluminal technique. Depending on the placement of the stay sutures, a 
triangulated anastomosis can also be fashioned (Dasgupta, 2006).  
 
Fig. 8. Lateral-to-lateral cavocavostomy. The recipient hepatic vein orifices have been closed. 
A partially occluding clamp is placed on recipient side to preserve caval flow 
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The liver can be flushed with either cold crystalloid solution through the PV prior to 
completing the PV anastomosis, or blood can be introduced though the completed PV 
anastomosis and allowed to vent through the open end of the donor cava, which is 
subsequently stapled closed. 
One issue to keep in mind with this technique, is that even though the recipient IVC is not 
fully clamped, in order to create a longitudinal cavotomy, one needs to partially clamp the 
IVC and the patient’s hemodynamic status needs to be carefully monitored. Advantages of 
the cavostomy technique include a widely patent anastomoses which minimizes outflow 
obstruction. Furthermore, this technique allows for better exposure and easier anastomoses 
in cases with difficult exposure, such as a large donor liver. The mobility and positioning of 
the liver may even facilitate the biliary anastomosis (Sonnenday et al., 2008). 
Other variations of the piggyback technique include the end-to-side configuration (Figure 
7a) which may involve enlarging the donor opening with a longitudinal cavotomy through 
the suprahepatic portion of the donor cava. Also, the recipient hepatic vein orifices may be 
included, for example, by creating a longitudinal cavotomy through the common trunk of 
the middle/left veins (Figure 9) (Klintmalm & Busuttil, 2005).  
 
Fig. 9. Another variation utilizing partial caval clamping 
3.4 Modification of the cavocavostomy 
A final variant of the caval anastomoses is to combine the cavocavostomy incision with the 
orifice of the hepatic veins on both the donor and recipient. This has been referred to as a 
suprahepatic cavoplasty (Wu et al., 2001) or a triangulating cavocavostomy (Dasgupta et al., 
2006). It is similar to the variant of the piggyback technique described above (Figure 9) but 
creates a much larger cavotomy. Also, this method requires full clamping of the IVC and, 
therefore, the hemodynamic changes are similar to the standard bicaval technique and the 
recipient may require the use of complete venovenous bypass.  
However, unlike the bicaval technique there is no need for retroperitoneal dissection of the 
IVC, nor is there a need for piggyback dissection.  
For this method, the recipient suprahepatic and infrahepatic IVC are fully dissected out. If 
the patient tolerates a test clamp, we will proceed with the hepatectomy, otherwise 
venovenous bypass is initiated. The PV is clamped and transected at its bifurcation. The 
suprahepatic and infrahepatic IVC are also clamped. Using Metzenbaum scissors, the short 
hepatics are sharply divided until the level of the hepatic veins. A small patch of the anterior 
IVC can also be resected along with short hepatics. Subsequently the hepatic veins are also 
transected intrahepatically, creating a large “triangular” opening along the length of the  
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intrahepatic IVC which also includes the orifice of the hepatic veins. The orifice of the short 
hepatic veins are either included in the segment of the anterior IVC that was removed, or for 
the most part can be excluded by the suture line.  
Transected veins that will not become part of the anastomosis are suture repaired, and the 
three hepatic vein orifices are converted into one opening continuous with the cavotomy. 
Extraneous tissue on the remnant hepatic veins is trimmed in preparation for the 
anastomosis (Figure 10). 
For the donor liver, a slit is created in the posterior aspect of the IVC starting from and 
incorporating the suprahepatic caval opening. This cavotomy is created to match the 
opening of the recipient IVC, but does not extend fully to the infrahepatic IVC of the donor 
(Figure 10). Using 3-0 prolene, the three corner sutures are placed. Care is taken to avoid 
compromising the hepatic vein orifices on the donor liver. Initially the right lateral wall is 
created, followed by the left side, and finally the superior aspect. Sometimes, it may be 
easier to perform the entire anastomosis from the left side by doing the right suture line 
intraluminally. Again, one liter of cold crystalloid solution is perfused through the donor PV 
and effluent is drained through the infrahepatic IVC. The infrahepatic donor cava is stapled 
closed (or left open for blood venting). 
         
Fig. 10. “Modified” cavocavostomy (triangulated anastomosis). The recipient hepatic vein 
orifices are incorporated into the anastomosis. The cava is totally occluded. Three corner 
stitches are shown 
Though this modification requires full IVC clamping with potential need for venovenous 
bypass, it is our preferred method for several reasons. First, it does create the largest 
possible outflow. Second, in cases with poor exposure, there is no posterior suprahepatic 
caval anastomosis, and there is better exposure during both the caval reconstruction and 
after reperfusion to allow examination of the suture line. Finally, since the short hepatic 
veins will be either removed with the patch of IVC or incorporated into the anastomoses, the 
hepatectomy phase is considerably shortened since one can simply “cut off” the anterior 
wall of the cava once the clamps are placed. There is no need to meticulously dissect the 
liver off the IVC. Furthermore, bleeding during this phase of the hepatectomy is minimized 
since there is full isolation of the IVC during mobilization of the liver off of the IVC. 
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The technique can be done expeditiously, and, thus, as experience is gained with the 
technique, it may be possible to forego systemic and/or portal bypass. In addition, size 
mismatch problems between donor and recipient are decreased (Wu et al., 2001).  
A variant of this technique has been called the “infrahepatic” cavocavostomy. (Khanmoradi, 
et al., 2009) In this case, the donor cava is opened from the infrahepatic side and the 
suprahepatic side is closed. A side-to-side anastomosis is created. This technique has been 
touted as an alternative when either recipient or donor characteristics make using the 
suprahepatic cava hazardous. For example, if a transjugular shunt is present or if there is a 
significant size mismatch between donor and recipient. It has also been used as a rescue 
technique if there is outflow obstruction following a piggyback anastomosis. (Quintini et al., 
2008). 
To summarize, each of the relative pros/cons of the above techniques have been debated. 
Advocates for the classic bicaval technique state that most cases can still be done without the 
need for cava preservation unless, for example, the donor graft is relatively small, or if 
retroperitoneal inflammation precludes dissection (Klintmalm and Busuttil,2005). Also, 
venous outflow complications may be lower with end-to-end anastomosis vs piggyback 
technique (Glanemann et al., 2002). Some teams have found that, in their hands, venovenous 
bypass may not even be necessary a majority of the time, even with the classic technique 
(Vieira de Melo et al., 2011). In cases of unfavorable anatomy, as with a large liver or 
caudate lobe, classic caval resection may be easier (Navarro et al., 1997).  
Advocates for caval preservation state that greater hemodynamic stability, less bleeding, 
decreased warm ischemic time, improved renal flow, better visualization are advantages of 
caval preservation. Technical modifications have reduced venous outflow complications 
(Mehrabi et al., 2009).Also,venovenous bypass with its inherent problems (e.g. air embolism, 
nerve injury, wound infections) can often be avoided, and splanchnic congestion can be 
handled with temporary portal caval shunting (Belghiti et al., 1995; Llado’ & Figueras, 2004). 
In many cases,portal shunting can also be avoided if the portal vein is maintained until the 
hepatectomy is finished (Lerut et al., 2003). With experience, cases originally thought too 
difficult can be performed with caval preservation (e.g. large polycystic livers, Budd-Chiari, 
retransplantation) (Belghiti et al., 2001). 
Many comparisons have been studied, but it is difficult to achieve large numbers with 
prospective studies (Perkins, 2007; Kahn et al., 2006; Lai et al., 2011). Ideally, a surgeon can 
become familiar with all the techniques in order to adapt to different situations (Eghtesad et 
al., 2005). 
3.5 Portal vein anastomosis 
Generally speaking, the PV reconstruction is usually the most straightforward of all the 
anastomoses. This is due to a lack of extra-hepatic PV anatomic variability (unlike the 
hepatic artery), and the fact that an end to end anastomoses is essentially the only feasible 
way of reconstructing the donor and recipient portal veins.  
There are however two key points that need to be addressed. One is to ensure that there is 
no redundancy in the PV anastomoses as this can lead to kinking, poor flow, and increased 
risk of post-transplant PV thrombosis. The second point is the management of chronic PV 
thrombus in the recipient. 
 
Liver Transplantation – Technical Issues and Complications 
 
106 
intrahepatic IVC which also includes the orifice of the hepatic veins. The orifice of the short 
hepatic veins are either included in the segment of the anterior IVC that was removed, or for 
the most part can be excluded by the suture line.  
Transected veins that will not become part of the anastomosis are suture repaired, and the 
three hepatic vein orifices are converted into one opening continuous with the cavotomy. 
Extraneous tissue on the remnant hepatic veins is trimmed in preparation for the 
anastomosis (Figure 10). 
For the donor liver, a slit is created in the posterior aspect of the IVC starting from and 
incorporating the suprahepatic caval opening. This cavotomy is created to match the 
opening of the recipient IVC, but does not extend fully to the infrahepatic IVC of the donor 
(Figure 10). Using 3-0 prolene, the three corner sutures are placed. Care is taken to avoid 
compromising the hepatic vein orifices on the donor liver. Initially the right lateral wall is 
created, followed by the left side, and finally the superior aspect. Sometimes, it may be 
easier to perform the entire anastomosis from the left side by doing the right suture line 
intraluminally. Again, one liter of cold crystalloid solution is perfused through the donor PV 
and effluent is drained through the infrahepatic IVC. The infrahepatic donor cava is stapled 
closed (or left open for blood venting). 
         
Fig. 10. “Modified” cavocavostomy (triangulated anastomosis). The recipient hepatic vein 
orifices are incorporated into the anastomosis. The cava is totally occluded. Three corner 
stitches are shown 
Though this modification requires full IVC clamping with potential need for venovenous 
bypass, it is our preferred method for several reasons. First, it does create the largest 
possible outflow. Second, in cases with poor exposure, there is no posterior suprahepatic 
caval anastomosis, and there is better exposure during both the caval reconstruction and 
after reperfusion to allow examination of the suture line. Finally, since the short hepatic 
veins will be either removed with the patch of IVC or incorporated into the anastomoses, the 
hepatectomy phase is considerably shortened since one can simply “cut off” the anterior 
wall of the cava once the clamps are placed. There is no need to meticulously dissect the 
liver off the IVC. Furthermore, bleeding during this phase of the hepatectomy is minimized 
since there is full isolation of the IVC during mobilization of the liver off of the IVC. 
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The technique can be done expeditiously, and, thus, as experience is gained with the 
technique, it may be possible to forego systemic and/or portal bypass. In addition, size 
mismatch problems between donor and recipient are decreased (Wu et al., 2001).  
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suprahepatic side is closed. A side-to-side anastomosis is created. This technique has been 
touted as an alternative when either recipient or donor characteristics make using the 
suprahepatic cava hazardous. For example, if a transjugular shunt is present or if there is a 
significant size mismatch between donor and recipient. It has also been used as a rescue 
technique if there is outflow obstruction following a piggyback anastomosis. (Quintini et al., 
2008). 
To summarize, each of the relative pros/cons of the above techniques have been debated. 
Advocates for the classic bicaval technique state that most cases can still be done without the 
need for cava preservation unless, for example, the donor graft is relatively small, or if 
retroperitoneal inflammation precludes dissection (Klintmalm and Busuttil,2005). Also, 
venous outflow complications may be lower with end-to-end anastomosis vs piggyback 
technique (Glanemann et al., 2002). Some teams have found that, in their hands, venovenous 
bypass may not even be necessary a majority of the time, even with the classic technique 
(Vieira de Melo et al., 2011). In cases of unfavorable anatomy, as with a large liver or 
caudate lobe, classic caval resection may be easier (Navarro et al., 1997).  
Advocates for caval preservation state that greater hemodynamic stability, less bleeding, 
decreased warm ischemic time, improved renal flow, better visualization are advantages of 
caval preservation. Technical modifications have reduced venous outflow complications 
(Mehrabi et al., 2009).Also,venovenous bypass with its inherent problems (e.g. air embolism, 
nerve injury, wound infections) can often be avoided, and splanchnic congestion can be 
handled with temporary portal caval shunting (Belghiti et al., 1995; Llado’ & Figueras, 2004). 
In many cases,portal shunting can also be avoided if the portal vein is maintained until the 
hepatectomy is finished (Lerut et al., 2003). With experience, cases originally thought too 
difficult can be performed with caval preservation (e.g. large polycystic livers, Budd-Chiari, 
retransplantation) (Belghiti et al., 2001). 
Many comparisons have been studied, but it is difficult to achieve large numbers with 
prospective studies (Perkins, 2007; Kahn et al., 2006; Lai et al., 2011). Ideally, a surgeon can 
become familiar with all the techniques in order to adapt to different situations (Eghtesad et 
al., 2005). 
3.5 Portal vein anastomosis 
Generally speaking, the PV reconstruction is usually the most straightforward of all the 
anastomoses. This is due to a lack of extra-hepatic PV anatomic variability (unlike the 
hepatic artery), and the fact that an end to end anastomoses is essentially the only feasible 
way of reconstructing the donor and recipient portal veins.  
There are however two key points that need to be addressed. One is to ensure that there is 
no redundancy in the PV anastomoses as this can lead to kinking, poor flow, and increased 
risk of post-transplant PV thrombosis. The second point is the management of chronic PV 
thrombus in the recipient. 
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If the patient has been on venovenous bypass, at this time the PV cannula is removed and 
the PV clamp is replaced back on. Systemic venovenous bypass is continued. In cases where 
a portacaval shunt has been created, a vascular clamp is placed on the pancreas side, the 
caval aspect of the shunt stapled off, and subsequently the shunt is transected. 
In order to avoid redundancy in the PV anastomoses, one must keep in mind that the 
distance between the donor and recipient PV is greatly exaggerated during the anhepatic 
phase. The rib cage is significantly retracted in a cephalad direction and the visceral contents 
of the abdomen, including the stomach and duodenum, are retracted down during the caval 
anastomoses.  
Though this provides optimal exposure to the IVC and retroperitoneum, one must keep in 
mind that this does increase the space between the recipient and donor PV stumps. If this is 
not accounted for, once the retractors are removed, there could be a noticeable kinking and 
redundancy in the PV anastomoses. To avoid this complication, an attempt must be made to 
bring the two PV stumps as close to their natural position as possible. Loosening the rib cage 
retractors or placing folded laparotomy pads behind the dome of the liver are two ways of 
bringing the donor liver closer to its natural position. On the recipient side, relaxing the 
bowel retractors allows the foregut, including the duodenum to return to its normal 
position. We prefer to put a spoon clamp on the donor PV approximately one to one and a 
half inches proximal to its bifurcation. This helps us gauge both the length of the donor PV 
needed and also maintains its orientation. The vascular clamps on the donor and recipient 
PV are lined up to avoid twisting of the two veins. Any excess length on both the recipient 
and donor PV are trimmed off. The anastomoses is created with either 5-0 or 6-0 prolene. 
Again, similar to the IVC anastomoses, the back wall is anastomosed initially followed by 
the front wall (Figure 11). Near the completion of the PV anastomoses, the donor PV clamp 
is kept on, the recipient clamp is removed, and about 300-500ml of blood is flushed out to 
remove any potential clots that may have formed and also to flush out the stagnant blood 
from the viscera. The PV anastomoses is completed while leaving a “growth factor”. 
Essentially, the running prolene is not tied fully down, and an air knot which would be 
around one half the diameter of the PV is left to allow for the expansion of the anastomoses 
once blood flow is restored. This step is done to avoid narrowing at the suture line.  
 
Fig. 11. Portal vein anastomosis. The posterior wall is completed intraluminally. The 
completed infrahepatic anastomosis is shown 
The second potential problem with the PV anastomoses is the chronic PV thrombus that can 
be encountered in about 15-10% of liver transplant recipients (Yerdel et al., 2000). In the vast 
majority of cases, this clot is non-occlusive and a simple eversion thrombectomy re-
establishes flow. (Dumortiera et al., 2002). This is performed by grasping the edges of the 
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recipient PV with non-crushing clamps, elevating the thrombus away from the wall of the 
PV using a dissector, and continuing circumferentially. Once a substantial portion of the clot 
is mobilized, a grasping instrument- such as ring forceps, can be used to forcefully extract 
the thrombus (Figure 12). The vascular clamp on the recipient PV will have to be 
periodically released to allow for full extraction of the thrombus as well as to check inflow. 
Once adequate thrombectomy has been performed the anastomoses can be completed as 
described above. 
 
Fig. 12. Eversion thrombectomy of portal vein 
If one fails to re-establish flow through the main recipient PV, several options exist. A 
venous jump graft to the proximal portal vein or the superior mesenteric vein may be 
constructed using donor iliac vein. This graft is passed behind the stomach and anterior to 
the pancreas. To perform this, the recipient SMV has to be patent. This structure is dissected 
out below the level of the transverse colon and proximal to the insertion of the middle colic 
vein into the SMV. (Nikitin et al., 2009) (Figure 13). 
 
Fig. 13. Venous conduit: Donor iliac vein connects superior mesenteric vein to donor portal 
vein 
In case there is no good target SMV, the inferior mesenteric vein can be used as a potential 
inflow. Other potential inflow sources include the splenic vein or a large collateral. Finally, 
if a conduit is not an option, a caval hemi-transposition can be performed. In this technique, 
the donor PV is anastomosed to the recipient infrahepatic IVC and subsequently the 
recipient IVC is stapled above the level of the PV anastomoses to divert all flow through the 
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recipient PV with non-crushing clamps, elevating the thrombus away from the wall of the 
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transplanted liver. Unfortunately, outcomes with this method are inferior as may be 
expected (Yan et al., 2008; Selvaggi et al., 2007). Even more rarely, a conduit may be 
constructed using donor vessels to supply arterial blood to the portal vein (arterialization). 
4. Reperfusion phase 
After the IVC and PV anastomoses are complete, the next step is reperfusion of the donor 
liver. Prior to re-establishing flow, one must closely communicate with the anesthesia team 
to ensure that the patient is ready for reperfusion. During the initial portion of the 
reperfusion phase, the right heart is exposed to a large volume of cold preservation solution, 
which may also be high in potassium, and also contains elevated levels of cytokines 
secondary to the ischemia of the donor organ. This can potentially lead to right heart failure 
of arrhythmias. Therefore, ensuring that the anesthesia team is ready for reperfusion is of 
paramount importance. 
The sequence of unclamping and reperfusing the liver depends on the method of IVC 
reconstruction. In the standard bicaval method or the “triangulation” technique where both 
the suprahepatic and infrahepatic portions are clamped, initially the suprahepatic IVC 
clamp is removed and the caval suture lines are closely examined for hemostasis. Second the 
infrahepatic caval clamp is removed. Finally the PV clamp is removed slowly. If the 
surgeon’s preference is to vent the first several hundred cc’s of blood, this is done through 
the untied infrahepatic caval anastomosis, which is subsequently tied. Once reperfusion is 
complete, all suture lines and the operative field is examined for full hemostasis prior to 
proceeding. If the patient had been on venovenous bypass, at this time the femoral vein is 
decannulated.  
In the piggyback and cavocavostomy techniques, there is only one caval clamp. Once this 
clamp is removed and hemostasis is achieved, the PV clamp is removed. If blood is to be 
vented, this is achieved through an opening in the donor cava which is subsequently closed. 
As above, reperfusion syndrome is diminished by slowly reestablishing portal flow. 
After reperfusion, the liver is assessed. The liver should attain a normal appearance. flow is 
poor if the liver is soft and dusky; outflow is poor if the liver is abnormally tense and 
swollen. Some surgeons use a flow meter to assess the portal and arterial flow. 
5. Hepatic artery reconstruction 
Usually, hepatic arterial reconstruction follows reperfusion. The order of portal vs arterial 
reperfusion does not seem to matter; however, sometimes it may be necessary to complete 
the artery first and reestablish flow to the liver to decrease warm ischemic time (e.g. 
unexpected difficulty dealing with a portal vein thrombosis) (Busuttil & Klintmalm, 2005). 
Unlike the PV, the hepatic artery (HA) anastomoses can be performed in a variety of 
different ways. This is due in part to variations in the donor and recipient anatomy, the need 
to optimize inflow and the surgeon’s preference.  
For a donor HA with standard anatomy and no replaced or accessory branches, several 
options exist for reconstruction. The celiac axis with or without a patch of aorta can be used. 
Alternatively, the celiac axis can be shortened near the take-off of the splenic artery. 
 
Vascular and Biliary Anastomoses in Deceased Donor Orthotopic Liver Transplantation 
 
111 
Subsequently, the celiac axis and splenic artery orifice are joined to create a fishmouth patch. 
The stump of the left gastric artery is tied off. 
On the recipient side, if the HA had been dissected out above the bifurcation of the left and 
right hepatic arteries, a small vascular clamp or bulldog can be placed on the proper hepatic 
artery distal to the gastroduodenal artery (GDA) and the right and left branches of the HA 
are be joined to form a common orifice. A second option is to dissect the proper HA, identify 
and dissect out the GDA and continue by mobilizing the common HA proximal to the GDA. 
A vascular clamp is then placed on the common HA, the distal aspect of the GDA is tied off, 
and a patch is created between the orifice of the GDA and proper HA at this time.  
While any combination of the above mentioned options can be used, the main concern with 
the HA reconstruction is that any excessive length can lead to twisting and looping once the 
retractors are removed and the liver returns to its native position. This can lead to an 
increased incidence of HA thrombosis. Therefore, in order to avoid redundancy, our 
preference is to resect the excess celiac trunk and use the celiac-splenic patch on the donor, 
which is then anastomosed to the recipient proper HA – GDA patch (Figure 14). 
 
Fig. 14. Typical arterial reconstruction with “common” anatomy. Branch patches are created 
on both the donor and recipient ends 
The two most common variations encountered in the HA anastomoses are replaced ( or 
accessory) right and left hepatic arteries. In case of a replaced or accessory left HA, the 
reconstruction is simple. The left HA is kept in continuity with the left gastric artery. On the 
backtable, the main trunk of the left gastric artery is ligated distal to the take-off of the 
replaced left HA. There are several small branches coming off the left HA which are also 
dissected out and tied off. If the splenic-celiac axis patch can be created on the donor 
without compromising the take-off of the left gastric artery, a standard reconstruction is 
performed similar to previously described. The second option would be to use the celiac 
trunk on the donor side and tie off the stump of the splenic artery (Figure 15a). 
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Subsequently, the celiac axis and splenic artery orifice are joined to create a fishmouth patch. 
The stump of the left gastric artery is tied off. 
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                                             (a)                                                                                            (b) 
Fig. 15. Hepatic reconstruction examples with (a) replaced left on donor, and (b) replaced 
right on donor 
For a replaced right HA, the reconstruction is technically more challenging. This structure is 
usually procured with a segment of the superior mesenteric artery (SMA). While several 
methods have been described, a common technique used is to resect the excess right HA and 
SMA trunk and subsequently anastomose the lumen directly to the orifice of the donor 
splenic artery or GDA. Our preference is to use the GDA to minimize the chance of a kink or 
twist during the reconstruction on the backtable. The replaced right HA orifice is spatulated 
and the orifice of the GDA is extended onto the common hepatic artery to create for a wider 
anastomoses and better outflow (Figure 15b). 
If variations in recipient anatomy result in inadequate inflow from the common hepatic 
artery, another inflow source can be used. For example, if the celiac is inadequate (as in 
arcuate ligament syndrome), the gastroduodenal artery may be dominant. Likewise, if a 
replaced right is dominant, it may be more appropriate as the recipient vessel. If no vessel is 
adequate, an aorta to donor artery conduit is created using donor iliac artery. Usually, the 
infrarenal aorta is chosen as the recipient side, although sometimes the supraceliac aorta is 
chosen as the proximal side. Similar to a portal venous conduit, it is tunneled retrocolic 
between the stomach and the pancreas. The tunnel location may vary depending on the 
anatomy. The aortic side is created with 5-0 prolene and the donor side with 6-0 prolene 
(Figure 16). 
 
Fig. 16. Arterial conduit: Donor iliac artery connects infrarenal aorta to donor hepatic artery 
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While the incidence of HA thrombosis is low, both arterial reconstruction of multiple vessels 
and increased time to arterial reperfusion are risk factors for this complication. (Warner et 
al., 2011; Oh et al., 2001; Pastacaldi et al., 2001). Therefore, both technique and time are of 
essence. 
6. Biliary anastomosis 
Once the liver is reperfused, biliary reconstruction is initiated. An end-to-end anastomosis 
(choledochocholedochostomy) is the most commonly used configuration. Otherwise, a 
Roux-en-Y is usually chosen as the second choice. Indications for a Roux include technical 
difficulty apposing the two duct ends (e.g. after removing a large polycystic recipient 
liver),size discrepancy, and poor condition or blood supply of recipient duct (e.g. during 
retransplantation).  
Another indication for a Roux is a diseased recipient duct. This can be related to 
choledocholithiasis, biliary atresia, secondary biliary cirrhosis, or primary sclerosing 
cholangitis. Recently, the tradition of using a Roux for a disease such as primary sclerosing 
cholangitis has been readdressed, and some authors have reported the use of duct-to-duct 
anastomosis when there is no evidence of extra-hepatic stricturing involving the distal duct 
and/or the duct appears visually healthy (Distante et al., 1996; Heffron et al., 2003). The use 
of choledochoduodenostomy has also been reported. Also, duct to duct anastomosis has 
been used during retransplantation (Sibulesky et al., 2011) 
Whatever technique is chosen, the goal is to achieve a tension-free anastomosis between two 
well vascularized structures. To start the end-to-end anastomosis, it is helpful to elevate the 
liver with several packs placed behind the right lobe. The donor and recipient ends are 
trimmed to achieve healthy, bleeding surfaces. Bleeders are controlled with suture ligation. 
Cautery is avoided. If the donor side contains the lumen of the cystic duct, a small 
septotomy is made between the cystic and common hepatic duct to create a common orifice. 
If the cystic duct opening is not in continuity with the common duct, it is marsupialized to 
avoid creating a fluid-filled “sac” that may eventually contort the main duct. The 
anastomosis is accomplished with 5-0 or 6-0 absorbable, monofilament (PDS) creating the 
posterior wall first. Although many surgeons interrupt the anastomosis, we run the suture 
line. If size discrepancies exist, one end may need to be spatulated or partially closed to 
allow anastomosis. Most of the time, this does not seem necessary. 
Traditionally, a T-tube is used. It’s purpose is to provide access to the biliary system, to 
allow monitoring of the quantity and quality of bile, and to “splint” the anastomosis. The 
current trend, however, is to avoid the use of T-tubes. This is due to the recognition that T-
tubes may be associated with biliary leaks as well as other technical problems (Riediger et 
al., 2010; Sotropoulos et al., 2009). 
A Roux-en-Y is constructed in a standard fashion, usually dividing the small bowel 15-20 
cm distal to the ligament of Treitz, and making a 40cm defunctionalized limb. The bowel 
anastomosis can be sewn or stapled. The end of the limb is reinforced with a seromuscular 
imbricating stitch. The limb is brought to the porta through a retro- or antecolic approach. 
If the colon is present, and the patient has inflammatory bowel disease, a retrocolic 
position will make subsequent colectomy easier. The donor duct is anastomosed to the 
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While the incidence of HA thrombosis is low, both arterial reconstruction of multiple vessels 
and increased time to arterial reperfusion are risk factors for this complication. (Warner et 
al., 2011; Oh et al., 2001; Pastacaldi et al., 2001). Therefore, both technique and time are of 
essence. 
6. Biliary anastomosis 
Once the liver is reperfused, biliary reconstruction is initiated. An end-to-end anastomosis 
(choledochocholedochostomy) is the most commonly used configuration. Otherwise, a 
Roux-en-Y is usually chosen as the second choice. Indications for a Roux include technical 
difficulty apposing the two duct ends (e.g. after removing a large polycystic recipient 
liver),size discrepancy, and poor condition or blood supply of recipient duct (e.g. during 
retransplantation).  
Another indication for a Roux is a diseased recipient duct. This can be related to 
choledocholithiasis, biliary atresia, secondary biliary cirrhosis, or primary sclerosing 
cholangitis. Recently, the tradition of using a Roux for a disease such as primary sclerosing 
cholangitis has been readdressed, and some authors have reported the use of duct-to-duct 
anastomosis when there is no evidence of extra-hepatic stricturing involving the distal duct 
and/or the duct appears visually healthy (Distante et al., 1996; Heffron et al., 2003). The use 
of choledochoduodenostomy has also been reported. Also, duct to duct anastomosis has 
been used during retransplantation (Sibulesky et al., 2011) 
Whatever technique is chosen, the goal is to achieve a tension-free anastomosis between two 
well vascularized structures. To start the end-to-end anastomosis, it is helpful to elevate the 
liver with several packs placed behind the right lobe. The donor and recipient ends are 
trimmed to achieve healthy, bleeding surfaces. Bleeders are controlled with suture ligation. 
Cautery is avoided. If the donor side contains the lumen of the cystic duct, a small 
septotomy is made between the cystic and common hepatic duct to create a common orifice. 
If the cystic duct opening is not in continuity with the common duct, it is marsupialized to 
avoid creating a fluid-filled “sac” that may eventually contort the main duct. The 
anastomosis is accomplished with 5-0 or 6-0 absorbable, monofilament (PDS) creating the 
posterior wall first. Although many surgeons interrupt the anastomosis, we run the suture 
line. If size discrepancies exist, one end may need to be spatulated or partially closed to 
allow anastomosis. Most of the time, this does not seem necessary. 
Traditionally, a T-tube is used. It’s purpose is to provide access to the biliary system, to 
allow monitoring of the quantity and quality of bile, and to “splint” the anastomosis. The 
current trend, however, is to avoid the use of T-tubes. This is due to the recognition that T-
tubes may be associated with biliary leaks as well as other technical problems (Riediger et 
al., 2010; Sotropoulos et al., 2009). 
A Roux-en-Y is constructed in a standard fashion, usually dividing the small bowel 15-20 
cm distal to the ligament of Treitz, and making a 40cm defunctionalized limb. The bowel 
anastomosis can be sewn or stapled. The end of the limb is reinforced with a seromuscular 
imbricating stitch. The limb is brought to the porta through a retro- or antecolic approach. 
If the colon is present, and the patient has inflammatory bowel disease, a retrocolic 
position will make subsequent colectomy easier. The donor duct is anastomosed to the 
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Roux limb with absorbable monofilament. Some surgeons use an internal or external stent 
(Figure 17). 
  
Fig. 17. Roux-en-y biliary anastomosis 
7. Closure 
Once the biliary reconstruction is complete, systematic inspection of the field is carried out. 
Mechanical hemostasis is achieved. Non-mechanical bleeding is addressed by the anesthesia 
team. Generally, two drains are left, one behind the right lobe towards the supahepatic cava, 
and one near the biliary anastomosis in an infrahepatic position. The midline incision is 
closed in a single layer, the bilateral subcostal incisions in two layers. 
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Roux limb with absorbable monofilament. Some surgeons use an internal or external stent 
(Figure 17). 
  
Fig. 17. Roux-en-y biliary anastomosis 
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team. Generally, two drains are left, one behind the right lobe towards the supahepatic cava, 
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1. Introduction 
1.1 Liver transplantation relevance 
Liver transplantation is a surgical technique designed for the treatment of patients suffering 
from end stage liver disease and who would not otherwise have a chance to survive. After 
the first liver transplantation, performed by Thomas Earl Starzl on the first of March, 1963 in 
Denver, Colorado, thousands of procedures have been performed all around the world. 5300 
liver transplantations were performed in the USA during 2002 and 5142 in Europe. The 
European liver transplantation registry has 93634 transplantations registered until December 
2009 (www.eltr.org). 
The evolution of liver transplantation was not easy initially, and survival was inferior to one 
year until 1967. Liver transplantation was not considered as the gold standard treatment for 
end stage liver diseases by National Institutes of Health until 1984 (National Institutes of 
Health Consensus Development Conference on Liver Transplantation, 1984). Two years 
later, this procedure was included by the Public Health department of the USA as a 
treatment modality (U.S. Department of Health and Human Services, Public Health Service, 
Health Resources and Services, 1986). 
2. Principles and techniques for liver transplantation 
Orthotopic liver transplantation requires total hepatectomy and substitution of the native 
liver by another one in the right hypochondrium. Vascular reconstruction is needed for the 
inferior vena cava, portal vein, and the hepatic artery. Biliary reconstruction is also needed, 
by either an end to end biliary anastomosis or a biliodigestive anastomosis. 
Classic technique for orthotopic liver transplantation requires resection of the intrahepatic 
part of the inferior vena cava, and the use of a veno-venous bypass to keep venous return to 
the heart. This technique has a considerable morbidity and mortality in some cases, and can  
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be avoided if resection of the inferior vena cava is not done, preserving it during the 
procedure. 
3. Anatomy of hepatic veins 
Couinaud described eight segments of the liver in which each segment has an independent 
vascular inflow and outflow and biliary drainage. Based on the location of the hepatic veins, 
the right liver is divided into the anterior section (segments V and VIII) and the posterior 
section (segments VI and VII). On the left, the falciform ligament demarcates the left lateral 
section (segments II and III) from the left medial section (segment IV). The caudate lobe 
(segment I) lies anterior to the IVC. 
The venous drainage of the liver is through the hepatic veins that ultimately coalesce into 
three hepatic veins that drain into the IVC superiorly. The left and middle hepatic veins may 
drain directly into the IVC but more commonly form a short common trunk before draining 
into the IVC. The right hepatic vein is typically larger, with a short extra hepatic course and 
drains directly into the IVC. Additional drainage occurs directly into the IVC via short retro 
hepatic veins and, on occasion, an inferior right accessory hepatic vein. The hepatic veins 
within the parenchyma are unique in that, unlike the portal venous system, they lack the 
fibrous, protective, encasing the Glisson capsule (Ger, 1989)  
The liver has a rather constant anatomic pattern, the knowledge of which allows for a safe 
surgical approach. There are some anatomic irregularities, in these cases a computed three-
dimensional reconstruction of anatomic detail is possible following computed tomographic 
or magnetic resonance imaging contrast scan. Software packages are currently available that 
allow for the mapping of the individual anatomy as well as for the calculation of volumes 
corresponding to the whole liver, liver sectors, and segments (Molmenti, 2007) 
Ultrasonography facilitates intraoperative mapping of the internal anatomy of the liver. The 
portal venous anatomy can readily be identified by the hyperechogenic Glisson capsule 
surrounding the portal veins, whereas the hepatic veins lack this. 
The IVC maintains an important and intimate association with the liver as it courses in a 
cranial-caudal direction to the right of the aorta. As the IVC travels cranially, it courses 
posterior to the duodenum, pancreas, porta hepatis, caudate lobe, and posterior surface of 
the liver as it approaches the bare area where it receives the hepatic venous outflow from 
the hepatic veins. Multiple small retro hepatic veins enter the IVC along its course, mostly 
from the right hepatic lobe. Hence, in mobilizing the liver or during major hepatic 
resections, it is imperative to maintain awareness of the IVC and its vascular tributaries at 
all times (Abdel-Misih, 2010) 
4. Recipient implantation 
In the Classic technique of orthotopic liver transplantation (OLT) the retrohepatic inferior 
vena cava (IVC) is included in the hepatectomy of the native liver (Starzl, 1968). To limit the 
hemodynamic complications associated with complete caval clamping, the routine use of 
the veno–venous bypass (VVB) was accepted particularly in noncirrhotic patients. (Shaw, 
1984). Although VVB has been proposed in order to reduce these hemodynamic disorders it 
is associated with high morbidity and increased operation time (Veroli, 1992 & Khoury, 
1987, 1990) 
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Preservation of the inferior vena cava (IVC) during orthotopic liver transplantation (OLT), 
described by Calne and Williams in 1968, was popularized in 1989 by Tzakis as the 
piggyback procedure (PB). The main advantages of this procedure were to avoid retrocaval 
dissection, to reduce the risk for bleeding and facilitate caval anastomosis in patients 
receiving large-for-size grafts (Tzakis, 1989 & Parrilla, 1999). 
5. Caval anastomosis 
Several methods of graft-to-inferior vena cava (IVC) implantation during orthotopic liver 
transplantation with preservation of the caval flow have been described. Large studies have 
shown that optimal outflow is essential to a successful piggyback procedure (Navarro & 
Parrilla, 1999). In the series by Tzakis (Tzakis, 1989) the caval anastomosis was performed 
between the supra hepatic part of donor IVC and the common orifice of all three hepatic 
veins or the common orifice of two hepatic veins (left and middle or right and middle). This 
is the so-called PB technique. 
In 1992, Belghiti developed a technique of caval anastomosis in a side-to-side fashion 
(Belghiti, 1992). In this technique, both ends of the donor IVC are closed. Anastomosis is 
made between two newly created openings: one on the anterior wall of the recipient IVC 
and one on the posterior wall of the donor IVC , but because of insufficient exposure during 
implantation of large grafts and to facilitate postoperative trans-jugular biopsy, they used an 
end-to-side fashion after 1993. (Belghiti, 1995) 
The third type of caval anastomosis is the end-to-side (ES) technique and can be found in the 
literature some modifications of this technique. Cherqui et al. described in their series, the 
distal end of the donor infra hepatic IVC was closed and the anastomosis was made between 
the end of the donor supra hepatic IVC and a longitudinal incision on the anterior wall of 
the recipient IVC. Additionally, a temporary portocaval shunt was routinely used (Cherqui, 
1994). Other authors report several variations of the technique, the middle and left hepatic 
veins are exposed and a Satinsky side clamp is applied to the caval side with partial IVC 
occlusion. The middle and left hepatic veins are divided, and the recipient liver is removed. 
A single hepatic venous outflow orifice is created from the middle and left hepatic venous 
trunks, and this orifice can be extended caudally (Fleitas, 1994 & Belghiti, 1995). 
Some authors suggest that the technique the 3-vein appears to be the most physiological 
way of achieving this goal. Although it has often been mentioned, the approach to creating a 
large 3-vein stoma without complete occlusion of the IVC is difficult. As Tayar reported 
(Tayar, 2011), anastomosis of the graft IVC to the joined orifice of the 3 main hepatic veins 
with partial caval occlusion was first mentioned by Lazaro (Lazaro, 1997). 
PB technique can be associated with some disadvantages and complications, including 
hepatic venous outflow obstruction (Cescon, 2005) and thrombosis in up to 10%, because of 
the inappropriate size of the hepatic vein outlet, which results in venous congestion of the 
liver allograft. This congestion increases the chance of post-transplant ascites and Budd-
Chiari syndrome (BCS) (Bilbao & Cirera, 2000; Mehrabi, 2009) 
6. History of the “piggyback” technique 
During the 5th and the 6th decade of 20th century, two pioneers in liver transplantation, 
Francis Daniels Moore and Thomas Earl Starzl, in Boston and Chicago respectively, were 
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trying to perform with success an experimental transplantation. Unfortunately, their model 
in dogs, did not tolerate blood flow interruption neither at the IVC, nor at the portal vein 
because they supposed half of the venous return of the animal. Bypass dispositive had to be 
developed to avoid the hemodynamic compromise that the total hepatectomy supposed in 
the animal (Moore, 1959) and, in the end, they were included as routine tools for 
transplantation surgery in the first era. Nevertheless, Calne and Starzl noticed that in human 
adults, it was not always necessary to bypass neither portal nor inferior cava vein blood 
flow during the anhepatic phase of the transplantation (Calne, 2008). 
Liver transplantation with IVC preservation was first performed by Sir Roy Calne in 
February 1968, at the Addenbrooke´s Hospital in Cambridge (UK) (Calne, 1968). Patient was 
a 46 year old female suffering from cholangiocarcinoma and donor was a 5 year old child 
that had virus related encephalitis. Because of the anatomical difference, Calne had to drain 
liver graft to the supra hepatic veins of the patient, completely preserving inferior cava vein 
during the procedure. The patient survived for 11 weeks, and it was the 3rd liver 
transplantation in Europe, and the 19th all around the world. 
Later, Tzakis and cols. (Tzakis, 1989) described this technique in 24 cases, in the early 1988 
with an indication index of 19%. They reported a greater technical difficulty of the 
procedure, the possibility of affected margins in the oncological indications at that moment, 
and a case with transitory thrombosis of the infra hepatic remnant cava vein, not 
recommending the routine use of inferior cava vein preservation. 
7. Our technique for venous outflow drainage in orthotropic liver 
transplantation 
In order to avoid the use of veno-venous bypass and to routinely preserve the IVC in our 
liver transplantation program, we adjusted our technique to the anatomical differences in 
the venous drainage of the liver. We designed our own model as follows (G. Fleitas, 1994): 
7.1 Total hepatectomy with complete preservation of the IVC 
Once identified and isolated, the liver pedicle elements are dissected adequately. With the 
vascular exclusion performed, we practice complete section of the falciform and triangular 
ligament in order to expose the confluence of the right hepatic vein and the left set (medial 
and left hepatic veins that usually drain together). After that, through the cavo-hepatic 
space, we perform a caudo-cranial dissection of the caudate lobe, with selective ligation of 
the hepatic veins. Their number varies, but the lesser the caliber, the greater the number is. 
The presence of a greater “inferior hepatic vein” that drains segment VI is very frequent. 
Usually, dissection extends by the left side of the IVC; dividing IVC and the caudate lobe 
until the arcuate ligament of the cavodiaphragmatic hiatus, very close to the mouth of the 
left phrenic vein, which usually has no venous drainage.  
Once this space has been dissected, and the anterior hepatic veins have been tied and cut 
(usually sagittal to the IVC) and inferior and medial part of caudate lobe is dissected 
(usually hypertrophied because of cirrhosis) it is possible to easily pass in between both 
hepatic veins, at their mouth in the IVC. We isolate and clamp the left venous set and cut it, 
leaving enough margins for a safe cavo-caval anastomosis. After this, usually the right 
hepatic vein mouth in to the liver is exposed at a coronal level of the IVC, approximately  
 




Fig. 1. Dissection of the infrahepatic IVC and left caudate lobule 
 
Fig. 2. Suprahepatic left and middle hepatic veins dissection 
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3 cm. far from the left venous set, suturing it with a continuous 3/0 polypropylene. After 
that, the right triangular ligament is cut, and right side of the IVC is dissected, cutting the 
corresponding veins, until caudate lobe is completely free from the IVC. This is the way how 
total hepatectomy is completed. 
7.2 Carving liver graft drain mouth 
This is an essential part of our technique. During this part, we clean the IVC of the graft, 
removing the tissues that are around its supra hepatic portion, cutting it at a level next to the 
supra hepatic veins mouth, at the level of the phrenic veins mouth, leaving a vascular sleeve 
to avoid the supra hepatic veins mouth being involved in the anastomosis. 
 
Fig. 3. Schematic lateral caval vein clamping and final result 
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Fig. 6. Preparing liver graft. Infra hepatic caval vein stump partial closure 
 
Fig. 7. The outlet and the entire graft IVC prepared for implantation 
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7.3 Left supra hepatic veins set cavoplasty 
While monitoring hemodynamic parameters (Cardiac output and pressure at the inferior 
cava vein), we perform a lateral partial clamp of the cava vein, enough to carve a good 
venous sleeve made at the confluence of the left and medial supra hepatic veins, concordant 
in size to the graft venous sleeve made before. This clamping also allows temporal porto-
cava anastomosis in case it is required without hemodynamic damage. 
7.4 Inferior vena cavotomy 
In some cases, when a left venous set can not be well defined or does not exist, and replace 
by a group of tiny veins interfering with safe anastomosis with a good drainage, we perform 
a craneocaudal cavotomy “de novo” in the IVC, as close to the right atrium as possible to 
achieve a negative pressure that allows better venous drainage of the liver graft, particularly 
in cases of Budd-Chiari Syndrome. 
7.5 Enlargement of the venous outflow orifice of the graft 
In order to achieve wider drainage of the supra hepatic veins, caudal cavotomy can be 
performed in the medial posterior side of the graft IVC, until supra hepatic veins orifices can 
be easily seen. 
 
Fig. 8. Piggyback posterior side anastomosis close to right hepatic vein outlet 
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7.6 Graft implantation 
Once adequate corresponding anastomotic orifices are achieved, and while keeping the 
vascular clamp on the recipient side of the IVC, we perform end to side, cavo-caval 
anastomosis using continuous 3/0 polypropylene. The aim is to provide wide anastomosis 
trying to achieve good outflow drainage of the graft. The distal end of the graft IVC is left 
open to allow “washing” of the graft after reperfusion, once the porto-portal anastomosis is 
done. 
8. Advantages of the piggyback technique 
Although initial attempts at preservation of the inferior vena cava in orthotopic liver 
transplantation by Sir Roy Calne, the so-called piggyback (PB) technique, was not initially 
worldwide accepted, it has become the most commonly used procedure in liver 
transplantation. Twenty years were necessary for Tzakis to describe the technique and its 
advantages over the classical caval reconstruction technique. Progressively in the 90’s more 
transplant groups reported the utility and feasibility of the piggyback. 
In addition, some modifications of the initial technique has been described, as the latero-
lateral cavoplasty which added some benefits as well as the use of different types veno-
venous bypass or portocaval shunts. These two options are controversial, with some 
benefits and drawbacks, and are not widely used. (G. Fleitas, 1994; Ducerf, 1996; Lai & 
Vieira, 2011). 
The advantages of the piggyback come from the disadvantages of the classical technique, 
due to clamping of the IVC next to the diaphragm and above the renal veins, during the 
anhepatic phase. This results in decreased venous return to the heart and reduction in 
cardiac output by as much as 50% and in blood pressure (Vieira, 2011). On the contrary, 
PB technique preserves caval flow, reduces hemodynamic instability, the needs of 
transfusions with less hemorrhage and allows shorter ischemia and operative times as 
will be explained. 
During the anhepatic phase, the PB technique allows adequate venous return to the heart, 
which maintains the patient hemodynamics and renal venous outflow (Lázaro, 1997). Partial 
clamping of the cava at the level of the hepatic veins does not usually cause significant 
changes in the mean arterial pressure, IVC pressure, systemic vascular resistance index and 
cardiac index. The urine output before, during and after revascularization do not change 
significatly (G. Fleitas, 1994). Acute renal failure is less frequent (Sakai, 2010), and, 
cyclosporine or tacrolimus therapy can be started early. (Busque, 1998)  
The PB procedure shortens the time of the liver transplant procedure, specially the warm 
ischemia time. Most groups report that with PB, and its modifications, no porto-caval shunt 
is needed. Even though there may be some exceptions, (situations in which no porto-
systemic collaterals exist as fulminant hepatitis). The significant reduction in the time 
improves the patient and graft survival (Lai, 2011; Nishida, 2006; Busque, 1998). This 
permits early extubation and shorter intensive care unit stay. In fact there is a 30% shorter 
intensive care unit stay and a similar reduction in the overall hospital stay. Moreover, these 
advantages have an impact on total hospital charges for about 85% of the transplants 
procedures, with a significant mean reduction of $23500 (Hossein, 2000). 
 




Fig. 9. Duplex-Doppler and CT Image showing the appearance of the normal caval stump. 
Yelow arrows pointing normal appearance of the graft caval stump and the black ones show 
the caval anastomotic outlet with adequate graft venous outflow drainage 
Comparing the classical and the PB techniques, the more extensive dissection involving the 
cava and suprarenal veins from the liver causes more profuse bleeding with the former 
technique. The latter is associated with less extentive dissection which shortens the 
procedure and reduces the blood loss (Vieira, 2011). According to this, several papers 
confirmed that PB technique decreases blood requirements (Busque, 1998; Hossein, 2000; 
Nishida, 2006), and therefore the incidence post-transfusion problems are much less. Other 
advantages of PB technique include, better maintenance of core body temperature, 
avoidance of external venous bypass which is usually required in the classical technique 
with its associated intraoperative coagulopathy and third-spacing of fluid are significantly 
reduced, and in turn, the needs for transfusion is reduced (Hossein, 2000)  
In addition, retransplantation may be easier if PB technique has been performed. Lateral 
clamping of the cava is again possible, and usually sufficient part of the wall of the IVC will 
be available for the anastomosis (Busque, 1998). This technique also makes easier to solve 
problems posed by mismatched recipient and donor IVC size, particularly in pediatrics, 
reduced-size, split, or living donor liver transplantation (Figueras, 2001; Calne, 1968). 
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In summary, adoptions of surgical techniques that minimize ischemia time, blood loss and 
shortens surgical times represent a surgical goal. PB technique seems to achieve the target. 
However some controversial points exist. General agreement is that PB technique can be 
used in almost any case of liver transplant. However, the exact procedure whether latero-
lateral cavoplasty or bypass porto-caval shunt, remains unclear or at least, lacks of definitive 
evidence. As pointed out by (Gurusamy, 2011) in a Cochrane review, there are very few 
prospective randomized papers comparing the classical with the PB technique and the 
existing ones present important bias. According to this paper no important differences exist 
between both procedures. 
9. Complications of piggyback technique 
Complications of PB technique are well described in the literature although some distinction 
should be done according to the type of modification within the PB technique.  
The reported morbidity is as low as 4% and the overall mortality is 0.7% (Navarro, 1999).  
The main concern about PB technique is venous outflow obstruction. However, some other 
adverse effects related to PB technique and its modifications must be taken into 
consideration. 
Intraoperative complications are basically related to bleeding or malposition of the graft and 
account for 2.5 %. Tears in the cava and release of the anastomosis running suture, were 
described as well as congestion of the graft after portal revascularization due to graft 
rotation. All of these complications can be satisfactorily resolved during the operation 
(Parrilla, 1999). 
The most significant complication of the PB technique in the postoperative period is the 
occlusion of the venous outflow. This can be a dramatic situation and may occur in the 
perioperative, immediate postoperative period, after the first postoperative week (25%) 
(Horton, 2008) or years after the transplant (Brosstoff, 2008). The incidence is rather low, 
0.54-7%, but the mortality rate in such cases may be as high as 24% (Navarro, 1999; Nishida, 
2006). The causes of outflow obstruction include inappropriate size of the hepatic 
anastomosis, malrotation or twisting of the anastomosis, direct compression of the graft, 
excessively tight sutures, and caval thrombosis. Late causes are likely secondary to intimal 
hyperplasia and fibrotic changes resulting in anastomotic stricture formation.  
Hepatic venous outflow obstruction results in Budd-Chiari syndrome. The patient presents 
with, abdominal pain, weight gain, ascites, lower extremity edema, pleural effusion, hepato-
splenomegaly, worsening hepatic function and eventually loss of the graft (Wang, 2005). A 
recurrent Budd-Chiari syndrome has been also described with an incidence as high as 27% 
(Horton, 2008). In these cases lifelong anticoagulation is recommended. A chronic outflow 
obstruction may occur after several weeks with massive ascites as main symptom (Parrilla, 
1999). 
In order to prevent this adverse event some modifications of the piggyback technique have 
been described in the last decades. One modification consists on a side-to-side anastomosis 
at the anterior face of the recipient cava (Belghiti, 1992). The incidence of Budd-Chiari 
syndrome is reported to be lower, 0.7% compared to 2.4% in the classic PB technique 
(Navarro, 1999) and 7 out of 500 cases in Meherabi series (Meherabi, 2009). Parrilla also 
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reported a decrease in the incidence from 1.6 to 0.28% when using a patch obtained by 
joining three instead of two hepatic veins when doing the anastomosis (Parrilla, 1999). The 
anastomosis performed, as previously described by the authors, is wide enough to allow a 
good flow and the liver is anchored securely. 
After graft reperfusion the restoration of the venous return results in a sudden central 
volume overload that can cause pulmonary edema. A decrease greater of 50% in median 
arterial pressure for more than one minute is described as “reperfusion syndrome” and has 
been reported in 30% of cases (Figueras, 2001) and two cases out of 1361 transplants 
presented with hemodynamic shock on reperfusion (Navarro, 1999). The PB technique has 
been found to be associated with more pulmonary infiltrates (Isern, 2004), but this was not 
clinically relevant or statistically significant when compared with the classic technique 
(Gurusamy, 2011). 
10. Treatment of complications of piggyback technique 
Hemorrhagic complications during the anastomosis performance or in the early postoperative 
are usually well controlled. Tears, anastomotic bleeding, loose running sutures are repaired. 
However in some cases, new anastomosis or modifications must be done, as a new side-to-
side cavo-caval reanastomosis. Special care must be taken in these situations since gaseous 
embolism and graft ischemia due to vascular clamping have been reported with negative 
consequences. (Navarro, 1999) 
Intraoperative liver simple congestion due to outflow problems because of malrotation or 
excessive tension of the anastomosis for discrepancies in size of the graft might be resolved 
by accommodating the liver to recipient bed, suturing the falciform ligament to the 
diaphragm or even using breast prosthesis as the authors have used in a case with poor 
positional drainage (Fig. 10.). 
 
Fig. 10. Picture showing the breast prosthesis (yellow arrow) and the partially compromised 
caval flow (white arrow) 
Treatment of Budd-Chiari syndrome varies from simple rotation of the graft to re-
transplantation. Nevertheless, depending on the mode of onset of the syndrome the 
therapeutic procedure will vary. Acute presentation, in the first hours-days, will be more 
suitable for open surgery. This may involve re-anastomosis (with thrombectomy if 
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necessary), conversion to standard liver transplant technique or emergency retransplantation, 
if the graft is seriously injured. Also a “bridge” end-to-side anastomosis with infrahepatic 
caval stump (Stieberg, 1997) could be performed, as we had performed twice before this 
technical solution was reported (Fig. 11.). 
 
Fig. 11. Above: Drawing from operation report form of our first “bridge” case on November, 
23th 1993. Below: Cholangio-NMR, 173 monts after the transplant showing adecuate flow 
through graft’s caval stump. Black arrow: Recipient’s cava. Yelow arrow: Graft’s caval 
stump, functioning as bridge flow (compare with Fig. 9. Image A) 
In a later onset of the obstruction, or even in an acute phase, non-surgical approaches have 
been described. A variety of treatment options have been proved useful. Thrombolysis with 
streptokinase was successfully used in a caval thrombosis. Diuretics can be used to control 
late and chronic BCS that manifests as massive ascites (Parrilla, 1999). However, the most 
commonly reported non-surgical approach is endovascular stent placement and 
endoluminal anastomotic dilatation (venoplasty). In the setting of a scarring and fibrotic 
stenosis, the endovascular route represents a less invasive and less risky option (Sze, 1999) 
and 100% success rate has been reported. The only reported complication is stent migration. 
Balloon dilatation can be repeated, if single dilatation does not resolve the stenosis 
permanently. 
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Late diagnosis is the most important single factor that affects the outcome. Delayed 
diagnosis can lead to a hepatic failure that will in turn make the treatment ineffective. In fact 
the best way to treat outflow problems is to prevent its occurrence. The length of the upper 
IVC of the graft should be kept short to prevent kinking; the length of the anastomosis is 
also important to allow good venous outflow. In addition, when the anastomosis is 
constructed using two hepatic veins (middle and left) instead of the three hepatic veins, the 
incidence of intraoperative congestion and acute and chronic BCS are significantly higher 
2.4% vs. 0.7% (Parrilla, 1999).  
In summary, outflow obstructions related to PB technique must be rapidly addressed and 
resolved since the risks of liver failure and mortality are high. Surgical approach may be 
inevitable but less aggressive non-surgical measures can be also effective, even in the first 
postoperative days, with a fresh anastomosis (Wang, 2005) 
11. Evolution of IVC preservation as the technique of choice for venous 
outflow drainage in the OLT 
Since the first case of our transplantation program on November 1990, we have performed 
503 orthotropic liver transplantations. Piggyback technique was performed in 502. The 
“classic” technique was performed in only one case with a huge liver due to polycystic 
disease. 
Since 1994, there were no series in the literature supporting the routine use of the piggyback 
technique although it seemed to us that it could be routinely used in a safe way (G. Fleitas, 
1994). Subsequently, larger series have demonstrated its utility (Parrilla, 1999), although the 
variability of the technique, mainly regarding to the venous outflow handling is very big. 
 
Fig. 12. European group patient survival (Source: European Liver Transplant Registry) 
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Fig. 12. European group patient survival (Source: European Liver Transplant Registry) 
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12. Valdecilla liver transplantation program 
Our liver transplantation series started in November 1990, having already performed  
until 24 August 2011, 503 liver transplantations in adult patients (460 transplants, 41 
retransplantations and 2 third transplantations). Their main characteristics are summarized 
in the following table, being similar to the other Spanish and European groups. 
media (SD) 46.5 (18.8) DONOR AGE 
n = 503 median (Range) 47 (30-62) 
media (SD) 59 (11) RECEPTOR AGE 
n = 460 median (Range) 65 (27-84) 
OH related Cirrhosis 35.5% 
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In all cases of our series, the piggyback technique has been used, with the exception of one 
case of policystosis and inflammatory adhesions at the retrohepatic IVC. There was a case of 
the “situs inversus”; the donor, graft implantation was made to the right hepatic vein of the 
recipient by making necessary the caudal cavotomy enlargement (Herrera, 1996). In five 
cases, “de novo” cavotomy was performed, because of hypoplasia or “malposition” of the 
hepatic veins. 
CASE PROBLEM SOLUTION RESULT SURVIVAL 
1º Huge graft Re Tx 48 h. Alive 241 months 
2º Technical Hanging liver and Re Tx Dead 8 days 
3º Technical Bridge Alive 226 months 
4º Unknown Bridge Alive 221 months 
5º Huge graft Re Tx Alive 74 months 
6º Poor drain Breast Prosthesis Dead (HCC recurrence) 73 months 
7º Budd-Chiari Endo-prosthesis cava Dead 1 month 
(Re Tx=Retransplantation; HCC=Hepatocellular carcinoma) 
Table 2. Complications and mortality related to a bad drain of the graft in our series 
 
Fig. 13. Liver graft from a “situs inversus” donor 
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providing, considerable hemodynamic stability, and avoiding the use of the veno-venous 
bypass to keep a good infrarenal venous pressure that provides an adequate renal filtration 
(Casanova, 2002). The extended use of piggyback technique in liver transplantation is 
mainly due to its hemodynamic advantages (Moreno, 2003). It has allowed to the 
performance of liver transplantation without the need for temporary veno-venous bypass. 
Although controversial issues have been raised, the use of veno-venous bypass is related to 
the preferences in each institution (Fonouni, 2008) rather than to its advantages, for which 
there is no supporting evidence nowadays (Gurusamy, 2011). In addition, avoiding the use 
of veno-venous bypass, minimizes the coagulation problems that happen on the surface of 
the bypass tubings. Another important advantage of the Piggyback technique is the better 
exploitation of grafts that allows using smaller grafts, with the accompanying disparity in 
the size or with unfavorable anatomy, as the case in “situs inversus” donors (Herrera, 1996) 
(Fig. 13.).  
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Cell Transplantation – A Possible  
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1. Introduction 
The progress made in the field of liver organ transplantation has revolutionized the treatment 
of a wide spectrum of liver diseases. Orthotopic liver transplantation (OLT), which requires 
removal of the entire native liver and transplantation of a high quality graft, has become an 
almost routine procedure with 1-year survival rates higher than 80%. However, with the 
ensuing interminable increase in the waiting list, the current major limitation is the 
considerable shortage in organ donors and the need of timely availability of suitable livers. 
As a result, although death rate after surgery is slowly decreasing, the number of total deaths 
in waiting list patients is steadily rising. Several solutions have been proposed to overcome 
this problem, such as legislative measures, mass media campaigns, optimization of available 
organ allocation, or innovative surgical techniques such as split-liver, living donor, non-heart 
beating donor, and domino transplantation. However, these measures have been met with 
only limited success in providing enough liver grafts (Neuberger, 2000; Thalheimer & Capra, 
2002). Hence, the research community endeavoured to establish clinical alternatives to liver 
transplantation. Cell-based therapies are emerging as an alternative to whole-organ 
transplantation, which has shown initial promise in both animal models and clinical cases. 
This novel technique may provide functional liver support while the native liver regenerates 
in patients of acute liver failure, may provide a short-term “bridge” to sustain critical patients 
until OLT, or may aid in replacing a missing enzyme function in metabolic conditions with 
the aim of avoiding OLT. Some of the most promising cells types that could be used in this 
emerging field are hepatocytes, embryonic stem cells (ESC), mesenchymal stromal cells 
(MSC), amnion epithelial (AE) cells, and induced pluripotent stem cells (iPSC).  
2. Cell transplant versus OLT 
Although still in the experimental stages, cell transplant (CTx) has a variety of potential 
advantages over whole liver transplant. OLT requires major invasive surgery associated 
with long recovery times and a high prevalence of post-surgical complications such as 
infections, renal failure, and acute rejection, which could all contribute to patient mortality. 
The financial cost of OLT and subsequent lifelong immunosuppression therapy is substantial,  
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and long term immunosuppression has also been linked to an increased incidence in 
cancers. Finally, the number of livers needed for transplant greatly outnumbers available 
livers, and timing is critical. In contrast, CTx is less invasive, less expensive, and is 
associated with less severe and fewer complications as well as shorter recovery times. 
Theoretically, stable patients, such as those with a metabolic disease, could potentially be 
given an infusion of cells as an outpatient procedure. Cells for transplant can be banked and 
cryopreserved for almost instant availability; therefore, procedural timing would no longer 
be a major concern. One significant benefit of CTx is that patients would retain their native 
liver. This is of particular relevance for patients with metabolic liver diseases. For example, a 
patient with Maple Syrup Urine Disease (MSUD) has a mutation in the enzyme complex 
that catalyzes the permanent degradation of branched-chain amino acids (BCAA), but can 
perform all other necessary liver functions. Therefore, transplanted cells would not need to 
provide complete liver support. In addition, since a metabolic disease patient is not reliant 
on the donor cells for other liver functions, loss of a graft or failure of the cells to perform 
would only return the recipient to pretransplant conditions. Cells can also be infused into 
patients multiple times, and OLT remains an option if CTx proves insufficient. Less 
immunosuppression may also be required, though this would likely depend on the type of 
cells used, the number of cells infused, and each patient’s individual needs. 
3. Cell types, utility for transplant, and major benefits / concerns 
Cell transplant may be clinically useful for cell support for acute liver failure, as a “bridge” 
therapy to whole liver transplantation, or for the treatment of metabolic liver disease (Strom 
& Ellis, 2011). Hepatocytes, as well as many stem or stem-like cells (ESC, MSC, AE, and 
iPSC), are all being investigated for use in this novel yet promising branch of regenerative 
medicine. Each cell type has its own associated risks and benefits, which will be discussed 
separately. 
3.1 Hepatocytes 
The adult human liver consists of approximately 250 billion hepatocytes organized in about 
one million hepatic lobules. Each capillary leads to a lobule. Hepatocytes, the basic 
metabolic cell of the liver, constitute approximately 65–80% of the cell population of the 
liver. These cells are involved in protein synthesis, storage and transformation of 
carbohydrates, synthesis of cholesterol, bile salts and phospholipids, detoxification, and 
modification and excretion of exogenous and endogenous substances (Kaplowitz, 1992). The 
hepatocyte also initiates the formation and secretion of bile. Other important cells of the 
liver include Kupffer cells, stellate cells, and endothelial cells. Kupffer cells are specialized 
macrophages located in the liver that form part of the reticuloendothelial system. Their 
development begins in the bone marrow with the genesis of peripheral blood monocytes, 
and completing their differentiation into Kupffer cells in the liver. The primary functions of 
Kupffer cells are to recycle old and non-functional red blood cells, phagocytosis, and 
clearance of pathogens. Stellate cells, also known as Ito cells, are pericytes found in the 
perisinusoidal space (space of Disse) and represent ~5-8% of the total liver cell number. In 
normal liver, stellate cells are largely quiescent, store vitamin A, and have cell body 
protrusions that wrap around sinusoids. The stellate cell is the major cell type involved in 
liver fibrosis, which is the formation of scar tissue in response to liver damage. When liver is 
damaged, stellate cells can change into an activated state, and are responsible for secreting  
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collagen and other extra-cellular molecules which can lead to cirrhosis. Endothelial cells 
constitute the wall of the liver sinusoids. They lie on a discontinuous extracellular matrix, 
creating a narrow extravascular fluid compartment into which hepatocytes project microvilli. 
This arrangement maximizes the surface area of hepatocytes with the extravascular fluid 
space and permits free movement of solutes into contact with the hepatocyte plasma 
membrane. 
In healthy individuals, regeneration is slow; it is commonly accepted that liver is replaced 
by normal tissue renewal approximately once a year. The liver is largely quiescent with only 
1:1000 hepatocytes in mitosis at any given time. This number decreases with increasing age, 
making regeneration slower and less complete in older animals (Steer, 1995). However, this 
slow cellular turnover is quickly altered when a chemical or physical trauma occurs to cause 
a significant loss to the liver. Sudden and massive hepatocyte proliferation then occurs due 
to a rapid increase in mitotic division resulting in restoration of functional liver mass 
(Bucher, 1963).  
3.1.2 Hepatocyte transplantation and route of administration 
Hepatocytes are capable of rapid proliferation as well as complete and functional 
regeneration of the liver following injury. Thus, this capacity for self-renewal has led some 
to regard the hepatocyte as essentially a “unipotent” stem cell. As early as 1977, hepatocyte 
transplantation (HTx) has been recognized as an attractive option for the management of 
metabolic liver disease (Groth et al., 1977). Groth and colleagues demonstrated that 
intraportal HTx in glucuronosyltransferase-deficient rats improved hyperbilirubinemia. 
Since then, continuing preclinical research determined that HTx can support liver function 
and improve survival in animal models of acute liver failure suggesting it had potential 
clinical application (Gupta & Chowdhury, 2002). There have also been a large number of 
studies with various animal models that show the efficacy of hepatocyte transplantation to 
correct metabolic liver disease (as reviewed in Malhi & Gupta, 2001; Strom et al, 2006). 
Importantly, Harding’s group showed the correction of murine phenylketonuria (PKU) 
despite low engraftment of cells (Hamman et al., 2005); Harding & Gibson (2010) later 
suggest only 10-20% repopulation may be sufficient to correct PKU clinically. Our group 
also recently reported a significant partial correction of murine intermediate MSUD despite 
very low (~3%) repopulation of the liver (Skvorak et al., 2009a; 2009b). As a result, HTx has 
gained attention as a potential therapeutic intervention for a number of liver diseases, and 
transplantation of hepatocytes corresponding to 1-5% of total liver mass (1.5-9.0 billion 
hepatocytes) can be expected to have a positive impact. It has been determined that 
approximately 3.5-7.5% of liver mass can safely be transplanted in one transplant event (Fox 
et al., 1998), whereby the transplant may be divided in up to 6 separate infusions over a 
number of hours. CTx is generally associated with an increase in portal pressures as blood 
flow is restricted by plugs of donor hepatocytes (Gupta et al., 1999). However, if 
transplanted cells are in the range of 5% of the total liver mass, this increased portal 
pressure usually resolves within minutes or hours. When portal pressures return to normal, 
or at least decrease to acceptable levels, it is then safe to infuse more cells. At present, the 
majority of hepatocyte transplant procedures have been performed in adults with acute or 
chronic liver failure, though HTx as a therapeutic alternative to treat metabolic hepatic 
disease is becoming more accepted. Thus far, there have been four reported clinical cases of 
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recovery from acute liver failure following HTx (Table 1), though the use of cell transplant 
as a “bridging” therapy to OLT is more common in both acute and chronic liver failure. 
Most published articles report a positive impact of HTx in clinical studies, and results are in 
general agreement with preclinical data using animal models. Table 1 summarizes clinical 
hepatocyte transplant studies to date, as well as significant results of those studies. 
HTx as an alternative treatment for metabolic liver disease is an appealing proposal. The 
progression of inherited metabolic liver disease usually varies less than cases of liver failure. 
In addition, objective parameters such as laboratory data (i.e. bile acid, clotting factors, etc.) 
can be determined to unequivocally assess the efficacy of the treatment. On the other hand, 
the situation is rarely immediately life threatening and often acceptable conventional 
therapies are available, such as a special diet. Therefore, the potential benefit must be 
carefully weighed against any possible complications, such as immunosuppression, 
embolisation of the pulmonary vascular system, sepsis, or hemodynamic instability. HTx is 
more often done as therapy for inborn errors of hepatic metabolism in which a specific 
absent protein can be measured from transplanted unmodified donor hepatocytes 
expressing the gene. The use of hepatocyte infusions to correct inborn errors of metabolism 
is logical when a specific metabolic deficiency, with well-studied animal modelling, can be 
measured. Then, after infusion of donor liver cells natively expressing the required gene, 
objective measures of required hepatocyte mass, engraftment percent, and survival 
advantage can be obtained. Thus far, therapeutic benefit has been seen clinically in the 
treatment of disorders of the urea cycle (citrullinemia, OTC, argininosuccinase lyase 
deficiency), familial cholesterolemia, Crigler-Najjar, biliary atresia, infantile refsum disease, 
Factor VII, and Glycogen storage disease type 1a & 1b (summarized in Table 1). To avoid the  
need for immunosuppression or the risk of rejection, transplantation of genetically modified 
autologous hepatocytes may also be an option, such as in a clinical study to treat familial 
cholesterolemia (Grossman et al., 1991). In this study, retrovirus was used to transduce and 
correct a patient’s deficient hepatocytes, which were then infused back into the patient to 
yield a partial correction of the disease. HTx to treat progressive familiar intrahepatic 
cholestasis and A1AT were also attempted, but no clinical benefit was determined likely due 
to the presence of fibrosis in the native liver (Strom et al., 1997a; Strom et al., 1999; Hughes 
et al., 2005). With respect to long-term engraftment, it will be important whether the 
transplanted hepatocytes will gain a selection advantage over the recipient’s cells. Damage 
or injury to the native liver triggers rapid proliferation of healthy hepatocytes; theoretically 
this would provide transplanted hepatocytes a selected growth advantage over native cells 
in patients with acute or chronic liver failure. Importantly, the livers of metabolic disease 
patients are not injured or damaged in most cases; transplanted cells would likely not 
receive selection advantage over the recipient’s cells. Therefore, higher numbers of 
transplanted hepatocytes, a need for better cell engraftment, and repeated transplantations 
may be necessary for the successful treatment of metabolic liver diseases.  
Cell therapy of end-stage liver disease (i.e. cirrhotic livers) is more problematic. Infusion 
into the liver via the portal vein is the preferred method of transplant in cases where liver 
architecture is intact (i.e., metabolic diseases, or in the case of acute liver failure). It is known 
from animal studies that hepatocytes infused via the portal vein disperse with the portal 
blood flow and finally translocate to the hepatic sinusoids in the periportal region of the 
liver lobules (Sokal et al., 2003). Single cells succeed in traversing the endothelial barrier and 
integrate into the parenchyma. After re-establishing intercellular contacts with neighbouring  
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Liver Disease  Outcome References 
α1-antitrypsin (A1AT) No clinical benefit likely due to the 
presence of fibrosis 
(Strom et al., 1997a; Strom 
et al., 1999) 
Acute liver failure Reversal of disease  (Fisher et al., 2000; Soriano, 
2002; Fisher & Strom, 2006; 
Ott et al., 2006) 
Argininosuccinate lyase 
deficiency  
Complete correction (Stephenne et al., 2006) 
Biliary atresia Partial correction - slow and 
continuous decrease in bilirubin 
levels 
(Khan et al., 2008) 
Chronic liver failure Bridge to OLT (Bilir et al. 200; Strom et al. 
1997b; Fisher & Strom, 
2006; Strom et al., 1999)  
Citrullinemia Partial correction – decreased 
citrulline and circulating ammonia 
at 6 months post- cell infusion 
(Meyburg et al., 2009a) 
Crigler-Najjar type 1 Partial correction - slow and 
continuous decrease in bilirubin 
levels; evidence of long term 
correction by hepatocyte graft (one 
patient was followed for > 1.5 
years) 
(Fox et al., 1998; Dhawan et 




Partial correction – cholesterol 
decrease and transgenic expression 
>4 months 
(Grossman et al., 1991) * 
Glycogen storage 
disease type 1a & 1b 
Partial correction – patients could 
maintain blood glucose between 
meals as well as higher and 
sustained glucose levels at meals 
(Muraca et al., 2002; Lee et 
al., 2007) 
Infantile refsum disease Partial correction – improved fatty 
acid metabolism, reduced pipecolic 
acid and bile salt levels, improved 
strength and weight gain 
(Sokal et al., 2003)  
Inherited Factor VII 
deficiency 
Partial correction – reduced FVII 
requirement 80%  




Partial correction – ammonia and 
glutamine levels were normalized 
following transplant. Most 
required OLT at a later date. 
(Strom et al., 1997a; Horslen 
et al., 2003; Mitry et al., 
2004; Stephenne et al., 2005; 
Puppi et al., 2008; Meyburg 
et al., 2009a; 2009b) 
Progressive familiar 
intrahepatic cholestasis 
No clinical benefit likely due to the 
presence of fibrosis 
(Hughes et al., 2005) 
* use of genetically modified autologous hepatocytes 
Table 1. Summary of clinical HTx to treat chronic liver failure, acute liver failure, and 
inherited metabolic diseases 
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recovery from acute liver failure following HTx (Table 1), though the use of cell transplant 
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is logical when a specific metabolic deficiency, with well-studied animal modelling, can be 
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objective measures of required hepatocyte mass, engraftment percent, and survival 
advantage can be obtained. Thus far, therapeutic benefit has been seen clinically in the 
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deficiency), familial cholesterolemia, Crigler-Najjar, biliary atresia, infantile refsum disease, 
Factor VII, and Glycogen storage disease type 1a & 1b (summarized in Table 1). To avoid the  
need for immunosuppression or the risk of rejection, transplantation of genetically modified 
autologous hepatocytes may also be an option, such as in a clinical study to treat familial 
cholesterolemia (Grossman et al., 1991). In this study, retrovirus was used to transduce and 
correct a patient’s deficient hepatocytes, which were then infused back into the patient to 
yield a partial correction of the disease. HTx to treat progressive familiar intrahepatic 
cholestasis and A1AT were also attempted, but no clinical benefit was determined likely due 
to the presence of fibrosis in the native liver (Strom et al., 1997a; Strom et al., 1999; Hughes 
et al., 2005). With respect to long-term engraftment, it will be important whether the 
transplanted hepatocytes will gain a selection advantage over the recipient’s cells. Damage 
or injury to the native liver triggers rapid proliferation of healthy hepatocytes; theoretically 
this would provide transplanted hepatocytes a selected growth advantage over native cells 
in patients with acute or chronic liver failure. Importantly, the livers of metabolic disease 
patients are not injured or damaged in most cases; transplanted cells would likely not 
receive selection advantage over the recipient’s cells. Therefore, higher numbers of 
transplanted hepatocytes, a need for better cell engraftment, and repeated transplantations 
may be necessary for the successful treatment of metabolic liver diseases.  
Cell therapy of end-stage liver disease (i.e. cirrhotic livers) is more problematic. Infusion 
into the liver via the portal vein is the preferred method of transplant in cases where liver 
architecture is intact (i.e., metabolic diseases, or in the case of acute liver failure). It is known 
from animal studies that hepatocytes infused via the portal vein disperse with the portal 
blood flow and finally translocate to the hepatic sinusoids in the periportal region of the 
liver lobules (Sokal et al., 2003). Single cells succeed in traversing the endothelial barrier and 
integrate into the parenchyma. After re-establishing intercellular contacts with neighbouring  
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levels 
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meals as well as higher and 
sustained glucose levels at meals 
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al., 2007) 
Infantile refsum disease Partial correction – improved fatty 
acid metabolism, reduced pipecolic 
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host cells, transplanted hepatocytes may start to proliferate when sufficient space is made 
for the infused cells. Donor cells and their descendents form gradually increasing clusters, 
thus finally repopulating the recipient liver. However, cirrhotic livers contain abnormalities 
of the hepatic architecture, as well as loss of functional hepatocytes, which contributes to the 
decrease in liver function. In addition, intrahepatic portal venous shunts may prevent an 
efficient exchange between hepatocytes and blood plasma, and cell infusions may cause 
prolonged portal hypertension and embolization in the lung (Strom et al., 1999). Preclinical 
HTx studies conducted on rat cirrhosis models discovered significantly increased 
intrapulmonary translocation of donor cells due to portal shunting (Gupta et al., 1993). Due 
to cirrhotic changes in the liver and associated portal hypertension, the infusion of donor 
hepatocytes into the liver via the portal vein without first restoring the normal liver 
architecture would likely cause serious complications in patients with portal hypertension. 
For safety purposes, transplantation into the spleen is preferable (Strom et al., 1997b; Fisher 
& Strom, 2006). Direct intrasplenic injection produced engraftment that was far superior to 
that obtained using splenic artery infusion and resulted in fewer serious complications 
(Nagata et al.; 2003). However, it is still unknown whether the human spleen is capable of 
accommodating a sufficient number of functional hepatocytes to compensate for the 
cirrhotic liver. For example, alcoholic cirrhotic patients showed only transient clinical 
improvement after treatment by splenic HTx (Strom et al., 1999; Sterling & Fisher, 2001). 
Another strategy that has been getting recent attention is the use of a bioartificial liver (BAL) 
to support metabolic function and regeneration (Koenig et al., 2005; Carpentier et al., 2009). 
Several devices are being tested clinically (as reviewed in Carpentier et al., 2009). However, 
current limitations of BAL devices are cost and, due to the shortage of allogenic hepatocytes, 
their prevalent use of porcine hepatocytes, which carry the risk of infection with porcine 
endogenous retrovirus and anaphylaxis (Chamuleau et al., 2005). Treatment of cirrhotic 
livers by CTx requires extra consideration regarding transplant site, cell number, and overall 
safety of the procedure. The continuing development of BAL is promising, but there are 
more challenges to overcome in this area before these devices can be considered a cost-
effective and safe option for the treatment of liver disease. 
3.1.3 Hepatocyte isolation, culture, and cryopreservation  
The major source of hepatocytes for HTx are livers that were rejected for OLT. Some of the 
most common reasons that procured livers are not used for transplantation are as follows:  
unavailability of a matched recipient, physical damage to the liver, pre-existing liver 
diseases, breach of sterility during the procurement process, high liver fat content (steatosis), 
inappropriate age (too old), or inappropriate warm ischemic time or cold storage time (cold 
ischemia). Though these organs may not be therapeutically useful for OLT, viable cells for 
CTx may still be acquired. 
Hepatocyte isolation was first employed in the late-1960s for rat livers (Howard et al., 1967; 
Berry & Friend, 1969). In 1976, the traditional two-step collagenase perfusion technique was 
developed for rat tissue (Seglan, 1976), which was later adapted for use with human tissue 
(Bojar et al., 1976). Another widely used method, which yields a high number of viable cells 
per gram of whole liver tissue, is the three-step collagenase perfusion technique (Dorko et 
al., 1994; Nakazawa et al., 2002; Mitry et al., 2004; Alexandrova et al.; 2005). More recently, 
the increasing application of these approaches in clinical grade cell therapies require the 
standardization of cell isolation procedures in accordance with GMP conditions (Gramignoli 
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et al., 2011). In general, after collagenase has disassociated the hepatocytes from the 
connective tissue, cells are separated by low speed centrifugation, and the hepatocyte pellets 
are washed with ice-cold buffer solution to purify the cells. The number and quality of the 
isolated hepatocytes vary depending on the composition of perfusion buffer solutions, the 
type and concentration of enzyme, and the type and quality of the tissue source used. 
Further purification of viable cells can be obtained through the use of the Percoll 
centrifugation technique (Olinga et al., 2000), though extensive loss in cell number (20-40% 
cell recovery) is a major disadvantage of this method (Dorko et al., 1994). Cell viability is 
determined using trypan blue exclusion. However, in vitro viability may not reflect good cell 
function in vivo.  
The primary requirement for both short-term and long-term culture of hepatocytes is their 
ability to efficiently attach to the culture plate. The culture dish should be pre-coated with a 
suitable attachment factor such as collagen (type I or IV) or Matrigel, which contains a 
mixture of extracellular matrices (Blaauboer & Paine, 1979; Chen et al., 1998). However, even 
under currently optimal in vitro cell culture conditions, mature human hepatocytes typically 
do not survive or maintain mature functionality for periods longer than 1-2 weeks, 
proliferation is extremely poor, and they appear to de-differentiate and lose hepatic 
potential (Tanaka et al., 2006, Nahmias et al., 2007). 
A shortage of donor liver tissue for the isolation of human hepatocytes necessitates the 
development of improved cryopreservation techniques for long-term storage. There are 
several reports describing various cryopreservation techniques and some of the associated 
complexities of the procedure (Diener et al., 1993; Terry et al., 2005; 2007). Hepatocytes are 
typically cryopreserved in suspension, which can occur immediately following isolation. No 
culture step is needed. The ultimate goal of any improved cryopreservation protocol is to 
minimize sudden intracellular formation of ice crystals that could result in ultrastructural 
damage, and thus maintain cell viability, attachment, and metabolic activity upon thawing. 
Storage time of cryopreserved hepatocytes at temperatures well below −100°C (e.g. liquid 
nitrogen or -140°C freezers) may play an important role in the quality of thawed cells. Cells 
are resuspended in ice-cold media (usually Belzer solution, also known as UW) containing 
cryoprotective agents. UW has been well established in the literature to have the best results 
in terms of viability and recovery. The cryoprotectants used can be permeating (e.g., 
DiMethylSulfoxide (DMSO), glycerol) or non-permeating molecules (e.g., polymers, sugars). 
DMSO is the cryoprotectant of choice because it is permeating and highly soluble. It is able 
to enter cells and reduce injury through reduction of ice crystal formation during freezing. 
DMSO, being a polar solvent, may also stabilize the plasma membrane by electrostatic 
interactions. The concentration of these cryoprotectants, as well as the rate at which they are 
added, final cell density, and freezing rate may also be crucial factors contributing to 
viability upon thawing. The standard optimum thawing protocol for hepatocytes is rapid 
thawing at 37°C with slow dilution of the cryoprotectant (to reduce osmotic imbalances) at 
4°C (to reduce possible toxicity of the cryoprotectant) (Karlsson et al., 1993; 1996; Pegg, 
2002). Upon thawing, cells are then washed to remove cryoprotectant to avoid potential 
adverse affects in patients.  
3.1.4 Benefits / concerns 
Due to the undeniable success of OLT, it is reasonable to use all suitable donor livers for 
organ transplantation. Therefore, an advantage of HTx is that it would not require obtaining 
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host cells, transplanted hepatocytes may start to proliferate when sufficient space is made 
for the infused cells. Donor cells and their descendents form gradually increasing clusters, 
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et al., 2011). In general, after collagenase has disassociated the hepatocytes from the 
connective tissue, cells are separated by low speed centrifugation, and the hepatocyte pellets 
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complexities of the procedure (Diener et al., 1993; Terry et al., 2005; 2007). Hepatocytes are 
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DMSO, being a polar solvent, may also stabilize the plasma membrane by electrostatic 
interactions. The concentration of these cryoprotectants, as well as the rate at which they are 
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thawing at 37°C with slow dilution of the cryoprotectant (to reduce osmotic imbalances) at 
4°C (to reduce possible toxicity of the cryoprotectant) (Karlsson et al., 1993; 1996; Pegg, 
2002). Upon thawing, cells are then washed to remove cryoprotectant to avoid potential 
adverse affects in patients.  
3.1.4 Benefits / concerns 
Due to the undeniable success of OLT, it is reasonable to use all suitable donor livers for 
organ transplantation. Therefore, an advantage of HTx is that it would not require obtaining 
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livers that could be used for OLT, which would only further stress an already stressed 
system. HTx would be using liver tissue that would otherwise be discarded. In addition, 
multiple patients could be treated with hepatocytes from a single tissue donor, and 
potentially, in cases of metabolic disease, a patient’s autologous hepatocytes could be 
collected, genetically manipulated to correct the deficiency, and infused back into the 
patient. Nonetheless, there are still many problems associated with the use of hepatocytes. 
Despite the use of discarded tissue, the current major limitation is the availability of human 
hepatocytes. Although hepatocytes in vivo have remarkable proliferation potential, primary 
hepatocytes proliferate very poorly in vitro, appear to de-differentiate and lose their hepatic 
potential, and display very limited survival (Tanaka et al., 2006, Nahmias et al., 2007). 
Therefore, the collection of hepatocytes for HTx is still limited by the availability of fresh 
liver tissue as cells cannot be expanded in culture. The numbers and/or quality of 
hepatocytes isolated from non-transplantable livers will not allow a widespread application 
of HTx. A second major limitation is the need for timely availability of hepatocytes. If 
hepatocytes cannot be successfully cryopreserved and thawed, some advantages of CTx 
over OLT are lost. Successful cryopreservation is needed for establishment of cell banks, 
which would allow cryopreserved hepatocytes to be available for emergency use in acute 
and chronic liver diseases, or for planned or repeated use in patients with liver-based 
metabolic disorders. A third major limitation is the consistently poor quality of cells after 
cryopreservation. Hepatocytes are very sensitive to freezing damage, and three distinct 
modes of cell death have been identified: cell rupture by the formation of ice crystals, 
necrosis, and apoptosis (Baust, 2002). Loss of membrane integrity, and thus leakage of 
important enzymes and cofactors which affect liver function, low attachment efficiency, and 
a loss in viability of 50% or greater is typical. This situation will remain unaltered until 
alternatives to primary hepatocytes becomes available, which are discussed in the next 
sections of this chapter, or more efficient methods of cryopreservation and storage of 
hepatocytes, as well as cell recovery from cryopreservation are determined.  
3.2 Embryonic stem cells 
Embryonic stem cells (ESC) are derived from totipotent cells of the inner cell mass of the 
blastocyst, an early stage of the developing embryo (Thomson et al., 1998). ESCs are 
pluripotent, meaning they can differentiate into all three germ layers (ectoderm, mesoderm, 
and endoderm), and express many specific gene factors that have come to be known as cell 
markers of pluripotency. Common markers of “stemness” include stage specific embryonic 
antigens (SSEA) 3 & 4, and the tumor rejection antigens (TRA) 1-60 & 1-81 (Thomson et al., 
1998), while some common molecular markers include OCT-4, SOX-2, and Nanog, as well as 
high expression of telomerase reverse transcriptase (TERT) (Thomson et al., 1998; Chambers 
et al., 2003). Telomerase maintains telomere length and adds telomere repeats to 
chromosome ends, which is important in a cell’s replicative lifespan (Vaziri & Benchimol, 
1998). However, high levels of telomerase activity are also found in 80-90% of human tumor 
samples (Chen & Chen, 2011). ESCs will readily become tumorigenic in vivo when injected 
into severe combined immunodeficient (SCID) mice forming either teratomas, tumors 
comprised of cells from all three germ layers, or teratocarcinomas, which are more 
aggressive, malignant teratomas (Ben-David & Benvenisty, 2011). In fact, teratoma 
formation is so characteristic of ESCs, it has become one of the most informative tests of 
pluripotency for ESC-like cells, such as induced pluripotent stem cells (iPSC). ESCs also 
display genetic instability (i.e. aneuplody) in vitro, another unfortunate characteristic they 
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share with cancer cells (Spits et al., 2008). Furthermore, ESCs express very low human 
leukocyte antigen (HLA) class I antigens (Baroja et al., 2004), and almost undetectable levels 
of HLA class II antigens and co-stimulatory factors (Drukker et al., 2006). ESCs are still 
subject to immune system targeting, however. Low expression of HLA class I molecules is 
sufficient to induce acute rejection through the action of cytotoxic T-cells and affect 
treatment tolerance (Robertson et al., 2007; Drukker et al., 2006), which suggests that 
immunosuppression would still be required if patients recieved stem cell-derived CTx. 
Sustaining pluripotency in vitro requires continued expression of Nanog and OCT-4 
(Chambers et al., 2003). The expression of these factors are maintained through co-culture 
with a feeder cell layer, most commonly mouse embryonic fibroblasts (MEFs), and either the 
addition of basic fibroblast growth factor (bFGF) for human ESC, or leukemia inhibitory 
factor (LIF) for mouse ESC. Without optimal culture conditions, ESC will rapidly and 
spontaneously differentiate into cells from all three germ layers (Chambers et al., 2003). 
Finally, ESCs are indefinitely self-renewing theoretically providing an unlimited therapeutic 
source of cells for regenerative medicine (Thomson et al., 1998).  
3.2.1 Inducing hepatic differentiation in ESC and laboratory / clinical data 
ESCs will spontaneously differentiate simply by removing factors and/or allowing the 
formation of spheroid clumps known as embryoid bodies (EB) in culture. ESCs can also be 
made to differentiate along a defined lineage through exposure to specific growth factors. In 
a developing embryo, signals from the cardiac mesoderm and septum transversum 
mesenchyme specify endoderm to accept a hepatic fate. It was eventually determined that 
FGFs and bone morphogenic proteins (BMPs) can mimic the appropriate signals and thus 
induce endoderm towards a hepatic fate (Jung et al., 1999). From there, targets of BMPs and 
FGFs, as well as other in vivo hepatic regulatory genes, such as FoxA genes and the GATA 
and hepatocyte nuclear factor (HNF) transcription factors, defined additional molecules 
tested in differentiation studies to produce hepatocyte-like cells from ESC. Currently there 
are many published protocols to differentiate ESC into various cell types from all three germ 
layers, which have been reviewed elsewhere (Trounson, 2006; Zaret & Grompe, 2008; Soto-
Gutierrez et al., 2008; Sancho-Bru et al., 2009). Hepatocyte-like cells that express α-
fetoprotein (AFP), albumin, cytochrome P450 (CYP450), cytokeratin (CK) 18, and display 
epithelial-like morphology have all been extensively described. However, expression of 
these few factors does not guarantee the differentiated stem cell is a “hepatocyte”; 
hepatocyte-like stem cells may express a few hepatic genes, but they could also be negative 
for many others important to hepatic function (Soto-Gutierrez et al., 2008). In addition, some 
of these hepatic markers are not limited to hepatocyte expression, such as CYP450. 
Therefore, there must be a more stringent check list to determine when a stem cell is 
considered to be completely differentiated.  
There have been many articles describing ESC derived hepatocyte-like cells transplanted 
into liver-damaged mice (e.g. review by Banas et al. 2007) but few have determined the cells 
significantly contribute to improved liver function and regeneration. Induction rates remain 
low regardless of the method used, and general hepatic function of the cells, even once 
transplanted, were very limited when compared to mature hepatocytes (Sharma et al., 2008). 
However, a successful report described ESCs demonstrating liver function able to overcome 
liver damage in mice (Heo et al., 2006). This is encouraging for the field of liver disease, but 
 
Liver Transplantation – Technical Issues and Complications 
 
150 
livers that could be used for OLT, which would only further stress an already stressed 
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share with cancer cells (Spits et al., 2008). Furthermore, ESCs express very low human 
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are many published protocols to differentiate ESC into various cell types from all three germ 
layers, which have been reviewed elsewhere (Trounson, 2006; Zaret & Grompe, 2008; Soto-
Gutierrez et al., 2008; Sancho-Bru et al., 2009). Hepatocyte-like cells that express α-
fetoprotein (AFP), albumin, cytochrome P450 (CYP450), cytokeratin (CK) 18, and display 
epithelial-like morphology have all been extensively described. However, expression of 
these few factors does not guarantee the differentiated stem cell is a “hepatocyte”; 
hepatocyte-like stem cells may express a few hepatic genes, but they could also be negative 
for many others important to hepatic function (Soto-Gutierrez et al., 2008). In addition, some 
of these hepatic markers are not limited to hepatocyte expression, such as CYP450. 
Therefore, there must be a more stringent check list to determine when a stem cell is 
considered to be completely differentiated.  
There have been many articles describing ESC derived hepatocyte-like cells transplanted 
into liver-damaged mice (e.g. review by Banas et al. 2007) but few have determined the cells 
significantly contribute to improved liver function and regeneration. Induction rates remain 
low regardless of the method used, and general hepatic function of the cells, even once 
transplanted, were very limited when compared to mature hepatocytes (Sharma et al., 2008). 
However, a successful report described ESCs demonstrating liver function able to overcome 
liver damage in mice (Heo et al., 2006). This is encouraging for the field of liver disease, but 
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more efficient differentiation and transplantation techniques must be established. Clinical 
ESC therapy for liver disease is not currently realistic, but at present there are four ongoing 
ESC clinical trials targeting other organs in the United States (Trounson et al., 2011). Two 
trials are in Phase I and are targeting spinal cord injuries or spinal muscular atrophy, while 
the remaining two are in Phase I/II and are targeting Macular Degeneration. All trials 
involve ESCs that were first differentiated in culture prior to transplantation. 
3.3 Mesenchymal stromal cells 
Mesenchymal stromal cells (MSC), formerly known as mesenchymal stem cells, are 
multipotent non-hematopoietic adult stem cells that have been isolated from a variety of 
tissues, including bone marrow, adipose tissue, Wharton’s jelly, umbilical cord blood, and 
different compartments of the placenta (Parolini et al., 2008). Since they originate from 
mesoderm, MSCs show in vitro differentiation potential into three cell lineages (adipogenic, 
chondrogenic, and osteogenic). These cells are highly proliferative fibroblast-like cells that 
display plastic adherence in culture and express specific surface markers (i.e. positive for 
CD105/CD90/CD73, and negative for CD34/CD45/CD11b, or CD14/CD19, or 
CD79α/HLA-DR1) (Dominici et al., 2006). Importantly, MSCs are TERT-negative 
(Zimmerman et al., 2003). Although tumorigenicity is lower than ESC, MSCs have been 
shown to assist tumor growth by transformation and suppression of the antitumor immune 
response (Ren et al., 2009). 
Similar to ESCs, MSCs display reduced immunogenicity, but MSCs also demonstrate a 
powerful immunomodulatory response in vivo (Hematti, 2008; Bifari et al., 2010). MSCs 
interfere with antigen-presenting cells and suppress B-cell differentiation causing inhibition 
of Natural Killer (NK) cells and cytotoxic T cells. They also express a broad number of anti-
inflammatory factors, such as a variety of cytokines and chemokines (Banas et al.; 2008). 
MSCs also inhibit local and systemic proinflammatory responses through inhibition of  
TNF-α and interleukin (IL)-1, which functions to prevent tissue damage (Lin et al., 2011), 
and can nonspecifically inhibit allogeneic lymphocyte proliferation. In addition, MSCs 
express low levels of HLA class I antigens and lymphocyte function-associating antigen 
(LFA)-3, and do not express HLA class II antigens or many co-stimulatory molecules which 
could function to upregulate HLA class II antigens in vivo (Bifari et al., 2010). By far, the 
most exciting and potentially useful characteristics of these cells are their immunomodulatory 
behaviors. MSCs significantly lower the incidence of graft-versus-host disease, autoimmune 
diseases, and can induce tolerance upon transplantation (Le Blanc et al, 2004; 2005; 2007). 
Nonetheless, it should be noted that MSC therapy may also increase the vulnerability to 
viral infections such as herpes (Sundin et al., 2006). 
3.3.1 Differentiation of MSCs and laboratory / clinical data 
Similar to ESC, MSCs are able to differentiate into various cell types by stimulation with 
specific growth factors, and there are many published protocols for differentiating MSCs 
along various cell lineages. For example, a recent review describes a number of protocols for 
differentiating along a hepatic lineage (Puglisi et al., 2011). The ability of MSCs to 
differentiate into hepatocyte-like cells was first reported in 2002 (Schwartz et al., 2002). The 
resulting hepatocyte-like cells performed hepatic functions such as albumin production, 
urea synthesis, glycogen storage, and low-density lipoprotein uptake (Jiang et al., 2002). 
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MSCs are able to differentiate into hepatocyte-like cells by stimulation with hepatocyte 
growth factor (HGF), epidermal growth factor (EGF), and FGF (Lange et al., 2005). MSC-
derived hepatocytes were able to engraft in the liver upon transplantation and have been 
shown to contribute towards improved hepatic function and regeneration (Kuo et al., 2008). 
Conversely, another report using bone marrow MSCs significantly increased the number of 
hepatic stellate cells and myofibroblasts, which could contribute to the fibrotic cascade 
(Russo et al., 2006). Despite the availability of many hepatic differentiation protocols, it is 
currently unclear whether MSCs are able to become hepatic cells through differentiation or 
by cell fusion, as evidenced by Sharma, et al. (2005). In addition, the homing mechanism by 
which intravenously injected MSCs can preferentially recruit to the injured liver is 
interesting (Sakaida et al., 2004), but also not well understood. MSCs preferentially target 
tissues undergoing remodeling; it has been suggested that inflammation might provide key 
regulatory factors in the targeted migration of MSCs into the diseased location (Kuo et al., 
2008).  
Due to their impressive immunomodulatory features, MSCs have been used to treat acute 
graft-versus-host disease and osteogenesis imperfecta in children (Le Blanc et al., 2005). 
MSCs also secrete several factors able to suppress hepatocyte apoptosis, inflammatory 
responses, and liver fibrosis, as well as stimulate hepatocyte proliferation and function (Lin 
et al., 2011; Zhou et al., 2009). Many such factors, for example HGF, can also aid in liver 
regeneration. Preclinical and clinical studies have suggested that MSC transplantation can 
moderately restore liver function and enhance survival rates in fulminant hepatic failure 
and end-stage liver disease (Yagi et al., 2009; Kuo et al., 2008; Banas et al., 2009), though it 
has been suggested that the benefits MSCs provide to damaged livers have more to do with 
the expression of immunomodulatory factors than engraftment and subsequent hepatic 
function of the transplanted cells (Banas et al., 2008). There is little evidence to date that 
verifies whether MSCs are able to form mature hepatocytes, either in culture or once 
transplanted. However, growing evidence does suggest that MSCs may improve cirrhotic 
liver function once infused into patients. For example, bone marrow MSCs transplantation 
reduced liver fibrosis, and improved liver function and survival in mice (Sakaida et al., 
2004) and rats (Abdel Aziz et al., 2007). This provided rationale for the use of autologous 
bone marrow MCSs for cell therapy to treat cirrhosis, which spurred several clinical trials 
investigating cell safety and feasibility (Kharaziha et al., 2009; Mohamadnejad et al., 2007; 
Salama et al., 2010). At present, there are 123 ongoing clinical trials involving MSCs 
investigating a variety of applications including bone, cartilage, and heart repair, immune 
rejection and autoimmune diseases, as well as treatment for cancer, gastrointestinal, and 
neurodegenerative diseases (Trounson et al., 2011). 
3.4 Benefits / concerns of ESCs and MSCs 
Since ESCs possess the ability of unlimited self-renewal, this relieves some pressure to 
identify new cell sources for regenerative medicine. However, although self-renewal is 
generally viewed as a powerful benefit, it is also a double-edged sword. Self-renewal, 
genetic instability, and tumorigenicity are characteristics shared by ESCs and cancer cells. In 
both differentiated and undifferentiated ESCs, there is a risk of malignancy due to their 
associated tumorigenicity and genetic instability (Stutchfield et al., 2010). The generation of 
spontaneous tumors is of particular concern for clinical applications, and much of the 
current research is dedicated to reducing and eventually overcoming this risk. Perhaps with 
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more efficient differentiation and transplantation techniques must be established. Clinical 
ESC therapy for liver disease is not currently realistic, but at present there are four ongoing 
ESC clinical trials targeting other organs in the United States (Trounson et al., 2011). Two 
trials are in Phase I and are targeting spinal cord injuries or spinal muscular atrophy, while 
the remaining two are in Phase I/II and are targeting Macular Degeneration. All trials 
involve ESCs that were first differentiated in culture prior to transplantation. 
3.3 Mesenchymal stromal cells 
Mesenchymal stromal cells (MSC), formerly known as mesenchymal stem cells, are 
multipotent non-hematopoietic adult stem cells that have been isolated from a variety of 
tissues, including bone marrow, adipose tissue, Wharton’s jelly, umbilical cord blood, and 
different compartments of the placenta (Parolini et al., 2008). Since they originate from 
mesoderm, MSCs show in vitro differentiation potential into three cell lineages (adipogenic, 
chondrogenic, and osteogenic). These cells are highly proliferative fibroblast-like cells that 
display plastic adherence in culture and express specific surface markers (i.e. positive for 
CD105/CD90/CD73, and negative for CD34/CD45/CD11b, or CD14/CD19, or 
CD79α/HLA-DR1) (Dominici et al., 2006). Importantly, MSCs are TERT-negative 
(Zimmerman et al., 2003). Although tumorigenicity is lower than ESC, MSCs have been 
shown to assist tumor growth by transformation and suppression of the antitumor immune 
response (Ren et al., 2009). 
Similar to ESCs, MSCs display reduced immunogenicity, but MSCs also demonstrate a 
powerful immunomodulatory response in vivo (Hematti, 2008; Bifari et al., 2010). MSCs 
interfere with antigen-presenting cells and suppress B-cell differentiation causing inhibition 
of Natural Killer (NK) cells and cytotoxic T cells. They also express a broad number of anti-
inflammatory factors, such as a variety of cytokines and chemokines (Banas et al.; 2008). 
MSCs also inhibit local and systemic proinflammatory responses through inhibition of  
TNF-α and interleukin (IL)-1, which functions to prevent tissue damage (Lin et al., 2011), 
and can nonspecifically inhibit allogeneic lymphocyte proliferation. In addition, MSCs 
express low levels of HLA class I antigens and lymphocyte function-associating antigen 
(LFA)-3, and do not express HLA class II antigens or many co-stimulatory molecules which 
could function to upregulate HLA class II antigens in vivo (Bifari et al., 2010). By far, the 
most exciting and potentially useful characteristics of these cells are their immunomodulatory 
behaviors. MSCs significantly lower the incidence of graft-versus-host disease, autoimmune 
diseases, and can induce tolerance upon transplantation (Le Blanc et al, 2004; 2005; 2007). 
Nonetheless, it should be noted that MSC therapy may also increase the vulnerability to 
viral infections such as herpes (Sundin et al., 2006). 
3.3.1 Differentiation of MSCs and laboratory / clinical data 
Similar to ESC, MSCs are able to differentiate into various cell types by stimulation with 
specific growth factors, and there are many published protocols for differentiating MSCs 
along various cell lineages. For example, a recent review describes a number of protocols for 
differentiating along a hepatic lineage (Puglisi et al., 2011). The ability of MSCs to 
differentiate into hepatocyte-like cells was first reported in 2002 (Schwartz et al., 2002). The 
resulting hepatocyte-like cells performed hepatic functions such as albumin production, 
urea synthesis, glycogen storage, and low-density lipoprotein uptake (Jiang et al., 2002). 
 
Cell Transplantation – A Possible Alternative to Orthotopic Liver Transplant (OLT) 
 
153 
MSCs are able to differentiate into hepatocyte-like cells by stimulation with hepatocyte 
growth factor (HGF), epidermal growth factor (EGF), and FGF (Lange et al., 2005). MSC-
derived hepatocytes were able to engraft in the liver upon transplantation and have been 
shown to contribute towards improved hepatic function and regeneration (Kuo et al., 2008). 
Conversely, another report using bone marrow MSCs significantly increased the number of 
hepatic stellate cells and myofibroblasts, which could contribute to the fibrotic cascade 
(Russo et al., 2006). Despite the availability of many hepatic differentiation protocols, it is 
currently unclear whether MSCs are able to become hepatic cells through differentiation or 
by cell fusion, as evidenced by Sharma, et al. (2005). In addition, the homing mechanism by 
which intravenously injected MSCs can preferentially recruit to the injured liver is 
interesting (Sakaida et al., 2004), but also not well understood. MSCs preferentially target 
tissues undergoing remodeling; it has been suggested that inflammation might provide key 
regulatory factors in the targeted migration of MSCs into the diseased location (Kuo et al., 
2008).  
Due to their impressive immunomodulatory features, MSCs have been used to treat acute 
graft-versus-host disease and osteogenesis imperfecta in children (Le Blanc et al., 2005). 
MSCs also secrete several factors able to suppress hepatocyte apoptosis, inflammatory 
responses, and liver fibrosis, as well as stimulate hepatocyte proliferation and function (Lin 
et al., 2011; Zhou et al., 2009). Many such factors, for example HGF, can also aid in liver 
regeneration. Preclinical and clinical studies have suggested that MSC transplantation can 
moderately restore liver function and enhance survival rates in fulminant hepatic failure 
and end-stage liver disease (Yagi et al., 2009; Kuo et al., 2008; Banas et al., 2009), though it 
has been suggested that the benefits MSCs provide to damaged livers have more to do with 
the expression of immunomodulatory factors than engraftment and subsequent hepatic 
function of the transplanted cells (Banas et al., 2008). There is little evidence to date that 
verifies whether MSCs are able to form mature hepatocytes, either in culture or once 
transplanted. However, growing evidence does suggest that MSCs may improve cirrhotic 
liver function once infused into patients. For example, bone marrow MSCs transplantation 
reduced liver fibrosis, and improved liver function and survival in mice (Sakaida et al., 
2004) and rats (Abdel Aziz et al., 2007). This provided rationale for the use of autologous 
bone marrow MCSs for cell therapy to treat cirrhosis, which spurred several clinical trials 
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Since ESCs possess the ability of unlimited self-renewal, this relieves some pressure to 
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generally viewed as a powerful benefit, it is also a double-edged sword. Self-renewal, 
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both differentiated and undifferentiated ESCs, there is a risk of malignancy due to their 
associated tumorigenicity and genetic instability (Stutchfield et al., 2010). The generation of 
spontaneous tumors is of particular concern for clinical applications, and much of the 
current research is dedicated to reducing and eventually overcoming this risk. Perhaps with 
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more complete differentiation protocols, this will become a concern of the past. In addition 
to safety issues, ESCs also carry religious, political, and ethical concerns, and there is 
legislation restricting or banning their use in certain countries, such as the United States and 
United Kingdom. In contrast to ESCs, MSCs have fewer ethical concerns, as these cells are 
easily accessible from a variety of postnatal tissues. They exhibit a lower risk of spontaneous 
tumors, and their impressive ability to hide from and modulate the immune response is of 
considerable interest. However, MSCs have been shown to contribute to tumor growth in 
vivo and increased risk of viral infections. Therefore, high-risk patients may not be feasible 
candidates for MSC transplantation.  
Despite many promising therapeutic reports in the literature stating stem cells are able to 
contribute to liver regeneration, particularly with MSCs, there are still many problems 
associated with their use. Even with the considerable number of differentiation protocols 
available to produce various cell types, differentiation methods have not been optimized. 
Though stem cells are abundantly proliferative, high induction rates of hepatic cells are 
currently not possible to provide the required number of cells for transplantation to treat 
disorders of the liver, an organ which contains several billion cells. Furthermore, 
differentiated cells display minimal hepatocyte function both in vitro and in vivo. Once 
transplanted, engraftment is very low with low contributions towards tissue regeneration. 
For these reasons, it is relatively unknown whether stem cell-derived hepatocyte-like cells 
will be useful to treat and correct liver disease. More research is required to determine more 
efficient ways to induce hepatocyte-like cells, and a standardized list of requirements should 
be established to verify complete differentiation. In brief, stem cell derived hepatocyte-like 
cells should demonstrate characteristic hepatic gene expression and function, express 
appropriate transport proteins and transcription factors, metabolize ammonia and 
billirubin, produce albumin and/or bile acids, and no longer express genes characteristic of 
ESC or other cell types. Therapeutically useful hepatocyte-like cells must be safe (i.e. 
nontumorigenic), contribute to liver function in vivo, and importantly, must express hepatic 
genes at a level comparable to mature hepatocytes.  Currently there are no definitive reports 
of any stem cell-derived hepatocytes with these ideal characteristics. 
3.5 Human placenta as a source for stem cells 
The human full term placenta is comprised of three distinct layers: amnion, chorion, and 
decidua (Figure 1). The amnion and chorion are fetal-derived while the decidua originates 
from maternal tissue. The trophoblast layer gives rise to the chorion; the amnion is derived 
from the pluripotent epiblast, which also gives rise to all three germ layers of the embryo. 
The amnion layer is established as early as day 8 following fertilization, well before 
gastrulation when cell fate is specified (day 15-17). The amnion is derived at a time when the 
epiblast remains pluripotent, and amnion epithelial (AE) cells retain some of these 
characteristics. AE cells are easily isolated from full term placenta following live birth, 
which would normally be discarded after delivery. Placenta is readily available and easily 
procured without invasive procedures or causing harm to either mother or baby. In 2007, 
there were 1.4 million cesarean births in the United States, which equates to ~32% of all U.S. 
births (Hamilton et al., 2009). Placentas for cell isolation are typically obtained from cesarean 
deliveries due to sterility concerns; however, all placentas should be considered a useful 
source for stem cells. Theoretically, placental stem cells could be isolated from all term births 
and cryopreserved in a cell bank for future use. Since it has been estimated that as little as 30  
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stem cell lines would be needed to match HLA haplotypes in >80% of the Japanese 
population (Nakatsuji et al., 2008), global banking of placental stem cells containing all HLA 
haplotypes worldwide may be considered a realistic and attainable goal. Therefore, 
placental amnion may provide a useful source of pluripotent stem cells that are plentiful 
and free from most ethical, religious, or political concerns. 
3.5.1 Amnion epithelial (AE) cells 
The amniotic layer is composed of a single-celled epithelial layer of cuboidal and columnar 
cells and a deeper mesodermal layer composed of an upper compact acellular layer and a 
lower fibroblast-containing layer (Figure 1). The epithelial layer of the amnion is in contact 
with the amniotic fluid, which serves to protect and cushion the fetus through gestation. The 
chorionic layer is comprised of a mesodermal layer and an extravillious trophoblast layer. 
The maternally derived decidua, which interacts with the fetal derived trophoblast, serves 
to support the fetus through gas, nutrition, and waste exchange, and protect the fetus from 






















Fig. 1. Cross-sectional representation of the human placenta. The amnion and chorion are 
fetal-derived membranes while the decidual membrane is maternally-derived. The amniotic 
layer is composed of a single-celled epithelial layer and a deeper mesodermal layer. The 
chorionic layer is comprised of a mesodermal layer and a trophoblast layer. The maternal 
decidua is intermingled with the fetal chorionic trophoblast. (AE: amniotic epithelium;  
AM: amniotic mesoderm; CM: chorionic mesoderm; CT: chorionic trophoblast.) 
AE cells in culture express stem cell surface markers (e.g. SSEA-3 & 4, TRA 1-60 & 1-81) as 
well as molecular markers of stem cells (e.g. OCT-4, Nanog, SOX-2, FGF-4, and Rex-1), and 
unlike ESC, do not require feeder cell layers to maintain OCT-4 and Nanog expression (Miki 
et al., 2005; Miki & Strom, 2006). Interestingly, AE cells do not express the stem cell marker 
TERT (Miki et al., 2005). Telomerase activity is found in human ESC, multipotent adult  
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more complete differentiation protocols, this will become a concern of the past. In addition 
to safety issues, ESCs also carry religious, political, and ethical concerns, and there is 
legislation restricting or banning their use in certain countries, such as the United States and 
United Kingdom. In contrast to ESCs, MSCs have fewer ethical concerns, as these cells are 
easily accessible from a variety of postnatal tissues. They exhibit a lower risk of spontaneous 
tumors, and their impressive ability to hide from and modulate the immune response is of 
considerable interest. However, MSCs have been shown to contribute to tumor growth in 
vivo and increased risk of viral infections. Therefore, high-risk patients may not be feasible 
candidates for MSC transplantation.  
Despite many promising therapeutic reports in the literature stating stem cells are able to 
contribute to liver regeneration, particularly with MSCs, there are still many problems 
associated with their use. Even with the considerable number of differentiation protocols 
available to produce various cell types, differentiation methods have not been optimized. 
Though stem cells are abundantly proliferative, high induction rates of hepatic cells are 
currently not possible to provide the required number of cells for transplantation to treat 
disorders of the liver, an organ which contains several billion cells. Furthermore, 
differentiated cells display minimal hepatocyte function both in vitro and in vivo. Once 
transplanted, engraftment is very low with low contributions towards tissue regeneration. 
For these reasons, it is relatively unknown whether stem cell-derived hepatocyte-like cells 
will be useful to treat and correct liver disease. More research is required to determine more 
efficient ways to induce hepatocyte-like cells, and a standardized list of requirements should 
be established to verify complete differentiation. In brief, stem cell derived hepatocyte-like 
cells should demonstrate characteristic hepatic gene expression and function, express 
appropriate transport proteins and transcription factors, metabolize ammonia and 
billirubin, produce albumin and/or bile acids, and no longer express genes characteristic of 
ESC or other cell types. Therapeutically useful hepatocyte-like cells must be safe (i.e. 
nontumorigenic), contribute to liver function in vivo, and importantly, must express hepatic 
genes at a level comparable to mature hepatocytes.  Currently there are no definitive reports 
of any stem cell-derived hepatocytes with these ideal characteristics. 
3.5 Human placenta as a source for stem cells 
The human full term placenta is comprised of three distinct layers: amnion, chorion, and 
decidua (Figure 1). The amnion and chorion are fetal-derived while the decidua originates 
from maternal tissue. The trophoblast layer gives rise to the chorion; the amnion is derived 
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and cryopreserved in a cell bank for future use. Since it has been estimated that as little as 30  
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stem cell lines would be needed to match HLA haplotypes in >80% of the Japanese 
population (Nakatsuji et al., 2008), global banking of placental stem cells containing all HLA 
haplotypes worldwide may be considered a realistic and attainable goal. Therefore, 
placental amnion may provide a useful source of pluripotent stem cells that are plentiful 
and free from most ethical, religious, or political concerns. 
3.5.1 Amnion epithelial (AE) cells 
The amniotic layer is composed of a single-celled epithelial layer of cuboidal and columnar 
cells and a deeper mesodermal layer composed of an upper compact acellular layer and a 
lower fibroblast-containing layer (Figure 1). The epithelial layer of the amnion is in contact 
with the amniotic fluid, which serves to protect and cushion the fetus through gestation. The 
chorionic layer is comprised of a mesodermal layer and an extravillious trophoblast layer. 
The maternally derived decidua, which interacts with the fetal derived trophoblast, serves 
to support the fetus through gas, nutrition, and waste exchange, and protect the fetus from 






















Fig. 1. Cross-sectional representation of the human placenta. The amnion and chorion are 
fetal-derived membranes while the decidual membrane is maternally-derived. The amniotic 
layer is composed of a single-celled epithelial layer and a deeper mesodermal layer. The 
chorionic layer is comprised of a mesodermal layer and a trophoblast layer. The maternal 
decidua is intermingled with the fetal chorionic trophoblast. (AE: amniotic epithelium;  
AM: amniotic mesoderm; CM: chorionic mesoderm; CT: chorionic trophoblast.) 
AE cells in culture express stem cell surface markers (e.g. SSEA-3 & 4, TRA 1-60 & 1-81) as 
well as molecular markers of stem cells (e.g. OCT-4, Nanog, SOX-2, FGF-4, and Rex-1), and 
unlike ESC, do not require feeder cell layers to maintain OCT-4 and Nanog expression (Miki 
et al., 2005; Miki & Strom, 2006). Interestingly, AE cells do not express the stem cell marker 
TERT (Miki et al., 2005). Telomerase activity is found in human ESC, multipotent adult  
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progenitor stem cells, human germ cells, and 80-90% of human tumor samples (Chen & 
Chen, 2011). Telomerase-positive stem cells display an unstable karyotype and can become 
tumorigenic, most commonly forming teratomas, when transplanted into SCID mice. 
Conversely, AE cells consistently display a normal karyotype and are nontumorigenic when 
transplanted into SCID mice (Miki & Strom, 2006; Marongiu et al., 2011). In addition, AE 
cells are derived from neonatal tissue and should therefore naturally possess less 
environmental and age-acquired DNA damage (Miki, 2011). It is commonly known in the 
field that amnion does not express HLA class II antigens and only expresses class I antigens 
at low levels, which later led to the premise that AE would be able to bypass the immune 
system. AE cells were also found to secrete anti-inflammatory and immunosuppressive 
factors, which inhibited inflammation and reduced the proliferation of T- and B-cells in vitro 
(Li et al., 2005). Volunteers transplanted with AE cells did not experience any immunological 
reaction, and to date no tumors have ever formed as a result (Akle et al., 1981; Yeager et al, 
1985; Scaggiante et al, 1987; Sakurgawa et al., 1992). Many of these characteristics identify 
AE cells as similar to ESC, but not identical.  
3.5.2 AE cell isolation and differentiation methods 
Placental tissues are obtained with local Institutional Review Board (IRB) approval in the 
U.S., or under appropriate Ethical Committee approval, as well as patient approval. The 
amnion membrane is easily stripped from the underlying layers of the placenta by carefully 
peeling it away from the chorion (Figure 2). The amnion membrane contains AE cells and 
amniotic mesenchymal (AM) fibroblasts. AE and AM cells can be isolated from the amnion 
membrane following simple protocols (Miki et al., 2010; Marongiu, 2010). In brief, for 
collection of AE, the amnion membrane is first washed several times to remove blood 
contamination. The membrane is then subjected to several trypsinization steps, which 
releases the AE cells from the amnion mesenchymal fibroblasts and the connective tissue. 
The trypsin digests are then centrifuged to pellet the AE cells and resuspended in standard  
 
Fig. 2. Isolation of the amnion membrane from the chorion of the placenta. The maternal 
side of the placenta is placed face down and a shallow X-shaped incision (dashed lines) is 
made through the center of the placenta. The thin, nearly transparent amnion membrane is 
then peeled from the chorion starting at the center of the cut and progressing outward 
(direction of the arrow) 
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culture medium. A density separation step is done to enrich the population of SSEA-4 
positive AE cells similar to the process used for hepatocytes. Cell viability is determined by 
trypan blue exclusion and counted with a hemocytometer. An estimated AE cell yield from 
one term placenta is 80-300 million cells (Miki et al.; 2010). When AE cells are cultured in the 
presence of epidermal growth factor (EGF), they readily proliferate with numerous mitotic 
events (Terada et al., 2000), though senescence routinely occurs after 6-10 passages (Miki & 
Strom, 2006).  
AE cells have previously shown the potential to differentiate into all three germ layers in 
vitro (Miki et al., 2005). Similar to ESC, differentiation of AE cells to other cell types is 
dependent upon the culture substrate, as well as which growth factors are added and at 
what concentration (Parolini et al., 2007; Miki, 2011). Our group previously published 
efficient methods to differentiate AE cells along a hepatic lineage (Miki, et al., 2009; 
Marongiu, et al., 2011); after differentiation, AE cells expressed many endodermal/hepatic 
marker genes such as A1AT, hepatocyte nuclear factor-4 (HNF4-α), albumin, CAAT 
enhancer binding protein-alpha (C/EBP-α), many CYP450 genes, CK 8, 18, and 19, CYP7A1, 
plus several others at the level of fetal hepatocytes. Interestingly, cultured AE hepatocyte-
like cells express both CYP3A7 and CYP3A4, which indicates that AE differentiates along a 
pathway similar to human fetal liver. Furthermore, the ratio of CYP3A4 to CYP3A7 implies 
that cells are progressing towards mature hepatocytes (Miki et al., 2009). Early studies 
demonstrated proof of principle for AE cell transplantation through the production of 
dopamine-expressing cells from AE, which could survive and function in a rat model of 
Parkinson’s disease (Kakishita et al, 2000; 2003). Importantly, it was found that when 
undifferentiated AE cells were transplanted into the livers of immunodeficient mice, cells 
displaying hepatic morphology were observed that expressed mature liver genes such as 
transporters, cytochromes, and albumin or A1AT; circulating A1AT was also detected in 
transplanted mice confirming functional engraftment (Miki & Strom, 2006; Marongiu et al.; 
2011).  
3.5.3 AE cell transplantation  
Amnion epithelial cells, due to their stem cell-like pluripotent characteristics, low 
immunogenicity, and anti-inflammatory properties, show exciting promise in the field of 
regenerative medicine. Recently, studies have shown lung protection following human AE 
cell transplantation in a SCID mouse model of bleomycin-induced lung injury (Moodley et 
al., 2010; Murphy et al., 2010). Studies have also shown the efficacy of AE cells on corneal 
resurfacing in horses (Plummer, 2009), rabbits (Wan et al., 2011), and humans patients 
(Nubile et al., 2011), in which amniotic membranes were transplanted as a graft over the 
injury site. These studies were done without immunosuppression and without evidence of 
acute rejection. Differentiated AE have also been used to treat a rat model of Parkinson’s 
disease (Kakishita et al, 2000; 2003). Important for the treatment of liver diseases by CTx, AE 
cells demonstrate hepatic gene expression and functions at a level of mature hepatocytes 
following implantation into the livers of SCID mice, which suggest they differentiate into 
hepatocyte-like cells once engrafted in the liver parenchyma (Miki & Strom, 2006; Marongiu 
et al., 2011). Undifferentiated AE cells were able to functionally engraft into the livers of 
immunocompromised mouse models of liver damage resulting in a reduction of hepatic 
fibrosis, inflammation, and hepatocyte apoptosis (Manuelpillai et al., 2010; Marongiu et al., 
2011). In addition, AE cells have also been used in clinics to correct lysosomal storage 
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progenitor stem cells, human germ cells, and 80-90% of human tumor samples (Chen & 
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field that amnion does not express HLA class II antigens and only expresses class I antigens 
at low levels, which later led to the premise that AE would be able to bypass the immune 
system. AE cells were also found to secrete anti-inflammatory and immunosuppressive 
factors, which inhibited inflammation and reduced the proliferation of T- and B-cells in vitro 
(Li et al., 2005). Volunteers transplanted with AE cells did not experience any immunological 
reaction, and to date no tumors have ever formed as a result (Akle et al., 1981; Yeager et al, 
1985; Scaggiante et al, 1987; Sakurgawa et al., 1992). Many of these characteristics identify 
AE cells as similar to ESC, but not identical.  
3.5.2 AE cell isolation and differentiation methods 
Placental tissues are obtained with local Institutional Review Board (IRB) approval in the 
U.S., or under appropriate Ethical Committee approval, as well as patient approval. The 
amnion membrane is easily stripped from the underlying layers of the placenta by carefully 
peeling it away from the chorion (Figure 2). The amnion membrane contains AE cells and 
amniotic mesenchymal (AM) fibroblasts. AE and AM cells can be isolated from the amnion 
membrane following simple protocols (Miki et al., 2010; Marongiu, 2010). In brief, for 
collection of AE, the amnion membrane is first washed several times to remove blood 
contamination. The membrane is then subjected to several trypsinization steps, which 
releases the AE cells from the amnion mesenchymal fibroblasts and the connective tissue. 
The trypsin digests are then centrifuged to pellet the AE cells and resuspended in standard  
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culture medium. A density separation step is done to enrich the population of SSEA-4 
positive AE cells similar to the process used for hepatocytes. Cell viability is determined by 
trypan blue exclusion and counted with a hemocytometer. An estimated AE cell yield from 
one term placenta is 80-300 million cells (Miki et al.; 2010). When AE cells are cultured in the 
presence of epidermal growth factor (EGF), they readily proliferate with numerous mitotic 
events (Terada et al., 2000), though senescence routinely occurs after 6-10 passages (Miki & 
Strom, 2006).  
AE cells have previously shown the potential to differentiate into all three germ layers in 
vitro (Miki et al., 2005). Similar to ESC, differentiation of AE cells to other cell types is 
dependent upon the culture substrate, as well as which growth factors are added and at 
what concentration (Parolini et al., 2007; Miki, 2011). Our group previously published 
efficient methods to differentiate AE cells along a hepatic lineage (Miki, et al., 2009; 
Marongiu, et al., 2011); after differentiation, AE cells expressed many endodermal/hepatic 
marker genes such as A1AT, hepatocyte nuclear factor-4 (HNF4-α), albumin, CAAT 
enhancer binding protein-alpha (C/EBP-α), many CYP450 genes, CK 8, 18, and 19, CYP7A1, 
plus several others at the level of fetal hepatocytes. Interestingly, cultured AE hepatocyte-
like cells express both CYP3A7 and CYP3A4, which indicates that AE differentiates along a 
pathway similar to human fetal liver. Furthermore, the ratio of CYP3A4 to CYP3A7 implies 
that cells are progressing towards mature hepatocytes (Miki et al., 2009). Early studies 
demonstrated proof of principle for AE cell transplantation through the production of 
dopamine-expressing cells from AE, which could survive and function in a rat model of 
Parkinson’s disease (Kakishita et al, 2000; 2003). Importantly, it was found that when 
undifferentiated AE cells were transplanted into the livers of immunodeficient mice, cells 
displaying hepatic morphology were observed that expressed mature liver genes such as 
transporters, cytochromes, and albumin or A1AT; circulating A1AT was also detected in 
transplanted mice confirming functional engraftment (Miki & Strom, 2006; Marongiu et al.; 
2011).  
3.5.3 AE cell transplantation  
Amnion epithelial cells, due to their stem cell-like pluripotent characteristics, low 
immunogenicity, and anti-inflammatory properties, show exciting promise in the field of 
regenerative medicine. Recently, studies have shown lung protection following human AE 
cell transplantation in a SCID mouse model of bleomycin-induced lung injury (Moodley et 
al., 2010; Murphy et al., 2010). Studies have also shown the efficacy of AE cells on corneal 
resurfacing in horses (Plummer, 2009), rabbits (Wan et al., 2011), and humans patients 
(Nubile et al., 2011), in which amniotic membranes were transplanted as a graft over the 
injury site. These studies were done without immunosuppression and without evidence of 
acute rejection. Differentiated AE have also been used to treat a rat model of Parkinson’s 
disease (Kakishita et al, 2000; 2003). Important for the treatment of liver diseases by CTx, AE 
cells demonstrate hepatic gene expression and functions at a level of mature hepatocytes 
following implantation into the livers of SCID mice, which suggest they differentiate into 
hepatocyte-like cells once engrafted in the liver parenchyma (Miki & Strom, 2006; Marongiu 
et al., 2011). Undifferentiated AE cells were able to functionally engraft into the livers of 
immunocompromised mouse models of liver damage resulting in a reduction of hepatic 
fibrosis, inflammation, and hepatocyte apoptosis (Manuelpillai et al., 2010; Marongiu et al., 
2011). In addition, AE cells have also been used in clinics to correct lysosomal storage 
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diseases with no adverse effects (Yeager et al, 1985; Scaggiante et al, 1987; Sakurgawa et al., 
1992). Finally, our group recently determined that AE cells could partially rescue a mouse 
model of intermediate MSUD (Skvorak et al., 2010), an inborn error of metabolism 
characterized by deficiency of the branched-chain keto-acid dehhydrogenase (BCKDH) 
enzyme complex and high levels of BCAA (Homanics et al., 2006). iMSUD mice were given 
multiple infusions of undifferentiated AE cells, either freshly isolated or cryopreserved, 
directly into the liver parenchyma. AE cell transplantation partially corrected iMSUD mice 
similarly to the partial correction previously obtained with hepatocyte transplantation 
(Skvorak et al, 2009a; 2009b). While untreated iMSUD mice grew sickly and all died prior to 
27 days of age, iMSUD-treated mice displayed improved BCKDH enzyme activity, reduced 
BCAA and other relevant metabolites in the brain and blood, their body weight mimicked 
that of healthy wildtype littermates, and >70% of animals survived to day of life 100 
(Skvorak et al., 2010). Immunosuppression was not used and there was no evidence of 
rejection. 
3.5.4 Benefits / concerns of AE cells 
Current research suggests that stem cells isolated from discarded placenta may be an 
abundant, noncontroversial, and safe source of cells for regenerative medicine. There are a 
multitude of reports in the literature, some going as far back as 1947, which describe the 
successful use of AE and amniotic membranes to treat a variety of disorders both 
preclinically and clinically. Furthermore, isolation is relatively easy, and does not require a 
special laboratory set up (Miki et al., 2007). An average of 100 million cells can be isolated 
from a single term placenta, and AE is able to proliferate robustly in culture; Miki, et al. 
(2005) estimates that 100 million AE cells could be expanded to 10-60 billion cells within six 
passages. Unlike hepatocytes, AE cell viability and morphology are also very stable when 
cryopreserved long term at -80°C. Taken together, these benefits greatly encourage the 
establishment of a placental cell bank. Current umbilical cord blood stem cell guidelines 
could be used as a template to set up similar procurement and banking procedures for 
placental-derived stem cells (Serrano-Delgado et al., 2009).  
AE cells meet many important criteria for clinically relevant cells: expression of anti-
inflammatory factors, nonimmunogenic, maintains a stable karyotype, and consistently 
nontumorigenic in vivo in both SCID mice and humans. Undifferentiated AE cells are 
proposed to become hepatocyte-like once engrafted in the liver parenchyma and have 
contributed to liver function in animal models of disease. There are also many published 
differentiation protocols describing induction along many cell lineages, including hepatic. 
However, though these cells exhibit many advantages, particularly over other stem cell 
types, the ability to produce therapeutically useful cells to treat liver diseases has still not 
been developed from AE cells. Though it is unknown whether differentiation prior to 
transplantation will be necessary, one should assume that differentiation into the required 
cell type will be the most clinically efficient and effective method of treatment. Therefore, 
hepatocyte-like cells derived from AE should be held to the same standardized list of 
requirements, outlined in Section 3.4, as cells differentiated from other classifications of stem 
cells. As with other types of stem cells, more research is required to establish better 
induction of therapeutically useful cells. However, the safety of these cells has been 
exhaustively established and they already have a long history of clinical use. Clinical 
application of AE for liver and other diseases may be in our near future.  
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3.6 Discovery and characterization of induced pluripotent stem cells (iPSC)  
Once an embryo reaches the blastocyst stage, highly specific (i.e. spatially and temporally 
controlled) molecular signaling events coordinate directed differentiation of cells to their 
appropriate cell fate. Therefore, a cell becomes specified not by changing its DNA sequence, 
but by controlling the expression of certain genes through specific signals. The first attempt 
to manipulate a cell’s developmental potential was known as somatic cell nuclear transfer, 
which led to the birth of live lambs (Wilmut et al., 1997). “Dolly” the sheep provided 
evidence that differentiation of a cell towards a somatic state is not accomplished by 
irreversible genetic manipulation.  
Almost a decade later, Yamanaka’s group successfully derived pluripotent ESC-like cells 
from murine somatic cells through forced expression of the reprogramming factors OCT-
3/4, SOX-2, c-MYC, and KLF-4 by lentiviral induction (Takahashi & Yamanaka, 2006). These 
“induced pluripotent stem cells” (iPSC) were similar to ESCs in morphology, growth 
properties, expression of ESC marker genes, display of an unstable karyotype, 
tumorigenicity and teratoma formation in SCID mice, and injection into a blastocyst yielded 
cells that contributed to mouse development. Human iPSC from adult skin fibroblasts were 
also generated using the same four factors as mice (Takahashi et al., 2007), and also by 
forced expression of a new set of four factors: OCT-4, SOX-2, Nanog, and Lin-28 (Yu et al., 
2007). Pluripotent iPSC should express the stem cell markers SSEA3, SSEA-4, TRA-1-60, 
TRA-1-81, OCT-4, alkaline phosphatase, TERT, SOX-2 and Nanog, and form teratomas in 
vivo. It has also been reported that a specific expression profile of stem cell markers 
corresponds to either a completely or partially reprogrammed cell (Chan et al., 2009). 
Recently, iPSCs have been derived from a variety of human tissues, such as umbilical cord 
matrix (Cai et al., 2010), fetal and juvenile tissues (Park et al., 2008a; Li et al., 2010; Aasen et 
al., 2008), placental tissue (Nagata et al., 2009; Cai et al., 2010; Zhao et al., 2010), and primary 
human hepatocytes. However, evidence that iPSC retain epigenetic memory of their cells of 
origin exist for both mouse (Kim et al., 2010; Polo et al., 2010) and human (Hu et al., 2010), 
which can affect their differentiation potential. This is a concern, but it also suggests that the 
best cell source to generate iPSC for the treatment of liver disease would be hepatocytes; 
hepatic-like cells differentiated from hepatocyte-derived iPSC would most closely resemble 
their primary cell counterparts. 
Currently, iPSC research is largely dedicated to reducing the tumorigenicity of the cells. The 
use of retroviruses and lentiviruses is a concern, which integrates into the target cell genome 
in a random fashion potentially causing cancer. The generation of mouse iPSC through the 
use of non-integrating adenoviruses (Stadtfeld et al., 2008) determined reprogramming 
could be achieved through transient expression. Vector integration-free human iPSCs have 
since been derived using Epstein-Barr virus-derived episomes (Yu et al., 2009), mRNA 
transfection (Yakubov et al., 2010), bacterial DNA-free episomal vectors (Jia et al., 2010), and 
proteins (Kim et al., 2009). However, viral integration is only one problem contributing to 
the tumorigenicity of iPSC. c-MYC is a well established oncogene, and the remaining factors 
(OCT-4, SOX-2, KLF-4) are also known to be highly expressed in cancers (Schoenhals et al., 
2009). Recent studies have shown that reprogramming could be successful without using c-
MYC and KLF-4 (Li et al., 2010; Huangfu et al., 2008). However, the use of viral-free vectors 
or the omission of c-MYC and KLF-4 drastically reduces reprogramming efficiency, and one 
study found no difference in tumorigenicity between viral and viral-free methods 
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diseases with no adverse effects (Yeager et al, 1985; Scaggiante et al, 1987; Sakurgawa et al., 
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BCAA and other relevant metabolites in the brain and blood, their body weight mimicked 
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(Skvorak et al., 2010). Immunosuppression was not used and there was no evidence of 
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successful use of AE and amniotic membranes to treat a variety of disorders both 
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cryopreserved long term at -80°C. Taken together, these benefits greatly encourage the 
establishment of a placental cell bank. Current umbilical cord blood stem cell guidelines 
could be used as a template to set up similar procurement and banking procedures for 
placental-derived stem cells (Serrano-Delgado et al., 2009).  
AE cells meet many important criteria for clinically relevant cells: expression of anti-
inflammatory factors, nonimmunogenic, maintains a stable karyotype, and consistently 
nontumorigenic in vivo in both SCID mice and humans. Undifferentiated AE cells are 
proposed to become hepatocyte-like once engrafted in the liver parenchyma and have 
contributed to liver function in animal models of disease. There are also many published 
differentiation protocols describing induction along many cell lineages, including hepatic. 
However, though these cells exhibit many advantages, particularly over other stem cell 
types, the ability to produce therapeutically useful cells to treat liver diseases has still not 
been developed from AE cells. Though it is unknown whether differentiation prior to 
transplantation will be necessary, one should assume that differentiation into the required 
cell type will be the most clinically efficient and effective method of treatment. Therefore, 
hepatocyte-like cells derived from AE should be held to the same standardized list of 
requirements, outlined in Section 3.4, as cells differentiated from other classifications of stem 
cells. As with other types of stem cells, more research is required to establish better 
induction of therapeutically useful cells. However, the safety of these cells has been 
exhaustively established and they already have a long history of clinical use. Clinical 
application of AE for liver and other diseases may be in our near future.  
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Once an embryo reaches the blastocyst stage, highly specific (i.e. spatially and temporally 
controlled) molecular signaling events coordinate directed differentiation of cells to their 
appropriate cell fate. Therefore, a cell becomes specified not by changing its DNA sequence, 
but by controlling the expression of certain genes through specific signals. The first attempt 
to manipulate a cell’s developmental potential was known as somatic cell nuclear transfer, 
which led to the birth of live lambs (Wilmut et al., 1997). “Dolly” the sheep provided 
evidence that differentiation of a cell towards a somatic state is not accomplished by 
irreversible genetic manipulation.  
Almost a decade later, Yamanaka’s group successfully derived pluripotent ESC-like cells 
from murine somatic cells through forced expression of the reprogramming factors OCT-
3/4, SOX-2, c-MYC, and KLF-4 by lentiviral induction (Takahashi & Yamanaka, 2006). These 
“induced pluripotent stem cells” (iPSC) were similar to ESCs in morphology, growth 
properties, expression of ESC marker genes, display of an unstable karyotype, 
tumorigenicity and teratoma formation in SCID mice, and injection into a blastocyst yielded 
cells that contributed to mouse development. Human iPSC from adult skin fibroblasts were 
also generated using the same four factors as mice (Takahashi et al., 2007), and also by 
forced expression of a new set of four factors: OCT-4, SOX-2, Nanog, and Lin-28 (Yu et al., 
2007). Pluripotent iPSC should express the stem cell markers SSEA3, SSEA-4, TRA-1-60, 
TRA-1-81, OCT-4, alkaline phosphatase, TERT, SOX-2 and Nanog, and form teratomas in 
vivo. It has also been reported that a specific expression profile of stem cell markers 
corresponds to either a completely or partially reprogrammed cell (Chan et al., 2009). 
Recently, iPSCs have been derived from a variety of human tissues, such as umbilical cord 
matrix (Cai et al., 2010), fetal and juvenile tissues (Park et al., 2008a; Li et al., 2010; Aasen et 
al., 2008), placental tissue (Nagata et al., 2009; Cai et al., 2010; Zhao et al., 2010), and primary 
human hepatocytes. However, evidence that iPSC retain epigenetic memory of their cells of 
origin exist for both mouse (Kim et al., 2010; Polo et al., 2010) and human (Hu et al., 2010), 
which can affect their differentiation potential. This is a concern, but it also suggests that the 
best cell source to generate iPSC for the treatment of liver disease would be hepatocytes; 
hepatic-like cells differentiated from hepatocyte-derived iPSC would most closely resemble 
their primary cell counterparts. 
Currently, iPSC research is largely dedicated to reducing the tumorigenicity of the cells. The 
use of retroviruses and lentiviruses is a concern, which integrates into the target cell genome 
in a random fashion potentially causing cancer. The generation of mouse iPSC through the 
use of non-integrating adenoviruses (Stadtfeld et al., 2008) determined reprogramming 
could be achieved through transient expression. Vector integration-free human iPSCs have 
since been derived using Epstein-Barr virus-derived episomes (Yu et al., 2009), mRNA 
transfection (Yakubov et al., 2010), bacterial DNA-free episomal vectors (Jia et al., 2010), and 
proteins (Kim et al., 2009). However, viral integration is only one problem contributing to 
the tumorigenicity of iPSC. c-MYC is a well established oncogene, and the remaining factors 
(OCT-4, SOX-2, KLF-4) are also known to be highly expressed in cancers (Schoenhals et al., 
2009). Recent studies have shown that reprogramming could be successful without using c-
MYC and KLF-4 (Li et al., 2010; Huangfu et al., 2008). However, the use of viral-free vectors 
or the omission of c-MYC and KLF-4 drastically reduces reprogramming efficiency, and one 
study found no difference in tumorigenicity between viral and viral-free methods 
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(Moriguchi et al., 2010). More recently described epigenetic factors such as cell memory and 
genetic imprinting may also contribute to the tumorigenicity of iPSC, which is not yet 
understood (Ben-David & Benvenisty, 2011). 
3.6.1 iPSC for disease modeling, hepatic differentiation, and transplantation 
Now that iPSC technology has been well established, disease-specific iPSC to model 
diseases in vitro and in vivo may help researchers better understand diseases in order to 
develop new treatments. Park et al. (2008b) described the generation of iPSC from a variety 
of inherited diseases, such as Huntington’s, Duchene’s and Beckers’s muscular dystrophy, 
diabetes mellitus type 1, Down’s syndrome, and Parkinson’s. iPSC have also been generated 
from inherited metabolic disease patients with A1AT, Crigler-Najjar, tyrosinemia type 1, 
familial hypercholesterolemia, and glycogen storage disease type 1a (Rashid et al., 2010), 
which were then differentiated into hepatocytes to more accurately model the disease in 
vitro. More recently, iPSC-derived hepatocyte-like cells generated from the dermal 
fibroblasts of a Wilson’s disease patient was shown to mimic the disease phenotype in vitro 
(Zhang et al., 2011). Importantly, iPSCs of metabolic disease could be genetically corrected 
in culture, differentiated into hepatocytes possessing the ability to make normal protein, and 
potentially infused back into patients to cure their disease. The use of autologous cells 
would also reduce the risk of immune issues and rejection theoretically avoiding the need 
for immunosuppression. Human artificial chromosome technology was used to deliver the 
entire dystrophin gene to genetically correct patient fibroblasts with Duchenne muscular 
dystrophy in vitro, and iPSC were generated from the corrected cells (Kazuki et al., 2010). In 
addition, iPSC-derived hepatocyte-like cells modeling Wilson’s disease were corrected in vitro 
using either lentiviral gene therapy or treatment of the drug curcumin (Zhang et al., 2011). 
 
Fig. 3. Examples of iPSC in vitro. A. undifferentiated iPS cell colony; B. a spontaneously 
differentiating iPS cell colony; C. iPS cell-derived hepatocytes formed after following an in 
vitro protocol adapted from Si-Tayeb et al. 2010. All cells were cultured on matrigel in 
mTeSR1 media 
Using established differentiation protocols for ESCs, researchers have been able to 
differentiate iPSCs into all three germ layers in culture, further proving these cells are truly 
pluripotent. Figure 3 shows examples of cultured iPSC in either an undifferentiated state 
(Figure 3A) or spontaneous differentiation (Figure 3B). Furthermore, there are several 
reports of differentiation of iPSC along a hepatic lineage (Figure 3C) using ESC protocols 
(Si-Tayeb et al., 2010; Song et al., 2009; Liu et al., 2011). However, in most reported cases 
iPSC-derived hepatocytes displayed very low hepatic function and gene expression in vitro 
when compared to primary hepatocytes. However, blastocysts from tyrosinema type 1 
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mouse models deficient in the FAH gene were injected with MEF-derived iPSC, and 
resulting pups with high chimerism could survive without NTBC drug (Espejel et al., 2010). 
FAH-negative pups with low levels of chimerism were dependent on NTBC to survive. 
These data demonstrate the potential for iPSC to form “mature” hepatocytes which can 
express sufficient levels of protein to correct a metabolic defect. However, Espejel et al. 
differentiated iPSC through injection into a blastocyst. As with other stem cells, improved in 
vitro differentiation protocols are needed to yield high amounts of therapeutically useful 
cells.  
3.6.2 Benefits / concerns of iPS cells 
Similar to ESC, the major benefits of iPSC are their self-renewal abilities and differentiation 
potential. iPSC could theoretically provide an unlimited pluripotent source of cells that 
could be banked and differentiated into hepatocytes for transplant when needed. Nakatsuji 
et al. (2008) estimated that an iPSC bank with only 30 stem cell lines could match the HLA 
haplotypes in >80% of the Japanese population. Unlike ESC, patient specific iPSC could be 
generated, corrected, and infused back into a patient avoiding immune problems and the 
need for immunosuppression. Importantly, there are no religious, ethical, or political 
controversies associated with the use of iPSCs. However, the field of iPSC research is very 
new and there are still a lot of unknowns. The major concern with iPSC use is a question of 
safety; iPSC have a high risk of tumorigenicity. Just like ESC, iPSC exhibit genetic instability, 
express TERT, and can produce teratomas in vivo. Furthermore, rapidly accumulating 
evidence suggests these two cell types have important genetic and epigenetic differences 
that influence their tumorigenicity, and that iPSC are likely more tumorigenic than ESC 
(reviewed by Ben-David & Benvenisty, 2011). Furthermore, the most reliable, reproducible, 
and efficient method to currently generate iPSC is through an integrating viral vector 
process that could induce cancers, and both integrating and non-integrating methods use 
reprogramming factors that are highly expressed in many tumor samples. Aside from the 
issue of safety, cell differentiation protocols and methods to enhance engraftment have not 
yet been optimized, and it is currently unknown whether long term survival of iPSCs in vivo 
is possible. Further research is needed to generate iPSC that are safe, effective, and 
therapeutically useful before these cells can be used for clinical cell therapies.  
4. Conclusions 
Alternatives to OLT must be found in order to circumvent the increasing amount of patient 
deaths due to long organ wait times and insufficient numbers of available livers. CTx has 
shown a great deal of promise, and the progress made over the past several decades of 
preclinical and clinical studies provides a growing amount of rationale for its use to treat a 
variety of liver disorders. Cells isolated from donor livers have been proven to provide safe 
and effective liver support for both short- and long-term function. There have been several 
reported clinical cases of disease reversal in acute liver failure, and HTx has provided partial 
correction for a variety of inherited metabolic diseases (Table 1). In vitro gene modification 
to correct allogenic hepatocytes is also possible to avoid immunogenicity of transplanted 
cells and a lifelong immunosuppression regimen. However, complete correction of a 
metabolic disorder by HTx has not yet been achieved, and more than one treatment would 
likely be required to sustain a patient through his/her lifetime. There are still several  
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would also reduce the risk of immune issues and rejection theoretically avoiding the need 
for immunosuppression. Human artificial chromosome technology was used to deliver the 
entire dystrophin gene to genetically correct patient fibroblasts with Duchenne muscular 
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mouse models deficient in the FAH gene were injected with MEF-derived iPSC, and 
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These data demonstrate the potential for iPSC to form “mature” hepatocytes which can 
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differentiated iPSC through injection into a blastocyst. As with other stem cells, improved in 
vitro differentiation protocols are needed to yield high amounts of therapeutically useful 
cells.  
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potential. iPSC could theoretically provide an unlimited pluripotent source of cells that 
could be banked and differentiated into hepatocytes for transplant when needed. Nakatsuji 
et al. (2008) estimated that an iPSC bank with only 30 stem cell lines could match the HLA 
haplotypes in >80% of the Japanese population. Unlike ESC, patient specific iPSC could be 
generated, corrected, and infused back into a patient avoiding immune problems and the 
need for immunosuppression. Importantly, there are no religious, ethical, or political 
controversies associated with the use of iPSCs. However, the field of iPSC research is very 
new and there are still a lot of unknowns. The major concern with iPSC use is a question of 
safety; iPSC have a high risk of tumorigenicity. Just like ESC, iPSC exhibit genetic instability, 
express TERT, and can produce teratomas in vivo. Furthermore, rapidly accumulating 
evidence suggests these two cell types have important genetic and epigenetic differences 
that influence their tumorigenicity, and that iPSC are likely more tumorigenic than ESC 
(reviewed by Ben-David & Benvenisty, 2011). Furthermore, the most reliable, reproducible, 
and efficient method to currently generate iPSC is through an integrating viral vector 
process that could induce cancers, and both integrating and non-integrating methods use 
reprogramming factors that are highly expressed in many tumor samples. Aside from the 
issue of safety, cell differentiation protocols and methods to enhance engraftment have not 
yet been optimized, and it is currently unknown whether long term survival of iPSCs in vivo 
is possible. Further research is needed to generate iPSC that are safe, effective, and 
therapeutically useful before these cells can be used for clinical cell therapies.  
4. Conclusions 
Alternatives to OLT must be found in order to circumvent the increasing amount of patient 
deaths due to long organ wait times and insufficient numbers of available livers. CTx has 
shown a great deal of promise, and the progress made over the past several decades of 
preclinical and clinical studies provides a growing amount of rationale for its use to treat a 
variety of liver disorders. Cells isolated from donor livers have been proven to provide safe 
and effective liver support for both short- and long-term function. There have been several 
reported clinical cases of disease reversal in acute liver failure, and HTx has provided partial 
correction for a variety of inherited metabolic diseases (Table 1). In vitro gene modification 
to correct allogenic hepatocytes is also possible to avoid immunogenicity of transplanted 
cells and a lifelong immunosuppression regimen. However, complete correction of a 
metabolic disorder by HTx has not yet been achieved, and more than one treatment would 
likely be required to sustain a patient through his/her lifetime. There are still several  
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challenges to overcome. For HTx, the first major challenge is the availability of donor livers 
for the isolation of hepatocytes. There are not enough donor livers rejected for OLT, thus 
making them available for HTx, to provide for everyone requiring treatment. The second is 
regarding reliable storage of isolated hepatocytes. Current cryopreservation and thawing 
protocols result in massive cell loss and decreased viability; this reduces the number of cells 
available for transplant, and cell quality influences cell engraftment, cell function, and thus 
patient outcome. These drawbacks emphasize our need for alternative cell sources. Research 
to use stem cells and stem-like cells (e.g. ESC, MSC, AE, iPSC) for CTx are currently in 
preclinical and, for some, early clinical stages. Though there have been some advances made 
in animal models, the safety and efficacy of these cells must be unequivocally determined. 
All the aforementioned alternative cell types display varying levels of immunomodulatory 
properties making them potentially less immunogenic than hepatocytes. However, ESC, 
MSC, and iPSC all have tumorigenicity risks associated with their use in vivo. It has been 
suggested that more complete differentiation of cells into hepatocyte-like cells may reduce 
tumor formation, though it is not known whether this strategy will completely ablate the 
risk. In addition, the recently discovered epigenetic factors in iPSC must be more thoroughly 
investigated. These epigenetic differences may influence differentiation efficiencies, and it 
has been suggested that they may make iPSC more tumorigenic than ESC (Ben-David & 
Benvenisty, 2011). AE cells are nontumorigenic in both an undifferentiated and 
differentiated state, are nonimmunogenic, and have been used in clinical studies for more 
than sixty years without immunosuppression and without evidence of acute rejection. AE 
cells are clearly the safest alternative to hepatocytes from the stem cells discussed in this 
chapter, but their effectiveness to correct liver disease is currently unknown.   
In summary, considerable progress has been gained in cell transplantation thus far, though 
future work is required to enhance utility of this novel branch of regenerative medicine.  
Improvement of cell engraftment remains the single biggest challenge to overcome. New 
methods to modulate the immune reaction and relieve changes in vascular pressures after 
cell transplant are currently being investigated to enhance engraftment and improve patient 
outcome. Preconditioning protocols of the recipient liver, such as hepatic irradiation, portal 
vein embolization, and surgical resection, may also help to improve engraftment by giving 
donor cells selected growth advantage (Soltys et al., 2010; Puppi et al., 2011), which will be 
of particular importance in patients of metabolic disease. Though hepatocytes remain the 
most preferred cell for cell transplantation, stem cells may provide a useful cell alternative 
to hepatocytes once the question of safety has been resolved and the ability to provide 
therapeutically useful cells at a scale suitable for transplantation is achieved. 
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1. Introduction  
The development and implementation of different surgical techniques and 
immunosuppressive regimens in liver transplantation have been based upon animal 
experimental studies. The first experimental attempt for liver transplantation was reported 
on dogs, in 1955, by Welch (Welch, 1955), who described the insertion of a heterotopic 
auxiliary liver, engrafted in either the pelvis or right paravertebral gutter. The portal vein 
was anastomosed to the inferior vena cava and the hepatic artery to the aorta or iliac artery, 
and no immunosuppression was used. The first experimental liver replacement with 
orthotopic liver transplantation (OLT) was reported by Cannon at the University of 
California at Los Angeles in 1956, but none of those dogs survived. (Cannon, 1956) 
Surgical techniques for experimental orthotopic liver transplantation on pigs were started 
by Garnier and colleagues in 1965 (Garnier et al., 1965), and continued by Cordier and 
colleagues in 1966 (Cordier et al., 1966), Mieny and colleagues in 1967 (Mieny et al., 1967), 
Calne and colleagues in 1968 (Calne et al., 1968). Surgical techniques and vascular bypass 
methods used on pigs were transposed from dogs. Methods of passive venous bypass used 
by Moore (external portal and systemic bypass) (Moore et al., 1959) and Starzl (external side-
to-side portacaval bypass) (Kaupp & Starzl 1960) on dog models facilitated the development 
and use by Calne of portal-jugular and portal-caval-jugular passive venous bypass methods 
and later the active venous bypass method on pigs (Calne et al., 1968). 
Pig orthotopic liver transplantation models offer some advantages over the dog models:  
(1) pigs are considered the most realistic choice due to the low cost, availability, and ethical 
reasons; (2) there is no outflow phenomenon because, different from dogs, pigs have no 
muscular sphincters at the confluence of suprahepatic inferior cava vein which tangle the 
blood flow at this level; (3) pig liver orthotopically transplanted into another animal remains 
fully functional even for periods of months without immunosuppressive therapy; (4) pig 
models offer a much closer resemblance with the human liver transplantation than dog 
models, because the pig liver is a firm and coherent organ, composed of eight segments 
(Filipponi et al., 1995) homologous to those of the human liver. 
Although pig liver transplantation models are favored, both anesthesia team and surgical 
team are challenged by anatomical and physiological differences between human and pig. 
The experimental studies must be in conformity with the International Guidelines of 
Biomedical Research Involving Animals. 
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In the present chapter we focus upon anesthesia and surgical procedures used by different 
authors for the orthotopic liver transplantation on swine model. 
2. Preoperative preparation 
The importance of conducting a proper anesthesia begins with the preoperative preparation 
in order to avoid the occurrence of potentially lethal malignant hyperthermia and porcine 
stress syndrome. Thus a very gentle handling with a minimum distress for pigs must be 
acknowledged. Before surgical interventions, the animals should be left to adapt to the 
environment for 24-48 h. Some authors recommend to have the animals delivered at least 2 
to 3 weeks before the experiments to get them acclimated to the personal conditions, 
location, and food. (Kaiser et al., 2006) The operations should be performed after a 12-24 h 
starvation period. During this time only ad libitum oral water intake is admitted. Brute force 
should be avoided. The immobilization of the pig should be conducted only by experienced 
staff otherwise it is stressful for both the animal and researcher. 
3. Anesthesia 
An anesthesia protocol is proposed: i.m. pre-anesthesia using Atropin 0.015 mg/kgc, 
Midazolam 2 mg/kgc, Ketamine 10 mg/kgc, i.v. (marginal ear veins) induction with 
Propofol 3 mg/kgc, gas maintained anesthesia with Halotane 3% - 4.5 l/min and orotracheal 
intubation. (Sirbu Boeti et al., 2008) Before intubation, 100% O2 is delivered via an inhalation 
mask to obtain a very good oxygenation of the animal. The orotracheal intubation is quite 
cumbersome but can be surpassed by positioning the pig in ventral decubitus and using a 
laryngoscope with long blade and a mandrel. (Kaiser et al., 2006) In difficult situations, 
larynx and trachea are manipulated from the outside to permit passage of the 6 Fr 
endotracheal tube. It is important for intubation to have the swallowing reflex completely 
abolished. The endotracheal tube is blocked by inflating the balloon with air and fixed with 
a bandage. The auscultation of the chest must confirm the proper positioning of the tube. 
The anesthesia machine is adjusted for a tidal volume of 500 ml at a ventilation rate of 18-20 
per minute. A venous line should be mounted on each ear for drug administration. A 
drainage tube should be passed via mouth into pig’s stomach to deflate it during the 
operation. The anesthesia depth can be assessed by mandible relaxation, inferior-medial eye 
balls deviation, and corneal reflex. During the entire intervention for both donor and 
recipient, SpO2, heart rhythm and respiratory frequency should be monitored. Body 
temperature is another important parameter to check using an intrarectal probe. However, 
the clinical observation of the swine remains a major part of the continuous monitoring of 
the pig. (Kaiser et al., 2006)  
Pigs are extremely sensible to medication administered during preanesthesia or anesthesia 
induction, being prone to developing epidermal allergic phenomenon with generalized skin 
rush, which may be relieved by corticoid administration. Although rare, an example of drug 
side effect is represented by the rapidly progressive liver decompensation with 
intraoperative death due to Halothane inhalation. Other inhaled anesthetics such as 
Isoflurane or Sevoflurane are better alternatives.  
There are two main anatomical differences between human and pig with great impact on 
the liver transplantation technique: (1) intrahepatic parenchymal trajectory of inferior vena 
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cava (Filipponi et al., 1995; Fondevila et al., 2010) which makes the dissection of this vein off 
the hepatic parenchyma impossible in pigs; (2) the existence of a very short segment of 
suprahepatic inferior vena cava, intimately attached to the diaphragm, which leads to 
difficulty in hepatic vascular reconstruction. (Sirbu Boeti et al., 2008)  
Donor and recipient pigs can be operated on by the same team of surgeons. All the surgeons 
of the team should posses basic skills in microsurgical techniques.  
4. Donor operation 
The donor operation is generally performed using only an intravenous catheter placed at the 
start of anesthesia.  
For liver harvesting, the abdomen of the donor pig is entered via a midline incision, 
avoiding the urethra. The liver is exposed after appropriate bilateral costal retraction, careful 
packing, and caudal retraction of the bowel. The liver is mobilized by dividing the falciform 
ligament, triangular ligament, and gastrohepatic ligament. The hepatic pedicle is exposed by 
moving away the small bowel using caudal and left traction of the bowel. The pedicle's 
elements are dissected and hepatic artery, portal vein, and common bile duct are encircled 
and isolated with a loop. Pedicle's elements must be dissected and divided as close as 
possible to the duodenum, obtaining an increased length for anastomosis. Inferior vena cava 
is dissected above and below the liver in order to permit its harvesting together with the 
whole liver. The skeletonization of the common bile duct should be avoided. The 
gallbladder is incised and drained if a biliary reconstruction with the cholecyst is planned. If 
not, an antegrade or retrograde cholecystectomy is performed. Aorta is exposed at the level 
of celiac trunk and iliac bifurcation on loops. The subject should receive 100 UI/Kgc of 
Heparine before splenic vein and aorta cannulation. The previously encircled terminal aorta 
is cannulated under the renal arteries for blood collection. The collected blood can be used 
during liver engraftment as needed. After 500 ml blood collection from the aorta, the 
preservative solution (e.g. lactated Ringer’s solution) cooled at 4º C is infused through portal 
cannula while the supraceliac and terminal aorta together with supra and infrahepatic vena 
cava are cross-clamped. Outflow of the infused solution is provided by inferior infrahepatic 
inferior vena cava through a slit made by cutting its wall. The liver effluent can also be 
allowed to drain into the thoracic cavity by cutting the diaphragm and suprahepatic inferior 
vena cava. Core cooling is supplemented by topical sterile ice.  
The liver can be perfused not only by the portal vein alone (single) but also by both the 
hepatic artery and portal vein (dual). (Foley et al. 2003) Some authors found that aortic 
flushing shortened the operation times and proposed it for routine liver procurement even 
from hemodynamically stable donors. (Filipponi et al., 1996)  
After core cooling, all the vascular attachments are divided. Hepatic artery is harvested with 
celiac trunk and a segment of abdominal aorta, after all branches of celiac trunk are divided. 
Portal vein should be transected near duodenum after one liter of cold preservation fluid 
has passed through the liver. Cranially inferior vena cava must be divided highly into the 
thorax maintaining a little rim of diaphragm around it. Caudally inferior cava vein is 
transected at the level of the right renal branch. When all vascular and peritoneal 
connections are transected, the liver is extracted from donor abdominal cavity. After liver 
harvesting the donor pig should be euthanasiated.  
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On the back table the fresh harvested liver is rinsed via portal infusion with 3 L, for each kg 
of liver mass, of cooled (4º C) preservation solution (e.g. normal saline, lactated Ringer's 
solution, Celsior solution (CS), an extracellular preservation solution, with Viaspan 
(University of Wisconsin solution, UW) (Audet et al., 2001), Collins C2 solution). UW 
solution can be supplemented with epidermal growth factor, insulin-like growth factor-1, 
nerve growth factor-beta, bactenecin, and substance P to create TF-supplemented (TFS) UW. 
If TFS UW is used instead of UW, hepatic function is better preserved when orthotopic liver 
transplantation is performed after 18 hr of static cold storage at 4º C. (Ambiru et al., 2004) 
OLT without cold perfusion of the donor liver is also feasible and prolonged survival of 
animals is possible, but the function of these organs is markedly reduced compared to the 
cold perfused organs. (Barbier et al., 1986) The liver is kept in the cold solution until 
implantation in the recipient. The donor liver is carefully prepared in order to secure any 
potential vascular bleeding points and adequately clean the vascular structures to facilitate 
anastomotic procedures. Lymphatic tissue from the pedicle is carefully removed.  
5. Recipient operation 
The operation on recipient can be performed with or without veno-venous bypass. (Falcini 
et al., 1990) The bypass can be active or passive.  
The pig poorly tolerates simultaneous clamping of the liver pedicle and inferior vena 
cava. Pigs are sensitive to the congestion of portal vein system. Obvious intestinal mucosa 
injury are noticed 45 min after blockage. Another issue is the retention of blood flow in 
portal vein system. Having short limbs and strong gastrointestinal tract, pigs have a high 
blood flow in portal vein and severe congestion in portal vein system certainly leads to 
whole body’s hemodynamic disturbances. The transplant without veno-venous bypass 
leads to severe hemodynamic disturbances. Hypotension occurs after more than 30 
minutes and leads to immediate or late irreversible shock. (Battersby et al., 1974) 
Temporary clamping of the supracoeliac aorta is performed by some authors to stabilize 
the hemodynamic conditions during the anhepatic phase without venous bypass. If the 
anhepatic phase without veno-venous bypass lasts less than 30 min, temporary aortic 
occlusion may not be mandatory. If the anhepatic time is less than 20 min, post-
reperfusion hypotension with reflex tachycardia is transient and responsive to i.v. fluid 
perfusion. (Fondevila et al., 2010) 
In case of a Y type veno-venous bypass afferent limb is placed into the jugular vein and two 
efferent limbs are placed into splenic vein and inferior cava vein. Before starting vascular 
cannulation, 100 UI/Kgc dose of Heparine should be administered to the recipient. The 
vascular cannula is filed with a saline-Heparine solution to remove air bubbles. Veno-
venous bypass is associated with an increased risk of bleeding, disorders of coagulation, air 
embolism, and venous thromboembolism. (Oike et al., 2001) 
The anesthetized animal is placed on its back, the skin is prepared and the draping is 
made so as to allow the left cervical access to jugular veins and the midline abdominal 
incision. The operation begins with the dissection and cannulation of the left external 
jugular vein. If the external jugular vein is too thin to be cannulated, the ipsilateral 
internal jugular vein can be used instead. The cannula is placed through a longitudinal 
venotomy in the jugular vein. The cranial end of the vein is ligated and the outside end of 
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the cannula is clamped until the introduction of the efferent limbs of the veno-venous 
bypass. The placement of the cannula should be done with caution to avoid all the air 
bubbles. After securing the afferent limb of the bypass, the abdomen of the recipient is 
opened via a vertical xifo-infraumbilical incision. The steps of abdominal operation are: 
establishment of the veno-venous bypass, hepatectomy, and engrafting of the donor liver. 
Prior to the mounting of the efferent limbs of veno-venous bypass, the mobilization of the 
liver and dissection of the elements of liver pedicle (Figure 1, 2), splenic vein (Figure 3), 
and inferior cava vein should be done. The technique of hepatectomy is similar to that 
performed on donor with special attention at the dissection of all the vessels and the bile 
duct near the liver in order to obtain maximal lengths of these structures needed for 
tension-free anastomoses. 
The first efferent cannula is inserted into splenic vein via a longitudinal venotomy. The 
cannula is advanced maximum 3 cm toward portal vein in order to avoid the obstruction of 
the venous branches, especially the superior mesenteric vein. The cannula is secured in 
position with a simple suture. The other segment of splenic vein is ligatured at the level of 
the splenic hilum. The second efferent limb of the bypass is inserted into infrahepatic 
inferior cava vein after its complete transversal section. The cannula is advanced caudally in 
the inferior vena cava maximum 2 cm toward but not obstructing the right renal vein 
opening. The cranial stump of inferior cava vein is clamped. The cannula is fixed similar to 
the first one. The active circulation can be maintained by Medtronic 550 Bio-Console Pump 
Speed equipped with a Medtronic Bio-Pump®Plus centrifugal blood pump with flow 
capacity of 30 ml/kg/min. (Sirbu Boeti et al, 2008) When using vascular bypass great 
caution must be paid to the catheters’ preparation and insertion in order to avoid air 
embolism and also blood clothing. For these, it is recommended to maintain all the catheters 
clamped until all of the veins are catheterized and their removal should be done selectively 
starting with portal vein and continuing with inferior vena cava, and ending with jugular 
vein, immediately after completing all the three venous anastomoses. It is also necessary to 
check all the tubes before connection by forced injection of Heparine-saline solution for the 
identification of the possible holes that can lead to air embolism, and maintain them filled 
with the same solution. In our previous study the active portal-caval jugular bypass proved 
to be better than the passive portal-jugular bypass. (Sirbu Boeti et al. 2008) Moreover other 
authors reported a low number of complications by using the active versus pasive bypass 
(e.g. pelvic congestion, that is the main cause for deep venous thrombosis and pulmonary 
emboli). (Filipponi et al., 1989; Filipponi et al., 1996, Filliponi et al., 1998)  
Maintaining a good stability in pulmonary hemodynamics during anhepatic period, 
together with a low rate of complications if properly used, the active portal-caval jugular 
bypass seems to be the standard for OLT in pigs. 
Regarding the engrafting technique, the most difficult problem in pigs is related to 
suprahepatic inferior caval vein anastomosis. The problem is raised by the fact that there is a 
very short segment of suprahepatic inferior caval vein. This anatomic feature determines to 
position the clamp on the inferior vena cava with the inclusion of a portion of the 
diaphragm. After transaction of inferior vena cava nearby the diaphragm, the opening of 
remaining vena cava to be anastomosed is kept enlarged due to the intimate connections 
with the diaphragmatic fibers. To overcome the incongruence between the cava vein edges 
two solutions can be applied.  
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Fig. 1. Dissection of the hepatic hilum. Left, median, and right hepatic artery are identified 
 
Fig. 2. Porta vein is dissected and encircled 
 
Fig. 3. The splenic vein is dissected near the splenic hilum for the introduction of one of the 
efferent limbs of veno-venous Y bypass 
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In most situations an adequate calibration of the donor inferior caval vein edge is needed. 
The most appropriate is the enlargement of the stump by suturing a V venous patch obtained 
by harvesting the liver together with a long segment of intrathoracic inferior cava vein.  
The possibility to perform an end-to-end anastomosis between donor and recipient caval 
vein without plasty exists but it is best accomplished entering the thoracic cavity via a 
phrenectomy around the inferior caval vein. For this approach longer segment of the donor 
inferior caval vein is also needed and must be tailored by transecting it as high as possible 
into thorax. However this second method is cumbersome due to the difficulty of the 
diaphragm reconstruction and impossibility of obtaining a tight sealing of the thoracic 
cavity. 
Immediately after declamping of the three cannula (inserted into splenic, inferior vena cava 
and jugular vein) and the activation of veno-venous bypass, the clamping and transection of 
the biliary common duct (Figure 4), hepatic artery, portal vein (Figure 5), and suprahepatic 
inferior vena cava (Figure 6) are done and the liver is removed. These anatomic structures 
should be transected near the donor’s liver. After liver removal, donor’s suprahepatic inferior 
vena cava is prepared for anastomosis by trimming the remnant liver parenchyma (Figure 7). 
 
Fig. 4. Recipient’s choledoch is identified and prepared to be cut between ligatures near the 
liver. The skeletization of the choledoch in hepatic hilum is avoided 
 
Fig. 5. Recipient’s portal vein is clamped near the liver 
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Fig. 6. Recipient’s suprahepatic inferior vena cava is clamped by including the adjacent 
diaphragm into the clamp 
 
Fig. 7. Donor’s suprahepatic inferior vena cava is prepared for anastomosis by removal of 
remnant liver parenchyma 
 
Fig. 8. Suprahepatic inferior vena cava is reconstructed in end-to-end fashion by starting the 
continuous suture on the left side and finishing it on the right side 
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Although models without the usage of bypass were described by some authors (Oike et al., 
2001), our previous results were better when the bypass was used. (Sirbu Boeti et al., 2008)  
After its back table preparation, the donor liver is properly placed and oriented into the 
right subphrenic space. The anastomoses are performed in the following order: suprahepatic 
inferior cava vein, portal vein, infrahepatic vena cava, arterial anastomosis, and biliary 
anastomosis remnant. 
The end-to-end anastomoses of inferior caval vein should be made using continuous suture 
of 5-0 monofilament polypropylene (Prolene®, Ethicon, Inc.), starting with the left wall and 
finishing with the right wall (Figure 8).  
While completing the suprahepatic caval anastomosis, the liver is perfused with warm 
lactated Ringer’s solution to remove the air bubbles (Figure 9). 
 
Fig. 9. The anastomosis of the suprahepatic inferior cava vein is continued on the right wall 
while liver is perfused with warm lactated Ringer’s solution 
Portal vein reconstruction is started with a continuous 5-0 monofilament polypropylene on 
the posterior wall (Figure 10) and is continued with the anterior wall. Before completing the 
anterior wall of the portal vein anastomosis, 500 ml of lactated Ringer's solution at room 
temperature are flushed into the liver, and after completing it portal vein clamp is removed 
and splenic cannula is cross-clamped. Both lactated Ringer's solution and about 250 ml of 
blood are let to flow out of the liver through the infrahepatic inferior vena cava stump, in 
order to wash-out the oxide radicals and the high potassium-containing preservation 
solution, and decrease the risk of hypothermic stress. It is important to tie the last suture of 
portal vein anastomosis leaving a growth factor of about half of the diameter of the 
anastomosis. Thus stenosis of portal vein is avoided on long term animal survivals. Before 
performing the infrahepatic inferior vena cava anastomosis, the tightness of suprahepatic 
vena cava (Figure 11) and portal anastomosis is verified (Figure 12). 
After the suprahepatic inferior cava vein and portal vein are declamped, reperfusion of the 
liver is re-established (Figure 13). The infrahepatic inferior caval vein of the donor liver is 
clamped proximal the right renal vein and the vena cava cannula is withdrawn in order to 
perform the anastomosis with the inferior vena cava (Figure 14, 15) of the recipient. The 
anastomosis is performed with continuous suture of 5-0 monofilament polypropylene. 
 




Fig. 6. Recipient’s suprahepatic inferior vena cava is clamped by including the adjacent 
diaphragm into the clamp 
 
Fig. 7. Donor’s suprahepatic inferior vena cava is prepared for anastomosis by removal of 
remnant liver parenchyma 
 
Fig. 8. Suprahepatic inferior vena cava is reconstructed in end-to-end fashion by starting the 
continuous suture on the left side and finishing it on the right side 
 
Experimental Liver Transplantation 
 
181 
Although models without the usage of bypass were described by some authors (Oike et al., 
2001), our previous results were better when the bypass was used. (Sirbu Boeti et al., 2008)  
After its back table preparation, the donor liver is properly placed and oriented into the 
right subphrenic space. The anastomoses are performed in the following order: suprahepatic 
inferior cava vein, portal vein, infrahepatic vena cava, arterial anastomosis, and biliary 
anastomosis remnant. 
The end-to-end anastomoses of inferior caval vein should be made using continuous suture 
of 5-0 monofilament polypropylene (Prolene®, Ethicon, Inc.), starting with the left wall and 
finishing with the right wall (Figure 8).  
While completing the suprahepatic caval anastomosis, the liver is perfused with warm 
lactated Ringer’s solution to remove the air bubbles (Figure 9). 
 
Fig. 9. The anastomosis of the suprahepatic inferior cava vein is continued on the right wall 
while liver is perfused with warm lactated Ringer’s solution 
Portal vein reconstruction is started with a continuous 5-0 monofilament polypropylene on 
the posterior wall (Figure 10) and is continued with the anterior wall. Before completing the 
anterior wall of the portal vein anastomosis, 500 ml of lactated Ringer's solution at room 
temperature are flushed into the liver, and after completing it portal vein clamp is removed 
and splenic cannula is cross-clamped. Both lactated Ringer's solution and about 250 ml of 
blood are let to flow out of the liver through the infrahepatic inferior vena cava stump, in 
order to wash-out the oxide radicals and the high potassium-containing preservation 
solution, and decrease the risk of hypothermic stress. It is important to tie the last suture of 
portal vein anastomosis leaving a growth factor of about half of the diameter of the 
anastomosis. Thus stenosis of portal vein is avoided on long term animal survivals. Before 
performing the infrahepatic inferior vena cava anastomosis, the tightness of suprahepatic 
vena cava (Figure 11) and portal anastomosis is verified (Figure 12). 
After the suprahepatic inferior cava vein and portal vein are declamped, reperfusion of the 
liver is re-established (Figure 13). The infrahepatic inferior caval vein of the donor liver is 
clamped proximal the right renal vein and the vena cava cannula is withdrawn in order to 
perform the anastomosis with the inferior vena cava (Figure 14, 15) of the recipient. The 
anastomosis is performed with continuous suture of 5-0 monofilament polypropylene. 
 




Fig. 10. Reconstruction of the portal vein starting with a continuous suture of the posterior 
wall 
 
Fig. 11. Check-up of suprahepatic inferior caval vein anastomosis 
 
Fig. 12. Check-up of portal vein anastomosis 
 




Fig. 13. The aspect of the graft at the moment of reperfusion 
 
Fig. 14. The donor’s infrahepatic inferior cava vein is anastomosed end-to-end to the 
recipient’s homolog vein first performing a continuous suture on the posterior wall 
 
Fig. 15. The infrahepatic inferior cava vein anastomosis is checked for bleeding sites 
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Fig. 13. The aspect of the graft at the moment of reperfusion 
 
Fig. 14. The donor’s infrahepatic inferior cava vein is anastomosed end-to-end to the 
recipient’s homolog vein first performing a continuous suture on the posterior wall 
 
Fig. 15. The infrahepatic inferior cava vein anastomosis is checked for bleeding sites 
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After revascularization of the liver, the role of the anesthesiologist is crucial in dealing with 
reperfusion syndrome. For this it is necessary to monitor the pulmonary pressure, central 
venous pressure and cardiac index using Swan-Ganz catheter fixed on the right cephalic 
vein. (Filliponi et al., 1998) No vasoconstrictive drugs are recommended to correct 
postreperfusion arterial hypotension. Only fluids to correct volemia should be used 
instead.  
During hypothermia of a liver to be transplanted, a large quantity of K+ and H+ 
accumulates, which may cause cardiac arrhythmia at revascularization. To preclude the 
reperfusion syndrome, the metabolites and potassium ions entering into systemic circulation 
can be removed from the graft by liver flushing. Before doing the portal revascularization of 
the donor livers, a washout via both the portal vein and hepatic artery can be performed 
with saline serum (Arias et al., 1987) or polygeline solution (Haemaccel) (Arias et al., 1990). 
The liver can also be washed only via portal vein with 500 ml warm (37º C) lactated Ringer's 
solution at room temperature before finishing the vein anastomosis. Then approximately 
250-500 ml of recipient's blood are allowed to drain through the intrahepatic inferior vena 
cava after finishing the portal anastomosis. (Sirbu Boeti et al., 2008) During all the warm 
perfusion time the suprahepatic cava is maintained clamped and the washing fluids 
(lactated Ringer's solution and blood) are aspirated through the infrahepatic inferior caval 
vein stump. This fact also contributes to the controlled heating of the liver before including 
it into the circulatory system. The procedure of liver warm reperfusion was inspired by 
previous studies made on rats. (Takei & et al., 1991; Xu et al., 1992) 
When the liver transplantation is performed without by-pass, the warm flush with lactated 
Ringer’s solution is performed before rather than after vascular clamping in the recipient. 
Flushing the graft with the vena cava and portal vein clamped add several more minutes of 
splanhnic venous stasis, leading to an even greater release of cytokines and inflammatory 
mediators upon the restoration of flow. (Fondevila et al., 2010) An extracorporeal circulation 
(ECC) equipped with a polyacrylonitrile dialyzer (PAN) between the previously 
anastomized inferior vena cava (IVC) below the liver and the jugular vein is a solution used 
to entrap and thus preclude the K+ to enter the systemic circulation. (Marino & De Luca, 
1985) Some authors consider that metabolic acidosis can be avoided by administration of 
sodium bicarbonate before declamping and corrections of alterations in serum electrolytes. 
(Torres et al., 2008)  
Immediately after declamping of suprahepatic inferior vena cava and portal vein with 
subsequent revascularization of the liver, the reperfusion syndrome must be readily 
recognized and controlled. Swine hemodynamic status during anhepatic phase was 
analyzed by different authors. (Fondevila et al. 2010; Heuer et al., 2010; Torres et al., 2008)  
In the unfortunate case of intraoperative sudden death of the recipient the operation should 
be continued with the aim of improvement of surgical techniques.  
The hepatic artery of the pig has a 1.5-2.5 mm caliber which makes its suturing difficult. 
Hepatic artery can be reconstructed using microsurgical techniques under a magnification of 
6.5 X. The donor’s artery is adequately tailored to avoid tension or kinking. Vascular edges 
are obliquely sectioned or "fish mouth" shaped, for obtaining a larger caliber and protecting 
the arterial anastomosis from thrombosis and stenosis. The arterial stumps should be  
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washed with Papaverine solution (1 vial in 15 ml of warm saline). A minimum resection of 
the adventitia is intended, removing only the fragments hanging outside the edges of the 
vessel. The end-to-end microsurgical anastomosis of the proper hepatic arteries of the donor 
and recipient can be executed according to 0-180º technique with separate 8-0 or 9-0 
monofilament stitches. (Sirbu Boeti et al., 2008) At the end of the anastomosis there is no 
need for the patency test. The arterial reconstruction can also be made using an aortic graft 
sutured end-to-side to the infrarenal aorta (Figure 16). (Oike et al., 2001; Oldhafer et al., 
1993) The cuff technique can also be used for arterial reconstruction. (Monden et al., 1982) A 
technique of orthotopic liver transplantation in the pig was described in which the main 
feature is the accomplishment of vascular anastomoses by the use of the Vogelfanger NRC 
vascular suturing instrument. The advantage of this instrument was the rapid 
accomplishment of safe leak-proof anastomoses. (Barron et al. 1975) 
   
Fig. 16. Arterial reconstruction using an aortic graft. A. Back bleeding in the aortic graft.  
B. Identification of infrarenal abdominal aorta. C. End-to-side arterial anastomosis between 
donor’s aortic graft and recipient’s infrarenal aorta 
Regarding the biliary reconstruction, some authors suggest choledocho-choledochostomy to 
be the most appropriate. The common biliary duct is wide enough to permit a safe 
anastomosis with 6-0 polydioxanone (PDS®, Ethicon, Inc.) suture. If a silastic tube is 
introduced in the open ends of the donor’s and recipient’s common bile duct, no sutures are 
necessary because the apposition is accomplished by securing the silastic tube with two 
ligatures which are then tied to one another. (Fondevila et al., 2010) Choledocho-
jejunostomy with a Roux-Y-loop, choledocho-duodenostomy, cholecysto-jejunostomy with a 
Roux-Y loop (Oike et al., 2001) and cholecysto-duodenostomy can also be chosen for the 
biliary reconstruction. If the donor’s gallbladder is preserved, a cholecysto-gastrostomy is 
very facile to be performed (Figure 17). However choledocho-choledochostomy is preferred 
to the biliary-duodenal anastomosis to avoid postoperative cholangitis and also to the 
biliary-jejunal anastomosis to avoid the danger of intestinal obstruction, which is highly 
common in pigs. (Lempinen et al., 1971) External biliary drainage is another alternative. 
(Oldhafer et al., 1993) 
When an end-to-end anastomosis of the bile duct is performed for orthotopic liver 
allotransplantation, 70% of the subjects develop jaundice at the end of the first week after 
transplantation. (Battersby et al., 1975) However the jaundice is generally a result of 
transient rejection and usually resolves spontaneously without immunosuppression. 
(Battersby et al., 1975) 
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Fig. 16. Arterial reconstruction using an aortic graft. A. Back bleeding in the aortic graft.  
B. Identification of infrarenal abdominal aorta. C. End-to-side arterial anastomosis between 
donor’s aortic graft and recipient’s infrarenal aorta 
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transplantation. (Battersby et al., 1975) However the jaundice is generally a result of 
transient rejection and usually resolves spontaneously without immunosuppression. 
(Battersby et al., 1975) 
 




Fig. 17. Cholecysto-gastrostomy performed with continuous 6-0 PDS suture 
6. Conclusions 
The orthotopic liver transplantation models on swine are straightforward and reproducible 
and offer surgeons and researchers the opportunity to perform and study liver 
transplantation in conditions similar to clinical practice.  
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1. Introduction 
Despite logistical and immunological advantages, various refinements in organ procurement, 
surgical techniques, and postoperative management, biliary complications remain a 
significant cause of morbidity and even mortality after orthotopic liver transplantation 
(OLT). They may appear in the immediate post-liver transplant period as well as years 
thereafter. With respect to the generally increased patients' vulnerability after OLT, it is 
necessary to manage these complications promptly and effectively to prevent irreversible 
liver damage and threat to the recipient's life. Biliary complications cannot be considered as 
a single issue, even if significant. They often develop as a consequence of the underlying 
problems typically associated with liver transplantation in patients with immunosuppression 
modulating their clinical manifestations and laboratory findings. Not exceptionally, they 
may occur together with other complications such as primary disease recurrence, rejection, 
vascular lesions or cytomegalovirus (CMV) infection, and these problems may modify the 
management accordingly. They may also mask biliary complications contributing hugely to 
their varying rates reported in particular studies. To assess the individual patient 
comprehensively and to correctly organize the management of such a complicated case is a 
masterpiece of medical skill. 
2. Biliary reconstruction of liver transplantation 
To achieve high technical success of endoscopic treatment of biliary complications, 
meticulous knowledge of the anatomy of biliary reconstruction as well as knowledge of 
specific issues of posttransplant pathophysiology is essential. Surgical reconstruction of the 
biliary tree is undertaken as the final step of OLT after vascular anastomosis determining 
both the diagnostic and therapeutic approaches. The gallbladder interposition technique 
was used in the pioneering years utilizing the gallbladder as the graft conduit between the 
donor and recipient bile ducts. In the early reports by Starzl and Calne, the association of 
bile stasis with stone formation and cholangitis resulted in morbidity of up to 50% and 
mortality up to 30% quite fittingly referred to as the Achilles' heel of this demanding 
surgical technique (Lebeau et. al, 1990). 
Clearly, an end-to-end duct-to-duct anastomosis is the preferred technique in most centres 
in recipients with healthy native bile ducts of compatible calibre as it maintains the anatomy 
and preserves the sphincter mechanism. Another advantage is that it provides continuity of 
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bile ducts with the original shape allowing access and effective treatment of complications 
by standard endoscopic techniques. Similarly good results were obtained by other centres 
using a side-to-side variant. More of historical interest, the reconstruction was 
complemented by temporary T-tube biliary drainage with two presumed goals: to visualise 
the bile ducts according to demand, and to prevent anastomotic stricture formation. The 
results of several comparative studies differ but the second expectation has never been 
reliably met, and frequent leaks prevailing in T-tube groups (Davidson et al., 1999; 
Graziadei et al., 2006) caused that the use of the preventive T-tube drainage has been rarely 
employed in choledocho-choledocho reconstruction. 
Roux-en-Y hepaticojejunostomy is utilized in patients with bile ducts involved by the pre-
existing disease like sclerosing cholangitis, occasionally also in patients with major 
incompatibility in size of ducts, and is usually preferred in the case of retransplantation 
because of inadequate recipient duct length. Roux-en-Y was also the routine reconstruction 
technique in the first series of living-related, reduced graft, and split liver transplantation 
procedures. With increasing knowledge of the blood supply around the biliary ducts and 
increasing experience, duct-to-duct anastomosis has been increasingly reported in reduced 
grafts of living-donor transplants and split transplant even if multiple anastomoses are 
needed. 
References Center Year N Total, % Leaks, % Strictures, % 
Duct – to – duct anastomosis 
Lebeau Pittsburgh 1990 193 20 2 18 
O´Connor Boston 1995 147 33 22 12 
Davidson Royal Free 1999 100 31 17 14 
Alazmi Indianapolis 2006 916 NA NA 16 
Graziadei Innsbruck 2006 515 16 NA 16 
 
Roux – en Y hepaticojejunostomy 
Ringer Hannover 1989 84 24 12 2 
Lebeau Pittsburgh 1990 187 12 9 3 
 
Living donor liver transplantation 
Tsujino Tokyo 2006 174 30 NA NA 
Giacomoni Milano 2006 23 48 22 26 
Wojcicki Birmingham 2006 70 26 20 4 
 
Cardiac death donors 
Suárez A Coruňa 2008 22 42 4 38 
De Vera Pittsburgh 2008 141 25 NA NA 
Kobayshi  Niigata 2009 63 46 29 32 
Table 1. Biliary complications in various surgical anastomosis techniques 
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3. Manifestation and diagnosis  
Manifestations of biliary complications comprise usual symptoms but often with different 
presentation as compared to non-transplant conditions. They involve fever, right upper 
quadrant pain, non-specific abdominal discomfort, and elevation of hepatic, particularly 
cholestatic enzymes. On the one hand, these manifestations may rapidly progress to the 
development of biliary peritonitis in large leaks but, more typically, they remain mild and 
indistinguishable from other causes of cholestasis such as hepatitis C virus (HCV) 
recurrence and acute rejection to mention at least two other common complications. The 
diagnosis comes after precise analysis of symptoms, laboratory examinations, liver biopsy 
and use of imaging methods. Usually, there is absence of intrahepatic bile ducts dilatation 
on ultrasound, particularly early after liver transplantation, even above a tight obstruction. 
The final step of diagnostic work-up is direct imaging by endoscopic retrograde 
cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC), 
which should be preceded by magnetic resonance cholangio-pancreatography (MRCP; Fig. 
1). Nevertheless, even MRCP has its logistic limitations and the picture of ducts fully 
corresponds to the picture on ERCP in about 70% of cases (Wojcicki et al., 2008). 
 
Fig. 1. Bile ducts with anastomotic stricture on MRCP 
4. Classification and aetiology of biliary complications  
Biliary complications comprise a wide and varied list of events with different frequency 
involving both direct ductal and extraluminal causes. In fact, the scope of complications 
corresponds to biliary problems appearing in non-transplant conditions. The difference is in 
the proportions and several specific aspects. The comprehensive pathogenesis of biliary 
complications is attributable to various factors including the rationale for selecting a 
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particular surgical technique, ischemic damage mostly due to hepatic artery thrombosis and 
ischemia-reperfusion injury, immunological principles such as ABO incompatibility, CMV 
infection, disease recurrence in primary sclerosing cholangitis, and others. The consequent 
cholestasis contributes to the generally increased vulnerability after liver transplantation 
strongly affecting namely the outcome in patients with recurrent hepatitis C (HCV) (Katz et 
al., 2006; Sanni et al., 2006). Technical reasons for biliary complications comprise imperfect 
suture with early T-tube-related leak or anastomotic stricture, leaks from the liver surface or 
inadvertent bile duct injuries.  
Intrinsic biliary complications Extrinsic biliary complications 
PSC recurrence False aneurysma 
Intrahepatic Secondary 
cholangitis 
Cystic duct mucocele 
Ischemic Lymphoproliferative disease 
Peri-hilar Idiopathic  
(ischemic-like) 
Chronic pancreatitis 
Anastomotic Recurrent/de novo cancer 
Strictures 






Missed segmental duct 
Stones, cast, T-tube remnant 
Haemobilia 
Recurrent sclerosing cholangitis 
  
Table 2. Intrinsic and extrinsic biliary complications 
5. Specific measurements before the scope is inserted 
5.1 Infection prevention 
After ERCP, infection remains to be a major complication occurring in about 1% of 
procedures overall. Several reasons may play a role. Similar to other invasive procedures, 
ERCP, even though rarely, may cause endocarditis in high-risk patients. Proper use of 
disposable accessories and utilization of standard technique can completely eliminate 
transmission of infection by the contaminated scope. Thanks to universally adopted 
measures, cases of endocarditis and nosocomial infection including hepatitis C, hepatitis B, 
and HIV related to endoscopy have been reported rarely in recent series. The American 
Heart Association recently revised their guidelines for prophylaxis of infective endocarditis, 
and a crucial change for endoscopic procedures is that antibiotic prophylaxis solely to 
prevent infective endocarditis is not recommended. Exceptions include high-risk cardiac 
conditions including: a prosthetic cardiac valve, a history of previous infective endocarditis, 
cardiac transplant recipients developing valvulopathy, patients with congenital heart 
disease with either uncorrected cyanosis or those with prosthetic material repair within 6 
 
Biliary Complications After Liver Transplantation 
 
195 
months after the procedure, or those with a residual defect. Since the enterococci making up 
part of the common bile duct flora in cholangitis are the invading agents in endocarditis, 
either amoxicillin or ampicillin should be included to the antibiotic protocol for enterococcal 
coverage. 
The most common pathogenesis for cholangitis after ERCP is flare-up of infection already 
present in the bile ducts. The usual pathogens encountered in bile ducts involve 
Pseudomonas aeruginosa, Klebsiella spp., E. coli, Bacteroides spp., and Enterococci. The 
infection is precipitated by an elevated intraductal pressure when complete bile drainage 
has not been achieved. To eliminate these factors, it is highly recommended to aspirate bile 
before contrast injection and to complete endoscopic treatment (stones removal, drainage of 
all relevant visualised strictures). The basic principle is not to overfill the duct above the 
stricture, and particularly in complicated anatomy, but to fill only what can be drained. The 
risk factors to be considered include jaundice, previous endoscopic treatment, previous 
cholangitis, combined endoscopic-percutaneous procedures, transplant patients on an 
immunosuppressive regimen, hilar tumours, and primary sclerosing cholangitis, because 
the bile duct obstruction is difficult to be completely relieved. The technique of ERCP should 
correspond to the technique in non-transplant conditions. The role of antibiotic prophylaxis 
is controversial and a variety of practices exist. Several randomized controlled trials (RCTs) 
have been published showing reduction of bacteraemia with an inevitably limited value due 
to the small numbers of patients with clinical infection. No RCT has to date been conducted 
exclusively in transplant patients. Taken together, the general attitude to antibiotic 
prophylaxis is becoming more and more selective with its application only in conditions 
with suspected high risk. Transplant patients are exactly the case of the highest-risk group. 
ERCP should be attempted only in transplant patients with highly suspected biliary 
obstruction. If not clear from the clinical picture and other examinations, MRCP is a must. 
On the other hand, the finding of infection cannot be relied on absolutely. We recommend 
400 mg of ciprofloxacin to be given intravenously (per oral administration is probably 
similarly effective) 2 hours before the procedure and to continue with the administration 
until complete drainage is achieved. Other options include gentamicin, quinolone, 
cephalosporin, and ureidopenicillin (ASGE guideline 2008; Cotton et al., 2008). In fact, most 
of these patients are already on an antibiotic regimen due to clinical/laboratory 
manifestations of infection of various organs. 
5.2 Coagulopathy – bleeding disorders 
After transplantation, abnormal coagulation due to liver dysfunction or anticoagulation 
therapy is a common concern. Other risk factors of invasive procedures include 
trombocytopaenia (included a haemodialysis-caused coagulation disorder) and initiation of 
anticoagulation therapy within three days of the invasive procedure; on the other hand, 
extension of previous sphincterotomy and the use of aspirin or non-steroidal anti-
inflammatory drugs do not seem to raise the risk. No data dealing specifically with 
sphincterotomy in patients with liver disorders are available and the commonly shared 
opinion is that coagulopathy should be managed according to rules applied to liver biopsy. 
Generally, there are widely divergent opinions about the values at which abnormal 
coagulation indexes begin to pose a major risk for any kind of invasive procedures including 
endoscopic sphincterotomy. The utility of usual tests: platelet count, prothrombin time 
(PT)/international normalized ration (INR) in predicting bleeding risk is uncertain and 
 
Liver Transplantation – Technical Issues and Complications 
 
194 
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months after the procedure, or those with a residual defect. Since the enterococci making up 
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risk factors to be considered include jaundice, previous endoscopic treatment, previous 
cholangitis, combined endoscopic-percutaneous procedures, transplant patients on an 
immunosuppressive regimen, hilar tumours, and primary sclerosing cholangitis, because 
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generally not supported by scientific evidence. Probably more important than any 
laboratory parameters is to take careful medical history whether any bleeding episode after 
an invasive procedure has appeared in the past, and to search for any possible signs of 
recent bleeding. Whether the use of prophylactic blood products alters the risk of bleeding is 
currently unknown. However, it is commonly assumed that platelet transfusion should be 
considered when thrombocytes count is less than 50,000-60,000/mL and, if prothrombin 
time is prolonged by 4-6 seconds, then transfusion of fresh frozen plasma may bring the 
presumed consequent increased bleeding risk into the desired range (Rockey et al., 2009). 
Appropriate practice of endoscopic procedures in patients on anticoagulation or antiplatelet 
therapy is precisely determined in the guidelines of endoscopic societies and the conditions 
of post-transplant care are not specific in any way. In short, sphincterotomy should not be 
performed by pure cutting current. Aspirin therapy can be maintained while clopidogrel 
should be withheld. Adoption of all these measures cannot completely eliminate the 
increased risk of haemorrhage in a complex bleeding disorder accompanying liver 
dysfunction in the post-transplant patient. The endoscopist should actively stop any 
bleeding appearing immediately after sphincterotomy by local endoscopic techniques. 
5.3 Sedation and anaesthesia 
Several specific features of this issue after transplantation should be addressed. During 
comprehensive pre-transplant evaluation and post-transplant follow-up, patients are often 
exposed to many endoscopic procedures which may possibly make them more anxious and 
less tolerant. Procedures early after transplantation or in patients in generally poor condition 
(ASA class IV-V-E) have to be performed with the assistance of an anaesthesiologist often 
under general anaesthesia. Therapeutic procedures are often prolonged due to the abnormal 
anatomy of reconstructed bile ducts. A considerable proportion of transplant procedures is 
performed in alcohol abusers. Chronic alcohol use increases dose requirements for general 
anaesthetic, sedative or analgesic agents. This is thought to be partly because of enzyme 
(particularly cytochrome P-450 2E1) induction or the development of cross tolerance. If the 
effective doses of propofol, opioids and other drugs are increased, the patient may – quite 
paradoxically – become agitated, uneasily controlled and less tolerant to any disturbing 
procedures. The increased anaesthetic demands may exacerbate the risk of cardiovascular 
instability in patients suffering from cardiomyopathy and increase the risk of adverse effects 
of all kinds. All these consequences make endoscopic procedures extraordinarily demanding. 
All the administered drugs have to be precisely titrated and the patient adequately 
monitored. The involvement of an anaesthesiologist in all procedures presumably associated 
with risk is highly recommended (Chapman & Plaat, 2009). 
6. Biliary complications after liver transplantation – Specific issues and their 
management 
Basically, treatment of biliary complications does not differ from that of the identical 
structural entities. Nevertheless, there are several specific features which have to be 
considered to avoid an unexpected surprise and to obtain optimal results. These specific 
techniques and tricks described below are based on our constantly expanding experience 
with more than 700 liver transplantations and management of approximately 200 biliary 
complications developing in a single department. This has given us the opportunity to 
follow the outcome from both immediate and long-term perspective and to discuss all 
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individual aspects with colleagues representing other specialties and involved in the 
transplant programme such as invasive radiologists, surgeons, and transplant hepatologists. 
In transplant medicine more than in non-transplant specialties, every patient is uniquely 
constituted and most of the conclusions and recommendations are based on observation 
rather than on comparative studies, which are enormously difficult to conduct. 
6.1 Endoscopic sphincterotomy 
The technique itself does not differ from sphincterotomy performed in other patients. Since 
the spontaneous motility of the bile duct is abolished due to the surgical reconstruction 
resulting in denervation of the biliary tree, evacuation of the contrast material cannot 
reliably serve as a measure of bile duct function. Even after standard-size sphincterotomy, 
which in a non-transplant condition be otherwise fully sufficient for what is aimed at – stent 
insertion or bile duct stone extraction – the cholestasis can persist. Therefore, we always 
recommend performing sphincterotomy to the maximal possible (safe) extent. 
6.2 Anastomotic strictures 
Anastomotic strictures being, together with leaks, the most common post-transplant biliary 
complication, are highly specific and almost unparalleled to non-transplant conditions. They 
are often asymmetrical with a shape that may be difficult to precisely project on x-ray due to 
overlap with one or two cysticus stumps. The shape of the prolonged reconstructed bile 
duct in the anastomotic area may resemble the letter S (Fig. 2, Fig. 3).  
Given the irregular lumen of the anastomosis with cysticus stumps, it may be exceptionally 
uneasy to pass the guide wire through the stricture (Fig. 4). Often, several types of wire with  
 
Fig. 2. S-shape of common bile duct after reconstruction on MRCP 
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Fig. 2. S-shape of common bile duct after reconstruction on MRCP 
 




Fig. 3. S-shape of common bile duct after reconstruction on urgent ERCP 
different properties in terms of diameter, flexibility/rigidity and slipperiness have to be 
tried. The direction of the wire tip can be enhanced by the use of an angled tip, 
sphincterotome or a balloon catheter. 
 
Fig. 4. Anastomotic stricture on ERCP with difficult access to common hepatic duct 
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Once the wire has been successfully inserted, a proper stent has to be selected. The stricture 
can be dilated by balloon before stenting, but we do not find it necessary if planning to insert a 
single stent. Both basic types of biliary stents, the Amsterdam with two flaps and the 
Tannenbaum with four flaps at their end are equally acceptable. The strategic principle is that 
a benign anastomotic stricture unlike a malignant stenosis needs not to be only bridged, but 
the lumen of the bile duct should to be completely reconstituted to correspond with normal 
anatomy. The chances for optimal remodelling of the anastomosis and the stricture seem to be 
higher if the diagnosis is established and treatment initiated early after transplantation and 
lower if a hard fibrotic stricture has already developed. If the reconstructed bile duct after liver 
transplantation is prolonged to form an S-shape, we select a longer stent than can be judged 
from the distance between the stricture and duodenum. The reason for this is that the stent 
passing through an S-shaped bile duct generates friction making the insertion more difficult. 
Should the stent be not long enough, the end may become impacted in the stricture orifice 
which makes it impossible to go through. On the other hand, when the curved stricture is 
overcome, the shape straightens and this may expel the proximal end of the stent far above the 
stricture, possibly above the hilar junction. This unfavourable position of the proximal end can 
hardly be prevented. We always place as many stents as possible according to the size of the 
bile ducts below and above the stricture (Fig. 5).  
 
Fig. 5. Multiple biliary stents of various lengths 
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can be dilated by balloon before stenting, but we do not find it necessary if planning to insert a 
single stent. Both basic types of biliary stents, the Amsterdam with two flaps and the 
Tannenbaum with four flaps at their end are equally acceptable. The strategic principle is that 
a benign anastomotic stricture unlike a malignant stenosis needs not to be only bridged, but 
the lumen of the bile duct should to be completely reconstituted to correspond with normal 
anatomy. The chances for optimal remodelling of the anastomosis and the stricture seem to be 
higher if the diagnosis is established and treatment initiated early after transplantation and 
lower if a hard fibrotic stricture has already developed. If the reconstructed bile duct after liver 
transplantation is prolonged to form an S-shape, we select a longer stent than can be judged 
from the distance between the stricture and duodenum. The reason for this is that the stent 
passing through an S-shaped bile duct generates friction making the insertion more difficult. 
Should the stent be not long enough, the end may become impacted in the stricture orifice 
which makes it impossible to go through. On the other hand, when the curved stricture is 
overcome, the shape straightens and this may expel the proximal end of the stent far above the 
stricture, possibly above the hilar junction. This unfavourable position of the proximal end can 
hardly be prevented. We always place as many stents as possible according to the size of the 
bile ducts below and above the stricture (Fig. 5).  
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We use both basic techniques of multiple stents insertion: two wires prior to inserting either 
stent or to insert a wire along and after the first stent insertion. The optimal number and 
position of multiple stents are usually determined during several sessions at short one- or 
two-week intervals. If inserting one stent into an S-shaped bile duct with anastomotic 
stricture, it may adopt the curve of the bile duct, while multiple stents straighten the duct as 
the optimal outcome. If the first one or two inserted stents are located with their proximal 
end high above the stricture, we select a shorter third stent to drain the bile from various 
levels of the bile ducts to avoid cholestasis and debris accumulation above the stricture. A 
hard S-shaped bile duct may expand the stent back to the duodenum with the risk of 
duodenal perforation by the stent on the side opposite to the orifice. Therefore we always 
try to insert more stents in parallel making the expulsion less likely. We do exchange of 
stents at three-month intervals as recommended elsewhere, and the stents are removed 
usually after an interval of six months to one year. In cases where the endoscopic access has 
failed, the transhepatic approach follows (Fig. 6). The first plastic stent can be inserted either 
transhepatically or by a rendezvous transpapillary technique. The disadvantage of the single 
transhepatic technique is that it does not enable to insert multiple stents in one session (Holt 
et al., 2007; Pasha et al., 2007; Kulaksiz et al., 2008). 
 
Fig. 6. Bridging of anastomotic stricture by the wire from transhepatic approach 
6.3 Non-anastomotic hilar strictures (ischemic-type biliary lesions) 
With an incidence in the range of between 5% and 15%, these biliary complications remain a 
substantial source of morbidity, graft loss, and even mortality after liver transplantation (Fig. 
7). Their multifactorial origin involves various events (risk factors) including ischemia due 
to hepatic artery thrombosis or prolonged cold and warm ischemia, use of University of 
Wisconsin solution vs. histidine tryptophan ketoglutarate, ABO incompatibility, extramural 
pressure by lymph nodes or tumour, recurrence of the original disease or it remains obscure.  
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Also the altered bile composition with a significantly lower phospholipids/bile salts ratio 
after liver transplantation and graft steatosis may contribute to the pathogenesis of these 
complications (Buis et al., 2005, 2009; Pascher et al., 2005). Compared to anastomotic 
strictures, non-anastomotic strictures pose a higher risk of progressive disease with a severe 
outcome and limited graft survival. The shape of ischemic and ischemic-like strictures may 
change surprisingly quickly. Endoscopic treatment consists of stent insertion similar to non-
transplant patients, but proper exploration and management of underlining conditions are 
essential. If the stricture involves the segmental branches, multiple stents bridging the 
strictures of all ducts are necessary. In specific conditions of malignant strictures, metallic 
stent insertion according to commonly shared rules is the choice. Full success of endoscopic 
treatment is less likely due to the location distant to the papilla making endoscopic 
manipulation less effective and, also, due to the various underlying conditions with 
different outcomes. Endoscopic treatment may be combined with the transhepatic approach 
if necessary. According to a recent study, percutaneous transhepatic Y-configured single-
catheter stenting may enlarge the armamentarium of drainage techniques in hilar strictures 
(Wang et al., 2011). 
 
Fig. 7. Ischemic-type biliary lesion 
6.4 Intrahepatic strictures 
They are not unequivocally classified against non-anastomotic ischemic-type biliary lesions, 
and the pathogenesis shares identical principles. Wan Lee et al. classified intrahepatic 
stenoses into 4 groups: unilateral focal, confluence, bilateral multifocal and diffuse (Fig. 8). 
The success of non-surgical, either endoscopic or transhepatic interventions, is reversely 
related to the extent of duct involvement with a frequent need of early retransplantation 
(Lee et al., 2007). 
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Fig. 8. Multiple intrahepatic stenoses - the recurrence of primary sclerosing cholangitis.  
Approach to hepatico-jejunoanastomosis with the enteroscope 
6.5 Distal strictures 
Strictures below the anastomosis are usually caused by chronic pancreatitis. Surprisingly, 
pancreatitis is often asymptomatic and cholestasis is the only manifestation of advanced 
pancreatic disease. Other causes include extramural pressure by malignancies, mucocele, 
and biloma. They can be managed in the same manner as non-transplant conditions 
(Pascher et al., 2005). 
6.6 Papillary stenosis (sphincter of Oddi dysfunction - SOD) 
Data concerning the occurrence of papillary stenosis/dysfunction after liver transplantation 
are less consistent compared to other specific and well defined biliary complications 
(anastomotic strictures, leaks). Cholestasis was observed in 3-7% of patients following T-
tube clamping early after liver transplantation but, according to some authorities, it used to 
be transient and self-limited. Papillary stenosis may be facilitated or unmasked by liver 
transplantation due to the abolished bile duct spontaneous motility by duct reconstruction 
and denervation. On the other hand, the fact that some patients develop sphincter of Oddi 
dysfunction (SOD) and others do not while undergoing the same surgical procedure, is 
intriguing (Douzdijan et al., 1994). The embarrassment and inevitable diversity of 
approaches can be demonstrated on a model case: a patient developed significant cholestasis 
several months after liver transplantation. Biopsy excluded other causes, sonography and 
MRCP showed dilatation of the recipient choledochus, as confirmed by ERCP. Multiple 
choices were as follows: either to perform manometry or sphincterotomy, to wait, or perhaps 
to insert a stent and wait; if the cholestasis has resolved, the patient can be either followed 
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only and, if it has appeared again, it would bring a strong argument for sphincterotomy. If 
sphincterotomy is the choice, a cut to a maximal safe extent is recommended. 
6.7 Bile duct stones 
While less frequent compared to leaks and anastomotic strictures, bile duct stones are still a 
relatively common complication after liver transplantation. Two basic categories of 
choledocholithiasis can be classified. Sludge or small stones usually develop as a late 
complication. A soft pigmented composition prevails suggesting that cholestasis and 
infection play a decisive role. Cholesterol supersaturation and related changes in 
lithogenicity are probably less important. The occurrence of stones is often associated with 
biliary strictures. More rarely, extensive casts completely filling biliary tree have been 
described. Casts usually appear relatively early after liver transplantation subsequently to 
prolonged ischemia resulting in severe diffuse biliary mucosal damage and defoliation. 
Endoscopic treatment responding to non-transplant conditions should be primarily 
preferred followed, alternatively, by the transhepatic approach or surgery in the case of 
failure. Nevertheless, the long-term outcome reflecting the underlying conditions may be 
limited when multiple stones or casts with diffuse bile duct damage occur (Sheng et al., 
1996; Spier et al., 2008). 
6.8 Post-transplant lymphoproliferative disorder (PTLD) 
PTLD is a serious and complex clinicopathologic disorder that has been related to several 
specific factors, particularly overimmunosuppression and viral infection. The rate of PTLD 
is approaching 3%. The early cases are located in the liver hilum causing biliary stenosis 
with cholestasis. Treatment is based on several principles. The degree of immunosuppression 
should be reduced. Antiviral drugs have been used mostly in children. Chemotherapy has 
been given to patients with EBV-negative monoclonal lymphomas developing with delay 
after transplantation. Other options include rituximab, a chimeric anti-CD20 antibody, 
radiotherapy and interferon-alpha. Local biliary involvement can be relieved by stent 
insertion from either the endoscopic or transhepatic approach or, exceptionally, by surgery. 
Endoscopic treatment corresponds to the endoscopic approach to hilar strictures of other 
causes with a common need of transhepatic assistance. The survival is determined by the 
pathobiology of the PTDL with a worse prognosis in early disease similar to the prognosis 
of other post-transplant malignancies (Aucejo et al., 2006). 
6.9 Bile leaks 
Bile leaks have been reported in 1-25% of OLTs performed. They can be divided into early, 
defined by a time period of 1-3 months after OLT, and late leaks. Anastomotic leaks are 
related to technically imperfect suture, or ischemic damage of the (usually) donor bile duct 
(Fig. 9).  
Other considered risk factors include recipient and donor age and the MELD score (Weilling 
et al., 2008). Bile leaks seem to be unrelated to the type of biliary duct-to-duct reconstruction. 
According to a recent RCT, neither end-to-end nor side-to-side choledocho-choledochostomy 
revealed significant differences in terms of the presentation of biliary complications. Early 
leakage may develop at the T-tube insertion site whenever yet typically after T-tube  
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Fig. 9. Anastomotic bile leak 
 
Fig. 10. Peripheral bile leak 
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removal, in up to 30% of procedures. The T-tube used to be inserted for a few months to 
maintain access to the biliary ducts and in the hope of preventing the development of a 
stricture at anastomosis. Other sites of leak comprise surface leaks and leaks from 
inadvertent bile ducts, usually after graft reduction (Fig. 10). The leaks can be treated either 
by stent or nasobiliary drainage insertion (after sphincterotomy). In small leaks, 
sphincterotomy alone may be sufficient (Skuhart et al., 1998). 
6.10 Roux-en-Y anastomosis 
Several small studies have focused on endoscopic treatment of patients with Roux-en-Y 
anastomosis, which in the past could be managed by either a standard duodenoscope or 
gastroscope with limited success only. Both with double- or single-balloon enteroscope, ERC 
is a feasible option with high success rate (Fig. 8). Limitations of this technique include the 
time requirement (1–2 hours) and the relatively narrow scale of accessories (Langer et al., 
2009; Mönkenmüller et al., 2008). 
6.11 Metal stents 
The originally designed uncovered self-expanding metal stents have been shown to 
maintain longer patency than plastic stents in malignant strictures (Fig. 11). Nevertheless, in 
benign strictures, they were mostly rejected and failed due to mucosal hyperplasia and 
impossible removability. The advantage of covered metal stents is to prevent tissue 
ingrowth and removability using the snare or rat-tooth technique. In a recent study, fully  
 
Fig. 11. Self-expanding metal stent due to ischemic-type stenosis 
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covered metal stents were inserted in 16 patients where plastic stent have failed. In six 
stents, migration occurred, nevertheless the stricture/leak resolved and a recurrent stricture 
developed in one patient. While a multicentre study is not easy to be designed, this is the 
only chance to reliably assess the potential of this modality (Costamagna et al. 2008; Kahaleh 
et al., 2008; Traina et al., 2009).  
6.12 Living donor liver transplantation (LDLT) 
The last decade has witnessed significant progress in LDLT. As compared to a whole liver 
transplant, the recipient of a partial graft in LDLT is faced with increased surgical 
complications associated with complicated hilar anastomotic variation requiring multiple 
biliary reconstructions. Since common biliary variations have been recognized, several types 
of biliary reconstructions have been developed. Both materials and type of the suture 
method have a major effect on the incidence biliary complications. To avoid bile duct 
devascularisation and consequent non-anastomotic biliary strictures, new surgical 
refinements have been also described. A variety of techniques have been reported to avoid 
injury to blood supply in LDLT. A detailed preoperative evaluation of the graft biliary 
system followed by an intraoperative cholangiogram through the cystic duct is a must. The 
optimal technique for biliary anastomosis in LDLT is still controversial. The currently most 
common techniques are either duct-to-duct or Roux-en-Y hepatico-jejunostomy. Since the 
late 1990, duct-to-duct anastomosis has been increasingly used, but the concerns regarding 
terms leaks and strictures seemed quite controversial. However, as the issue of LDLT is 
enormously complicated, prospective randomized studies are not realistic and so is not the 
ultimate judgment. Stenting of the anastomosis which was almost abandoned in whole liver 
transplantation remains another controversy in more complicating anastomoses. At this 
moment, several principles are universally accepted, but the type of anastomosis and 
possible stenting should be decided freely according to the aetiology of liver disease, duct 
anatomy, and type of presumed anastomosis. The endoscopist can expect greater 
engagement and, in the case of complicated anastomosis, a creative approach with the use of 
a wide range of instruments as described above (Giacomoni et al., 2006; Grande et al., 1999; 
Kobayashi et al., 2009; Wojcicki et al., 2006). 
6.13 Donation after cardiac death donors 
The increased number of patients listed for liver transplantation requires expansion of the 
pool of donors. To balance the donor organ shortage, livers donated after cardiac death is 
increasingly used. Nevertheless, both graft and patient survival rates compared to donation 
after brain death remain inferior, often due to biliary complications whose incidence ranges 
from 25% to 60%. Compared to brain death donors, in organs donated after cardiac death, 
ischemic cholangiopathy without hepatic artery injury frequently requires urgent 
retransplantation. Often there is a discrepancy between acceptable hepatocellular function 
and dim prognosis due to septic cholangitis. Therefore, the MELD score is useless when 
considering retransplantation. As a bridge, attempts of multiple endoscopic and transhepatic 
draining are often needed carrying the risk of other complications. Currently, the only way 
of minimizing the risk of cholangiopathy seems to be careful selection of young donors and 
cold ischemic time well below 8 hours (Feng et al., 2011; Foley et al., 2011; de Vera et al., 
2009). 
 




The high rates and wide range of biliary complications after liver transplantation remain a 
most important issue. The advent of new strategies and techniques, such as split- or 
reduced-size liver, living related liver transplantation, and non-heart beating donors 
incorporating new technical and pathogenetic principles will maintain the rate of 
complications on a significant level. Management has to arise from individual assessment of 
the patient with its unique complexity comprising the morphology of the lesion, presumed 
pathogenesis, comorbidities, and prior surgery including the patient´s preference. Analyses 
that consider all these factors should determine the strategy that may offer optimal profit for 
the patient. Management of biliary complications requires a multidisciplinary approach, in 
which all three main options, endoscopic, radiologic and surgical, have to be weighed one 
against each other. Generally, endoscopic management has to be considered as the first 
therapeutic option due its complexity, efficacy and safety in the majority of patients. The 
radiologic approach can be used alternatively in the majority of complications, preferably if 
there is not transluminal access to the biliary tree. Proper location of the stent by x-ray alone 
is more difficult to control, and multiple stents usually cannot be inserted. Both approaches 
can be combined. The disadvantage of these methods is the need for multiple sessions 
annoying the patient and increasing the risk of complications. Surgery – usually Roux-en-Y 
anastomosis – is a demanding technique potentially eliminating the obstruction forever. 
However, anastomosis obstruction and episodes of reflux cholangitis may compromise 
long-term outcome in up to 20% of patients. The standard therapeutic approach to biliary 
complications has not been uniformly defined and local expertise, usually inevitably 
uneven, plays an important role. The same biliary complication, i.e. extrahepatic stricture 
can be (and used to be) either treated by endoscopy, interventional radiology, or surgery, 
without significant difference in the results among the studies. A direct comparative study 
has not been published yet and one cannot be expected to be conducted even in the future. 
The diverse nature of the complications requires usual endoscopic techniques of treatment 
and, similar to non-transplant conditions, sphincterotomy, stent insertion with or without 
dilatation, and stone extraction are the most common therapeutic modalities. With the 
advent of new technologies like metal (semi-) covered stents and balloon enteroscopes, the 
range of options will enlarge. Specific issues of endoscopic procedures after liver 
transplantation include prevention of postprocedural cholangitis, consideration of 
coagulation disorders, and sedation of patients with various mental impairments. 
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ischemic cholangiopathy without hepatic artery injury frequently requires urgent 
retransplantation. Often there is a discrepancy between acceptable hepatocellular function 
and dim prognosis due to septic cholangitis. Therefore, the MELD score is useless when 
considering retransplantation. As a bridge, attempts of multiple endoscopic and transhepatic 
draining are often needed carrying the risk of other complications. Currently, the only way 
of minimizing the risk of cholangiopathy seems to be careful selection of young donors and 
cold ischemic time well below 8 hours (Feng et al., 2011; Foley et al., 2011; de Vera et al., 
2009). 
 




The high rates and wide range of biliary complications after liver transplantation remain a 
most important issue. The advent of new strategies and techniques, such as split- or 
reduced-size liver, living related liver transplantation, and non-heart beating donors 
incorporating new technical and pathogenetic principles will maintain the rate of 
complications on a significant level. Management has to arise from individual assessment of 
the patient with its unique complexity comprising the morphology of the lesion, presumed 
pathogenesis, comorbidities, and prior surgery including the patient´s preference. Analyses 
that consider all these factors should determine the strategy that may offer optimal profit for 
the patient. Management of biliary complications requires a multidisciplinary approach, in 
which all three main options, endoscopic, radiologic and surgical, have to be weighed one 
against each other. Generally, endoscopic management has to be considered as the first 
therapeutic option due its complexity, efficacy and safety in the majority of patients. The 
radiologic approach can be used alternatively in the majority of complications, preferably if 
there is not transluminal access to the biliary tree. Proper location of the stent by x-ray alone 
is more difficult to control, and multiple stents usually cannot be inserted. Both approaches 
can be combined. The disadvantage of these methods is the need for multiple sessions 
annoying the patient and increasing the risk of complications. Surgery – usually Roux-en-Y 
anastomosis – is a demanding technique potentially eliminating the obstruction forever. 
However, anastomosis obstruction and episodes of reflux cholangitis may compromise 
long-term outcome in up to 20% of patients. The standard therapeutic approach to biliary 
complications has not been uniformly defined and local expertise, usually inevitably 
uneven, plays an important role. The same biliary complication, i.e. extrahepatic stricture 
can be (and used to be) either treated by endoscopy, interventional radiology, or surgery, 
without significant difference in the results among the studies. A direct comparative study 
has not been published yet and one cannot be expected to be conducted even in the future. 
The diverse nature of the complications requires usual endoscopic techniques of treatment 
and, similar to non-transplant conditions, sphincterotomy, stent insertion with or without 
dilatation, and stone extraction are the most common therapeutic modalities. With the 
advent of new technologies like metal (semi-) covered stents and balloon enteroscopes, the 
range of options will enlarge. Specific issues of endoscopic procedures after liver 
transplantation include prevention of postprocedural cholangitis, consideration of 
coagulation disorders, and sedation of patients with various mental impairments. 
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1. Introduction 
Orthotopic Liver Transplantation (OLT) is the only treatment capable to reverse end-stage 
chronic liver disease, and is also indicated for the treatment of hepatocellular carcinoma, 
acute liver failure and a series of metabolic disorders caused by liver dysfunction, even 
those that do not course with cirrhosis. The evolution of surgical techniques, the proper 
selection of potential recipients, perioperative and ICU care, and better organ preservation 
solutions and immunosuppressive medications currently available, greatly increase success 
rates and survival after liver transplantation. Despite these many advances liver 
transplantation continues to have a high number of postoperative complications, with 
significant morbidity and mortality. These include biliary complications, that because of 
their high incidence have been called the Achilles’ heel of liver transplantation. In initial 
reports the complication rates in the biliary tree range from 34 to 50%, with mortality 
reaching up to 30% of transplanted patients. In more recent series these complications have 
been reduced to 10 from 30% and associated mortality to about 10% (Welling et al. 2008). 
Biliary complications can occur both in the area of the anastomosis or be intrahepatic. The 
forms of biliary fistula or stenosis are different not only in clinical presentation and 
treatment, but also in the period in which they occur. The association with vascular 
complications, arterial thrombosis specifically, makes treatment even more complicated. The 
incidence following transplants with living donors is greater, given the wide anatomical 
variation and smaller size of bile ducts in this situation. 
2. Types of biliary reconstruction 
Biliary anastomosis is the final step in a liver transplant, being performed after the 
completion of vascular reconstruction and graft reperfusion. [Figure 1] The technique of 
end-to-end duct-to-duct anastomosis is the widely accepted standard, although some 
controversy exists on whether or not the bile duct T-tube drains should be used. [Table 1] 
This type of reconstruction has the advantage of maintaining the physiological mechanism 
of biliary excretion and be easily accessible by endoscopy, which is very useful in the case of 
anastomotic or intrahepatic biliary complications. There are reports of some groups that 
vary this form of reconstruction with side-to-side anastomosis, in order to enlarge the 
anastomosis, thus trying to prevent stenosis (O’Connor et al. 1995). 
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The choice for Roux-en-Y hepaticojejunostomy is an exception in transplants with deceased 
donors. It is indicated when there is some anomaly in the recipient bile duct, such as 
obstruction, atresia, sclerosing cholangitis, or large size difference between the donor and 
recipient bile ducts. In the case of living donor transplantation or the use of spit liver, 
hepaticojejunostomy has been considered the standard, due to the small size, anatomical 
variation and the presence of multiple ducts to be drained. 
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In right lobe living donor liver transplantation (LDLT) there are several reports of duct-to-
duct anastomosis, and this type of reconstruction is already well accepted. In the case of left 
lobe LDLT there is still a tendency to perform Roux-en-Y hepaticojejunostomy in published 
reviews. However, there are reports of successful transplants carried out with multiple duct-
to-duct anastomosis for drainage of various liver segments, which uses the right and left 
recipient hepatic branch ducts, or sometimes even the cystic duct to obtain the drainage path 
for reconstruction (Azoulay et al. 2001). 
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3. Bile duct drainage 
In the firsts series of liver transplantation bile duct drainage with the use of T-tubes was 
performed routinely. The aim was to decompress the bile flow and reduce pressure on the 
anastomosis, allowing greater control over the excretory function of the liver and easy 
access for performing contrasted studies of the biliary tree during the postoperative period. 
[Figure 2] The presence of T-tube drains in the area of anastomosis prevents the formation of 
cicatricial stenosis, ensuring a minimum diameter molded into the drain. 
 
Fig. 2. T-tube drain cholangiography with short, anastomotic type stricture 
The occurrence of various complications related to T-tube drain and its removal led to 
questioning of its real benefit. The occurrence of bile leaks after the drain removal occurs in 
up to 15% of cases. When added to other complications such as obstruction, displacement 
and cholangitis, complications directly related to the drain reach between 10 and 22% of 
patients (Gantxegi et al. 2011). 
The use of immunosuppressive drugs and high-dose corticosteroids in liver transplantation 
delays fibrogenesis, preventing the formation of a fibrous path around the drain, which 
justifies such a high number of complications. Several attempts to reduce these numbers 
have been tried, such as using rubber tubes instead of silicone ones and late removal of the 
drain, between 4 to 6 months post transplant. A prospective randomized trial in the late ’90s 
demonstrated objectively that duct-to-duct anastomosis without bile duct T-tube drains was 
possible, with lower complication rates and cost-effectiveness (Verran et al. 1997). 
Currently, the use of bile duct drains after deceased donor liver transplantation (DDLT) is 
carried out selectively. In the case of partial liver transplants, either by LDLT or split DDLT, 
bile duct T-tube drain has the advantage of relieving the pressure in the biliary tree, 
preventing fistula formation in the liver cut surface. Because of this, drain use is still more 
frequent in this type of transplantation. 
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4. Types of biliary complications 
Occurrence of fistulas and stenosis account for about 80% of all biliary complications, and 
the remaining 20% are due to less frequent causes, such as extrinsic compression, hemobilia, 
mucoceles, and obstructions caused by biliomas, stones, biliary sludge or nematodes. 
These complications are related to a number of factors such as technical errors, thrombosis 
or stenosis of the hepatic artery, recurrence of underlying disease and ischemic-type lesions. 
In case of partial liver grafts there is also the risk of inadvertent injury during duct 
dissection and section of hepatic parenchyma, leading to cicatricial strictures or fistulas, and 
the risk of bile leak in the cut surface (Noujaim et al. 2003). 
 
Fig. 3. Endoscopic Retrograde Cholangiography with short segmental stricture 
The type of injury varies according to etiology. In case of technical errors in the anastomosis 
confection single and short extrahepatic stenosis is the rule. [Figure 3] Because of the 
peculiarities of biliary tree vasculature, in a radial manner, the excessive dissection of the 
duct in the recipient or in the graft may lead to ischemia in the anastomosis area, resulting in 
necrosis and fistula or late cicatricial retraction. [Figure 4] 
Strictures of the ischemic type are characterized by multiple areas of stenosis within the 
liver, interspersed with areas of dilation. The main cause of this type of injury is the 
occurrence of stenosis and thrombosis of the hepatic artery. However several other factors 
may be involved, such as prolonged cold and hot ischemia periods, poor preservation of the 
graft, delayed arterialization of the liver, recurrence of underlying disease, and toxicity of 
drugs and immune-mediated injury. Among the causes immune-mediated chronic rejection, 
ABO incompatibility and cytomegalovirus infection must be remembered. It is also 
suggested that the presence of bile salts in contact with the epithelium during cold ischemia 
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period is toxic, leading to autolysis of the mucosal lining. So the practice of washing the 
biliary tract with saline before arterial clamping and cold perfusion of the graft during the 
donor's removal procedure can prevent this type of complication. 
 
Fig. 4. Necrotic biliary tree 
5. Clinical presentation 
Most biliary complications occur early after liver transplant, with 60% occurring in the first 
six months postoperatively. The clinical presentation can be very varied, ranging from 
jaundice or bile leaks through abdominal drains to unspecific pictures of worsening liver 
tests and infections. 
The presence of bile in abdominal drain in early postoperative is diagnosis of fistula, but is 
not always present. Formation of biliomas or choleperitonitis may occur even without 
significant clinical manifestations, a fact due to immunosuppression and high doses of 
corticosteroids used in the initial postoperative phase. 
The occurrence of postoperative cholestasis is a common signal for a series of complications, 
not to specific abnormalities in the biliary tree. Common causes of cholestasis include acute 
cellular rejection, liver graft dysfunction, preservation injury, medication toxicity, recurrence 
of viral hepatitis, vascular thrombosis or stenosis of the hepatic artery and portal vein, 
ascending cholangitis, or simply be due to severe sepsis. 
Changes in postoperative evolution of a transplanted patient such as detection of altered 
liver function tests or clinical deterioration with development of sepsis should be 
investigated with specific protocols to detect the most common complications. The 
performance of Doppler ultrasound examination is a good initial measure, because it allows 
the evaluation of arterial and portal blood flow, presence of bile ducts dilation and 
assessment of liver parenchyma for its surface and texture, and also is a good initial method 
to identify liver abscesses and biliomas or extrahepatic collections. The absence of dilatation 
of the bile ducts should not be a factor sufficient to preclude the existence of complications 
such as biliary strictures, as there are several related cases of significant stenosis that do not 
course with biliary dilation. This can be explained by the presence of greater peri-duct 
fibrosis in transplanted livers. 
When suspicion of biliary complications cannot be ruled out by the initial screening or when 
persistent cholestasis occurs even after exclusion of acute and chronic rejection or viral 
hepatitis recurrence a more detailed evaluation of the biliary tract should be performed. 
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Magnetic Resonance Imaging (MRI) Cholangiography allows detailed images of the biliary 
tract anatomy, with identification of areas of narrowing, presence of gallstones and bile 
leakage points, and is a good method for diagnosis and treatment planning. Endoscopic 
Retrograde Cholangiography (ERCP) and Percutaneous Transhepatic Cholangiography 
(PTC) allow not only the diagnosis of biliary lesions but also their treatment, either with 
endoscopic sphincterotomy, placement of biliary drains and external naso-biliary catheters 
or direct manipulation of lesions, with stricture dilation and passage of various types of 
biliary prostheses. 
The strong association of biliary injury with the occurrence of hepatic artery thrombosis or 
stenosis should be remembered. Research with angio-CT or MRI should be performed 
whenever there is suspicion after the initial screening with Doppler ultrasound. 
6. Biliary fistulas 
Bile leaks usually occur in the early period after liver transplantation. Its presentation can be 
very variable, from a bile leak from abdominal drains to biliomas formation without further 
clinical repercussions, until the occurrence of diffuse choleperitonitis and sepsis. 
Bile leak incidence varies between 0.5 and 20% and is often related to technical error in the 
biliary anastomosis. Its origin can be in the anastomosis itself or in areas of injury to the bile 
duct during dissection. Devascularization of end bile ducts in the area of anastomosis due to 
excessive dissection can progress to necrosis of the duct and fistula formation. In cases of 
partial liver grafts, from LDLT or split DDLT, there may be damage to the ducts on the cut 
surface of the parenchyma, leading to fistula formation. 
The initial goal of treatment is to control sepsis. Percutaneous ultrasound or CT-guided 
drainage of biliomas can be performed. In cases of massive leaks and choleperitonitis it 
could be necessary to perform laparotomy. The definitive treatment of fistulas depends on 
the type of transplant performed, as well as the form of biliary reconstruction and the 
placement or not of T-tube drain in the biliary tract. 
In transplants performed with whole liver grafts from deceased donors, fistulas originate 
almost exclusively from the anastomosis. Other less frequent causes are due to common bile 
duct injuries during dissection or fistula originating from areas of laceration in liver 
parenchyma due to prior trauma. In transplants performed with partial liver grafts, due to 
LDLT or split DDLT, fistulas originating from intra-parenchymal ducts or from the cut 
surface area of liver section have major significance. 
When reconstruction is performed with duct-to-duct anastomosis ECPR treatment is usually 
the first option. [Figure 5] The performance of sphincterotomy and biliary stenting often 
induces the closure of fistulas in most cases, with mean treatment duration ranging from 60 
to 90 days according to some series (Londono et al. 2008). Another option is the passage of 
naso-biliary tubes, with the advantage of easy access to perform contrast-enhanced studies 
of the biliary tract. When a T-tube drain is left during the transplantation procedure simply 
opening the drain should be sufficient to resolve the fistula. Surgery, as a definitive 
treatment, is usually indicated only in case of failure of the initial endoscopic treatment, in 
this case the conversion of the anastomosis to hepaticojejunostomy to be resolutive. 
In fistula occurring after reconstruction with Roux-en-Y hepaticojejunostomy the treatment 
is more complicated. This type of anastomosis is virtually inaccessible by endoscopy, forcing 
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early surgery indication. The reconfiguration of the anastomosis is usually effective for the 
resolution of this picture. One controversial option is to perform a jejunostomy stoma, to 
allow endoscopic access to the anastomosis if necessary in the future. This stoma could be 
closed a few months after resolution of symptoms. 
 
Fig. 5. Bile leak in duct-to-duct anastomosis 
Fistulas originating after removal of biliary drains are also initially treated with endoscopic 
papillotomy. Primary surgical indication to suture the drain hole, allows faster resolution of 
the fistula, but with higher associated morbidity. 
The occurrence of bile leaks leads to significant morbidity and mortality after orthotopic 
liver transplantation. Although not altering the function or long-term survival of the liver 
graft after its resolution, it is a risk factor for the occurrence of cicatricial stenosis. 
7. Biliary strictures 
The occurrence of biliary strictures after liver transplantation has declined over the years 
due to improved surgical materials, better organ preservation and postoperative care. 
Incidence of up to 40% initially reported fell from 5 to 15% in recent reviews. In LDLT it still 
occurs in about 30 to 35%, according to published series (Renz et al. 2004). While the vast 
majority of stenosis occur within the first year after transplantation, with peak incidence 
between 5 and 8 months, it is known that the incidence is progressively increased with 
longer follow-up periods. The early occurrence of stenosis is related to technical conditions, 
such as improper suture materials, tension at the anastomosis and duct size difference 
between recipient and donor. Late presenting strictures are usually related to ischemic or 
immunologic events or inadequate organ preservation. 
Strictures can be of two types, anastomotic or non-anastomotic. Strictures that occur in the 
region of the anastomosis are influenced by local factors and are usually short and unique. 
[Figure 6] The incidence appears to be greater after the completion of Roux-en-Y 
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hepaticojejunostomy than after duct-to-duct anastomosis. The use of T-tube bile drains 
seems to have a protective effect on the occurrence of stenosis, while the occurrence of 
fistula is an independent risk factor for stricture development. 
Risk factors for Biliary Strictures 
Anastomotic Suture technique 
Bile leaks 
Bile duct dissection 
Ischemic type Hepatic artery Thrombosis 
Prolonged cold ischemia period 
Prolonged arterialization time 
Donor related: 
Age  
High dose vasoactive drugs 
Cardiac arrest 
Immune-mediated: 
Chronic ductopenic rejection 
ABO incompatibility  
Bile salts toxicity 
Infection 
Citomegalovirus 
Viral hepatitis recurrence 
Table 2. Risk factor for biliary stricture 
Strictures of late onset usually are related to ischemic or immunological events. The 
ischemic causes may be related or not to hepatic artery thrombosis, other causes being long 
cold or hot ischemia period, prolonged graft arterialization time, removal of the organ after 
donor cardiac arrest, excessive use of vasoactive drugs or high age of the donor. Root causes 
are mostly alo-immune ABO incompatibility, chronic ductopenic rejection, recurrence of 
underlying disease such as sclerosing cholangitis and autoimmune hepatitis, bile salts 
toxicity to the epithelium, recurrent viral hepatitis and cytomegalovirus infection (Suarez et 
al. 2008). These types of stenosis, classified as ischemic type, usually are long, multiple, 
interspersed with areas of dilation and can occur both intra and extra hepatic. [Table 2] 
There may be asymptomatic presentation or only with vague symptoms like fatigue, itching 
and jaundice. The change in liver function markers, such as elevated bilirubin, gamma-
glutamyl transferase, alkaline phosphatase and serum aminotransferases should raise 
suspicion for biliary stenosis or obstructions. 
Doppler ultrasound evaluation should be performed to evaluate the presence of hepatic 
blood flow. If stenosis or artery obstruction is suspected, complete evaluation by 
angiography or angio-MRI should be performed. 
The assessment of biliary obstruction by ultrasonography has poor accuracy in transplanted 
patients and is not a reliable marker of good biliary drainage. The sensitivity for detection of 
obstructions varies from 40 to 65%, with a high number of false negatives. The biliary tree in 
transplanted livers may not dilate, even in the presence of significant obstruction. This is 
explained by the possible presence of peri-ductal fibrosis that can occur in these patients. 
 




Fig. 6. Anastomitic type biliary stricture, shown in ERCP 
The gold standard test for the detection of biliary strictures is cholangiography, both when 
percutaneous or endoscopic. This test allows proper identification of the cause of 
obstruction to bile flow and allows therapeutic measures, such as stone removal, dilation 
and biliary stent insertion. The preference is for performing endoscopic procedure (ERCP) 
because it is less invasive, with lower bleeding or fistula risk when compared with 
percutaneous procedure (PTC). The existence of anastomosis in Roux-en-Y is an 
impediment to the conduct of endoscopic procedure. Although there are series that could 
demonstrate factual ERCP using ballon-enteroscopy or through previously made stomas, 
this is not usually available in clinical practice. When ERCP is not possible or when it is not 
adequate PTC could be tried. 
The performance of MRI-cholangiography shows results comparable to ERCP in diagnostic 
aspect. In a prospective trial, MRI-cholangiography achieved 95% accuracy and 98% 
sensitivity, when compared to ERCP. The lack of therapeutic capability is a major drawback 
of the method, serving as an intermediate examination prior to invasive procedures in 
interventional radiology. 
Treatment of biliary obstruction is time consuming, requiring multiple interventions and 
with high risk of relapse. The initial therapeutic option is interventional radiology 
procedures, endoscopic or percutaneous whenever possible. Dilation of strictures with 
balloon dilators when performed alone has a long-term success rate of only 40%. The 
placement of biliary prostheses, ranging between 7 and 10fr increases the effectiveness to 
about 75%. Studies with the placement of multiple parallel plastic stents solved up to 90% of 
cases of strictures (Williams & Draganov, 2009). The procedure should be repeated at 
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hepaticojejunostomy than after duct-to-duct anastomosis. The use of T-tube bile drains 
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sensitivity, when compared to ERCP. The lack of therapeutic capability is a major drawback 
of the method, serving as an intermediate examination prior to invasive procedures in 
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about 75%. Studies with the placement of multiple parallel plastic stents solved up to 90% of 
cases of strictures (Williams & Draganov, 2009). The procedure should be repeated at 
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regular intervals to prevent obstruction of the stents and cholangitis. Intervals of three to six 
months are well accepted, but the carrying out of more aggressive treatments at intervals of 
two weeks, has shown good results. 
Recurrence of stenosis is the rule, with multiple procedures being needed to settle the case, 
with treatment periods ranging from one to two years. The use of self-expandable metal 
stents seems to allow a longer period of symptom relief, with need of fewer procedures, but 
there are still not many published results (Kusano et al. 2005). 
Endoscopic treatment failure leads to the need for a surgical approach. In cases of 
anastomotic stenosis the resolution and prognosis are good. If the primary reconstruction  
is duct-to-duct anastomosis, the procedure is the conversion to Roux-en-Y 
hepaticojejunostomy. If the obstruction occurs on a previously performed enteric bypass the 
anastomosis should be reconfigured. In selected cases, some services choose to make a 
jejunostomy stoma to allow access to future possible endoscopic interventions in the biliary 
tree, if needed. 
Ischemic stenosis type has a worse prognosis and lower resolvability even with surgical 
treatment. The failure to obtain adequate biliary drainage has a strong association with 
decreased graft survival. Patients with unresolved biliary strictures evolve to liver failure, 
with up to 30 to 50% progressing to death or retransplantation, despite continuous 
endoscopic and percutaneous drainage (Yazumi et al. 2006). 
Retransplantation is indicated especially in cases associated with arterial thrombosis, or in 
cases that progress to cirrhosis secondary to chronic biliary obstruction. The mortality 
associated with this procedure is significantly higher than in the first transplant (Verdonk et 
al. 2006). 
8. Other complications 
In addition to fistulas and strictures, several other forms of complications can occur in the 
bile ducts after liver transplantation. Obstruction of the biliary tract by extrinsic causes, 
bleeding and recurrence of pre-existing diseases are most common (Wojcickia et al. 2008). 
Extrinsic compression of the bile ducts can occur by several factors, such as hepatic hilar 
lymph nodes, recurrence of hepatic neoplasms, compression by other anatomical structures 
such as the hepatic artery and pseudoaneurysms, and because of mucoceles. Treatment of 
this type of compression can be with interventional radiology stenting or Roux-en-Y 
hepaticojejunostomy in refractory cases. 
Mucocele of the cystic duct stump is infrequent, occurring when the donor cystic duct is 
blindly sutured to the anastomosis. The accumulation of mucus produced by the biliary 
epithelium leads to expansion of this segment, with compression of the common bile duct. 
The prevention of this complication should be performed by complete excision of the cystic 
duct of the donor or by section of the septum and communication of both ducts before the 
anastomosis. Cholangiography with typical findings of external compression and thinning 
of the distal bile duct make the diagnosis. The treatment is excision of the cystic duct 
remnant and biliary bypass with hepaticojejunostomy. 
Cases of jaundice and dilatation of the distal bile duct without an obstructive factor 
identified on cholangiography may be due to sphincter of Oddi or ampullary dysfunction. 
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This variation can occur in up to 3% of transplanted patients and is justified due to 
denervation of autonomic plexus during the surgery. Although the diagnosis can only be 
confirmed with duodenal papilla manometry, the resolution after endoscopic papillotomy 
strongly supports this hypothesis. 
The occurrence of spontaneous hemobilia is rare after liver transplantation and may occur 
due to rupture of pseudoaneurysms of the hepatic artery. Bleeding is more common after 
invasive procedures such as liver biopsies and percutaneous transhepatic cholangiography, 
in these cases with an incidence of 2%. The clinical presentation is of upper gastrointestinal 
bleeding and the diagnosis made by endoscopy. In cases of major bleeding or lack of 
spontaneous resolution arteriography with selective embolization of the responsible 
branches should be performed. Endoscopic retrograde cholangiography may be indicated 
for the removal of blood clots and passage of biliary stent. 
Recurrent disease after liver transplant may be up to 20% of patients with autoimmune 
hepatitis, primary biliary cirrhosis and sclerosing cholangitis. The development of multiple 
biliary strictures can occur and are often difficult to differentiate from ischemic injury. In 
patients with confirmed diagnosis of sclerosing cholangitis prior to liver transplantation, 
biliary reconstruction is done preferably by Roux-en-Y hepaticojejunostomy, aiming for the 
prevention of recurrent disease in the receptor distal common bile duct remnant. Duct-to-
duct anastomosis has been performed selectively in patients who show no signs of stenoses 
or inflammation in the distal bile duct during the transplant. However, a recent multicenter 
review showed higher risk of stenosis and lower graft survival rates in patients with 
primary sclerosing cholangitis undergoing duct-to-duct anastomosis compared to those 
submitted to Roux-en-Y hepaticojejunostomy (Welling et al. 2008). 
9. Experience at unit of liver transplantation – Unicamp 
Between September/1991 and May/2011 528 orthotopic liver transplants from deceased 
donors were conducted. Follow-up period ranged from 1 month to 19 years. 
The type of biliary reconstruction used was end-to-end duct-to-duct anastomosis in 477 
patients (90.4%). Biliary T-tube drains were used in only 17 patients (3.5%). Patients 
undergoing Roux-en-Y hepaticojejunostomy represented 9.6% of the total (51 patients). 
[Table 3] 
We identified 95 cases of complications in the biliary tract, representing an incidence of 
17.9%, consistent with the literature. Among these complications 86.3% were stenosis and 
13.7% were bile leaks. The association of arterial thrombosis with biliary complications was  
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consistent with recent reports published by various centers, with 32.6% of all leaks and 
strictures due to ischemic events. 
The analysis of incidence of complications in relation to the type of reconstruction employed 
had a slightly higher complication rate of 21.5% in the group undergoing hepaticojejunostomy 
against 17.6% in the group with duct-to-duct anastomosis. The highest incidence of fistulas 
was observed after Roux-en-Y reconstruction, 36.4% versus 10.8%. But the small number of 
patients undergoing this type of anastomosis precluded a more detailed analysis. [Table 4] 






















Artery Thrombosis 28/84 (33,3%) 3/11 (27,2%) 31/95 (32,6%) 
Table 4. Complications incidence related to reconstruction technique 
Complications after duct-to-duct anastomosis were initially treated with endoscopic 
retrograde cholangiography (ERCP) in 72.6% of cases, and in about 35% of the patients this 
was the only treatment employed. [Figure 7] Reference to percutaneous cholangiography 
(PTC) was restricted in this group, in only 3.5%. Surgical treatment had to be carried out in 
54% of these patients, including percutaneous drainage, laparotomy for peritonitis and 
sepsis and hepaticojejunostomy anastomosis conversion. [Table 5] 
In the group with Roux-en-Y bileo-enteric shunt, indication of initial surgical treatment was 
approximately 64% and in about 20% of cases percutaneous cholangiography was 
performed. The main indication for surgery as initial treatment in this group is consistent 
with the difficulty in addressing this anastomosis by interventional radiological techniques. 
Retransplant was indicated in approximately 8% of patients with biliary strictures, all of 
which were associated with hepatic artery thrombosis. In 85% of these patients, other forms 
of treatment had been tried before retransplantation. The cumulative mortality of patients 
undergoing retransplantation was 50%. 
Treatment Duct-to-Duct Hepaticojejunostomy Deaths 
ERCP 61 (72,6%) 0 - 16 (26,2%) 
PTC 3 (3,5%) 2 (18,2%) 2 (40%) 
Surgery 46 (54,7%) 7 (63,6%) 9 (17%) 
Retransplant 6 (7,1%) 2 (18,2%) 4 (50%) 
Total 84  11  26 (27,4%) 
Table 5. Treatment of biliary complications at Unit of Liver Transplantation – Unicamp 
The group undergoing combined surgical and endoscopic treatment showed the highest 
resolution rate of the complications, achieved in 75% of the cases. Despite the various forms 
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of treatment employed, the mortality from biliary complications remained high, 27.4%, 
consistent with the data in the literature. 
  
Fig. 7. Endoscopic treatment of biliary stricture. Left: Pre-procedure cholangiography with 
short segmental stricture. Right: Radiological control after stent placement 
10. Conclusions 
Several advances in the care of patients undergoing liver transplantation have increased the 
survival of grafts and recipients. Despite this, the complications arising in the bile ducts are 
still of great importance to its incidence, difficulty of treatment, morbidity and mortality. 
The proper technical care in the anastomosis confection and in the selection of donors, organ 
preservation, reduction in the ischemic period and arterialization time are the best ways to 
prevent this type of complication. A fact demonstrated by the lower incidence and the 
increasing role of hepatic artery thrombosis in the development of biliary complications as 
the transplant teams gain more experience. 
The diagnosis and treatment of biliary leakage and stenosis depend on a large number of 
imaging and interventional procedures. So the care of such patients should be 
individualized, depending on experience and availability of local resources. 
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Ischemic Type Biliary Lesions 
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Charité Campus Virchow / General, Visceral and Transplant Surgery / Berlin, 
Germany 
1. Introduction 
Liver transplantation (LT) is an established therapy for end-stage liver disease based on a 
substantial progress in surgical and immunological management of concomitant post- 
transplant phenomena. Apart from rejection and HCV-recurrence, the development of 
biliary strictures is one of the most serious complications observed after LT significantly 
affecting graft and patient survival [1, 2]. Frequently compared to Achilles foot, the 
dynamics of post-transplant biliary restitution may determine the overall transplant success 
and play the role of a critical step after LT. Post-transplant complications in the biliary 
system occur in 10-50% with significant mortality in up to 19% and re-transplantation rates 
of 6-12.5% [3-6]. Early post-transplant biliary complications are predominantly related to 
technical aspects of the operation regarding the insufficiency of bile duct anastomosis, 
biliary leaks or anastomotic stenosis [7]. One third of all biliary complications occur later 
than first two months after LT affecting intrahepatic integrity on donor side and 
functionality of distal parts of the biliary tree in the recipient including the bile duct 
anastomosis and the ampulla of Vater [1, 2, 8]. In contrast to the anastomotic strictures, 
which can be successfully treated endoscopically or surgically, non-anastomotic strictures 
represent a significant therapeutic problem [9, 10]. Non-anastomotic strictures of the bile 
duct may develop in up to 20% of all LTs. Untreated stricture-associated complications may 
lead to cholestasis, severe graft dysfunction, cholangiosepsis, secondary cirrhosis and even 
death [6, 8, 11, 12]. Non-anastomotic strictures may be classified according to their etiology 
into strictures related to PSC-recurrence (primary sclerosing cholangitis), strictures 
occurring due to vascular complications in case of a manifest hepatic artery thrombosis as 
ischemic biliary lesions (IBL), strictures occurring after prolonged ischemia (e.g. successfully 
treated hepatic artery thrombosis) and strictures occurring without an obvious vascular 
complication. In the presence of a macroscopically obviously undisturbed perfusion they are 
described as so-called ischemic type biliary lesions (ITBL). The occurrence of biliary lesions 
after primarily successful LT justifies the necessity to introduce ITBL as an independent 
pathologic entity. In spite of a certain descriptive inaccuracy, the terms “non-anastomotic 
strictures”, “intrahepatic biliary strictures” and “ischemic type biliary strictures” are usually 
used as synonyms for post- transplant strictures, diffuse dilatations and segmental ectasia of 
the biliary tract as a result of inflammation and fibrotic remodeling (figs. 1 and 2) [13]. Due 
to terminological diversity, the incidence of ITBL significantly varies among published 
studies between 1.4 and 26% [1, 5, 14]. The diagnosis “ITBL” may be made only after  
the exclusion of vascular (IBL) and immunologic pathologies (PSC-recurrence and chronic  
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1. Introduction 
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transplant phenomena. Apart from rejection and HCV-recurrence, the development of 
biliary strictures is one of the most serious complications observed after LT significantly 
affecting graft and patient survival [1, 2]. Frequently compared to Achilles foot, the 
dynamics of post-transplant biliary restitution may determine the overall transplant success 
and play the role of a critical step after LT. Post-transplant complications in the biliary 
system occur in 10-50% with significant mortality in up to 19% and re-transplantation rates 
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technical aspects of the operation regarding the insufficiency of bile duct anastomosis, 
biliary leaks or anastomotic stenosis [7]. One third of all biliary complications occur later 
than first two months after LT affecting intrahepatic integrity on donor side and 
functionality of distal parts of the biliary tree in the recipient including the bile duct 
anastomosis and the ampulla of Vater [1, 2, 8]. In contrast to the anastomotic strictures, 
which can be successfully treated endoscopically or surgically, non-anastomotic strictures 
represent a significant therapeutic problem [9, 10]. Non-anastomotic strictures of the bile 
duct may develop in up to 20% of all LTs. Untreated stricture-associated complications may 
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death [6, 8, 11, 12]. Non-anastomotic strictures may be classified according to their etiology 
into strictures related to PSC-recurrence (primary sclerosing cholangitis), strictures 
occurring due to vascular complications in case of a manifest hepatic artery thrombosis as 
ischemic biliary lesions (IBL), strictures occurring after prolonged ischemia (e.g. successfully 
treated hepatic artery thrombosis) and strictures occurring without an obvious vascular 
complication. In the presence of a macroscopically obviously undisturbed perfusion they are 
described as so-called ischemic type biliary lesions (ITBL). The occurrence of biliary lesions 
after primarily successful LT justifies the necessity to introduce ITBL as an independent 
pathologic entity. In spite of a certain descriptive inaccuracy, the terms “non-anastomotic 
strictures”, “intrahepatic biliary strictures” and “ischemic type biliary strictures” are usually 
used as synonyms for post- transplant strictures, diffuse dilatations and segmental ectasia of 
the biliary tract as a result of inflammation and fibrotic remodeling (figs. 1 and 2) [13]. Due 
to terminological diversity, the incidence of ITBL significantly varies among published 
studies between 1.4 and 26% [1, 5, 14]. The diagnosis “ITBL” may be made only after  
the exclusion of vascular (IBL) and immunologic pathologies (PSC-recurrence and chronic  
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ductopenic rejection) [1]. As a diagnosis of exclusion, ITBL is regarded as a serious 
transplant complication and a notable graft disease, undeniably deserving scientific 
attention. 
1.1 Anatomical aspects of the biliary tract 
Biliary tract is a complex network of ductal structures beginning with Hering-canals, 
merging into major ducts and finally into intestine in a highly coordinated manner [15, 16]. 
Apart from conductive functions, the biliary epithelium demonstrates morphological 
heterogeneity, which depends upon functional requirements [17]. The ability to undergo 
phenotypic changes, to participate in inflammatory processes and even to behave as liver 
progenitor cells underlines the uniqueness of cholangiocytes under physiological conditions 
[15, 18]. In contrast to parenchymal blood supply of liver sinusoids via portal vein and 
hepatic artery, biliary tree predominantly depends on the integrity of the hepatic artery and 
periductal plexus being more vulnerable to transplant-related disrupted blood supply and 
immunologic processes justifying the metaphoric comparison to Achilles foot [19, 20]. 
1.2 Biliary tract reconstruction 
One of the most important surgical steps and goals during LT is the reconstruction of the 
biliary tract and the restitution of its function. The most widely employed reconstructive 
techniques are choledocho-choledochostomy (with or without T-tube) performed in patients 
with uncomplicated anatomy and intact distal segment of the biliary tract including 
functioning sphincter Oddi and Roux-en-Y hepatico-jejunostomy, which is usually reserved 
for cases with intrinsic damage to the biliary system (e.g. PSC) and technically difficult 
anastomosis (e.g. re-transplantation, living donor LT) [6, 21, 22]. Underlying liver disease, 
size of biliary tracts of the donor and the recipient, anatomic aspects, prior surgery on the 
biliary duct and surgeon preference may influence the choice of the reconstructive technique 
[23]. 
2. Non-anastomotic strictures: Morphology 
Chronic disturbance of bile flow, accompanied by inflammatory processes, may lead to the 
development of irregular strictures, dilatations and sequestrations of the biliary tree (figs 1 
and 2). Bacterial ascension, causing cholangitis, cholangiohepatitis and cholangiosepsis, may 
forward the progression of ITBL. Macroscopically, ITBL is classified according to the 
localization of pathological alterations in three groups (type-I: extrahepatic; type-II: 
intrahepatic; type-III: intra- and extrahepatic), which may determine the severity of the 
disease, its course and therapeutic options. Inflammation and remodeling represent the 
functional backbone of ITBL-development. Presence of intracellular cholestasis, abundance 
of lymphocytes and granulocytes and proliferation of new bile ducts represent the 
microscopic picture of ITBL, hardly differing from biliary pathologies with unrelated 
etiologies [24]. Remodeling processes result in the formation of connective tissue. Degree, 
localization and duration of inflammation determine the extent of the disease. Resulting in a 
“scar” and the perpetuation of bile flow obstruction, inflammation and progression of 
biliary damage may promote secondary alterations and forward extensive fibrogenesis and 
tissue remodelling of the graft parenchyma [25]. Finally, graft atrophy and the reduction of 
functional reserve may develop, compromising the result of an initially successful LT. 
 




Fig. 1. Cholangiograph. Illustration of central stenosis at the level of distal right and left 
ductus hepatici, diffuse biliary strictures and dilatations in the left lobe, cholestasis in the 
right lobe. ITBL developed within the first post-transplant year 
  
                                           (A)                                                                                     (B) 
Fig. 2. (A) Resected graft with ITBL (left liver lobe). Macroscopically evident atrophy of liver 
parenchyma with broad peribiliary shroud of connective tissue (B) Microscopic view of the 
same graft depicting a profound periductular inflammation (lymphocytes, granulocytes), 
connective tissue and remaining islets of liver parenchyma 
Significant morphological similarities are observed in a non-transplant setting as well: in 
patients with HIV-associated cholangiopathy as vanishing bile duct-syndrome, sclerosing 
cholangitis and shock-liver [1, 26]. In summary, chronic inflammation caused by any 
noxious effectors may lead to the uniform picture described above. Frequently, significant 
difficulties arise in the attempt of differentiation between recurrent PSC and ITBL in the 
graft. Morphologically these entities may present identical pictures [1]. 
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Age (years) older than 60 
Size small-for-size 
Donor  
LT-mode living donor 
Stage of liver disease Child & Pugh C > A or B 
Solution UW > HTK 
retrograde caval Perfusion mode 
gravity arterial perfusion 
Periductal tissue little 
Surgery 
Reconstructive technique hepatico-jejunostomy 
Cold and warm ischemia prolonged 
Reperfusion injury not assessable 
Periductal plexus altered 
Ischemic factors 
Re-arterialization present 
External bile drainge no T-tube Cholangial pressure 
& bile toxicitiy 
Bile acids high bile-to-
phospholipid ratio 
ABO-system incompatible 
Immunosuppression Low level 
Rejection chronic / ductopenic 
Autoimmune disease PSC, PBC, AIH 
Co-infection CMV 
Immunologic factors 
Genetic variants CCRdelta32, Mdr-2 
Table 1. Suspected risk factors for the development of ITBL 
3. Pathophysiology 
The process of ITBL-development is not clearly understood yet. ITBL seems to be a 
polygenic disease, influenced by a whole variety of confounders. Currently identified risk 
factors may be divided into four major pathogenetic columns: peri-operative ischemia 
(including preserving solution), immunologic damage, toxicity of bile salts and 
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epidemiological confounders [1, 27]. The degree and relation of the functional impact 
among risk factors are not fully investigated. Hereby, ischemic injury seems to be the most 
important factor including cold and warm ischemia during transplantation, disturbed blood 
flow in the peribiliary plexus resulting from an inappropriate procurement of the donor 
liver with little periductal tissue, and hypoxemia during the postoperative period [12, 27]. 
Immunological injury including ABO-incompatibility, rejection, pre-existing liver disease 
with autoimmune component, CMV-Infection, immunosuppressive medication and chronic 
rejection also seem to play a role in the development of the non-anastomotic strictures [1, 27, 
28]. Moreover, bile fluid has been shown to be toxic for the vulnerable biliary epithelium of 
the graft [29]. Although biliary strictures have been reported to be more frequent in 
transplant patients with hepatico-jejunostomy, they may occur, disregarding the type of 
biliary tract reconstruction [6, 30]. Finally, factors related to epidemiology (older donor age, 
advanced stage of pre-transplant liver disease) and donation (preservation solution, 
perfusion technique) also seem to be relevant in the pathogenesis of ITBL [1, 27, 31]. Table 1 
summarizes currently known risk factors. 
4. Diagnostics 
The diagnosis of non-anastomotic lesions or ITBL is made by clinical presentation, exclusion 
of evident vascular complications, histological pattern and cholangiography as gold 
standard either by ERC (endoscopic retrograde cholangiography) or by PTC (percutaneous 
transhepatic cholangiography) [1, 2, 32]. Increased expertise in diagnostic and therapeutic 
ERC in transplant-related liver diseases has been demonstrated to be a safe and effective 
tool. Therefore ERC has been suggested to be the primary method for diagnosis and 
treatment of most transplant-related biliary complications except for acute surgical 
complications (broad insufficiency of biliary duct anastomosis) [33]. The diagnosis “ITBL” is 
made when typical signs of segmental strictures and dilatations appear on the 
cholangiography (fig. 1, 3, 4). 
4.1 Clinical aspects 
Characteristic and disease-specific aspects of clinical presentation do not exist. Symptoms 
reflect cholestasis and subsequent infective tendency ranging from unspecific discomfort in 
the right abdomen, elevated temperatures, shivering and jaundice. Clinical presentation of 
ITBL-patients may cover the whole range of complaints and symptoms originating from the 
biliary tract. Classical symptoms are pruritus, jaundice and fever. Untreated ITBL may lead 
to cholangiosepsis, graft insufficiency and patient death [27]. Clinically, ITBL closely 
resembles liver diseases with chronic inflammation of the biliary tract (PSC, SSC, 
cholangitis) [1]. 
4.2 Laboratory 
Although laboratory parameters are frequently normal or only slightly elevated, alkaline 
phosphatase (AP), gamma glutamyltransferase (γ-GT) and bilirubin may indicate 
pathological processes in the biliary tree. Biochemical results do not reliably reflect early 
stages of the disease and easily be misinterpreted as normal or acceptable in the post- 
transplant setting. Highly sensitive but not disease-specific, laboratory parameters are, 
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nevertheless, helpful as a non-invasive tool and their deviation is frequently the first sign 
perceived in the outpatient setting of most follow-up programs. Cholestatic profile with 
leukocytosis usually indicates complicated biliary pathology. Clinical symptoms and 
pathological laboratory findings may necessitate hospitalization and the initiation of further 
diagnostic procedures [32]. 
  
                                       (A)                                                                                         (B) 
Fig. 3. (A) Cholangiograph (ERC): Illustration of central stenosis at the level of distal right 
and left ductus hepatici, diffuse biliary strictures and dilatations in the left lobe and 
cholestasis in the right lobe. (B) Cholangiograph (ERC): Diffuse strictures and dilatations 
nearly in the entire biliary tree 
  
                                         (A)                                                                                         (B) 
Fig. 4. (A) Cholangiograph (ERC): Central stenosis and proximal cholestasis in both graft 
lobes (B) Cholangiograph (ERC): Relevant strictures close to the biliary bifurcation with 
dilatations in both graft lobes 
 




Radiological examination is the most important column in ITBL-diagnostics comprising 
conventional X-ray performed during ERC or PTC and indirect imaging methods: 
ultrasound, computer tomography (CT) and magnetic resonance cholangiography (MRC). 
4.3.1 Ultrasound 
As a safe and easily accessible tool, ultrasound examination including Doppler-mode is 
definitely helpful and routinely performed to rule out vascular causes for biliary 
dysfunction. In contrast to early changes, advanced stages of ITBL may well be assessed by 
ultrasound, revealing dilatations, stenosis and sediment, which predispose to the 
development of secondary complications regarding infection and disease progression. 
However, morphologic differences between naive liver and graft must be considered. Due 
to a higher stiffness of the graft, dilatations caused by strictures tend to appear more slowly 
and less distinctly in the affected biliary tract and may remain invisible or mistaken for 
normal conditions on a routine ultrasound examination. 
4.3.2 Conventional cholangiography 
Cholangiography is usually performed by ERC as the method of choice, if technically 
possible in the absence of contra-indications [9, 32]. Based on the classical endoscopic 
examination of the upper digestive tract, the goal of ERC is the visualization of the biliary 
tract by a selective instillation of contrast agent through the sphincter Oddi (fig. 3, 4). As a 
rather invasive diagnostic method, ERC should be performed with maximal accuracy, in 
order to avoid frequently observed pancreatitis, which is a potentially severe iatrogenic 
complication [34]. In contrast to the usually easily assessable biliary tract, if reconstructed as 
standard choledochocholedochostomy, endoscopic cholangiography is impossible with the 
majority of patients with hepatico-jejunostomy [32]. Occasionally, ERC may be feasible in 
patients with short efferent loops of hepatico-jejunal anastomosis if examined by 
experienced endoscopists. In most cases, cholangiography must be performed 
percutaneously as transhepatic punction and instillation of contrast fluid in the biliary 
system (fig. 6) [2, 35]. Elevated pressure and subsequent dilatation of the biliary tract may 
facilitate the examination. In spite of high effectiveness, transhepatic punction may cause 
graft damage, bleeding and injury of adjacent abdominal organs. Therefore, maximal 
accuracy and caution are required when applying this method. Simultaneous diagnostic and 
therapeutical options are the major advantages of conventional cholangiography (ERC or 
PTC). 
4.3.3 Computer tomography (CT) 
CT-scan may accurately visualize graft perfusion using contrast agent and biliary pathology 
regarding the localization, structural changes and secondary complications (abscess, 
atrophy). In spite of frequent incapability to detect short segment stenosis without pre 
stenotic dilatations, full-blown ITBL can easily be diagnosed by this method [32, 36]. In 
general, CT is considered to be a reliable diagnostic tool. 
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4.3.4 Magnetic resonance cholangiography (MRC) 
MRC is a reliable noninvasive technique to visualize the biliary anastomosis and depict 
biliary strictures after LT (fig. 5) [37]. MR-cholangiography has been shown to be an 
accurate imaging technique to non-invasively detect biliary complications in patients 
especially in patients with bilio-enteric anastomosis with high positive and negative 
predictive values [32, 38]. However, no direct therapeutical options are available during this 
procedure. Non-invasiveness and significant risk reduction for side events are major 
advantages of MRC. Further progress in MRC-processing may increase the potential to 
complement or even replace conventional cholangiographic methods [32]. 
  
                                           (A)                                                                                        (B) 
Fig. 5. (A) Cholangiograph (MRC): Central strictures and proximal diffuse dilatation (B) 
Cholangiograph (MRC): Diffuse strictures and dilatations of the entire biliary tract 
5. Therapy 
Early identification of high risk patients for ITBL-occurrence may help to initiate necessary 
therapeutical steps and possibly prevent disease progression. The goal of ITBL-treatment 
implies the reduction of morbidity and mortality among the diseased transplant population. 
Previously, surgery including re-transplantation of the diseased liver had been thought to 
be the leading therapeutical option for ITBL-patients [39]. Modern ITBL-treatment strategy 
comprises a multimodal approach and an excellent cooperation between departments of 
radiology, endoscopy and surgery (fig. 6) [2, 10, 25]. In most cases the treatment of strictures 
is performed conservatively by endoscopic or transhepatic dilatation [24, 33, 40]. Supportive 
measures should comprise antibiotic prophylaxis and treatment with ursodesoxycholic  
acid [2]. 
5.1 Endoscopic and transhepatic treatment 
Most of the ITBL-patients are currently treated by the endoscopic or percutaneous 
placement of stents and balloon dilatation [32, 33, 40]. However, significantly different 
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success rates are observed depending upon the localization and occurrence of the strictures. 
Anastomotic strictures are usually easier to treat than intrahepatic lesions. Early non-
anastomotic strictures demonstrate higher success rates than strictures appearing later than 
three months after LT [41-43]. Endoscopic and transhepatic treatment options are limited in 
patients with impaired liver function similarly to the diagnostic procedure. Complication 
rates (bleeding, pancreatitis) are reported to be 3.4% for PTC and up to 7% for endoscopic 
treatment [44]. 
5.2 Surgery 
Surgical intervention may still be required in patients who do not respond to dilatative 
treatment or in patients with circumscribed localization of the strictures either in the 
extrahepatic biliary tree or resectable graft lobe [2, 33, 39]. Endoscopic or radiological 
dilatation of strictures has been shown to be ineffective in some patients, who may profit 
from surgical treatment [10]. Therefore, reconstructive surgical approach should be reserved 
to ITBL patients not responsive to endoscopic or trans-hepatic interventions [2]. 
5.2.1 Resection 
Sufficient evidence exists about beneficial effects of partial graft resection, resection of 
biliary bifurcation and performance of hepatico-jejunostomy in liver transplant recipients 
with anatomically limited biliary damage, thus avoiding re-transplantation and preserving 
scarce donor organs [25, 45, 46]. In spite of higher vulnerability of the graft and a certain 
reluctance, graft resection in ITBL-patients with a sufficient graft function is possible and 
comparable to common liver surgery. 
5.2.2 Re-transplantation 
In spite of encouraging progress in interventional non-surgical ITBL-treatment, and 
achievements in graft resection, up to 50% of patients with non-anastomotic strictures still 
require re-transplantation of the liver [30, 43, 47, 48]. Re-transplantation of the liver is 
supposed to be the definitive therapy of graft damage being the last resort of therapeutical 
options. Unfortunately, survival rates after re-transplantation are significantly lower than 
after first LT. In technically more complicated re-transplant setting, cold ischemia and 
MELD-score have been shown to be associated with higher mortality rates [49]. Prevention 
of re-transplantation should be aspired as the goal of ITBL-treatment, especially in the era of 
organ shortage. 
In summary, ITBL-treatment may require an unpredictable amount of patience regarding 
the strategy, performance and follow-up. Exemplarily, more than two dozens of dilatative 
interventions and one graft resection (left hemihepatectomy) have been reported in one case 
of successful ITBL-treatment, preventing re-transplantation of the liver (fig. 6) [25]. 
6. Prevention 
The principle of ITBL-prevention focuses on the major pathogenic factors mentioned above 
and should be considered in the peri-operative period as far as possible. Hereby, allocation, 
preservation, reduction of ischemia, reconstructive techniques and adequate 
immunosuppression seem to be very important. Once, immunological effects were claimed 
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4.3.4 Magnetic resonance cholangiography (MRC) 
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                                           (A)                                                                                        (B) 
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Cholangiograph (MRC): Diffuse strictures and dilatations of the entire biliary tract 
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to cause spasms in hepatic arteries, resulting in hypoxemia of the bile duct system [50]. 
Currently, the mechanism of the disease is considered to be multifactorial. Immunological 
injury including ABO-incompatibility, rejection, pre-existing disease with autoimmune 
component, CMV-Infection and chronic rejection also seem to play a role in the 
development of the non-anastomotic strictures [12, 47]. Finally the toxicity of the bile fluid 
has been shown to be relevant in the pathogenesis of ITBL [51]. In summary, the 
development of ITBL is influenced by a whole range of donor, recipient, technical and 
immunological factors. 
     
                           (A)                                                        (B)                                                         (C) 
Fig. 6. (A) ERC after left hemihepatectomy in a patient with ITBL after LT for HCV-induced 
cirrhosis demonstrating a significant stenosis of the right hepatic duct and proximal dilatations 
(B) PTC via Yamakawa-drain of the same patient during the dilatative treatment (C) ERC 
after the completion of treatment depicting acceptable conditions in the right biliary tree 
6.1 Ischemic time 
Several studies have demonstrated a significant correlation of ITBL-incidence with ischemic 
time before reperfusion. In spite of controversial discussion, cold ischemic time especially of 
more than 10 hours may affect the development of ITBL [1, 12, 52]. Analogously, re 
oxigenation and warm ischemia time also seem to be involved in the pathogenesis of the 
disease [27, 53]. Moreover, delayed re-arterialization of the graft may favor the occurrence of 
ITBL [2, 43, 54]. Therefore, the time period between explantation and reperfusion should be 
as short as possible under an adequate preserving temperature. 
6.2 Epidemiologic aspects 
The use of donor organs particularly older than 60 years is associated with ITBL [1, 31]. 
Furthermore, patients with advanced liver disease before transplantation seem to be more 
likely to develop ITBL compared to lower Child and Pugh-stages [1]. Deteriorated pre- 
operative status, early biliary complications and “small-for-size” transplantation are 
currently suspected to contribute to the occurrence and progression of ITBL [55]. Further 
potential confounders regarding the recipient (age, gender) do not seem to play a significant 
role in the pathogenesis of ITBL [1]. Interestingly, the incidence of ITBL seems to be higher 
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in patients undergoing living-donor-liver-transplantation of the right lobe [14, 56]. A 
differentiated selection of donor and recipient simply based on epidemiological data might 
help to avoid the accumulation of predisposing factors. 
6.3 Reconstructive technique 
In spite of ischemia reduction in LDLT-recipients, the increased susceptibility may be 
explained by the difference of biliary reconstruction, which is performed as hepatico- 
jejunostomy compared choledocho-choledochostomy in patients receiving whole organs. 
Bacterial ascension leading to cholangitis may negate the expected advantage of reduced 
cold ischemia time [55, 57]. Thus, the main advantages of choledocho-choledochostomy 
comprise the integrity of anatomic barrier regarding the reflux of intestinal flora to a great 
extent, better technical feasibility than Roux-en-Y and physiological condition for an 
endoscopic access [35, 58]. Choledocho-choledochostomy in side-to-side-technique seems to 
be the most reliable reconstructive method [22, 59]. Particular attention should be paid to 
periductal tissue. The integrity of the periductal vascular plexus must be guaranteed. 
6.4 Preservation and perfusion 
Among the two commonly used preservation solutions, the UW-solution (University of 
Wisconsin) has been shown to increase the risk of ITBL-occurrence compared to the less 
viscous HTK-solution [1, 60, 61]. Furthermore, retrograde graft perfusion via vena cava 
seems to exhibit a negative effect on the development of ITBL, whereas, additional back-
table arterial graft perfusion lowers the risk of ITBL [1, 62]. Regular gravity arterial 
perfusion has been suspected to be insufficient to flush the arterial system of the biliary tract 
completely [1]. All inflammatory active and potential fibrogenic blood compounds should 
be removed before transplantation. Therefore, additional arterial pressure perfusion 
preferably with a HTK-solution should be performed [1]. 
6.5 Toxicity of the bile 
Bile acids may exhibit their toxic potential on vulnerable cholangiocellular epithelium and 
therefore, be relevant in the pathogenesis of ITBL. In contrast to hydrophilic bile salts, 
hydrophobic compounds are cytotoxic [29, 63]. Prolonged warm ischemia is associated with 
the formation of an unfavorable bile salt-to-phospholipid ratio subsequently contributing to 
bile duct injury [51]. The exposure of biliary epithelium to toxic bile compounds can be 
minimized by the careful retrograde flushing of the bile duct with perfusion solution during 
liver explantation, strictly avoiding bile duct ligation [27]. 
6.6 Genetic aspects 
Highly variable rates of functional impairment suggest the existence of endogenous risk 
compounds both in natural and post-transplant settings of the disease. The maximal 
capacity to produce different levels of cytokines in response to noxious stimulation has been 
shown to be under genetic control and differs among liver graft recipients. Chemokine 
receptor 5delta32 polymorphism has been suggested to increase the incidence of ITBL and to 
reduce patient survival [64]. As demonstrated in a rat model, genetic polymorphisms of the 
multidrug resistance protein 2 (Mdr-2), which is involved in the regulative processes of bile  
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fluid composition, may negatively affect bile salt to phospholipid ratio, and contribute to 
cholangiocellular vulnerability [27]. Although, the exact mechanism is not yet understood in 
detail, both, donor and recipient genetics may interact. The expression of disease-related 
effectors may be individual and tissue dependant [65]. In spite of the pathogenetic 
heterogeneity, the role of genetic variants in the development of ITBL should be 
investigated in large scale multi-center trials regarding diagnostic, therapeutic and 
predictive values. Currently, no conclusion can be made considering ITBL-management. 
6.7 External bile drainage 
Internal or external drainage of the bile in the early postoperative period may have an 
impact on the development of non-anastomotic strictures [34]. Although the external bile 
drainage via T-tube is currently a subject of controversy, T-tube insertion has been 
demonstrated to reduce the risk for ITBL in several randomized studies and recent a meta- 
analysis [23, 34, 66-69]. T-tube may prevent the occurrence of ITBL and potentially reduces 
long-term morbidity especially regarding late strictures [34, 67]. The arterial perfusion of the 
biliary tract, which is at risk in transplant setting, remains one of the most important 
determinants of ITBL. Manipulations on ligamentum hepatoduodenale may affect the 
function of sphincter Oddi and result in discoordinated motility of the biliary tract. [6, 33]. 
Sphincter spasms may contribute to bile flow obstruction as demonstrated by elevated intra-
biliary pressure after LT, which has been observed to be twice as high (up to 20mm H2O) as 
in livers without dyskinesia of the biliary tract (10mm H2O) (unpublished data). Elevated 
intra-biliary pressure may aggravate blood supply, which is predominantly maintained by 
periductal arterial plexus [20, 70]. Any kind of tools, which are capable of pressure reduction 
(intra-operative insertion of T-tube, pre-transplant sphincterotomy) should be regarded as 
helpful methods for ITBL-prevention. Moreover, T-tube has been demonstrated to prevent 
bile leakage in split-liver transplantation via pressure reduction [71]. Therefore, T-tube 
should be used in biliary tract reconstruction as side-to-side choledocho-choledochostomy 
during LT, in order to avoid the negative effect of elevated pressure and theoretically 
increased toxic impact of bile acids [59, 66]. 
6.8 Immunological aspects 
Although a rejection is likely to induce significant damage in the biliary tree, no clear 
evidence is currently available about the role in the development of ITBL except for chronic 
ductopenic rejection [1, 2]. Compared to sinusoidal liver parenchyma, cholangiocytes are 
more vulnerable and seem to have less potential for regeneration [15]. Triggered by 
insufficient immunosuppression, immune complexes may induce inflammatory and fibrotic 
processes in tiny arteries of the biliary tract, thus forwarding ischemic damage [47, 72, 73]. 
Unfortunately, only inconsistent data are currently present regarding the role of 
immunosuppression mode and CMV-infection in the development of ITBL [1, 2]. Therefore, 
these factors should be re-evaluated in larger cohorts based on multi-center concepts. In 
contrast to patients transplanted due to virally or metabolically induced liver disease, the 
immunosuppression in patients with autoimmune component should be sufficient and 
preferably stronger according to current standards, in order to prevent rejection processes. 
ABO-incompatibility should be completely avoided because the antigens of the blood-type 
system may also be expressed on biliary epithelium and serve as immunologic target for 
preformed blood group antibodies. 
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7. Conclusion and future prospective 
The development of non-anastomotic strictures in the biliary tract after LT is a serious post-
transplant complication, potentially compromising the initial success of the surgical 
treatment of patients with advanced liver disease. ITBL represents a post-transplant biliary 
disease, which cannot be explained by vascular damage or PSC-recurrence. Due to a strong 
similarity to ischemia-induced biliary injury, and ischemia-reperfusion injury, disrupted or 
disturbed microcirculation seems to be the main pathogenic column. Most probably, ITBL 
develops in a highly individual manner from ischemic injury acquired in the peri-operative 
period predominantly before LT in spite of the restored arterial blood supply. The integrity 
of arterial perfusion separates ischemia-related strictures from IBL, playing a central role in 
the definition of the disease. In spite of the significant correlation between ITBL-incidence 
and pre-transplant ischemia, current definition of ITBL, based on radiological evidence of an 
undisturbed graft perfusion, does not depict the actual extent of ischemic damage. The 
assessment of ischemia- and reperfusion-related alterations should be therefore performed 
at the cellular level. Moreover, additive ischemic damage caused by thrombosis of the 
hepatic artery, occurring in about 10%, may contribute to the total cellular hypoxygenation. 
Not assessable pathogenic effect of prolonged ischemia in patients after a successful 
thrombectomy and restitution of blood supply may increase the risk for the development of 
ITBL in spite of formally intact vascular status. Unfortunately, current definition of ITBL 
does not allow a clear categorization of this subpopulation. Remarkable similarities of ITBL 
and PSC or biliary pathologies in non-transplant setting resulting from chronic 
inflammation, fibrotic remodeling with a secondary loss of organ function seem to be 
uniform. Although patients transplanted due to PSC may also develop ITBL, no diagnostic 
method can definitively guarantee the differentiation between ITBL and PSC-recurrence. 
Therefore, the relatively high chance of misclassification regarding patient cohorts 
undergoing statistical analysis of etiologic risk factors including epidemiologic aspects may 
explain differences in ITBL-incidence reported in the literature [10, 74]. After the exclusion 
of PSC-patients and managed post-transplant vascular complications the incidence of ITBL 
is supposed to be much lower than 20% [27, 40, 47, 75]. Recent analysis performed in a 
homogenous cohort after the exclusion of patients with prolonged re-arterialization and 
PSC-recurrence, seems to reflect the incidence of ITBL (3.9%) most accurately [1]. Therefore, 
a precise and uniform definition of the disease, awareness of risk factors and potential 
confounders may help to understand the mechanism of ITBL-development, prevent its 
occurrence and progression, select and initiate an adequate treatment. Any progress in the 
understanding of the development and clinical course of post-transplant biliary strictures 
should be welcome at a time of donor organ shortage. 
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1. Introduction 
Liver transplantation is the only potentially curative treatment for patients with end-stage 
liver disease or unresectable primary hepatic tumors. Biliary atresia accounts for 
approximately 40% of liver transplant performed in children in the United State (Carter et 
al, 2006). Intra-hepatic cholestasis and inborn metabolic errors resulting in cirrhosis 
constitute the second most common group. Progressive liver failure and finally acute liver 
failure following hepatitis or drug toxicity represent a small referral group. 
First human liver transplantation was performed by Starzl in 1963 at the University of 
Colorado Health Science Center on a three years old patient with biliary atresia and the 
patient died before the completion of the surgery (Starzl et al, 1963). First successful liver 
transplantation was performed in 1967 on an eighteen months old patient with malignant 
liver tumor and the patient survived for 400 days before she succumbed from disseminated 
malignancy (Carter et al, 2006). Survival after pediatric liver transplantation has improved 
significantly in recent decades because of the advances in surgical techniques, 
immunosuppressive therapy, and peri-operative care (Jain et al, 2002). Pediatric liver 
transplant recipients also have benefited from major technologic advances in diagnostic and 
interventional radiology. Radiology has acquired a key role in both pediatric and adult liver 
transplantation programs because it allows early detection and prompt treatment of post-
transplantation vascular and nonvascular complications, helping to improve graft and patient 
survival and obviating surgical revision or repeat transplantation in most cases (Amesur & 
Zajko, 2006; Rose et al, 2001; Sze & Esquivel, 2002). Various interventional radiology 
procedures may be applied during the follow-up of pediatric liver transplant recipients to 
detect and diagnose graft disease and to treat vascular and biliary complications. The 
interventional radiology procedures most commonly used in this context include 
percuntaneous and transjugular liver biopsies for the diagnosis of graft disease; angioplasty 
and stent placement for the treatment of vascular stenosis or occlusion; biliary drain 
placement for the treatment of biliary strictures; coil embolization and stent graft placement 
for the treatment of pseduoaneurysm and artriovenous fistulas. Brief description of the 
surgical technique for split liver transplantation, the technical considerations involved in 
interventional radiology procedures, the expected results, and the possible complications 
are described in details in this chapter. 
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interventional radiology procedures, the expected results, and the possible complications 
are described in details in this chapter. 
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2. Surgical technique for split liver transplantation 
Reduced liver technique or split liver transplantation represents a major advance in liver 
transplantation that significantly reduced the waiting period for liver transplantation. 
Most pediatric liver transplantations are performed today by using left lateral segmental 
(II&III) transplantation or so called split liver transplantation (Fig. 1), a technique that 
accommodates the needs of pediatric patients without depleting the pool of organs available 
for adult patients with excellent patient and graft survival rate (90 and 87% respectively) 
(Deshpande et al, 2002) . Radiologist should be familiar with the surgical techniques used in 
the transplantation such as Piggy back technique for the anastomosis between the inferior 
vena cava of the recipient and the hepatic veins of the graft, end to end or interposition 
conduit for the hepatic arterial and the portal venous anastomosis, and Roux-en-y technique 
for the hepaticojejunostomy biliary anastomosis (Fig. 2). 
 
Fig. 1. Schematic diagram of split liver to provide two grafts from single donor, left lateral 
segment for a child and the right lobe for an adult recipient 
  
Fig. 2. Schematic diagram illustrating orthotopic segmental liver transplantation. Piggy back 
hepatic vein to IVC anastomosis. Hepatic arteries and portal veins end to end anastomosis. 
Roux-en-y hepaticojejunostomy biliary anastmosis 
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3. Imaging spectrum and image-guided procedures for the management of 
complications after split liver transplantation 
3.1 Organ rejection 
Organ rejection develops in about 50% of patients, but improved immunosuppressive 
medications permit successful management of this problem in most cases (Zalasin et al, 
1998). The ultrasound appearances of acute rejection are nonspecific, and the only 
identifiable abnormality is heterogeneity of the liver parenchyma, which may, however, 
have other causes (Crossin et al, 2003; Marder et al, 1989; Zalasin et al, 1998). The role of 
imaging consists of excluding these other possible causes, which can manifest with clinical 
signs and symptoms similar to those of acute rejection (Crossin et al, 2003). The diagnosis of 
acute rejection, one of the most serious complications following liver transplantation, is 
established by graft biopsy and histologic study (Nghiem, 1998). 
3.1.1 Percutaneous liver biopsy 
Percutaneous ultrasonography (US)-guided random liver biopsy is frequently requested 
after pediatric liver transplantation. Any alteration in liver function test results that cannot 
be explained on the basis of findings at diagnostic imaging requires a liver biopsy to exclude 
organ rejection. US guidance of biopsy is necessitated by the small volume of the 
transplanted liver, especially in split-liver transplantation, and the need to avoid perforating 
the bowel, other adjacent organs, and important intrahepatic vascular structures. If a 
coagulation defect is present (eg, platelet count of less than 50 × 1000 per microliter, 
prothrombin activity less than 50% of the normal level), patients receive an infusion of 
platelets, fresh frozen plasma, or both. If the presence of massive perihepatic ascites make 
liver biopsy infeasible, a percutaneous drainage catheter might be placed first to eliminate 
the ascites. The use of a coaxial technique in pediatric patients also has been described. In 
this procedure, a coaxial sheath is used to inject slurry of microfibrillar collagen into the 
needle tract to reduce the risk of bleeding after biopsy (Hoffer, 2000). An antibiotic is 
administered prophylactically before the procedure. Core biopsies are performed by using 
an 18-gauge needle and monitored anesthesia care with additional local anesthesia 
administered at the site selected for puncture. An anterior approach is usually the only one 
possible in patients with a split-liver transplant. After the biopsy, manual compression is 
applied to the puncture site for ten minutes. Possible major complications of percutaneous 
liver biopsy are bleeding, hemobilia, arterioportal fistula, and infection; these have been 
reported in 4.6% of pediatric patients who have undergone the procedure (Amaral et al, 
2006).  
3.1.2 Transjugular liver biopsy 
The transjugular approach is widely used for random liver biopsies in adult patients with 
massive perihepatic ascites, severe coagulopathy, or both because it is associated with a 
lower rate of bleeding complications than is percutaneous biopsy (Furuya, 1992). The 
transjugular technique incurs a lower risk of hemorrhage because a biopsy specimen is 
acquired through the hepatic vein and any bleeding from the puncture site remains within 
the vascular space. In addition, if there are clinical signs of portal hypertension, the hepatic 
vein pressure gradient can be measured during the transjugular biopsy procedure. The use 
 
Liver Transplantation – Technical Issues and Complications 
 
244 
2. Surgical technique for split liver transplantation 
Reduced liver technique or split liver transplantation represents a major advance in liver 
transplantation that significantly reduced the waiting period for liver transplantation. 
Most pediatric liver transplantations are performed today by using left lateral segmental 
(II&III) transplantation or so called split liver transplantation (Fig. 1), a technique that 
accommodates the needs of pediatric patients without depleting the pool of organs available 
for adult patients with excellent patient and graft survival rate (90 and 87% respectively) 
(Deshpande et al, 2002) . Radiologist should be familiar with the surgical techniques used in 
the transplantation such as Piggy back technique for the anastomosis between the inferior 
vena cava of the recipient and the hepatic veins of the graft, end to end or interposition 
conduit for the hepatic arterial and the portal venous anastomosis, and Roux-en-y technique 
for the hepaticojejunostomy biliary anastomosis (Fig. 2). 
 
Fig. 1. Schematic diagram of split liver to provide two grafts from single donor, left lateral 
segment for a child and the right lobe for an adult recipient 
  
Fig. 2. Schematic diagram illustrating orthotopic segmental liver transplantation. Piggy back 
hepatic vein to IVC anastomosis. Hepatic arteries and portal veins end to end anastomosis. 
Roux-en-y hepaticojejunostomy biliary anastmosis 
Minimal Invasive (Endovascular and Percutaneous)  
Treatment of Post Liver Transplantation Complications in Pediatrics 
 
245 
3. Imaging spectrum and image-guided procedures for the management of 
complications after split liver transplantation 
3.1 Organ rejection 
Organ rejection develops in about 50% of patients, but improved immunosuppressive 
medications permit successful management of this problem in most cases (Zalasin et al, 
1998). The ultrasound appearances of acute rejection are nonspecific, and the only 
identifiable abnormality is heterogeneity of the liver parenchyma, which may, however, 
have other causes (Crossin et al, 2003; Marder et al, 1989; Zalasin et al, 1998). The role of 
imaging consists of excluding these other possible causes, which can manifest with clinical 
signs and symptoms similar to those of acute rejection (Crossin et al, 2003). The diagnosis of 
acute rejection, one of the most serious complications following liver transplantation, is 
established by graft biopsy and histologic study (Nghiem, 1998). 
3.1.1 Percutaneous liver biopsy 
Percutaneous ultrasonography (US)-guided random liver biopsy is frequently requested 
after pediatric liver transplantation. Any alteration in liver function test results that cannot 
be explained on the basis of findings at diagnostic imaging requires a liver biopsy to exclude 
organ rejection. US guidance of biopsy is necessitated by the small volume of the 
transplanted liver, especially in split-liver transplantation, and the need to avoid perforating 
the bowel, other adjacent organs, and important intrahepatic vascular structures. If a 
coagulation defect is present (eg, platelet count of less than 50 × 1000 per microliter, 
prothrombin activity less than 50% of the normal level), patients receive an infusion of 
platelets, fresh frozen plasma, or both. If the presence of massive perihepatic ascites make 
liver biopsy infeasible, a percutaneous drainage catheter might be placed first to eliminate 
the ascites. The use of a coaxial technique in pediatric patients also has been described. In 
this procedure, a coaxial sheath is used to inject slurry of microfibrillar collagen into the 
needle tract to reduce the risk of bleeding after biopsy (Hoffer, 2000). An antibiotic is 
administered prophylactically before the procedure. Core biopsies are performed by using 
an 18-gauge needle and monitored anesthesia care with additional local anesthesia 
administered at the site selected for puncture. An anterior approach is usually the only one 
possible in patients with a split-liver transplant. After the biopsy, manual compression is 
applied to the puncture site for ten minutes. Possible major complications of percutaneous 
liver biopsy are bleeding, hemobilia, arterioportal fistula, and infection; these have been 
reported in 4.6% of pediatric patients who have undergone the procedure (Amaral et al, 
2006).  
3.1.2 Transjugular liver biopsy 
The transjugular approach is widely used for random liver biopsies in adult patients with 
massive perihepatic ascites, severe coagulopathy, or both because it is associated with a 
lower rate of bleeding complications than is percutaneous biopsy (Furuya, 1992). The 
transjugular technique incurs a lower risk of hemorrhage because a biopsy specimen is 
acquired through the hepatic vein and any bleeding from the puncture site remains within 
the vascular space. In addition, if there are clinical signs of portal hypertension, the hepatic 
vein pressure gradient can be measured during the transjugular biopsy procedure. The use 
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of combined US and Fluoroscopic guidance during transjugular hepatic biopsies in pediatric 
patients has been reported to help reduce the risk of capsule perforation (Habdank, 2003). 
Complications of this biopsy procedure, which have been reported in 3%–11% of cases, 
include subcapsular hematoma, intraperitoneal bleeding, Subclavian artery puncture, 
pneumothorax, and hemothorax (Furuya, 1992; Kaye et al, 2000; Habdank, 2003). Transjugular 
random liver biopsy with catheterization of the right hepatic vein also has been reported in 
pediatric whole-liver transplant recipients (Habdank, 2003). Prophylactic antibiotics are 
routinely administered before the biopsy procedure, and an infusion of platelets or fresh 
frozen plasma is administered if coagulation defects are present. The small size of the liver 
in pediatric patients with a left lateral transplant and patient weight of less than 15 kg are 
considered relative contraindications to the procedure. 
3.2 Vascular complications and treatment 
Vascular complications that occur after pediatric liver transplantation are associated with 
high rates of morbidity, graft loss, and mortality (Sieders et al, 2000). These complications 
may involve the hepatic artery, hepatic vein, portal vein, or inferior vena cava. Most 
vascular complications appear within 3 months after transplantation. Clinical manifestations 
vary from mildly elevated values on hepatic function tests to fulminant hepatic failure 
(Bergey et al, 1998; Furuya, 1992; Hasegawa et al, 2002; Hoffer, 2000). Because their clinical 
manifestations often are indistinguishable from those of biliary complications, graft rejection, 
graft dysfunction, and infection, imaging is necessary for diagnosis. Color Doppler US, 
Multidetector computed tomography (CT), and magnetic resonance (MR) imaging all are 
useful for the diagnosis and follow-up. US is the primary screening modality used for the 
detection of vascular complications and imaging by Doppler US starts intra-operatively, in 
the ICU and twice daily for the first three days. The normal Doppler US parameters should 
include hepatopetal (toward the liver), pulsatile, low resistant flow in the hepatic artery 
with systolic velocity of more than 30 cm/s (fig. 3a), hepatopetal flow in the portal vein  
with velocity of at least 10 cm/s (fig. 3b) and phasic hepatofugal (outward the liver)  
 
Fig. 3. Normal Doppler US study of the hepatic artery and portal vein after liver 
transplantation. (A) Pulsatile, low resistant hepatopetal flow in hepatic artery with velocity 
of 58.6 cm/s. (B) Phasic hepatopetal flow in portal vein with velocity of 18.5 cm/s 
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flow in the hepatic veins. MR angiography is performed to confirm abnormalities 
demonstrated at US or in patients in whom the US study is suboptimal. CT.scan is less 
frequently used today in this patient population due to the concern about the high radiation 
dose associated with it. Conventional vascular studies are currently reserved for 
endovascular treatment of these complications. 
3.2.1 Hepatic artery stenosis 
Hepatic artery stenosis occurs in 11%–20% of patients who have undergone pediatric liver 
transplantation (Moray, 2005). Most hepatic artery stenosis arise at the anastomosis site 
within 3 months after transplantation and are due to the small caliber of the arteries or to 
arterial injury by a vascular clamp during transplantation. However, nonanastomotic 
stenosis may occur in cases of graft rejection or necrosis. Early diagnosis and intervention 
may help to reduce ischemic damage to the graft, consequent bile duct damage, and 
progression to hepatic artery thrombosis. Doppler US is the imaging modality of choice for 
diagnosis and follow-up. The reported sensitivity of Doppler US for the detection of hepatic 
artery stenosis is 80%–90% (Abbasoglu et al, 1997; Crossin et al, 2003; Kok et al, 1998). 
Spectral broadening and focal accelerated velocity greater than 2 m/sec (Crossin et al, 2003; 
Nghiem et al, 1996; Platt et al, 1997) at the site of arterial anastomosis indicate stenosis. 
However, the site of narrowing is often difficult to identify by US due to overlying bowel 
gas especially in conduit graft, and the diagnosis is usually made on the basis of the Doppler 
US findings obtained distal to the stenosis. Intrahepatic arterial waveforms distal to the 
stenosis display a tardus parvus pattern with a decreased resistive index (<0.5) and 
prolonged acceleration time (80 msec) (Fig. 4a) (Dodd et al, 1994; Platt et al, 1997; Vignali et 
al, 2004). Associated turbulences distal to the stenosis are commonly observed at color 
Doppler US (Crossin et al, 2003; Platt et al, 1997). A tardus parvus pattern may be a normal 
finding during the first 72 hours after transplantation due to edema at the anastomotic site 
(Kok et al, 1998). In these cases, serial US will reveal a normal waveform 3–4 days after 
transplantation. MR angiography offers an alternative noninvasive technique for confirming 
the stenosis and for better evaluation of the anastomosis and the entire hepatic artery (Ito et 
al, 2000; Vignali et al, 2004). Conventional arteriography is currently reserved for 
endovascular treatment of the stenosis (Boraschi& Donati, 2004; Vignali et al, 2004). Early 
hepatic artery stenosis (less than two weeks post transplantation) should be treated 
surgically because endovascular treatment has the risk of suture line rupture. The use of 
percutaneous transluminal angioplasty with or without stent placement to treat hepatic 
artery stenosis in adult and pediatric liver transplant recipients have been reported 
(Hashikura et al, 2001; Kok et al, 1998; Nghiem et al, 1996). Possible complications that have 
been described include dissection, pseudoaneurysm, and rupture of the hepatic artery. 
When Doppler US or MRA findings are suggestive of hepatic artery stenosis, hepatic 
arteriography is performed by using a transfemoral approach and a standard 4-F 
angiographic catheter with monitored anesthesia care or general anesthesia. A coaxial 
microcatheter is then advanced through the stenosis, and the trans-stenotic pressure 
gradient is measured. If a significant pressure gradient is present (>10 mm Hg), angioplasty 
is performed. Before angioplasty, 0.2 mg nitroglycerin and 100 IU heparin per kilogram of 
body weight are infused into the hepatic artery to reduce the risks of spasm and thrombosis. 
A 6-F guiding catheter is inserted, and a balloon catheter is advanced over a 0.018- or 0.014-
inch stiff wire. The balloon diameter varies in accordance with the diameter of the hepatic 
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Liver Transplantation – Technical Issues and Complications 
 
248 
artery (Figs. 5&6). Procedural success is defined as the reduction or absence of stenosis at 
arteriography, accompanied by a significant reduction of the trans-stenotic pressure 
gradient. Angioplasty is technically successful in about 80% of the cases with restenosis rate 
of 30-60%. The long-term patency of stents is unknown; for this reason, stent placement in 
pediatric patients is recommended only if angioplasty fails or if complications such as 
hepatic artery dissection or rupture ensue. Doppler US is performed the day after the 
procedure to obtain baseline measurements of the intra and extrahepatic arterial resistive 
index (RI) and systolic acceleration time for comparison with follow up measurements (Fig. 
4c). 
  
Fig. 4. Early hepatic arterial stenosis (Surgically treated). (A) Doppler US performed day 5 
post liver transplant shows tardus parvus waveform and low acceleration times in the right, 
left and main hepatic arteries. (B) Catheter angiogram, subtracted and un-subtracted images, 
confirms the stenosis at the proper hepatic artery. (C) post surgical revision follow up 
Doppler US reveals normal hepatic arteries wave forms 
  
Fig. 5. (A) Celiac angiogram demonstrates sever stenosis at the anastomosis (arrow).  
(B) Hepatic artery stenosis (arrow) confirmed with selective proper hepatic angiogram with 
a small outpouching due to a ligated gastrodoudenal artery (arrowhead). (C) Post angioplasty 
with no significant residual stenosis 
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Fig. 6. Hepatic artery stenosis treated with stent. (A,B,C) angiogram of the aorta-hepatic 
artery conduit with persistent severe stenosis (arrow in A) in the proper HA. As stenosis 
persists after angioplasty (arrowhead in B), it was treated with a 4 x 20 mm balloon 
expandable stent (arrow in C). Stenosis is resolved in post stenting angiogram (C).  
(D) Follow up MRA demonstrates stent artifact in the proper hepatic artery with adequate 
flow proximal and distal to the stent 
3.2.2 Hepatic artery thrombosis 
In the past, hepatic artery thrombosis was the most common and dreads vascular complication 
of orthotopic liver transplantation, with a prevalence of 4%–12% in adult recipients, a 
prevalence of up to 40% in children, and a mortality rate of 50%–58% (Mazzaferro et al, 
1989). Microsurgical techniques have improved these results, and the prevalence of hepatic 
artery thrombosis during the first thirty days after transplantation has been reduced to 
approximately 5% in whole liver transplantation (Settmacher et al, 2000). However, hepatic 
artery thrombosis is more common in split or living donor liver transplantation (Ghobrial et 
al, 2000; Hashikura et al, 2001; Katyal et al, 2000). Associated risk factors include prolonged 
cold ischemia time of the donor liver, previous orthotopic liver transplantation, significant 
differences in caliber between the donor and recipient hepatic arteries, an interposition 
conduit for the anastomosis, small donor or recipient vessels, acute rejection, ABO blood 
type incompatibility, and cytomegalovirus infection (Crossin et al, 2003; Dodd, 1995; 
Vivarelli et al, 2004). As in hepatic artery stenosis, clinical manifestations vary considerably, 
ranging from mild elevation of liver enzyme levels to delayed bile leak, bile duct stricture or 
ischemic changes, or fulminant hepatic necrosis (Ametani et al, 2001; Dodd et al, 1994; Ito et 
al, 2000). Patency of the hepatic artery is vital for long-term survival of the graft because this 
artery is the sole blood supply to the biliary epithelium of the transplanted liver, unlike in a 
native liver (Crossin et al, 2003; Kaneko et al 2004). As a result, complete occlusion of the 
hepatic artery results in infarction or necrosis of the liver parenchyma and may lead to 
fulminant hepatic failure in the early post-transplantation period. Doppler US allows correct 
identification of hepatic artery thrombosis in up to 90% of cases (Crossin et al, 2003; Garc´a-
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Criado et al, 2003; Glockner & Forauer 1999; Nghiem et al, 1996). At doppler US 
examination, there is usually complete absence of both proper hepatic and intrahepatic 
arterial flow (Chong, 2004; Kok T et al, 1998; Nghiem et al, 1996). The initial doppler 
waveform of the hepatic artery may be normal, with follow-up doppler US images showing 
a progressive decrease in systolic and diastolic flow, followed by absent diastolic flow, 
dampening of the systolic peak, and, finally, total loss of the hepatic waveform (Nolten & 
Sproat, 1996). After thrombosis, arterial collateral vessels can develop, especially in children, 
and intrahepatic flow may be identified. Nevertheless, the intra-hepatic arterial waveform 
will display a tardus parvus pattern with an acceleration time greater than 80 msec and a 
resistive index less than 0.5 (Chong, 2004; Crossin et al, 2003; Dodd, 1995). Therefore, a 
complete absence of flow in the main hepatic artery and a tardus parvus pattern in the 
intrahepatic branches of the hepatic artery are highly suggestive of hepatic artery 
thrombosis and should be confirmed with other imaging techniques (Hall et al, 1990). MR 
angiography is a useful and noninvasive method for evaluating the patency of the hepatic 
artery and may play an important role in identifying patients who require hepatic 
angiography (Glockner et al, 2000; Ito et al, 2000). When thrombosis is present, MR 
angiography accurately demonstrates the location of the thrombus by showing arterial 
opacification up to the thrombus, abrupt cutoff of the hepatic artery at the thrombus, and 
lack of opacification of distal branches (Fig. 7a) (Glockner et al, 2000; Ito et al, 2000).  
 
Fig. 7. Hepatic artery thrombosis (A) MRA demonstrating common hepatic artery (arrow) 
visualized to the level of the anastomosis, and complete occlusion of the hepatic artery 
beyond the anastomosis. (B) Selective celiac angiogram confirms hepatic artery thrombosis 
Angiography is useful when fibrinolytic endovascular therapy is indicated (Fig. 7b). With 
early diagnosis, thrombectomy and revision of the transplant can be used to salvage the 
graft. Thrombolysis has high risk of hemorrhage in early hepatic artery thrombosis, 
especially if associated with liver infarction. If occlusion occurs at a late stage, the graft may 
survive with the support of portal venous flow, but there may be necrosis of the bile duct 
epithelium and consequent biliary strictures or leaks (Chong, 2004; Lorenz et al, 2001). Late 
hepatic artery thrombosis can be treated safely with thrombectomy, fibrinolysis, angioplasty 
and stenting Fig. 8. 
3.2.3 Hepatic artery pseudoaneurysms (HAP) 
Hepatic artery pseudoaneurysm is a rare complication after liver transplantation seen mostly 
at the donor-recipient anastomosis and less often at the ligation site of the gastrodoudenal 
artery and those are likely related to infection, technical failure or biliary leakage. Intrahepatic 
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pseudoaneurysm can also be seen and may be related to percutaneous biliary procedures or 
liver biopsies. Mycotic hepatic artery pseudoaneurysm can fistulize to the portal vein or 
bilary tree and presents with hemobilia, gastrointestinal bleeding or hemoperitoneum. 
Endovascular treatment may be performed by transcatheter or percutaneous coil 
embolization or exclusion of the pseudoaneurysm with covered stent (Figs. 9&10). Surgical 
excision and revascularization using bypass graft can also be performed. 
 
Fig. 8. Management of late hepatic artery thrombosis (A) Pre- and (B) Post-thrombolysis 
hepatic angiograms demonstrating recanalization of the hepatic artery (arrow). Sever 
stenosis (arrowhead) is seen at the hepatic artery bifurcation. (C) The stenosis was 
angioplastied with a 5 x 20 mm balloon (arrow) with no residual stenosis seen in the final 
angiogram (D) 
3.2.4 Hepatic vein stenosis\thrombosis 
Hepatic vein stenosis with resultant outflow insufficiency is a major postoperative 
complication that leads to graft failure in 5% of pediatric liver transplant recipients; most 
often in those with a partial liver graft (Buell et al, 2002) and Piggy back hepatic venous 
anastomosis. Hepatic veins stenosis usually produce hepatic congestion, refractory ascites 
and alteration of liver function test results. Transjugular or transfemoral angioplasty or 
metallic stent placement usually is selected as the first-line treatment for this complication 
(Cheng et al, 2005; Lorenz et al, 2006). In pediatric patients, balloon dilation is the preferred 
treatment choice because the long-term patency of metallic stents is unknown and repeat 
transplantation is always possible. Metallic stent placement should be reserved for the 
treatment of persistent hepatic vein stenosis that is unresponsive to multiple angioplasties. 
The persistence of a pressure gradient of more than 5 mm Hg between the hepatic vein and 
the right atrium after several angioplasties is an indication for metallic stent placement 
(Lorenz et al, 2006). Good technical and clinical success rates are reported after hepatic veins 
angioplasty and stenting with patency rates ranging from 70% at 3 months to 50% at 36 
months (Lorenz et al, 2006). Long term patency may require repeated interventions. In adult 
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and pediatric patients in whom transjugular or transfemoral recanalization of the stenotic or 
occluded hepatic vein stenosis has failed, the use of a percutaneous transhepatic approach 
or a combined transhepatic-transjugular approach has been reported (Kubo et al, 2006; 
Miraglia et al, 2007). For the transhepatic approach, preprocedural drainage of ascites and 
postprocedural embolization of the transhepatic tracts are, in our opinion, mandatory to 
reduce the risk of bleeding. Hepatic vein stenosis usually occurs at the anastomosis site; less 
frequently, an intrahepatic stenosis is found that is likely due to injury of the hepatic vein 
during a previous surgical or percutaneous procedure (eg, biopsy or biliary catheter 
placement). Treatment is performed with angioplasty or metallic stent placement (Fig. 11). 
Doppler US should be performed the day after the procedure for a baseline evaluation of the 
hepatic vein velocity and flow spectrum, which are compared with the findings at follow up 
Doppler US evaluations. Imaging follow-up is performed every 3 months in the first post 
procedural year or at any occurrence of ascites or any alteration in liver function test results,  
  
Fig. 9. Management of hepatic artery pseudoaneurysms (HAP). (A,B,C) Extrahepatic 
aneuryusm: (A) MRA and (B) graft hepatic angiogram revealing an outpouching (HAP) at 
the lateral aspect of the graft (arrowhead). (C) After stent graft deployment, angiogram 
reveals no further filling of the Pseudoaneurysm. (D,E,F) Intrahepatic HAP s/p ERCP (D&E) 
catheter angiography shows a bilobed collection of contrast from the right hepatic artery 
(arrow) in this patient with hemobilia. (F) Post-coil embolization (arrowhead), no filling of 
the HAP is seen 
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Fig. 10. Management of hepatic arteriovenous fistula. (A) Right hepatic angiogram reveals 
filling of the portal vein (arrowhead) and the hepatic artery (arrow) at the same time.  
(B) Post coil embolization reveals minimal filling of the fistulous communication (arrow) 
 
Fig. 11. Management of hepatic vein stenosis\thrombosis. (A) Doppler US reveals thrombus 
in the left hepatic vein (arrow) with abnormal monophasic flow. (B) Hepatic venogram 
reveals patent hepatic veins-IVC anastomosis and non-occlusive thrombus (arrow) in the 
hepatic vein confluent. (C) After local thrombolysis, thrombectomy and venoplasty, 
improved flow with residual thrombus (arrow) 
both being suggestive of stenosis recurrence. If clinical or imaging signs of recurrent stenosis 
are present, hepatic vein phlebography with trans-stenotic pressure gradient measurement 
is recommended. 
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both being suggestive of stenosis recurrence. If clinical or imaging signs of recurrent stenosis 
are present, hepatic vein phlebography with trans-stenotic pressure gradient measurement 
is recommended. 
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3.2.5 Inferior vena cava stenosis\thrombosis 
Inferior Vena Cava (IVC) stenosis is more common in the pediatric population, especially 
among recipients of partial liver transplants, including living donor liver transplants, 
reduced-size liver transplants, and split liver transplants (Carnevale et al, 2004; Egawa et al, 
1997). IVC stenosis may occurs acutely secondary to an anastomotic size discrepancy or 
suprahepatic caval kinking from organ rotation. Delayed caval stenosis may occur 
secondary to fibrosis, a chronic thrombus, or neointimal hyperplasia (Carnevale et al, 2004; 
Katyal et al, 2000). Clinical manifestations include pleural effusions, hepatomegaly, ascites, 
and lower extremity edema. A significant suprahepatic caval stenosis may result in reversed 
flow or absence of phasicity in the hepatic veins (Crossin et al, 2003). Nevertheless, 
monophasic waveforms are not specific for hepatic vein stenosis (Chong, 2004). A 
monophasic flat waveform with a relatively low average peak velocity in the hepatic vein 
(mean, 11 cm/sec) is a common finding. Sometimes, graft growth and twisting are causes of 
IVC pseudostenosis (Ametani et al, 2001), which may increase or disappear depending on 
the patient’s posture. Hemodynamically significant IVC stenosis can be differentiated from  
pseudostenosis on the basis of the presence of features of Budd-Chiari syndrome and 
Doppler velocity measurements. IVC stenosis and hepatic vein stenosis may manifest as 
Budd-Chiari syndrome, with hepatomegaly, ascites, reversed flow or absence of phasicity in 
the hepatic veins, and reversed flow in the portal vein (Buell et al, 2002; Crossin et al, 2003; 
Katyal et al, 2000). Contrast-enhanced CT is useful in demonstrating congestive changes in 
the liver parenchyma as a manifestation of blocked outflow but is of little help in depicting 
the stenosis itself (Ametani et al, 2001; White et al, 2004). Coronal MR imaging is useful in 
determining the extent of IVC stenosis and associated anomalies (Ito et al, 2000). Frequently, 
cavogram is required to confirm the stenosis. Pressure gradient measurements can help 
distinguish physiologically significant lesions from pseudostenoses (Carnevale et al, 2004). 
Treatment includes IVC recanalization, balloon angioplasty and stent placement (Fig. 12). 
Color Doppler US performed after the interventional procedure is also useful in confirming 
the restoration of normal hepatic venous flow by demonstrating a multiphasic waveform 
and an objective increase in flow velocity (Huang et al, 2004; Totsuka et al, 2004). Ascites 
usually disappears rapidly after the procedure. IVC thrombosis is a rare occurrence. It tends 
to occur at the superior and inferior caval anastomoses. Risk factors include technical 
problems during transplantation, use of intravascular catheters, and compression of vessels 
by a fluid collection. Color Doppler US may reveal obvious vessel narrowing or an 
echogenic intraluminal thrombus with absence of flow. At MR angiography, IVC 
thrombosis is seen as an intraluminal defect. Coronal imaging is useful for determining the 
extent of IVC thrombosis (Chong, 2004; Glockner et al, 2000). 
3.2.6 Portal vein stenosis 
Portal vein stenosis has been reported to occur as a postoperative complication in 4%–8% of 
pediatric liver transplant recipients (Ueda et al, 2005). It occurs more frequently in reduced-
size liver transplantation than in whole liver transplantation owing to the limited length of 
the portal vein that can be obtained from the donor (Unsinn et al, 2003). A difference in 
caliber between donor and recipient portal veins is normal and can be helpful in locating the 
portal venous anastomosis. An echogenic shelf like ring can often be seen at the anastomotic 
site. These findings should not be misinterpreted as a stenosis. At gray-scale US, portal vein  
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Fig. 12. Managment of IVC occlusion. (A&B) CT.scan of the upper abdomen demonstrating 
absence of the suprahepatic IVC in (A) and congested azygus vein (arrow) in B. (C) Initial 
cavogram confirms the occlusion of the IVC with opacification of the azygus system. (D&E) 
Successful recanalization and stenting of the IVC. The arrow in E points to the piggyback 
stump. (F) Follow up cavogram after six months confirms the patency of the stented IVC 
stenosis is diagnosed when a reduction of the vessel lumen of 50% or more is observed (Fig. 
13) at the site of narrowing relative to the prestenotic area, or when the caliber of the vessel 
is 2.5 mm or less at the site of narrowing (Boraschi & Donati, 2004; Crossin et al, 2003; 
Glockner & Forauer, 1999). Color Doppler US shows focal color aliasing at the vascular 
anastomosis. At pulsed doppler US, the waveform shows a systolic velocity greater than 20 
m/sec or a velocity in the stenotic segment that is three to four times greater than that in the 
prestenotic segment. A poststenotic jet with a velocity between 1 and 3 m/sec is a 
characteristic finding (Crossin et al, 2003; Nghiem et al, 1996; Stell et al, 2004). MR 
angiography can provide excellent visualization of portal vein stenosis (Fig. 13). Portography 
helps confirm the presence of the stenosis, and a pressure gradient may be obtained to 
determine the hemodynamic significance of the stenosis (Nghiem, 1996).Clinical symptoms 
of hemodynamically significant portal vein stenosis are related to portal hypertension and 
include bleeding from varices, splenomegaly, and ascites. Percutaneous transhepatic 
angioplasty is considered the standard treatment for portal vein stenosis. The placement of 
metallic stents also has been reported for treatment of recurrent or nonresponsive elastic 
stenosis (Funaki et al, 2000; Zajko et al, 1994). In the largest patient series for which data are 
available, a very good patency rate of 100% was found at 46 months after treatment with 
angioplasty and metallic stent placement (Funaki et al, 2000). A transhepatic puncture of the 
portal vein is performed with a 21-gauge needle while using US for guidance. An introducer 
system is advanced over an 0.018-inch nitinol wire to the portal branch and then exchanged 
for a 6-F vascular sheath over a 0.035-inch wire. The trans-stenotic pressure gradient is 
measured by using a 5-F hydrophilic catheter. Before balloon dilation, a bolus of heparin 
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the patient’s posture. Hemodynamically significant IVC stenosis can be differentiated from  
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portal venous anastomosis. An echogenic shelf like ring can often be seen at the anastomotic 
site. These findings should not be misinterpreted as a stenosis. At gray-scale US, portal vein  
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Fig. 12. Managment of IVC occlusion. (A&B) CT.scan of the upper abdomen demonstrating 
absence of the suprahepatic IVC in (A) and congested azygus vein (arrow) in B. (C) Initial 
cavogram confirms the occlusion of the IVC with opacification of the azygus system. (D&E) 
Successful recanalization and stenting of the IVC. The arrow in E points to the piggyback 
stump. (F) Follow up cavogram after six months confirms the patency of the stented IVC 
stenosis is diagnosed when a reduction of the vessel lumen of 50% or more is observed (Fig. 
13) at the site of narrowing relative to the prestenotic area, or when the caliber of the vessel 
is 2.5 mm or less at the site of narrowing (Boraschi & Donati, 2004; Crossin et al, 2003; 
Glockner & Forauer, 1999). Color Doppler US shows focal color aliasing at the vascular 
anastomosis. At pulsed doppler US, the waveform shows a systolic velocity greater than 20 
m/sec or a velocity in the stenotic segment that is three to four times greater than that in the 
prestenotic segment. A poststenotic jet with a velocity between 1 and 3 m/sec is a 
characteristic finding (Crossin et al, 2003; Nghiem et al, 1996; Stell et al, 2004). MR 
angiography can provide excellent visualization of portal vein stenosis (Fig. 13). Portography 
helps confirm the presence of the stenosis, and a pressure gradient may be obtained to 
determine the hemodynamic significance of the stenosis (Nghiem, 1996).Clinical symptoms 
of hemodynamically significant portal vein stenosis are related to portal hypertension and 
include bleeding from varices, splenomegaly, and ascites. Percutaneous transhepatic 
angioplasty is considered the standard treatment for portal vein stenosis. The placement of 
metallic stents also has been reported for treatment of recurrent or nonresponsive elastic 
stenosis (Funaki et al, 2000; Zajko et al, 1994). In the largest patient series for which data are 
available, a very good patency rate of 100% was found at 46 months after treatment with 
angioplasty and metallic stent placement (Funaki et al, 2000). A transhepatic puncture of the 
portal vein is performed with a 21-gauge needle while using US for guidance. An introducer 
system is advanced over an 0.018-inch nitinol wire to the portal branch and then exchanged 
for a 6-F vascular sheath over a 0.035-inch wire. The trans-stenotic pressure gradient is 
measured by using a 5-F hydrophilic catheter. Before balloon dilation, a bolus of heparin 
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(100 IU/kg) is administered intravenously to reduce the risk of thrombosis during balloon 
induced occlusion. Technical success is represented by resolution of the stenosis on a follow-
up portogram and by a significant reduction in the trans-stenotic pressure gradient (Fig. 14). 
The persistence of a pressure gradient of more than 5 mm Hg has been considered an 
indication for metallic stent placement (Funaki et al, 2000). Coil or gelfoam embolization of 
transhepatic needle tracts can be done to reduce the risk of bleeding. Doppler US should be 
performed on the day after the procedure for baseline evaluation of the portal vein velocity 
and flow spectrum. If findings at doppler US or clinical signs are suggestive of stenosis 
recurrence, MRI can be performed to confirm the findings before percutaneous intervention 
is repeated. 
 
Fig. 13. Portal vein stenosis. (A&B) MRA reveals moderate stenosis (arrow) of the main 
portal vein. (C&D) US and color US shows portal vein stenosis and turbulent flow 
  
Fig. 14. Angioplasty of portal vein (PV) stenosis. (A&B) Percutaneous portogram reveals 
saccular dilatation of the portal vein (arrowhead) and moderate stenosis at the PV anastomosis 
(arrow) with an 8 mm pressure gradient noted. (C&D) Post venoplasty with 6 x 40 mm 
balloon, mild residual stenosis is noted with gradient drop to 3 mm Hg indicating successful 
treatment. (E) follow up US demonstrates improved velocities and decrease in the spatial 
gradient across the stenosis 
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3.2.7 Portal vein thrombosis 
Portal vein thrombosis occurs more frequently in reduced size liver transplantation, mostly 
involving the main extrahepatic portal segment. Risk factors include surgical difficulties, 
decreased portal venous inflow; the presence of portosystemic shunts before transplantation; 
prior splenectomy; excessive vessel redundancy; and use of the venous conduits, most 
commonly cryopreserved iliac veins (Buell et al, 2002; Hashikura et al, 2003; Nghiem, 1998). 
Clinical manifestations include new-onset massive ascites, variceal bleeding, elevated values 
on hepatic function tests, splenomegaly, hepatic failure, and lower extremity edema (Buell et 
al, 2002; Millis et al, 1996). An acute thrombus is frequently anechoic and may be 
imperceptible on gray-scale US images and the portal vein appears normal. In these cases, 
color flow and spectral doppler analysis will show no detectable flow within the portal vein 
(Langnas et al, 1991; Nghiem, 1998). Vessel narrowing or an echogenic luminal thrombus 
with no Doppler flow may also be seen (Nghiem et al, 1996). Partial portal vein thrombosis 
may appear as a nonocclusive filling defect at US. Resultant luminal narrowing can be 
mistaken for portal vein stenosis at gray-scale, spectral, and color doppler US (Funaki et al, 
2000; Langnas et al, 1991). Occasionally, reversed flow in the intrahepatic branches may be 
observed in patients with portal vein thrombosis with complete absence of flow in the main 
portal vein. This finding is due to arterioportal shunts that develop soon after the 
thrombosis. Care should be taken to avoid making a false-negative diagnosis (Nghiem, 1996, 
1998; Stell et al, 2004). MR venography can provide an excellent visualization of portal vein 
thrombosis and can facilitate the differentiation of thrombosis from slow flow (Stafford-
Johnson et al, 1998; Unsinn et al, 2003). At contrast material–enhanced CT, portal vein 
thrombosis is seen as a low-attenuation filling defect (Ametani et al, 2001; Garc´a-Criado et 
al, 2003; Unsinn et al, 2003). Portal vein stenosis with thrombus formation in the immediate 
postoperative period is quickly diagnosed with Doppler US and is managed surgically. 
Treatment of portal vein thrombosis may include mechanical thrombectomy, segmental 
portal vein resection, percutaneous thrombolysis and stent placement, or balloon 
angioplasty (Fig. 15) (Holbert et al, 1995; Rossi et al, 2004). However, when the thrombus 
extends to the periphery of the intrahepatic portal venous branches, it can no longer be 
treated with balloon dilation or thrombolysis, and the patient must undergo repeat 
transplantation (Ametani et al, 2001). Thus, early diagnosis of portal vein thrombosis before 
formation of a complete thrombus is important. Occasionally, portal vein thrombosis is  
  
Fig. 15. Portal vein thrombosis. (A) Percutaneous portogram reveals occlusion of the main 
portal vein. (B) The portal vein was recanalized and thrombectomy was performed. (C) Post 
recanalization portogram reveals patent mesenteric veins (arrow) with filling of collateral 
varices 
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(100 IU/kg) is administered intravenously to reduce the risk of thrombosis during balloon 
induced occlusion. Technical success is represented by resolution of the stenosis on a follow-
up portogram and by a significant reduction in the trans-stenotic pressure gradient (Fig. 14). 
The persistence of a pressure gradient of more than 5 mm Hg has been considered an 
indication for metallic stent placement (Funaki et al, 2000). Coil or gelfoam embolization of 
transhepatic needle tracts can be done to reduce the risk of bleeding. Doppler US should be 
performed on the day after the procedure for baseline evaluation of the portal vein velocity 
and flow spectrum. If findings at doppler US or clinical signs are suggestive of stenosis 
recurrence, MRI can be performed to confirm the findings before percutaneous intervention 
is repeated. 
 
Fig. 13. Portal vein stenosis. (A&B) MRA reveals moderate stenosis (arrow) of the main 
portal vein. (C&D) US and color US shows portal vein stenosis and turbulent flow 
  
Fig. 14. Angioplasty of portal vein (PV) stenosis. (A&B) Percutaneous portogram reveals 
saccular dilatation of the portal vein (arrowhead) and moderate stenosis at the PV anastomosis 
(arrow) with an 8 mm pressure gradient noted. (C&D) Post venoplasty with 6 x 40 mm 
balloon, mild residual stenosis is noted with gradient drop to 3 mm Hg indicating successful 
treatment. (E) follow up US demonstrates improved velocities and decrease in the spatial 
gradient across the stenosis 
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3.2.7 Portal vein thrombosis 
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prior splenectomy; excessive vessel redundancy; and use of the venous conduits, most 
commonly cryopreserved iliac veins (Buell et al, 2002; Hashikura et al, 2003; Nghiem, 1998). 
Clinical manifestations include new-onset massive ascites, variceal bleeding, elevated values 
on hepatic function tests, splenomegaly, hepatic failure, and lower extremity edema (Buell et 
al, 2002; Millis et al, 1996). An acute thrombus is frequently anechoic and may be 
imperceptible on gray-scale US images and the portal vein appears normal. In these cases, 
color flow and spectral doppler analysis will show no detectable flow within the portal vein 
(Langnas et al, 1991; Nghiem, 1998). Vessel narrowing or an echogenic luminal thrombus 
with no Doppler flow may also be seen (Nghiem et al, 1996). Partial portal vein thrombosis 
may appear as a nonocclusive filling defect at US. Resultant luminal narrowing can be 
mistaken for portal vein stenosis at gray-scale, spectral, and color doppler US (Funaki et al, 
2000; Langnas et al, 1991). Occasionally, reversed flow in the intrahepatic branches may be 
observed in patients with portal vein thrombosis with complete absence of flow in the main 
portal vein. This finding is due to arterioportal shunts that develop soon after the 
thrombosis. Care should be taken to avoid making a false-negative diagnosis (Nghiem, 1996, 
1998; Stell et al, 2004). MR venography can provide an excellent visualization of portal vein 
thrombosis and can facilitate the differentiation of thrombosis from slow flow (Stafford-
Johnson et al, 1998; Unsinn et al, 2003). At contrast material–enhanced CT, portal vein 
thrombosis is seen as a low-attenuation filling defect (Ametani et al, 2001; Garc´a-Criado et 
al, 2003; Unsinn et al, 2003). Portal vein stenosis with thrombus formation in the immediate 
postoperative period is quickly diagnosed with Doppler US and is managed surgically. 
Treatment of portal vein thrombosis may include mechanical thrombectomy, segmental 
portal vein resection, percutaneous thrombolysis and stent placement, or balloon 
angioplasty (Fig. 15) (Holbert et al, 1995; Rossi et al, 2004). However, when the thrombus 
extends to the periphery of the intrahepatic portal venous branches, it can no longer be 
treated with balloon dilation or thrombolysis, and the patient must undergo repeat 
transplantation (Ametani et al, 2001). Thus, early diagnosis of portal vein thrombosis before 
formation of a complete thrombus is important. Occasionally, portal vein thrombosis is  
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portal vein. (B) The portal vein was recanalized and thrombectomy was performed. (C) Post 
recanalization portogram reveals patent mesenteric veins (arrow) with filling of collateral 
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detected in patients with normal allograft function and no portal hypertension. In these 
patients, sufficient hepatopetal collateralization has developed to maintain adequate venous 
flow (Holbert et al, 1995; Unsinn et al, 2003). A cavernomatous transformation is the usual 
finding at Doppler US in these cases. 
3.3 Biliary complications imaging and treatment 
Biliary complications are the most common complications following pediatric liver 
transplantation estimated to involve 20%–40% of pediatric liver transplant recipients, more 
frequently seen in children who have undergone reduced-size transplantation. Most biliary 
complications develop during the first 3 months after pediatric liver transplantation, but 
strictures and stones may develop months or years later. Complications include anastomotic 
leakage and stenosis with bile duct dilatation; intrahepatic bile duct stones, sludge, or 
debris; and biloma. These complications are related to the surgical method of biliary 
reconstruction and to prolonged cold ischemia time, immunologic reactions, hepatic artery 
thrombosis, ABO blood group system incompatibility between donor and recipient, and 
cytomegalovirus infection (Ametani et al, 2001). Non-anastomotic strictures are probably 
caused by hepatic arterial insufficiency from either stenosis or thrombosis. These ischemic 
arterial events may result in bile duct strictures or leaks, increasing the risk of cholangitis, 
sepsis, and abscess (Boraschi & Donati, 2004; Glockner & Forauer, 1999). The blood supply 
to the recipient CBD is rich because of collateral flow, whereas the vascularity of the donor 
duct and the proximal intrahepatic ducts is derived solely from the reconstructed hepatic 
artery. Biliary disease should be suspected in a post-transplantation patient who presents 
with elevated values on hepatic function tests, jaundice, fever, or abdominal pain (Lorenz et 
al, 2001; Vitellas & Guttikonda, 2002). The clinical manifestations of biliary complications 
often are indistinguishable from those of vascular complications, graft rejection, graft 
dysfunction, and infections. Although US is commonly performed to screen for biliary 
complications, the false-negative rate is high; therefore, negative findings at US do not 
suffice to exclude biliary complications. MRCP can be used as a non-invasive imaging tool 
to confirm US findings. Percutaneous trans-hepatic cholangiography can depict the type, 
location, and severity of biliary complications, allowing treatment in many cases. 
3.3.1 Anastomotic biliary strictures 
Anastomotic biliary strictures are a common problem after pediatric liver transplantation, 
with a reported incidence of 10%–35% (Lallier et al, 1993; Heffron et al, 1992). Such strictures 
are usually related to scar tissue and retraction at the suture site. Untreated biliary strictures 
are associated with high morbidity and mortality. Because hepatico-jejunostomy with Roux-
en-Y reconstruction is the most common type of biliary anastomosis in pediatric liver 
transplant recipients, endoscopy is rarely feasible and percutaneous intervention is usually 
the only treatment approach possible. Percutaneous treatment of biliary strictures in 
pediatric liver transplant recipients is considered safe and effective, and in most cases 
obviates surgical revision of the affected anastomoses (Lorenz et al, 2005; Schwarzenberg et 
al, 2002). Possible complications of percutaneous transhepatic cholangiography include 
hemobilia, intra- or extrahepatic hematoma, and fever with bacteremia; a cumulative 
incidence of 10.8% is reported for these complications in the pediatric population (Lorenz et 
al, 2005). Among 35 pediatric liver transplant recipients who underwent percutaneous 
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treatment of biliary strictures, the reported success rate was 34% after a single course of 
therapy and 60% after repeat percutaneous therapy, with a median follow-up period of 4.5 
years (Sunku et al, 2006). Suspicion about the presence of a biliary stricture may be aroused 
by one or more of the following findings, clinical manifestations such as fever or cholangitis; 
biochemical indicators such as increased levels of alkaline phosphatase, direct bilirubin, and 
transaminases; biliary duct dilatation observed at US, CT, or MR imaging; and liver biopsy 
with histologic findings indicative of cholestasis due to biliary obstruction. Biliary strictures 
may be present also in the absence of ductal dilatation (Berrocal et al, 2006). Some investigators 
have reported better sensitivities (80%–100%) when using MR cholangiography for the 
detection of biliary obstruction (Kitazono et al, 2007; Norton et al, 2001). However, in 
pediatric patients, deep sedation or general anesthesia is necessary during MR 
cholangiography and adds considerably to the cost of management; for this reason, MR 
cholangiography is not generally used as a screening modality in children. It does afford a 
global evaluation of the ductal anatomy, a capability that might be especially helpful when 
planning the placement of a biliary drainage catheter in a patient with two separate 
hepaticojejunostomies and a nondilated bile duct, because it allows avoidance of puncture 
of a hepatic segment with a normal bile duct. As an alternative, hepatobiliary scintigraphy 
with technetium 99m Mebrofenin iminodiacetate could be performed, with a segmental 
delay in clearance of the radiotracer being suggestive of a biliary stricture. Percutaneous 
transhepatic cholangiography is performed to confirm clinical, histologic, or imaging 
evidence of biliary strictures. Percutaneous transhepatic cholangiography is performed with 
monitored anesthesia care, spontaneous respiration, and additional local anesthesia. 
Intravenous antibiotic prophylaxis is administered before the procedure. If coagulation 
defects (platelet count < 50 × 1000/μL, prothrombin activity < 50%) are present, the patient 
receives an infusion of platelets, fresh frozen plasma, or both. Percutaneous transhepatic 
cholangiography is usually performed with a subxiphoid approach by using a 20-gauge 
needle positioned in a peripheral bile duct with US and fluoroscopic guidance. If the 
cholangiogram shows an anastomotic stricture, the biliary tree is catheterized by using an 
introducer system over a nitinol wire; the stricture is crossed, when possible, with 0.035- or 
0.038-inch hydrophilic wire, and a transanastomotic biliary catheter (diameter range,  
5–6.6 F) is placed with side holes above and below the stricture (Fig. 16).  
The catheter is left in place to allow external gravity drainage for at least 1 day. If the patient 
has no fever or cholangitis the day after the procedure, the catheter is clamped to allow 
internal drainage. Diagnostic cholangiography and the first session of balloon dilation of the 
anastomosis are performed on different days to reduce the risk of sepsis. The first session of 
balloon dilation is usually performed 1 week after cholangiography, with a 5-F or 6-F sheath 
and with a balloon size ranging from 5 mm to 7 mm at a pressure of 6–11 atm. The balloon 
size selected is usually 1 mm larger than the diameter of the intrahepatic bile duct above the 
stricture. In every session, trans-anastomotic balloon dilation should be performed three 
times, 10 minutes each. A transanastomotic biliary catheter is placed after every session of 
dilation, with the catheter size ranging from 6 to 12 F, according to the diameter of the 
anastomosis. The antibiotic infusion is repeated 6 hours after the procedure. A minimum of 
three separate sessions of biliary anastomotic dilations are performed, followed by a 
cholangiographic evaluation, and if necessary, further sessions of dilation every 4–6 weeks. 
At each session of dilation, the size of the balloon catheter is increased by 1 mm, until a 
maximum diameter of 10 mm is reached. The drainage catheter is finally removed when   
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detected in patients with normal allograft function and no portal hypertension. In these 
patients, sufficient hepatopetal collateralization has developed to maintain adequate venous 
flow (Holbert et al, 1995; Unsinn et al, 2003). A cavernomatous transformation is the usual 
finding at Doppler US in these cases. 
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Biliary complications are the most common complications following pediatric liver 
transplantation estimated to involve 20%–40% of pediatric liver transplant recipients, more 
frequently seen in children who have undergone reduced-size transplantation. Most biliary 
complications develop during the first 3 months after pediatric liver transplantation, but 
strictures and stones may develop months or years later. Complications include anastomotic 
leakage and stenosis with bile duct dilatation; intrahepatic bile duct stones, sludge, or 
debris; and biloma. These complications are related to the surgical method of biliary 
reconstruction and to prolonged cold ischemia time, immunologic reactions, hepatic artery 
thrombosis, ABO blood group system incompatibility between donor and recipient, and 
cytomegalovirus infection (Ametani et al, 2001). Non-anastomotic strictures are probably 
caused by hepatic arterial insufficiency from either stenosis or thrombosis. These ischemic 
arterial events may result in bile duct strictures or leaks, increasing the risk of cholangitis, 
sepsis, and abscess (Boraschi & Donati, 2004; Glockner & Forauer, 1999). The blood supply 
to the recipient CBD is rich because of collateral flow, whereas the vascularity of the donor 
duct and the proximal intrahepatic ducts is derived solely from the reconstructed hepatic 
artery. Biliary disease should be suspected in a post-transplantation patient who presents 
with elevated values on hepatic function tests, jaundice, fever, or abdominal pain (Lorenz et 
al, 2001; Vitellas & Guttikonda, 2002). The clinical manifestations of biliary complications 
often are indistinguishable from those of vascular complications, graft rejection, graft 
dysfunction, and infections. Although US is commonly performed to screen for biliary 
complications, the false-negative rate is high; therefore, negative findings at US do not 
suffice to exclude biliary complications. MRCP can be used as a non-invasive imaging tool 
to confirm US findings. Percutaneous trans-hepatic cholangiography can depict the type, 
location, and severity of biliary complications, allowing treatment in many cases. 
3.3.1 Anastomotic biliary strictures 
Anastomotic biliary strictures are a common problem after pediatric liver transplantation, 
with a reported incidence of 10%–35% (Lallier et al, 1993; Heffron et al, 1992). Such strictures 
are usually related to scar tissue and retraction at the suture site. Untreated biliary strictures 
are associated with high morbidity and mortality. Because hepatico-jejunostomy with Roux-
en-Y reconstruction is the most common type of biliary anastomosis in pediatric liver 
transplant recipients, endoscopy is rarely feasible and percutaneous intervention is usually 
the only treatment approach possible. Percutaneous treatment of biliary strictures in 
pediatric liver transplant recipients is considered safe and effective, and in most cases 
obviates surgical revision of the affected anastomoses (Lorenz et al, 2005; Schwarzenberg et 
al, 2002). Possible complications of percutaneous transhepatic cholangiography include 
hemobilia, intra- or extrahepatic hematoma, and fever with bacteremia; a cumulative 
incidence of 10.8% is reported for these complications in the pediatric population (Lorenz et 
al, 2005). Among 35 pediatric liver transplant recipients who underwent percutaneous 
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treatment of biliary strictures, the reported success rate was 34% after a single course of 
therapy and 60% after repeat percutaneous therapy, with a median follow-up period of 4.5 
years (Sunku et al, 2006). Suspicion about the presence of a biliary stricture may be aroused 
by one or more of the following findings, clinical manifestations such as fever or cholangitis; 
biochemical indicators such as increased levels of alkaline phosphatase, direct bilirubin, and 
transaminases; biliary duct dilatation observed at US, CT, or MR imaging; and liver biopsy 
with histologic findings indicative of cholestasis due to biliary obstruction. Biliary strictures 
may be present also in the absence of ductal dilatation (Berrocal et al, 2006). Some investigators 
have reported better sensitivities (80%–100%) when using MR cholangiography for the 
detection of biliary obstruction (Kitazono et al, 2007; Norton et al, 2001). However, in 
pediatric patients, deep sedation or general anesthesia is necessary during MR 
cholangiography and adds considerably to the cost of management; for this reason, MR 
cholangiography is not generally used as a screening modality in children. It does afford a 
global evaluation of the ductal anatomy, a capability that might be especially helpful when 
planning the placement of a biliary drainage catheter in a patient with two separate 
hepaticojejunostomies and a nondilated bile duct, because it allows avoidance of puncture 
of a hepatic segment with a normal bile duct. As an alternative, hepatobiliary scintigraphy 
with technetium 99m Mebrofenin iminodiacetate could be performed, with a segmental 
delay in clearance of the radiotracer being suggestive of a biliary stricture. Percutaneous 
transhepatic cholangiography is performed to confirm clinical, histologic, or imaging 
evidence of biliary strictures. Percutaneous transhepatic cholangiography is performed with 
monitored anesthesia care, spontaneous respiration, and additional local anesthesia. 
Intravenous antibiotic prophylaxis is administered before the procedure. If coagulation 
defects (platelet count < 50 × 1000/μL, prothrombin activity < 50%) are present, the patient 
receives an infusion of platelets, fresh frozen plasma, or both. Percutaneous transhepatic 
cholangiography is usually performed with a subxiphoid approach by using a 20-gauge 
needle positioned in a peripheral bile duct with US and fluoroscopic guidance. If the 
cholangiogram shows an anastomotic stricture, the biliary tree is catheterized by using an 
introducer system over a nitinol wire; the stricture is crossed, when possible, with 0.035- or 
0.038-inch hydrophilic wire, and a transanastomotic biliary catheter (diameter range,  
5–6.6 F) is placed with side holes above and below the stricture (Fig. 16).  
The catheter is left in place to allow external gravity drainage for at least 1 day. If the patient 
has no fever or cholangitis the day after the procedure, the catheter is clamped to allow 
internal drainage. Diagnostic cholangiography and the first session of balloon dilation of the 
anastomosis are performed on different days to reduce the risk of sepsis. The first session of 
balloon dilation is usually performed 1 week after cholangiography, with a 5-F or 6-F sheath 
and with a balloon size ranging from 5 mm to 7 mm at a pressure of 6–11 atm. The balloon 
size selected is usually 1 mm larger than the diameter of the intrahepatic bile duct above the 
stricture. In every session, trans-anastomotic balloon dilation should be performed three 
times, 10 minutes each. A transanastomotic biliary catheter is placed after every session of 
dilation, with the catheter size ranging from 6 to 12 F, according to the diameter of the 
anastomosis. The antibiotic infusion is repeated 6 hours after the procedure. A minimum of 
three separate sessions of biliary anastomotic dilations are performed, followed by a 
cholangiographic evaluation, and if necessary, further sessions of dilation every 4–6 weeks. 
At each session of dilation, the size of the balloon catheter is increased by 1 mm, until a 
maximum diameter of 10 mm is reached. The drainage catheter is finally removed when   
 




Fig. 16. Anastomotic biliary stricture. (A) Percutaneous cholangiogram demonstrating 
dilated biliary ducts with total occlusion of the hepatico-jejunostomy (arrow). (B) Successful 
recanalization and a balloon cholangioplasty of the biliary anastomosis. (C) Final 
cholangiogram demonstrated patent anastomosis with contrast drained into the jejunum. 
(D) Internal\external biliary drain placed across the anastomosis 
cholangiography performed through a sheath depicts resolution of the stricture and a good 
transanastomotic bile flow, which is defined as a complete passage of contrast material from 
the bile duct to the bowel loop within three minutes after injection. Biliary manometry or 
clinical trial using a capped “end-hole” catheter proximal to the treated duct or anastomosis 
can also be performed to determine the treatment success and the resolution of the 
anastomotic biliary stricture (Scott et al, 1998). In up to 41% of left lateral split-liver 
transplant recipients, the ducts for segments II and III are separately anastomosed to the 
jejunum (Broelsch et al, 1991). In these patients, biliary strictures may develop in one or both 
anastomoses (Fig. 17 a&b). For this reason, it is mandatory to know the number of 
hepaticojejunostomies present in a patient before performing percutaneous transhepatic 
cholangiography. In partial liver transplant recipients with an occlusive anastomotic biliary 
stricture that is not traversable with standard interventional radiology techniques, sharp 
percutaneous recanalization of the hepaticojejunostomy may be performed using a long 
needle, thus obviating surgery (Miraglia et al, 2007) (Fig. 17 C&D). 
3.3.2 Intrahepatic biliary strictures and bilomas 
Intrahepatic biliary strictures are usually related to chronic transplant rejection or arterial 
insufficiency caused by hepatic artery stenosis or thrombosis. A single focal stricture or 
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multiple or combined intrahepatic and anastomotic strictures may be present (Fig. 18). 
Percutaneous treatment of intrahepatic biliary strictures is usually performed with the same 
techniques used for anastomotic biliary strictures; however, a recurrence rate of 90% was 
reported in a long-term follow-up study of intrahepatic strictures (Sunku et al, 2006).  
Intrahepatic bilomas develop in the presence of arterial insufficiency due to hepatic artery 
stenosis or thrombosis or because of ABO incompatibility. Bilomas frequently are infected 
by gram-negative organisms that enter via the biliary anastomosis from the gastrointestinal 
tract. Percutaneous drainage of intrahepatic bilomas usually is performed with US guidance 
and is mandatory to reduce the risk of sepsis and graft loss (Hoffer et al, 1988). 
3.3.3 Bile leakage 
Postoperative bile leakage is a complication that usually occurs within few weeks after 
pediatric liver transplantation. Bile may leak from the bile duct anastomosis or from the 
resection margin in a split-liver transplant. Nonanastomotic leaks are usually associated 
with hepatic artery thrombosis.  
  
Fig. 17. Sharp recanalization of occlusive hepatico-jejunostomy. (A&B) MRI coronal images 
and MRCP demonstrating two separate heptico- jejunostomy with multiple filling defects in 
the superior bile duct. (C) Cholangiogram demonstrated external drain in the lower 
segmental bile duct with total occlusion of the inferior anastomosis, a plastic stent is noted 
across the superior anastomosis. (D) S/p sharp recanalization of the inferior anastomosis 
with the contrast drained through the anastomosis into the jejunum 
 




Fig. 16. Anastomotic biliary stricture. (A) Percutaneous cholangiogram demonstrating 
dilated biliary ducts with total occlusion of the hepatico-jejunostomy (arrow). (B) Successful 
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(D) Internal\external biliary drain placed across the anastomosis 
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Fig. 18. Ischemic biliary duct injuries. (A) Intra-hepatic biliary ducts stenosis seen by ERCP 
cholangiogram. (B) Combined intra-hepatic and anastomotic biliary stricture 
  
Fig. 19. (A) CT showing multiple bilomas (arrows). (B) Percutanous  cholangiogram reveals 
irregular and dilated bile ducts (arrow) consistent  with ischemic injury due to hepatic 
artery thrombosis. (C) Percutaneous  cholangiogram in different duct reveals a small biloma 
(arrowhead). (D)  Follow up CT of the abdomen reveals resolving bilomas with draining 
catheter in site (arrow). Retroperitoneal lymphadenopathy (curved arrow) consistent with 
post transplant lymphoproliferative disorder (PTLD) 
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Fig. 20. (A&B) ERCP demonstrating bile leakage from CHD (arrow in A) and stricture at the 
distal CBD (arrowhead). Plastic stent is placed through the scop (arrow in B). (C) Percntaneous 
cholangiogram after the removal of the internal stent revealing a kink and narrowing at the 
CBD anastomosis (arrow). (D) 6.5 Fr internal\external drainage catheter was placed 
Another possible site of leakage is the T-tube insertion in patients with a choledocho-
choledochal anastomosis. Small leaks usually resolve spontaneously; whereas large ones are 
associated with significant morbidity and occasional mortatlity, thus require treatment. 
Clinical manifestation of bile leak vary, and can be presented as fever, abdominal pain, fluid 
and electrolyte depletion, fat malabsorption, and the possibility of sepsis or bleeding due to 
hilar vascular erosion. The bile extravasates into the peritoneal cavity or forms a perihepatic 
fluid collection. These fluid collections are usually well depicted at US. Percutaneous 
drainage catheters are placed with US guidance to drain these large bile collections. Bile leak 
can be confirmed by hepatobiliary scintigraphy with Technitum 99m Mebrofenin 
iminodiacetate. Recently, MR cholangiography performed with specific contrast agents has 
proved useful in the diagnosis of small bile leaks (Akin et al, 2004; Vitellas & Guttikonda, 
2002). Adult patients who have undergone endoscopic or percutaneous transhepatic 
treatment for large bile leaks have experienced good outcomes obviating surgical repair in 
most cases (Akin et al, 2004; Kok et al, 1996). In pediatric liver transplant recipients, 
percutaneous transhepatic cholangiography and biliary catheter placement may be 
attempted for the treatment of large bile leaks from anastomoses only if the bile duct and the 
jejunal loop have not completely separated. A modified multipurpose drainage catheters 
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can be placed in the intrahepatic biliary ducts crossing the leaking anastomosis into the 
distal bowel loop by adding holes proximally to reduce the contact between the bile and the 
anastomotic lesion and thereby facilitate the repair process Fig. (20). Surgical revision often 
is necessary or strongly recommended if cholangiography shows complete separation of the 
bile duct from the jejunal loop. 
  
Fig. 21. Percutaneous retrieval of biliary stones. (A) a basket inserted co- axially with the 
cholangioscope through a large percutaneous access sheath  to the left hepatic duct. (B) On 
table mage shows the retrieved stones. (C and D) pre and post stone retrieval 
cholangiogram demonstrated successful treatment with no residual stone and resolution of 
the biliary duct dilatation 
3.3.4 Bile duct stones 
Although stones and sludge occur only infrequently after transplantation, they are 
associated with high morbidity. Several factors can lead to the formation of biliary stones 
and sludge. Cyclosporine can alter the bile composition, inducing crystal formation, which 
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results in biliary sludge and stone formation (Fulcher & Turner, 1999). Other causes include 
retained stones within the graft or stones formed secondary to bile stasis from biliary 
strictures. Biliary stones are well depicted with US and MR imaging (Kok et al, 1996; Laghi 
et al, 1999; Linhares et al, 2004). Interventional procedures may be useful for obviating 
surgery in these patients (Lorenz et al, 2005). Biliary stone removal can be performed 
through the percutaneous access to the involved bile duct and the stone can be retrieved 
using a basket or can be fragmented into small pieces using small forceps to drain with the 
bile into the intestine Fig. (21).  
4. Conclusion 
Liver transplantation is the ultimate treatment for children with end-stage liver disease. The 
application of reduced-size transplantation and the development of living related donor 
partial liver transplantation have expanded the donor pool, which, however, has in turn 
increased the risk for vascular and biliary complications. Imaging studies are extremely 
important for early diagnosis of post-transplantation complications because the clinical 
manifestations of these complications are frequently nonspecific and vary widely. Doppler 
US plays the leading role in the postoperative evaluation of pediatric patients. It is the 
imaging tool of choice for initial screening for biliary, arterial, and venous complications and 
is helpful in determining the next logical imaging test to confirm these complications. 
Current MR imaging techniques, including MR angiography and MR cholangiography, may 
provide a comprehensive evaluation of the transplanted liver; reveal abnormalities of 
vascular structures, bile ducts, and liver parenchyma; and depict extrahepatic tissues. If 
available, MR imaging should be used when US is inconclusive. CT is a valuable 
complement to US in the evaluation of complications involving the hepatic parenchyma as 
well as extrahepatic sites, especially the thorax. A number of complications can be corrected 
by using interventional radiologic techniques. Advances in minimally invasive, image-
guided percutaneous and endovascular techniques of various vascular and nonvascular 
complications of liver transplantation, have led to improved Graft and patient survival and 
have obviated surgical revision or repeat transplantation in most cases. 
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1. Introduction 
Liver transplantation, whether living donor (LDLT) or deceased donor (DDLT), is currently 
the treatment of choice for patients with advanced liver disease. While initially the focus 
was on acceptable short-term survival, currently the efforts are aimed at improving long-
term prognosis. Thus, focus is now on the quality of life after liver transplantation, as well as 
prediction and management of conditions related to morbidity and mortality in long-term 
survivors. Renal dysfunction is an important problem in this scenario. Both acute (ARD) and 
chronic renal dysfunctions (CRD) develop frequently after liver transplantation and can 
seriously jeopardize postoperative patient survival.  
Acute kidney injury is one of the most common complications of liver transplantation. It 
occurs more frequently in those who have hepatorenal syndrome at the time of liver 
transplantation. Acute renal dysfunction has been associated with an 8-fold increase in 
mortality risk, prolonged intensive care unit stay and a greater risk for infectious 
complications. In the subgroup of patients who develop acute renal failure and survive, 80% 
to 90% regain some degree of renal function, whereas the rest develop permanent renal 
dysfunction. Chronic renal dysfunction, not only has implications in terms of an increased 
demand on resources, but is also significantly associated with a higher patient mortality 
rate. 
In order to minimize the occurrence of ARD and CRD thereafter, it is vital to define the 
possible preoperative, intraoperative and postoperative risk factors. In this review, we 
discuss the various definitions, diagnostic tools, predictors of renal dysfunction after liver 
transplantation together with discussion of specific causes of renal dysfunction. This 
information will be useful in developing strategies for preventing the development or 
progression of renal dysfunction in liver transplant recipients, especially in view of the 
current availability of nonnephrotoxic immunosuppressive drugs. 
2. Assessment of renal function prior to transplantation 
With broadening of the inclusion criteria for liver transplantation, the majority of liver 
transplant recipients have some impairment of renal function prior to transplantation and 
most have clinically apparent renal insufficiency at some time in the posttransplant period. 
Among those with renal impairment at the time of transplant are patients whose renal 
failure is due to the same underlying process that caused the liver disease (hepatitis B, 
hepatitis C, analgesic overdose, amyloidosis, autoimmune disease), patients with underlying 
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parenchymal renal disease from diseases such as diabetes and hypertension, and other 
patients in whom the functional renal impairment is caused by the liver failure itself and its 
complications. The latter group may have manifestations ranging from mild sodium 
retention to oliguric renal failure termed hepatorenal syndrome (HRS) (Smith, 2006). 
For both prognostic and therapeutic reasons it is important to assess the level of renal function 
in patients being considered for liver transplantation and to determine if there is any 
reversible component. Also given organ shortage it should be essential to determine which 
patients will experience progressive and severe renal dysfunction after liver transplantation 
(Burra et al., 2009). 
2.1 Methods of measurement of renal function 
The most commonly used markers of glomerular filtration rate (GFR), blood urea nitrogen 
(BUN) and serum creatinine (Scr), have limitations that should be kept in mind, especially in 
the setting of liver transplantation. Because urea is generated by the liver from the 
metabolism of protein and ammonia, both malnutrition and poor hepatic function may 
cause a falsely low BUN that can lead to an overestimation of GFR. Conversely, 
corticosteroids, bleeding (particularly in the gastrointestinal tract), and renal hypoperfusion 
cause higher BUN levels than one would expect for a given level of GFR (Cholongitas et al., 
2007 a).  
Also current diagnostic paradigms for acute kidney injury are limited by reliance on serum 
creatinine (Scr), which is affected by age, gender, nutrition and the amount of muscle mass 
which may render the values inaccurate. Thus, most patients with endstage liver disease 
with decreased muscle mass may have a misleadingly low Scr. In addition, elevations in Scr 
may occur several days after the actual injury (Fieghen et al., 2009). Also, a number of 
medications (including trimethoprim) inhibit the secretion of creatinine, so that when these 
medications are used, Scr may rise without any true change in GFR (Cholongitas et al., 
2007). Furthermore, creatinine is both filtered and secreted by the nephron, so that its 
clearance is an overestimate of GFR. It should also be noted that the relationship between 
the serum creatinine and GFR is not linear; at high levels of GFR, the Scr is insensitive to 
large changes in GFR, while at low levels of GFR, small changes in GFR cause large changes 
in serum creatinine (Mariat et al., 2004). A problem, not often recognized is that 
measurement of Scr suffers from a variety of interferences (Cholongitas et al., 2007 b) and 
absence of international standard for measurement (Seronie-Vivien et al., 2005). Serum 
creatinine is usually measured by the Jaffè method, but this is prone to interference, for 
example, from protein, ketones and bilirubin. Hence, hyperbilirubinemia often impacts on 
the measurement of Scr in endstage liver disease population (Owen et al., 2006). These 
findings can result in an underestimation of renal function.  
Despite the above limitations, the endogenous creatinine clearance from a timed urine 
collection or as calculated from the Cockcroft–Gault formula {(140- age)/Cr × (weight in 
kg/72) (× 0.85 for females)} (Cockcroft and Gault, 1976) remains the most common measure 
of GFR (Lewandowska  & Matuszkiewicz-Rowinska, 2011). If a timed urine collection is 
performed, the amount of creatinine excreted in 24 hours should be 12–25 mg/kg body 
weight as a crude test for completeness of the collection. Because of the variability in the 
accuracy of timed collections performed by outpatients, and the excellent correlation of the 
Cockcroft–Gault calculation with timed creatinine clearance measurements under controlled 
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conditions, a timed collection may be necessary only for a baseline creatinine clearance and 
to measure protein excretion. It can then be repeated only as necessary to confirm abrupt or 
unexpected changes in the serum creatinine (Smith, 2006). However, it should be noted that 
there is some debate concerning the use of the Cockcroft–Gault equation to estimate GFR 
(Gonwa et al., 2004). This formula may be inaccurate and pick up small differences in GFR 
that are statistically significant but clinically irrelevant. Although GFR calculations often 
overestimate GFR measurements (Poge et al., 2005), even using the best formulas available, 
the Cockcroft–Gault equation has been used in many published studies and was widely 
used in clinical practice (Burra et al., 2009). 
Modification of diet in renal disease (MDRD) equation (Levey et al., 1999) is another method 
that is considered more accurate than other formulas to measure GFR in patients with intact 
kidney function. MDRD equation: GFR = 170 x [Serum creatinine]-0.999 x [Age]-0.176 x 
[0.762 if patient is female] x [1.180 if patient is black] x [BUN]-0.170 x [Albumin] + 0.318. 
Most often, the formula, excluding urea and albumin (four variables), is used to calculate 
GFR, as it is as accurate as the original six-variable formula (Levey et al., 2006). Neither these 
formulas nor calculation of creatinine clearance from a 24-hour urine collection has been 
well studied or validated in patients with decompensated cirrhosis. Preliminary data 
suggest that the MDRD equation is more precise in liver transplant (LT) patients than other 
renal formulas, but the MDRD equation actually underestimates GFR measured by the gold 
standard of iothalamate clearance. There are now online calculators that provide a 
convenient way to estimate GFR (e.g. http://nephron.com/gi-bin/MDRDSIdefault.cgi) 
(Fabrizi et al., 2010). However, in LT recipients, even the best performing equation, the six-
variable MDRD equation, provides an estimate that is within 30% of the actual GFR only 
two-thirds of the time (Gonwa et al., 2004). 
Ideally, renal function can be estimated through the use of inulin, (125I) iothalamate, or 
51Cr-EDTA clearance methods, but these are costly and often impractical. Many nuclear 
medicine departments perform isotopic GFR measurements based on the decay of the 
plasma level of an injected radiolabeled GFR marker over a few hours (Mariat et al., 2004). 
However the cost of the radiolabeled GFR markers and the precautions needed in handling 
them make these tests expensive. 
2.2 Diagnosis of pre-transplant kidney dysfunction 
Patients with cirrhosis are candidates to develop acute renal failure from different causes; 
each of them requiring specific treatments. In cirrhotic patients with ascites, pre-renal failure 
(42%) and acute tubular necrosis (ATN) (38%) represent the most common forms of acute 
renal failure while hepatorenal syndrome (HRS) is somewhat less frequent (20%) (Fasolato 
et al., 2007). Approximately 18% will develop HRS at 1 year and 39% at 5 years (Terra et al., 
2005). However, it may be difficult to identify the cause and start the appropriate treatment 
(Moreau and Lebrec, 2003). The different causes of acute renal failure in cirrhotics are 
discussed below. Table 1 shows the differential diagnosis of the causes that are most 
commonly encountered during preparation for liver transplant. 
2.2.1 Hepatorenal syndrome  
Patients with end-stage liver disease may exhibit a spectrum of functional renal impairment 
from mild sodium retention and clinically inapparent reduction in GFR, to an oliguric state 
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parenchymal renal disease from diseases such as diabetes and hypertension, and other 
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conditions, a timed collection may be necessary only for a baseline creatinine clearance and 
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variable MDRD equation, provides an estimate that is within 30% of the actual GFR only 
two-thirds of the time (Gonwa et al., 2004). 
Ideally, renal function can be estimated through the use of inulin, (125I) iothalamate, or 
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medicine departments perform isotopic GFR measurements based on the decay of the 
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However the cost of the radiolabeled GFR markers and the precautions needed in handling 
them make these tests expensive. 
2.2 Diagnosis of pre-transplant kidney dysfunction 
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each of them requiring specific treatments. In cirrhotic patients with ascites, pre-renal failure 
(42%) and acute tubular necrosis (ATN) (38%) represent the most common forms of acute 
renal failure while hepatorenal syndrome (HRS) is somewhat less frequent (20%) (Fasolato 
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with severe intrarenal vasoconstriction, avid sodium conservation, and very low GFR 
referred to as hepatorenal syndrome (Eckardt, 1999). In almost half the cases of HRS, one or 
more precipitating factors may be identified, including bacterial infections (57%), 
gastrointestinal hemorrhage (36%), and large volume paracentesis (7%) (Fasolato et al., 
2007). The hallmark of HRS is intense renal vasoconstriction with predominant peripheral 
arterial vasodilation. Kidney histology is normal (Wadei et al., 2006). 
HRS is a diagnosis of exclusion, requiring the absence of sepsis and nephrotoxic agents, less 
than 500 mg/day of protein excretion and no microhaematuria, an ultrasound showing no 
evidence of obstruction or parenchymal renal disease, and a lack of improvement of serum 
creatinine (<1.5mg/dl) with cessation of diuretic therapy and plasma volume expansion 
(albumin 1 g/kg upto max. of 100g/day) (New International Ascites Club’s diagnostic criteria of 
hepatorenal syndrome (Salerno et al., 2007). If the syndrome persists, acute tubular necrosis 
may result. Thus, the urine sodium concentration is less than 10 meq/L early in the process, 
but as tubular ischemia occurs, the urine sodium rises, clouding the diagnostic issue. 
2.2.2 Volume depletion induced renal dysfunction 
Prerenal failure usually occurs in patients with decompensated cirrhosis. These patients 
already have significant circulatory dysfunction characterized by low arterial pressure, renal 
vasoconstriction and decreased renal blood flow; but they have no or only mild reduction in 
GFR. Volume depletion further decreases renal blood flow and induces a marked decline in 
GFR which may be rapidly reversible if the underlying cause is corrected (Moreau and 
Lebrec, 2003). Ten to twenty percent of patients with gastrointestinal hemorrhage have 
hypovolemic shock on admission. This true hypovolemia is one cause of prerenal azotemia. 
A retrospective study showed that 5% of patients with cirrhosis hospitalised for acute upper 
gastrointestinal hemorrhage had early renal failure that lasted less than 7 days after index 
bleeding (Cardenas et al., 2001). Patients admitted for hemorrhage may also develop 
prerenal failure due to other causes such as bacterial infection (Cardenas et al, 2001).  
True hypovolemia and subsequent renal failure may also result from vomiting, diarrhea, 
glycosuria or diuretic treatment used to mobilize ascites. 
2.2.3 Severe sepsis  
Patients with cirrhosis are susceptible to bacterial infections, in particular spontaneous 
bacterial peritonitis (SBP). Septic shock and subsequent prerenal azotemia occurs in 10% of 
patients with SBP. At the onset of SBP, 20-40% of patients have renal failure without shock 
(Moreau and Lebrec, 2006). Thirty percent of those admitted for SBP or for another bacterial 
infection develop type 1 HRS during hospitalization (Terra et al., 2005). 
2.2.4 Drugs 
NSAIDS 
Cyclo-Oxygenase (COX)-derived vasodilator prostaglandins protect renal perfusion in 
patients with cirrhosis and ascites. Hence administration of non-selective non-steroidal anti-
inflammatory drugs (NSAIDs) (i.e., drugs that can inhibit cyclooxygenase-1 (COX-1)) and 
cyclooxygenase-2) in cirrhotic patients may lead to marked renal hypoperfusion and 
 
Renal Dysfunction and Liver Transplantation 
 
277 
subsequent prerenal failure following COX inhibition induced by non-selective NSAIDs. It 
was also shown that COX-2 inhibitors, like non-selective NSAIDs, may also induce prerenal 
failure in patients with cirrhosis and ascites (FitzGerald and Patrono, 2001). 
Antibiotics 
Patients with cirrhosis and ascites are predisposed to aminoglycoside nephrotoxicity, the 
reported incidence of which (32%) is much higher than that found by other investigators in 
the general population (3–11%). Aminoglycoside nephrotoxicity is associated with a marked 
deterioration in renal function (Cabrera et al., 1982). Patients with decompensated cirrhosis 
are prone to develop this complication, since they frequently have impaired renal blood 
flow and glomerular filtration rates, and renal accumulation of aminoglycosides is greater 
with renal impairment (Moore et al., 1984). 
2.2.5 Contrast induced nephropathy 
This is defined as impairment of renal function subsequent to the administration of contrast 
media in the absence of any other cause. Contrast induced nephropathy (CIN) is diagnosed 
when there is an increase in serum creatinine concentration of > 0.5 mg/dl or a relative 
increase of > 25% from the baseline within 72 hrs after contrast media administration 
(Barrett and Parfrey, 1994).  
Pre-existing renal dysfunction and diabetes mellitus are the two most important risk factors 
for CIN. The incidence of CIN is less than 2% when basal creatinine is less than 1.6 mg/dl 
and increases to 12-29% when above 1.6 mg/dl and to 38% when above 2.0 mg/dl. The 
presence of more than one risk factor increases the risk to develop CIN by many folds (Liu 
et al., 2005). The incidence of CIN also rises with increase in the volume of the contrast 
media. It is less than 2% when patients receive less than 125 ml of contrast media compared 
with 19% in patients receiving more than that volume. Peri-procedural hydration is 
regarded as a simple and effective means to prevent CIN. Results of a large number of 
clinical trials go in favour of post-procedural acetylcystine which is a free radical scavenger 
and precursor of antioxidant glutathione (Tepel et al., 2006). Recovery occurs in the majority 
of cases within 2–3 weeks; few patients require dialysis for recovery (Barrett & Parfrey, 
1994). 
2.2.6 Intrinsic renal failure 
2.2.6.1 Viral hepatitis and associated glomerular diseases 
Viral infections such as hepatitis B (HBV) and C (HCV) are well-known to induce 
concomitant severe hepatic and renal injuries with ultimate endstage renal disease. The 
most common clinical presentation in both cases is the nephrotic syndrome with a slowly 
progressive decline in renal function (Lai & Lai, 1991 and Johnson et al., 1994a). The 
proteinuria remits spontaneously in a minority of patients, but may also recur. The degree 
of proteinuria appears to correlate with viremia as spontaneous remission of the 
glomerulopathy is usually associated with clearance of viral antigens from the blood. The 
mechanisms whereby different viral infections induce distinct glomerular lesions and/or 
systemic complications have not been fully elucidated. Circulating and most likely in situ 
immune complexes involving viral antigens and host anti-viral antibodies have been 
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with severe intrarenal vasoconstriction, avid sodium conservation, and very low GFR 
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creatinine (<1.5mg/dl) with cessation of diuretic therapy and plasma volume expansion 
(albumin 1 g/kg upto max. of 100g/day) (New International Ascites Club’s diagnostic criteria of 
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may result. Thus, the urine sodium concentration is less than 10 meq/L early in the process, 
but as tubular ischemia occurs, the urine sodium rises, clouding the diagnostic issue. 
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Prerenal failure usually occurs in patients with decompensated cirrhosis. These patients 
already have significant circulatory dysfunction characterized by low arterial pressure, renal 
vasoconstriction and decreased renal blood flow; but they have no or only mild reduction in 
GFR. Volume depletion further decreases renal blood flow and induces a marked decline in 
GFR which may be rapidly reversible if the underlying cause is corrected (Moreau and 
Lebrec, 2003). Ten to twenty percent of patients with gastrointestinal hemorrhage have 
hypovolemic shock on admission. This true hypovolemia is one cause of prerenal azotemia. 
A retrospective study showed that 5% of patients with cirrhosis hospitalised for acute upper 
gastrointestinal hemorrhage had early renal failure that lasted less than 7 days after index 
bleeding (Cardenas et al., 2001). Patients admitted for hemorrhage may also develop 
prerenal failure due to other causes such as bacterial infection (Cardenas et al, 2001).  
True hypovolemia and subsequent renal failure may also result from vomiting, diarrhea, 
glycosuria or diuretic treatment used to mobilize ascites. 
2.2.3 Severe sepsis  
Patients with cirrhosis are susceptible to bacterial infections, in particular spontaneous 
bacterial peritonitis (SBP). Septic shock and subsequent prerenal azotemia occurs in 10% of 
patients with SBP. At the onset of SBP, 20-40% of patients have renal failure without shock 
(Moreau and Lebrec, 2006). Thirty percent of those admitted for SBP or for another bacterial 
infection develop type 1 HRS during hospitalization (Terra et al., 2005). 
2.2.4 Drugs 
NSAIDS 
Cyclo-Oxygenase (COX)-derived vasodilator prostaglandins protect renal perfusion in 
patients with cirrhosis and ascites. Hence administration of non-selective non-steroidal anti-
inflammatory drugs (NSAIDs) (i.e., drugs that can inhibit cyclooxygenase-1 (COX-1)) and 
cyclooxygenase-2) in cirrhotic patients may lead to marked renal hypoperfusion and 
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subsequent prerenal failure following COX inhibition induced by non-selective NSAIDs. It 
was also shown that COX-2 inhibitors, like non-selective NSAIDs, may also induce prerenal 
failure in patients with cirrhosis and ascites (FitzGerald and Patrono, 2001). 
Antibiotics 
Patients with cirrhosis and ascites are predisposed to aminoglycoside nephrotoxicity, the 
reported incidence of which (32%) is much higher than that found by other investigators in 
the general population (3–11%). Aminoglycoside nephrotoxicity is associated with a marked 
deterioration in renal function (Cabrera et al., 1982). Patients with decompensated cirrhosis 
are prone to develop this complication, since they frequently have impaired renal blood 
flow and glomerular filtration rates, and renal accumulation of aminoglycosides is greater 
with renal impairment (Moore et al., 1984). 
2.2.5 Contrast induced nephropathy 
This is defined as impairment of renal function subsequent to the administration of contrast 
media in the absence of any other cause. Contrast induced nephropathy (CIN) is diagnosed 
when there is an increase in serum creatinine concentration of > 0.5 mg/dl or a relative 
increase of > 25% from the baseline within 72 hrs after contrast media administration 
(Barrett and Parfrey, 1994).  
Pre-existing renal dysfunction and diabetes mellitus are the two most important risk factors 
for CIN. The incidence of CIN is less than 2% when basal creatinine is less than 1.6 mg/dl 
and increases to 12-29% when above 1.6 mg/dl and to 38% when above 2.0 mg/dl. The 
presence of more than one risk factor increases the risk to develop CIN by many folds (Liu 
et al., 2005). The incidence of CIN also rises with increase in the volume of the contrast 
media. It is less than 2% when patients receive less than 125 ml of contrast media compared 
with 19% in patients receiving more than that volume. Peri-procedural hydration is 
regarded as a simple and effective means to prevent CIN. Results of a large number of 
clinical trials go in favour of post-procedural acetylcystine which is a free radical scavenger 
and precursor of antioxidant glutathione (Tepel et al., 2006). Recovery occurs in the majority 
of cases within 2–3 weeks; few patients require dialysis for recovery (Barrett & Parfrey, 
1994). 
2.2.6 Intrinsic renal failure 
2.2.6.1 Viral hepatitis and associated glomerular diseases 
Viral infections such as hepatitis B (HBV) and C (HCV) are well-known to induce 
concomitant severe hepatic and renal injuries with ultimate endstage renal disease. The 
most common clinical presentation in both cases is the nephrotic syndrome with a slowly 
progressive decline in renal function (Lai & Lai, 1991 and Johnson et al., 1994a). The 
proteinuria remits spontaneously in a minority of patients, but may also recur. The degree 
of proteinuria appears to correlate with viremia as spontaneous remission of the 
glomerulopathy is usually associated with clearance of viral antigens from the blood. The 
mechanisms whereby different viral infections induce distinct glomerular lesions and/or 
systemic complications have not been fully elucidated. Circulating and most likely in situ 
immune complexes involving viral antigens and host anti-viral antibodies have been 
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implicated in hepatitis B- associated membranous glomerulonephropathy (Pham et al., 
2005).  
HCV-related glomerulonephritis 
Hepatitis C has been associated most closely with mesangiocapillary glomerulonephritis 
(Bursten & Rodby, 1993, Johnson et al., 1993 & Johnson et al., 1994b). Many of the patients with 
chronic HCV and mesangiocapillary glomerulonephritis also have hypocomplementemia, 
cryoglobulinemia (the cryoprecipitates contain HCV-RNA), and rheumatoid factors (IgM 
antibodies directed against anti-HCV antibodies). Other symptoms and signs of mixed 
cryoglobulinemia such as skin lesions, arthritis, and neuropathy may not be present. Indeed, 
even the hepatitis associated with the renal disease may be asymptomatic and the 
transaminases may be normal (Johnson et al., 1994b). Less commonly, non-cryoglobulinemic 
mesangiocapillary glomerulonephritis, focal and segmental glomerulosclerosis, mesangial 
proliferation with IgA deposition, fibrillary and immunoactoid glomerulopathies occur (Dore 
et al., 2007). A purely membranous glomerulonephritis has also been reported in patients with 
HCV, and may have a different pathogenesis (Stehman-Breen et al., 1995). McGuire et al 
performed kidney biopsies at the time of liver transplantation in 30 patients with HCV-related 
cirrhosis and a median creatinine of 1.4 mg/dL; immune complex glomerulonephritis was 
reported in 83% of the patients (McGuire et al., 2006). 
   
A. Increased cellularity, expansion of mesangium,  
Thickening & splitting of capillary walls 
   B. Capillary wall deposits of Ig G 
   
C. Capillary wall deposits of IgM D. EM of glomerular capillary: subendothelial 
immune deposits as tactoids (arrows) & 
microtubules (arrowheads) characteristic of 
cryoglobuinns 
Fig. 1. Renal Biopsy specimen from a patient with Hepatitis C (Johnson et al., 1993) 
 




HBV-related glomerulonephritis is more often found in children. Membranous 
glomerulonephritis is the most common form of HBV-related glomerulonephritis, but 
mesangiocapillary glomerulonephritis, mesangial proliferative glomerulonephritis, focal 
segmental glomerulosclerosis, IgA nephropathy and minimal change disease have all been 
described. In addition, in patients with HBV-associated polyarteritis nodosa, a variety of 
histologic patterns have been documented (Lai & Lai, 1991). Immune complexes of hepatitis 
B surface, core, and e antigens as well as antibodies together with complement components 
have been demonstrated in glomerular basement membrane and mesangium. HBV antigens 
have been localized in the glomeruli using immunofluorescent antibodies, electron 
microscopy, and molecular techniques. HBeAg has been consistently associated with 
capillary basement membrane deposits (membranous form of glomerulopathy), while 
HBsAg is more closely associated with deposits in the mesangium (Lai and Lai., 1991; 
Takekoshi et al., 1991). 
Liver disease tends to be mild in patients who present with HBV-related 
glomerulonephritis. Disease remission is especially evident after HBeAg seroconversion. A 
significant percent of adults (30%) may progress to renal failure and as many as 10% will 
require maintenance dialysis (Bhimma et al., 2002).  
2.2.6.2 Renal disease associated with poor hepatic function 
Patients with poor hepatic function of any cause may develop parenchymal renal disease 
manifested by nonnephrotic proteinuria, microscopic hematuria, and reduced GFR. The 
most common histologic picture is a mesangiopathic glomerulonephritis with deposition of 
IgM and often IgA, perhaps because of impaired clearance by the liver. It has not been 
proved that these immune complexes are the cause of the renal disease (Smith, 2006). 








 Urine sodium <10 mEq/L  >30 mmol/L <10 mmol/L >30 mmol/L 
Urine to plasma  
creatinine ratio >30:1 <20:1 >30:1 <20:1 
Proteinuria <100mg <500mg <500mg Variable 
Table 1. Differential Diagnosis of Acute renal failure in advanced liver disease. (Eckardt, 1999) 
Renal failure post liver transplantation 
Renal insufficiency, whether acute renal failure (ARF) or chronic kidney disease (CKD), is a 
common complication after liver transplantation and represents a major cause of morbidity 
and mortality following LT (Yalavarthy et al., 2007). 
3. Acute renal failure 
3.1 Epidemiology 
Acute renal failure (ARF) is one of the most common complications of liver transplantation 
(LT), with a variable incidence rate in different studies. The incidence of acute kidney injury 
(AKI) has been reported to vary between 17% to 95% post-liver transplantation (Bilbao et al., 
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Acute renal failure (ARF) is one of the most common complications of liver transplantation 
(LT), with a variable incidence rate in different studies. The incidence of acute kidney injury 
(AKI) has been reported to vary between 17% to 95% post-liver transplantation (Bilbao et al., 
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1998, Lima et al., 2003). The difference in the incidence reported may be due in part to the 
large difference in the criteria used to define ARF. 
Campbell et al., 2005 and Lebrón Gallardo et al., 2004 used a value of serum creatinine 
above 1.5 mg/dl as diagnostic of acute Kidney injury (AKI) and reported an incidence as 
high as 64%. On the other hand, Junge et al, 2006, reported a relatively low incidence of 
11.9% and defined AKI post-LT as serum creatinine of 2.5 mg/dl in the first week only. 
Actually the incidence rate of post-LT ARD differs even in the same center when variable 
definitions are used. Barri and colleagues, 2009 conducted a study on 1050 patients who 
underwent LT, using changes in serum creatinine from baseline as the main marker for 
acute kidney injury (AKI). They used three different definitions to diagnose post-LT AKI. 
Defining AKI as a rise in serum creatinine of >0.5 mg/dL resulted in the highest incidence 
of AKI (78%). The second definition of AKI was a rise in serum creatinine of >1 mg/dl and 
this resulted in an incidence of AKI 46%. When AKI was defined as a rise of serum 
creatinine of >50% from baseline to above 2 mg/dl, the lowest incidence of AKI (14%) was 
found (Barri et al., 2009). Hence, these variations in definitions cause difficulties in 
comparing different studies and demonstrate the need for a consensus in the diagnosis of 
acute renal disease after LT. 
3.2 Definition of acute renal failure 
Several researchers have evaluated the problem of renal impairment post-LT but it is 
difficult to meaningfully compare these studies as a series of different definitions are used 
(Cabezuelo et al., 2002).  
To address this issue, RIFLE classification was introduced in 2002. RIFLE is an acronym for 
risk of renal dysfunction, injury to the kidney (ARI), failure of the kidney (ARF), loss of 
kidney function and end-stage kidney disease (Table 2). It was later modified and is 
functioning as AKIN (Acute Kidney Injury Network) classification since 2005 (Table 3). The 
AKI term includes a wide range of renal dysfunction, starting with a very early and discrete 
renal failure with minimal changes in the serum creatinine level (stage 1, Risk), through 
moderate changes (stage 2, Injury), to an advanced renal failure (stage 3, Failure), often 
requiring renal replacement therapy (Bellomo et al., 2004 & Mehta et al., 2007). Two 
additional stages (Loss of function and Endstage- renal-disease) were introduced in order to 
classify cases of a partial or total and permanent loss of renal function. Some studies used 
these criteria to determine the incidence of ARF post-LT. Kundakci reported that AKD 
occurred in more than half of LTs postoperatively. AKI occurred in 64 (57%) LTs with risk, 
injury, and failure frequencies of 19%, 11%, and 28%, respectively (Kundakci et al., 2010). 
Zhu et al reported that postoperatively, AKI was found in 60% of patients. According to the 
AKIN criteria, it was: stage 1 – in 30%, stage 2 – in 13%, and stage 3 – in 17% of the 
individuals (Zhu et al., 2010). 
AKIN classification was introduced with great enthusiasm, but soon proved to be of little 
use. Its main disadvantages include undersensitivity and no reference to aetiology or 
pathophysiology of AKI. Thus, it does not distinguish between the prerenal azotemia and a 
real injury of the renal parenchyma. Serum creatinine level and eGFR based on it are not 
useful parameters in the early diagnostics of AKI. First of all, the increase in creatinine level 
occurs late, after a few days, with an injury of more than 50% of the renal parenchyma. 
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Moreover, it is influenced by too many factors of creatinine synthesis and secretion in the 
renal tubules. In patients with graft dysfunction, these indicators are even less reliable, 
because of malnutrition and – frequently observed in these patients – high levels of serum 
bilirubin which interferes with creatinine measurements and causes a significant reduction 
in serum creatinine level (Cholongitas et al., 2007a). 
Risk Increase of serum creatinine  
1.5-2 times baseline 
Less than 0.5ml/kg/hr for 
>6hrs 
Injury Increase of serum creatinine  
2-3 times baseline 
Less < 0.5ml/kg/hr for >12hrs 
Failure Increase of serum creatinine of  
> 3 times baseline 
<0. <0.3ml/kg/hr for >24hrs or 
anuria>12hrs
Loss Persistent need for RRT 
for >4 weeks 
End-stage Persistent need for RRT  
for >3 months 
 
Table 2. Risk, Injury, Failure, Loss of Kidney Function, End-stage (RIFLE) Kidney Disease 
classification (Mehta et al., 2007) 
Acute Kidney Injury Recovery 
Stage1 Stage 2 Stage 3 Loss of function>4 weeks but <3 months 
Rise in serum  
creatinine ≥0.3 mg/dl or 
Increase to ≥150%  
to 200%  
(1.5-fold to 2-fold)  
from baseline. 
Increase in serum 
creatinine to  
> 200%- 300%  
(> 2-fold to 3-fold)  
from baseline. 
Increase in serum 
creatinine to > 300% 
(> 3-fold) from baseline, 
or serum creatinine  
≥4.0 mg/dl with an 
acute increase of  
at least 0.5 mg/dl. 
End-stage renal failure 
>3 months 
Urine output < 0.5 
ml/kg/hour for > 6 hrs.
Urine output < 0.5 
ml/kg/hour for > 12 
hrs. 
Urine output < 0.3 
ml/kg/hr for 24 hrs, or 
anuria for 12 hrs. 
Death 
Table 3. Classification/staging system for acute kidney injury modified from RIFLE criteria. 
(Bellomo et al., 2004) 
3.3 Aetiology and risk factors of acute kidney injury after liver transplantation 
In order to apply protective strategies to minimize the occurrence of acute renal dysfunction 
(ARD) and chronic renal dysfunction thereafter, it is vital to define risk factors for ARD and 
manage properly as early as possible (Barri et al., 2009). 
The evaluation of predictive factors for renal failure that occurs postoperatively has been the 
matter of several investigations. Clinical studies evaluating these risk factors have yielded 
variable results. Although the risk factors for AKI are often multifactorial and difficult to 
establish, they can be linked to three distinct time frames in relation to the liver transplant: 
the pretransplant (pre-LT), intraoperative, and post-LT periods as follows: pre-transplant 
(HRS, pre-transplant kidney dysfunction, high bilirubin concentrations), intra-operative 
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1998, Lima et al., 2003). The difference in the incidence reported may be due in part to the 
large difference in the criteria used to define ARF. 
Campbell et al., 2005 and Lebrón Gallardo et al., 2004 used a value of serum creatinine 
above 1.5 mg/dl as diagnostic of acute Kidney injury (AKI) and reported an incidence as 
high as 64%. On the other hand, Junge et al, 2006, reported a relatively low incidence of 
11.9% and defined AKI post-LT as serum creatinine of 2.5 mg/dl in the first week only. 
Actually the incidence rate of post-LT ARD differs even in the same center when variable 
definitions are used. Barri and colleagues, 2009 conducted a study on 1050 patients who 
underwent LT, using changes in serum creatinine from baseline as the main marker for 
acute kidney injury (AKI). They used three different definitions to diagnose post-LT AKI. 
Defining AKI as a rise in serum creatinine of >0.5 mg/dL resulted in the highest incidence 
of AKI (78%). The second definition of AKI was a rise in serum creatinine of >1 mg/dl and 
this resulted in an incidence of AKI 46%. When AKI was defined as a rise of serum 
creatinine of >50% from baseline to above 2 mg/dl, the lowest incidence of AKI (14%) was 
found (Barri et al., 2009). Hence, these variations in definitions cause difficulties in 
comparing different studies and demonstrate the need for a consensus in the diagnosis of 
acute renal disease after LT. 
3.2 Definition of acute renal failure 
Several researchers have evaluated the problem of renal impairment post-LT but it is 
difficult to meaningfully compare these studies as a series of different definitions are used 
(Cabezuelo et al., 2002).  
To address this issue, RIFLE classification was introduced in 2002. RIFLE is an acronym for 
risk of renal dysfunction, injury to the kidney (ARI), failure of the kidney (ARF), loss of 
kidney function and end-stage kidney disease (Table 2). It was later modified and is 
functioning as AKIN (Acute Kidney Injury Network) classification since 2005 (Table 3). The 
AKI term includes a wide range of renal dysfunction, starting with a very early and discrete 
renal failure with minimal changes in the serum creatinine level (stage 1, Risk), through 
moderate changes (stage 2, Injury), to an advanced renal failure (stage 3, Failure), often 
requiring renal replacement therapy (Bellomo et al., 2004 & Mehta et al., 2007). Two 
additional stages (Loss of function and Endstage- renal-disease) were introduced in order to 
classify cases of a partial or total and permanent loss of renal function. Some studies used 
these criteria to determine the incidence of ARF post-LT. Kundakci reported that AKD 
occurred in more than half of LTs postoperatively. AKI occurred in 64 (57%) LTs with risk, 
injury, and failure frequencies of 19%, 11%, and 28%, respectively (Kundakci et al., 2010). 
Zhu et al reported that postoperatively, AKI was found in 60% of patients. According to the 
AKIN criteria, it was: stage 1 – in 30%, stage 2 – in 13%, and stage 3 – in 17% of the 
individuals (Zhu et al., 2010). 
AKIN classification was introduced with great enthusiasm, but soon proved to be of little 
use. Its main disadvantages include undersensitivity and no reference to aetiology or 
pathophysiology of AKI. Thus, it does not distinguish between the prerenal azotemia and a 
real injury of the renal parenchyma. Serum creatinine level and eGFR based on it are not 
useful parameters in the early diagnostics of AKI. First of all, the increase in creatinine level 
occurs late, after a few days, with an injury of more than 50% of the renal parenchyma. 
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Moreover, it is influenced by too many factors of creatinine synthesis and secretion in the 
renal tubules. In patients with graft dysfunction, these indicators are even less reliable, 
because of malnutrition and – frequently observed in these patients – high levels of serum 
bilirubin which interferes with creatinine measurements and causes a significant reduction 
in serum creatinine level (Cholongitas et al., 2007a). 
Risk Increase of serum creatinine  
1.5-2 times baseline 
Less than 0.5ml/kg/hr for 
>6hrs 
Injury Increase of serum creatinine  
2-3 times baseline 
Less < 0.5ml/kg/hr for >12hrs 
Failure Increase of serum creatinine of  
> 3 times baseline 
<0. <0.3ml/kg/hr for >24hrs or 
anuria>12hrs
Loss Persistent need for RRT 
for >4 weeks 
End-stage Persistent need for RRT  
for >3 months 
 
Table 2. Risk, Injury, Failure, Loss of Kidney Function, End-stage (RIFLE) Kidney Disease 
classification (Mehta et al., 2007) 
Acute Kidney Injury Recovery 
Stage1 Stage 2 Stage 3 Loss of function>4 weeks but <3 months 
Rise in serum  
creatinine ≥0.3 mg/dl or 
Increase to ≥150%  
to 200%  
(1.5-fold to 2-fold)  
from baseline. 
Increase in serum 
creatinine to  
> 200%- 300%  
(> 2-fold to 3-fold)  
from baseline. 
Increase in serum 
creatinine to > 300% 
(> 3-fold) from baseline, 
or serum creatinine  
≥4.0 mg/dl with an 
acute increase of  
at least 0.5 mg/dl. 
End-stage renal failure 
>3 months 
Urine output < 0.5 
ml/kg/hour for > 6 hrs.
Urine output < 0.5 
ml/kg/hour for > 12 
hrs. 
Urine output < 0.3 
ml/kg/hr for 24 hrs, or 
anuria for 12 hrs. 
Death 
Table 3. Classification/staging system for acute kidney injury modified from RIFLE criteria. 
(Bellomo et al., 2004) 
3.3 Aetiology and risk factors of acute kidney injury after liver transplantation 
In order to apply protective strategies to minimize the occurrence of acute renal dysfunction 
(ARD) and chronic renal dysfunction thereafter, it is vital to define risk factors for ARD and 
manage properly as early as possible (Barri et al., 2009). 
The evaluation of predictive factors for renal failure that occurs postoperatively has been the 
matter of several investigations. Clinical studies evaluating these risk factors have yielded 
variable results. Although the risk factors for AKI are often multifactorial and difficult to 
establish, they can be linked to three distinct time frames in relation to the liver transplant: 
the pretransplant (pre-LT), intraoperative, and post-LT periods as follows: pre-transplant 
(HRS, pre-transplant kidney dysfunction, high bilirubin concentrations), intra-operative 
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(hemodynamic instability, intraoperative bleeding), and postoperative factors (contrast 
nephropathy, acute tubular necrosis secondary to ischemic or toxic agents, liver allograft 
dysfunction, multiple antibiotic use, reoperations especially re-transplantation). Actually the 
most common cause of ARF early after LTx is ischemic acute tubular necrosis, followed later 
by cyclosporine toxicity and sepsis (Fabrizi et al., 2010). 
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Table 4. Risk factors for Post liver transplant Acute Renal Dysfunction  (Lewandowska & 
Matuszkiewicz-Rowinska, 2011) 
3.3.1 Pretransplant renal dysfunction 
The rate of renal failure among patients awaiting liver transplantation (LT) and the waiting 
time for LT have increased in recent years. The introduction of the Model for End-Stage 
Liver Disease (MELD) score will likely further enrich the proportion of LT candidates who 
have renal dysfunction, as creatinine is a key component of MELD calculation. The decision 
to perform combined kidney/liver transplantation (CKLT) as opposed to liver 
transplantation alone can be difficult in patients with end-stage liver disease and recent 
onset renal insufficiency. Because of scarce organ resources, it is important to predict 
accurately which patients with pretransplant renal dysfunction will recover after LT and 
who will have persistent or progressive kidney disease. 
*Pretransplantation serum creatinine level: is an important predictor of post-LT survival and 
renal dysfunction (Brown et al., 1996, Lafayette et al.,1997,  Bilbao et al., 1998, Markmann et 
al., 2001, Nair et al., 2002, Pawarode et al., 2003 and Campbell et al., 2005). Even relatively 
mild elevations in preoperative creatinine (>1.0-1.5 mg/dL) may portend poor renal function  
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postoperatively (Lafayette et al., 1997, Bilbao et al., 1998 and  Pawarode et al., 2003). Bilbao 
(1998), Sanchez (2004) and Yalavarthy (2007) observed that preoperative creatinine >1.5 
mg/dl was predictive of the need for postoperative renal replacement therapy (RRT) and 
also the risk of postoperative infection. Contreras et al reported that preoperative blood urea 
nitrogen was also an important predictive factor for the need for renal replacement therapy 
post-transplant (Contreras et al., 2002). Nair et al, (2002) demonstrated that patients with an 
average preoperative serum creatinine of 0.8 mg/dl had a 5-year patient survival of 62% 
compared to a 5-year survival of only 42% in patients with a preoperative serum creatinine 
of 2.7 mg/dL. Organ Procurement and Transplantation Network/United Network for 
Organ Sharing (OPTN/UNOS) data from 1988 to 1995 demonstrated that patients with a 
preoperative serum creatinine >2 mg/dl had a 5-year survival of only 50%. Furthermore, 
patients requiring preoperative RRT had worse outcomes compared to those not requiring 
RRT (Jeyarajah et al., 1997).  
Cause of renal disease 
May also help predict posttransplantation creatinine. Certainly patients with underlying 
chronic kidney diseases such as glomerulonephritis, diabetic nephropathy would be expected to 
have persistently poor or worsening renal function after LT alone, particularly in the setting 
of calcineurin inhibitor–based immunosuppression. Sezer et al., reported that 
microalbuminuria is a main risk for renal function deterioration (Sezer et al., 2011). Many 
transplant centers have reported that a large majority of their CKLT patients underwent 
transplantation for chronic kidney disease. In contrast, hepatorenal syndrome (in studies 
from the early 1990s) demonstrated a good post-LT alone renal outcome and hence 
concomitant renal transplantation may be avoided. Of patients with ARF due to the 
hepatorenal syndrome, approximately two-thirds will recover, although recovery may be 
delayed 3 months or longer after LT (Yalavarthy et al., 2007). Because waiting times for liver 
transplantation and duration of renal dysfunction prior to transplantation have increased 
since then, it is possible that renal outcomes after LT alone in patients with HRS may be less 
favorable now. 
Duration of pretransplant renal dysfunction 
Bahirwani et al., 2008 showed that patients with preexisting renal dysfunction, especially if 
the duration is more than 12 weeks, experience a significant fall in eGFR after liver 
transplantation alone.  
Most studies agreed on reporting the negative impact of pretransplant renal dysfunction on 
posttransplant renal function, regardless of the criteria that they depended upon to define 
the dysfunction. Lebrón Gallardo (2004), Faenza (2006) and Burra (2009), used serum creatinine; 
Gonwa et al., 2004 used pre-LT GFR & Kim et al., 2004 used creatinine clearance. Indeed 
mortality after LT is affected modestly by the presence of pretransplant acute renal failure 
(<2-fold increase), but increases markedly (up to 8-fold) in the face of acute renal failure 
posttransplant (Yalavarthy et al., 2007). 
3.3.2 MELD score 
The proportion of patients undergoing liver transplantation (LT) with renal insufficiency 
has significantly increased after the MELD era due to the fact that more patients with high 
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(hemodynamic instability, intraoperative bleeding), and postoperative factors (contrast 
nephropathy, acute tubular necrosis secondary to ischemic or toxic agents, liver allograft 
dysfunction, multiple antibiotic use, reoperations especially re-transplantation). Actually the 
most common cause of ARF early after LTx is ischemic acute tubular necrosis, followed later 
by cyclosporine toxicity and sepsis (Fabrizi et al., 2010). 
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onset renal insufficiency. Because of scarce organ resources, it is important to predict 
accurately which patients with pretransplant renal dysfunction will recover after LT and 
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postoperatively (Lafayette et al., 1997, Bilbao et al., 1998 and  Pawarode et al., 2003). Bilbao 
(1998), Sanchez (2004) and Yalavarthy (2007) observed that preoperative creatinine >1.5 
mg/dl was predictive of the need for postoperative renal replacement therapy (RRT) and 
also the risk of postoperative infection. Contreras et al reported that preoperative blood urea 
nitrogen was also an important predictive factor for the need for renal replacement therapy 
post-transplant (Contreras et al., 2002). Nair et al, (2002) demonstrated that patients with an 
average preoperative serum creatinine of 0.8 mg/dl had a 5-year patient survival of 62% 
compared to a 5-year survival of only 42% in patients with a preoperative serum creatinine 
of 2.7 mg/dL. Organ Procurement and Transplantation Network/United Network for 
Organ Sharing (OPTN/UNOS) data from 1988 to 1995 demonstrated that patients with a 
preoperative serum creatinine >2 mg/dl had a 5-year survival of only 50%. Furthermore, 
patients requiring preoperative RRT had worse outcomes compared to those not requiring 
RRT (Jeyarajah et al., 1997).  
Cause of renal disease 
May also help predict posttransplantation creatinine. Certainly patients with underlying 
chronic kidney diseases such as glomerulonephritis, diabetic nephropathy would be expected to 
have persistently poor or worsening renal function after LT alone, particularly in the setting 
of calcineurin inhibitor–based immunosuppression. Sezer et al., reported that 
microalbuminuria is a main risk for renal function deterioration (Sezer et al., 2011). Many 
transplant centers have reported that a large majority of their CKLT patients underwent 
transplantation for chronic kidney disease. In contrast, hepatorenal syndrome (in studies 
from the early 1990s) demonstrated a good post-LT alone renal outcome and hence 
concomitant renal transplantation may be avoided. Of patients with ARF due to the 
hepatorenal syndrome, approximately two-thirds will recover, although recovery may be 
delayed 3 months or longer after LT (Yalavarthy et al., 2007). Because waiting times for liver 
transplantation and duration of renal dysfunction prior to transplantation have increased 
since then, it is possible that renal outcomes after LT alone in patients with HRS may be less 
favorable now. 
Duration of pretransplant renal dysfunction 
Bahirwani et al., 2008 showed that patients with preexisting renal dysfunction, especially if 
the duration is more than 12 weeks, experience a significant fall in eGFR after liver 
transplantation alone.  
Most studies agreed on reporting the negative impact of pretransplant renal dysfunction on 
posttransplant renal function, regardless of the criteria that they depended upon to define 
the dysfunction. Lebrón Gallardo (2004), Faenza (2006) and Burra (2009), used serum creatinine; 
Gonwa et al., 2004 used pre-LT GFR & Kim et al., 2004 used creatinine clearance. Indeed 
mortality after LT is affected modestly by the presence of pretransplant acute renal failure 
(<2-fold increase), but increases markedly (up to 8-fold) in the face of acute renal failure 
posttransplant (Yalavarthy et al., 2007). 
3.3.2 MELD score 
The proportion of patients undergoing liver transplantation (LT) with renal insufficiency 
has significantly increased after the MELD era due to the fact that more patients with high 
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serum creatinine are being transplanted and hence affecting the posttransplant kidney 
function (Sharma et al., 2009). An association was observed between postoperative ARF and 
a higher Model for End-Stage Liver Disease (MELD) score (Sanchez et al., 2004, Campbell et 
al., 2005, Tinti et al., 2010 and Sezer et al., 2011) and between ARF and a reduced pre-LT 
serum albumin (Tinti et al., 2010). No association was noted between ARF and other pre-LT 
parameters. The association of ARF with MELD and hypoalbuminemia may be the result of 
a close relationship between renal and hepatic functions among cirrhotic patients (Tinti et 
al., 2010). Schnitzbauer reported that time on the waiting list with endstage hepatic disease 
is a major risk factor associated with early posttransplant renal impairment (Schnitzbauer et 
al., 2010). 
3.3.3 Early liver allograft dysfunction 
Several studies reported that early liver allograft dysfunction is among the major risk factors 
associated with early posttransplant renal impairment (Fraley et al.,1998, Gainza et al., 2002, 
Ojo et al., 2003, Lebrón Gallardo et al., 2004, Cabezuolo et al., 2006, Yalavarthy et al., 2007 
and Schnitzbauer et al., 2010). Small-for-size (SFS) grafts, which may lead to specific problems 
of delayed function or SFS syndrome (characterized by prolonged cholestasis, ascites or 
coagulopathy) may also aggravate the problem of post-transplant renal dysfunction. Lee et 
al., 2007 in their study on 248 adult patients who underwent LDLT reported a significant 
relationship between small-for-size grafts (GRWR < 0.8) and early postoperative renal 
dysfunction. Yamamoto et al., 2004 also demonstrated this relationship. 
3.3.4 CNI nephrotxicity 
Acute, reversible nephrotoxicity accompanying CNI therapy results from the imbalance in 
vasoactive substance release. The administration of CNI causes vasoconstriction of both the 
afferent and, to a greater degree, the efferent arterioles, which leads to a decrease in renal 
blood flow and glomerular filtration rate (GFR), and an increase in renal vascular resistance. 
In its most extreme form, there is tubular damage and a clinical picture of acute tubular 
necrosis, perhaps on the basis of ischemia. Kidney biopsy histopathology shows 
characteristic isometric vacuoles in proximal and distal tubular cells. Calcineurin inhibitors 
can also cause an acute form of nephrotoxicity manifested by acute renal failure in the early 
posttransplant period. Renal biopsy in these patients shows endothelial damage, formation 
of fibrin thrombi in capillary loops (Fig. 2), eosinophilic material in the walls of arterioles 
and small arteries, with patchy necrosis of smooth muscle cells. This lesion is histologically 
similar to that seen in malignant hypertension and thrombotic thrombocytopenic purpura. 
Indeed, thrombocytopenia sometimes accompanies this syndrome in transplanted patients 
(Remuzzi & Bertani, 1989).  
Diagnosis of ARF 
Vigilant postoperative care including not only monitoring of renal parameters, but also a 
thorough analysis of risk factors of renal dysfunction is vital. 
3.4 Postoperative monitoring of renal parameters 
At present, monitoring of the renal function bases mostly on the results of the serum 
creatinine level and the estimated glomerular filtration rate (eGFR rate) calculated with the 
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use of MDRD and Cockcroft-Gault formula and on monitoring of diuresis (Cockcroft & 
Gault, 1976 and Levey et al., 1999).  
 
Fig. 2. Thrombotic angiopathy of cyclosporine toxicity. The arrowheads point to fibrin 
thrombi in the capillary loops of a glomerulus from a patient with acute cyclosporine 
toxicity. (Smith, 2006: Photomicrograph courtesy of David Howell)  
Because of the above-mentioned limitations of AKIN criteria, it is now attempted to find 
new biomarkers released by the renal tubules, which (if increased in urine or blood serum) 
would allow for an early diagnosis of AKI or identification of a group at increased risk of 
AKI. The most frequently mentioned indicators of this type include: cystatin C (Biancofiore 
et al., 2006), NGAL (neutrophil gelatinase-associated lipocalin) (Portal et al., 2010), KIM-1 (kidney 
injury molecule-1) or interleukin-18 (Lewandowska  & Matuszkiewicz-Rowinska, 2011). 
Recently, there have been a few reports published that evaluated the usefulness of the latest 
methods of an early AKI assessment in post-LT patients. Portal et al. evaluated the 
usefulness of serum and urine NGAL level measurements in patients immediately after liver 
transplantation, in prognosing the risk of AKI development within the next 48 hours. A 
multivariate regression analysis showed two independent risk factors of AKI development: 
APACHE II (OR 1.64/point; 95% CI, 1.22–2.21, P=0.001) and serum NGAL level (OR 
1.01/ng/ml, 95% CI, 1.00–1.02, P=0.002). When combined together (so called renal risk 
index), these two factors revealed the highest predictive value. Index with APACHE II score 
of >13 and serum NGAL level of >258 ng/ml, calculated at ≥1, showed a sensitivity of 100% 
and a specificity of 76% in the prediction of severe AKI [Portal et al., 2010]. 
3.4.1 Analysis of risk factors 
Xu and colleagues, on the basis of the analysis of data from 102 patients subjected to LT, 
developed a predictive model of AKI incidence following LT. A multivariate analysis 
showed that independent risk factors of this complication included: preoperative creatinine 
level of >1.2 mg/dl, intraoperative diuresis of ≤60 ml/hour, intraoperative hypotension,  
and use of noradrenaline. They calculated the risk score as follows: [–2.128 + 1.109× 
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serum creatinine are being transplanted and hence affecting the posttransplant kidney 
function (Sharma et al., 2009). An association was observed between postoperative ARF and 
a higher Model for End-Stage Liver Disease (MELD) score (Sanchez et al., 2004, Campbell et 
al., 2005, Tinti et al., 2010 and Sezer et al., 2011) and between ARF and a reduced pre-LT 
serum albumin (Tinti et al., 2010). No association was noted between ARF and other pre-LT 
parameters. The association of ARF with MELD and hypoalbuminemia may be the result of 
a close relationship between renal and hepatic functions among cirrhotic patients (Tinti et 
al., 2010). Schnitzbauer reported that time on the waiting list with endstage hepatic disease 
is a major risk factor associated with early posttransplant renal impairment (Schnitzbauer et 
al., 2010). 
3.3.3 Early liver allograft dysfunction 
Several studies reported that early liver allograft dysfunction is among the major risk factors 
associated with early posttransplant renal impairment (Fraley et al.,1998, Gainza et al., 2002, 
Ojo et al., 2003, Lebrón Gallardo et al., 2004, Cabezuolo et al., 2006, Yalavarthy et al., 2007 
and Schnitzbauer et al., 2010). Small-for-size (SFS) grafts, which may lead to specific problems 
of delayed function or SFS syndrome (characterized by prolonged cholestasis, ascites or 
coagulopathy) may also aggravate the problem of post-transplant renal dysfunction. Lee et 
al., 2007 in their study on 248 adult patients who underwent LDLT reported a significant 
relationship between small-for-size grafts (GRWR < 0.8) and early postoperative renal 
dysfunction. Yamamoto et al., 2004 also demonstrated this relationship. 
3.3.4 CNI nephrotxicity 
Acute, reversible nephrotoxicity accompanying CNI therapy results from the imbalance in 
vasoactive substance release. The administration of CNI causes vasoconstriction of both the 
afferent and, to a greater degree, the efferent arterioles, which leads to a decrease in renal 
blood flow and glomerular filtration rate (GFR), and an increase in renal vascular resistance. 
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use of MDRD and Cockcroft-Gault formula and on monitoring of diuresis (Cockcroft & 
Gault, 1976 and Levey et al., 1999).  
 
Fig. 2. Thrombotic angiopathy of cyclosporine toxicity. The arrowheads point to fibrin 
thrombi in the capillary loops of a glomerulus from a patient with acute cyclosporine 
toxicity. (Smith, 2006: Photomicrograph courtesy of David Howell)  
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usefulness of serum and urine NGAL level measurements in patients immediately after liver 
transplantation, in prognosing the risk of AKI development within the next 48 hours. A 
multivariate regression analysis showed two independent risk factors of AKI development: 
APACHE II (OR 1.64/point; 95% CI, 1.22–2.21, P=0.001) and serum NGAL level (OR 
1.01/ng/ml, 95% CI, 1.00–1.02, P=0.002). When combined together (so called renal risk 
index), these two factors revealed the highest predictive value. Index with APACHE II score 
of >13 and serum NGAL level of >258 ng/ml, calculated at ≥1, showed a sensitivity of 100% 
and a specificity of 76% in the prediction of severe AKI [Portal et al., 2010]. 
3.4.1 Analysis of risk factors 
Xu and colleagues, on the basis of the analysis of data from 102 patients subjected to LT, 
developed a predictive model of AKI incidence following LT. A multivariate analysis 
showed that independent risk factors of this complication included: preoperative creatinine 
level of >1.2 mg/dl, intraoperative diuresis of ≤60 ml/hour, intraoperative hypotension,  
and use of noradrenaline. They calculated the risk score as follows: [–2.128 + 1.109× 
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(preoperative creatinine level of >1.2 mg/dl) + 2.243 × (intraoperative diuresis of ≤60 ml/hr) 
+ 1.542 × (intraoperative hypotension) – 2.463 × (intraoperative use of noradrenaline)]. Next, 
the authors studied the usefulness and predictive value of the developed formula in a 
prospective study including 44 patients after LT, assuming that the probability of AKI = 
EXP (risk score)/ [1 + EXP (risk score)]. Aiming to achieve the highest sensitivity and 
specificity of the indicator (75% and 93.8%, respectively), a cut-off value of –0.2 was 
assumed as optimal in determining the prognosis of AKI. This meant that among patients 
with an index value of ≥–0.2, the risk of AKI development was significantly higher than in 
patients with an index value of <–0.2. The model developed by the authors proved to be 
reliable: AKI occurred in 9 out of 11 patients from the group of high risk, and only in 3 
individuals out of 33 from the low-risk group (Xu et al., 2010). 
3.5 Prevention of acute renal dysfunction 
To prevent acute kidney injury effectively, it is necessary to know its risk factors, to evaluate 
the patient in detail before liver transplantation, and to obey the rules of conduct, 
characteristic for all clinical situations that could lead to AKI development. 
3.5.1 General measures 
- thorough monitoring of the water and electrolyte balance,  
- avoidance of nephrotoxic drugs,  
- discontinuation of preparations inhibiting the effect of angiotensin II,  
- careful dosing of other medicines, with adjustments of doses to the current renal 
function. 
Unfortunately, despite promising results of in vitro and experimental studies, it was 
impossible to prove the protective effect of N-acetylcysteine on kidneys in that population 
(Hilmi et al., 2010, Sagias et al., 2010 and Jegatheeswaran & Siriwardena, 2011).  
3.5.2 Modification of nephrotoxic immunosuppressive regimens  
To avoid postoperative acute renal failure and/or chronic renal failure has met with 
variable results (Fabrizi et al., 2010). There are no data to suggest that switching from one 
calcineurin inhibitor to another at equipotent doses will result in less nephrotoxicity. 
However, as trough tacrolimus levels correlate more closely with the area under the curve of 
drug exposure than do trough cyclosporine levels, it may be easier to avoid calcineurin 
inhibitor toxicity using tacrolimus. If cyclosporine is used, the blood level drawn 2hrs post 
dose (C2 level) should be used to monitor therapy. 
Strategies to limit CNI exposure include CNI minimization, avoidance, and withdrawal 
Candidates for such a treatment would be first of all patients with impaired renal function 
found before transplantation. There is no well-defined protocol to prevent or minimize 
cyclosporine or tacrolimus nephrotoxicity.  
Some centers advocate Calcineurin inhibitor minimization using mycophenolate mofetil or 
sirolimus. This may be associated with a modest increase in creatinine clearance (CrCl) and 
a decrease in serum creatinine (SCr) in the short term. Mycophenolate mofetil may improve 
renal outcomes during CNI minimization more than sirolimus. Despite improvement in  
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CrCl or SCr, CNI nephrotoxicity is progressive over time when CNI exposure is maintained. 
Persistent damage is observed on biopsies as long as the CNIs are continued.  
CNI withdrawal 
May be the best option by delivering CNIs during the early period of immunologic graft 
injury and then converting them to less nephrotoxic agents before significant renal damage 
occurs (Flechner et al., 2008). Late CNI withdrawal has achieved variable results, possibly 
because withdrawal was attempted after the kidney damage was too extensive. In a case 
report on 3 patients with renal function impairment who switched from CNI to sirolimus, 2 
improved substantially and came off dialysis, while in 1 (whose renal dysfunction was 
initially milder, not severe enough to require dialysis) serum creatinine levels remained 
altered after switching to sirolimus (Kamar et al., 2007). Early CNI withdrawal, prior to 
significant kidney damage, has generally improved CrCl and markers of fibrosis, a finding 
also observed with sirolimus in most studies. Successful withdrawal appears to be more 
effective than CNI minimization. Lam et al stressed that sirolimus conversion should be 
initiated early since late conversion rarely improves chronic renal dysfunction (Lam et al., 
2004). In fact, several studies have shown that in patients with pre-existing renal disease, 
sirolimus can even worsen nephrotoxicity and promote proteinuria (Bumbea et al., 2005, 
Letavarnier et al., 2005 and Diekmann et al., 2007). 
Antibody induction with delayed CNI initiation 
It has been suggested that in case of high serum creatinine levels at the time of grafting, it 
may be wise to delay the use of calcineurin inhibitor based immunosuppression in the 
immediate post-operative period (Distant & Gonwa, 1993). Polyclonal antibody 
(thymoglobulin) induction was used to delay CNI use and avoid renal toxicity without 
increasing the risk of rejection or HCV recurrence. However side-effects such as “first dose 
reaction” have been reported in 80% of patients. This can often be ameliorated by 
premedication with antipyretics and steroids. Other side-effects include thrombocytopenia, 
CMV infection, posttransplant lymphoproliferative disease (PTLD), serum sickness and 
anaphylaxis (Pillai & Levitsky, 2009).  
Later, monoclonal antibody induction using basiliximab (anti-CD25 monoclonal anti-body) 
and alemtuzumab (anti-CD 52 antibody) was used. These antibodies remain in the 
circulatory system for weeks after initiation of therapy and have been used successfully with 
low-dose CNIs. Neuhaus (2002) and Liu (2004) reported successful use of basiliximab with 
less nephrotoxicity and fewer side-effects compared to the antithymocyte globulins. Also, 
Tzakis (2004) and Marcos (2004) showed that liver transplant recipients who received 
alemtuzumab induction with low dose tacrolimus had less renal toxicity than those who 
received standard doses of tacrolimus. The use of these antibodies may be effective to limit 
CNI exposure, but longer-term follow-up data are required (Flechner et al., 2008). Actually a 
recent study showed that induction with basiliximab resulted in 30-day and 1-year patient, 
graft and renal outcomes comparable with a control group receiving standard CNI-based 
immunosuppression. The authors concluded that antibody induction with delayed CNI 
should be further studied prospectively (Verna et al., 2011).Also a recent study showed that 
steroid-free alemtuzumab induction regimen was associated with less hypertension and 
rejection but with more infectious complications. Thus, the overall benefit of alemtuzumab 
induction in LT recipients is called into question (Levitsky et al., 2011). 
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CrCl or SCr, CNI nephrotoxicity is progressive over time when CNI exposure is maintained. 
Persistent damage is observed on biopsies as long as the CNIs are continued.  
CNI withdrawal 
May be the best option by delivering CNIs during the early period of immunologic graft 
injury and then converting them to less nephrotoxic agents before significant renal damage 
occurs (Flechner et al., 2008). Late CNI withdrawal has achieved variable results, possibly 
because withdrawal was attempted after the kidney damage was too extensive. In a case 
report on 3 patients with renal function impairment who switched from CNI to sirolimus, 2 
improved substantially and came off dialysis, while in 1 (whose renal dysfunction was 
initially milder, not severe enough to require dialysis) serum creatinine levels remained 
altered after switching to sirolimus (Kamar et al., 2007). Early CNI withdrawal, prior to 
significant kidney damage, has generally improved CrCl and markers of fibrosis, a finding 
also observed with sirolimus in most studies. Successful withdrawal appears to be more 
effective than CNI minimization. Lam et al stressed that sirolimus conversion should be 
initiated early since late conversion rarely improves chronic renal dysfunction (Lam et al., 
2004). In fact, several studies have shown that in patients with pre-existing renal disease, 
sirolimus can even worsen nephrotoxicity and promote proteinuria (Bumbea et al., 2005, 
Letavarnier et al., 2005 and Diekmann et al., 2007). 
Antibody induction with delayed CNI initiation 
It has been suggested that in case of high serum creatinine levels at the time of grafting, it 
may be wise to delay the use of calcineurin inhibitor based immunosuppression in the 
immediate post-operative period (Distant & Gonwa, 1993). Polyclonal antibody 
(thymoglobulin) induction was used to delay CNI use and avoid renal toxicity without 
increasing the risk of rejection or HCV recurrence. However side-effects such as “first dose 
reaction” have been reported in 80% of patients. This can often be ameliorated by 
premedication with antipyretics and steroids. Other side-effects include thrombocytopenia, 
CMV infection, posttransplant lymphoproliferative disease (PTLD), serum sickness and 
anaphylaxis (Pillai & Levitsky, 2009).  
Later, monoclonal antibody induction using basiliximab (anti-CD25 monoclonal anti-body) 
and alemtuzumab (anti-CD 52 antibody) was used. These antibodies remain in the 
circulatory system for weeks after initiation of therapy and have been used successfully with 
low-dose CNIs. Neuhaus (2002) and Liu (2004) reported successful use of basiliximab with 
less nephrotoxicity and fewer side-effects compared to the antithymocyte globulins. Also, 
Tzakis (2004) and Marcos (2004) showed that liver transplant recipients who received 
alemtuzumab induction with low dose tacrolimus had less renal toxicity than those who 
received standard doses of tacrolimus. The use of these antibodies may be effective to limit 
CNI exposure, but longer-term follow-up data are required (Flechner et al., 2008). Actually a 
recent study showed that induction with basiliximab resulted in 30-day and 1-year patient, 
graft and renal outcomes comparable with a control group receiving standard CNI-based 
immunosuppression. The authors concluded that antibody induction with delayed CNI 
should be further studied prospectively (Verna et al., 2011).Also a recent study showed that 
steroid-free alemtuzumab induction regimen was associated with less hypertension and 
rejection but with more infectious complications. Thus, the overall benefit of alemtuzumab 
induction in LT recipients is called into question (Levitsky et al., 2011). 
 




The use of the so-called renal-sparing agents is still debatable. Avoidance is hampered by 
lack of experience and possible sirolimus-induced side effects (delay in surgical wound 
repair because it inhibits fibrogenesis (Montalbano et al., 2004), inducing proteinuria, 
anaemia, thrombocytopenia, peripheral swelling, hypercholesterolemia and gastrointestinal 
disorders (Vivarelli et al., 2006). Use of sirolimus with mycophenolate mofetil to avoid CNI 
exposure de novo has improved glomerular filtration rate for at least two years in most 
studies in kidney transplantation; however, experience is limited in liver and heart 
transplantation, and reports of delayed graft function and wound healing with sirolimus 
may have dampened enthusiasm for de novo use. There is hardly published evidence for 
CNI-free de novo approaches with mTOR-inhibitors in liver transplant collectives. 
Schnitzbauer et al are conducting a prospective, noncontrolled, two-stage study 
(PATRON07) on patients with serum creatinine >1.5mg/dl or eGFR < 50 ml/min at the time 
of transplantation. Its objective is to evaluate the feasibility of a de novo CNI-free 
immunosuppressive regimen based on induction therapy with basiliximab (20 mg IV day 0 
and day 4 after transplantation), prednisolone 500mg during reperfusion then 1mg/kg and 
tapered by month 6 after LT, mycophenolate mofetil (2g/d bid), and mTOR-inhibition with 
sirolimus after day 10 after LT aiming at trough-levels of 4 to 10 ng/ml. The primary 
endpoint is defined as the incidence of steroid-resistant acute rejection within the first 30 
days after liver transplantation. The authors hope that the results of PATRON07 may be the 
basis for a large multicenter randomized controlled trial in patients with poor renal function 
at the time-point of liver transplant (Schnitzbauer et al., 2010). 
If CNI-free-"bottom-up” immunosuppression strategies are safe and effective, this may be 
an innovative concept that could improve the patient short and long-time outcome with 
regards to renal function, infectious complications and avoidance of over-
immunosuppression after LT. 
Future direction of immunosuppression: Costimulation blockade (Belatacept) 
Belatacept is a soluble cytotoxic T-lymphocyte antigen-4 (CTLA-4) agent which binds CD80 
and CD86 and inhibits T cell activation. Belatacept competes with the CD28 receptor on T 
cells which normally binds CD80 and CD86 on the antigen presenting cell as a co-
stimulatory signal required for T cell activation. Belatacept is administered intravenously 
once a month and does not carry the renal toxicity of CNIs. Clinical trials in liver transplant 
patients are currently ongoing with this agent (Pillai & Levitsky, 2009). 
3.5.3 Surgical technique of ‘piggy back’ 
It is necessary to conduct further studies in order to answer the question whether the new 
surgical technique of ‘piggy back’ type will allow for a reduction of AKI incidence 
(Cabezuelo et al., 2003 and 2006). 
3.6 Dialysis in the liver transplant patient 
Around 8-17% of the patients with AKI after LT require renal replacement therapy 
(Lewandowska  & Matuszkiewicz-Rowinska, 2011). Dialytic therapy in the immediate 
postoperative period requires close attention to hemodynamics and coagulation parameters. 
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(Smith, 2006 and Lewandowska & Matuszkiewicz-Rowinska, 2011).The most frequently 
used perioperative treatment methods include continuous techniques in 75% of cases, such 
as continuous veno-venous haemo(dia)filtration (CVVHD), dialysis of SLED type (slow low 
efficiency dialysis), and intermittent haemodialysis in 25% of cases. Continuous techniques 
are preferred for two main reasons: the patients are frequently haemodynamically unstable 
and remain at a significant risk of brain oedema. However, the real advantage of these 
methods over the applied standard haemodialysis has not been proven so far. 
In the liver transplant patient with impaired hepatic clearance and renal failure, attention 
should be paid to the route of excretion of all pharmacologic agents given and doses 
adjusted accordingly. Cyclosporine, tacrolimus, prednisone, and mycophenolate mofetil are 
not removed by hemodialysis to any significant extent, while methylprednisolone and 
azathioprine (and its active metabolite mercaptopurine) are cleared partially during dialysis. 
Most angiotensin-converting enzyme inhibitors are dialyzable, with benazepril and 
quinapril being exceptions. Calcium channel blockers are generally not cleared by 
hemodialysis, while many of the beta-blockers (atenolol, acebutalol, metoprolol, nadalol, 
sotalol) are cleared. Because atenolol is primarily cleared by the kidneys, the dose to achieve 
a desired effect is much lower in patients with poor renal function. Metoprolol on the other 
hand is primarily metabolized by the liver. Metabolites of verapamil with atrioventricular 
(AV) node-blocking properties, but little antihypertensive effect can accumulate in patients 
on hemodialysis. This agent is thus best avoided in end-stage renal disease (Smith, 2006). 
In some of the cases, there may appear a need for renal replacement therapy during LT 
procedure mostly due to hypervolemia and the risk of brain oedema (Lewandowska & 
Matuszkiewicz-Rowinska, 2011). Townsend et al. used intraoperative CVVHD in 41 out of 
636 patients (6.4%) that they operated on. A mean time of dialysis was 258 minutes and a 
mean filtration rate was 1–1.5 l/h. No significant complications were observed apart from 
blood clotting in the dialyser (no anticoagulation was used in most of the patients) in 40% of 
cases. Indications included either typical, life threatening symptoms of AKI, such as 
overhydration or hyperkalemia, or disorders typical for this group of patients: lactic 
acidosis, hyponatremia, risk of brain oedema or necessity of transfusion of large volumes of 
blood preparations. In 78% of cases, CVVHD procedures were continued after OLT for 3–11 
days (Townsend et al., 2009). 
3.7 Prognosis of acute kidney injury 
Acute renal failure (ARF) has been associated with an 8-fold increase in mortality risk, 
prolonged ventilation time and intensive care unit (ICU) stay, greater risk for infectious 
complications, and greater hospital costs. De Simone et al reported an in-hospital mortality 
rate as high as 41% for patients with ARF versus 5% for those with preserved renal function 
(De Simone et al., 2009). Mortality of patients who required renal replacement therapy is 
from 45.1% to 67% (Cabezuelo et al., 2002, Faenza et al., 2006). 
Zhu and colleagues analysed retrospectively the influence of the renal function following LT 
on late clinical outcomes in 193 patients. Among patients with acute kidney injury (AKI), the 
28-day and 1-year mortality was significantly higher than in non-AKI patients (15.5% and 
25.9% vs. 0% and 3.9%, respectively; P<0.5). One-year survival of non-AKI patients was 96%, 
and of AKI patients in stage 1, 2, and 3– 85.5%, 84%, and 45.3%, respectively. The Cox 
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regression analysis showed that the independent risk factors of death in the first year 
following the transplantation included postoperative AKI (HR 12.1; P<0.05), postoperative 
infection (HR 4.7; P<0.01), postoperative hypertension (HR 4.4; P<0.01), and postoperative 
APACHE II index of ≥10 (HR 3.6; P<0.05) (Zhu et al., 2010). Similar results were published 
by Gonwa et al. (2001a) and by Ishitani et al. (1993). 
During the later course, renal dysfunction exerts an important influence on the quality of life 
of transplant recipients (Alessandria et al., 2005, Lewandowska & Matuszkiewicz-Rowinska, 
2011). AKI significantly increases the risk of development of chronic renal failure in the late 
post-LT period. The risk of developing chronic renal failure after LT is approximately 20% 
after 5 years, associated with the use of calcineurin inhibitors and a 4-fold increased 
mortality risk (Sharma et al., 2009 and Schnitzbauer et al., 2010). 
4. Chronic renal dysfunction 
With improved survival of liver transplant recipients, chronic kidney disease has emerged 
as a major long-term complication after OLT (Bahirwani & Reddy, 2009). In fact, liver 
transplant recipients have the highest five-yr incidence of CRF of any non-renal solid organ 
transplant recipient; additionally, the risk of death is at least fourfold higher in patients who 
develop CRF (Ojo et al., 2003). Numerous studies have been performed in the last decade in 
order to clarify the epidemiology and clinical significance of chronic kidney dysfunction 
among liver recipients (Fisher et al., 1998, Brown et al., 2001, Cohen et al., 2002 & Herlenius 
et al., 2008). 
4.1 Epidemiology of chronic renal dysfunction 
The incidence of chronic kidney disease (CKD) post-Liver transplant varies widely, from 10 
to 83%, most likely owing to the lack of a standard definition of post-transplantation chronic 
renal disease, differences in the methodology utilised to estimate renal function, and variable 
periods of follow-up (Fabrizi et al., 2010).The frequency of CKD (defined as eGFR <60 ml/min) 
according to recent series is listed in Table 5. However the incidence of the milder forms of 
renal dysfunction (GFR between ≥30 mL/min and ≤70 mL/min) is likely to be considerably 
higher than estimated (Fisher et al., 1998, Randhawa and Shapiro, 2005). Definitely, the 
incidence of CKD increases with time. The latest report on the epidemiology of CKD after 
liver transplantation has been offered by Lee et al (2010). A cohort of 431 recipients who 
underwent liver transplantation between 1997 and 2008 was included. The cumulative 
incidence of CKD (eGFR <60 ml/min) was 17% at 1 year, 23% at 3 years, and 27% at 5 years. 
Sharma et al., 2009 reported the cumulative incidence of post-LT CRF at 1, 3, and 5 years 
was 8%, 17% and 22%, respectively.  
Authors Frequency Time post-LT 
Lee J, et al (2010) 
Burra P, et al (2009) 
Kim S, et al (2004) 
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4.2 Definitions of chronic kidney disease 
The most common definition used is eGFR<60ml/min. Other definitions of CKD have been 
used. Gonwa and colleagues, defined post-LT CRD as sustained serum creatinine >2.5 
mg/dl. They reported that the combined incidence of CKD with end-stage renal disease (on 
RRT), was 4.3% at 5 years and 18% after 13 years of follow-up (Gonwa et al., 2001b). Ojo et 
al, 2003 in a larger study analyzed the data from the Scientific Registry of Transplant 
Recipients for 36,849 adult patients who had LT in the United States between 1990, and 2000. 
The incidence of post-LT CRD was 18% at 5 years and 26% at 10 years. This study defined 
post-LT CRD as GFR < 29 mL/minute/1.73 m2 or the development of end-stage renal 
disease, which was defined as initiation of RRT or listing for renal transplantation. 
Chronic renal dysfunction, not only has implications in terms of an increased demand on 
resources, but is also significantly associated with a higher patient mortality rate. Hence 
identification of the risk factors for its development of chronic renal dysfunction after liver 
transplantation is crucial. 
4.3 Risk factors for posttransplant chronic kidney disease 
Although previously attributed largely to calcineurin inhibitor toxicity (Ojo et al., 2003, 
Pillebout et al., 2005), it has become clear that the onset of chronic renal failure following LT 
is multifactorial, and reported to be correlated with posttransplant acute renal failure (Lee et 
al., 2010 and Tinti et al., 2010), pre-transplant renal dysfunction (Kamath et al., 2001; Burra et 
al., 2009 and Tinti et al., 2011), hepatitis C status, age, female gender, diabetes mellitus, 
hypertension, Model for End Stage Liver Disease (MELD), pretransplant proteinuria (Lee et 
al., 2010), pretransplant hepatorenal syndrome, alcohol intake (Hetz et al., 2005, Pillebout et 
al., 2005 and Randhawa & Shapiro, 2005), smoking and dyslipidemia (Sezer et al.,2011). 
4.3.1 Postoperative acute renal failure (ARF) and dialysis requirement in the post-
transplantation period 
Post-LT ARF was proved to be an early predictor of chronic kidney disease (CKD) in several 
studies (Ojo et al., 2003; Kim et al., 2004; Burra et al., 2009 and Sharma et al, 2009). Barri and 
his colleagues, 2009 stated clearly that the high incidence of acute kidney injury post–liver 
transplantation is an important risk factor for long-term renal dysfunction and its associated 
morbidity and mortality. Ojo et al., 2003 reported a relative risk of 2.13. In the study by Tinti 
and colleagues, post-LT CKD was present in 44.4% of patients with ARF in contrast to 6.7% 
of patients without ARF (Tinti et al., 2010). A multivariate Cox regression analysis revealed 
that the overall risk of CKD development (eGFR < 60 mL/min/1.73 m2) was associated with 
the existence of posttransplant ARF and its severity. In fact, a recent consensus conference 
on acute kidney injury(AKI) suggested that since AKI is a very strong predictor of CKD, a 
milder definition for AKI should be used to detect this problem early and to intervene 
before it is severe and progresses to CRD (Barri et al., 2009). 
4.3.2 Abnormal GFR at different intervals posttransplant 
Sanchez et al., 2010 in a study conducted on 592 liver transplant recipients also confirmed 
this finding and showed that patients with GFR less than 60 ml/min per 1.73 m2 at month 3 
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post-LT CRD as GFR < 29 mL/minute/1.73 m2 or the development of end-stage renal 
disease, which was defined as initiation of RRT or listing for renal transplantation. 
Chronic renal dysfunction, not only has implications in terms of an increased demand on 
resources, but is also significantly associated with a higher patient mortality rate. Hence 
identification of the risk factors for its development of chronic renal dysfunction after liver 
transplantation is crucial. 
4.3 Risk factors for posttransplant chronic kidney disease 
Although previously attributed largely to calcineurin inhibitor toxicity (Ojo et al., 2003, 
Pillebout et al., 2005), it has become clear that the onset of chronic renal failure following LT 
is multifactorial, and reported to be correlated with posttransplant acute renal failure (Lee et 
al., 2010 and Tinti et al., 2010), pre-transplant renal dysfunction (Kamath et al., 2001; Burra et 
al., 2009 and Tinti et al., 2011), hepatitis C status, age, female gender, diabetes mellitus, 
hypertension, Model for End Stage Liver Disease (MELD), pretransplant proteinuria (Lee et 
al., 2010), pretransplant hepatorenal syndrome, alcohol intake (Hetz et al., 2005, Pillebout et 
al., 2005 and Randhawa & Shapiro, 2005), smoking and dyslipidemia (Sezer et al.,2011). 
4.3.1 Postoperative acute renal failure (ARF) and dialysis requirement in the post-
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Post-LT ARF was proved to be an early predictor of chronic kidney disease (CKD) in several 
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his colleagues, 2009 stated clearly that the high incidence of acute kidney injury post–liver 
transplantation is an important risk factor for long-term renal dysfunction and its associated 
morbidity and mortality. Ojo et al., 2003 reported a relative risk of 2.13. In the study by Tinti 
and colleagues, post-LT CKD was present in 44.4% of patients with ARF in contrast to 6.7% 
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this finding and showed that patients with GFR less than 60 ml/min per 1.73 m2 at month 3 
 
Liver Transplantation – Technical Issues and Complications 
 
292 
post-transplant have a higher risk of developing renal failure; however, those who avoid 
renal failure seem to maintain renal function long-term. Kamar et al. reported the eGFR after 
6 months was the only risk factor of renal failure for further 60±48 months. This was also a 
predictor of glomerular sclerosis found in 50% of glomerules in the renal biopsy performed 
afterwards (Kamar et al., 2011). Other studies have reported that an abnormal GFR at 1 year 
identifies patients at risk of chronic renal dysfunction (Cohen et al., 2002 & O’Riordan et al., 
2006).  
4.3.3 Pretransplant renal dysfunction 
Impaired pre-transplantat kidney function is a prognostic indicator for chronic kidney 
disease (CKD) following liver transplantation, as recently highlighted by a meta-analysis of 
clinical, observational studies. A stratified analysis including only studies provided with 
baseline GFR, revealed that the summary estimate of RR and 95% CIs for occurrence of 
chronic renal failure after liver transplantation in patients with diminished renal function at 
transplantation was 2.12 (95% CI, 1.01-4.46, p=0.01) (Fabrizi et al., 2011). Even relatively 
mild elevations in pre-transplant creatinine >1.5 mg/dL may portend poor long term renal 
function. This was confirmed by many investigators (Moreno et al., 2003, Kim et al., 2004 
and Burra et al., 2009). A multivariate Cox regression analysis performed by Lee et al 
revealed that the overall risk of CKD development was associated with low pre transplant 
eGFR in addition to post-transplant acute renal failure (Lee et al., 2010). In fact, Sharma et 
al., 2009 concluded that the estimated GFR at LT was the most important determinant of 
post-LT chronic renal failure. Sezer reported that after 5 years, GFR negatively correlated 
with initial Renal Resistive Index (r=-0.32; P<.01).  
Duration of pretransplant dysfunction 
Campbell (2005) suggested that duration, rather than the cause, of pretransplant renal 
dysfunction (pre-LT RD) is the key to predicting creatinine at 12 months after 
transplantation. ROC analysis among LT alone patients showed that the duration of renal 
disease by itself had a moderate ability to predict creatinine >1.5 mg/dL at 12 months 
posttransplantation (area under ROC curve = 0.71). The optimal predictive cutoff was 3.6 
weeks. However they stated that they cannot at this time recommend that all patients with 
duration of renal disease longer than 3.6 weeks undergo combined liver kidney 
transplantation (CLKT) since creatinine of 1.5 mg/dL 1 year after transplantation is not 
necessarily high enough to justify concomitant renal transplantation. Instead they 
recommended that a threshold duration of renal dysfunction in combination with other 
predictive clinical variables (e.g height of creatinine, requirement for RRT) be prospectively 
investigated as an aid to clinical decision making. 
Indeed for liver transplant (LT) candidates with pretransplant mild to moderate chronic 
renal impairment or recent-onset ARF, the decision of whether to perform LT alone or CLKT 
can be challenging because no single factor has been shown to be predictive of the degree of 
progression of chronic kidney disease following successful LT. Although Pham et al., 2007 
suggested, like Campbell, that the duration of pretransplant renal dysfunction had a 
negative impact on posttransplant renal function outcome, Marik et al., 2006 and Sharma et 
al., 2009, in contrast, failed to demonstrate that the duration of pretransplant renal 
dysfunction was predictive of post-LT renal outcome. 
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4.3.4 Calcineurin inhibitors (CNI) 
Chronic CNI nephrotoxicity is caused by immunological and non-immunological damage. 
Histopathological examination shows renal tubular atrophy with typical microcalcification, 
patchy fibrosis and nodular arteriolar hyalinosis. According to Mihatsch, arteriolopathy, the 
main symptom of CNI nephrotoxicity, is a variant of thrombotic microangiopathy with 
slow, subclinical course. Differentiation between arteriolar hyalinosis associated with CNI 
administration and arteriolar sclerosis in hypertension, diabetes, or the elderly poses a 
challenge. A typical feature of CNI toxicity is substitution of smooth muscle cells by hyaline 
deposits in the external media layer; while in arteriolar hyalinosis in other clinical situations 
the smooth muscle cells are intact and hyaline deposits accumulate beneath the endothelium 
(Mihatsh et al., 1994).  
There is no precise classification to assess CNI nephrotoxicity; that is why new scales and 
classifications are developed in order to enhance the precision of diagnosing CNI 
nephrotoxicity. The new scales to evaluate CNI nephrotoxicity, like the older ones, show 
arteriolar hyalinosis as the most typical abnormality (Kambham et al., 2007). One histologic 
study reported the association of these changes with cyclosporine dose and over time. Mild 
arteriolar hyalinosis at six months appeared to be associated with high doses and was 
reversible. By comparison, at three years, irreversible severe arteriolar hyalinosis and 
glomerosclerosis was observed, despite decreased doses and trough levels (Nankivell et al., 
2003). 
 
Fig. 3. Nodular hyalinosis typical of CNI (John et al., 2010) 
Chronic lesions and acute nephrotoxicity in CNI treatment are caused by various mediators, 
including renin–angiotensin–aldosterone (RAA) system, which by activating angiotensin 
type 1 receptor is not only a contributory factor in renal vascular bed constriction, but also 
influences kidney fibrosis and aldosterone release. Activation of RAA system through CNI 
may cause harmful hemodynamic (vasoconstriction) and nonhemodynamic changes (via 
enhanced synthesis of transforming growth factor-β, vascular endothelial growth factor and 
enhanced renal cell apoptosis) (Friedlander, 2007). The CNI-induced TGF-β formation 
produces tubulointerstitial fibrosis by increased synthesis and decreased extracellular 
matrix degradation (Khanna et al., 2002). Administration of losartan, AT1 blocker, in 
transplant patients leads to a significant decrease in TGF-β serum levels and increased GFR 
(Campistol et al., 2001). 
Recent trials have shown that aldosterone, the final product in the RAA system, may play an 
important role in CNI nephrotoxicity; therefore, spironolactone administration may be an 
effective strategy in the prevention of CNI nephrotoxicity (Perez-Rojas et al., 2007). During 
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post-transplant have a higher risk of developing renal failure; however, those who avoid 
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2006).  
4.3.3 Pretransplant renal dysfunction 
Impaired pre-transplantat kidney function is a prognostic indicator for chronic kidney 
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baseline GFR, revealed that the summary estimate of RR and 95% CIs for occurrence of 
chronic renal failure after liver transplantation in patients with diminished renal function at 
transplantation was 2.12 (95% CI, 1.01-4.46, p=0.01) (Fabrizi et al., 2011). Even relatively 
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function. This was confirmed by many investigators (Moreno et al., 2003, Kim et al., 2004 
and Burra et al., 2009). A multivariate Cox regression analysis performed by Lee et al 
revealed that the overall risk of CKD development was associated with low pre transplant 
eGFR in addition to post-transplant acute renal failure (Lee et al., 2010). In fact, Sharma et 
al., 2009 concluded that the estimated GFR at LT was the most important determinant of 
post-LT chronic renal failure. Sezer reported that after 5 years, GFR negatively correlated 
with initial Renal Resistive Index (r=-0.32; P<.01).  
Duration of pretransplant dysfunction 
Campbell (2005) suggested that duration, rather than the cause, of pretransplant renal 
dysfunction (pre-LT RD) is the key to predicting creatinine at 12 months after 
transplantation. ROC analysis among LT alone patients showed that the duration of renal 
disease by itself had a moderate ability to predict creatinine >1.5 mg/dL at 12 months 
posttransplantation (area under ROC curve = 0.71). The optimal predictive cutoff was 3.6 
weeks. However they stated that they cannot at this time recommend that all patients with 
duration of renal disease longer than 3.6 weeks undergo combined liver kidney 
transplantation (CLKT) since creatinine of 1.5 mg/dL 1 year after transplantation is not 
necessarily high enough to justify concomitant renal transplantation. Instead they 
recommended that a threshold duration of renal dysfunction in combination with other 
predictive clinical variables (e.g height of creatinine, requirement for RRT) be prospectively 
investigated as an aid to clinical decision making. 
Indeed for liver transplant (LT) candidates with pretransplant mild to moderate chronic 
renal impairment or recent-onset ARF, the decision of whether to perform LT alone or CLKT 
can be challenging because no single factor has been shown to be predictive of the degree of 
progression of chronic kidney disease following successful LT. Although Pham et al., 2007 
suggested, like Campbell, that the duration of pretransplant renal dysfunction had a 
negative impact on posttransplant renal function outcome, Marik et al., 2006 and Sharma et 
al., 2009, in contrast, failed to demonstrate that the duration of pretransplant renal 
dysfunction was predictive of post-LT renal outcome. 
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CNI treatment, disturbances in nitric oxide (NO) release and NO synthase activity may 
generate reactive oxygen species; all of them might be involved in tubular epithelial to 
mesenchymal transition (Sharma et al., 2000 and Han et al., 2006). Protein kinase C (PKC-β) 
contributes to CNI-dependent fibrosis. It has been proved that cyclosporine administration 
enhanced PKC-β mRNA and protein expression; adding hispidine, a PKC-β inhibitor, 
inhibited TGF-β1 synthesis in proximal tubule cells (Liu, 2006).Genetic susceptibility to 
cyclosporine nephrotoxicity has been suggested. Cyclosporine is a substrate for the 
transmembrane pump P-glycoprotein. There is some evidence in animals and in vitro that 
decreased expression of this pump may contribute to increased cyclosporine levels, leading 
to nephrotoxicity. Altered protein pump expression has also been observed in association 
with several polymorphisms in its gene. As an example, the TT genotype is associated with 
decreased P-glycoprotein expression in the kidney. In a case control study of donor and 
recipient pairs, the TT genotype in the donor directly correlated with chronic cyclosporine 
nephrotoxicity in the allograft recipient. This suggests that underlying genetic factors that 
increase cyclosporine concentrations in the kidney may contribute to chronic nephrotoxicity 
(Hauser et al., 2005). 
Progressive obliterative arteriolopathy and chronic interstitial fibrosis with glomerulosclerosis 
develop in LT recipients in a dose-dependent and time-dependent fashion and have limited 
potential for reversibility (Fabrizi et al., 2010).  
Manifestations of Chronic calcineurin inhibitor nephrotoxicity: renal insufficiency due to 
glomerular and vascular disease, abnormalities in tubular function, and an increase in blood 
pressure (Hauser et al., 2005).  
Abnormalities in tubular function include:  
- hyperkalemia (due to reducing of potassium excretion both by decreasing the activity of 
the renin-angiotensin-aldosterone system and by impairing tubular responsiveness to 
aldosterone) (Tumlin and Sands, 1993).  
- hypophosphatemia (due to urinary phosphate wasting) (Moz et al., 2004) 
- hypercalciuria (Nijenhuis et al., 2004). 
- hypomagnesemia — presumably due to drug effects on magnesium reabsorption. 
Hypomagnesemia has been implicated as a contributor to the nephrotoxicity associated 
with cyclosporine (Miura et al., 2002).  
Difference between cyclosporine and tacrolimus: There are conflicting views in the literature 
regarding any difference in the nephrotoxic effect of either cyclosporine or tacrolimus. Many 
investigators did not identify any difference in the impact of either drug on the immediate 
postoperative kidney function (Burra et al., 2009, Dehghani et al., 2008, Kim et al., 2004 and 
Wei et al., 2006). On the other hand, O’Riordan et al., 2006 found a beneficial effect of 
tacrolimus use, compared with cyclosporine, which retarded the progression of acute renal 
disease to chronic renal disease. This has been previously noted by Filler et al., 2005 and 
Lucey et al., 2005. In contrast, a previous long-term trial comparing cyclosporine and 
tacrolimus in liver transplant recipients found a similar incidence of early acute renal failure 
and late hypertension, while late renal insufficiency was more prevalent with tacrolimus 
(Porayko et al., 1994). Recently, Lee and colleagues, 2010 in a multivariate Cox regression 
analysis revealed that the overall risk of CKD development was associated with 
cyclosporine more than tacrolimus.  
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4.3.5 Hepatitis C  
Hepatitis C recurrence after transplant is almost universal. Infection with hepatitis C virus 
(HCV) is the leading indication for LT worldwide and one explanation for the higher 
incidence of renal failure in LT patients is that HCV per se and the severity of HCV 
recurrence are risk factors for renal dysfunction (Asfandiyar et al., 2006). The mechanism by 
which HCV infection may induce early renal failure is not yet fully understood. HCV 
infection has been associated with mesangiocapillary glomerulonephritis and 
cryoglobulinemia (Braun et al., 2003), conditions that have been reported in HCV+ve LT 
recipients (Abrahamian et al., 2000 and Kendrick et al., 1997). Immunosuppressive therapy 
results in an early and significant increase in HCV replication after LT (Gane et al.., 1996), 
which may increase the risk of glomerular damage if concurrent renal transplantation is not 
performed [Pascual et al., 1997]. Moreover in these series, the presence of lower GFR before 
transplant (although not statistically significant) and the significant higher incidence of 
diabetes mellitus after transplantation in HCV group, compared to non-HCV group, could 
be additional factors justifying the worse renal function of HCV+ve liver transplant 
recipients (Burra et al., 2009). 
Studies have reported a different influence of hepatitis C on chronic renal dysfunction after 
liver transplantation. Pillebout (2005) found a strong association linking HCV infection with 
end-stage renal disease at biopsy, relating particularly to interferon therapy. In contrast, 
Burra et al., 2009 found no such association between the onset of chronic renal failure and 
the use of interferon before or after LT. Instead they stressed that HCV status had a negative 
impact on the median GFR in the first year of liver transplantation. Later on, HCV may lose 
this negative impact, while early stage renal failure continues to play a part in impaired 
renal function. Actually this study stated that HCV status, pre-LT GFR and serum creatinine 
levels were independent predictors of renal function a year after LT. Asfandiyar and 
colleagues, 2006 also demonstrated that infection with hepatitis C is an independent risk 
factor for chronic kidney disease as well as the relation with severity of HCV. Actually, Ojo 
et al., 2003, found that HCV was an independent risk factor for chronic renal dysfunction 
after all non-renal solid organ transplants and not just liver transplantation. 
4.3.6 Glomerulonephritis 
Only a few, small-sized studies on the histological features of chronic kidney disease (CKD) 
among LT recipients exist. In addition to histological lesions attributable to calcineurin 
inhibitor toxicity, a large spectrum of glomerular abnormalities was noted. Gonwa et al 
observed calcineurin inhibitor toxicity (n=33; 73%), non-recovered HRS (n=3; 7%), and focal 
segmental glomerulosclerosis (n=3; 7%) in their cohort of 45 patients who underwent kidney 
biopsy post-liver transplantation (Gonwa et al., 2001b). In another study by Pillebout, chronic 
renal failure was attributed to (i) specific chronic cyclosporine/tacrolimus arteriolopathy; 
(ii) typical diabetic nephropathy; (iii) acute or chronic thrombotic microangiopathy 
attributed to cyclosporine/tacrolimus arteriolopathy or alpha-interferon (Pillebout et al., 
2005). In hepatitis B, CNI toxicity and focal segmental sclerosis, but not immune-complex 
disease, were revealed as significant contributors to CKD after LT (Lee et al., 2010). The 
question whether those cases with glomerular lesions represent de novo glomerulonephritis 
or progression of pre-existing disease was unanswered; only prospective studies with serial 
kidney biopsies can address this point (Fabrizi et al., 2010). Pre-transplant proteinuria is a 
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significant and independent risk factor for CKD after liver transplantation, according to Lee 
et al., 2007 and O’Riordan et al., 2006.  
4.3.7 Pre-existing comorbidities such as diabetes mellitus, hypertension 
A few studies have looked at the relation between diabetes mellitus and hypertension and 
chronic renal dysfunction. Karie-Guigues et al., 2009 reported incidence rates of 10.5% for 
pre-LT hypertension and 43.4% for new-onset hypertension at one year post-
transplantation. Diabetes mellitus was reported in 12.5% of the patients before LT and 19.2% 
developed new onset diabetes after one year of LT. They showed that neither hypertension 
nor diabetes (pre-transplant or de novo for both) were significantly associated with a GFR 
decrease at any time points after LTx. These results are in line with those previously 
reported by Ojo et al, 2003 for hypertension and by O’Riordan et al, 2006 for diabetes. 
4.3.8 Child-pugh score and high model for end-stage renal disease (MELD) score 
At 3 years after LT, GFR negatively correlated with initial Child-Pugh score (Sezer et al., 
2011) and pretransplantat direct bilirubin. After 5 years, GFR negatively correlated with 
prothrombin time (r=-0.29; P<.05). Overall risk of CKD development (eGFR < 60 
mL/min/1.73 m2) was associated with high Child-Pugh score and high Model for End-Stage 
Renal Disease (MELD) score (Lee et al., 2010). Especially in recipients whose pre-operative 
eGFR was high (>or=60 mL/min/1.73 m2), rapid progression of kidney disease was 
associated with Child-Pugh score (in addition to high tacrolimus level and posttransplant 
acute renal failure) (Fabrizi et al., 2011).  
4.4 Prevention of CKD 
Especially patients undergoing LT for HCV may benefit particularly from methods for 
protecting kidney function, such as: 
- an optimal control of glucose metabolism,  
- dyslipidemia and proteinuria, and an  
- aggressive blood pressure containment treatment (Opelz et al., 1998, Randhawa and 
Shapiro, 2005 and Pillebout et al., 2005). 
- Minimizing CNI exposure. Use of CNIs is an important contributor to CRF after liver 
transplant, accounting for >73% of the renal diagnoses in those patients, (Gonwa et al., 
2001b) and this had led to a number of strategies to minimize CNI exposure (mentioned 
above). 
4.5 Outcome of chronic kidney disease after liver transplantation 
4.5.1 CVS morbidity/mortality 
Chronic kidney disease is a known risk factor for cardiovascular morbidity/mortality in the 
non-transplantation setting. The Heart Outcomes and Prevention Evaluation (HOPE) study 
suggested that even mild renal insufficiency was a significant risk factor for a subsequent 
cardiovascular event (Mann et al., 2001). The Cooperative Cardiovascular project 
demonstrated that the mortality risk for patients with moderate renal insufficiency for 
myocardial infarction was three times higher than that of patients with intact kidney 
function (Shlipak et al., 2002). These results suggest that renal insufficiency is an 
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independent risk factor for cardiovascular disease and should be considered in addition to 
other traditional risk factors. Transplant recipients are at increased risk of cardiovascular 
disease, and information gained in the last decade suggests that the occurrence of CKD 
appears to further increase the burden of cardiovascular disease among LT recipients. 
Therefore, the most common endpoint among LT recipients with CKD is not the need for 
renal replacement therapy or kidney transplantation but death secondary to cardiovascular 
disease (Fabrizi et al., 2010). 
Calcineurin inhibitors also contribute to the development of diabetes mellitus, dyslipidemia, 
hypertension, and oxidative stress, all of which contribute to cardiovascular morbidity 
(Merville, 2005). 
4.5.2 Mortality 
The occurrence of CKD after liver transplantation has a major impact on post-LT mortality. 
Many investigators confirmed this observation. Moreno et al evaluated 289 consecutive LT 
patients with post-transplant follow-up longer than 6 months. Patient survival was 
significantly lower among LT patients with chronic renal dysfunction than in those without 
this complication (63% vs. 71%, p=0.024). Ojo (2003) conducted a population-based cohort 
analysis among 69,321 persons who received non-renal transplants (liver, lung, heart, 
intestine, heart-lung) in the United States between 1990 and 2000. The occurrence of CRF 
significantly increased the risk of death (RR, 4.55; 95% CIs, 4.38 to 4.74; P<0.0001). The 13-
year survival rate in patients with end-stage renal disease posttransplant in a study 
performed by Gonwa et al., 2001 was only 28.2% versus 54.6% in those without 
posttransplant kidney disease. 
Sharma (2009) evaluated retrospectively 221 adult LT recipients who had LT in the MELD 
era (Feb 2002-Feb 2007). In their multivariate analysis, the decrease in GFR during post-LT 
follow-up was the only independent predictor of post-LT mortality after adjustment for age, 
etiology, MELD score, and GFR at liver transplantation. The risk of post-LT patient 
mortality was 2.9 (1.3-6.4; p=0.008) for patients with GFR <30 versus >30-60 ml/min and 3.2 
(1.19-8.67; p=0.02) for patients with GFR <30 versus>60 ml/min. Pawarode (2003) studied 
172 consecutive LT recipients over a median follow-up of 72.4 months (range, 6.5 to 100.6 
months). Severe renal failure was associated with significantly lower survival by Cox 
regression analysis (p=0.004). O’Riordan (2006) followed 230 patients after liver 
transplantation over 5.6 years (Irish National Liver Transplant database); the 10-year 
cumulative incidence of CKD stage 4 (GFR 15-29 ml/min) and 5 (dialysis or GFR <15 
ml/min) was 6.1% and 2.6%, respectively. Cox regression analysis of overall patient survival 
suggested that the post-LT GFR < 30 ml/min was associated with a hazard ratio of 3.05 (95% 
CI, 1.21-7.7; p=0.02); the other independent risk factors of lower patient survival being 
fulminant hepatic failure and retransplantation. 
Authors Relative Risk P 
Ojo A, et al (2003) 4.55(4.38;4.74) 0.001 
Pawarode A, et al (2003) NA 0.004 
O’Riordan A, et al (2006) 3.05 (1.21;7.70) 0.02 
Sharma P, et al (2009) 3.2 (1.19;8.67) 0.02 
Table 6. Impact of Posttransplant Chronic renal dysfunction on Mortality 
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independent risk factor for cardiovascular disease and should be considered in addition to 
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4.5.2 Mortality 
The occurrence of CKD after liver transplantation has a major impact on post-LT mortality. 
Many investigators confirmed this observation. Moreno et al evaluated 289 consecutive LT 
patients with post-transplant follow-up longer than 6 months. Patient survival was 
significantly lower among LT patients with chronic renal dysfunction than in those without 
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mortality was 2.9 (1.3-6.4; p=0.008) for patients with GFR <30 versus >30-60 ml/min and 3.2 
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• There has been abundant evidence over the last decade on the importance of kidney 
dysfunction among liver transplant recipients. However, still questions need to be 
assessed. 
• Acute kidney injury (AKI) has significant prognostic implications for long-term 
outcomes in patients undergoing liver transplantation. Hence, every effort has to be 
undertaken to preserve renal function throughout all stages of patient care. 
• In this review we discussed the important risk factors that negatively affect kidney 
function. A specially increased risk frequently exists among liver transplant recipients 
with pretransplant renal dysfunction. 
• Diagnosis of acute kidney injury was also discussed. To better define acute kidney injury, 
new markers (e.g. neutrophil gelatinase-associated lipocalin) have become available 
that help to identify patients at risk for renal injury within hours of a triggering insult. 
Larger studies are required to validate the results. These newly established markers for 
injury, such as NGAL, in conjunction with improved markers for renal function will 
allow us to further delineate the natural course of AKI during liver transplantation. 
• The occurrence of chronic kidney disease after liver transplantation has a major impact on 
mortality. Additional studies are needed to understand better the natural history of 
chronic kidney disease among liver transplant recipients. Strategies need to be put in 
place for the early detection of these individuals and then preventive measures 
introduced to retard the progression of chronic kidney disease.  
• Hepatitis C appears to be an additional risk factor affecting renal function in the long 
term in liver transplanted patients. Further dedicated prospective studies aiming to 
evaluate the possible pathogenetic mechanism of HCV damage on long-term renal 
function after liver transplantation are needed. For the present time, it would be 
advisable to avoid combinations of risk factors for renal impairment, at least in the first 
year after LT in HCV+ve recipients. 
• Modification of nephrotoxic immunosuppressive regimens to avoid postoperative acute 
renal failure and/or chronic renal failure has met with variable results. Although there 
is no well-defined protocol to prevent or minimize cyclosporine or tacrolimus 
nephrotoxicity, some centers currently advocate the use of a calcineurin-sparing 
protocol adjusted for the degree of renal dysfunction. Hence, the clinical evaluation of 
the presence of multiple risk factors for renal insufficiency and etiology of liver disease 
would be important to select patients who would benefit from a renal sparing regime of 
immunosuppression. However, dedicated large studies meticulously evaluating these 
renal sparing regimes in patients with risk factors for renal dysfunction are still 
recommended. Also trials on novel agents targeting different sites of the immune 
cascade and without renal toxicity are on the way. Until then, finding the balance 
between preserving graft function and optimizing immunosuppression while 
minimizing renal toxicity remains a challenge. 
• Studies that incorporate renal diagnosis and other prognostic indicators (such as 
proteinuria) to stratify liver transplant candidates according to risk for kidney 
dysfunction post-liver transplant are in progress.  
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Post-transplant lymphoproliferative disorder (PTLD) is a clearly recognized and potentially 
life threatening complication after solid organ or bone marrow transplantation. It comprises 
a spectrum of diseases ranging from infectious mononucleosis and lymphoid hyperplasia to 
highly aggressive lymphoma. The disease has increased clinical importance in view of the 
constantly rising number of organ transplant recipients and the development of more potent 
and specific immunosuppressive drugs. 
PTLD is a relatively common malignancy after transplantation with a reported incidence 
ranging from 2% to 10%. It is the most common form of post-transplant malignancy after 
skin cancer with an overall mortality often exceeding 50%.  
Registry-based reports however usually do not provide details of treatment and outcome: 
the existing single institution studies are largely reports and only a few studies include a 
significant number of patients with PTLD. Most cases of PTLD are associated with Epstein 
Barr virus (EBV) that leads to uncontrolled B cell proliferation in patients with a decreased 
function of EBV specific T cell because of immunosuppressive drugs. PTLD is not 
exclusively associated with EBV infection as EBV-negative PTLD, often developing late after 
transplantation. 
Post transplant lymphomas differ from lymphomas in general population in 
histopathological findings, increased extranodal involvement, a more aggressive clinical 
course and poorer response to conventional treatment.  
Treatment of PTLD consists always in reduction of immunosuppression (RI) as first step. 
The role of chemotherapy (CT) remains unclear. In the past it was reserved for patients in 
whom other treatment options have failed even if the increased toxicities from cytotoxic 
agents, the high susceptibility to life-threatening infections and the necessity to maintain the 
allograft. Actually (Rituximab Hera) most authors consider new anti CD20 monoclonal 
antibodies (mAB) essential for treatment or as single agent or in association with CT but 
there is not a definitive agreement about schedules, duration of treatment and setting of 
patients. 
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The appearance of PTLD is often associated with clinical or serological reactivation of 
Epstein Barr virus infection. Tumour tissues often contain EBV-DNA sequences and express 
viral protein (Purtilo DT,1980; Young L et al, 1989; Hanto DW et al, 1981). In normal 
individuals, host defence mechanism make EBV infection a self limited disease and B cell 
proliferation is controlled by specific T cell lymphocytes. The infection is however not 
eradicated, but persists in clinical latent form. In transplanted patients, partial suppression 
of T lymphocyte to prevent graft rejection, makes EBV-driven B cell proliferation uncontrolled 
and predispose to development of PTLD.  
Several single centre studies have found that EBV seronegative patients had a 10-76 times 
greater incidence of PTLD than EBV seropositive recipients (Walker RC et al, 1995). 
Active viral replication in immunosuppressed patients results in the expression of EBV 
encoded genes including oncogenes as LMP1, a gene that inhibits apoptosis by up 
regulating the anti-apoptotic gene BCL-2 (Kulwichit W et al, 1998). 
Data suggests also that prophylactic anti-Cytomegalovirus (CMV) immunoglobulin prevent 
the development of early post-transplant non Hodgkin lymphoma while prophylactic 
treatment with antiviral drugs does not reduce the risk of PTLD (Opelz G et al, 2007). 
Locker and Nalesnick (Locker J & Nalesnick M, 1989) demonstrated that monomorphic 
PTLDs display a strong clonal immunoglobulin rearrangement band on Southern Blotting 
and a c-myc gene rearrangement exhibits disease progression. Also alterations of p53 and N-
ras seem to be implied in pathogenesis of PTLD. BCL 6, that encodes a transcriptional 
repressor gene rearranged in 35-40% of diffuse large B cell lymphoma in immunocompetent 
patients (Bastard C et al, 1994; Lo Coco F et al, 1994), presents frequent somatic mutations in 
PTLD representing probably a consistent step in the progression from a PTLD that can be 
controlled by a reconstituted immune system to one that will require more aggressive 
therapeutic intervention (Cesarman E et al, 1998). 
PTLD also have genomic aberration common to lymphomas in immunocompetent patients 
such as gain of 8q24, 3q2718q21 and loss of 17p13. 
In conclusion viral oncogenes, impaired immune system, chronic antigen stimulation and 
genetic aberration probably contribute together to pathogenesis of PTLD (Poirel HA et al, 
2005).  
3. Risk factors 
The most important risk factor for PTLD development is the intensity of 
immunosuppression administered. Induction and rejection treatment with anti-T cell 
antibodies, especially OKT3 and ATG may lead to an increased risk of PTLD, as 
demonstrated by the higher incidence of early PTLD in hearth and hearth/lung recipient. 
With longer follow-up, is now evident that antibody prophylaxis increased the risk of 
lymphoma primarily during the first post-transplant year, whereas in subsequent years the 
risk is similar to that in non antibody-treated patients. Whether IL2 receptor blocking 
monoclonal antibody, which was introduced in the late 1990s, also increases the risk of 
lymphoma is of great interest. Analysis of the critical 12-months data showed that use of 
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anti IL2 receptor antibodies was not associated with an increased risk of lymphoma (Opelz 
G et al, 2003).  
There is no conclusive evidence that development of PTLD is associated with a single 
immunosuppressive agent (Gao SZ et al, 2003; Pirsch JD et al, 1997; Weisner RH et al, 1998; 
Younes BS et al, 2000). Also the effect of everolimus and sirolimus on PTLD development is 
not clear. These drugs may theoretically be associated with a lower risk as demonstrated in 
animal model but the lack of prospective randomized trial assessing these differences 
restrains any firm conclusion (Yakupoglu YK et al, 2006; Majewski M et al, 2003; Kusuki S et 
al, 2009).  
A special category of patient at risk (10 to 50 fold increased risk) are EBV seronegative 
patients receiving allograft from EBV seropositive donors, leading to primary EBV infection 
(Walker RC et al, 1995). This is also the reason for the higher incidence of early PTLD 
observed in paediatric transplant recipients who often are still EBV seronegative at the time 
of transplantation.  
A high incidence of EBV related lymphoproliferative disorders has been reported in a 
number of congenital immunodeficiency syndromes including severe combined 
immunodeficiency (SCID), ataxia teleangiectasia and Wischott Aldrich syndrome 
Waldmann TA et al, 1983). Acquired immunodeficiency due to HIV disease has become a 
major clinical problem in many parts of the world. An increased incidence of aggressive non 
Hodgkin lymphoma which shares many of the unusual characteristics of PTLD is a 
manifestation of AIDS. The introduction of the Highly Active Antiretroviral Therapy 
(HAART) has dramatically reduced the incidence of this life threatening manifestation of 
HIV. 
The underlying indication for transplantation may also influence the risk for PTLD. For 
example Hepatitis C infection (Burra P et al, 2006) is associated with a particularly high risk 
of PTLD in liver transplant recipients. 
Recent data also suggest Hepatitis B virus reactivation as a possible risk factor for 
development of PTLD( Leblond V & Choquet S, 2004; Duvoux C et al, 2002; Zhang A et al 
2009). 
Also patients with immunological disorders before liver transplantation receiving steroids 
and patient transplanted for autoimmune hepatitis seems to be at higher risk for 
development of PTLD (Zimmermann T et al, 2010; Shpilberg O et al, 1999) 
4. Epidemiology 
The incidence of PTLD after solid organ transplantation is different in children and adults 
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anti CD3 antibody or T cell depletion of donor marrow. The incidence of PTLD would be 
expected to increase with the duration of immunosuppression and few studies standardise 
their data on incidence for this variable. Also the lack of standardised diagnostic criteria for 
PTLD may reflect the wide range in incidence. 
Although PTLD may occur at any time after transplantation, the risk of developing PTLD is 
greatest within the first year and declines over time thereafter. A report by the Transplant 
Collaborative Study showed the incidence of PTLD to be 224/100000 in the first year, 
54/100000 in the second year and 31/100000 in the sixth year following transplantation11.  
The higher incidence of PTLD in paediatric transplant recipient is attributable in large part 
to the development of primary EBV infection after transplantation. EBV seronegative adults 
who acquire primary EBV infection after transplantation are also at increased risk of PTLD 
but since most adults are already EBV seropositive at the time of transplantation this is a 
less problem. 
In both children and adult, PTLD is more common after hearth and lung transplantation 
than after kidney or liver transplantation. This may be because more intensive 
immunosuppression is used in recipient of thoracic organ. In lung recipient the large 
number of EBV-infected lymphocytes residing in lung transplants in the form of bronchus 
associated lymphoid tissue may be a contributing factor in EBV seronegative recipients. 
5. Pathologic features 
A standardised approach to the classification of PTLD is important to allow consistency of 
reporting and to enable comparison of different treatments. Histology is essential also in 
differentiation between rejection and PTLD involvement of the graft. The classification of 
PTLD currently used is based on the histopathological appearance of the tumour. PTLD can 
be divided into three distinct morphological groups, as reported by the World Health 
Organization classification of neoplastic disease of the haematopoietic and lymphoid tissues.  
The first group comprises diffuse B cell hyperplasia, characterised by differentiated plasma 
cell and preservation of the normal lymphoid architecture. This type of PTLD is most often 
seen in children and young adults, usually occur within the first year following 
transplantation and responds well to reduction of immunosuppression (Kahan BD et al, 
2000). 
The second group comprises polymorphic PTLD characterised by nuclear atypia, tumour 
necrosis and destruction of underlying lymphoid architecture. Lesions in this group are 
highly polymorphic, usually monoclonal and include plasmacytes and blast form. 
Polymorphic PTLD is the most common type of PTLD in both children and adults and may 
occur at any time after transplantation. 
The third group comprises monomorphic PTLD and includes high grade invasive 
lymphoma of B or T lymphocytes. This type of PTLD is often seen several years after 
transplantation and resembles non Hodgkin lymphoma. Monomorphic B cell PTLD can be 
further divided into diffuse large cell lymphoma and Burkitt or Burkitt like lymphoma. 
PTLD may also present with discordant lesions, in which different histological subtypes can 
be present in a single patient. 
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Although the association between EBV and PTLD is well established, the presence of EBV in 
tumour cell is not required for the diagnosis. So, according to the international classification, 
any lymphoma arising in the post-transplant patient is considered to be a PTLD. 
At least 90% of PTLD that occur in solid organ transplant patients arise from recipient cells 
(Weissmann DJ et al, 1995) and the opposite apply in the case of bone marrow 
transplantation. Donor derived PTLD in organ transplant patient may have a predilection 
for the allograft (Strazzabosco M et al, 1996). Some authors have suggested that they may 
have a worse and some a better prognosis than recipient organ PTLD even if further studies 
are needed in this area (Lones MA et al, 1997; Howard TK et al, 1992).  
Clinical recurrence of PTLD has been estimated to occur in approximately 5% of cases. Wu 
et al.30 (Wu TT et al 1996) examined a series of 11 such patients and found that the recurrent 
tumours comprised a heterogeneous assortment. In some cases the recurrence was 
morphologically and clonally identical to the original tumour. In several cases PTLD 
recurred in a more aggressive form. For example, patients with mononucleosis-like PTLD 
could present later with polymorphic PTLD, and patients whose original disease was 
polymorphic PTLD might later develop one of the lymphomatous forms of PTLD. 
6. Clinical presentation  
The clinical presentation of PTLD is highly variable. PTLD may arise at any time after 
transplantation with a significantly higher risk in the first post-transplant year, especially in 
heart and lung recipient because of the high dose of immunosuppression. Most patients 
present with fever (seen in 50%), lymphadenopathy (seen in 30%) or non-specific symptoms 
such as tonsillitis (particularly children) and weight loss. Around 15% of patients present as 
an emergency with intestinal perforation (Kahan BD et al 2000) or with fulminant PTLD 
characterised by disseminated systemic disease that clinically resembles septic shock 
(Orjuela M et al, 2003). Keeping in mind that PTLD often present at extra nodal sites (Bakker 
NA et al, 2005), including the allograft and digestive tract, there may be early signs and 
symptoms that should at least include PTLD in the differential diagnosis. This is especially 
true for allograft involvement of PTLD. The most commonly affected extranodal site of 
PTLD is observed in the gastrointestinal tract (G.I.). There seem to be no relation between 
the time of onset and the development of PTLD in the G.I. tract (Leblond V et al, 1995). The 
CNS is involved in up to 30% of cases of PTLD and in many of these the disease is confined 
to the CNS (Maecker B et al, 2007; Penn I & Porat G, 1995). In this respect, PTLD contrasts 
with NHL in the general population where only around 1% of cases shows isolated CNS 
involvement. Skin involvement is observed in approximately 5-10% of all PTLD patients 
and must be differentiated by other cutaneous malignancy, given the fact that organ 
allograft recipients have an increased risk for the development of cutaneous malignancy 
such as squamous and basal cell carcinoma (Beynet DP et al, 2004). The Canadian PTLD 
Survey Group analysed 90 cases of PTLD occurring in 4283 solid organ transplant recipients 
followed over a nine-year period (Allen U et al, 2001). Approximately two thirds of patients 
presented with disease localised to a single site, of which only a quarter were within the 
lymph nodes. The remaining patients had solitary lesions at extra-nodal sites including 
kidney, bowel, liver, mediastinum and skin. More rarely, solitary lesions were seen in the 
lung, tonsils and central nervous system (CNS). In particular, CNS involvement, especially 
in paediatric patients seems to be a risk factor for poor prognosis (Maecker B et al, 2007). In 
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patients presenting with multiple lesions, the lymph nodes and liver were most commonly 
affected. In PTLD occurring after liver transplantation abdominal findings are the most 
common manifestation including PTLD within liver allograft and splenic abnormalities (Wu 
L et al, 2001). Portal masses have also been reported presenting as lesion with mass effect 
and intrahepatic bile duct dilatation: they have sometimes initially been treated as abscess 
until the diagnosis of PTLD was made (Strouse PJ et al, 1996; Armes JE et al, 1994; Sokal EM 
et al, 1993). Some studies have reported rates of 50% and 30% of PTLD affecting the bowel 
associated with high perforation rate. So after transplantation the presence of 
gastrointestinal disturbance should alert the clinician to the potential diagnosis of PTLD as 
well as the more common complications of infection and inflammation (Starzl TE et al, 1984; 
Steiber AC et al, 1991). Given this myriad of nonspecific clinical signs and symptoms, often 
masquerading PTLD as infection or adverse drug effects or reactions, or even absence of 
symptoms at all, methods for early detection of PTLD in transplant recipients would be 
extremely valuable. 
7. Diagnosis of PTLD 
The diagnosis of PTLD should be based on histological examination of biopsy tissue. 
Excision biopsy is preferable and needle biopsy should only be performed where excision of 
affected tissue in not practicable, also because PTLD may contain large areas of necrosis. 
Cytological preparation are useful, particularly in the analysis of effusion (Lechapt-Zalcman 
E et al, 2001) and can provide adequate diagnostic material particularly if ancillary studies 
such as phenotypic, clonal and viral analysis are also performed. Tissue should be subjected 
to standard histology, examined for the presence of EBV by immunostaining or in-situ 
hybridization, cellular infiltrates characterised by relevant phenotypic markers and clonality 
estimated. Although it would be ideal to sample each tumour in cases of multicenter PTLD, 
this is seldom possible. Each tumour may represent a separate clone and the histological 
grade may be underestimated in multicentric cases. The surgeon run also the risk, in this 
case, of sampling a reactive node that may contain evidence of EBV infection, while the 
primary lymphomatous PTLD lies elsewhere. It is also useful consider biopsy of any lesion 
that respond in an atypical fashion, particularly if regression is documented in other 
concurrent lesion. 
There is no separate staging system for PTLD and it is currently staged using the same 
system as non Hodgkin Lymphoma (NHL) in the normal population. Staging of the disease 
should include computed tomography (CT) of the abdomen and thorax and bone marrow 
aspiration. Fluorodeoxyglucose positron emission tomography (FDG-PET) scanning is 
increasingly used as an important tool in the visualization of malignant lymphoma, 
especially for the detection of extranodal localization and post-treatment evaluation and has 
shown to be superior over conventional diagnostic techniques to differentiate between 
residual masses as a result of vital tumour or scar tissue. Bakker et al. (Bakker NA et al, 
2006) reported a cases of 12 patients whit a highly avid FDG PTLD. Additional sites of 
extranodal localization of PTLD not visualized on CT scanning were found in 50% of all 
patients. (figure 1) 
Additional investigations should be performed as indicated, e.g. CT or magnetic resonance 
scan of the cranium and spinal cord or further gastrointestinal imaging. The presence of 
PTLD within the graft itself may sometimes be mistaken for acute rejection and if there is 
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diagnostic doubt, in-situ hybridisation for EBV encoded RNA, and PCR for VDJ heavy-chain 
rearrangements to determine clonality may be helpful. Molecular analysis of oncogenes and 
tumour suppressor genes will undoubtedly play an increasingly important role in 
predicting behaviour even if, at present, these techniques are not widely available and few 
genes have been analyzed. 
 
Fig. 1. Example of discordant finding. CT abdomen (A) and FDG PET fused with the same 
CT scan (B). Arrow indicates the histologically confirmed focal lesion with high uptake of 
FDG, whereas the CT scan (A) does not show any abnormalities at the site of high FDG 
uptake. The high uptake in the allograft, including the kidney calices and pyelum, is 
physiological, as is the modest uptake in liver and spleen 
8. EBV DNA load monitoring after transplantation 
Because elevation of EBV-DNA load in blood is considered to reflect aberrant EBV induced 
B-cell proliferation, much effort has been put in developing methods that might identify 
patients at risk for developing PTLD by measuring the amount of circulating EBV-DNA in 
the peripheral blood. More recently, pre-emptive strategies to prevent PTLD have been 
evaluated. Mc Diarmid et al. (McDiarmid SV et al, 1998) treated pre-emptively with 
intravenous ganciclovir 18 high-risk (donor positive for EBV serology, recipient negative for 
EBV serology) paediatric liver recipient and no one developed PTLD whereas they 
previously reported 10% incidence of post transplant lymphoproliferative disease (PTLD) in 
paediatric patients receiving first liver grafts and primarily immunosuppressed with 
tacrolimus. Despite the consensus that PTLD patients have a significantly higher EBV-DNA 
load compared with healthy EBV-seropositive donors or non-PTLD transplant recipients, it 
is still unclear which threshold values are predictive for PTLD. Many different threshold 
values have been reported, all with different sensitivity (60–100%) and specificity (71–100%) 
(Lee TC et al, 2005; Rowe DT et al, 2001; Tsai DE et al, 2002). Another limitation of EBV- 
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DNA load monitoring may be the observation that PTLD developing late after 
transplantation is not necessarily associated with EBV (negative staining for EBV in the 
tumour), and may therefore develop without a concomitant rise in EBV-DNA load. Indeed, 
there are studies showing EBV-negative PTLD developing late after transplantation without 
a rise in EBV-DNA load. These observations suggest that, although increased EBV-DNA 
load is generally considered to represent an increase in circulating EBV-positive tumour 
cells, these high EBV-DNA loads in reality may represent a separate population of 
proliferating B-cells that may have nothing to do with development of PTLD. Instead, these 
proliferating B-cells may only reflect a general state of decreased T-cell surveillance in the 
transplant recipient. In conclusion, because of the many variables that may influence the 
immune response of the individual transplant recipient, such as level of 
immunosuppression, time after transplantation, concomitant infections, type of organ 
transplanted, but also genetic factors, an exact cut-off value of EBV-DNA load critical for the 
development of PTLD in the individual patient cannot be defined. Therefore, rising EBV-
DNA loads in the individual patient, instead of using a cut-off value, may be more 
appropriate to identify the individual patient at risk for the development of PTLD. It has 
been suggested that concomitant combined monitoring of EBV-DNA load and EBV-specific 
cytotoxic T lymphocytes (CTL) responses (the absence of which may be used as a marker for 
possible overimmunosuppression) might better identify the individual patient at risk for 
PTLD development. The positive predictive value of high EBV-DNA loads as a predictor for 
PTLD development might be improved with this method. Smets et al.(Smets F et al, 2002) 
showed that high EBV-DNA loads in patients who underwent primary EBV infection were 
indicative for PTLD development only if there was a low concomitant cellular immune 
response.  
9. Clinical management 
The treatment of PTLD poses a major therapeutic challenge and, although there is 
reasonable agreement about the overall principles of treatment no controlled studies have 
been undertaken and most of the recommendations result from small cohorts at single 
institutions.  
Even if no uniform approaches to the treatment have emerged, general principles are largely 
shared. 
• Treatment must be individualised according to clinical situation and the type of organ 
transplanted 
• Unlike non-Hodgkin lymphoma in immunocompetent patients, PTLD can be 
eradicated by surgical resection 
• Reduction of immunosuppression is considered the first line treatment 
• Antiviral agents have showed to induce regression of disease in some cases 
• Chemotherapy, traditionally considered a last resort treatment, is associated with high 
response rate and long progression free survival 
• Rituximab has emerged as treatment of choice especially in early PTLD after failure in 
reduce/withdrawal immunosuppression 
• Radiotherapy may be appropriate for treatment of localized PTLD together with 
reduction in immunosuppression 
 








Treatments enhancing recipient CTL function 
Reduction of 
immunosuppression 
First line treatment for PTLD 
 More likely to induce remission in early or polymorphic 
PTLD 
Adoptive T cell therapy Risk of graft versus host disease in case of allogenic 
CTLs and need for dedicated facilities. 
Need for growing autologous CTLs 
Cytokine based therapies 
Interferon-alpha Several case reports of successful induction of remission with 
reduction of immunosuppression and interferon-a 
 May significantly increase the risk of organ rejection 
Anti IL-6 antibodies Promising results in phase one to two trials 
Antiviral agent Under development 
Acyclovir, ganciclovir 
Treatments reducing tumour mass 
Surgical excision For localized disease 
 Most cases not amenable to surgical resection 
Local radiation Adjunct to surgical excision 
 Treatment of choice for CNS PTLD 
Chemotherapy Used in aggressive disease 
 High mortality from sepsis and toxicity 
 Effective in around 2/3 of selected patients 
Rituximab Promising results when combined with reduction in 
immunosuppression 
 Longer term results required to determine relapse rates 
Table 1. Treatment of PTLD 
9.1 Reduction of immunosuppression 
Reduction of immunosuppression is the initial treatment in all patients with PTLD with the 
aim of increase antitumor activity. In EBV driven PTLD, this may partially restores CTL 
function resulting in an increase of EBV specific CTLs and elimination of virally infected 
lymphocytes, including those which constitute the tumour. The approach to reduce 
immunosuppressive drugs needs to be carefully individualised and will depend on the 
nature and extent of disease, the type of transplant recipient (life or no-life supporting graft) 
and the time from transplantation. 
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DNA load monitoring may be the observation that PTLD developing late after 
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In general most clinicians adjust the corticosteroid dose to 10 mg of Prednisone daily in the 
hope to prevent allograft rejection. Steroids also are an important component of most 
chemotherapy regimen for PTLD and lymphoma in general. 
A response to reduction in immunosuppression is usually seen within 2-4 weeks (Green M 
et al, 1999). 
Reduction in immunosuppression leads to long term disease remission in 40-86% of 
paediatric patients and 25-63% of adults. 
If PTLD develops within one year of the transplant up to 80% will respond to reducing in 
immunosuppression. 
In contrast, after one year the response rate falls to 10% with 80% of mortality (Armitage JM 
et al, 1991). 
9.2 The role of rituximab 
PTLD is usually of B cell origin and the use of mAB to deplete B cell is a logical approach for 
treatment. Rituximab, a monoclonal antibody directed against CD20 antigen expressed on 
mature and immature B cells, results in profound and long-lasting depletion of B cell (6-8 
months), together with hypogammaglobulinemia.  
Rituximab is widely used in the treatment of diffuse large B cell lymphoma in 
immunocompetent patients with an overall survival at two years of 70% compared with 
57% of patients treated with chemotherapy alone (Coiffier B et al, 2002). 
Many more case reports and case series of using rituximab in PTLD are described in 
literature. This cases included paediatric and adult PTLD patients who underwent solid 
organ or bone marrow transplantations and achieved excellent results with rituximab. Most 
of the patients also underwent concurrent RI and some received also antiviral therapy. 
Many patients experienced clinical improvement within a few days after the first infusion. 
Most patients were treated with the standard dose of rituximab at 375 mg/m2 once a week 
for four consecutive weeks. The majority of the case reports describe the use of rituximab in 
the early onset PTLD, but it might be effective also for patients with late onset PTLD. 
Gonzalez-Barca et al (Gonzalez-Barca E et al, 2004) reviewed data on 108 adult solid organ 
transplanted patients with PTLD including 36 patients who received rituximab. With a 
mean follow-up of 15 months, the OS of patients treated with rituximab was significantly 
better than for the whole group (76% vs. 21). In a multicenter, prospective phase II study, 
Oertel et al.(Oertel SH et al, 2005) treated 17 adult patients with PTLD with standard dose of 
rituximab. The mean follow-up time was 24 months. Overall response rate was obtained in 
12 (71%) patients. Nine patients (53%) achieved complete remission (CR), with a mean 
duration of 17.8 months. Two patients relapsed, respectively 3 and 5 months after obtaining 
CR. The mean overall survival was 37 months with 11 (65%) patients alive at the end of the 
study. Adverse events were rare and of low grade. Patients whose tumour was EBV positive 
were significantly more likely to achieve CR than patients with tumors that were EBV 
negative. The largest prospective trial of using rituximab in PTLD was published by 
Choquet et al.(Choquet S et al, 2005). This multicenter, open label, European phase II trial, 
enrolled 63 patients with PTLD after solid organ transplantation who did not improve after 
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reduction of immunosuppression. The study included both paediatric and adult patients 
who were treated with standard dose of Rituximab 375 mg/m2 weekly for 4 weeks. Most of 
the PTLD cases were of relatively late onset with only 17 patients with PTLD diagnosed 
<1 year after their transplantation. The overall response rate after single agent rituximab 
was 59% with a CR rate of 42% and a partial response rate of 17%. Stable disease was 
observed in 3% of patients and 38% progressed during treatment. At a median follow up of 
16,3 months, median progression free survival was 6.0 months. Trappe et al. (Trappe RU et 
al, 2007) reported the efficacy of single agent Rituximab in eight patients (seven adults, one 
paediatric) with PTLD relapsed or refractory to chemotherapy after failure of reduction in 
immunosuppression. Complete remission was obtained in three patients and partial 
remission in two. Patient achieving CR either remain in CR or were successfully salvaged 
again with single agent Rituximab. In conclusion patients treated with rituximab benefit 
from the short duration of such therapy in terms of response rate and less toxic effect. 
However, because of the high relapse rate observed in several studies, the combination of 
Rituximab with cytotoxic drugs is recommended to be evaluated.  
9.3 Antiviral agents 
Because most PTLDs arise as a consequence of EBV infection, prophylactic measures should 
include avoiding over-immunosuppression of the recipient such as the use of anti-
lymphocyte preparations, antiviral agents, EBV vaccination, in-vitro generated EBV specific 
CTL lines and avoiding, in EBV seronegative recipients, transplantation with an organ from 
an EBV positive donor. Regression has been described following high dose acyclovir. 
Targeting EBV by antiviral agents has been attempted also for prophylaxis of PTLD. An 
alternative approach, especially in high risk recipients, is to prospectively monitor the EBV 
viral load after transplantation and to initiate therapy when a pre-determined threshold is 
exceeded. One problem with this approach is that only a minority of patients with high EBV 
loads develops PTLD, and some patients with EBV-positive PTLD may have a low serum 
viral load  
9.4 Cytokine based therapy 
Agents that alter the cytokine environment of the tumour to favour remission, notably 
interferon-α (Davis CL et al, 1998) and anti-IL-6 have been tried as adjuvant along with 
reduction of immunosuppression, but at present there is insufficient evidence to 
recommend their routine use. Interferon-α enhances T-lymphocyte cytotoxicity and has 
been used as an adjunct to chemotherapy to treat B cell malignancies in non-transplanted 
patients and in the maintenance of remission in such patients. Swinnen et al. (Swinnen LJ et 
al, 2008) recently reported results of a trial for treatment of PTLD starting with a defined 
course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to 
chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant 
recipients. Reduction in immunosuppression produced no CR, progressive disease and 
rejection were frequent; response to IFN was rare while chemotherapy resulted in 57% 
durable CR. IL-6 may play a role in the development of PTLD by promoting the growth of 
EBV-infected B cells and increasing tumour development in EBV-immortalised cells. Serum 
levels of IL-6 are raised in the majority of patients with PTLD. Anti-IL-6 mAb has been used 
in a phase 1–2 multi-centre clinical trial in 12 patients with PTLD that was refractory to a 
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reduction of immunosuppression (Haddad E et al, 2001). Five of the 12 patients showed a 
complete response with no residual tumour and three patients showed a decrease in tumour 
size, which in one case was sufficient to allow surgical removal of a previously unresectable 
tumour. Anti-IL-6, therefore, appears to be a promising adjunct in the treatment of PTLD 
but further studies are needed to fully assess its efficacy. 
9.5 Rapamycine 
Rapamycine is increasingly used as an immunosuppressive agent for solid organ 
transplantation. In addition to its immunosuppressive effects, it also displays anti-
angiogenic and anti-tumour properties, and this make it a potentially attractive agent for 
patients in remission from PTLD, particularly those who develop chronic allograft rejection 
as a consequence of a reduction of immunosuppression. Rapamycin inhibits the growth of 
EBV-transformed B lymphocyte lines in-vitro by arresting cell cycle in the G1 phase 
(Vaysberg M et al, 2007). There are no prospective studies addressing the use of rapamycin 
in the treatment or prevention of PTLD. 
9.6 Adoptive T cell therapy 
Adoptive T cell therapy using EBV-specific CTL lines has generated considerable interest as 
a treatment for PTLD. Adoptive immunotherapy was initially advocated in allogenic bone 
marrow transplantation to control PTLD that was donor cell in origin. Donor CTL would 
restore immune surveillance against EBV driven proliferation and control PTLD. A potential 
risk was graft versus host disease due to the donor cell infusion: this risk could be reduced 
by selecting donor EBV-specific T cell ex vivo prior to infusion. This approach has been used 
with success as prophylaxis and treatment of PTLD after stem cell transplantation using 
CTL lines derived from the donor and specific for EBV gene products even if it is limited by 
the time required to generate the CTLs (weeks to months) and the expense for dedicated 
facilities. Haque et al (Haque T et al, 2007) presented the results of a recent multicenter 
clinical trial using Epstein-Barr virus-specific CTL generated from EBV-seropositive blood 
donors to treat patients with EBV-positive PTLD on the basis of the best HLA match and 
specific in vitro cytotoxicity. The response rate (complete or partial) in 33 patients was 64% 
at 5 weeks and 52% at 6 months. Fourteen patients achieved a complete remission, 3 showed 
a partial response, and 16 had no response at 6 months (5 died before completing treatment). 
No adverse effects of CTL infusions were observed. These results showed that allogeneic 
CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for 
individual patients. After solid organ transplantation, PTLD is usually of recipient origin 
and recipient derived CTLs are required for effective killing of EBV infected B cells. It is 
possible to generate autologous EBV-specific CTLs from recipients who were EBV 
seropositive prior to transplantation. However, this approach is not applicable when PTLD 
arises in recipients who were EBV seronegative prior to transplantation. Savoldo et al 
(Savoldo B et al, 2006) treated 12 patients with persisting high EBV-DNA viral load with no 
evidence of PTLD (6 patients) or high EBV-DNA load with previous or current clinical 
diagnosis of PTLD (6 patients). Ten of the 12 patients had no evidence of overt PTLD 
following CTLs therapy, despite being categorized at high risk because of persisting of high 
EBV-DNA viral load. The two remaining patients both had evidence of pre-existing PTLD 
and both appeared to respond to CTLs infusion. 
 




Conventional cytotoxic chemotherapy which has been shown to be curative for many 
lymphomas in non-PTLD setting, has been viewed as a treatment of last resort due to very 
high morbidity and mortality rates. Chemotherapy is commonly used in the treatment of 
PTLD when reduction in immunosuppression fails to control the disease. 
Various multi-drug regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) have been used in PTLD patients (Wasson S et al, 2006; Elstrom RL et al, 
2006; Trappe R et al, 2007; Taylor AL et al, 2006; Fohrer C et al, 2006; Buadi F et al, 2007; 
Patel H et al, 2007; Aversa SML et al, 2008) 
In spite of the high response rate up to 70%, the associated toxicity is significant and 
includes treatment-related deaths in about 25% of patients. The high mortality of the 
standard chemotherapy regimens in the PTLD population might occur because of various 
factors including baseline pharmacologic immunosuppression, graft dysfunction, and 
colonization with resistant or hospital acquired infectious organisms. 
Sepsis and other complication of chemotherapy have been the major problem in some 
centres, while others have found refractory disease to be common.  
PTLDs after liver transplantation reported in literature are most of all cases report and only 
few studies analyze a larger group of this disease. (Table 2) 
Ben-Ari et al ( Ben-Ari Z et al, 1999) reported a series of 7 patients who developed PTLD 
between 1988 and 1997. 2 patients with late PTLD received anthracycline based 
chemotherapy and actually they are alive with no recurrence of disease respectively 10 
months and 24 months after the end of treatment. Another one with polyclonal tumour EBV 
positive, was initially treated with high dose acyclovir IV. However he progressed to 
monoclonalty and systemic chemotherapy (CHOP) was instituted: the patient died 7 months 
later after one cycle of chemotherapy of septicaemia and rapidly progressive lymphoma. 
Norin et al (Norin S et al, 2004) observed, in a population of 500 consecutive recipients of 
liver graft, 9 cases of monomorphic PTLD, one case of polymorphic PTLD and two case of 
unclassifiable NHL developed at a median time from transplantation of 19,5 months (1,5-
148). Chemotherapy (CHOP or VACOP-B) was used in all patients mostly upfront but in 
one patient 4 months after diagnosis because of lack of response to reduced 
immunosuppression alone. Ten patients had a complete remission, one a partial remission 
and one a stable disease. Six patients are alive and in complete remission more than 4 years 
after the lymphoma diagnosis while 6 patients died because of progression of lymphoma in 
three, neutropenic sepsis in two and recurrence of cirrhosis in one. 
Lorenzini et al (Lorenzini S et al, 2006) described a small series of 4 monomorphic PTLD. 
Two were early PTLD and EBV was detected in tumour tissue. The other was late PTLD and 
only one presented Latent membrane protein type 1 in lymphoma tissue. In all patients the 
immunosuppressive regimen was reduced. All patients underwent also two consecutive 
cycles of Rituximab and no severe adverse events were observed during the treatment 
period. Two patients received chemotherapy at progression but they died despite CHOP 
therapy. Only one patient, with monomorphic late PTLD is alive 5 years after disease onset. 
In this case lymphoma remission was obtained with reduction in immunosuppression and 
Rituximab administration. 
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therapy. Only one patient, with monomorphic late PTLD is alive 5 years after disease onset. 
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CR: complete remission; PD: progression disease; SD: stable disease; CHOP-R cyclophosphamide, 
doxorubicin, vincristine, prednisone, rituximab; MACOP B: Methotrexate, doxorubicin, 
cyclophosphamide, vincristine, prednisone, bleomycin; CEBOP: cyclophosphamide, etoposide, 
bleomycin, vincristine, prednisone; VACOP-B: etoposide, doxorubicin, cyclophosphamide, vincristine, 
prednisone, bleomycin; BACOP: bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone; 
CVP: cyclophosphamide, vincristine, prednisone ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine. 
Table 2. Chemotherapy treatment of patients with PTLD after liver transplantation 
In a retrospective study by Kremers et al (Kremers WK et al, 2006), among 1206 liver 
transplantation recipients, 37 patients developed PTLD. Eleven received chemotherapy 
(CHOP-BACOP) because of stable or progressive disease despite reduction of 
immunosuppression. Surprisingly, survival post PTLD diagnosis was very similar both for 
the EBV positive and EBV negative PTLD regardless of treatment received. 
Avolio et al (Avolio AW et al, 2007) treated 5 patients with PTLD after liver transplantation. 
Two patients with early EBV positive PTLD received three doses of R-CVP and CHOP 
respectively but, after an initial response, they relapsed with progression of lymphoma and 
rapidly died. Among the three cases of late PTLD, 2 presented a monomorphic monoclonal 
disease and one a Hodgkin Lymphoma. EBV was negative in one. They received soon 
discontinuance of immunosuppression and chemotherapy (R-CHOP-ABVD) and they are 
alive without evidence of disease. 
In a retrospective analysis of 17 consecutive cases (6 early and 11 late disease) of PTLD 
associated with liver transplantation (Patel H et al, 2007), 5 patients received chemotherapy 
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(CHOP), 4 obtained CR and one developed progression of disease. At a median follow up of 
4,25 years only 5 patients of the entire series are alive and in clinical and radiological 
remission. 
Marino et al (Marino D et al, 2010) reported on 10 consecutive cases of PTLD after liver 
transplantation with seven monomorphic diseases. Chemotherapy was used in eight 
patients. No treatment-related mortality was observed and no patient developed graft 
rejection during chemotherapy. At a median follow-up period of 25 months, 6 of the 10 
patients were alive and without evidence of disease. 
10. Conclusion 
The patients with PTLD can be treated with chemotherapy with an overall response rate of 
77% obtaining a long term disease free survival. 
In immunocompetent patients, Rituximab administration represents an important step in 
the treatment of non Hodgkin Lymphoma and currently immunochemotherapy is the gold 
standard for this kind of patients (Coiffier B et al, 2002; Pfreundschuh M et al, 2008). 
However, Rituximab increases the risk of CMV and Aspergillus infections (Hirokawa M et 
al, 2007; Askoy S et al, 2007; Suzan F et al, 2001; Van der Velden WJ et al, 2006) both in 
immunocompetent and in post transplant immunosuppressed patients. Recent data also 
report an anti-rejection activity of Rituximab (Kaposztas Z et al, 2009; Mulley WR et al 2009).  
In conclusion Rituximab represents a good option in the treatment of PTLD but there are 
few studies with small population, so the survival rate with the use of this antibody needs to 
be assessed together with chemotherapy administration in patients with PTLD. 
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1. Introduction 
Post-transplantation lymphoproliferative disorders (PTLD), one of the most serious 
complications occurring after transplantation, have been recognized as a complication of 
organ and cell transplantation for more than 30 years. (Starzl, 1968) 
Transplantation of solid organs has been successful in large part due to the development  
of immunosuppressive regimens that have controlled the recipient's immune system  
from rejecting the allograft. By suppressing recipient T lymphocytes with cyclosporin  
or tacrolimus or reversing rejection with antilymphocyte agents such as ATGAM or  
OKT3, rejection has become a rare cause of allograft loss.  (Jain et al., 2000) The ‘‘trade off’’ 
for this non-specific immunosuppression is the increased risk of the patient contracting 
opportunistic infections (i. e. viral, fungal and protozoal organisms) and increased risk of 
malignancies. (Fung et al., 2001) In 1968, lymphoid tumors were first described in transplant 
patients with a subgroup of these termed ‘‘pseudolymphomas’’ in recognition of their 
ability to undergo regression after reduction of immunosuppression. (Starzl et al., 1984) 
‘‘post-transplant lymphoproliferative disease’’ (PTLD) is now a well recognized 
complication of solid organ transplantation and therapeutic immunosuppression. As a 
result, PTLD is a major concern in the post transplant period and also a very complex 
disease, that encompasses a spectrum of lymphoproliferative disorders that can rise from 
either cells of B, T or natural killers cell origin. We will focus on the B cell type 
lymphoproliferative disorders in this chapter. This type is by far the most common and is 
usually associated with Epstein-Barr virus (EBV) infection. By definition, PTLD is a 
heterogeneous lymphoproliferation, ranging from benign B cell hyperplasia to aggressive B 
cell lymphoma, that arise in the setting of bone marrow or solid organ transplantation.  
2. Incidence of PTLD 
The incidence of various de novo tumors can be very dramatic in the post transplant period, 
either in the adult or pediatric population. Post-transplantation lymphoproliferative 
disorders are different from lymphoproliferative disorders that occur in the general 
population. Although relatively uncommon, the risk of developing lymphoma after 
transplantation has been reported to be 28 to 49 times greater than that in the general 
population. (Boubenider et al., 1997) According to the Cincinnati Transplant Tumor Registry 
(CTTR), which has collected data on more than 6,000 patients, PTLD accounts for 16% of 
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cancers in transplant recipients compared with 5% in the general population. However, 
these data are heavily skewed toward kidney transplant recipients. (Penn, 1996) 
Although the incidence of PTLD has been reported to be as high as 65% after primary and 
30% after reactivation EBV infection, (Birkeland et al., 1999) overall frequency ranges from 
1% to 10%. Most estimates are based on relatively small transplant series from individual 
institutions. (Penn et al., 1998) In an analysis of tumors in 512 patients in the CTTR, PTLD 
comprised 52% of all tumors. There was a disproportionately high incidence of PTLD 
among nonrenal allograft recipients compared with renal allograft recipients (81% vs 31%) 
in this group of patients.  
The frequency of PTLD depends on many variables such as the allograft type, for example. 
Kidney can correspond to 1% to 4% of incidence; heart, 2% to 10%; heart and lung, 5% to 9%; 
intestine, 19%. (Fizzera, 1992) The overall incidence of PTLD after liver transplantation has 
been quoted as 2–8.4%. (Wu et al., 2001) In the case of bone marrow recipients, the 
frequency is 1% to 2% excepting cases of mismatched T-cell-depleted allografts, for which 
the frequency has been historically as high as 24% (Shapiro et al., 1988). Innovations such as 
removal of B cells from the marrow allograft have reduced and in some series eliminated 
this complication. (Cavazzana et al., 1998) Patients who receive allogeneic hematopoietic 
stem cell transplants also have an approximate 1% risk of developing PTLD. (Gross et al., 
1999) 
Another variable that influences the incidence of PTLD is definitely the age of the recipient 
at the time of the transplant. The series of Ho and colleagues, 1988, highlights differences in 
the frequency of PTLD based on patient age at the time of transplantation. Pediatric patients 
have a higher frequency of PTLD in general than do adult patients receiving similar 
allografts, Shapiro and colleagues 1988, reported a 10.1% PTLD frequency in pediatric 
kidney transplant recipients compared with a 1. 2% frequency in the adult renal transplant 
population; 86% percent of pediatric cases and 50% of adult cases involved a transplant 
from an EBV-seropositive donor to an EBV-seronegative recipient. Thus, at least part of the 
difference in frequency between adults and children may be explained by the higher 
proportion of EBV-seronegative patients in the pediatric as opposed to the adult population.  
In children lymphomas are by far the most common tumors, and in the adults is the second 
most common following skin type lesions. (Penn, 1998) In an recent study 38% and 66% of 
patients developed a skin cancer after 10 years and 23 years, respectively. (Penn, 1998) This 
incidence is far greater than in the general population older than 75 years of age (20% to 
25%). Malignant lymphomas are the second most common malignancy in transplant 
patients reported to the CTTR, accounting for 16% of the total tumor incidence. Most 
lymphomas reported are of the large-cell type; 85% of these are of B-cell origin and 90% to 
95% are EBV-related.  
Kaposi's sarcoma (KS) accounts for 5. 7% of cancers reported to the CTTR. Both nonvisceral 
(59%) and visceral types (41%) arise. Mortality was higher in patients with visceral KS (53% 
vs 23%) and remission rates were lower (30% vs 55%). Preventive measures (ie, sunscreen, 
therapy for oncogenic viruses) and screening measures (ie, mammogram, Pap smear, 
colonoscopy) are recommended for all age- and sex-appropriate transplant recipients 
together with an informed approach to the reduction and/or avoidance of drugs with 
oncogenic potential. (Martinez, 2008) 
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3. Risk factors 
There is a lot of work trying to identify risk factors for PTLD. Clearly, EBV seronegativity is 
an important factor. This situation occurs when the recipient has not been exposed to EBV 
virus prior to the transplant and acquires the infection on the setting of 
immunosuppression. This scenario is often seen in children who are typically 
immunological naive to the virus and then acquire the virus with the graft, usually from an 
adult donor who is EBV infected.  
PTLD has been documented in three transplant immunosuppression eras: conventional 
(precyclosporine), cyclosporine, and postcyclosporine. The level of immunosuppression (ie, 
intensity, type, and amount) is an independent risk factor for PTLD. Ciancio and colleagues, 
1997, reported on the incidence of PTLD under different immunosuppressant regimens 
during an 18-year period. They noted a recent increase in the incidence of PTLD with the 
advent of newer immunosuppressive agents. By contrast, the use of mycophenolate mofetil 
in a steroid-free immunosuppressive protocol with concomitant acyclovir therapy was 
associated with a lower incidence of primary and reactivation EBV infection and PTLD. 
(Birkeland, 1999) 
Efforts have been made to identify a specific immunosuppression that might predispose 
PTLD. The introduction of calciuneurin inhibitor has been associated with an increase in the 
incidence of PTLD. T cell depletion regimens, especially OKT3, have also been implicated, and 
more recently, the use of biologics has been followed by an increase in EBV associated tumors. 
According to CTTR data, the average time after transplantation to the development of 
lymphomas was 50 months when corticosteroids and azathioprine were used; when CsA was 
added, this interval dropped to 13 months and when OKT3 was used it dropped to 7 months. 
Nevertheless, no one particular agent has proven to be associated with the development of this 
disease. It is more the cumulative amount and the duration of imunossupression. Prolonged or 
powerful immunosuppressive therapy in renal transplantation is complicated by the 
development of an unusually high incidence of malignancy.  
As previously mentioned, there is also a range in the incidence depending on the type of 
organ transplanted. Whether it has to do with the lymphoid compartment that is transferred 
with the graft, the aloreactivity of the graft or the amount of imunossupression required in 
the transplant is unclear. Several studies have implicated concurrent cytomegalovirus 
(CMV) and/or hepatitis C infection as risk factor for the development of PTLD, but that also 
has remained unclear. And finally several articles have been published looking for the role 
of cytokine gene polymorphisms in the genesis of PTLD. (Martinez, 2010) 
Reports have suggested that underlying disease may represent a risk factor for PTLD. 
Shpilberg and colleagues, 1999, suggest that, in liver transplant patients, underlying 
autoimmune disorders such as autoimmune hepatitis or primary biliary cirrhosis may 
predispose to PTLD. An even more striking association was reported in one series of 
patients who underwent liver transplantation for treatment of Langerhans cell 
histiocytosis (Newell et al., 1999). In this group, two thirds of patients developed PTLD. 
Underlying hepatitis C virus (HCV) infection was also found to be associated with a 
10.5% frequency of PTLD in one series, whereas liver transplant for other diseases was 
associated with a 1. 7% frequency. (Hezode et al., 1999) Although patients with HCV were 
noted to have a higher requirement for immunosuppression with antilymphocyte 
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antibodies, the authors observed that an increased risk remained even after this variable 
had been accounted for.  
Risk factors for PTLD 
• EBV seronegativity 
• Type and duration of immunosuppression 
• Type of organ transplanted 
• Concurrent CMV and/or HCV infection? 
• Cytokine gene polymorphisms? 
Table 1. Risk factors for PTLD 
4. Epstein Barr Virus (EBV) 
EBV is a B lymphotrophic DNA gamma herpes virus and it infects cells through CD21, a 
complement receptor (CR2), using HLA class II as a co-receptor. Once infected, persists in 
the cell as episome in subset of latently infected memory B cells. Using this strategy the 
virus is very effective, as EBV infects over 90% of the population. In addition to the PTLD, 
this virus is known to cause infectious mononucleosis in the general population and also has 
a strong association with Burkitt’s lymphoma, Hodgkin’s lymphoma, and other tumor of 
epithelial origin such as nasopharyngeal carcinoma. (Snow et al., 2006) 
Understanding the life cycle of EBV in a healthy person can help us in the pathogenesis of 
PTLD. Typically is transmitted through the saliva and infects B cells. One of two things can 
happen, it can set up a lytic infection where virus particles are produced and the cells are 
lysed and the viral particles are released to infect other cells, or it can set up a latent 
infection, expression of the define viral gens, including EBV Nuclear Antigen (EBNAs) and 
Latent Membrane Protein 1 (LMP-1) proteins. By expressing these two antigens, the cell is 
now able to proliferate autonomously and becoming essentially a lymphoblast. Cytotoxic T 
cells and NK cells control the expansion of these cells. (Cohen, 2000) 
Eventually the expression of LMP-2 antigen is shutted off and the cell exists the cell cycle, 
goes on to a type 2 latency state, and goes through germinal center reactions and emerges as 
a memory B cell, where the virus persists. Occasionally the cell can reactivate the virus and 
produces additional viral particles or can revert into the lymphoblast-like activity.  
5. Mechanisms of oncogenesis 
One of most important protein involved in the genesis of these tumors is the LMP-1, the 
major oncogene of EBV. It has been demonstrated that it is sufficient by itself for 
transformation of rodent fibroblast and is also necessary for transformation of human B cells. 
In an infected B cell that is undergoing a latent state, LMP-1 is expressed in the membrane of 
the cell via an expression of multiple spanning domains. The cytoplasmic region, signaling 
domain, of the molecule does not have intrinsic kinase activity, but via tumor tips, C 
Terminal Activating Regions (CTAR1 and CTAR2), allows the recruitment of various  
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adaptor proteins from the cell, activating a number of cellular signaling pathways. These 
cellular signaling pathways are responsible for the oncogenic function of the virus. 
(Martinez et al., 2008) 
It has been shown that tumor derived LMP-1 contains unique mutations, in position 212 and 
366 (Vaysberg et al., 2008). Also, the wild type form of LMP-1 expressed on the B cell induces 
only a transient activation, known as benign or weakly oncogenic. In contrary, tumor 
derived LMP-1 is able to induce activation of various proto-oncogenes. These mutations 
identified in tumor derived LMP-1 may account for the oncogenic function of EBV.  
A number of various cytokines is produced by EBV infected B cells, and in many cases the 
actual viral gene itself has been identified to be responsible for inducing the production of 
cellular cytokine. Some of these cytokines, especially IL-10, functions as autocrine growth 
factor for these tumor cells.  
Also, EBV is very effective at immune evasion, a characteristic that allows for the virus to 
coopt and borrow a number of different cellular pathways to allow it to persist and avoid 
detection by the immune system. (Martinez & Gruji, 2008) 
6. Classification 
Lymphoproliferative lesions are currently classified according to histologic parameters. 
Histologic findings refer to the microscopic appearance and characteristics of the tissue. 
Polymorphic lesions contain a proliferation of cells with varied morphologic structure, 
whereas monomorphic PTLDs generally contain a uniform population of cells. With the 
rapid progress in molecular diagnostic techniques, including DNA array technology, it is 
likely that the classic approach will soon be supplemented or superseded by more 
comprehensive molecular approaches. (Nalesnik et al., 2000) 
The features of PTLD have been categorized by the World Health Organization in 1997 and 
revised in 2008. It classifies PTLD into four different categories. Early lesions can be the 
reactive plasmacytic B cell type hyperplasia or infectious mononucleosis-like syndrome. 
Those are often seen as consequence of a primary disease. Various types of B cells 
infiltrating the lesion characterize the polymorphic PTLDs, including small B cells and 
lymphoblast plasma cells, and those are often seen in children. The monomorphic PTLD 
include those that are T cell or natural killer (NK) cell origin as well as the B cell 
lymphomas, the most common B cell lymphomas. They usually look like diffuse large B cell 
lymphomas. Finally, the classic Hodgkin lymphoma type PTDL, is diagnosed as in the non-
transplant patients. (Martinez, 2010) 
Classification of PTLD 
• Early 
• Polymorphic PTLD 
• Monomorphic PTLD 
• Classic Hodgkin linfoma-type PTLD 
Table 2. Classification of PTLD 
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• Classic Hodgkin linfoma-type PTLD 
Table 2. Classification of PTLD 
 




The stage of PTLD represents the extent of the disease. For example, it can be local or 
disseminated and nodal or organ involvement. In approximately 50% of cases, multiple 
organs or sites are involved at the time of presentation. (Boubenider et al., 1997) The lymph 
nodes and GI tract are the 2 most common sites. No formal system of PTLD staging exists, 
and it is suggested that the standard Ann Arbor classification with Cotswold modification, 
which is used to stage non-Hodgkin’s lymphomas, be used when possible in reporting 
cases. (Paya et al., 1999) 
The cases are placed into one of four stages (I-IV), based upon the sites of involvement, the 
number of lymph node regions involved and the presence or absence of systemic symptoms 
or of bulky or extended disease. Apart from these four stages, there is a subclassification, in 
witch “E” indicates extra-nodal involvement; “A” to indicate the absence or “B” to indicate 
the presence of systemic symptoms (weight loss, fever, or night sweats) and “X” to denote 
bulky disease, which is more than 10cm in maximum dimension or involves more than one 
third of the chest diameter (seen on chest x-ray).  
All organs known or suspected to be involved in PTLD and the evidence for their 
involvement (histologic, radiologic, and/or biochemical) should be recorded. The presence 
or absence of allograft involvement should also be explicitly stated for each case. (Preiksaitis 
& Keay, 2001) 
Stage Criteria 
I In 1 lymph region only 
II In ≥ 2 lymph regions on the same side of the diaphragm 
III In the lymph nodes, spleen, or both and on both sides of the diaphragm 
IV Extranodal involvement (eg, bone marrow, lung, liver) 
Table 3. Cotswold Modification of Ann Arbor Staging of Hodgkin Lymphoma and Non-
Hodgkin Lymphoma 
8. Clinical presentation 
Due to the complexity of the disease, clinical presentation can be quite variable, depending 
on the type of immunosuppression, type of organ transplanted and type of PTLD. 
Generalized systemic illness symptoms, such as fever, sweats, malaise, and rapid 
enlargement of tonsils or cervical nodes are commonly seen in PTLD patients. In some cases 
the nodes are involved, and sometimes it presents as a localized disease and sometimes as a 
disseminated disease.  
The gastrointestinal tract is a common site of extra nodal disease and it can cause abdominal 
pain with hemorrhage and may perforate, leading to acute abdomen. Central nervous 
system disease may also occur causing symptoms secondary to local necrosis and tumor 
mass effect. However, PTLD can occur at any site. For example, isolated skin involvement 
has been noted, (McGregor et al., 1993) and gallbladder involvement has been observed in 
one case as well (Heller et al., 2000). Disease limited to the graft is a common manifestation 
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of early PTLD. Its differentiation from acute cellular rejection in this situation is critically 
important. Lesions may be limited and progress slowly, or the patient may present with a 
fulminant, multiple-system, sepsis-like syndrome. This last form is an uncommon 
presentation, occurring in approximately 1% of cases (Nalesnik et al., 2000). PTLD may 
resemble a self-limited infection or be indistinguishable from non-Hodgkin lymphoma. An 
unexplained infectious syndrome in a transplant recipient should raise the suspicion of 
PTLD. A mononucleosis syndrome may occur early after transplantation, particularly in 
association with a primary EBV infection. This presentation is particularly common in the 
pediatric population, and indeed, in some cases it is infectious mononucleosis. 
Otolaryngologic symptoms and findings are often the first manifestation of PTLD in 
children. (Posey et al., 1999) Patients may present with tonsillitis, tonsillar necrosis, 
lymphadenitis, sinusitis, and otitis media. There is a tendency for more severe upper airway 
symptoms, including airway obstruction. It should also be noted that the underlying process 
in these cases, ie, infectious mononucleosis vs frank tumorous PTLD, cannot always be 
inferred from the clinical picture alone.  
PTLD can present as early as less than a month or lately as several years after 
transplantation. In a series of 71 liver transplant recipients in a pediatric population the 
incidence of PTLD was 9.85%. The median time from the first symptoms to the initial 
treatment was 9. 7 days (Wiederkehr et al., 2010). In general, however, PTLD is remarkable 
for a short post-transplantation time of onset. In the CTTR, the latest case occurred 25 years 
after transplantation. As a general rule patients who presentas lateonset (>1 year) have more 
aggressive tumours with poorer prognosis (Molnar & Keung, 2001).  
PTLDs that do not contain EBV tend to arise at a later time than those that do contain the 
virus. In one series, 50% of EBV-positive PTLDs arose by 6 months following 
transplantation, whereas the 50% mark for occurrence of EBV-negative PTLDs was not 
reached until 5 years after transplantation (Leblond et al., 1998). PTLDs of T-cell origin are 
uncommon and may also arise later in the posttransplantation course, but a case of a 
monoclonal T-cell tumor arising 2 months after transplantation has been described. (Kim et 
al., 1999) 
A PTLD that occurs later is more likely to be circumscribed anatomically and to be 
associated with a more gradual clinical course. In this situation, extranodal disease with 
visceral involvement is common with gastrointestinal, pulmonary, or central nervous 
system (CNS) symptoms. Lymphadenopathy is painless, and atypical lymphocytes may or 
may not be present in the white blood cell differential count.  
Most patients with PTLD present with at least 1 tumor. About two thirds of these tumors are 
extranodal, and about one third are nodal. (Penn, 1994) There is a tendency to involve 
specific sites. The gastrointestinal tract is involved in about 26% of cases and CNS in about 
27% of cases (Chen et al., 1993). The allograft can also be involved. In this case, the 
frequency of involvement varies according to the specific type of allograft. PTLDs that arise 
in lung or intestinal transplant recipients involve those allografts in up to 80% of cases. The 
reason for this is not known. However, it is interesting that the lung and bowel are 
transplanted with a large indigenous lymphoid population. PTLDs that occur in patients 
receiving other types of allografts, such as liver and kidney, involve the allograft in about 
one third of cases (Cohen, 1993). In contrast, the transplanted heart is only rarely involved 
with these tumors (Hanasono, 1995). 
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unexplained infectious syndrome in a transplant recipient should raise the suspicion of 
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association with a primary EBV infection. This presentation is particularly common in the 
pediatric population, and indeed, in some cases it is infectious mononucleosis. 
Otolaryngologic symptoms and findings are often the first manifestation of PTLD in 
children. (Posey et al., 1999) Patients may present with tonsillitis, tonsillar necrosis, 
lymphadenitis, sinusitis, and otitis media. There is a tendency for more severe upper airway 
symptoms, including airway obstruction. It should also be noted that the underlying process 
in these cases, ie, infectious mononucleosis vs frank tumorous PTLD, cannot always be 
inferred from the clinical picture alone.  
PTLD can present as early as less than a month or lately as several years after 
transplantation. In a series of 71 liver transplant recipients in a pediatric population the 
incidence of PTLD was 9.85%. The median time from the first symptoms to the initial 
treatment was 9. 7 days (Wiederkehr et al., 2010). In general, however, PTLD is remarkable 
for a short post-transplantation time of onset. In the CTTR, the latest case occurred 25 years 
after transplantation. As a general rule patients who presentas lateonset (>1 year) have more 
aggressive tumours with poorer prognosis (Molnar & Keung, 2001).  
PTLDs that do not contain EBV tend to arise at a later time than those that do contain the 
virus. In one series, 50% of EBV-positive PTLDs arose by 6 months following 
transplantation, whereas the 50% mark for occurrence of EBV-negative PTLDs was not 
reached until 5 years after transplantation (Leblond et al., 1998). PTLDs of T-cell origin are 
uncommon and may also arise later in the posttransplantation course, but a case of a 
monoclonal T-cell tumor arising 2 months after transplantation has been described. (Kim et 
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A PTLD that occurs later is more likely to be circumscribed anatomically and to be 
associated with a more gradual clinical course. In this situation, extranodal disease with 
visceral involvement is common with gastrointestinal, pulmonary, or central nervous 
system (CNS) symptoms. Lymphadenopathy is painless, and atypical lymphocytes may or 
may not be present in the white blood cell differential count.  
Most patients with PTLD present with at least 1 tumor. About two thirds of these tumors are 
extranodal, and about one third are nodal. (Penn, 1994) There is a tendency to involve 
specific sites. The gastrointestinal tract is involved in about 26% of cases and CNS in about 
27% of cases (Chen et al., 1993). The allograft can also be involved. In this case, the 
frequency of involvement varies according to the specific type of allograft. PTLDs that arise 
in lung or intestinal transplant recipients involve those allografts in up to 80% of cases. The 
reason for this is not known. However, it is interesting that the lung and bowel are 
transplanted with a large indigenous lymphoid population. PTLDs that occur in patients 
receiving other types of allografts, such as liver and kidney, involve the allograft in about 
one third of cases (Cohen, 1993). In contrast, the transplanted heart is only rarely involved 
with these tumors (Hanasono, 1995). 
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9. Diagnosis of PTLD 
The diagnosis of PTLD requires an awareness of the myriad appearances of this syndrome. 
Isolated or systemic lymphadenopathy or "lumps and bumps" that suddenly appear should 
include PTLD in the differential diagnosis. (Nalesnik et al., 2000) Abdominal pain, 
particularly with evidence of intestinal bleeding, raises the possibility of PTLD in the GI 
tract. In one pediatric series, diarrhea and/or gastrointestinal bleeding in the presence of 
active EBV infection was associated with PTLD in 43% of cases. (Cao et al., 1998) Persistent 
headaches or CNS symptoms suggest localization to the brain. Upper respiratory tract 
infections that may be associated with lymphadenopathy or that do not resolve after a 
course of antibiotics should raise a suspicion of PTLD.  
Several laboratory assays have applicability in suggesting or supporting the diagnosis of 
PTLD. Badley and colleagues, 1996, demonstrated monoclonal gammopathy in 71% of 
transplant recipients with and in 27% of transplant recipients without PTLD. A separate 
study showed that PTLD developed in 9% of all transplant recipients who had monoclonal 
gammopathy. (Pageaux, 1998) 
The gold standard is the analyses of histology of the biopsy tissue. (Dusenbery et al., 1997) 
The first effort is to identify the virus, usually done by looking for EBV encoded RNA 
(EBER) or LMP-1 with immunohistochemical stain. Clonality and phenotyping can also be 
done to identify the origin of the cells involved in the tumor.  
The term 'PTLD' encompass the full range of EBV-related lymphoproliferative states, 
including benign processes. However, when not otherwise specified, PTLD should refer to 
the neoplastic end of the PTLD spectrum. Neoplasia should be defined by two of the 
following three characteristics: (1) destruction of the underlying lymph node architecture; 
(2) monoclonality (regardless of morphology); (3) evidence of EBV infection in the neoplastic 
cells. (Loren et al., 2003)  
Regarding serology, it is not diagnostic of PTLD rather than a tool to identify primary 
infection or reactivation. Epstein-Barr viral serologic testing may be used to evaluate the 
presence of recent or remote infection and thus may provide indirect information relevant to 
the diagnostic workup for PTLD. However, a diagnosis of EBV infection, active or remote, is 
not synonymous with a diagnosis of PTLD. For example, one study (Smets et al., 2000) of 
EBV-seronegative pediatric liver transplant recipients showed an 80% conversion rate to 
seropositivity within the first 3 months after transplantation. Of these patients, 
approximately 85% were asymptomatic and only 15% developed PTLD.  
Of the various serologic assays for EBV infection, IgM antiviral capsid antigen (IgM-VCA) is 
particularly useful in detecting active infection. In one study, IgM-VCA antiviral capsid 
antigen level was elevated an average of 5 days after a detectable rise in circulating EBV 
genomes shown by polymerase chain reaction (PCR) assay. (Bodeus et al., 1999) 
Quantitative estimation of the number of EBV genomes in the peripheral blood by use of the 
PCR assay provides a more useful correlate of the EBV infection types most likely to be 
associated with PTLD.  
This technique was applied following the observation that patients with PTLD had early 
and spontaneous outgrowth of virus when peripheral blood cells were cultured in vitro. 
(Rooney et al., 1995) Such outgrowth does not occur in "normal" EBV-positive patients. It 
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was subsequently shown that patients with PTLD had elevated numbers of circulating viral 
genomes. Hanasono and colleagues, 1995, showed that normal EBV-positive patients had 
less than 2,000 viral genomes per microgram of blood cell DNA, whereas the number of 
genomes was increased 10- to 100-fold in patients with PTLD. Rowe and colleagues found 
an increased risk of PTLD when the number of circulating EBV genomes exceeded 500/105 
peripheral blood lymphocytes. Furthermore, regression of PTLD was associated with a 
decrease in the number of circulating viral genomes, indicating that this parameter also 
served as a useful means of monitoring therapy. (Rogers et al., 1998) 
Some tests done for confirmation of diagnosis of PTLD are HE staining, which is important 
to determine the morphology of the tumor and the extent of infiltration and tissue 
architecture destruction; phenotyping of B cells, NK cells or T cells; Ki-67 which is an 
important marker for the proliferative index and shows how rapidly the tumor is dividing; 
and EBER staining to confirm the presence of the virus itself.  
10. Radiographic features 
CT-scans and/or MRI are usually done for staging of the disease. The range of appearances 
is large due to the number of possible sites. If the disease affect solid organs (liver, spleen, 
kidney) it can be showed as nodules with characteristic such as hypoechoic, low density on 
CT or as a diffuse infiltration. When the disease affects bowel, it can appear as a 
circumferential wall thickening, an aneurysmal dilattation, an ulceration or perforation, and 
even bowel obstruction. In the lung, it can appear as nodules usually homogeneous, may 
centrally cavitate, or as diffuse infiltration. When the object of study is the brain, must be 
considered characteristics similar to lymphoma in the setting of HIV infection and also 
necrosis and hemorrhage. Overall, nodes can appear as non-specific nodal enlargement, 
similar to other lymphomas. (Pickhardt et al., 2000) 
The single most frequent imaging finding is lymphadenopathy within the abdomen, as 
expected, being the most common region involved. Previous studies have reported 
lymphadenopathy between 55% and 74%. (Steiber et al., 1991) Pickhardt & Siegel, 2000, 
reported a lower incidence of 34%, but only concentrated on intra-abdominal abnormalities.  
11. Differential diagnoses 
The differential diagnosis depends on the location of PTLD and is therefore broad. If the 
disease locates at the small bowel the differential diagnosis can be inflammatory bowel 
disease - especially Crohn’s disease – or acute rejection. If the disease locates at the lung, 
metastases, infection, lymphoid interstitial pneumonia (LIP) must be considered. When 
located in the head and neck, infections mononucleosis or reactive nodal enlargements are 
diagnostic possibilities.  
12. PCR monitoring for EBV DNA 
EBV titers have been shown to be sensitive to adjustments of immunosuppressive therapy, 
and it has been suggested that immunosuppressive therapy could be reduced when a rising 
titer is observed, thus preempting the development of PTLD. Studies examining this have 
concentrated on the pediatric population where it is thought that EBV exposure occurs at  
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Fig. 1. CT confirmed multiple low attenuation lesions within the liver and the presence of 
ascites. (Dhillon et al., 2007) 
 
Fig. 2. Small bowel involvement: barium follow-through presenting a small bowel 
obstruction with an extensive stricture within the terminal ileum. (Dhillon et al., 2007) 
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the time of transplantation so that PTLD is most frequently observed during the first post-
transplant year. (McDiarmid et al., 1998) However, in adults, there is often pre-transplant 
EBV immunity and this is reflected in the later development of PTLD.  
In high-risk patients, such as children who are seronegative at transplant, determination of 
viral load throughout the post-transplant period may be useful. Increases in viral DNA can 
be detected months before clinical onset of PTLD. Viral load determination can also be used 
to monitor response to the treatment. The problem of this approach is that not all patients 
with PTLD will have an increase in the viral load, and only a minority of patients with high 
viral load will develop PTLD. Although there is no consensus on the threshold value, as 
well as standard methodology and compartment measured, some reports indicate 200 
copies/105 PBMC correlates with symptomatic disease in children. (Martinez, 2010) 
It has been revealed that there are subsets of patients who are chronic high load carriers, 
with no symptomatic or clinical disease. This is typically of patients who have undergone a 
primary infection and were seronegative at the time of transplant. It can also occur after 
asymptomatic primary infection of after EBV disease, including PTLD. (Martinez, 2010) 
13. Prevention 
Prophylactic treatment with antivirals, acyclovir and gancyclovir, is used in many high-risk 
patients. Those drugs are not effective in the context of PTLD because at that stage the virus 
is in a latent infection and the antivirals depend upon viral replication. One way to 
overcome such problem is to use arginine butyrate to re-initiate a lytic infection and 
combined that with antiviral drugs.  
The reports that prophylactic antiviral drugs minimize PTLD risk have been somewhat 
unconvincing, involving very small number of patients in observational studies. Each 
investigator defined ‘high-risk’ differently: some included only patients with elevated EBV 
viral loads, while others included EBVnegative patients receiving organs from EBV-positive 
donors, or patients receiving high-dose immunosuppression or specific anti-lymphocyte 
therapy.  
Antiviral agents (such as intravenous immunoglobulin containing neutralizing antibody or 
acyclovir, ganciclovir, and foscarnet) that target steps in the lytic virus cycle are sometimes 
used for PTLD prevention. The potential efficacy of these agents depends on the relative 
importance of EBV-driven lymphoproliferation (which is not influenced by these agents) 
and the lytic virus cycle (which is) on EBV-induced lymphomagenesis. (Preiksaiti, 2004) 
However, historical comparisons of the incidence of PTLD among patients receiving and 
patients not receiving ganciclovir prophylaxis, either immediately after transplantation or 
during antilymphocyte antibody therapy, suggest that prophylactic antiviral therapy may 
be of some benefit (Preiksaiti, 2003). A multicenter, randomized controlled trial of CMV 
immunoglobulin prophylaxis in EBV-seronegative, pediatric SOT recipients was 
inconclusive with respect to PTLD prevention. This was likely the result of 
immunosuppression modification by clinicians in response to EBV load data, resulting in an 
overall reduction over time in the incidence of PTLD, irrespective of the prophylactic 
regimen used. (Green et al., 2003) Antiviral agents may have indirect benefit on PTLD risk 
by eliminating other viral infections, such as CMV infection, that act as cofactors in PTLD 
development. For this reason, the use of ganciclovir may be preferred over the use of 
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combined that with antiviral drugs.  
The reports that prophylactic antiviral drugs minimize PTLD risk have been somewhat 
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therapy.  
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used for PTLD prevention. The potential efficacy of these agents depends on the relative 
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during antilymphocyte antibody therapy, suggest that prophylactic antiviral therapy may 
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acyclovir. Antiviral agents may also influence global immunosuppression by preventing the 
expression of EBV immunomodulatory proteins expressed during the lytic cycle. There is an 
urgent need for additional multicenter controlled trials that evaluate the efficacy of agents 
used alone and together for prophylaxis. (Preiksaiti, 2004) 
An alternative approach to prevention employs a preemptive strategy in which intervention 
(usually in the form of reduction in immunosuppression and/or the use of antiviral drugs, 
with or without immunoglobulin) is administered in response to “trigger points,” usually 
high EBV loads. This approach has been used in both intestinal transplant recipients and 
pediatric liver transplant recipients. (Green et al., 2001) Although the simultaneous use of 
multiple interventions makes it difficult to determine the efficacy of any single approach, 
the incidence of PTLD decreased in these populations, compared with historical controls, 
when preemptive strategies were applied. (Preiksaiti, 2004) 
14. Treatment 
Primary approach for of PTLD is to reduce immunosuppression in these patients. The 
response rate for this strategy varies from 23-100%, which in some cases places the allograft 
in danger for rejection, and occurs as a potential complication in 39% of the patients. It is not 
the ideal approach but it has been effective for some patients. Predictors of lack of response 
to reduction of immunosuppression include a serum LDH 42. 5 times the upper limit of 
normal, organ dysfunction, and multiple visceral sites of disease. (Tsai et al., 2001) In 
patients with life-sustaining organ transplants such as hearts, livers and lungs, reduction in 
immunosuppression should be more moderate and closely monitored as allograft rejection 
may be swift and fatal. (Loren et al., 2003) 
Initial attempts to prevent PTLD in the solid-organ transplant population were focused 
primarily on using antiviral therapies, such as thymidine kinase inhibitors ganciclovir or 
acyclovir, to eradicate or control EBV for high-risk patients. These drugs inhibit the 
replication of other herpes viruses, such as herpes simplex and cytomegalovirus. In vivo, 
however, they are ineffective against EBV, because EBV survives as an episome outside of 
the lymphocyte’s genome. In addition, these drugs do not eradicate latently infected B cells. 
(Crumpacker et al., 1996) 
The use of humanized antibody to CD20 (anti-CD20 mAbs, Rituxan) has been shown to be 
effective, although there are some issues with relapse and it is restricted to CD20 positive 
tumors. Chemotherapy, surgery and radiation can also be used in some patients with 
variable outcomes. (Muchak et al., 2010)  
Chemotherapy has also been used to treat PTLD, generally after patients have failed to 
respond to surgical excision with or without reduction of immunosuppression. Regimens 
are similar to those used for non-Hodgkin’s lymphoma, such as CHOP and ProMACE-
CytaBOM.  
While chemotherapy may occasionally provide long-term relapse-free survival, it is 
accompanied by a high infection and mortality rate. (Mamzer-Bruneel et al., 2000) 
When possible, complete surgical excision of localized disease is highly effective as well as 
local radiation. Localized disease treated with definitive local therapy (surgery or radiation), 
combined with reduction of immunosuppression, have an excellent prognosis, with PTLD-
related mortality rates reported between 0 and 26%. (Davis et al., 1998) 
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Treatment Response Rate (%) 
Reduction immunosupression 23-100 
Anti-CD20mAbs (Rituxan) 44-68 
Chemotherapy 24-65 
Surgery and radiation Variable 
Table 4. Therapeutic strategies for PTLD and their efficacy 
Two new strategies have been shown to be of some value in the treatment of PTLD patients. 
One is to improve the immune system response against the virus, and a second one is to try 
to lower the viral load or the number of infected cells. T cell lines – CTL, specifically directed 
against B cell can be obtained in vitro. (Haque, 2002) 
Attempts to establish a competent immune to control EBV-related lymphoproliferations, 
with immune modulators such as cytokines with or without immunoglobulins have been 
made. Several case series and case reports have described responses to interferon-alpha and 
interferon-alpha combined with intravenous IgG. (Davis, 1998) Interleukin-6, a cytokine that 
promotes the growth and proliferation of B cells, provides another potential target. It is 
difficult to assess the effectiveness of cytokine therapy as most studies utilizing these agents 
have also incorporated concurrent reduction in immunosuppression or antiviral agents.  
Rapamycin and everolimus, mTOR inhibitors, that are antiproliferative agents may be 
effective in preventing PTLD. (Nepomuceno et al., 2003) Also, mTOR inhibitors provide an 
option of switching immunosuppression while providing some anti-tumor effect as an 
alternative to removal of immunosuppression. (Vaysberg et al., 2007 and Krams et al., 2008) 
A promising therapeutic option to control B-cell proliferation is anti-B-cell antibody therapy. 
Expression of B-cell antigens is variable in PTLD, most likely because of the dysregulation 
by EBV infection. Nevertheless, results have been quite promising with many patients 
achieving longterm relapse-free survival.  
15. Prognosis 
Overall response and survival rates are difficult to compare because of the wide range of 
PTLD forms and therapies. Furthermore, crude rather than actuarial survival rates are often 
reported. Within these limitations, a review of relevant literature shows responses that tend 
to vary according to histology and stage. In two separate series, (Knowles et al., 1995 and 
Cohen eta l. , 1991) mortality from polymorphic and monomorphic PTLDs ranged from 0% 
to 20% and 67% to 87%, respectively. PTLDs with abnormalities of oncogenes or tumor 
suppressor genes would fit within the monomorphic category, and these abnormalities 
appear to augur a worse prognosis. (Knowles et al., 1995 and Locker et al., 1989) According 
to Cohen, 1991, it was observed that 44% of PTLD survivors had involvement of only one 
organ, and involvement of 3 or more organs occurred in 57% of fatal cases. Dror and 
colleagues considered thrombocytopenia and neutropenia to represent negative prognostic 
indicators and PTLD histology and stage to be marginally significant in their series. An 
absence of stage effect on survival was also reported in a retrospective review of 27 pediatric 
patients. (Donnelly et al., 1998) In this series, mortality was more closely related to the 
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underlying procedure, with BMT and heart transplant recipients having higher mortality 
rates than liver and kidney transplant recipients. Gross and colleagues reported 92% 
mortality in PTLD arising in recipients of allogeneic hematopoietic stem cell transplants. In 
their series, the only responders seen were among those patients treated with interferon 
alpha. In a separate pediatric liver transplant series, (Praghakaran, 1999) 4 patients with B-
cell lymphoma and 1 with B-cell leukemia were successfully treated with reduced 
immunosuppression and high-dose acyclovir alone or with this treatment followed by 
chemotherapy. (Praghakaran, 1999) In our series of 7 liver transplants in small children with 
PTLD, median age at transplantation was 35.14 months, and the mortality was 57%. 
(Wiederkehr et al., 2010) 
The heterogeneity of these reports exemplifies the variable results seen with different 
treatment regimens among different centers and argues for standardized multicenter 
therapeutic trials against this disease. According to Nalesnik’s series of 256 patients with 
PTLD, the overall 2-year actuarial survival is 90%, and the overall actuarial 5-year survival 
is 77%. (Nalesnik et al., 2000) 
According to a study made by Jain et al., 2002, the actuarial patient survival rates for entire 
population of PTLD patients at 1, 5, 10, 15 and 20 years were 85%, 69%, 55%, 47%, and 45% 
respectively. In the article there was a numerical difference in survival, with women having 
a better survival than men but this was only evident at 10 years after PTLD diagnosis and 
did not reach statistical significance. Long-term survival rates for pediatric patients with 
PTLD were better than for adults (60% pediatric at 15 years, compared to 39% for adults). 
Survival in the tacrolimus group was significantly better than for cyclosporin (60% vs. 40% 
by 12 years). Other factors that appeared to have a positive effect on survival included single 
site versus multiple site. Overall, mortality due to PTLD ranges from 22% to 70%. (Levi et 
al., 1993 and Newell et al., 1996) 
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1. Introduction 
The survival of patients who undergo liver transplantation has improved over recent years, 
due to the perfectioning of the surgical technique, the optimization of immunosuppressive 
therapy and the prevention of infection, and is estimated to be 90% at one year and 70% at 
five years (Pagadala et al., 2009). However, at the same time the incidence of metabolic 
complications has increased, and they now constitute one of the main causes of mortality 
unrelated to the graft (Muñoz & ElGenaidi, 2005; Watt et al., 2010). The metabolic syndrome 
(MS), which associates overweight, dyslipidaemia, hyperglycaemia and hypertension, has a 
greater prevalence in patients who have a liver transplant as compared with the general 
population (Francioso et al., 2008; Sorice et al., 2011). Though the impact of the MS on post-
transplant mortality is controversial, its diagnosis or the presence of certain of its 
components increases the risk of cardiovascular complications, renal failure or fatty liver 
disease in the graft, and it has also been related with a greater risk for infections and 
rejection. The MS has special relevance in patients with hepatitis C, as the development of 
the MS in general, and diabetes in particular, can affect the natural history of the hepatitis C 
in the graft (Vedt et al., 2009). The identification of modifiable predisposing factors and early 
treatment of hypertension, hyperglycaemia and dyslipidaemia, together with the prevention 
of overweight during the peri-transplant period, can all help to reduce the morbidity and 
mortality in this population. 
2. Diagnosis and prevalence of the metabolic syndrome in liver transplant 
patients  
Many definitions for the MS can be found in the literature. The criteria defined by the 
National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATPIII) 
adapted by the National Heart, Lung and Blood Institute/American Heart Association 
(NHLBI/AHA) and International Diabetes Federation (IDF) are detailed in Table 1(Grundy 
et al., 2004; Alberti et al., 2006). 
These criteria all have in common insulin resistance (IR) as the physiological basis of the MS. 
IR is defined as the reduction of sensitivity of tissues to the action of insulin, which implies a 
compensating hyperinsulinaemia that in the end exhausts the capacity of the pancreatic beta 
cells to produce insulin. Secondary to this is produced hyperglycaemia and diabetes. IR is 
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Many definitions for the MS can be found in the literature. The criteria defined by the 
National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATPIII) 
adapted by the National Heart, Lung and Blood Institute/American Heart Association 
(NHLBI/AHA) and International Diabetes Federation (IDF) are detailed in Table 1(Grundy 
et al., 2004; Alberti et al., 2006). 
These criteria all have in common insulin resistance (IR) as the physiological basis of the MS. 
IR is defined as the reduction of sensitivity of tissues to the action of insulin, which implies a 
compensating hyperinsulinaemia that in the end exhausts the capacity of the pancreatic beta 
cells to produce insulin. Secondary to this is produced hyperglycaemia and diabetes. IR is 
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measured using the HOMA (Homeostatic Model Assessment) index, though its 
measurement is not necessary for the diagnosis of the MS (Matthews et al., 1985).  
HOMA= fasting insulin (mU/ml) x fasting glucose (mmol/L)/22.5 
American Heart Association International Diabetes Federation 
At least 3 of the following criteria: 
• Waist circumference >88 cm for 
women and >102 cm for men 
• Fasting glucose >100 mg/dl 
• Systolic blood pressure> 130mmHg 
and/or diastolic blood pressure >85 
mmHg or on antihypertensive 
treatment in a patient with history of 
hypertension 
• HDL <50 mg/dl for women and <40 
mg/dl for men 
• Triglycerides >150 mg/dl or on drug 
treatment for elevated TG 
Abdominal obesity according to gender 
and ethnicity specific values (i.e. waist 
circumference >80 cm for women and >90 
cm for men if they are American or 
European) and at least 2 the following 
criteria: 
• Fasting glucose>100 mg/dl 
• Systolic blood pressure >130 mmHg 
and/or diastolic blood pressure >85 
mmHg or on antihypertensive 
treatment 
• HDL <50 mg/dl for women and <40 
mg/dl for men 
• Triglycerides >150 mg/dl 
Table 1. Definition of the metabolic syndrome by NHLBI/AHA and IDF 2005 
The prevalence of the MS in the general population is approximately 30% (Ford et al., 2004). 
However, in liver transplant patients it is considerably higher, approximately 40-50% 
(Laryea et al., 2007; Bianchi et al, 2008), though these percentages can vary according to 
geographical area, and are slightly lower, for example, in the Spanish population, both 
transplanted and non-transplanted (Ruiz-Rebollo et al., 2010). 
Independent analysis of each of the components of the MS also shows a greater incidence in 
the transplanted population; 40-85% develop hypertension, 13-61% diabetes, 40-66% 
dyslipidaemia, mainly hypertriglyceridaemia, and up to 40% obesity, which can reach 70% 
three years post-transplant (Laish et al., 2011). 
3. Risk factors for post-transplant metabolic syndrome  
Different studies have evaluated possible risk factors for the development of post-transplant 
metabolic syndrome (PTMS) in an attempt to identify them early and treat them as far as 
possible. 
In general, considering that IR triggers the MS, the situations that predispose to this 
condition are applicable, in addition to the underlying aetiology of the liver disease and the 
use of immunosuppressive drugs. 
Of the causes leading to the liver transplant, HCV infection (Bigam et al., 2000) and 
cryptogenic cirrhosis are significantly associated with PTMS (Ong et al., 2001), versus other 
 
Metabolic Syndrome After Liver Transplantation 
 
351 
factors such as autoimmune disorders or hepatitis B. Biliary diseases are not related with 
PTMS, perhaps because of the later hepatocyte involvement, which is, after all, responsible 
for glucose metabolism (Laryea et al., 2007). Review of all the publications available 
confirms the two-way relation of the hepatitis C virus, insulin-resistance and the 
development of diabetes (Hanouneh et al., 2008). 
Immunosuppressive drugs, particularly steroids and calcineurin inhibitors, are associated 
with the appearance of cardiovascular risk factors, though tacrolimus is more diabetogenic 
and cyclosporine predisposes more to hypertension and dyslipidaemia (Marchetti & 
Navalesi, 2000). In fact, most of the metabolic complications appear during the first months 
after the transplant, when the immunosuppressive treatment is greater. Nevertheless, no 
clear relation exists between the MS and a particular immunosuppressive regimen, probably 
because of its multifactorial origin (Bianchi et al., 2008). 
The characteristics of the donor and the recipient also influence the development of PTMS; 
mainly the age of both, the presence of any of the components of the MS prior to the 
transplant, and the existence and degree of graft steatosis are considered risk factors. 
4. Components of PTMS 
4.1 Obesity 
Overweight is defined as a body mass index (BMI) of 25-30 and obesity as a BMI >30, with 
the latter being classified into class I (BMI of 30-35), class II (BMI of 35-40) and class III 
(BMI>40). Obesity can also be differentiated between peripheral or central obesity, with the 
latter having more implication in the metabolism (Watt, 2010). 
Pre-transplant obesity is associated with greater peri-operative morbidity and mortality, 
with a longer hospital stay and reduced patient and graft survival. An analysis by the 
Scientific Registry of Transplant Recipients showed that five-year post-transplant 
mortality was greater in recipients with class II and III obesity (Nair et al., 2002), though 
no consideration was given to the influence of ascites on overweight. Studies that 
corrected obesity for ascites found no significant differences regarding morbidity or 
survival between obese and non-obese recipients, though ascites was found to be 
indicative of a worse postoperative course (Leonard et al., 2008). These studies could, 
however, be influenced by the fact that the obese patients were studied more closely from 
the cardiological aspect, with more exhaustive screening for pre-transplant cardiovascular 
risk.  
Post-transplant obesity is very usual. Patients who are overweight prior to the transplant 
usually remain so, and up to one third develop de novo obesity (Wawrzynonowicz-
Syczewska et al., 2009). The main triggering factor is the return to dietary habits but not to 
physical activity (Painter et al., 2001), which leads to a progressive weight gain, generally 
greater during the first post-transplant months. The immunosuppressive medication has 
traditionally been considered a trigger of overweight, though the association is in fact 
controversial and it has only been shown with the long-term use of steroids (Everhart et al., 
1998). 
Whilst not associated with greater mortality, post-transplant obesity, particularly central 
obesity, causes an imbalance in the production of adipokines, favouring those that produce 
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measured using the HOMA (Homeostatic Model Assessment) index, though its 
measurement is not necessary for the diagnosis of the MS (Matthews et al., 1985).  
HOMA= fasting insulin (mU/ml) x fasting glucose (mmol/L)/22.5 
American Heart Association International Diabetes Federation 
At least 3 of the following criteria: 
• Waist circumference >88 cm for 
women and >102 cm for men 
• Fasting glucose >100 mg/dl 
• Systolic blood pressure> 130mmHg 
and/or diastolic blood pressure >85 
mmHg or on antihypertensive 
treatment in a patient with history of 
hypertension 
• HDL <50 mg/dl for women and <40 
mg/dl for men 
• Triglycerides >150 mg/dl or on drug 
treatment for elevated TG 
Abdominal obesity according to gender 
and ethnicity specific values (i.e. waist 
circumference >80 cm for women and >90 
cm for men if they are American or 
European) and at least 2 the following 
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• Systolic blood pressure >130 mmHg 
and/or diastolic blood pressure >85 
mmHg or on antihypertensive 
treatment 
• HDL <50 mg/dl for women and <40 
mg/dl for men 
• Triglycerides >150 mg/dl 
Table 1. Definition of the metabolic syndrome by NHLBI/AHA and IDF 2005 
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However, in liver transplant patients it is considerably higher, approximately 40-50% 
(Laryea et al., 2007; Bianchi et al, 2008), though these percentages can vary according to 
geographical area, and are slightly lower, for example, in the Spanish population, both 
transplanted and non-transplanted (Ruiz-Rebollo et al., 2010). 
Independent analysis of each of the components of the MS also shows a greater incidence in 
the transplanted population; 40-85% develop hypertension, 13-61% diabetes, 40-66% 
dyslipidaemia, mainly hypertriglyceridaemia, and up to 40% obesity, which can reach 70% 
three years post-transplant (Laish et al., 2011). 
3. Risk factors for post-transplant metabolic syndrome  
Different studies have evaluated possible risk factors for the development of post-transplant 
metabolic syndrome (PTMS) in an attempt to identify them early and treat them as far as 
possible. 
In general, considering that IR triggers the MS, the situations that predispose to this 
condition are applicable, in addition to the underlying aetiology of the liver disease and the 
use of immunosuppressive drugs. 
Of the causes leading to the liver transplant, HCV infection (Bigam et al., 2000) and 
cryptogenic cirrhosis are significantly associated with PTMS (Ong et al., 2001), versus other 
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factors such as autoimmune disorders or hepatitis B. Biliary diseases are not related with 
PTMS, perhaps because of the later hepatocyte involvement, which is, after all, responsible 
for glucose metabolism (Laryea et al., 2007). Review of all the publications available 
confirms the two-way relation of the hepatitis C virus, insulin-resistance and the 
development of diabetes (Hanouneh et al., 2008). 
Immunosuppressive drugs, particularly steroids and calcineurin inhibitors, are associated 
with the appearance of cardiovascular risk factors, though tacrolimus is more diabetogenic 
and cyclosporine predisposes more to hypertension and dyslipidaemia (Marchetti & 
Navalesi, 2000). In fact, most of the metabolic complications appear during the first months 
after the transplant, when the immunosuppressive treatment is greater. Nevertheless, no 
clear relation exists between the MS and a particular immunosuppressive regimen, probably 
because of its multifactorial origin (Bianchi et al., 2008). 
The characteristics of the donor and the recipient also influence the development of PTMS; 
mainly the age of both, the presence of any of the components of the MS prior to the 
transplant, and the existence and degree of graft steatosis are considered risk factors. 
4. Components of PTMS 
4.1 Obesity 
Overweight is defined as a body mass index (BMI) of 25-30 and obesity as a BMI >30, with 
the latter being classified into class I (BMI of 30-35), class II (BMI of 35-40) and class III 
(BMI>40). Obesity can also be differentiated between peripheral or central obesity, with the 
latter having more implication in the metabolism (Watt, 2010). 
Pre-transplant obesity is associated with greater peri-operative morbidity and mortality, 
with a longer hospital stay and reduced patient and graft survival. An analysis by the 
Scientific Registry of Transplant Recipients showed that five-year post-transplant 
mortality was greater in recipients with class II and III obesity (Nair et al., 2002), though 
no consideration was given to the influence of ascites on overweight. Studies that 
corrected obesity for ascites found no significant differences regarding morbidity or 
survival between obese and non-obese recipients, though ascites was found to be 
indicative of a worse postoperative course (Leonard et al., 2008). These studies could, 
however, be influenced by the fact that the obese patients were studied more closely from 
the cardiological aspect, with more exhaustive screening for pre-transplant cardiovascular 
risk.  
Post-transplant obesity is very usual. Patients who are overweight prior to the transplant 
usually remain so, and up to one third develop de novo obesity (Wawrzynonowicz-
Syczewska et al., 2009). The main triggering factor is the return to dietary habits but not to 
physical activity (Painter et al., 2001), which leads to a progressive weight gain, generally 
greater during the first post-transplant months. The immunosuppressive medication has 
traditionally been considered a trigger of overweight, though the association is in fact 
controversial and it has only been shown with the long-term use of steroids (Everhart et al., 
1998). 
Whilst not associated with greater mortality, post-transplant obesity, particularly central 
obesity, causes an imbalance in the production of adipokines, favouring those that produce 
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peripheral insulin resistance, and thus PTMS (Fox et al., 2007). In addition, obesity is related 
with osteoarthritis, sleep apnoea syndrome, and alterations in the distribution volume of 
drugs. The toxicity of non-lipophylic drugs that are adjusted to weight may be increased, 
and the blood levels of lipophylic drugs reduced (Watt & Charlton, 2010). Obesity can also 
affect the activity of the cytochrome P450 (Kotlyar & Carson, 1999). 
The management of pre-transplant overweight is mainly based on dietary measures and 
lifestyle recommendations. Though there is currently no BMI that is an absolute 
contraindication for liver transplantation, obesity is considered a surgical and post-operative 
risk factor. The recommendations after the transplant are similar to those for the general 
population. Weight should be controlled, and the patient instructed about the prevention  
of obesity, with a suitable diet and physical exercise. Immunosuppression, especially 
corticosteroids, should be minimized as far as possible. 
Bariatric surgery has been considered as a treatment option in patients with morbid obesity 
(Takata et al., 2008). However, performing it before the transplant operation is associated 
with technical difficulties, and after transplantation it may affect the absorption of the 
immunosuppressive medication, with repercussions on graft viability, and may also make 
treatment of any biliary problems more difficult (Butte et al., 2007). 
Concerning pharmacological measures, pancreatic lipase inhibitors like tetrahydrolipstatin 
(orlistat), which can be used in the general population with morbid obesity, present 
important interactions with the immunosuppressive agents, and thus have to be limited in 
the transplant population (Desai et al., 2010). 
4.2 Diabetes 
Candidate patients for a liver transplant may have diabetes or, more likely, glucose 
intolerance due to the IR present in many patients with hepatic cirrhosis. In this context, IR 
can be related with the hyperglucagonaemia found in many cirrhotic patients, as well as 
with the lower insulin degradation by a diseased liver or by the leakage phenomena from a 
portosystemic shunt. After the transplant, the insulin levels and glucose metabolism become 
normal in up to 6% of these patients (Watt & Charlton, 2010). However, from 20% to 60% 
remain diabetic or develop post-transplant diabetes mellitus (PTDM). The main risk factors 
for the development of PTDM are prior diabetes, obesity, hepatitis C and a family history of 
diabetes (Anastáscio et al., 2010). 
After the transplant, the immunosuppressive drugs are the main trigger for de novo DM. 
Steroids induce IR in a dose-dependent manner, by reducing the pancreatic production of 
insulin and increasing hepatic gluconeogenesis (Schake et al., 2002). Calcineurin inhibitors 
can also reduce insulin production via a direct toxic effect and/or reduction in the 
peripheral use of insulin. Tacrolimus seems to have a greater diabetogenic effect than 
cyclosporine (Haddad et al., 2006). The effect of mTOR inhibitors on the development of IR 
is unclear; on one hand they may favour the response to insulin and thus reduce the risk of 
diabetes, though on the other hand they can also block the proliferation of pancreatic beta 
cells, thereby predisposing to PTDM (Vodenik et al., 2009). 
PTDM is associated with cardiovascular complications, increased and accelerated 
progression of fibrosis in patients with hepatitis C, and a reduction in the response to 
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antiviral therapy (Veldt et al., 2009). It is also associated with a greater incidence of chronic 
rejection and late hepatic artery thrombosis. The survival of transplant patients who develop 
diabetes is lower than that for those without diabetes. In addition, these patients can present 
the same microvascular complications as in the general population, including retinopathy, 
nephropathy and infections (Desai et al., 2010). 
The aims of treatment in the transplant patient with diabetes are similar to those in the 
general population: fasting blood glucose levels of 80-130 mg/dl, post-prandial levels of 
140-180 mg/dl and glycosylated haemoglobin <6.5-7% (Bilbao et al., 2010).. 
The treatment of PTDM includes dietary measures, limiting the intake of carbohydrates, and 
physical activity. A reduction in steroids or their complete withdrawal, plus dose optimization 
of calcineurin inhibitors or their minimization, adding other immunosuppressive drugs 
(mycophenolate or mTOR inhibitors) may suffice, thereby avoiding pharmacological therapy 
(Dumortier et al., 2006; Herrero el at., 2006).  
Hyperglycaemia during the early post-transplant period requires treatment with insulin, 
which can later be reduced or even stopped. The drugs of choice for maintenance therapy 
are oral antidiabetic agents (Marchetti, 2005). The choice of oral antidiabetic agent to be 
used should be based on the advantages and possible side effects of each drug group in 
general or each drug in particular. The sulphonylureas can favour overweight and 
hypoglycaemia and should be avoided in patients with advanced kidney failure; the alpha 
glucosidase inhibitors can produce adverse side effects in the digestive system; the 
thiazolidinediones, which have a greater glucose lowering action, have been shown to 
increase the cardiovascular risk in the general population and are not therefore advised 
(Watt & Charlton, 2010). Metformin may be the most suitable oral antidiabetic agent 
because it lacks hepatic metabolism and is the recommended first line drug of choice, 
though it should be remembered that it can produce lactic acidosis in patients with kidney 
failure (Sharif, 2011). 
4.3 Dyslipidaemia 
Prior to the transplant, most cirrhotic patients do not have dyslipidaemia, due to the lower 
liver production of lipids and the malnutrition experienced by most of them. An exception, 
though, is patients with cholestatic liver disease, but in these cases the pattern of 
dyslipidaemia is not associated with a greater risk of arteriosclerosis (Muñoz & ElGenaidi, 
2005). 
After the transplant, however, dyslipidaemia, both hypertriglyceridaemia and 
hypercholesterolaemia, is very frequent, occurring in up to 70% of transplant patients within 
one year (Bianchi et al., 2008). Some authors consider dyslipidaemia to be the main 
cardiovascular risk factor (Reuben, 2001). 
As with the other components of the PTMS, the aetiology of dyslipidaemia involves many 
factors, though the immunosuppressive agents are the main triggering factor. Steroids are 
associated with hyperlipidaemia as they stimulate the activity of acetyl-CoA carboxylase 
and the synthesis of fatty acids, thus raising concentrations of total cholesterol and 
triglycerides (Ballantyne et al., 1992). M-TOR inhibitors increase lipoprotein-lipase activity, 
increasing the hepatic synthesis of triglycerides (Morrisett et al., 2003). Calcineurin 
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peripheral insulin resistance, and thus PTMS (Fox et al., 2007). In addition, obesity is related 
with osteoarthritis, sleep apnoea syndrome, and alterations in the distribution volume of 
drugs. The toxicity of non-lipophylic drugs that are adjusted to weight may be increased, 
and the blood levels of lipophylic drugs reduced (Watt & Charlton, 2010). Obesity can also 
affect the activity of the cytochrome P450 (Kotlyar & Carson, 1999). 
The management of pre-transplant overweight is mainly based on dietary measures and 
lifestyle recommendations. Though there is currently no BMI that is an absolute 
contraindication for liver transplantation, obesity is considered a surgical and post-operative 
risk factor. The recommendations after the transplant are similar to those for the general 
population. Weight should be controlled, and the patient instructed about the prevention  
of obesity, with a suitable diet and physical exercise. Immunosuppression, especially 
corticosteroids, should be minimized as far as possible. 
Bariatric surgery has been considered as a treatment option in patients with morbid obesity 
(Takata et al., 2008). However, performing it before the transplant operation is associated 
with technical difficulties, and after transplantation it may affect the absorption of the 
immunosuppressive medication, with repercussions on graft viability, and may also make 
treatment of any biliary problems more difficult (Butte et al., 2007). 
Concerning pharmacological measures, pancreatic lipase inhibitors like tetrahydrolipstatin 
(orlistat), which can be used in the general population with morbid obesity, present 
important interactions with the immunosuppressive agents, and thus have to be limited in 
the transplant population (Desai et al., 2010). 
4.2 Diabetes 
Candidate patients for a liver transplant may have diabetes or, more likely, glucose 
intolerance due to the IR present in many patients with hepatic cirrhosis. In this context, IR 
can be related with the hyperglucagonaemia found in many cirrhotic patients, as well as 
with the lower insulin degradation by a diseased liver or by the leakage phenomena from a 
portosystemic shunt. After the transplant, the insulin levels and glucose metabolism become 
normal in up to 6% of these patients (Watt & Charlton, 2010). However, from 20% to 60% 
remain diabetic or develop post-transplant diabetes mellitus (PTDM). The main risk factors 
for the development of PTDM are prior diabetes, obesity, hepatitis C and a family history of 
diabetes (Anastáscio et al., 2010). 
After the transplant, the immunosuppressive drugs are the main trigger for de novo DM. 
Steroids induce IR in a dose-dependent manner, by reducing the pancreatic production of 
insulin and increasing hepatic gluconeogenesis (Schake et al., 2002). Calcineurin inhibitors 
can also reduce insulin production via a direct toxic effect and/or reduction in the 
peripheral use of insulin. Tacrolimus seems to have a greater diabetogenic effect than 
cyclosporine (Haddad et al., 2006). The effect of mTOR inhibitors on the development of IR 
is unclear; on one hand they may favour the response to insulin and thus reduce the risk of 
diabetes, though on the other hand they can also block the proliferation of pancreatic beta 
cells, thereby predisposing to PTDM (Vodenik et al., 2009). 
PTDM is associated with cardiovascular complications, increased and accelerated 
progression of fibrosis in patients with hepatitis C, and a reduction in the response to 
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antiviral therapy (Veldt et al., 2009). It is also associated with a greater incidence of chronic 
rejection and late hepatic artery thrombosis. The survival of transplant patients who develop 
diabetes is lower than that for those without diabetes. In addition, these patients can present 
the same microvascular complications as in the general population, including retinopathy, 
nephropathy and infections (Desai et al., 2010). 
The aims of treatment in the transplant patient with diabetes are similar to those in the 
general population: fasting blood glucose levels of 80-130 mg/dl, post-prandial levels of 
140-180 mg/dl and glycosylated haemoglobin <6.5-7% (Bilbao et al., 2010).. 
The treatment of PTDM includes dietary measures, limiting the intake of carbohydrates, and 
physical activity. A reduction in steroids or their complete withdrawal, plus dose optimization 
of calcineurin inhibitors or their minimization, adding other immunosuppressive drugs 
(mycophenolate or mTOR inhibitors) may suffice, thereby avoiding pharmacological therapy 
(Dumortier et al., 2006; Herrero el at., 2006).  
Hyperglycaemia during the early post-transplant period requires treatment with insulin, 
which can later be reduced or even stopped. The drugs of choice for maintenance therapy 
are oral antidiabetic agents (Marchetti, 2005). The choice of oral antidiabetic agent to be 
used should be based on the advantages and possible side effects of each drug group in 
general or each drug in particular. The sulphonylureas can favour overweight and 
hypoglycaemia and should be avoided in patients with advanced kidney failure; the alpha 
glucosidase inhibitors can produce adverse side effects in the digestive system; the 
thiazolidinediones, which have a greater glucose lowering action, have been shown to 
increase the cardiovascular risk in the general population and are not therefore advised 
(Watt & Charlton, 2010). Metformin may be the most suitable oral antidiabetic agent 
because it lacks hepatic metabolism and is the recommended first line drug of choice, 
though it should be remembered that it can produce lactic acidosis in patients with kidney 
failure (Sharif, 2011). 
4.3 Dyslipidaemia 
Prior to the transplant, most cirrhotic patients do not have dyslipidaemia, due to the lower 
liver production of lipids and the malnutrition experienced by most of them. An exception, 
though, is patients with cholestatic liver disease, but in these cases the pattern of 
dyslipidaemia is not associated with a greater risk of arteriosclerosis (Muñoz & ElGenaidi, 
2005). 
After the transplant, however, dyslipidaemia, both hypertriglyceridaemia and 
hypercholesterolaemia, is very frequent, occurring in up to 70% of transplant patients within 
one year (Bianchi et al., 2008). Some authors consider dyslipidaemia to be the main 
cardiovascular risk factor (Reuben, 2001). 
As with the other components of the PTMS, the aetiology of dyslipidaemia involves many 
factors, though the immunosuppressive agents are the main triggering factor. Steroids are 
associated with hyperlipidaemia as they stimulate the activity of acetyl-CoA carboxylase 
and the synthesis of fatty acids, thus raising concentrations of total cholesterol and 
triglycerides (Ballantyne et al., 1992). M-TOR inhibitors increase lipoprotein-lipase activity, 
increasing the hepatic synthesis of triglycerides (Morrisett et al., 2003). Calcineurin 
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inhibitors reduce the excretion of cholesterol to the bile and the peripheral LDL-cholesterol 
receptors, thereby raising circulating levels of cholesterol (Chan et al., 1998). 
Treatment of the hypercholesterolaemia starts with dietary measures, including supplements 
of omega 3 fatty acid. In most cases, though, this is insufficient and it is necessary to initiate 
pharmacological treatment. The recommendations for this are the same as for the general 
population. In patients with no cardiovascular events, the LDL cholesterol should be 
maintained <130 mg/dl, though for secondary prevention this level should be <100 mg/dl. 
Statins are the drugs of choice in both the general and the transplant populations, reducing 
cardiovascular disease as well as having a certain immunosuppressive effect that has been 
related with a lower incidence of rejection (Martin et al., 2008). Most statins use the same 
metabolic pathways as calcineurin inhibitors (P450 cytochrome), which explains the 
pharmacological interactions and the greater risk for myositis and rhabdomyolysis (Desai et 
al., 2010). It is therefore recommended to start with low doses and gradually increase them 
according to needs. In particular, pravastatin is eliminated via the kidneys and fluvastatin 
uses a different cytochrome, so that these two may be the statins of choice (Watt & Charlton, 
2010). Treatment with ion exchange resins, whilst it may help normalize cholesterol levels, 
interrupts the enterohepatic circulation and may, secondarily, alter levels of calcineurin 
inhibitors, particularly cyclosporine. 
Hypertriglyceridaemia is better treated with dietary restriction, with drugs generally being 
reserved for patients with severe hypertriglyceridaemia. Fibrates, such as gemfibrozil, are 
indicated in these cases, but with caution if associated with statins due to the greater 
muscular toxicity.  
Ezetimibe, an inhibitor of the enterohepatic recirculation of lipids, has been show to be well- 
tolerated and effective when used in combination with statin, but interacts with 
immunosuppressive drugs and can produce hepatotoxicity (Almutairi et al., 2009). 
In all cases the use of steroids should be kept to a minimum and calcineurin inhibitors 
optimized. 
4.4 Hypertension 
The incidence of hypertension before transplant is very low. However, after transplantation, 
the hyperdynamic circulation of the cirrhotic patient is reverted, with an increase in blood 
pressure that can reach values considered normal. Once again, the immunosuppressive 
drugs, whether or not in the presence of other risk factors, are related with the onset of 
hypertension, considered as a systolic pressure ≥140 mmHg and a diastolic pressure ≥90 
mmHg; this occurs in around 60-70% of all patients (Watt et al., 2010). The pathophysiology 
of post-transplant hypertension does not reside in alterations of the renin-angiotensin-
aldosterone system, as occurs in the non-transplanted population. The fundamental 
mechanism is related to the systemic and renal haemodynamic changes produced by the 
immunosuppressive drug. Calcineurin inhibitors, particularly cyclosporine, produce renal 
vasoconstriction of the afferent arteriole, with secondary renal hypoperfusion leading to 
reabsorption of sodium and water (Textor et al., 2000). Steroids potentiate this latter 
situation through their mineralocorticoid effect and mTOR inhibitors can produce 
hypertension if associated with calcineurin inhibitors. 
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The aims of treatment are to maintain blood pressure figures <140/90 mmHg (or lower in 
the presence of other risk factors), and the first step is restriction of dietary salt, coupled 
with control of other risk factors and the undertaking of physical activity.  
As far as drugs are concerned, calcium antagonists are considered the first choice as they 
can reverse renal vasoconstriction. Within this group of drugs, diltiazem, verapamil or 
nicardipine interfere in the hepatic metabolism of calcineurin whilst amlodipine does not, 
and this latter is thus the most used (Watt, 2010). Angiotensin converting enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARB) produce vasodilation of the efferent 
arteriole, reducing glomerular pressure and hyperfiltration (Desai et al., 2010). They are 
the choice group for patients with proteinuria and renal failure because they slow its 
progress. 
Beta blockers are not first-line drugs, but they can be used in selected cases. Finally, 
diuretics in association with other antihypertensive drugs are beneficial in cases that  
are difficult to control, but should not be used as a single therapy and also require  
strict electrolyte control. The reduction of calcineurin inhibitors favours blood pressure 
control. 
5. Consequences of the metabolic syndrome 
5.1 Major cardiovascular complications 
Major cardiovascular complications or events mainly include ischaemic heart disease, stroke 
or peripheral ischaemia phenomena. Transplant patients who develop PTMS have an 
accumulated incidence of cardiovascular disease around twice that of transplant patients 
without PTMS (12.9% vs. 4.9%, respectively; Figure 1, Laish et al 2011). Cardiovascular 
mortality can reach 40% (Laish et al., 2011; Laryea et al., 2007; Anastáscio et al., 2010). 
5.2 Fatty liver graft disease 
Up to 60% of patients transplanted due to nonalcoholic steatohepatitis (NASH) relapse at 
one year and 100% at five years. In cases of cryptogenic cirrhosis, the presence of different 
degrees of steatosis in the graft is 50% at two years post-transplant. Although no exact study 
has been undertaken on the repercussion of steatosis on graft function, between 2.5% and 
15% of relapses of NASH are estimated to end in cirrhosis. The main independent risk factor 
for fatty liver graft disease is a 10% increase in body mass index (Charlton, 2009; Dureja et 
al., 2011).  
5.3 Influence of HCV recurrence  
A bidirectional relation exists between HCV and IR, with 21% of HCV-positive patients 
being diabetic, and the presence of HCV multiplies the long-term risk of developing 
diabetes by 2-3 times. A recent analysis of cardiovascular risk after liver transplantation 
according to HCV status showed higher incidence of DM among HCV-positive patients 
(Pérez et al., 2011). Inversely, IR or the presence of established diabetes is associated with 
greater viral replication, a higher degree of steatosis and fibrosis and worse response to 
antiviral therapy (Arase et al., 2009). The main reason for this association is that not only 
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inhibitors reduce the excretion of cholesterol to the bile and the peripheral LDL-cholesterol 
receptors, thereby raising circulating levels of cholesterol (Chan et al., 1998). 
Treatment of the hypercholesterolaemia starts with dietary measures, including supplements 
of omega 3 fatty acid. In most cases, though, this is insufficient and it is necessary to initiate 
pharmacological treatment. The recommendations for this are the same as for the general 
population. In patients with no cardiovascular events, the LDL cholesterol should be 
maintained <130 mg/dl, though for secondary prevention this level should be <100 mg/dl. 
Statins are the drugs of choice in both the general and the transplant populations, reducing 
cardiovascular disease as well as having a certain immunosuppressive effect that has been 
related with a lower incidence of rejection (Martin et al., 2008). Most statins use the same 
metabolic pathways as calcineurin inhibitors (P450 cytochrome), which explains the 
pharmacological interactions and the greater risk for myositis and rhabdomyolysis (Desai et 
al., 2010). It is therefore recommended to start with low doses and gradually increase them 
according to needs. In particular, pravastatin is eliminated via the kidneys and fluvastatin 
uses a different cytochrome, so that these two may be the statins of choice (Watt & Charlton, 
2010). Treatment with ion exchange resins, whilst it may help normalize cholesterol levels, 
interrupts the enterohepatic circulation and may, secondarily, alter levels of calcineurin 
inhibitors, particularly cyclosporine. 
Hypertriglyceridaemia is better treated with dietary restriction, with drugs generally being 
reserved for patients with severe hypertriglyceridaemia. Fibrates, such as gemfibrozil, are 
indicated in these cases, but with caution if associated with statins due to the greater 
muscular toxicity.  
Ezetimibe, an inhibitor of the enterohepatic recirculation of lipids, has been show to be well- 
tolerated and effective when used in combination with statin, but interacts with 
immunosuppressive drugs and can produce hepatotoxicity (Almutairi et al., 2009). 
In all cases the use of steroids should be kept to a minimum and calcineurin inhibitors 
optimized. 
4.4 Hypertension 
The incidence of hypertension before transplant is very low. However, after transplantation, 
the hyperdynamic circulation of the cirrhotic patient is reverted, with an increase in blood 
pressure that can reach values considered normal. Once again, the immunosuppressive 
drugs, whether or not in the presence of other risk factors, are related with the onset of 
hypertension, considered as a systolic pressure ≥140 mmHg and a diastolic pressure ≥90 
mmHg; this occurs in around 60-70% of all patients (Watt et al., 2010). The pathophysiology 
of post-transplant hypertension does not reside in alterations of the renin-angiotensin-
aldosterone system, as occurs in the non-transplanted population. The fundamental 
mechanism is related to the systemic and renal haemodynamic changes produced by the 
immunosuppressive drug. Calcineurin inhibitors, particularly cyclosporine, produce renal 
vasoconstriction of the afferent arteriole, with secondary renal hypoperfusion leading to 
reabsorption of sodium and water (Textor et al., 2000). Steroids potentiate this latter 
situation through their mineralocorticoid effect and mTOR inhibitors can produce 
hypertension if associated with calcineurin inhibitors. 
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The aims of treatment are to maintain blood pressure figures <140/90 mmHg (or lower in 
the presence of other risk factors), and the first step is restriction of dietary salt, coupled 
with control of other risk factors and the undertaking of physical activity.  
As far as drugs are concerned, calcium antagonists are considered the first choice as they 
can reverse renal vasoconstriction. Within this group of drugs, diltiazem, verapamil or 
nicardipine interfere in the hepatic metabolism of calcineurin whilst amlodipine does not, 
and this latter is thus the most used (Watt, 2010). Angiotensin converting enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARB) produce vasodilation of the efferent 
arteriole, reducing glomerular pressure and hyperfiltration (Desai et al., 2010). They are 
the choice group for patients with proteinuria and renal failure because they slow its 
progress. 
Beta blockers are not first-line drugs, but they can be used in selected cases. Finally, 
diuretics in association with other antihypertensive drugs are beneficial in cases that  
are difficult to control, but should not be used as a single therapy and also require  
strict electrolyte control. The reduction of calcineurin inhibitors favours blood pressure 
control. 
5. Consequences of the metabolic syndrome 
5.1 Major cardiovascular complications 
Major cardiovascular complications or events mainly include ischaemic heart disease, stroke 
or peripheral ischaemia phenomena. Transplant patients who develop PTMS have an 
accumulated incidence of cardiovascular disease around twice that of transplant patients 
without PTMS (12.9% vs. 4.9%, respectively; Figure 1, Laish et al 2011). Cardiovascular 
mortality can reach 40% (Laish et al., 2011; Laryea et al., 2007; Anastáscio et al., 2010). 
5.2 Fatty liver graft disease 
Up to 60% of patients transplanted due to nonalcoholic steatohepatitis (NASH) relapse at 
one year and 100% at five years. In cases of cryptogenic cirrhosis, the presence of different 
degrees of steatosis in the graft is 50% at two years post-transplant. Although no exact study 
has been undertaken on the repercussion of steatosis on graft function, between 2.5% and 
15% of relapses of NASH are estimated to end in cirrhosis. The main independent risk factor 
for fatty liver graft disease is a 10% increase in body mass index (Charlton, 2009; Dureja et 
al., 2011).  
5.3 Influence of HCV recurrence  
A bidirectional relation exists between HCV and IR, with 21% of HCV-positive patients 
being diabetic, and the presence of HCV multiplies the long-term risk of developing 
diabetes by 2-3 times. A recent analysis of cardiovascular risk after liver transplantation 
according to HCV status showed higher incidence of DM among HCV-positive patients 
(Pérez et al., 2011). Inversely, IR or the presence of established diabetes is associated with 
greater viral replication, a higher degree of steatosis and fibrosis and worse response to 
antiviral therapy (Arase et al., 2009). The main reason for this association is that not only 
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does HCV block the intracellular signals that trigger insulin after binding to the receptor, 
but also IR stimulates hepatic lipogenesis and stellate cells, thus increasing steatosis and 
fibrosis. IR and hyperinsulinaemia induce resistance to interferon, such that patients with a 
HOMA >2 have a lower percentage of sustained viral response (SVR). In parallel, those 
patients who achieve a SVR have a lower risk of developing diabetes because, in the absence 
of viral replication, the IR almost disappears (Romero et al., 2009)  
5.4 Renal failure 
In both the general population and in persons who have a transplant, patients with the MS 
present a greater incidence of renal failure. The reduction in glomerular filtration and the 
presence of microalbuminuria are associated with the number of components of the MS 
present. IR, and secondary hyperinsulinaemia and hyperglycaemia, cause an imbalance 
between vasodilatating and vasoconstricting substances, in favour of the latter; they favour 
oxidative stress and endothelial damage; stimulate the renin-angiotensin-aldosterone axis 
and release of growth factors. This all leads to structural damage in the kidney, mainly 
tubular atrophy, glomerulosclerosis and tubulointerstitial fibrosis, damage that eventually 
produces a reduction in glomerular filtration, proteinuria and a rise in creatinine. If added 
to this there is renal damage caused by the immunosuppressive drugs, transplant patients 
with PTMS thus have a greater incidence of chronic transplant nephropathy (Morales et al., 
2006).  
6. Prevention and treatment of PTMS 
It is necessary to identify patients with risk factors for PTMS as obesity, pretransplant diabetes, 
older age, and transplantation due to HCV infection or cryptogenic cirrhosis, which in many 
cases is in fact an unrecognized steatohepatitis. Usual check-ups should include a search for 
the early detection of components of PTMS and, if found, they should be treated as per the 
recommendations above. In all cases good dietary advice is recommended as well as the 
promotion of physical activity. Concerning immunosuppression, the use of steroids and 
calcineurin inhibitors should be reduced as much as is possible. This generally means the 
early introduction of other immunosuppressive drugs, mainly mycophenolate and mTOR 
inhibitors, which permits calcineurin inhibitors to be spared. In patients presenting with 
several cardiovascular risk factors or in those who have had a cardiovascular event, 
antiaggregation therapy should be considered.  
7. Conclusions 
The MS and each of its individual components are more prevalent in transplant patients 
than in the general population. The presence of PTMS is associated with a grater incidence 
of cardiovascular diseases and chronic transplant nephropathy. It is related with a worse 
course of HCV recurrence and favours the onset of fatty liver graft disease. 
Immunosuppressive drugs are the main factor related with PTMS. Strict vigilance should  
be exercised at the regular clinic visits for the appearance of any of the components of MS 
and treatment started accordingly. The immunosuppression should be individualised, 
recommending the early introduction of calcineurin inhibitor sparing drugs, with fewer 
metabolic and renal side effects. 
 
Metabolic Syndrome After Liver Transplantation 
 
357 
8. References  
Alberti KG, Zimmet P, & Shaw J. Metabolic syndrome a new world-wide definition.  
A consensus statement from the international diabetes federation. Diabet 2006; 23: 
469-480. 
Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, & Peltekian KM. Safety and 
effectiveness of ezetimibe in liver transplant recipients with hypercholesterñemia. 
Liver transplantation 2009; 15: 504-508.  
Anastácio LR, Lima AS, & Toulson Davisson Correia MI. Metabolic syndrome and its 
components after liver transplantation: incidence, prevalence, risk factors, and 
implications. Clinical nutrition 2010; 29: 175-179. 
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayasi M, Kawamura Y, et al. Sustained 
virological response reduces incidence of onset of type 2 diabetes in chronic 
hepatitis C. Hepatology 2009; 49: 739-744. 
Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipedaemia after heart 
transplantation: report of a 6 year experience with treatment recommendations.  
J Am Coll Cardiol 1992; 19: 1315-1321. 
Bianchi G, Marchesini G, Marzicchi R, Pinna A & Zoli M. Metabolic syndrome in liver 
transplantation relation to etiology and immunosuppression. Liver transplantation 
2008; 14: 1648-1654. 
Bigam Dl, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Crosford R, et al. 
Hepatitis C-related cirrhosis: a predictor of diabetes mellitus after liver 
transplantation. Hepatology 2000; 32: 87-90. 
Bilbao I, Castells Ll, Lázaro JL, Campos I, Rodriguez R, Charco R. Sindrome metabólico 
postrasplante. Cir Esp 2010; 88: 71. 
Butte J, Devaud N, Jarufe NP, Boza C, Perez G, Torres J, et al. Sleeve gastrectomy as 
treatment for severe obesity after orthotopic liver transplantation. Obes Surg 2007; 
17: 1517- 1519. 
Chan FK, Zhang Y Lee SS, Shaffer EA. The effects of liver transplantation and cyclosporine 
on bile formation and lipid composition: an experimental study in the rat. J Hepatol 
1998; 28: 329-336. 
Charlton M. Obesity, Hyperlipidemia, and metabolic syndrome. Liver Transplantation 2009; 
15: S83-S89. 
Desai S, Hong J, & Saab S. Cardiovascular risk factors following orthotopic liver 
transplantation: predisposing factors, incidence and management. Liver International 
2010; 10: 948-957. 
Dumortier J, Bernard S, Bouffard Y, & Boillot O. Conversion from tacrolimus to cyclosporine 
in liver transplanted patients with diabetes mellitus. Liver transplantation 2006;  
12: 659-664. 
Dureja P, Mellinger J, Agni RA, Chang F, Avey G, Lucey M, & Said A. NAFLD recurrence in 
liver transplant recipients. Transplantation 2011; 91: 684-689. 
Everhart JE, Lombardero M, Lake JR, Wiesnwr RH, Zetterman RK, & Hoofnagle JH. Weight 
change and obesity after liver transplantation: incidence and risk factors. Liver 
Transpl Surg 1998; 4: 285-296. 
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among 
U.S. adults. Diabetes Care 2004; 27: 2444-2449  
 
Liver Transplantation – Technical Issues and Complications 
 
356 
does HCV block the intracellular signals that trigger insulin after binding to the receptor, 
but also IR stimulates hepatic lipogenesis and stellate cells, thus increasing steatosis and 
fibrosis. IR and hyperinsulinaemia induce resistance to interferon, such that patients with a 
HOMA >2 have a lower percentage of sustained viral response (SVR). In parallel, those 
patients who achieve a SVR have a lower risk of developing diabetes because, in the absence 
of viral replication, the IR almost disappears (Romero et al., 2009)  
5.4 Renal failure 
In both the general population and in persons who have a transplant, patients with the MS 
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presence of microalbuminuria are associated with the number of components of the MS 
present. IR, and secondary hyperinsulinaemia and hyperglycaemia, cause an imbalance 
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oxidative stress and endothelial damage; stimulate the renin-angiotensin-aldosterone axis 
and release of growth factors. This all leads to structural damage in the kidney, mainly 
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to this there is renal damage caused by the immunosuppressive drugs, transplant patients 
with PTMS thus have a greater incidence of chronic transplant nephropathy (Morales et al., 
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cases is in fact an unrecognized steatohepatitis. Usual check-ups should include a search for 
the early detection of components of PTMS and, if found, they should be treated as per the 
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calcineurin inhibitors should be reduced as much as is possible. This generally means the 
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inhibitors, which permits calcineurin inhibitors to be spared. In patients presenting with 
several cardiovascular risk factors or in those who have had a cardiovascular event, 
antiaggregation therapy should be considered.  
7. Conclusions 
The MS and each of its individual components are more prevalent in transplant patients 
than in the general population. The presence of PTMS is associated with a grater incidence 
of cardiovascular diseases and chronic transplant nephropathy. It is related with a worse 
course of HCV recurrence and favours the onset of fatty liver graft disease. 
Immunosuppressive drugs are the main factor related with PTMS. Strict vigilance should  
be exercised at the regular clinic visits for the appearance of any of the components of MS 
and treatment started accordingly. The immunosuppression should be individualised, 
recommending the early introduction of calcineurin inhibitor sparing drugs, with fewer 
metabolic and renal side effects. 
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1. Introduction  
Autoimmune hepatitis (AIH) is a progressive, chronic inflammatory liver disease of 
unknown etiology that occurs in children and adults with a prevalence of female. This 
clinical syndrome is caused by an immune response that is misdirected against self or 
foreign antigens that resemble self-antigens, leading to a progressive inflammatory and 
fibrotic process of the liver (Krawitt, 2006; Czaja, 2001, 2007a, 2007b; Vergani et al, 2002; 
Manns & Vogel, 2006, Vergani & Mieli-Vergani, 2008). The complications of AIH are the 
same as any other progressive liver disease. Primary hepatocellular carcinoma is a known 
consequence; in some patients, chronic hepatitis progresses to cirrhosis and, ultimately, to 
carcinoma. Liver transplantation is required when end stage liver disease develops (Krawitt, 
2006).  
AIH has been widely described in liver transplant recipients with and without AIH before 
transplantation. In the first scenario the term of recurrent AIH has been proposed, while de 
novo AIH implies the development of AIH in the graft of a recipient who did not have the 
disease before. De novo and recurrent AIH develop in the clinical context of immune 
suppression. Consequently the diagnosis may depend more heavily on the exclusion of 
other causes for allograft dysfunction rather than on the presence of criteria for the 
diagnosis of classic AIH codified by the international scoring system. The careful analysis of 
these cases provides exiting and exceptional opportunities to study the pathogenesis of AIH 
in a human model. To understand the bases for recurrent and de novo AIH after liver 
transplantation, it is necessary to apply current hypotheses of pathogenesis for classic 
disease.  
2. Pathogenic mechanism of AIH 
The pathogenesis of AIH remains uncertain, but conditions that favor its emergence are 
becoming clearer. Environmental agents like viruses, toxins or drugs (Krawitt, 2006, Czaja et 
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al, 1992, Czaja, 1999a) may trigger a cascade of T-cell mediated events against liver antigens 
in a context of genetic predisposition (Czaja & Manns, 1995; Alvarez, 1999, Molmenti et al, 
2002; Sanchez-Urdazpal et al, 1992), leading to a progressive necroinflammatory liver disease. 
Although multiple genes are probably involved in a predisposition to AIH, human 
leukocyte antigen (HLA) genes appear to play the dominant role (Donaldson et al 1998, 
Donaldson, 2002). Type 1 AIH, characterized by circulating antinuclear antibodies, smooth 
muscle antibodies, antiactin antibodies, atypical perinuclear antineutrophilic cytoplasmic 
antibodies and autoantibodies against soluble liver antigen and liver-pancreas antigen is 
associated with the HLA DR3 serotype, particularly among white patients. In Japan the 
most common associated HLA locus is HLA DR4; among white North Americans and 
northern Europeans, susceptibility relates to the alleles DRB1-0301 and DRB1-0401 
(Hytiroglou et al, 2009; Hennes et al, 2008). Type 2 AIH, a rare disorder characterized by 
antibodies against liver-kidney microsome 1 and liver cytosol 1 has been associated with the 
HLA DRB1 and HLA DQB1 alleles (Djilali-Saiah et al 2004).  
Loss of self tolerance is the requisite for autoimmune disease, and it distinguishes autoimmune 
conditions from disorders associated with immunologic reactions to foreign antigens. The 
most promising considerations are defects in the negative selection of autoreactive 
immunocytes (Czaja, 2007c; Czaja & Carpenter, 2006) and clonal expansion of immunocytes 
cross-reactive to homologous antigens (molecular mimicry) (Hubscher, 2001; Prados et al, 
1998; Ayata et al, 2000). The negative selection removes thymocytes that are capable of 
strongly binding with self peptides presented by major histocompatibility complex (MHC). 
This process is an important component of immunological tolerance and serves to prevent the 
formation of self reactive T cells. According to experimental evidences the risk of autoimmune 
disease probably relates to actions of genes that limit this process (Czaja & Carpenter, 2006; 
Banff Working Group, 2006). Molecular mimicry has been proposed as pathogenetic 
mechanism for AIH. This hypothesis has been substantiated in experimental models by 
showing that the immunocytes can be activated by diverse but similar epitopes, and they can 
be clonally expanded to show a broad cross-reactivity. Such cells then can be directed against 
self-antigens that mimic foreign antigens (Hubscher, 2001; Prados et al, 1998; Ayata et al, 2000). 
Molecular mimicry is a useful concept to explain how different viruses, drugs or unknown 
environmental agents might produce a self-perpetuating hepatic injury with the same clinical 
expression. It also may explain how AIH recurs or develops de novo after liver 
transplantation. In addition, experimental evidences suggest that genetic polymorphisms 
affecting the cytokine microenvironment (Gonzales-Koch et al, 2001; Donaldson et al, 1991), 
immune regulators (Czaja et al, 1993a) and the mechanism of apoptosis (Czaja et al, 1997) 
could influence the immunocyte activation and perpetuate the immune response.  
The identification of CD4+ regulatory T cells has reinvoked the concept that failure of or 
escape from normal suppression of reactivity against the self has an essential role in the 
development of autoimmune disease. Recent experimental evidence suggests that 
immunoregulatory dysfunction characterized by decreased numbers of CD4+CD25+ 
regulatory T cells may occur in AIH (Longhi et al, 2004). 
2.1 Pathogenesis of recurrent AIH 
AIH recurs after liver transplantation in 11% to 83% of cases with considerable variation 
between studies depending on the diagnostic criteria applied. Many studies suggest that the  
 
Autoimmune Hepatitis After Liver Transplantation 
 
363 
risk of recurrence increases with the time after transplantation (Birnabaum et al, 1997; 
Campsen et al, 2008; Prados et al, 1998; Sempoux et al, 1997). In an interesting study, Duclos-
Vallee et al. suggest that the histological recurrence of AIH may develop 1-5 years before the 
laboratory manifestations (Duclos-Vallee et al, 2003). 
The pathogenesis of recurrent AIH is uncertain, although it is widely accepted that a strong 
genetic predisposition may affect its occurrence, behavior and outcome (Czaja, 2008a), as 
well as its risk of recurrence (Czaja, 1999b, 2002, 2009). HLA mismatching between donor 
and recipient has been proposed as a factor in recurrent disease (Wright, 1992), but its 
importance continues to be disputed (Gonzales-Koch et al, 2001; Ayata et al, 2000; 
Milkiewicz, 1999, Reich, 2000, Devlin, 1995). Some authors suggest that matched rather than 
mismatched HLA may be a factor influencing the development and severity of the disease 
(Neumann et al, 2003; Futagawa & Terasaki, 2004). In this instance, it seems that similar 
class II MHC molecules between donor and recipient can intensity the autoreactive 
response. 
HLA DRB1*03 is present in over 70% of the recipients who experience recurrence (Gonzales-
Koch et al, 2001), and the DRB1*0301 allele may be a factor in promoting disease severity 
before transplantation (Czaja, et al, 1997) and disease recurrence after transplantation 
(Gonzales-Koch et al, 2001, Czaja, 2008b, Devlin et al, 1995). Other autoimmune promoters 
might include gene polymorphisms that alter the cytokine microenvironment (Czaja et al, 
1999a) or involve polymorphisms of genes affecting immunocyte activation, such as those 
encoding cytotoxic T lymphocyte antigen-4 (Agarwal, 2000). Furthermore, the female 
predisposition for recurrent AIH suggests that an acquired preferential X chromosome 
inactivation (that has been described in primary biliary cirrhosis) may also be important 
(Miozzo et al, 2007). Potential associations with loci in other chromosomes are under 
investigation (Fukagawa et al, 2001; Vogel et al, 2002).  
The donor liver may contain antigenic substrates against which the recipient-derived 
immunocytes can react, and these substrates could be normal components that share 
homologies with other self-antigens within the recipient (Czaja, 2002). The structural and 
conformational homologies between antigenic targets within the donor liver and those 
within the recipient might provoke a promiscuous T cell response through molecular 
mimicry.  
Knowledge concerning antigenic targets responsible for initiating the cascades of events in 
recurrent AIH is still rudimentary. A leading candidate has been the asialoglycoprotein 
receptor, a surface membrane protein. Hepatocytic microsomal enzymes, such as CYP2D6, 
and cytosolic components, such as transfer ribonucleoprotein complexes, are also under 
investigation (Czaja, 2002). Professional antigen presenting cells exist outside the liver, and 
antigenic peptides can be presented and subsequently processed independently of the graft 
(Obhrai, 2006; Bell & Westermann, 2008; Vierling, 1999). T cell subsets, cross-reactive to 
homologous hepatic antigens, could be expanded by the presentation of donor antigens on 
recipient-derived antigen-presenting cells that replace those of the donor liver (Vierling, 
1999). The rapidity of this replacement and the number of antigen-presenting cells in the 
recipient lymph nodes and spleen might affect the timing and severity of the recurrence 
(Czaja, 2002). 
Promiscuous T cells that have been primed to react to molecular homologies are probably 
already present within the recipient (Sprent, 1993; Vierling, 1999), and the appearance and 
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severity of recurrent AIH simply reflect the dose of antigenic targets within the donor liver 
(Czaja, 2002). Alternatively, the immunological response may be newly created by 
protracted exposure to donor-derived hepatic antigens (Czaja 2002, 2009). This hypothesis 
suggests that recurrent AIH could reflect an immune response against donor liver antigens 
that is not HLA-restricted (Czaja, 2002). The class II MHC molecules within the donor liver 
could directly activate the immunocytes of the recipient and generate a response that is not 
dependent on the presentation of antigenic peptide or HLA matching (Vierling, 1999). In 
this instance, the MHC molecules of the donor liver would be the antigenic targets and HLA 
restrictions on immunocyte activation would be overridden. 
Components of the Autoreactive 
Response 
Putative Mechanisms 
Class II MHC molecules Present autoantigen to T helper lymphocyte 
Initiate immunocyte activation 
HLA susceptibility alleles 
 
Encode structure of the antigen binding 
groove of the class II MHC molecule 
Determine optimal autoantigen for 
presentation 
DRB1*03 in white North Americans 
Professional antigen presenting cells 
 
Macrophages and dendritic cells 
Exist outside the liver within the recipient 
Re-populate the donor liver after 
transplantation 
Donor liver autoantigens Promote promiscuous T cell response 
against homologous targets in the donor 
liver, such as microsomal antigens 
(CYP2D6, UDGT), cytosolic components 
(ribonucleoprotein complexes), surface 
membrane receptors (asialoglyoprotein 
receptor), class II MHC molecules, or 
superimposed viral antigens 
Promiscuous T lymphocytes Target multiple antigens in the donor liver 
that resemble the original activating epitope 
Retain long memories for the antigenic 
target 
Re-invigorate after long dormancy 
Counter-regulatory cytokines or 
regulatory T cell populations 
Facilitate autoreactivity by reduced 
suppressive actions 
Abbreviations: CYP2D6, cytochrome 2D6; HLA, human leukocyte antigen; MHC, major histocompatibility 
complex; UDGT, uridine diphosphate glucuronosyltransferase 
Table 1. Pathogenic Mechanisms of Recurrent Autoimmune Hepatitis 
 
Autoimmune Hepatitis After Liver Transplantation 
 
365 
Viral infections are another source of antigenic homologies that may activate promiscuous T 
cells (Czaja, 2002) (Table 1). The genomic sequences of hepatitis C virus, herpes simplex 
virus, and cytomegalovirus have homologies with CYP2D6 (Manns et al, 1991; Ma et al, 
2006), and other mimicries between viral and self-antigens undoubtedly exist that can 
trigger recurrent AIH (Vergani et al, 2002; Bogdanos et al, 2001). Viruses may also produce 
an inflammatory process within the graft that may resemble the recurrent AIH. An anti-
graft response against a viral antigen may be indistinguishable from an autoimmune 
response, and the recurrent AIH in this instance could represent a normal immune response 
against an unsuspected viral agent in an immunosuppressed host (Vierling, 1999). The 
complexity and inner connectivity of the counter-regulatory mechanisms that must be 
disrupted to cause recurrent AIH allows broad speculation about the triggering events and 
the factors which perpetuate the disease (Czaja 2002, 2008b).  
Another factor related to the recurrence of AIH is represented by the net state of 
immunosuppression. Corticosteroid withdrawal, adjustments in the dose and nature of the 
immunosuppressive drugs (cyclosporine, tacrolimus, and mycophenolate mofetil), acute 
and chronic rejection, superimposed infection, and drug toxicities are post-transplantation 
events that have all been implicated in the recurrence of AIH (Hubscher, 2001; Neuberger, 
2002; Schreuder et al, 2009). Recurrence has been associated with reduction in the doses of 
immunosuppressive medication, especially corticosteroids (Neuberger et al, 1984; Gonzalez- 
Koch et al, 2001; Prados et al, 1998; Khalaf et al, 2007). These observations indicate that the 
pathogenic mechanisms of AIH are perpetuated after liver transplantation and that they can 
be suppressed but not eradicated by treatment schedules that are properly dosed (Czaja, 
1999b). Recent studies, however, have indicated that the requirement for corticosteroid 
suppression may not be permanent after liver transplantation and that corticosteroid 
therapy can be successfully withdrawn in 50-68% of patients (Campsen et al, 2008; Trouillot 
et al, 1999). There is evidence that AIH recurs in 35% of individuals withdrawn from 
corticosteroids, but the recurrence has not been associated with discontinuation of the 
medication by multivariate analysis (Campsen et al, 2008). These findings do not discount 
the earlier observations that corticosteroid withdrawal or dose reduction contributes to 
disease recurrence, but they suggest that successful withdrawal is possible if the effort is 
persistent, individualized and well-timed (Czaja, 1999b). 
Patients transplanted for AIH have a higher frequency of acute and chronic rejection (81% 
versus 47%, p<0.001) and corticosteroid-resistant rejection (38% versus 13%, p=0.003) than 
patients transplanted for other conditions (Vogel et al, 2004; Hayashi et al, 1998), and in one 
series, the frequency of acute cellular rejection was higher (33% versus 14%) than in other 
transplanted patients from the same institution and from other institutions (33% versus 4%) 
(Czaja, 1999b; Trouillot et al, 1999). The propensity for acute and chronic cellular rejection 
may reflect an intrinsic immune hyper-reactivity within the patient with AIH (Czaja, 1999b). 
Alternatively, rejection may be the basis for releasing hepatic antigens that sensitize the 
susceptible individual and trigger the recurrence (Czaja, 2009). Patients with recurrent AIH 
have a higher frequency of rejection during the first 3, 6 and 12 months after transplantation 
than patients without recurrent disease, but previous rejection is not a requisite for 
recurrence (Molmenti et al, 2002). Another factor that has been implicated in recurrence has 
been the calcineurin inhibitors used in the immunosuppressive regimen after 
transplantation (Schreuder et al, 2009; Gautam et al, 2006). Cyclosporine and tacrolimus may 
have paradoxical effects which can promote the autoreactive response. Cyclosporine inhibits 
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versus 47%, p<0.001) and corticosteroid-resistant rejection (38% versus 13%, p=0.003) than 
patients transplanted for other conditions (Vogel et al, 2004; Hayashi et al, 1998), and in one 
series, the frequency of acute cellular rejection was higher (33% versus 14%) than in other 
transplanted patients from the same institution and from other institutions (33% versus 4%) 
(Czaja, 1999b; Trouillot et al, 1999). The propensity for acute and chronic cellular rejection 
may reflect an intrinsic immune hyper-reactivity within the patient with AIH (Czaja, 1999b). 
Alternatively, rejection may be the basis for releasing hepatic antigens that sensitize the 
susceptible individual and trigger the recurrence (Czaja, 2009). Patients with recurrent AIH 
have a higher frequency of rejection during the first 3, 6 and 12 months after transplantation 
than patients without recurrent disease, but previous rejection is not a requisite for 
recurrence (Molmenti et al, 2002). Another factor that has been implicated in recurrence has 
been the calcineurin inhibitors used in the immunosuppressive regimen after 
transplantation (Schreuder et al, 2009; Gautam et al, 2006). Cyclosporine and tacrolimus may 
have paradoxical effects which can promote the autoreactive response. Cyclosporine inhibits 
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signal transduction from the engaged T cell antigen receptor (Hess et al, 2001), and it may 
also have a direct toxic effect on the thymic stroma (Beschorner et al, 1988). These actions 
may alter the editing of T lymphocytes within the thymus and impair the negative selection 
of autoreactive cells. Furthermore, the impairment of T cell antigen receptor signaling can 
prevent the apoptosis of autoreactive lymphocytes which can in turn extend their survival 
(Lotem et al, 1999; Wang et al, 1999). Tacrolimus affects the thymic microenvironment in a 
fashion like cyclosporine, and it might also paradoxically enhance immune reactivity 
(Cooper et al, 1991). These theoretical considerations have not been established in human 
disease (Gautam et al, 2006), and both medications have been used successfully in the 
treatment of recurrent AIH (Hubscher, 2001). Nevertheless, the failure of recurrent AIH to 
respond to one calcineurin inhibitor might warrant institution of the other (Hurtova et al, 
2001). 
Risk Factor Theoretical Consequences 




Corticosteroids are withdrawn 
Immunosuppressive regimens 
are reduced 
Acute or chronic cellular rejection 
occurs 
Drug toxicity develops 
Viral infection superimposed 
Corticosteroid withdrawal Facilitates autoimmune response 
Reduced immunosuppression Facilitates autoimmune response 
Acute or chronic rejection Releases hepatic antigens 
Invigorates promiscuous 
lymphocytes 
Calcineurin inhibitor Reduces thymic negative 
selection of immunocytes 




HLA matching or mismatching Intensifies autoreactive response 
Female gender 
 
Acquired preferential X 
chromosome inactivation 
Impairs mechanisms that protect 
self-tolerance 
Severity of original disease Immune reactivity persists post-
transplant 
Genetic predisposition for severe 
disease facilitates recurrence 
Table 2. Risk Factors Associated with Recurrent Autoimmune Hepatitis After 
Transplantation 
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The severity of the original liver disease may also be a factor in disease recurrence after liver 
transplantation. Patients with recurrent AIH have higher serum levels of immunoglobulin G 
and histological findings of plasma cell infiltration and severe inflammatory activity more 
often immediately prior to transplantation than patients without recurrence (Montano-Loza 
et al, 2009). These observations suggest that recurrent AIH is a continuum of the original 
disease or a newly created process in a susceptible host with a propensity for severe 
immune reactivity (Czaja, 2009). They imply that aggressive disease suppression 
immediately prior to transplantation might alter the consequences after transplantation 
(Montano-Loza et al, 2009) or that an vulnerable individual may be identified early who 
warrants close surveillance after transplantation (Czaja, 2009). Most likely, the intrinsic 
bases for recurrent AIH interact with the extrinsic factors to define the true risk. 
2.2 Pathogenesis of de novo AIH  
De novo AIH is a late complication that develops in patients undergoing transplantation for 
nonautoimmune liver disease (Czaja, 2002, 2007b). Since its first description by the King’s 
College group (Kerkar et al, 1998), it has been widely reported in both adult and child 
recipients after deceased or living liver donor (Hernandez et al, 2001; Gupta et al, 2001; 
Henegan et al, 2001; Salcedo et al, 2002; Aguilera et al, 2001; Miyagawa et al, 2004; Inui et al, 
2005; Venick et al, 2007; Di Cocco et al, 2008). The frequency of de novo disease may be 
increased because the population at risk is exposed to a great number of risk factors. 
Children seem to have a predilection for the syndrome (Birnbaum et al, 1997; Campsen et al, 
2008; Duclos-Valle et al, 2003; Yao et al, 2007; Czaja & Freese, 2002) and immunosuppression 
with cyclosporine is a common feature (Birnbaum et al, 1997; Pappo et al, 1995; Czaja & 
Freese, 2002). 
Pathogenic mechanisms involved in the de novo AIH probably are the same as those 
responsible for the disease before transplantation. Impaired negative selection of 
autoreactive immunocytes and molecular mimicry are still the principal pathogenic 
considerations, but their emergence as initiators of disease must be analyzed within the 
context of the clinical setting. Immunosuppressive therapy and exposure to diverse 
pathogens after transplantation may severely compromise the ability of an immune system 
already weakened by chronic illness and/or immaturity to preserve self tolerance.  
Cyclosporine inhibits signal transduction from the engaged T-cell antigen receptor (Ayata et 
al, 2002) and also may have a direct toxic effect on the thymic stroma (Seyam et al, 2007). 
These actions may alter the editing of T lymphocytes within the thymus and impair the 
negative selection of autoreactive cells. Impairment of T cell antigen-receptor signaling can 
prevent the apoptosis of class II MHC-restricted autoreactive lymphocytes, which in turn 
may leak into the peripheral compartment and be intolerant of self. Cyclosporine inhibits 
the calcineurin-mediated pathway in the signaling of the apoptosis, and in this fashion, it 
may extend the survival of autoreactive cells (Czaja, 1999b, 2007b; Khalaf et al, 2007). Active 
immune mediated lesions within the colon, liver, stomach, and pancreas have been 
described in an animal model treated with cyclosporine, and the findings constitute 
cyclosporine-induced autoimmune disease (Trouillot et al, 1999).  
A T-cell-dependent autoaggressive disease also has been reported after syngenic and/or 
autologous bone marrow transplantation in recipients treated with cyclosporine (Hayashi et 
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signal transduction from the engaged T cell antigen receptor (Hess et al, 2001), and it may 
also have a direct toxic effect on the thymic stroma (Beschorner et al, 1988). These actions 
may alter the editing of T lymphocytes within the thymus and impair the negative selection 
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(Cooper et al, 1991). These theoretical considerations have not been established in human 
disease (Gautam et al, 2006), and both medications have been used successfully in the 
treatment of recurrent AIH (Hubscher, 2001). Nevertheless, the failure of recurrent AIH to 
respond to one calcineurin inhibitor might warrant institution of the other (Hurtova et al, 
2001). 
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The severity of the original liver disease may also be a factor in disease recurrence after liver 
transplantation. Patients with recurrent AIH have higher serum levels of immunoglobulin G 
and histological findings of plasma cell infiltration and severe inflammatory activity more 
often immediately prior to transplantation than patients without recurrence (Montano-Loza 
et al, 2009). These observations suggest that recurrent AIH is a continuum of the original 
disease or a newly created process in a susceptible host with a propensity for severe 
immune reactivity (Czaja, 2009). They imply that aggressive disease suppression 
immediately prior to transplantation might alter the consequences after transplantation 
(Montano-Loza et al, 2009) or that an vulnerable individual may be identified early who 
warrants close surveillance after transplantation (Czaja, 2009). Most likely, the intrinsic 
bases for recurrent AIH interact with the extrinsic factors to define the true risk. 
2.2 Pathogenesis of de novo AIH  
De novo AIH is a late complication that develops in patients undergoing transplantation for 
nonautoimmune liver disease (Czaja, 2002, 2007b). Since its first description by the King’s 
College group (Kerkar et al, 1998), it has been widely reported in both adult and child 
recipients after deceased or living liver donor (Hernandez et al, 2001; Gupta et al, 2001; 
Henegan et al, 2001; Salcedo et al, 2002; Aguilera et al, 2001; Miyagawa et al, 2004; Inui et al, 
2005; Venick et al, 2007; Di Cocco et al, 2008). The frequency of de novo disease may be 
increased because the population at risk is exposed to a great number of risk factors. 
Children seem to have a predilection for the syndrome (Birnbaum et al, 1997; Campsen et al, 
2008; Duclos-Valle et al, 2003; Yao et al, 2007; Czaja & Freese, 2002) and immunosuppression 
with cyclosporine is a common feature (Birnbaum et al, 1997; Pappo et al, 1995; Czaja & 
Freese, 2002). 
Pathogenic mechanisms involved in the de novo AIH probably are the same as those 
responsible for the disease before transplantation. Impaired negative selection of 
autoreactive immunocytes and molecular mimicry are still the principal pathogenic 
considerations, but their emergence as initiators of disease must be analyzed within the 
context of the clinical setting. Immunosuppressive therapy and exposure to diverse 
pathogens after transplantation may severely compromise the ability of an immune system 
already weakened by chronic illness and/or immaturity to preserve self tolerance.  
Cyclosporine inhibits signal transduction from the engaged T-cell antigen receptor (Ayata et 
al, 2002) and also may have a direct toxic effect on the thymic stroma (Seyam et al, 2007). 
These actions may alter the editing of T lymphocytes within the thymus and impair the 
negative selection of autoreactive cells. Impairment of T cell antigen-receptor signaling can 
prevent the apoptosis of class II MHC-restricted autoreactive lymphocytes, which in turn 
may leak into the peripheral compartment and be intolerant of self. Cyclosporine inhibits 
the calcineurin-mediated pathway in the signaling of the apoptosis, and in this fashion, it 
may extend the survival of autoreactive cells (Czaja, 1999b, 2007b; Khalaf et al, 2007). Active 
immune mediated lesions within the colon, liver, stomach, and pancreas have been 
described in an animal model treated with cyclosporine, and the findings constitute 
cyclosporine-induced autoimmune disease (Trouillot et al, 1999).  
A T-cell-dependent autoaggressive disease also has been reported after syngenic and/or 
autologous bone marrow transplantation in recipients treated with cyclosporine (Hayashi et 
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al, 1998), and it may reflect cyclosporine-induced failure of T-lymphocytes to recognize class 
II MHC antigens as self (Gautam et al, 2006; Hess et al, 2001). Pretreatment of animal models 
of bone marrow transplantation with monoclonal antibodies against class II MHC 
determinants prevents adoptive transfer of syngenic graft-versus-host disease, whereas 
antibodies against class I MHC antigens are unable to prevent this outcome (Beschorner et 
al, 1988; Lotem et al, 1999). Tacrolimus affects the thymic microenvironment in a fashion like 
cyclosporine, and it also can induce a graft-versus-host-like reaction after syngenic bone 
marrow transplantation in rats (Cooper et al, 1991). These observations suggest that such 
immunosuppressive drugs (cyclosporine and tacrolimus) may have paradoxical effects in 
some liver transplant patients. Immunosuppression is the desired primary action, but 
enhanced autoreactivity may be a secondary consequence in some individuals. Young 
patients with immature immune system would logically be most vulnerable for the 
autoimmune response and most instances of de novo AIH have been reported in the 
pediatric group. An active thymus, immature T-cell-antigen receptor repertoire and 
repeated exposure to multiple homologous infectious and/or drug-related antigens would 
be likely additional requisites for de novo disease. 
Importantly, no conclusive data show that cyclosporine or tacrolimus induce AIH in 
humans, and both medications have been used successfully to treat classic AIH in adults 
and children (Cooper et al, 1991; Hurtova et al, 2001; Czaja, 2008; Wright et al, 1992; Reich et 
al, 2000; Devlin et al, 1995). Furthermore, animal models of cyclosporine-induced AIH have 
been highly perturbed models that may have no clinical relevance (Trouillot et al, 1999). 
3. Clinical features and diagnostic criteria  
AIH is an inflammatory process of unknown cause that is characterized by increased serum 
aspartate (AST) and alanine (ALT) aminotransferase levels, hypergammaglobinemia, 
autoantibodies, and interface hepatitis on histological examination (Krawitt, 2006; Czaja & 
Freese, 2002). Immunoglobulin G is the predominant serum γ-globulin component that is 
abnormally increased, and the typical autoantibodies associated with the disease are 
antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and antibodies to liver 
kidney microsome type 1 (anti-LKM1) (Czaja, 2007b). 
Antinuclear antibodies and SMA tend to cluster together, and they are not commonly 
expressed in association with anti-LKM1 (Homberg et al, 1987; Czaja et al, 1992; Czaja, 
1999a). This mutual exclusivity has justified the designations of type 1 AIH to identify the 
disease associated with ANA and SMA and type 2 AIH to identify the disease associated 
with anti-LKM1 (Czaja & Manns, 1995). These terms have not been endorsed by the 
International Autoimmune Hepatitis Group (IAIHG) since the serological types may not be 
distinct pathological entities (Alvarez et al, 1999). Nevertheless, the designations have been 
useful descriptors in clinical practice and in research studies, and they have become 
entrenched in the terminology of the disease. The same basic features of AIH in the native 
liver have characterized recurrent AIH in the transplanted liver. 
Transplant recipients with AIH are younger and more commonly women than other 
transplant recipients (Molmenti et al, 2002), and they have HLA DRB1*03 more frequently 
(Sanchez-Urdazpal et al, 1992; Gonzalez-Koch et al, 2001). HLA DRB1*03 and DRB1*04 are 
the principal susceptibility factors for AIH in white North American and northern European 
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patients (Donaldson et al, 1991), and HLA DRB1*03 has been associated with early age of 
disease onset and a higher frequency of treatment failure than patients with other HLA 
(Czaja et al, 1993, 1997; Czaja & Carpenter, 2006). The same clinical phenotype that has 
typified AIH in native patients also characterizes the patients who develop recurrent disease 
after transplantation (Gonzalez-Koch et al, 2001; Hubscher, 2001). In de novo AIH, Salcedo 
et al. found a significant increase in the prevalence of HLA DR3 and a trend to higher 
frequencies for HLA-B8, -DR15, -DR51 and –Q6 (Salcedo et al, 2002). Symptoms may vary 
from none to severe (jaundice and hepatic failure), and the presence of disease must be 
actively sought in asymptomatic patients by the regular monitoring of liver indices (serum 
AST, ALT, bilirubin, and γ-globulin levels) and protocol liver biopsies (Pappo et al, 1995; 
Duclos-Vallee et al, 2003; Yao et al, 2007).  
Type Feature Frequency 
Clinical Female Common 
 Young Common 
 Asymptomatic Common 
 Jaundice Rare 
Laboratory Increased Serum AST/ALT Required 
 Increased Serum γ-globulin  Usual 
 Increased Serum immunoglobulin G Usual 
 HLA DRB1*03 Common (ethnic dependent) 
 No viral markers Required 
Serological ANA/SMA  Common 
 Anti-LKM1 Possible 
Histological Interface hepatitis Required 
 Plasma cell infiltration Common 
 Lobular hepatitis Rare 
 Acidophil bodies Rare 
 Mixed features Possible 
 Non-specific hepatitis Possible 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ANA, antinuclear 
antibodies; anti-LKM1, antibodies to liver/kidney microsome type 1; HLA, human leukocyte antigen; 
SMA, smooth muscle antibodies 
Table 3. Clinical Features of Recurrent Autoimmune Hepatitis After Liver Transplantation 
The importance of autoantibodies in the diagnosis of recurrent and de novo AIH is still 
debated. The majority of patients in whom a diagnosis of recurrent AIH is made have 
positive autoantibodies. However, several studies have shown that autoantibodies persist in 
the majority of patients who undergo transplantation for AIH, generally at lower titers than 
before liver transplantation, irrespective of other features suggestive of disease recurrence 
(Ahmed et al, 1997; Prados et al, 1998; Gotz et al, 1999; Reich et al, 2000). This is analogous to 
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al, 1998), and it may reflect cyclosporine-induced failure of T-lymphocytes to recognize class 
II MHC antigens as self (Gautam et al, 2006; Hess et al, 2001). Pretreatment of animal models 
of bone marrow transplantation with monoclonal antibodies against class II MHC 
determinants prevents adoptive transfer of syngenic graft-versus-host disease, whereas 
antibodies against class I MHC antigens are unable to prevent this outcome (Beschorner et 
al, 1988; Lotem et al, 1999). Tacrolimus affects the thymic microenvironment in a fashion like 
cyclosporine, and it also can induce a graft-versus-host-like reaction after syngenic bone 
marrow transplantation in rats (Cooper et al, 1991). These observations suggest that such 
immunosuppressive drugs (cyclosporine and tacrolimus) may have paradoxical effects in 
some liver transplant patients. Immunosuppression is the desired primary action, but 
enhanced autoreactivity may be a secondary consequence in some individuals. Young 
patients with immature immune system would logically be most vulnerable for the 
autoimmune response and most instances of de novo AIH have been reported in the 
pediatric group. An active thymus, immature T-cell-antigen receptor repertoire and 
repeated exposure to multiple homologous infectious and/or drug-related antigens would 
be likely additional requisites for de novo disease. 
Importantly, no conclusive data show that cyclosporine or tacrolimus induce AIH in 
humans, and both medications have been used successfully to treat classic AIH in adults 
and children (Cooper et al, 1991; Hurtova et al, 2001; Czaja, 2008; Wright et al, 1992; Reich et 
al, 2000; Devlin et al, 1995). Furthermore, animal models of cyclosporine-induced AIH have 
been highly perturbed models that may have no clinical relevance (Trouillot et al, 1999). 
3. Clinical features and diagnostic criteria  
AIH is an inflammatory process of unknown cause that is characterized by increased serum 
aspartate (AST) and alanine (ALT) aminotransferase levels, hypergammaglobinemia, 
autoantibodies, and interface hepatitis on histological examination (Krawitt, 2006; Czaja & 
Freese, 2002). Immunoglobulin G is the predominant serum γ-globulin component that is 
abnormally increased, and the typical autoantibodies associated with the disease are 
antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and antibodies to liver 
kidney microsome type 1 (anti-LKM1) (Czaja, 2007b). 
Antinuclear antibodies and SMA tend to cluster together, and they are not commonly 
expressed in association with anti-LKM1 (Homberg et al, 1987; Czaja et al, 1992; Czaja, 
1999a). This mutual exclusivity has justified the designations of type 1 AIH to identify the 
disease associated with ANA and SMA and type 2 AIH to identify the disease associated 
with anti-LKM1 (Czaja & Manns, 1995). These terms have not been endorsed by the 
International Autoimmune Hepatitis Group (IAIHG) since the serological types may not be 
distinct pathological entities (Alvarez et al, 1999). Nevertheless, the designations have been 
useful descriptors in clinical practice and in research studies, and they have become 
entrenched in the terminology of the disease. The same basic features of AIH in the native 
liver have characterized recurrent AIH in the transplanted liver. 
Transplant recipients with AIH are younger and more commonly women than other 
transplant recipients (Molmenti et al, 2002), and they have HLA DRB1*03 more frequently 
(Sanchez-Urdazpal et al, 1992; Gonzalez-Koch et al, 2001). HLA DRB1*03 and DRB1*04 are 
the principal susceptibility factors for AIH in white North American and northern European 
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patients (Donaldson et al, 1991), and HLA DRB1*03 has been associated with early age of 
disease onset and a higher frequency of treatment failure than patients with other HLA 
(Czaja et al, 1993, 1997; Czaja & Carpenter, 2006). The same clinical phenotype that has 
typified AIH in native patients also characterizes the patients who develop recurrent disease 
after transplantation (Gonzalez-Koch et al, 2001; Hubscher, 2001). In de novo AIH, Salcedo 
et al. found a significant increase in the prevalence of HLA DR3 and a trend to higher 
frequencies for HLA-B8, -DR15, -DR51 and –Q6 (Salcedo et al, 2002). Symptoms may vary 
from none to severe (jaundice and hepatic failure), and the presence of disease must be 
actively sought in asymptomatic patients by the regular monitoring of liver indices (serum 
AST, ALT, bilirubin, and γ-globulin levels) and protocol liver biopsies (Pappo et al, 1995; 
Duclos-Vallee et al, 2003; Yao et al, 2007).  
Type Feature Frequency 
Clinical Female Common 
 Young Common 
 Asymptomatic Common 
 Jaundice Rare 
Laboratory Increased Serum AST/ALT Required 
 Increased Serum γ-globulin  Usual 
 Increased Serum immunoglobulin G Usual 
 HLA DRB1*03 Common (ethnic dependent) 
 No viral markers Required 
Serological ANA/SMA  Common 
 Anti-LKM1 Possible 
Histological Interface hepatitis Required 
 Plasma cell infiltration Common 
 Lobular hepatitis Rare 
 Acidophil bodies Rare 
 Mixed features Possible 
 Non-specific hepatitis Possible 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ANA, antinuclear 
antibodies; anti-LKM1, antibodies to liver/kidney microsome type 1; HLA, human leukocyte antigen; 
SMA, smooth muscle antibodies 
Table 3. Clinical Features of Recurrent Autoimmune Hepatitis After Liver Transplantation 
The importance of autoantibodies in the diagnosis of recurrent and de novo AIH is still 
debated. The majority of patients in whom a diagnosis of recurrent AIH is made have 
positive autoantibodies. However, several studies have shown that autoantibodies persist in 
the majority of patients who undergo transplantation for AIH, generally at lower titers than 
before liver transplantation, irrespective of other features suggestive of disease recurrence 
(Ahmed et al, 1997; Prados et al, 1998; Gotz et al, 1999; Reich et al, 2000). This is analogous to 
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the situation that exists for patients undergoing liver transplantation for primary biliary 
cirrhosis; most remain positive for antimitochondrial antibodies without necessarily having 
other features to suggest disease recurrence (Esquivel et al, 1988; Mattalia et al, 1997). One 
study suggested that the presence of autoantibodies in titers exceeding pretransplantation 
levels may be the manifestation of recurrent AIH (Reich et al, 2000) but this observation, 
based on small number of cases requires further confirmation. It is possible as suggested by 
Gonzales-Koch et al., that the formation of autoantibodies may be impaired in the setting of 
immunosuppression (Gonzales-Koch et al, 2001). Impaired antibody formation after liver 
transplantation is well recognized in hepatitis C virus (HCV)-positive patients, many of 
whom have high viral RNA levels without detectable anti-HCV antibodies (Poterucha et al, 
1992; Hsu et al, 1994).  
Autoantibodies arising de novo after liver transplantation have also been noted in 
association with episodes of rejection (Duclos-Valle et al, 2000). Classic autoantibodies are 
commonly present in the serum of these patients but atypical serum autoantibodies are 
characteristically observed (Alvarez et al, 1999; Hubscher, 2001). Among these atypical 
antibodies, one antibody type seems to be direct against the cytosolic enzyme glutathione S-
transferase T1. Interestingly GSTT1 mismatch between the donor and the recipient has been 
reported as a prerequisite for the development of de novo AIH after liver transplantation 
(Aguilera et al, 2001; Inui et al, 2005). In addition the early detection of anti-GSTT1 
antibodies may help to identify a subset of patients at risk of developing de novo AIH 
(Salcedo et al, 2009).  
Several studies have shown the important role of the routine liver biopsies in the diagnosis 
of AIH without biochemical evidence of hepatitis (Ahmed et al, 1997; Prados et al, 1998; 
Gotz et al, 1999). Interface hepatitis is the histological hallmark of recurrent AIH after 
transplantation, and plasma cell infiltration is a feature of the disease (Gonzalez-Koch et al, 
2001; Hubscher, 2001; Ayata et al, 2000; Banff Working Group et al, 2006) Concurrent 
immunosuppressive therapy can modify the nature and severity of the inflammatory 
infiltrate, and the histological diagnosis may be based on more subtle changes than those 
observed in the native disease (Gonzalez-Koch et al, 2001; Hubscher, 2001). Plasma cell 
infiltration is neither specific nor required for the diagnosis of recurrent AIH (Banff Working 
Group et al, 2006). Acidophil bodies in conjunction with lymphoplasmacytic infiltrates are 
seen in early recurrent AIH (Ayata et al, 2000), and an acute lobular hepatitis is also 
compatible with the diagnosis (Ayata et al, 2000; Sempoux et al, 1997). The histological 
changes of acute or chronic rejection may occur simultaneously with those of AIH, and 
concurrent pathological processes must be considered when confusing mixed and atypical 
histological features are present (Pappo et al, 1995; Hytiroglou et al, 2009). 
The histological findings of de novo AIH may differ from the interface hepatitis usually 
found in the classic AIH (Gupta et al, 2001). In de novo AIH there is histological evidence of 
portal and periportal hepatitis with or without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate with a variable degree of plasma cells. Histological 
features of bile ductular proliferation and markedly increased serum concentrations of 
gamma glutamyl transpeptidase suggest the likelihood of treatment failure and probably 
indicate a variant syndrome of AIH (Campsen et al, 2008; Berg et al, 2002). De novo disease 
in some adults has been associated with severe centrilobular necrosis that may confound 
diagnosis and adult patients have been reported to express an atypical antiliver/kidney 
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cytosolic antibody of uncertain pathogenic significance (Czaja, 2007b). This antibody reacts 
to rat hepatocyte cytoplasm, chiefly in the centrilobular area, and also shows indirect 
immunofluorescence in distal and proximal tubules of rat kidney (Czaja, 2007b). 
The diagnostic guidelines (Alvarez et al, 1999), not tested in patients receiving 
immunosuppressive therapy, cannot be used with confidence in the post-transplantation 
setting (Hubscher, 2001; Li & Neuberger, 2009; Neuberger, 2002; Duclos-Valle, 2005; 
Schreuder et al, 2009). As stated before, the diagnosis of recurrent and de novo AIH 
requires the presence of compatible clinical, laboratory and histological findings, and it 
depends mainly on the exclusion of other conditions that can resemble it (Milkiewicz et al, 
1999).  
Acute or chronic cellular rejection is the main diagnosis that must be excluded (Banff 
Working Group et al, 2006; Lefkowitch, 2002). The key clinical distinctions between AIH 
after liver transplantation and acute cellular rejection are time to disease onset, HLA 
DRB1*03 status, and autoantibody production. Recurrent autoimmune hepatitis develops 
after a median interval of 2 years (Czaja, 2002, 2009; Gonzalez-Koch et al, 2001), whereas 
acute cellular rejection typically develops within 6 weeks after transplantation with a 
median interval of 8 days (Wiesner et al, 1998). Patients with recurrent AIH commonly have 
HLA DRB1*03, and they have autoantibodies of substantial titer (Sanchez-Urdazpal et al, 
1992; Gonzalez-Koch et al, 2001). The major histological distinctions between recurrent AIH 
and acute cellular rejection are the moderate-severe interface hepatitis and plasma cell 
infiltration that characterize AIH, and the eosinophils, endotheliitis, and cholangitis that 
characterize acute cellular rejection (Lefkowitch, 2002). 
Autoimmune hepatitis and chronic rejection each occur months after transplantation, but 
this is their only point of resemblance. Each condition should be easily distinguished from 
the other as cholestasis, portal ductopenia, centrilobular fibrosis, and foam cell arteriopathy 
characterize chronic rejection (Banff Working Group et al, 2006; Lefkowitch, 2002). The 
principal pathogenic distinctions between the recurrent AIH and the rejection responses 
probably relate to the origin of the antigen-presenting cells that initiate the immune 
response and the nature of the antigens that are targeted by the activated immunocytes. The 
autoimmune response requires re-population of the donor liver with antigen-presenting 
cells (such as dendritic cells and macrophages) from the recipient. The presentation of self-
antigens common to both the donor and recipient can initiate the autoimmune response in 
the donor liver. In contrast, the rejection response is based on the reactivity of promiscuous 
cytotoxic T lymphocytes from the recipient against foreign antigens presented by the donor 
liver, including class II MHC molecules, viral proteins, and novel donor organ antigens 
(Czaja, 2002; Vierling, 1999). 
Plasma cell hepatitis and isolated central perivenulitis can also confuse the diagnosis of 
recurrent AIH. Each condition is probably a variant of rejection. Plasma cell hepatitis does 
not improve with corticosteroid treatment; it may develop as immunosuppressive therapy is 
reduced; and it improves as the immunosuppressive regimen is intensified (Demetris & 
Sebagh, 2008; Fiel et al, 2008). Isolated central perivenulitis can be found in 28% of allografts, 
and it can lead to de novo autoimmune hepatitis or chronic liver injury, especially if it 
occurs late after transplantation (Krasinskas et al, 2008). Typically, perivenulitis is untreated, 
but this approach is debated and anti-rejection therapy has been proposed. 
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the situation that exists for patients undergoing liver transplantation for primary biliary 
cirrhosis; most remain positive for antimitochondrial antibodies without necessarily having 
other features to suggest disease recurrence (Esquivel et al, 1988; Mattalia et al, 1997). One 
study suggested that the presence of autoantibodies in titers exceeding pretransplantation 
levels may be the manifestation of recurrent AIH (Reich et al, 2000) but this observation, 
based on small number of cases requires further confirmation. It is possible as suggested by 
Gonzales-Koch et al., that the formation of autoantibodies may be impaired in the setting of 
immunosuppression (Gonzales-Koch et al, 2001). Impaired antibody formation after liver 
transplantation is well recognized in hepatitis C virus (HCV)-positive patients, many of 
whom have high viral RNA levels without detectable anti-HCV antibodies (Poterucha et al, 
1992; Hsu et al, 1994).  
Autoantibodies arising de novo after liver transplantation have also been noted in 
association with episodes of rejection (Duclos-Valle et al, 2000). Classic autoantibodies are 
commonly present in the serum of these patients but atypical serum autoantibodies are 
characteristically observed (Alvarez et al, 1999; Hubscher, 2001). Among these atypical 
antibodies, one antibody type seems to be direct against the cytosolic enzyme glutathione S-
transferase T1. Interestingly GSTT1 mismatch between the donor and the recipient has been 
reported as a prerequisite for the development of de novo AIH after liver transplantation 
(Aguilera et al, 2001; Inui et al, 2005). In addition the early detection of anti-GSTT1 
antibodies may help to identify a subset of patients at risk of developing de novo AIH 
(Salcedo et al, 2009).  
Several studies have shown the important role of the routine liver biopsies in the diagnosis 
of AIH without biochemical evidence of hepatitis (Ahmed et al, 1997; Prados et al, 1998; 
Gotz et al, 1999). Interface hepatitis is the histological hallmark of recurrent AIH after 
transplantation, and plasma cell infiltration is a feature of the disease (Gonzalez-Koch et al, 
2001; Hubscher, 2001; Ayata et al, 2000; Banff Working Group et al, 2006) Concurrent 
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compatible with the diagnosis (Ayata et al, 2000; Sempoux et al, 1997). The histological 
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histological features are present (Pappo et al, 1995; Hytiroglou et al, 2009). 
The histological findings of de novo AIH may differ from the interface hepatitis usually 
found in the classic AIH (Gupta et al, 2001). In de novo AIH there is histological evidence of 
portal and periportal hepatitis with or without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate with a variable degree of plasma cells. Histological 
features of bile ductular proliferation and markedly increased serum concentrations of 
gamma glutamyl transpeptidase suggest the likelihood of treatment failure and probably 
indicate a variant syndrome of AIH (Campsen et al, 2008; Berg et al, 2002). De novo disease 
in some adults has been associated with severe centrilobular necrosis that may confound 
diagnosis and adult patients have been reported to express an atypical antiliver/kidney 
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cytosolic antibody of uncertain pathogenic significance (Czaja, 2007b). This antibody reacts 
to rat hepatocyte cytoplasm, chiefly in the centrilobular area, and also shows indirect 
immunofluorescence in distal and proximal tubules of rat kidney (Czaja, 2007b). 
The diagnostic guidelines (Alvarez et al, 1999), not tested in patients receiving 
immunosuppressive therapy, cannot be used with confidence in the post-transplantation 
setting (Hubscher, 2001; Li & Neuberger, 2009; Neuberger, 2002; Duclos-Valle, 2005; 
Schreuder et al, 2009). As stated before, the diagnosis of recurrent and de novo AIH 
requires the presence of compatible clinical, laboratory and histological findings, and it 
depends mainly on the exclusion of other conditions that can resemble it (Milkiewicz et al, 
1999).  
Acute or chronic cellular rejection is the main diagnosis that must be excluded (Banff 
Working Group et al, 2006; Lefkowitch, 2002). The key clinical distinctions between AIH 
after liver transplantation and acute cellular rejection are time to disease onset, HLA 
DRB1*03 status, and autoantibody production. Recurrent autoimmune hepatitis develops 
after a median interval of 2 years (Czaja, 2002, 2009; Gonzalez-Koch et al, 2001), whereas 
acute cellular rejection typically develops within 6 weeks after transplantation with a 
median interval of 8 days (Wiesner et al, 1998). Patients with recurrent AIH commonly have 
HLA DRB1*03, and they have autoantibodies of substantial titer (Sanchez-Urdazpal et al, 
1992; Gonzalez-Koch et al, 2001). The major histological distinctions between recurrent AIH 
and acute cellular rejection are the moderate-severe interface hepatitis and plasma cell 
infiltration that characterize AIH, and the eosinophils, endotheliitis, and cholangitis that 
characterize acute cellular rejection (Lefkowitch, 2002). 
Autoimmune hepatitis and chronic rejection each occur months after transplantation, but 
this is their only point of resemblance. Each condition should be easily distinguished from 
the other as cholestasis, portal ductopenia, centrilobular fibrosis, and foam cell arteriopathy 
characterize chronic rejection (Banff Working Group et al, 2006; Lefkowitch, 2002). The 
principal pathogenic distinctions between the recurrent AIH and the rejection responses 
probably relate to the origin of the antigen-presenting cells that initiate the immune 
response and the nature of the antigens that are targeted by the activated immunocytes. The 
autoimmune response requires re-population of the donor liver with antigen-presenting 
cells (such as dendritic cells and macrophages) from the recipient. The presentation of self-
antigens common to both the donor and recipient can initiate the autoimmune response in 
the donor liver. In contrast, the rejection response is based on the reactivity of promiscuous 
cytotoxic T lymphocytes from the recipient against foreign antigens presented by the donor 
liver, including class II MHC molecules, viral proteins, and novel donor organ antigens 
(Czaja, 2002; Vierling, 1999). 
Plasma cell hepatitis and isolated central perivenulitis can also confuse the diagnosis of 
recurrent AIH. Each condition is probably a variant of rejection. Plasma cell hepatitis does 
not improve with corticosteroid treatment; it may develop as immunosuppressive therapy is 
reduced; and it improves as the immunosuppressive regimen is intensified (Demetris & 
Sebagh, 2008; Fiel et al, 2008). Isolated central perivenulitis can be found in 28% of allografts, 
and it can lead to de novo autoimmune hepatitis or chronic liver injury, especially if it 
occurs late after transplantation (Krasinskas et al, 2008). Typically, perivenulitis is untreated, 
but this approach is debated and anti-rejection therapy has been proposed. 
 
Liver Transplantation – Technical Issues and Complications 
 
372 
Diagnosis Distinctive Features 
Recurrent autoimmune hepatitis Late onset (median, 2 years) 
Interface hepatitis 
Plasma cell infiltration 
Autoantibodies (serum titer ≥1:320) 
HLA DRB1*03 (ethnic dependent) 
Acute cellular rejection Early onset (median, 8 days) 
Endotheliitis 
Cholangitis (histological finding) 
Eosinophilic infiltrates 
Chronic cellular rejection Late onset (range, 3-8 months) 
Cholestasis (histological finding) 
Portal ductopenia 
Centrilobular fibrosis 
Foam cell arteriopathy 
Plasma cell hepatitis Rejection variant 
Associated with reduced 
immunosuppression 
Unresponsive to corticosteroids 
Improves with increased 
immunosuppression 
Isolated central perivenulitis Rejection variant 
Progressive if late occurrence 
May result in autoimmune hepatitis 
Hepatitis C virus infection Portal lymphoplasmacytic response possible 
Serological markers of active viremia 
De novo AIH Late onset (median, 2 years)  
Children predilection 
Interface hepatitis 
Portal and periportal hepatitis with or 
without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate  
Autoantibodies (classic and atypical) 
Response to prednisone and azathioprine 
Table 4. Differential Diagnosis of Recurrent and De Novo AIH After Transplantation 
Superimposed viral infections, especially HCV, must always be excluded in patients with 
graft disruption after transplantation because may elicit a pronounced lymphoplasmacytic 
response within the portal tract that can be difficult to distinguish from recurrent AIH (Banff 
Working Group et al, 2006; Demetris & Sebagh, 2008). Furthermore, recurrent AIH and HCV 
infection may occur together in the same allograft (Pappo et al, 1995). A comprehensive 
virological assessment is warranted to exclude infection in all patients with features of 
recurrent AIH after transplantation. 
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The absence of reliable diagnostic markers for recurrent AIH has compelled reliance on the 
histological findings to support the diagnosis, and the features of nonspecific chronic 
hepatitis have been the minimal bases for the diagnosis in some cases (Hubscher, 2001). 
Seronegative AIH has been described in native patients (Czaja et al, 1993; Gassert et al, 2007; 
Heringlake et al, 2009), and there is an emerging experience that suggests that it may be a 
relevant consideration in patients with graft dysfunction after liver transplantation 
(Nakhleh et al, 2005; Berg et al, 2002; Ayata et al, 2002; Seyam et al, 2007). Most patients who 
undergo liver transplantation for cryptogenic chronic hepatitis can be classified into 
conventional diagnostic categories after review of their liver tissue specimens before and 
after liver transplantation, but 15% remain cryptogenic and at risk for disease recurrence 
and progression (Ayata et al, 2002). 
Cirrhosis may develop after transplantation in seronegative patients with recurrent 
histological features of chronic hepatitis, especially in those patients transplanted for 
seronegative fulminant hepatitis, and the possibility of recurrent seronegative AIH cannot 
be excluded in these individuals (Seyam et al, 2007). Consequently, recurrent AIH should be 
considered in all patients with acute and chronic graft dysfunction after liver 
transplantation. The diagnostic criteria must accommodate the atypical manifestations 
encountered after transplantation that may reflect superimposed medication effects and 
diverse other diseases associated with the transplantation. 
4. Outcome 
Recurrent AIH is typically a mild inflammatory process in an asymptomatic individual who 
has been inadequately immunosuppressed after transplantation or prematurely withdrawn 
from corticosteroids (Gonzalez-Koch et al, 2001; Prados et al, 1998; Neuberger, 2002; Khalaf, 
2007). Recurrent disease usually responds to the re-introduction of corticosteroid therapy or 
adjustments in the doses of the original immunosuppressive agents (Gonzalez-Koch et al, 
2001; Faust, 2000, 2001). The frequency of recurrence does not correlate with the frequency 
of graft loss, and patient and graft survivals after recurrence have been similar to those of 
other transplanted diseases (Li &Neuberger, 2009; Schreuder, 2009). Survival in patients 
with recurrent disease has ranged from 78-89% (Vogel et al, 2004; Yusoff et al, 2002). 
Progression to cirrhosis and graft loss can occur (Milkiewicz et al, 1999; Ratziu et al, 1999; 
Rowe et al, 2008), and recurrent AIH with graft loss after the second transplantation has been 
reported (Reich et al, 2000). Furthermore, not all patients with recurrent AIH are inadequately 
immunosuppressed at the time of presentation (Ratziu et al, 1999) or responsive to the re-
institution of corticosteroid therapy (Prados et al, 1998; Neuberger, 2002). Patients with severe, 
aggressive recurrent AIH have not been fully characterized, and the individuals at risk for a 
dire outcome cannot be reliably identified. The serological type of the original disease may 
affect the need for transplantation (Cattan et al, 2002), but it does not correlate with prognosis 
after transplantation (Vogel et al, 2004). Similarly, the severity of the disease at transplantation 
does not predict outcome after the procedure (Montano-Loza et al, 2009). Patients transplanted 
for fulminant AIH have lower frequencies of recurrence after transplantation and better 
survivals than patients transplanted for chronic AIH (Reich et al, 2000; Nunez-Martinez et al, 
2003), but most patients who develop recurrent AIH do not have fulminant presentations. The 
outcome of de novo AIH remains largely unknown, but several cases with severe liver damage 
 
Liver Transplantation – Technical Issues and Complications 
 
372 
Diagnosis Distinctive Features 
Recurrent autoimmune hepatitis Late onset (median, 2 years) 
Interface hepatitis 
Plasma cell infiltration 
Autoantibodies (serum titer ≥1:320) 
HLA DRB1*03 (ethnic dependent) 
Acute cellular rejection Early onset (median, 8 days) 
Endotheliitis 
Cholangitis (histological finding) 
Eosinophilic infiltrates 
Chronic cellular rejection Late onset (range, 3-8 months) 
Cholestasis (histological finding) 
Portal ductopenia 
Centrilobular fibrosis 
Foam cell arteriopathy 
Plasma cell hepatitis Rejection variant 
Associated with reduced 
immunosuppression 
Unresponsive to corticosteroids 
Improves with increased 
immunosuppression 
Isolated central perivenulitis Rejection variant 
Progressive if late occurrence 
May result in autoimmune hepatitis 
Hepatitis C virus infection Portal lymphoplasmacytic response possible 
Serological markers of active viremia 
De novo AIH Late onset (median, 2 years)  
Children predilection 
Interface hepatitis 
Portal and periportal hepatitis with or 
without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate  
Autoantibodies (classic and atypical) 
Response to prednisone and azathioprine 
Table 4. Differential Diagnosis of Recurrent and De Novo AIH After Transplantation 
Superimposed viral infections, especially HCV, must always be excluded in patients with 
graft disruption after transplantation because may elicit a pronounced lymphoplasmacytic 
response within the portal tract that can be difficult to distinguish from recurrent AIH (Banff 
Working Group et al, 2006; Demetris & Sebagh, 2008). Furthermore, recurrent AIH and HCV 
infection may occur together in the same allograft (Pappo et al, 1995). A comprehensive 
virological assessment is warranted to exclude infection in all patients with features of 
recurrent AIH after transplantation. 
 
Autoimmune Hepatitis After Liver Transplantation 
 
373 
The absence of reliable diagnostic markers for recurrent AIH has compelled reliance on the 
histological findings to support the diagnosis, and the features of nonspecific chronic 
hepatitis have been the minimal bases for the diagnosis in some cases (Hubscher, 2001). 
Seronegative AIH has been described in native patients (Czaja et al, 1993; Gassert et al, 2007; 
Heringlake et al, 2009), and there is an emerging experience that suggests that it may be a 
relevant consideration in patients with graft dysfunction after liver transplantation 
(Nakhleh et al, 2005; Berg et al, 2002; Ayata et al, 2002; Seyam et al, 2007). Most patients who 
undergo liver transplantation for cryptogenic chronic hepatitis can be classified into 
conventional diagnostic categories after review of their liver tissue specimens before and 
after liver transplantation, but 15% remain cryptogenic and at risk for disease recurrence 
and progression (Ayata et al, 2002). 
Cirrhosis may develop after transplantation in seronegative patients with recurrent 
histological features of chronic hepatitis, especially in those patients transplanted for 
seronegative fulminant hepatitis, and the possibility of recurrent seronegative AIH cannot 
be excluded in these individuals (Seyam et al, 2007). Consequently, recurrent AIH should be 
considered in all patients with acute and chronic graft dysfunction after liver 
transplantation. The diagnostic criteria must accommodate the atypical manifestations 
encountered after transplantation that may reflect superimposed medication effects and 
diverse other diseases associated with the transplantation. 
4. Outcome 
Recurrent AIH is typically a mild inflammatory process in an asymptomatic individual who 
has been inadequately immunosuppressed after transplantation or prematurely withdrawn 
from corticosteroids (Gonzalez-Koch et al, 2001; Prados et al, 1998; Neuberger, 2002; Khalaf, 
2007). Recurrent disease usually responds to the re-introduction of corticosteroid therapy or 
adjustments in the doses of the original immunosuppressive agents (Gonzalez-Koch et al, 
2001; Faust, 2000, 2001). The frequency of recurrence does not correlate with the frequency 
of graft loss, and patient and graft survivals after recurrence have been similar to those of 
other transplanted diseases (Li &Neuberger, 2009; Schreuder, 2009). Survival in patients 
with recurrent disease has ranged from 78-89% (Vogel et al, 2004; Yusoff et al, 2002). 
Progression to cirrhosis and graft loss can occur (Milkiewicz et al, 1999; Ratziu et al, 1999; 
Rowe et al, 2008), and recurrent AIH with graft loss after the second transplantation has been 
reported (Reich et al, 2000). Furthermore, not all patients with recurrent AIH are inadequately 
immunosuppressed at the time of presentation (Ratziu et al, 1999) or responsive to the re-
institution of corticosteroid therapy (Prados et al, 1998; Neuberger, 2002). Patients with severe, 
aggressive recurrent AIH have not been fully characterized, and the individuals at risk for a 
dire outcome cannot be reliably identified. The serological type of the original disease may 
affect the need for transplantation (Cattan et al, 2002), but it does not correlate with prognosis 
after transplantation (Vogel et al, 2004). Similarly, the severity of the disease at transplantation 
does not predict outcome after the procedure (Montano-Loza et al, 2009). Patients transplanted 
for fulminant AIH have lower frequencies of recurrence after transplantation and better 
survivals than patients transplanted for chronic AIH (Reich et al, 2000; Nunez-Martinez et al, 
2003), but most patients who develop recurrent AIH do not have fulminant presentations. The 
outcome of de novo AIH remains largely unknown, but several cases with severe liver damage 
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and hepatic failure leading to death have been described (Hernandez et al, 2001), indicating 
the needing for specific management of this complication.  
5. Treatment 
The first course of action is to establish the correct diagnosis, reassess the adequacy of the 
immunosuppressive regimen, and determine the compliance of the patient. Measurement 
of the drug metabolites in blood may be necessary to ensure the adequacy of dosing and 
the compliance of the individual (Rumbo et al, 2004). The second course of action is to 
optimize the doses of the conventional immunosuppressive medication and to re-
introduce corticosteroids if they have been withdrawn (Neuberger, 2002). Treatment with 
prednisone and azathioprine is typically effective in recurrent (Birnbaum et al, 1997; 
Pappo et al, 1995; Duclos-Vallee et al, 203; Czaja & Freese, 2002; Czaja, 2007b) and de novo 
AIH (Salcedo et al, 2002). Failure to respond or disease progression despite compliance 
with therapy justifies a closely monitored empiric trial with alternative 
immunosuppressive agents. The calcineurin inhibitor could be changed to another drug in 
this same category (Hurtova et al, 2001); a purine antagonist (azathioprine or 
mycophenolate mofetil) could be added or its dose optimized (Rumbo et al, 2004); or 
rapamycin, which is a mTOR (mammalian target of rapamycin) inhibitor, could be 
introduced (Kerkar et al, 2005). These agents have been reported as effective salvage 
therapies in small single-center case reports, but none have been established by large 
multicenter experiences or organized clinical trials. Patients in whom therapy fails have 
worsening fibrosis and possible graft loss (Vogel et al, 2004; Campsen et al, 2008) and 
those not administered corticosteroids progress to cirrhosis, require re-transplantation or 
die of liver failure (Czaja, 2007b). Re-transplantation must be considered if the disease 
continues to progress with the understanding that the disease could recur in the second 
graft and again jeopardize its survival (Reich et al, 2000). 
6. Summary 
AIH commonly recurs after liver transplantation, and asymptomatic histological recurrence 
may precede clinical recurrence by 1-5 years. Acute and chronic cellular rejection, drug 
toxicity, and viral infection must be confidently excluded, and treatment typically requires 
adjustment in the doses of immunosuppressive medication or the re-institution of 
corticosteroid therapy. Empiric treatments with another calcineurin inhibitor, purine 
antagonist (azathioprine or mycophenolate mofetil), or mTOR inhibitor (rapamycin) are 
available for refractory disease, and re-transplantation may be necessary. 
Future studies are needed to codify diagnostic criteria, define risk factors that are predictive 
of recurrence and its progression, standardize surveillance schedules after transplantation, 
develop a uniform management algorithm, and elucidate mechanisms of disease. 
Insights into the pathogenesis of recurrent and de novo AIH may elucidate a similar 
behavior in the native disease. Native AIH also exacerbates frequently after corticosteroid 
withdrawal, and this flare may occur after long intervals of quiescence. The concepts that 
activated immunocytes can trigger the same disease after a long dormancy or that a 
susceptible host with a genetic predisposition can develop newly created episodes of the 
same disease may apply to both conditions. The experiences in liver transplantation have 
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much to teach about AIH, and future investigations that clarify the mechanisms of recurrent 
and of de novo AIH will have broad implications for autoimmune diseases in general, not 
only for classical AIH. Future investigations must continue to utilize the human 
transplantation experience to elucidate the key mechanisms of the autoimmune response in 
the native liver. 
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1. Introduction 
The frequency of disorders of bone metabolism (osteopenia, osteoporosis) after liver 
transplantation is stated up to 50%. The first three to six months after transplantation are 
linked to the greatest bone density loss. The probability for sustaining a fracture in the post-
transplantation phase is indicated with up to 65%. Most fractures are sustained still within 
the first two years after the transplantation and the most common site is the spine followed 
by costal fractures and femoral neck fractures. Vertebral body fractures and femoral 
fractures in particular cause a dramatic limitation of the patients’ mobility and quality of 
life; in addition, an increase of mortality occurs. 
2. Definition of osteoporosis 
Osteoporosis is a systematic skeletal disease; its course is characterized by a reduction of 
bone mass, a microarchitectural deterioration of bone and thus an increase of bone fragility 
and a susceptibility to fracture. The reference standard of the WHO allows quantifying the 
extent of bone mineral density reduction with DXA method. A T-score – the standard 
deviations of the measurement from the average of 30-year-old healthy Caucasians – 
between -1 and -2.5 indicates osteopenia whereas scores below -2.5 indicate osteoporosis. 
After occurrence of one or several fractures due to low-energy trauma an apparent 
osteoporosis is existent. 
3. Pathophysiology  
Genesis of post-transplantation bone disease after liver transplantation (LT) is multifactorial, 
it comprises among others the pre-existent bone density loss in case of chronic liver disease, 
hypogonadism, deficit of vitamin D and increase of parathyroid hormone, malnutrition, 
nicotine and alcohol abuse. These factors will be potentiated by postoperative immobility, 
the medical substitution of immunosuppressives, glucocorticoids and of heparins.  
 
Liver Transplantation – Technical Issues and Complications 
 
382 
Wright, HL; Bou-Abboud, CF; Hassanein, T; Block, GD; Demetris, AJ; Starzl, TE; et al. 
Disease recurrence and rejection following liver transplantation for autoimmune 
chronic active liver disease. Transplantation. 1992;53(1):136-9 
Yao, H; Michitaka, K; Tokumoto, Y; Murata, Y; Mashiba, T; Abe, M; et al. Recurrence of 
autoimmune hepatitis after liver transplantation without elevation of alanine 
aminotransferase. World J Gastroenterol. 2007;13(10):1618-21 
Yusoff, IF; House, AK; De Boer, WB; Ferguson, J; Garas, G; Heath, D; et al. Disease 
recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol. 
2002;17(2):203-7 
18 
Bone Disease After Organ  
Transplantation with Special Regard  
of Post Transplantation-Osteoporosis  
After Liver Transplantation 
Daniel Kaemmerer1 and Gabriele Lehmann2 
1Zentralklinik Bad Berka, 
 2Department of Internal Medicine III, University Hospital Jena 
Germany 
1. Introduction 
The frequency of disorders of bone metabolism (osteopenia, osteoporosis) after liver 
transplantation is stated up to 50%. The first three to six months after transplantation are 
linked to the greatest bone density loss. The probability for sustaining a fracture in the post-
transplantation phase is indicated with up to 65%. Most fractures are sustained still within 
the first two years after the transplantation and the most common site is the spine followed 
by costal fractures and femoral neck fractures. Vertebral body fractures and femoral 
fractures in particular cause a dramatic limitation of the patients’ mobility and quality of 
life; in addition, an increase of mortality occurs. 
2. Definition of osteoporosis 
Osteoporosis is a systematic skeletal disease; its course is characterized by a reduction of 
bone mass, a microarchitectural deterioration of bone and thus an increase of bone fragility 
and a susceptibility to fracture. The reference standard of the WHO allows quantifying the 
extent of bone mineral density reduction with DXA method. A T-score – the standard 
deviations of the measurement from the average of 30-year-old healthy Caucasians – 
between -1 and -2.5 indicates osteopenia whereas scores below -2.5 indicate osteoporosis. 
After occurrence of one or several fractures due to low-energy trauma an apparent 
osteoporosis is existent. 
3. Pathophysiology  
Genesis of post-transplantation bone disease after liver transplantation (LT) is multifactorial, 
it comprises among others the pre-existent bone density loss in case of chronic liver disease, 
hypogonadism, deficit of vitamin D and increase of parathyroid hormone, malnutrition, 
nicotine and alcohol abuse. These factors will be potentiated by postoperative immobility, 
the medical substitution of immunosuppressives, glucocorticoids and of heparins.  
 
Liver Transplantation – Technical Issues and Complications 
 
384 
3.1 Hepatic osteodystrophia 
Osteoporosis in combination with chronic liver diseases is based on the imbalance between 
bone formation and degradation. The existing cirrhosis is often a result of alcohol abuse. 
Bone biopsies from patients with ethyl toxic liver cirrhosis show a lower trabecular bone 
volume. At the same time, a clear reduction of osteoblast activity and a lower bone 
formation rate occur. 
Patients with primary biliary cirrhosis (PBC) often show lower vitamin K levels. Vitamin K 
is linked to the synthesis of osteocalcin and has an anti-apoptotic effect on osteoblasts; 
lowered vitamin K levels thus can favour an osteopenia in case of PBC.  
A hyperbilirubinemia is associated with proliferation-inhibiting effects on osteoblasts. 
However, a direct link to lower bone mineral density is not proven. Bone resorptive 
components play an important pathophysiologic role for the hepatic osteodystrophia. In the 
course of the inflammatory process and the fibrosis in the liver, there is an increase of IL-1, 
IL-6 and TNFα. These inflammatory mediators lead to a release of RANKL from osteoblasts. 
Due to the linking to RANK, which is expressed by osteoclasts, there is an increase in the 
genesis of osteoclasts from progenitor cells and in osteoclast activity. This leads to an 
acceleration of bone resorption. A hypogonadism often occurs in patients with chronic liver 
disease. The reasons are the reduction of releasing hormones of the hypothalamus and the 
reduction of gonad function. That leads in women to low levels of oestrogens which induce 
the activation of bone resorption and thus a bone density loss. In men that leads to lowered 
testosterone levels and elevated levels of oestrogens due to the increased aromatase reaction 
with augmented transformation of testosterone to oestrogen. 
The growth factor IGF-1 is produced to a large extent by liver cells; the decreased liver 
function due to chronic liver disease thus causes lowered IGF-1 levels. Glucocorticoids are 
applied within the therapy of autoimmune hepatitis and immediately after liver 
transplantation; they influence the bone metabolism in many ways. 
3.2 Immunosuppressive therapy  
The immunosuppressive therapy is indicated as another important factor for the 
development of post transplantation bone disease after liver transplantation. Especially the 
effect of glucocorticoids on the bone metabolism must be pointed out. Particularly in the 
first six months after liver transplantation, high dosage glucocorticoids are used. Because an 
indirect link between the applied amount of cortisone and the bone mineral density after 
transplantation is assumed, cortisone has a quite important effect on the bone metabolism in 
liver transplanted patients.  
The effects of corticosteroids on the bone metabolism after liver transplantation can be 
divided into two stages. In the first six months after the transplantation, glucocorticoids 
provoke a decoupling between bone formation and resorption due to a decrease of 
osteoblast activity and a simultaneous increase of osteoclast activity. This decoupling is 
marked by a rapid loss of bone mineral density and accumulated occurrence of fractures. In 
the ensuing period and thus the reduction of applied cortisone doses, the bone density loss 
is firstly slowed down and finally, due to the reoccurring of coupling of bone formation and 
resorption, it comes to the recovery of bone metabolism.  
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Steroids have many direct and indirect effects on the bone metabolism. Indirect effects do 
not concern single cell lines, their targets are in the field of endocrinologic processes which 
are linked to the bone metabolism. 
Glucocorticoids conduct to a lowered expression of calcium channels in the intestine and 
thus to lowered calcium absorption and they increase the kidney’s excretion of calcium. The 
consequence is a calcium loss which can lead to a secondary hyperparathyroidism and to a 
higher osteoclast activity.  
Glucocorticoids influence the hypothalamo-hypophyseal axis. They induce an inhibition of 
growth hormone production and of testosterone or oestrogen production. The consequence 
is a higher osteoclast activity and a lower osteoblast activity. 
In combination with the occurrence of a steroid myopathy, the limitation of musculoskeletal 
interaction due to glucocorticoids leads to a further decrease in osteoblast activity. The 
consequence is a higher osteoclast activity and a lower osteoblast activity. 
A direct effect on bone resorption originates from changes in the RANK 
Ligand/osteoprotegerin system. Under treatment with glucocorticoids, an increased 
synthesis of RANK Ligand from osteoblasts can be observed, whereas osteoprotegerin 
synthesis is inhibited. 
RANK Ligand binds to the RANK receptor on osteoclasts and thus increases the osteoclast 
activity. At the same time, the lowered expression of osteoprotegerin facilitates the docking 
of RANK Ligand on RANK because osteoprotegerin is unable to neutralize RANK Ligand.  
M-CSF is essential for osteoclast maturation and its production is increased by the 
glucocorticoids. The inhibition of caspase 3 leads to a decreased apoptosis rate of osteoclasts 
and results in longer survival time of osteoclasts. Moreover, glucocorticoids cause a higher 
production of collagenase 3 so that the synthesis of type I collagen is inhibited. The result of 
liver transplantation is an elevated resorption of bone matrix.  
The effects that have glucocorticoids on osteoblasts are closely linked to the increased 
expression of caspase 3 and the formation of the dickkopf-related protein. Caspase 3 causes 
an increase of the osteoblast apoptosis rate whereas the dickkopf-related protein inhibits the 
genesis of osteoblasts. In course of a glucocorticoid therapy, the apoptosis of osteocytes is 
increased and due to a feedback mechanism, there is an increase of osteoblast activity. The 
glucocorticoids also influence the differentiation of mesenchymal stem cells. Due to 
stimulation of the PPARγ2, the mesenchymal stamm cells differenciate increasingly to 
adipozytes instead of osteoblasts. 
In addition, in course of a glucocorticoid therapy less Runx2 is generated and in 
consequence, the osteoblast genesis is increased additionally. 
Apart from steroids, other immunosuppressive drugs are applied in course of liver 
transplantation. Cyclosporin A, tacrolimus and azathioprine are applied as traditional 
immunosuppressive drugs; but also more recent substances as sirolimus and 
mycophenolate mofetil (MMF) are applied more and more frequently at present. 
Cyclosporin A, tacrolimus and mycophenolate mofetil have very different effects on the 
bone metabolism. Osteopenia occurred more often by appliance of cyclosporine than by 
tacrolimus (whereas mycophenolate mofetil seems not to have negative effects on the bone 
mineral density). 
 
Liver Transplantation – Technical Issues and Complications 
 
384 
3.1 Hepatic osteodystrophia 
Osteoporosis in combination with chronic liver diseases is based on the imbalance between 
bone formation and degradation. The existing cirrhosis is often a result of alcohol abuse. 
Bone biopsies from patients with ethyl toxic liver cirrhosis show a lower trabecular bone 
volume. At the same time, a clear reduction of osteoblast activity and a lower bone 
formation rate occur. 
Patients with primary biliary cirrhosis (PBC) often show lower vitamin K levels. Vitamin K 
is linked to the synthesis of osteocalcin and has an anti-apoptotic effect on osteoblasts; 
lowered vitamin K levels thus can favour an osteopenia in case of PBC.  
A hyperbilirubinemia is associated with proliferation-inhibiting effects on osteoblasts. 
However, a direct link to lower bone mineral density is not proven. Bone resorptive 
components play an important pathophysiologic role for the hepatic osteodystrophia. In the 
course of the inflammatory process and the fibrosis in the liver, there is an increase of IL-1, 
IL-6 and TNFα. These inflammatory mediators lead to a release of RANKL from osteoblasts. 
Due to the linking to RANK, which is expressed by osteoclasts, there is an increase in the 
genesis of osteoclasts from progenitor cells and in osteoclast activity. This leads to an 
acceleration of bone resorption. A hypogonadism often occurs in patients with chronic liver 
disease. The reasons are the reduction of releasing hormones of the hypothalamus and the 
reduction of gonad function. That leads in women to low levels of oestrogens which induce 
the activation of bone resorption and thus a bone density loss. In men that leads to lowered 
testosterone levels and elevated levels of oestrogens due to the increased aromatase reaction 
with augmented transformation of testosterone to oestrogen. 
The growth factor IGF-1 is produced to a large extent by liver cells; the decreased liver 
function due to chronic liver disease thus causes lowered IGF-1 levels. Glucocorticoids are 
applied within the therapy of autoimmune hepatitis and immediately after liver 
transplantation; they influence the bone metabolism in many ways. 
3.2 Immunosuppressive therapy  
The immunosuppressive therapy is indicated as another important factor for the 
development of post transplantation bone disease after liver transplantation. Especially the 
effect of glucocorticoids on the bone metabolism must be pointed out. Particularly in the 
first six months after liver transplantation, high dosage glucocorticoids are used. Because an 
indirect link between the applied amount of cortisone and the bone mineral density after 
transplantation is assumed, cortisone has a quite important effect on the bone metabolism in 
liver transplanted patients.  
The effects of corticosteroids on the bone metabolism after liver transplantation can be 
divided into two stages. In the first six months after the transplantation, glucocorticoids 
provoke a decoupling between bone formation and resorption due to a decrease of 
osteoblast activity and a simultaneous increase of osteoclast activity. This decoupling is 
marked by a rapid loss of bone mineral density and accumulated occurrence of fractures. In 
the ensuing period and thus the reduction of applied cortisone doses, the bone density loss 
is firstly slowed down and finally, due to the reoccurring of coupling of bone formation and 
resorption, it comes to the recovery of bone metabolism.  
Bone Disease After Organ Transplantation with Special Regard  
of Post Transplantation-Osteoporosis After Liver Transplantation 
 
385 
Steroids have many direct and indirect effects on the bone metabolism. Indirect effects do 
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The bone status before transplantation functions as predictive factor for the bone density 
loss after liver transplantation. Low bone density data before transplantation thus increase 
the risk to suffer after the liver transplantation from bone density loss. The extended 
immobilisation in course of the hospitalization and an inadequate low-calcium diet are still 
linked to post-transplantation bone disease.  
3.3 Vitamin D and parathyroid hormone deficiency 
Patients suffering from chronic liver disease often present after liver transplantation a 
lowered vitamin D status and increased parathyroid hormone levels. The parathyroid 
hormone level seems to correlate negatively with the patients’ bone mineral density. 
Disorders of bone metabolism already develop during the progression of chronic liver 
disease and are closely linked with its pathogenesis. Analysis of the lowered bone density 
prevalence are available for cholestatic liver diseases, for viral hepatitis, for alcohol-related 
liver diseases  and for hereditary haemochromatosis.  
By interpretation of bone density loss, it has to be considered that obesity and ascites may 
lead to measurement errors. It is thus indispensable to consider other risk factors 
(hypogonadism, immobility, low body mass index) to evaluate the risk of fracture.  
Because the extent of the bone metabolism disorder at the time of liver transplantation has 
an important effect on the further progression, an evaluation of bone turnover and skeletal 
status prior to transplantation is needed. Among bone mineral density measurement, spinal 
radiographs are used to detect vertebral body deformations. Blood tests include calcium  
and phosphate levels, alkaline phosphatase, parathyroid hormone levels and  
25-hydroxycholecalciferol as indicator of vitamin D status. 
4. Therapy  
To date, no evidence-based recommendations exist for the prophylaxis and therapy of bone 
metabolism disorders by chronic liver diseases and after liver transplantation. The need for 
compensation of the deficiency in 25-hydroxycholecalciferol, for a daily calcium supply of 1-
2 gram  and for a reduction in glucocorticoid dosage with the aim of a glucocorticoid-free 
immunosuppression is consensus. 
To avoid bone mass loss, several antiresorptive agents are applied. But most of these studies 
demonstrate considerable deficiencies and do not comply with the requirements of 
evidence-based medicine.  
The database to the application of biophosphonates after liver transplantation is limited. It 
refers to the application of pamidronate, zoledronate, ibandronate intravenously and 
etidronate and alendronate per os.  
A therapy with calcitonin (40 IU/d by 17 patients) started after liver transplantation 
showed, compared to etidronate (400 mg p.o. for 15 days every 3 months, 23 patients), a 
significant increase in bone mineral density after one year of 6.4 vs. 8.2%. The examined 
bone formation markers osteocalcin and procollagen I propetid have been unaltered high in 
both groups during time of treatment. Because of the absence of a control group a 
conclusion about the efficiency is not possible.  
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Against that, Hay has been unable to prove in a controlled 12 months study effects on bone 
mineral density and fracture incidence in patients with primary sclerosing cholangitis 
(n=37) and with primary biliary cirrhosis (n=26) by application of calcitonin (100 IU daily 
for 6 months after transplantation). 
In a survey with 53 patients was observed that application of alfacalcidol in combination 
with calcium and cyclic etidronate after liver transplantation does not influence bone 
density loss and fracture incidence. Against that, Neuhaus has proven an increase in bone 
mineral density on lumbar spine for all treatment groups by a therapy started six months 
after liver transplantation with calcitriol with or without calcium and sodium fluoride.  
4.1 Alendronate 
The effect of alendronate in comparison with etidronate has been examined in 2003 in 32 
women with PBC. 16 patients each received either 10 mg alendronate/day or etidronate 
400 mg/day for 14 days every 3 months. 26 patients have completed the two-year study. 
There were no changes in lumbar and femoral BMD in the etidronate group. After 2 years, 
lumbar spine BMD increased by 5.8±1.4% in patients on alendronate vs.1.9±1.1% in patients 
on etidronate; femoral neck BMD increased by 3.5±0.9% vs. 0.4±1.3%. No new vertebral 
fractures occurred. 
A prospective uncontrolled study examined in 136 patients awaiting liver transplantation 
the effect of a prophylactic alendronate therapy in case of densitometric detection of 
osteoporosis and osteopenia and in patients whose initial normal BMD decreases after liver 
transplantation. It was possible to prove not only the prohibition of bone density loss post 
transplantationem in patients with initial osteoporosis diagnosis but an increase of bone 
mineral density after two years. 
This result is consistent with the one for a therapy with alendronate, calcium and calcitriol 
by 59 patients post liver transplantation who had in comparison with an historic control 
group without an antiosteoporotic therapy a significant increase in mineral density after 12 
months and no fractures [22].  
In a prospective, controlled, open study with 98 patients with liver cirrhosis for over 24 
months, the same authors have shown a significant increase in mineral bone density on 
lumbar spine, femoral neck and femur total by therapy with 70 mg alendronate weekly in 
the first three months after liver transplantation compared to a control group with patients 
receiving only calcium and calcitriol. Vertebral body fractures emerged in both treatment 
groups (18.8% by calcium and calcitriol and 6.8% by alendronate added). Osteocalcin and 
urinary DPD decreased in the alendronate group according to baseline values by -35.6% and 
-63% and increased in the control group by 30% and 15%.  
4.2 Pamidronate 
A not-randomised study reports on a reduction of fracture risk due to monthly infusion 
with pamidronate three months before and up to nine months after liver transplantation. 
However, only 13 patients have been treated with pamidronate, so a generalization is out of 
question. 
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In a prospective examination with 99 patients, it was not possible to prove after a singular 
infusion of pamidronate pre-liver transplantation any effects on the development of bone 
mineral density and the fracture rate in the first year post liver transplantation. 
A histomorphometric examination describes the bone remodeling at tissue level in paired 
biopsies before and three months after successful liver transplantation in seven patients 
after a single infusion of pamidronate before liver transplantation in comparison to five 
untreated patients. In contrast to the untreated patients, those with pamindronate treatment 
did not show an increased bone formation rate but a significant reduction in the size of 
resorption lacunae. The data suggest a reduction of postoperative high turnover due to 
preoperative pamidronate therapy.  
Recently, the results of a randomised, double-blind, placebo-controlled study with 79 
patients have shown that the application of 90 mg pamidronate (38 pat.) two weeks before 
and three months after liver transplantation leads to a significant increase of lumbar BMD 
after 12 months with an increase in density of 2.9% vs.1%. There was no difference in the 
density loss of femoral neck and the fracture incidence.  
4.3 Zoledronate 
The ability to prevent bone loss after infusion of zoledronate within 7 days of 
transplantation and 1, 3, 6 and 9 months after liver transplantation in 32 patients compared 
to 30 placebo-treated ones could be demonstrated.  
Moreover, in a controlled, prospective, open study after eight infusions each of 4 mg 
zoledronate in the first 12 months after liver transplantation in 47 patients has shown a 
reduction in serological and histological bone turnover markers and a reduction of fracture 
incidence.  
4.4 Ibandronate 
In an open, prospective, placebo-controlled study, 34 patients have been treated for over one 
year with 2 mg ibandronate every 12 weeks intravenously, calcium and cholecalciferol 
starting on the day of liver transplantation. The control group received exclusively calcium 
and cholecalciferol. BMD measurements were carried out after 3, 6, 12 and 24 months. 
Fractures have been detected constantly.  
A further reduction of BMD at all measured sites in the first few months after liver 
transplantation has been shown for all patients. However, after 12 and 24 months 
ibandronate treated patients demonstrated significant higher BMD and lower prevalence of 
fractures. 
5. Conclusion 
In summarising, a great variability can be observed in the available data about the extent of 
the impact on BMD and on the risk of fracture due to application of bisphosphonates or 
other osteotropic agents in course of a liver transplantation. The capability to reduce the 
BMD loss in the early stages after liver transplantation due to bisphosphonates is reported 
consistently. Despite this ambiguity, it has to be recommended to evaluate the bone status 
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before liver transplantation and to start a bisphosphonate therapy in case of osteoporosis. 
For differential therapeutic outcomes, randomised, double-blind, prospective and controlled 
studies are necessary. Informing and guiding patients to a bone-healthier lifestyle and the 
elimination of avoidable risk factors remains unaffected. 
6. References 
Atamaz, F., S. Hepguler, M. Akyildiz, Z. Karasu, and M. Kilic. "Effects of Alendronate on 
Bone Mineral Density and Bone Metabolic Markers in Patients with Liver 
Transplantation." [In eng]. Osteoporosis international: a journal established as result of 
cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA 17, no. 6 (2006): 942-9. 
Bell, H., N. Raknerud, J. A. Falch, and E. Haug. "Inappropriately Low Levels of 
Gonadotrophins in Amenorrhoeic Women with Alcoholic and Non-Alcoholic 
Cirrhosis." [In eng]. Eur J Endocrinol 132, no. 4 (Apr 1995): 444-9. 
Bernstein, C. N., W. D. Leslie, and M. S. Leboff. "Aga Technical Review on Osteoporosis in 
Gastrointestinal Diseases." [In eng]. Gastroenterology 124, no. 3 (Mar 2003): 795-841. 
Beuers, U., K. H. Wiedmann, G. Kleber, and W. E. Fleig. "[Therapy of Autoimmune 
Hepatitis, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Consensus 
of the German Society of Digestive System and Metabolic Diseases]." [In ger]. Z 
Gastroenterol 35, no. 12 (Dec 1997): 1041-9. 
Canalis, E. "Mechanisms of Glucocorticoid-Induced Osteoporosis." [In eng]. Curr Opin 
Rheumatol 15, no. 4 (Jul 2003): 454-7. 
Canalis, E., G. Mazziotti, A. Giustina, and J. P. Bilezikian. "Glucocorticoid-Induced 
Osteoporosis: Pathophysiology and Therapy." [In eng]. Osteoporos Int 18, no. 10 
(Oct 2007): 1319-28. 
Chappard, D., B. Plantard, H. Fraisse, S. Palle, C. Alexandre, and G. Riffat. "Bone Changes in 
Alcoholic Cirrhosis of the Liver. A Histomorphometric Study." [In eng]. Pathol Res 
Pract 184, no. 5 (May 1989): 480-5. 
Cohen, A., P. Sambrook, and E. Shane. "Management of Bone Loss after Organ 
Transplantation." J Bone Miner Res 19, no. 12 (Dec 2004): 1919-32. 
Collier, J. "Bone Disorders in Chronic Liver Disease." [In eng]. Hepatology 46, no. 4 (Oct 2007): 
1271-8. 
Compston, J. E. "Osteoporosis after Liver Transplantation." Liver Transpl 9, no. 4 (Apr 2003): 
321-30. 
Crawford, B. A., C. Kam, J. Pavlovic, K. Byth, D. J. Handelsman, P. W. Angus, and G. W. 
McCaughan. "Zoledronic Acid Prevents Bone Loss after Liver Transplantation: A 
Randomized, Double-Blind, Placebo-Controlled Trial." [In eng]. Annals of internal 
medicine 144, no. 4 (Feb 21 2006): 239-48. 
de Kroon, L., G. Drent, A. P. van den Berg, and E. B. Haagsma. "Current Health Status of 
Patients Who Have Survived for More Than 15 Years after Liver Transplantation." 
[In eng]. Neth J Med 65, no. 7 (Jul-Aug 2007): 252-8. 
Eastell, R., E. R. Dickson, S. F. Hodgson, R. H. Wiesner, M. K. Porayko, H. W. Wahner, S. L. 
Cedel, B. L. Riggs, and R. A. Krom. "Rates of Vertebral Bone Loss before and after 
Liver Transplantation in Women with Primary Biliary Cirrhosis." Hepatology 14, no. 
2 (Aug 1991): 296-300. 
 
Liver Transplantation – Technical Issues and Complications 
 
388 
In a prospective examination with 99 patients, it was not possible to prove after a singular 
infusion of pamidronate pre-liver transplantation any effects on the development of bone 
mineral density and the fracture rate in the first year post liver transplantation. 
A histomorphometric examination describes the bone remodeling at tissue level in paired 
biopsies before and three months after successful liver transplantation in seven patients 
after a single infusion of pamidronate before liver transplantation in comparison to five 
untreated patients. In contrast to the untreated patients, those with pamindronate treatment 
did not show an increased bone formation rate but a significant reduction in the size of 
resorption lacunae. The data suggest a reduction of postoperative high turnover due to 
preoperative pamidronate therapy.  
Recently, the results of a randomised, double-blind, placebo-controlled study with 79 
patients have shown that the application of 90 mg pamidronate (38 pat.) two weeks before 
and three months after liver transplantation leads to a significant increase of lumbar BMD 
after 12 months with an increase in density of 2.9% vs.1%. There was no difference in the 
density loss of femoral neck and the fracture incidence.  
4.3 Zoledronate 
The ability to prevent bone loss after infusion of zoledronate within 7 days of 
transplantation and 1, 3, 6 and 9 months after liver transplantation in 32 patients compared 
to 30 placebo-treated ones could be demonstrated.  
Moreover, in a controlled, prospective, open study after eight infusions each of 4 mg 
zoledronate in the first 12 months after liver transplantation in 47 patients has shown a 
reduction in serological and histological bone turnover markers and a reduction of fracture 
incidence.  
4.4 Ibandronate 
In an open, prospective, placebo-controlled study, 34 patients have been treated for over one 
year with 2 mg ibandronate every 12 weeks intravenously, calcium and cholecalciferol 
starting on the day of liver transplantation. The control group received exclusively calcium 
and cholecalciferol. BMD measurements were carried out after 3, 6, 12 and 24 months. 
Fractures have been detected constantly.  
A further reduction of BMD at all measured sites in the first few months after liver 
transplantation has been shown for all patients. However, after 12 and 24 months 
ibandronate treated patients demonstrated significant higher BMD and lower prevalence of 
fractures. 
5. Conclusion 
In summarising, a great variability can be observed in the available data about the extent of 
the impact on BMD and on the risk of fracture due to application of bisphosphonates or 
other osteotropic agents in course of a liver transplantation. The capability to reduce the 
BMD loss in the early stages after liver transplantation due to bisphosphonates is reported 
consistently. Despite this ambiguity, it has to be recommended to evaluate the bone status 
Bone Disease After Organ Transplantation with Special Regard  
of Post Transplantation-Osteoporosis After Liver Transplantation 
 
389 
before liver transplantation and to start a bisphosphonate therapy in case of osteoporosis. 
For differential therapeutic outcomes, randomised, double-blind, prospective and controlled 
studies are necessary. Informing and guiding patients to a bone-healthier lifestyle and the 
elimination of avoidable risk factors remains unaffected. 
6. References 
Atamaz, F., S. Hepguler, M. Akyildiz, Z. Karasu, and M. Kilic. "Effects of Alendronate on 
Bone Mineral Density and Bone Metabolic Markers in Patients with Liver 
Transplantation." [In eng]. Osteoporosis international: a journal established as result of 
cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA 17, no. 6 (2006): 942-9. 
Bell, H., N. Raknerud, J. A. Falch, and E. Haug. "Inappropriately Low Levels of 
Gonadotrophins in Amenorrhoeic Women with Alcoholic and Non-Alcoholic 
Cirrhosis." [In eng]. Eur J Endocrinol 132, no. 4 (Apr 1995): 444-9. 
Bernstein, C. N., W. D. Leslie, and M. S. Leboff. "Aga Technical Review on Osteoporosis in 
Gastrointestinal Diseases." [In eng]. Gastroenterology 124, no. 3 (Mar 2003): 795-841. 
Beuers, U., K. H. Wiedmann, G. Kleber, and W. E. Fleig. "[Therapy of Autoimmune 
Hepatitis, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Consensus 
of the German Society of Digestive System and Metabolic Diseases]." [In ger]. Z 
Gastroenterol 35, no. 12 (Dec 1997): 1041-9. 
Canalis, E. "Mechanisms of Glucocorticoid-Induced Osteoporosis." [In eng]. Curr Opin 
Rheumatol 15, no. 4 (Jul 2003): 454-7. 
Canalis, E., G. Mazziotti, A. Giustina, and J. P. Bilezikian. "Glucocorticoid-Induced 
Osteoporosis: Pathophysiology and Therapy." [In eng]. Osteoporos Int 18, no. 10 
(Oct 2007): 1319-28. 
Chappard, D., B. Plantard, H. Fraisse, S. Palle, C. Alexandre, and G. Riffat. "Bone Changes in 
Alcoholic Cirrhosis of the Liver. A Histomorphometric Study." [In eng]. Pathol Res 
Pract 184, no. 5 (May 1989): 480-5. 
Cohen, A., P. Sambrook, and E. Shane. "Management of Bone Loss after Organ 
Transplantation." J Bone Miner Res 19, no. 12 (Dec 2004): 1919-32. 
Collier, J. "Bone Disorders in Chronic Liver Disease." [In eng]. Hepatology 46, no. 4 (Oct 2007): 
1271-8. 
Compston, J. E. "Osteoporosis after Liver Transplantation." Liver Transpl 9, no. 4 (Apr 2003): 
321-30. 
Crawford, B. A., C. Kam, J. Pavlovic, K. Byth, D. J. Handelsman, P. W. Angus, and G. W. 
McCaughan. "Zoledronic Acid Prevents Bone Loss after Liver Transplantation: A 
Randomized, Double-Blind, Placebo-Controlled Trial." [In eng]. Annals of internal 
medicine 144, no. 4 (Feb 21 2006): 239-48. 
de Kroon, L., G. Drent, A. P. van den Berg, and E. B. Haagsma. "Current Health Status of 
Patients Who Have Survived for More Than 15 Years after Liver Transplantation." 
[In eng]. Neth J Med 65, no. 7 (Jul-Aug 2007): 252-8. 
Eastell, R., E. R. Dickson, S. F. Hodgson, R. H. Wiesner, M. K. Porayko, H. W. Wahner, S. L. 
Cedel, B. L. Riggs, and R. A. Krom. "Rates of Vertebral Bone Loss before and after 
Liver Transplantation in Women with Primary Biliary Cirrhosis." Hepatology 14, no. 
2 (Aug 1991): 296-300. 
 
Liver Transplantation – Technical Issues and Complications 
 
390 
Encke, J., W. Uhl, W. Stremmel, and P. Sauer. "Immunosuppression and Modulation in Liver 
Transplantation." [In eng]. Nephrol Dial Transplant 19 Suppl 4 (Jul 2004): iv22-5. 
Gallagher, J. C. "Advances in Bone Biology and New Treatments for Bone Loss." [In eng]. 
Maturitas 60, no. 1 (May 20 2008): 65-9. 
Garcia-Valdecasas-Campelo, E., E. Gonzalez-Reimers, F. Santolaria-Fernandez, M. J. De la 
Vega-Prieto, A. Milena-Abril, M. J. Sanchez-Perez, A. Martinez-Riera, and L. 
Gomez-Rodriguez Mde. "Serum Osteoprotegerin and Rankl Levels in Chronic 
Alcoholic Liver Disease." [In eng]. Alcohol Alcohol 41, no. 3 (May-Jun 2006): 261-6. 
Guanabens, N., A. Pares, I. Ros, L. Alvarez, F. Pons, L. Caballeria, A. Monegal, et al. 
"Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in 
Osteopenic Patients with Primary Biliary Cirrhosis." [In eng]. The American journal 
of gastroenterology 98, no. 10 (Oct 2003): 2268-74. 
Guichelaar, M. M., R. Kendall, M. Malinchoc, and J. E. Hay. "Bone Mineral Density before 
and after Olt: Long-Term Follow-up and Predictive Factors." Liver Transpl 12, no. 9 
(Sep 2006): 1390-402. 
Guichelaar, M. M., J. Schmoll, M. Malinchoc, and J. E. Hay. "Fractures and Avascular 
Necrosis before and after Orthotopic Liver Transplantation: Long-Term Follow-up 
and Predictive Factors." [In eng]. Hepatology 46, no. 4 (Oct 2007): 1198-207. 
Hay, J. E., M. Malinchoc, and E. R. Dickson. "A Controlled Trial of Calcitonin Therapy for 
the Prevention of Post-Liver Transplantation Atraumatic Fractures in Patients with 
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis." [In eng]. J Hepatol 
34, no. 2 (Feb 2001): 292-8. 
Hofbauer, L. C., and M. Rauner. "Minireview: Live and Let Die: Molecular Effects of 
Glucocorticoids on Bone Cells." [In eng]. Mol Endocrinol 23, no. 10 (Oct 2009): 1525-
31. 
Hommann, M., D. Kammerer, G. Lehmann, A. Kornberg, B. Kupper, W. Daffner, G. Wolf, 
and U. Settmacher. "Prevention of Early Loss of Bone Mineral Density after Liver 
Transplantation by Prostaglandin E1." [In eng]. Transplant Proc 39, no. 2 (Mar 2007): 
540-3. 
Janes, C. H., E. R. Dickson, R. Okazaki, S. Bonde, A. F. McDonagh, and B. L. Riggs. "Role of 
Hyperbilirubinemia in the Impairment of Osteoblast Proliferation Associated with 
Cholestatic Jaundice." J Clin Invest 95, no. 6 (Jun 1995): 2581-6. 
Jia, D., C. A. O'Brien, S. A. Stewart, S. C. Manolagas, and R. S. Weinstein. "Glucocorticoids 
Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density." 
[In eng]. Endocrinology 147, no. 12 (Dec 2006): 5592-9. 
Kaemmerer, D., G. Lehmann, G. Wolf, U. Settmacher, and M. Hommann. "Treatment of 
Osteoporosis after Liver Transplantation with Ibandronate." [In eng]. Transpl Int 23, 
no. 7 (Jul: 753-9. 
Kanis, J. A. "Assessment of Fracture Risk and Its Application to Screening for 
Postmenopausal Osteoporosis: Synopsis of a Who Report. Who Study Group." [In 
eng]. Osteoporos Int 4, no. 6 (Nov 1994): 368-81. 
Kanis, J. A., N. Burlet, C. Cooper, P. D. Delmas, J. Y. Reginster, F. Borgstrom, and R. Rizzoli. 
"European Guidance for the Diagnosis and Management of Osteoporosis in 
Postmenopausal Women." [In eng]. Osteoporos Int 19, no. 4 (Apr 2008): 399-428. 
Kanis, J. A., P. Delmas, P. Burckhardt, C. Cooper, and D. Torgerson. "Guidelines for 
Diagnosis and Management of Osteoporosis. The European Foundation for 
Osteoporosis and Bone Disease." [In eng]. Osteoporos Int 7, no. 4 (1997): 390-406. 
Bone Disease After Organ Transplantation with Special Regard  
of Post Transplantation-Osteoporosis After Liver Transplantation 
 
391 
Kanis, J. A., and C. C. Gluer. "An Update on the Diagnosis and Assessment of Osteoporosis 
with Densitometry. Committee of Scientific Advisors, International Osteoporosis 
Foundation." [In eng]. Osteoporos Int 11, no. 3 (2000): 192-202. 
Kanis, J. A., E. V. McCloskey, H. Johansson, A. Oden, L. J. Melton, 3rd, and N. Khaltaev. "A 
Reference Standard for the Description of Osteoporosis." [In eng]. Bone 42, no. 3 
(Mar 2008): 467-75. 
Khan, K. M., S. Mulia, R. Kaul, and S. Raatz. "Effect of Nutrition and Body Composition on 
Bone Density after Liver Transplantation." [In eng]. Transplant Proc 39, no. 10 (Dec 
2007): 3292-4. 
Khan, M. A., and S. L. Morgan. "Tone the Bones of Your Chronic Liver Disease Patients." [In 
eng]. Clin Gastroenterol Hepatol 7, no. 8 (Aug 2009): 814-5. 
Kim, H. J., H. Zhao, H. Kitaura, S. Bhattacharyya, J. A. Brewer, L. J. Muglia, F. P. Ross, and S. 
L. Teitelbaum. "Glucocorticoids Suppress Bone Formation Via the Osteoclast." [In 
eng]. J Clin Invest 116, no. 8 (Aug 2006): 2152-60. 
Kowdley, K. V., M. J. Emond, J. A. Sadowski, and M. M. Kaplan. "Plasma Vitamin K1 Level 
Is Decreased in Primary Biliary Cirrhosis." [In eng]. Am J Gastroenterol 92, no. 11 
(Nov 1997): 2059-61. 
Kulak, C. A., V. Z. Borba, J. Kulak Junior, and E. Shane. "Transplantation Osteoporosis." [In 
eng]. Arq Bras Endocrinol Metabol 50, no. 4 (Aug 2006): 783-92. 
Leslie, W. D., C. N. Bernstein, and M. S. Leboff. "Aga Technical Review on Osteoporosis in 
Hepatic Disorders." Gastroenterology 125, no. 3 (Sep 2003): 941-66. 
Maalouf, N. M., and E. Shane. "Osteoporosis after Solid Organ Transplantation." [In eng].  
J Clin Endocrinol Metab 90, no. 4 (Apr 2005): 2456-65. 
Millonig, G., I. W. Graziadei, D. Eichler, K. P. Pfeiffer, G. Finkenstedt, P. Muehllechner, A. 
Koenigsrainer, R. Margreiter, and W. Vogel. "Alendronate in Combination with 
Calcium and Vitamin D Prevents Bone Loss after Orthotopic Liver Transplantation: 
A Prospective Single-Center Study." Liver Transpl 11, no. 8 (Aug 2005): 960-6. 
Monegal, A., N. Guanabens, M. J. Suarez, F. Suarez, G. Clemente, M. Garcia-Gonzalez, M. 
De la Mata, et al. "Pamidronate in the Prevention of Bone Loss after Liver 
Transplantation: A Randomized Controlled Trial." [In eng]. Transpl Int 22, no. 2 
(Feb 2009): 198-206. 
Neuhaus, R., R. Lohmann, K. P. Platz, O. Guckelberger, M. Schon, M. Lang, J. Hierholzer, 
and P. Neuhaus. "Treatment of Osteoporosis after Liver Transplantation." [In eng]. 
Transplant Proc 27, no. 1 (Feb 1995): 1226-7. 
Ninkovic, M., S. Love, B. D. Tom, P. W. Bearcroft, G. J. Alexander, and J. E. Compston. "Lack 
of Effect of Intravenous Pamidronate on Fracture Incidence and Bone Mineral 
Density after Orthotopic Liver Transplantation." J Hepatol 37, no. 1 (Jul 2002): 93-
100. 
Papatheodoridis, G. V., and S. Manolakopoulos. "Easl Clinical Practice Guidelines on the 
Management of Chronic Hepatitis B: The Need for Liver Biopsy." [In eng]. J Hepatol 
51, no. 1 (Jul 2009): 226-7. 
Pares, A., and N. Guanabens. "Treatment of Bone Disorders in Liver Disease." [In eng].  
J Hepatol 45, no. 3 (Sep 2006): 445-53. 
Pignata, S., B. Daniele, M. G. Galati, G. Esposito, P. Vallone, F. Fiore, P. Ricchi, and M. 
Pergola. "Oestradiol and Testosterone Blood Levels in Patients with Viral Cirrhosis 
and Hepatocellular Carcinoma." [In eng]. Eur J Gastroenterol Hepatol 9, no. 3 (Mar 
1997): 283-6. 
 
Liver Transplantation – Technical Issues and Complications 
 
390 
Encke, J., W. Uhl, W. Stremmel, and P. Sauer. "Immunosuppression and Modulation in Liver 
Transplantation." [In eng]. Nephrol Dial Transplant 19 Suppl 4 (Jul 2004): iv22-5. 
Gallagher, J. C. "Advances in Bone Biology and New Treatments for Bone Loss." [In eng]. 
Maturitas 60, no. 1 (May 20 2008): 65-9. 
Garcia-Valdecasas-Campelo, E., E. Gonzalez-Reimers, F. Santolaria-Fernandez, M. J. De la 
Vega-Prieto, A. Milena-Abril, M. J. Sanchez-Perez, A. Martinez-Riera, and L. 
Gomez-Rodriguez Mde. "Serum Osteoprotegerin and Rankl Levels in Chronic 
Alcoholic Liver Disease." [In eng]. Alcohol Alcohol 41, no. 3 (May-Jun 2006): 261-6. 
Guanabens, N., A. Pares, I. Ros, L. Alvarez, F. Pons, L. Caballeria, A. Monegal, et al. 
"Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in 
Osteopenic Patients with Primary Biliary Cirrhosis." [In eng]. The American journal 
of gastroenterology 98, no. 10 (Oct 2003): 2268-74. 
Guichelaar, M. M., R. Kendall, M. Malinchoc, and J. E. Hay. "Bone Mineral Density before 
and after Olt: Long-Term Follow-up and Predictive Factors." Liver Transpl 12, no. 9 
(Sep 2006): 1390-402. 
Guichelaar, M. M., J. Schmoll, M. Malinchoc, and J. E. Hay. "Fractures and Avascular 
Necrosis before and after Orthotopic Liver Transplantation: Long-Term Follow-up 
and Predictive Factors." [In eng]. Hepatology 46, no. 4 (Oct 2007): 1198-207. 
Hay, J. E., M. Malinchoc, and E. R. Dickson. "A Controlled Trial of Calcitonin Therapy for 
the Prevention of Post-Liver Transplantation Atraumatic Fractures in Patients with 
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis." [In eng]. J Hepatol 
34, no. 2 (Feb 2001): 292-8. 
Hofbauer, L. C., and M. Rauner. "Minireview: Live and Let Die: Molecular Effects of 
Glucocorticoids on Bone Cells." [In eng]. Mol Endocrinol 23, no. 10 (Oct 2009): 1525-
31. 
Hommann, M., D. Kammerer, G. Lehmann, A. Kornberg, B. Kupper, W. Daffner, G. Wolf, 
and U. Settmacher. "Prevention of Early Loss of Bone Mineral Density after Liver 
Transplantation by Prostaglandin E1." [In eng]. Transplant Proc 39, no. 2 (Mar 2007): 
540-3. 
Janes, C. H., E. R. Dickson, R. Okazaki, S. Bonde, A. F. McDonagh, and B. L. Riggs. "Role of 
Hyperbilirubinemia in the Impairment of Osteoblast Proliferation Associated with 
Cholestatic Jaundice." J Clin Invest 95, no. 6 (Jun 1995): 2581-6. 
Jia, D., C. A. O'Brien, S. A. Stewart, S. C. Manolagas, and R. S. Weinstein. "Glucocorticoids 
Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density." 
[In eng]. Endocrinology 147, no. 12 (Dec 2006): 5592-9. 
Kaemmerer, D., G. Lehmann, G. Wolf, U. Settmacher, and M. Hommann. "Treatment of 
Osteoporosis after Liver Transplantation with Ibandronate." [In eng]. Transpl Int 23, 
no. 7 (Jul: 753-9. 
Kanis, J. A. "Assessment of Fracture Risk and Its Application to Screening for 
Postmenopausal Osteoporosis: Synopsis of a Who Report. Who Study Group." [In 
eng]. Osteoporos Int 4, no. 6 (Nov 1994): 368-81. 
Kanis, J. A., N. Burlet, C. Cooper, P. D. Delmas, J. Y. Reginster, F. Borgstrom, and R. Rizzoli. 
"European Guidance for the Diagnosis and Management of Osteoporosis in 
Postmenopausal Women." [In eng]. Osteoporos Int 19, no. 4 (Apr 2008): 399-428. 
Kanis, J. A., P. Delmas, P. Burckhardt, C. Cooper, and D. Torgerson. "Guidelines for 
Diagnosis and Management of Osteoporosis. The European Foundation for 
Osteoporosis and Bone Disease." [In eng]. Osteoporos Int 7, no. 4 (1997): 390-406. 
Bone Disease After Organ Transplantation with Special Regard  
of Post Transplantation-Osteoporosis After Liver Transplantation 
 
391 
Kanis, J. A., and C. C. Gluer. "An Update on the Diagnosis and Assessment of Osteoporosis 
with Densitometry. Committee of Scientific Advisors, International Osteoporosis 
Foundation." [In eng]. Osteoporos Int 11, no. 3 (2000): 192-202. 
Kanis, J. A., E. V. McCloskey, H. Johansson, A. Oden, L. J. Melton, 3rd, and N. Khaltaev. "A 
Reference Standard for the Description of Osteoporosis." [In eng]. Bone 42, no. 3 
(Mar 2008): 467-75. 
Khan, K. M., S. Mulia, R. Kaul, and S. Raatz. "Effect of Nutrition and Body Composition on 
Bone Density after Liver Transplantation." [In eng]. Transplant Proc 39, no. 10 (Dec 
2007): 3292-4. 
Khan, M. A., and S. L. Morgan. "Tone the Bones of Your Chronic Liver Disease Patients." [In 
eng]. Clin Gastroenterol Hepatol 7, no. 8 (Aug 2009): 814-5. 
Kim, H. J., H. Zhao, H. Kitaura, S. Bhattacharyya, J. A. Brewer, L. J. Muglia, F. P. Ross, and S. 
L. Teitelbaum. "Glucocorticoids Suppress Bone Formation Via the Osteoclast." [In 
eng]. J Clin Invest 116, no. 8 (Aug 2006): 2152-60. 
Kowdley, K. V., M. J. Emond, J. A. Sadowski, and M. M. Kaplan. "Plasma Vitamin K1 Level 
Is Decreased in Primary Biliary Cirrhosis." [In eng]. Am J Gastroenterol 92, no. 11 
(Nov 1997): 2059-61. 
Kulak, C. A., V. Z. Borba, J. Kulak Junior, and E. Shane. "Transplantation Osteoporosis." [In 
eng]. Arq Bras Endocrinol Metabol 50, no. 4 (Aug 2006): 783-92. 
Leslie, W. D., C. N. Bernstein, and M. S. Leboff. "Aga Technical Review on Osteoporosis in 
Hepatic Disorders." Gastroenterology 125, no. 3 (Sep 2003): 941-66. 
Maalouf, N. M., and E. Shane. "Osteoporosis after Solid Organ Transplantation." [In eng].  
J Clin Endocrinol Metab 90, no. 4 (Apr 2005): 2456-65. 
Millonig, G., I. W. Graziadei, D. Eichler, K. P. Pfeiffer, G. Finkenstedt, P. Muehllechner, A. 
Koenigsrainer, R. Margreiter, and W. Vogel. "Alendronate in Combination with 
Calcium and Vitamin D Prevents Bone Loss after Orthotopic Liver Transplantation: 
A Prospective Single-Center Study." Liver Transpl 11, no. 8 (Aug 2005): 960-6. 
Monegal, A., N. Guanabens, M. J. Suarez, F. Suarez, G. Clemente, M. Garcia-Gonzalez, M. 
De la Mata, et al. "Pamidronate in the Prevention of Bone Loss after Liver 
Transplantation: A Randomized Controlled Trial." [In eng]. Transpl Int 22, no. 2 
(Feb 2009): 198-206. 
Neuhaus, R., R. Lohmann, K. P. Platz, O. Guckelberger, M. Schon, M. Lang, J. Hierholzer, 
and P. Neuhaus. "Treatment of Osteoporosis after Liver Transplantation." [In eng]. 
Transplant Proc 27, no. 1 (Feb 1995): 1226-7. 
Ninkovic, M., S. Love, B. D. Tom, P. W. Bearcroft, G. J. Alexander, and J. E. Compston. "Lack 
of Effect of Intravenous Pamidronate on Fracture Incidence and Bone Mineral 
Density after Orthotopic Liver Transplantation." J Hepatol 37, no. 1 (Jul 2002): 93-
100. 
Papatheodoridis, G. V., and S. Manolakopoulos. "Easl Clinical Practice Guidelines on the 
Management of Chronic Hepatitis B: The Need for Liver Biopsy." [In eng]. J Hepatol 
51, no. 1 (Jul 2009): 226-7. 
Pares, A., and N. Guanabens. "Treatment of Bone Disorders in Liver Disease." [In eng].  
J Hepatol 45, no. 3 (Sep 2006): 445-53. 
Pignata, S., B. Daniele, M. G. Galati, G. Esposito, P. Vallone, F. Fiore, P. Ricchi, and M. 
Pergola. "Oestradiol and Testosterone Blood Levels in Patients with Viral Cirrhosis 
and Hepatocellular Carcinoma." [In eng]. Eur J Gastroenterol Hepatol 9, no. 3 (Mar 
1997): 283-6. 
 
Liver Transplantation – Technical Issues and Complications 
 
392 
Reeves, H. L., R. M. Francis, D. M. Manas, M. Hudson, and C. P. Day. "Intravenous 
Bisphosphonate Prevents Symptomatic Osteoporotic Vertebral Collapse in Patients 
after Liver Transplantation." Liver Transpl Surg 4, no. 5 (Sep 1998): 404-9. 
Riemens, S. C., A. Oostdijk, J. J. van Doormaal, C. J. Thijn, G. Drent, D. A. Piers, E. W. Groen, 
et al. "Bone Loss after Liver Transplantation Is Not Prevented by Cyclical 
Etidronate, Calcium and Alphacalcidol. The Liver Transplant Group, Groningen." 
[In eng]. Osteoporos Int 6, no. 3 (1996): 213-8. 
Sambrook, P. N., P. J. Kelly, A. M. Keogh, P. Macdonald, P. Spratt, J. Freund, and J. A. 
Eisman. "Bone Loss after Heart Transplantation: A Prospective Study." J Heart Lung 
Transplant 13, no. 1 Pt 1 (Jan-Feb 1994): 116-20; discussion 21. 
Sanchez, A. J., and J. Aranda-Michel. "Liver Disease and Osteoporosis." Nutr Clin Pract 21, 
no. 3 (Jun 2006): 273-8. 
Segal, E., Y. Baruch, R. Kramsky, B. Raz, A. Tamir, and S. Ish-Shalom. "Predominant Factors 
Associated with Bone Loss in Liver Transplant Patients - after Prolonged Post-
Transplantation Period." Clin Transplant 17, no. 1 (Feb 2003): 13-9. 
Shah, S. H., T. D. Johnston, H. Jeon, and D. Ranjan. "Effect of Chronic Glucocorticoid 
Therapy and the Gender Difference on Bone Mineral Density in Liver Transplant 
Patients." J Surg Res 135, no. 2 (Oct 2006): 238-41. 
Shi, X. M., H. C. Blair, X. Yang, J. M. McDonald, and X. Cao. "Tandem Repeat of C/Ebp 
Binding Sites Mediates Ppargamma2 Gene Transcription in Glucocorticoid-Induced 
Adipocyte Differentiation." [In eng]. J Cell Biochem 76, no. 3 (Jan 2000): 518-27. 
Smallwood, G. A., J. M. Wickman, E. Martinez, A. C. Stieber, and T. G. Heffron. 
"Osteoporosis Screening in an Outpatient Liver Transplant Clinic: Impact of 
Primary Immunosuppression." Transplant Proc 34, no. 5 (Aug 2002): 1569-70. 
Smith, D. L., N. J. Shire, N. B. Watts, T. Schmitter, G. Szabo, and S. D. Zucker. 
"Hyperbilirubinemia Is Not a Major Contributing Factor to Altered Bone Mineral 
Density in Patients with Chronic Liver Disease." [In eng]. J Clin Densitom 9, no. 1 
(Jan-Mar 2006): 105-13. 
Stein, E., P. Ebeling, and E. Shane. "Post-Transplantation Osteoporosis." [In eng]. Endocrinol 
Metab Clin North Am 36, no. 4 (Dec 2007): 937-63; viii. 
Valero, M. A., C. Loinaz, L. Larrodera, M. Leon, E. Moreno, and F. Hawkins. "Calcitonin and 
Bisphosphonates Treatment in Bone Loss after Liver Transplantation." Calcif Tissue 
Int 57, no. 1 (Jul 1995): 15-9. 
Vedi, S., M. Ninkovic, N. J. Garrahan, G. J. Alexander, and J. E. Compston. "Effects of a 
Single Infusion of Pamidronate Prior to Liver Transplantation: A Bone 
Histomorphometric Study." Transpl Int 15, no. 6 (Jun 2002): 290-5. 
Wang, F. S., J. Y. Ko, D. W. Yeh, H. C. Ke, and H. L. Wu. "Modulation of Dickkopf-1 
Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic 
Differentiation, and Bone Mass Loss." [In eng]. Endocrinology 149, no. 4 (Apr 2008): 
1793-801. 
Willenberg, H. S., and H. Lehnert. "[Basics and Management of Glucocorticoid-Induced 
Osteoporosis]." [In ger]. Internist (Berl) 49, no. 10 (Oct 2008): 1186-90, 92, 94-6. 
Wu, Y. L., J. Ye, S. Zhang, J. Zhong, and R. P. Xi. "Clinical Significance of Serum Igf-I, Igf-Ii 
and Igfbp-3 in Liver Cirrhosis." [In eng]. World J Gastroenterol 10, no. 18 (Sep 15 
2004): 2740-3. 
19 
Betaherpesviruses in  
Adult Liver Transplant Recipients 
Ronaldo Luis Thomasini et al.*  
Department of Clinical Medicine – State University of Campinas 
Laboratory of Clinical Pathology – Hermínio Ometto Foundation – University Center 
Brazil 
1. Introduction 
Liver transplantation similar to other allograft transplants requires the use of 
immunossupressive therapy to avoid graft rejection in the host. Immunossupressive drugs 
can also decrease the capacity of the host immune system to response against infectious 
agents which would not be a problem to immunocompetent persons. Many infectious 
agents such as bacteria, fungus, protozoa and viruses can cause serious complication in the 
post-transplant course (Blair & Shimon, 2005). 
Several different viruses have been studied at long of the time and these studies have 
demonstrated that herpesviruses can be important infectious agents and affects the 
management of the liver transplant recipients (Kotton, 2010).  
Herpesviruses belong to the Herpesviridae family (Hudnall et al., 2008), and have been 
isolated eight different types of these viruses (Table 1). The human herpesvirus simples type 
I and type II (HSV-1 and HSV-2), are usually associated with labial and genital herpes, 
respectively. However, genital herpes can be a consequence of HSV-1 infection and labial 
herpes can also be caused by HSV-2. The human herpesvirus type 3 (varicella-zoster) causes 
chickenpox, especially in children, and re-infection or reactivation, may be the cause of the 
appearance of zoster. Human herpesvirus type 4 (Epstein-Barr virus) is associated with 
infectious mononucleosis syndrome, Burkitt's lymphoma and nasopharyngeal carcinoma. 
The human herpesvirus type 8 is associated with Kaposi's sarcoma, and can cause death in 
immunosuppressed individuals, especially in acquired immunodeficiency syndrome 
(HIV/AIDS). 
Cytomegalovirus (CMV), Human Herpesvirus 6 (HHV-6) and Human Herpesvirus 7 (HHV-7) 
are DNA viruses, members of the betaherpesvirinae subfamily of the Betaherpesviridae (Tong et 
al., 2000). Cytomegalovirus primary infection causes ‘mononucleosis like syndrome’ and 
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HHV-6 and HHV-7 primary infections cause common febrile infectious syndromes in early 
childhood, known as exanthem subitum and roseola.  
Virus Synonymous Sub-family Abbreviation 
Human herpesvirus -1 Herpes simplex-1 α HSV-1/HHV-1 
Human herpesvirus -2 Herpes simplex-2 α HSV-2/HHV-2 
Human herpesvirus -3 Varicella-zoster α VZV/HHV-3 
Human herpesvirus -4 Epstein-Barr γ EBV/HSV-4 
Human herpesvirus -5 Cytomegalovirus β CMV/HHV-5 
Human herpesvirus -6 None β HHV-6 
Human herpesvirus -7 None β HHV-7 
Human herpesvirus -8 None γ KSHV/HHV-8 
Table 1. Complete list of the human herpesviruses 
Betaherpesviruses are ubiquitous and seropositivity for these viruses can differ dependently 
of geographical region and other characteristics of the studied cohort. CMV seroprevalence 
is largely known around the world while HHV-6 and HHV-7 seroprevalences remain less 
studied. However, is estimated that HHV-6 and HHV-7 prevalences would also be high in 
the majority of the places.  
In immunocompetent individuals, beteherpesviral primary infections are usually self-
limiting although some cases of neurological manifestations have been described especially 
regarding HHV-6 in children (Donati et al., 2003; Matsumoto et al., 2011). It is not clear 
whether the neurological manifestation is caused by herpesviral brain tissue invasion or is 
an indirect effect of the infection.  
After primary infection, betaherpesviruses remain latent in the host and could reactivate 
sporadically leading to a transient viremia. Although some syndromes (e.g. chronic fatigue 
syndrome and multiple sclerosis) have been related to herpesviral reactivation, the role of 
the viruses in these syndromes remains unclear (Dewhurst, 2004).   
CMV, HHV-6 and HHV-7 can more frequently reactivate during immunosuppression 
following organ transplantation (Tong et al., 2000). CMV infection is known as major 
infectious complications after transplantation and has been considered an important cause 
of morbidity and mortality in bone marrow transplantation and solid organ transplant 
recipients. Although the role and impact of CMV infection on the post-transplant course is 
well characterized, the other two members of the betaherpesviruses family have been 
acknowledged only recently.  
1.1 Cytomegalovirus 
The diseases caused by CMV occur in underdeveloped and developing countries and the 
prevalence varies from 40 to 60% in the northern hemisphere countries, while in Africa and 
Latin America rates from 80 to 100% were observed (Suassuna et al., 1995; Costa et al., 1999). 
About 80% of the population between the late childhood and early adolescence is already 
infected by CMV (Almeida et al., 2001) and can harbor the virus in several body sites, 
especially in the salivary glands and different types of leukocytes. The peripheral blood 
mononuclear cells appear to be the most important site for CMV latency. 
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There are different variants or genetically distinct strains of CMV and therefore the cross-
protective immunity is considered partial (Ishibashi et al., 2006). The possibilities for the 
occurrence of a new exposure to another CMV strain are numerous. Immunosuppressed 
patients can be submitted to transfusions of blood components containing latent viruses, 
they may receive bone marrow or solid organs containing CMV and, in some cases, 
undergoing dialysis in equipment contaminated with viruses. It is for this reason that has 
been verified that the rate of cytomegalovirus infection/reinfection in these circumstances 
can be high (approximately 50%). 
In healthy adults, CMV is usually asymptomatic. Some individuals may have symptoms 
similar to infectious mononucleosis syndrome, such as lymphadenopathy, fever, rash, 
malaise, arthralgia, hepatomegaly and splenomegaly. In immunocompromised patients, 
CMV may modulate the immune response and leads to more complex clinical presentation 
including death, dependently of the situation involved. 
The American Society of Transplantation classified the presence of CMV in the body into 
two situations (Kotton et al., 2010). 
- CMV infection: evidence of CMV replication regardless of symptoms (different from 
latent CMV). 
- CMV disease: evidence of CMV infection associated with symptoms. CMV disease can 
be further categorized as a viral syndrome with fever, malaise, leukopenia, 
thrombocytopenia or as a tissue invasive disease. 
Whereas liver transplantation, epidemiological studies demonstrate a high incidence of 
CMV active infection. Some facts should be considered, for example, the previously infected 
patients who receive organs from donors with genotypically distinct latent viruses may 
develop a new infection. In addition, the surgical stress generated by the transplantation 
procedure may lead to a reactivation of latent CMV (Kotton et al., 2010). 
CMV disease is considered one of the most common complications after liver transplant 
recipients, with significant morbidity and mortality (Thomasini et al., 2007). Studies in the 
transplant series have shown that higher viral load values correlate with increased risk for 
development of disease. 
Thus, sensitive techniques were described in an attempt to identify earlier individuals who 
have higher risk to development of CMV disease with the goal to reduce the severity of the 
cases. The direct detection of the virus by conventional techniques, urine or saliva, is a 
procedure with limited clinical value. Moreover, it is technically difficult, expensive and 
provides results only after 3-5 weeks. Culture of CMV in blood or urine has low sensitivity. 
Culture of tissue samples is an option for confirmatory diagnosis of invasive diseases, 
especially in the case of gastrointestinal manifestations, in which, generally molecular and 
antigen-based diagnosis are negatives (Kotton et al., 2010). 
Before liver transplantation, serology for CMV can be used in both the organ donor and the 
recipient. A quantitative test for anti-CMV IgG should be used in combination with IgM test 
due to IgG serological tests are more specific than IgM tests. The serology of donor and 
recipient is the key to predicting the risk of infection. In the case of donor and recipient were 
sero-negative during the pre transplant, serology should be repeated at the time of 
transplantation, if there is a significant time between screening and transplantation. 
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However, recent blood transfusion could present false results in the serological tests. In 
patients after liver transplantation, serology has no role in diagnosis of active CMV disease.  
The detection of CMV antigen matrix (pp65) –antigenemia is a technique highly sensitive, 
rapid, quantitative, and with significant clinical correlation (van der Bij et al., 1988; Bonon et 
al., 2005). Patients who present positive results can be submitted to antiviral therapy and the 
response can be monitored periodically to demonstrate the efficacy of the treatment and the 
possibility of drug resistance. The limitation may be the definition of a limit of positivity 
(‘cut-off’) to start the treatment. Moreover, neutropenia can raise difficulties to perform this 
technique due to the fact that antigenemia requires a sufficient number of neutrophils to 
detect CMV viral antigen. CMV causes an abortive replication within neutrophils and leads 
to uptake of antigen in perinuclear area (Kas-Deelen et al., 2001) which can be detected by 
use of monoclonal antibodies against pp65-antigen. Either fluorescent or enzyme labelled 
conjugate can be used to reveal the reaction. However, enzyme labelled conjugate can be 
revealed by coloured reaction and dispenses the use of ultraviolet microscope. Figure 1 
shows positive pp65-antigenemia using enzyme labelled conjugate.  
 
Fig. 1. Nuclei of neutrophils stained in brown indicating positive pp65-atigenemia 
(counterstained with Harris´s hematoxylin). Mouse C10 and C11 monoclonals atibody 
against pp65-matrix CMV antigen and rabitt anti-mouse Ig horseradish peroxidase 
conjugate. The reaction was revealed by hydrogen peroxide and amino-ethyl-carbazole 
(Sampaio et al., 2011) 
Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Sequence 
Based Amplification (NASBA) had gradually been incorporated in the laboratorial diagnosis 
of CMV.  
Whereas the viral biology, it is necessary to demonstrate the presence of viral mRNA, or 
portions of the viral genome expressed only in the replicative phase and not in latency. 
Using PCR the sensitivity of the PCR should be adjusted to detect only significant viral 
loads which could not easily performed. Unfortunately, due to very high sensitivity, 
molecular techniques may reveal positive results without relevant clinical features 
(Thomasini et al., 2007). In patients with higher risk level to progression of the CMV disease, 
such as liver transplantation, positive results in molecular tests can be an indicative to 
introduction to the preemptive therapy despite some of these patients not have clinical 
manifestation.  
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Antigenemia has been considered to be less sensitive than molecular tests although has 
significant clinical correlation. In other hand, the molecular techniques are more sensitive, 
but may be dissociated of clinical manifestation in some situations. Thus, in patients at high 
risk (liver transplant recipients, CMV sero-negative patients who received organs from sero-
positive patients, patients who used mycophenolate or anti-OKT 3) would be benefited 
whether monitored by molecular techniques or by antigenemia relying on lower ‘cut-off’ 
levels. 
More recently, real-time PCR has been considered faster, very sensitive and provides more 
accurate discrimination than other molecular techniques. However, the establishment of the 
‘cut-off’ levels to discriminate between significant viral load and transient viremia is also 
necessary. Moreover, real-time PCR has been considered expensive and requires specialized 
staff. Either plasma or whole blood specimens can provide diagnosis and prognostic 
information regarding CMV disease. Qualitative PCR is an option for surveillance if this 
technique is the unique available option. The diagnosis of tissue invasive CMV disease, 
should be confirmed by immunohistochemistry or in situ DNA hybridization The decision 
regarding which test to use will depend on many factors including available resources, 
technical staff, patient population, volume of samples tested and cost (Kotton et al., 2010). 
The gold standard for treatment of CMV is intravenous ganciclovir, although oral 
valganciclovir is non inferior in nonlife-threatening disease. In patients with life-threatening 
CMV disease and in children, intravenous ganciclovir still the preferred drug, because data 
on the effect of oral treatment are limited. The treatment should be monitored weekly by 
viral loads and treating must continue until one or two consecutive negative samples are 
obtained, but not shorter than 2 weeks (Kotton et al., 2010). 
Universal prophylaxis involves the administration of antiviral drugs to overall of patients or 
a subset of “at risk” patients. Antiviral administration are usually started in the immediate 
or very early post transplant period and continued about 3 to 6 months. Several antivirals 
have been used, including acyclovir, valacyclovir intravenous ganciclovir, oral ganciclovir 
and valganciclovir. In the preemptive therapy, laboratory monitoring detects asymptomatic 
viral replication and antiviral therapy is initiated to prevent the progression to clinical 
disease. One of the major concerns with preemptive therapy is that it may not prevent the 
indirect effects on graft and patient survival. 
Dosing of antiviral medications should be based on standard recommended dosing 
algorithms (for patients with normal creatinine clearance: valganciclovir 900 mg once a day, 
intravenous ganciclovir 5 mg/kg once a day, or oral ganciclovir 1,000 mg three times a day) 
and carefully adjusted for renal function. 
Drug resistance in some CMV strain had been reported and this fact must be considered in 
non-responsive patients. Some studies have focused in genotyping of CMV which could 
indicate strains presenting resistance to conventional treatment. 
1.2 Human Herpesvirus 6 
In Brazil serological prevalence surveys conducted in North and Southeast regions show 
that antibodies against HHV-6 were present in 90% of the individuals among the studied 
population (0-40 years-old) with occurrence of the primary infection in the first years of life 
 
Liver Transplantation – Technical Issues and Complications 
 
396 
However, recent blood transfusion could present false results in the serological tests. In 
patients after liver transplantation, serology has no role in diagnosis of active CMV disease.  
The detection of CMV antigen matrix (pp65) –antigenemia is a technique highly sensitive, 
rapid, quantitative, and with significant clinical correlation (van der Bij et al., 1988; Bonon et 
al., 2005). Patients who present positive results can be submitted to antiviral therapy and the 
response can be monitored periodically to demonstrate the efficacy of the treatment and the 
possibility of drug resistance. The limitation may be the definition of a limit of positivity 
(‘cut-off’) to start the treatment. Moreover, neutropenia can raise difficulties to perform this 
technique due to the fact that antigenemia requires a sufficient number of neutrophils to 
detect CMV viral antigen. CMV causes an abortive replication within neutrophils and leads 
to uptake of antigen in perinuclear area (Kas-Deelen et al., 2001) which can be detected by 
use of monoclonal antibodies against pp65-antigen. Either fluorescent or enzyme labelled 
conjugate can be used to reveal the reaction. However, enzyme labelled conjugate can be 
revealed by coloured reaction and dispenses the use of ultraviolet microscope. Figure 1 
shows positive pp65-antigenemia using enzyme labelled conjugate.  
 
Fig. 1. Nuclei of neutrophils stained in brown indicating positive pp65-atigenemia 
(counterstained with Harris´s hematoxylin). Mouse C10 and C11 monoclonals atibody 
against pp65-matrix CMV antigen and rabitt anti-mouse Ig horseradish peroxidase 
conjugate. The reaction was revealed by hydrogen peroxide and amino-ethyl-carbazole 
(Sampaio et al., 2011) 
Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Sequence 
Based Amplification (NASBA) had gradually been incorporated in the laboratorial diagnosis 
of CMV.  
Whereas the viral biology, it is necessary to demonstrate the presence of viral mRNA, or 
portions of the viral genome expressed only in the replicative phase and not in latency. 
Using PCR the sensitivity of the PCR should be adjusted to detect only significant viral 
loads which could not easily performed. Unfortunately, due to very high sensitivity, 
molecular techniques may reveal positive results without relevant clinical features 
(Thomasini et al., 2007). In patients with higher risk level to progression of the CMV disease, 
such as liver transplantation, positive results in molecular tests can be an indicative to 
introduction to the preemptive therapy despite some of these patients not have clinical 
manifestation.  
 
Betaherpesviruses in Adult Liver Transplant Recipients 
 
397 
Antigenemia has been considered to be less sensitive than molecular tests although has 
significant clinical correlation. In other hand, the molecular techniques are more sensitive, 
but may be dissociated of clinical manifestation in some situations. Thus, in patients at high 
risk (liver transplant recipients, CMV sero-negative patients who received organs from sero-
positive patients, patients who used mycophenolate or anti-OKT 3) would be benefited 
whether monitored by molecular techniques or by antigenemia relying on lower ‘cut-off’ 
levels. 
More recently, real-time PCR has been considered faster, very sensitive and provides more 
accurate discrimination than other molecular techniques. However, the establishment of the 
‘cut-off’ levels to discriminate between significant viral load and transient viremia is also 
necessary. Moreover, real-time PCR has been considered expensive and requires specialized 
staff. Either plasma or whole blood specimens can provide diagnosis and prognostic 
information regarding CMV disease. Qualitative PCR is an option for surveillance if this 
technique is the unique available option. The diagnosis of tissue invasive CMV disease, 
should be confirmed by immunohistochemistry or in situ DNA hybridization The decision 
regarding which test to use will depend on many factors including available resources, 
technical staff, patient population, volume of samples tested and cost (Kotton et al., 2010). 
The gold standard for treatment of CMV is intravenous ganciclovir, although oral 
valganciclovir is non inferior in nonlife-threatening disease. In patients with life-threatening 
CMV disease and in children, intravenous ganciclovir still the preferred drug, because data 
on the effect of oral treatment are limited. The treatment should be monitored weekly by 
viral loads and treating must continue until one or two consecutive negative samples are 
obtained, but not shorter than 2 weeks (Kotton et al., 2010). 
Universal prophylaxis involves the administration of antiviral drugs to overall of patients or 
a subset of “at risk” patients. Antiviral administration are usually started in the immediate 
or very early post transplant period and continued about 3 to 6 months. Several antivirals 
have been used, including acyclovir, valacyclovir intravenous ganciclovir, oral ganciclovir 
and valganciclovir. In the preemptive therapy, laboratory monitoring detects asymptomatic 
viral replication and antiviral therapy is initiated to prevent the progression to clinical 
disease. One of the major concerns with preemptive therapy is that it may not prevent the 
indirect effects on graft and patient survival. 
Dosing of antiviral medications should be based on standard recommended dosing 
algorithms (for patients with normal creatinine clearance: valganciclovir 900 mg once a day, 
intravenous ganciclovir 5 mg/kg once a day, or oral ganciclovir 1,000 mg three times a day) 
and carefully adjusted for renal function. 
Drug resistance in some CMV strain had been reported and this fact must be considered in 
non-responsive patients. Some studies have focused in genotyping of CMV which could 
indicate strains presenting resistance to conventional treatment. 
1.2 Human Herpesvirus 6 
In Brazil serological prevalence surveys conducted in North and Southeast regions show 
that antibodies against HHV-6 were present in 90% of the individuals among the studied 
population (0-40 years-old) with occurrence of the primary infection in the first years of life 
 
Liver Transplantation – Technical Issues and Complications 
 
398 
(Freitas et al., 1997; Linhares et al., 1991). Reactivation of latent HHV-6 is common after  
liver transplantation, possibly induced and facilitated by allograft rejection and 
immunosuppressive therapy (Abdel et al., 2009; Griffths et al., 2000). HHV-6 may affect the 
success of the transplant procedure which is observed clinical findings as: fever, 
neutropenia, nervous central system manifestations or other visceral involvements 
(DesJardin et al., 2001). In addition, HHV-6 viremia is an independently significant 
predictive factor for invasive fungal infections and is associated with late mortality in liver 
transplantation recipients (Rogers et al., 2000). On the other hand, the rejection of the 
transplanted organ can also be enhanced when the patient is co-infected with CMV 
(Lautenschlager et al., 2000; Humar et al., 2000).  
The expression of different cellular antigens can be dramatically altered in HHV-6-infected 
tissues which the viral infection can induce to CD4 up regulation and CD3 down 
modulation in the T cells. HHV-6 can severely affect the physiology of secondary lymphoid 
organs through direct infection of T lymphocytes and modulation of key membrane 
receptors and chemokines (Grivel et al., 2003). Since the effects of HHV-6 in cellular immune 
system it could be affect the response against other infectious agents or facilitate the 
mechanism of graft rejection in the host. 
The diagnosis of reactivation or new infection by HHV-6 is not made easily. Serological 
techniques are available but the contribution of a positive result is limited by the high 
prevalence of infection in adults, as mentioned above (Freitas et al., 1997; Linhares et al., 
1991). The report of specific HHV-6 IgM in sera or a four-fold rise in IgG antibodies can be 
used as diagnostic criteria, but is not as sensitive as desired. Moreover, the interpretation of 
serological results is complicated by the fact that both primary and secondary infections 
with other herpes viruses may be associated with a concurrent antibody response to HHV-6 
(Osman et al., 1997). In addition, the presence of residual IgM against HHV-6 in the 
bloodstream can complicate the interpretation of the serological tests (Peigo et al., 2009).  
Antigenemia techniques to detect HHV-6 in blood have been described in the literature 
(Sampaio et al., 2011; Lautenschlager et al., 2002). Similar to pp65-atigenemia used for CMV, 
monoclonals antibodies against specific HHV-6 protein could be use with the purpose to 
detect only active infections. The antigenemia could be an alternative to molecular 
techniques because is a quantitative method and requires relatively few apparatus. HHV-6 
antigenemia, different from CMV, requires the use of purified lymphocytes to detect 
antigen. Positivity in peripheral monocytes occurs occasionally although lymphocytes are 
more frequently positive.  
Although the use of HHV-6 antigenemia could be promissory, the technique still needs 
improvements and establishment of ‘cut-off’ values to clinical use. Moreover, the sensitivity 
and specificity to detect HHV-6 active infection have been not completely studied.  
The techniques based on nuclei acid amplification are also available for the diagnosis of 
HHV-6 (Secchiero et al., 1995). However, the results obtained are controversial, because it 
depends on the PCR’s method employed (Shibata et al., 1992; Demmler et al., 1998).  
Since HHV-6 disease can be established, infection can be treated with intravenous 
ganciclovir, foscarnet, or cidofovir and this should be complemented by a reduction in 
immunosuppression (Razonable & Lautenschlager, 2010). The efficacy of acyclovir against 
HHV-6 infection seems to be lower than others. Moreover, foscarnet and cidofovir could be 
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more effective than ganciclovir against HHV-6 infection of astroglioma cells. Although 
ganciclovir and cidofovir are therapeutic options, on the basis of in vitro data and limited 
clinical experience reported in the literature, foscarnet is probably the preferred treatment 
for HHV-6 associated encephalitis.  
Patients could be treated with intravenous ganciclovir (2.5 mg/kg daily) for 3-6 weeks, 
cidofovir 5mg/kg once weekly for 2 consecutive weeks or intravenous foscarnet (40 mg/kg 
every 12 hours) for 3-4 weeks (Vinnard et al., 2009). However, in patients with renal failure, 
dose must be adjusted to avoid toxicity in the patients. In addition, viral monitoring is 
necessary (by PCR or antigenemia) to avoid interruption of the treatment prior 
disappearance of viremia.  
Similar to CMV, some strains of HHV-6 can present drug resistance and the strategies 
described above could also not have efficacy.  
1.3 Human Herpesvirus 7 
HHV-7 has been isolated from T-CD4+ cells purified from peripheral blood mononuclear 
cells of a healthy individual by Frenkel et al. (1990). HHV-7 like other betaherpesviruses 
remains latent or at low level of viral replication after primary infection or can reactivate 
during immunosuppressed states (Ihira et al., 2001). HHV-7 shares many properties of 
HHV-6, suggesting that the factors that control their reactivation or increased viral 
replication in immunosuppressed patients may be similar (Mendez et al., 2001). 
HHV-7 infects most specifically, T-CD4+ cells, which could result in cytotoxicity and 
mmunomodulatory activities (Secchiero et al., 2001). It has also been demonstrated that 
the down modulation of human leukocyte antigen (HLA) and beta-2-microglobulin 
expression by HHV-7 is linked to viral replication and is not merely the consequence of 
the interaction of virions with the cell surface. Infected cells can therefore efficiently 
escape from host immune pressure that might explain the persistence of HHV-7–positive 
cells in several types of tumors and chronic infectious diseases (Mirandola, 2006). 
Although HHV-7 has restricted tropism to CD4+ cells, it should be noted that HHV-7–
infected T-CD4+ cells kill uninfected T-CD8+ cells in vitro. Moreover, HLA class I and beta-
2-microglobulin are also down modulated in the T-CD8+ cells on the presence of HHV-7–
infected leukocytes in vitro (Secchiero et al., 2001). Similar to HHV-6, HHV-7 infection 
could modulate the host immune system enhancing the risk to graft rejection and other 
type of infections.   
Although in liver transplant recipients HHV-6 has been related to clinical consequences 
(Feldstein et al., 2003), the specific clinical syndrome spectrum of HHV-7 remains not 
clear (Ihira et al., 2001; Mendez et al., 2001). Several methods and different biological 
materials have been proposed to detect HHV-7 infection. Serological assays presents the 
same problems reported to HHV-6 and interpretation of these test are frequently difficult. 
Nested polymerase chain reaction (nested-PCR) using DNA extracted from either serum 
or plasma could detect only HHV-7 active infection (Ihira et al., 2001; Feldstein et al., 
2003).  
In our center, we found that nested-PCR carried out in DNA extracted from sera did not 
detect latent HHV-7 in a healthy cohort (Thomasini et al., 2008). In addition, positive IgM 
anti-HHV-7 and/or significant increase in IgG anti-HHV-7 titers were correlated with 
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(Freitas et al., 1997; Linhares et al., 1991). Reactivation of latent HHV-6 is common after  
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more effective than ganciclovir against HHV-6 infection of astroglioma cells. Although 
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type of infections.   
Although in liver transplant recipients HHV-6 has been related to clinical consequences 
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clear (Ihira et al., 2001; Mendez et al., 2001). Several methods and different biological 
materials have been proposed to detect HHV-7 infection. Serological assays presents the 
same problems reported to HHV-6 and interpretation of these test are frequently difficult. 
Nested polymerase chain reaction (nested-PCR) using DNA extracted from either serum 
or plasma could detect only HHV-7 active infection (Ihira et al., 2001; Feldstein et al., 
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In our center, we found that nested-PCR carried out in DNA extracted from sera did not 
detect latent HHV-7 in a healthy cohort (Thomasini et al., 2008). In addition, positive IgM 
anti-HHV-7 and/or significant increase in IgG anti-HHV-7 titers were correlated with 
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positive nested-PCR for HHV-7 in adult liver transplant recipients (Peigo et al., 2009). 
However, many technical and clinical aspects remain to be clarified regarding these tests.  
Antigenemia can be performed to detected HHV-7 antigen in peripheral lymphocytes using 
similar technique describe to HHV-6 (Sampaio et al., 2011; Lautenschlager et al., 2002). 
HHV-7 antigen can be detected mainly in lymphocytes probably in T-CD4+ lymphocytes.  
The majority of HHV-7 infections do not require antiviral medication, but the severe 
complications could be treated with ganciclovir and its derivates or foscarnet and cidofovir 
(Ongrádi et al., 2010). 
There a few reports in the literature regarding treatment against HHV-7 infection probably 
due to fact that HHV-7 commonly causes not remarkable clinical outcomes.  However, 
studies have demonstrated that treatment based on ganclclovir or valganciclovir following 
the same protocol used to CMV can be effective against concomitant HHV-6 and HHV-7 
infection after lung and heart-lung transplantation (Lehto et al., 2007). Thus, the same 
protocol could hypothetically be used against HHV-7 in liver transplant patients. 
2. Experience of the State University of Campinas regarding 
betaherpesviruses in liver transplantation  
The aim of this study was to detect and to monitor CMV, HHV-6 and HHV-7 active 
infections in adult liver transplant recipients using nested-PCR and to describe the clinical 
aspects related to betaherpesviruses in these patients. 
2.1 Materials and methods 
Twenty-nine adult liver transplant patients (20 man and 9 woman), median age of 47 years 
(range 18 to 66), transplanted at the Liver Transplant Unit (University Hospital, State 
University of Campinas – Sao Paulo – Brazil) were included in this study.  
The basic immunosuppressive therapy consisted of cyclosporine (0.4 mg/kg/d), 
methylpredinisolone (1.0 g first month, 20 mg at 30 days decreasing to 5 mg/mo to 90 days), 
azathioprine (100mg/d). Mycophenolate mofetil (100 mg/d) and tracolimus (FK) (0.1 
mg/kg/d) were prescribed based on selected patient’s characteristics and specific protocol 
studies. Acyclovir (5 mg/kg per day for 2 months) was employed as antiviral prophylaxis to 
Herpes simplex.  
No routine CMV prophylaxis was used and ganciclovir (5mg/kg/d) for 6 weeks was 
administrated as treatment for symptomatic CMV patients. High doses of 
methylpredinisolone were used as antirejection treatment. Patient’s characteristics related to 
age, sex and underlying liver disease were summarized in Table 2. 
Peripheral blood was obtained from patients at the time of transplantation, as well as 
weekly for the first month and once a month to 180 days. Ethylenediamine tetraacetic acid 
(EDTA)-treated blood samples were used to DNA extraction from peripheral blood 
leukocytes (PBL) and serum (from without anticoagulant tube) of each blood sample was 
also separated by centrifugation. The obtained sera were then frozen (-20°C) until testing. 
The protocol was designed on accordance with the requirements for research involving 
human subjects in Brazil, and it was approved by the Institutional Ethics Committee. 
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2.1.1 CMV serological assay 
Anti-CMV IgG and IgM were tested in sera of the donors and patients before 
transplantation. Assays were carried out using ELISA-Commercial Kits (Sorin Diagnostics, 




Median age (years) 47 (range: 18-66) 
Sex (male/female) 20/9 
 
Diagnosis of underlying liver disease 
 
Hepatitis C 15 
Alcoholic liver disease 3 
Hepatitis B 2 
Hepatitis C and alcohol 2 
Cryptogenic cirrhosis 2 
Hepatitis B and alcohol 1 
Primary biliary cirrhosis 1 
Autoimmune hepatitis 1 
Primary sclerosing cholangitis 1 
Hemochromatosis and alcohol 1 
Table 2. Demographic characteristics of the patients studied 
2.1.2 HHV-6 and -7 serological assays 
IgG and IgM antibodies against HHV-6 and HHV-7 were tested in sera of the donors and 
patients before transplantation by an indirect immunofluorescent assay. The standard HHV-
6 and HHV-7 antigens were prepared from viral culture of each virus (cord blood 
mononuclear cells infected by only one virus) and absence of cross-infectivity was 
confirmed by immunological or molecular methods. Infected cells were coated onto wells of 
immunofluorescence slides, air dried, and then fixed (cold methanol-acetone). The wells 
were covered with serial dilutions of patients’ sera (starting from a 1:10 dilution) and 
incubated for 1 h at 37°C. For IgM detection, a single dilution of 1:20 of each sample was 
carried out. Slides were washed 3 times with PBS, wells were covered with anti-human IgG 
or IgM fluorescent conjugate diluted PBS/Evans’s blue (Biomerieux Inc., Lyon, France), and 
then incubated for 1 h at 37°C.The slides were washed 3 times with PBS, buffered glycerin 
mounted, and immediately observed under an ultraviolet (UV) photo microscope (Leica 
DM2000,Wetzlar, Germany). All the samples were pre-treated with RFAb-sorbant (Hoescht-
Behring, Kanata, Ontario, Canada) to avoid interference of IgG and rheumatoid factor in the 
IgM immunofuorescent assay (Ihira et al., 2001; Ablashi et al., 1998). The antibody titer was 
defined as the reciprocal of the serum dilution showing specific fluorescence.  
2.1.3 Peripheral blood leukocyte (PBL) DNA extraction 
Briefly, PBL were lysed after separation following protocol previously described (Bonon et 
al., 2005). PBL DNA was precipitated with cold ethanol and then eluted in 50µL of TE-buffer 
(10mM Tris, 1mM EDTA) and stored frozen (-20°C) until PCR analysis. 
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positive nested-PCR for HHV-7 in adult liver transplant recipients (Peigo et al., 2009). 
However, many technical and clinical aspects remain to be clarified regarding these tests.  
Antigenemia can be performed to detected HHV-7 antigen in peripheral lymphocytes using 
similar technique describe to HHV-6 (Sampaio et al., 2011; Lautenschlager et al., 2002). 
HHV-7 antigen can be detected mainly in lymphocytes probably in T-CD4+ lymphocytes.  
The majority of HHV-7 infections do not require antiviral medication, but the severe 
complications could be treated with ganciclovir and its derivates or foscarnet and cidofovir 
(Ongrádi et al., 2010). 
There a few reports in the literature regarding treatment against HHV-7 infection probably 
due to fact that HHV-7 commonly causes not remarkable clinical outcomes.  However, 
studies have demonstrated that treatment based on ganclclovir or valganciclovir following 
the same protocol used to CMV can be effective against concomitant HHV-6 and HHV-7 
infection after lung and heart-lung transplantation (Lehto et al., 2007). Thus, the same 
protocol could hypothetically be used against HHV-7 in liver transplant patients. 
2. Experience of the State University of Campinas regarding 
betaherpesviruses in liver transplantation  
The aim of this study was to detect and to monitor CMV, HHV-6 and HHV-7 active 
infections in adult liver transplant recipients using nested-PCR and to describe the clinical 
aspects related to betaherpesviruses in these patients. 
2.1 Materials and methods 
Twenty-nine adult liver transplant patients (20 man and 9 woman), median age of 47 years 
(range 18 to 66), transplanted at the Liver Transplant Unit (University Hospital, State 
University of Campinas – Sao Paulo – Brazil) were included in this study.  
The basic immunosuppressive therapy consisted of cyclosporine (0.4 mg/kg/d), 
methylpredinisolone (1.0 g first month, 20 mg at 30 days decreasing to 5 mg/mo to 90 days), 
azathioprine (100mg/d). Mycophenolate mofetil (100 mg/d) and tracolimus (FK) (0.1 
mg/kg/d) were prescribed based on selected patient’s characteristics and specific protocol 
studies. Acyclovir (5 mg/kg per day for 2 months) was employed as antiviral prophylaxis to 
Herpes simplex.  
No routine CMV prophylaxis was used and ganciclovir (5mg/kg/d) for 6 weeks was 
administrated as treatment for symptomatic CMV patients. High doses of 
methylpredinisolone were used as antirejection treatment. Patient’s characteristics related to 
age, sex and underlying liver disease were summarized in Table 2. 
Peripheral blood was obtained from patients at the time of transplantation, as well as 
weekly for the first month and once a month to 180 days. Ethylenediamine tetraacetic acid 
(EDTA)-treated blood samples were used to DNA extraction from peripheral blood 
leukocytes (PBL) and serum (from without anticoagulant tube) of each blood sample was 
also separated by centrifugation. The obtained sera were then frozen (-20°C) until testing. 
The protocol was designed on accordance with the requirements for research involving 
human subjects in Brazil, and it was approved by the Institutional Ethics Committee. 
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2.1.1 CMV serological assay 
Anti-CMV IgG and IgM were tested in sera of the donors and patients before 
transplantation. Assays were carried out using ELISA-Commercial Kits (Sorin Diagnostics, 




Median age (years) 47 (range: 18-66) 
Sex (male/female) 20/9 
 
Diagnosis of underlying liver disease 
 
Hepatitis C 15 
Alcoholic liver disease 3 
Hepatitis B 2 
Hepatitis C and alcohol 2 
Cryptogenic cirrhosis 2 
Hepatitis B and alcohol 1 
Primary biliary cirrhosis 1 
Autoimmune hepatitis 1 
Primary sclerosing cholangitis 1 
Hemochromatosis and alcohol 1 
Table 2. Demographic characteristics of the patients studied 
2.1.2 HHV-6 and -7 serological assays 
IgG and IgM antibodies against HHV-6 and HHV-7 were tested in sera of the donors and 
patients before transplantation by an indirect immunofluorescent assay. The standard HHV-
6 and HHV-7 antigens were prepared from viral culture of each virus (cord blood 
mononuclear cells infected by only one virus) and absence of cross-infectivity was 
confirmed by immunological or molecular methods. Infected cells were coated onto wells of 
immunofluorescence slides, air dried, and then fixed (cold methanol-acetone). The wells 
were covered with serial dilutions of patients’ sera (starting from a 1:10 dilution) and 
incubated for 1 h at 37°C. For IgM detection, a single dilution of 1:20 of each sample was 
carried out. Slides were washed 3 times with PBS, wells were covered with anti-human IgG 
or IgM fluorescent conjugate diluted PBS/Evans’s blue (Biomerieux Inc., Lyon, France), and 
then incubated for 1 h at 37°C.The slides were washed 3 times with PBS, buffered glycerin 
mounted, and immediately observed under an ultraviolet (UV) photo microscope (Leica 
DM2000,Wetzlar, Germany). All the samples were pre-treated with RFAb-sorbant (Hoescht-
Behring, Kanata, Ontario, Canada) to avoid interference of IgG and rheumatoid factor in the 
IgM immunofuorescent assay (Ihira et al., 2001; Ablashi et al., 1998). The antibody titer was 
defined as the reciprocal of the serum dilution showing specific fluorescence.  
2.1.3 Peripheral blood leukocyte (PBL) DNA extraction 
Briefly, PBL were lysed after separation following protocol previously described (Bonon et 
al., 2005). PBL DNA was precipitated with cold ethanol and then eluted in 50µL of TE-buffer 
(10mM Tris, 1mM EDTA) and stored frozen (-20°C) until PCR analysis. 
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2.1.4 Serum DNA extraction 
Briefly, DNA was extracted from 200 µL of serum using a phenol-chloroform protocol after 
incubation overnight in lysis buffer (10mM Tris-HCl pH 8.0, 10 mM EDTA, 10 mM NaCl, 
0.2% dodecyl sodium sulfate and 100 µg proteinase K) at 56ºC followed by DNA 
precipitation with cold ethanol. The resulting DNA pellet was eluted in 50µL of TE-buffer 
(10mM Tris, 1mM EDTA) and stored frozen (-20°C) until PCR analysis. 
2.1.5 CMV nested-PCR 
Five microliters of DNA extracted from PBL, as described above, were used in the nested-
PCR using reaction mixture containing specific primers to CMV following protocol 
previously described (Shibata et al.,1992; Demmler et al.,1998).  
2.1.6 HHV-6 and HHV-7 nested-PCR 
Nested-PCR was carried out for each virus using 5 μL of DNA, extracted from serum as 
described above. Primers and protocol used to HHV-6 nested-PCR were previously 
described by Secchiero et al. (1995). Primers and protocol used to HHV-7 nested-PCR were 
previously described by Pozo et al. (1999) with some modifications (originally a multiplex-
PCR).  
Amplifications were carried out on a Peltier Thermal Cycler - MJ Research (Watertown–MA-
USA).This The nested-PCR product was analyzed under UV light after electrophoresis in 2% 
agarose (Gibco-BRL) stained with ethidium bromide. All nested-PCR was carried out in 
duplicate using a second fresh aliquot. Polymerase chain reaction for beta-globin gene was 
carried out to detect contamination of serum with leukocytes and false negative results from 
incorrect DNA extraction from PBL. 
Positive and negative controls for each virus were included systematically. Genomes 
amplifications using the referred primers results in DNA fragments containing 159, 258 and 
122 base pairs of CMV, HHV-6 and HHV-7, respectively. Some nested-PCR products of each 
virus were sequenced analyzed and compared to the GenBank database using Software 
ChromasPro® (Thecnelysium Pty Ltd).  
2.1.7 Definitions 
CMV active infection was defined based on detection of CMV DNA in PBL by nested-PCR. 
HHV-6 and HHV-7 active infections were also defined based on detection of virus DNA in 
serum by nested-PCR. Transient viremia was defined when virus DNA was detectable only 
once or in no-consecutive samples.  
Latent infection, reinfection and reactivation were defined base on criteria proposed by 
Ljungman et al., 2002. Co-infections were defined when two or more viruses were detected 
in the same sample.  
Symptomatic CMV infection (‘CMV disease’) was divided into two situations: Tissue-
invasive disease and “CMV viral syndrome” (Kotton et al., 2010).  
Briefly, Tissue-invasive disease was defined based on symptoms consistent with CMV 
disease including fever, malaise, myalgia, anorexia and leukopenia accompanied of CMV 
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active infection and when biopsy proven CMV identification (Taber et al. 2004, Ljungman et 
al., 2002). “CMV hepatitis” and “CMV gastrointestinal disease” was diagnosed based on 
criteria proposed by Ljungman et al. (2002). “CMV viral syndrome” was defined based on 
unexplained fever (>37.5ºC) for at least 3 days, in combination with at least one of the 
following features: arthralgia, leukopenia (<3 x109/l), thrombocytopenia (<150x109/l), liver 
enzymes elevation (ALT>50 U/l). Asymptomatic CMV infection was defined when CMV 
active infection occurs without signs, symptoms, or laboratory abnormalities described 
above. 
Clinical symptoms such as fever, encephalitis, interstitial pneumonitis, hepatitis and 
laboratorial findings as leukopenia and thrombocytopenia were taken into account and 
CMV, HHV-6 and HHV-7 active infections were compared to these episodes. The 
laboratorial monitoring of graft function was based on elevation of serum alanine 
aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirrubins. 
Rejection episodes were documented based on histopathological analysis of the liver 
biopsies (Banffs schema). 
2.1.8 Statistical analysis 
The comparison of categorical variables was performed using Fisher’s exact test or chi-
squired test and Mann-Withney-U test for continuous variables. A p<0.05 was considered 
statistically significant. 
3. Results 
All patients and donors had positives anti-CMV, anti-HHV-6 and anti-HHV-7 IgG before 
transplantation (D+/R+), indicating that all of them patients were virus 
reactivations/reinfections. CMV DNA was detected in 20 (68.9%) of 29 patients, median 
time to first CMV detection was of 50 days (range 7 to181). HHV-6 DNA was detected in 13 
(44.8%) of 29 patients, median time to first HHV-6 detection was of 27 days (range 0 to 143). 
HHV-7 DNA was detected in 14 (48.2%) of 29 patients, median time to first HHV-7 detection 
was of 19 days (range 0 to 170). Six patients had HHV-7 DNA detectable already at the time 
of transplantation contrasting with two cases of HHV-6 and none of CMV. IgM against 
HHV-7 was detected in 100% of these patients who had detectable DNA already at the time 
of transplantation (P=0.002). Neither patient nor donor had positive IgM against CMV and 
HHV-6.  
The three viruses together were found in 6/29 (20.7%) patients but in none sample at the 
same time. Co-infections by CMV/HHV-6, CMV/HHV-7 and HHV6/HHV-7 occurred in 5 
(17.2%), 2 (6.9%) and 2 (6.9%) of the patients, respectively. Kinetic of the detection for three 
viruses was shown in Figure 2. 
The statistical analysis showed that the detection of CMV, HHV-6 and HHV-7 was 
independent of one another (P>0.05). Diagrams illustrating positive nested-PCR for any 
combination of betaherpesviruses were shown in Figure 3. 
Among the 20 patients with detectable CMV DNA, 10 (34.4% of total of the patients enrolled 
in this study) developed symptomatic CMV infections including “CMV viral syndrome” 
(n=5), CMV hepatitis (n=4) and CMV gastrointestinal disease (n=1). The symptoms have 
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Five microliters of DNA extracted from PBL, as described above, were used in the nested-
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2.1.6 HHV-6 and HHV-7 nested-PCR 
Nested-PCR was carried out for each virus using 5 μL of DNA, extracted from serum as 
described above. Primers and protocol used to HHV-6 nested-PCR were previously 
described by Secchiero et al. (1995). Primers and protocol used to HHV-7 nested-PCR were 
previously described by Pozo et al. (1999) with some modifications (originally a multiplex-
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Amplifications were carried out on a Peltier Thermal Cycler - MJ Research (Watertown–MA-
USA).This The nested-PCR product was analyzed under UV light after electrophoresis in 2% 
agarose (Gibco-BRL) stained with ethidium bromide. All nested-PCR was carried out in 
duplicate using a second fresh aliquot. Polymerase chain reaction for beta-globin gene was 
carried out to detect contamination of serum with leukocytes and false negative results from 
incorrect DNA extraction from PBL. 
Positive and negative controls for each virus were included systematically. Genomes 
amplifications using the referred primers results in DNA fragments containing 159, 258 and 
122 base pairs of CMV, HHV-6 and HHV-7, respectively. Some nested-PCR products of each 
virus were sequenced analyzed and compared to the GenBank database using Software 
ChromasPro® (Thecnelysium Pty Ltd).  
2.1.7 Definitions 
CMV active infection was defined based on detection of CMV DNA in PBL by nested-PCR. 
HHV-6 and HHV-7 active infections were also defined based on detection of virus DNA in 
serum by nested-PCR. Transient viremia was defined when virus DNA was detectable only 
once or in no-consecutive samples.  
Latent infection, reinfection and reactivation were defined base on criteria proposed by 
Ljungman et al., 2002. Co-infections were defined when two or more viruses were detected 
in the same sample.  
Symptomatic CMV infection (‘CMV disease’) was divided into two situations: Tissue-
invasive disease and “CMV viral syndrome” (Kotton et al., 2010).  
Briefly, Tissue-invasive disease was defined based on symptoms consistent with CMV 
disease including fever, malaise, myalgia, anorexia and leukopenia accompanied of CMV 
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active infection and when biopsy proven CMV identification (Taber et al. 2004, Ljungman et 
al., 2002). “CMV hepatitis” and “CMV gastrointestinal disease” was diagnosed based on 
criteria proposed by Ljungman et al. (2002). “CMV viral syndrome” was defined based on 
unexplained fever (>37.5ºC) for at least 3 days, in combination with at least one of the 
following features: arthralgia, leukopenia (<3 x109/l), thrombocytopenia (<150x109/l), liver 
enzymes elevation (ALT>50 U/l). Asymptomatic CMV infection was defined when CMV 
active infection occurs without signs, symptoms, or laboratory abnormalities described 
above. 
Clinical symptoms such as fever, encephalitis, interstitial pneumonitis, hepatitis and 
laboratorial findings as leukopenia and thrombocytopenia were taken into account and 
CMV, HHV-6 and HHV-7 active infections were compared to these episodes. The 
laboratorial monitoring of graft function was based on elevation of serum alanine 
aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirrubins. 
Rejection episodes were documented based on histopathological analysis of the liver 
biopsies (Banffs schema). 
2.1.8 Statistical analysis 
The comparison of categorical variables was performed using Fisher’s exact test or chi-
squired test and Mann-Withney-U test for continuous variables. A p<0.05 was considered 
statistically significant. 
3. Results 
All patients and donors had positives anti-CMV, anti-HHV-6 and anti-HHV-7 IgG before 
transplantation (D+/R+), indicating that all of them patients were virus 
reactivations/reinfections. CMV DNA was detected in 20 (68.9%) of 29 patients, median 
time to first CMV detection was of 50 days (range 7 to181). HHV-6 DNA was detected in 13 
(44.8%) of 29 patients, median time to first HHV-6 detection was of 27 days (range 0 to 143). 
HHV-7 DNA was detected in 14 (48.2%) of 29 patients, median time to first HHV-7 detection 
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The statistical analysis showed that the detection of CMV, HHV-6 and HHV-7 was 
independent of one another (P>0.05). Diagrams illustrating positive nested-PCR for any 
combination of betaherpesviruses were shown in Figure 3. 
Among the 20 patients with detectable CMV DNA, 10 (34.4% of total of the patients enrolled 
in this study) developed symptomatic CMV infections including “CMV viral syndrome” 
(n=5), CMV hepatitis (n=4) and CMV gastrointestinal disease (n=1). The symptoms have 
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occurred 16 days (average) after first CMV DNA detection. Considering the patients with no 
detectable CMV DNA in their blood, none had CMV disease. The relationship between the 
detection of CMV DNA and symptomatic CMV infection was considered statistically 
significant (P=0.009). HHV-6 was detected in 50% of the patients with symptomatic CMV 
infection and in 30% of the patients without symptoms (P=0.32). HHV-7 was also detected 
in 60% of the symptomatic CMV infection and in 70% of the patients with asymptomatic 
infection (P=0.50). Of 10 patients who had liver dysfunction, 7 (70%, P=0.006) had 





















Fig. 2. Kinetic of detection for CMV, HHV-6 and HHV-7 in liver transplant recipients by 
nested-PCR 
Of 10 patients that had liver dysfunction, five presented episodes of graft rejection graded 
as mild. One was related to CMV hepatitis. One had symptomatic CMV/HHV-6 co-
infection (CMV hepatitis) 36 days prior rejection and one other had symptomatic 
CMV/HHV-7 co-infection (“CMV viral syndrome”) 45 days prior rejection. Two patients 
that had co-infection before graft rejection were accompanied with persistent liver 
dysfunction until rejection episode. Another two patients had only HHV-6 infection 
accompanied with thrombocytopenia and leukopenia were related with rejection 
episodes. Unfortunately, we were not able to perform viral antigens detection in liver 
biopsies. In patients who had liver dysfunction and/or graft rejection, no underlying liver 
disease (HCV or HBV) were relapsed until end of the monitoring (180 days) and no other 
infectious agent was found. Only one case of “CMV viral syndrome” was recurrent and 
occurred after graft rejection.  
Two episodes of pneumonitis were related with HHV-6/HHV-7 co-infection. One case of 
pneumonitis and two of encephalitis were also related with only HHV-6 infection and no 
others infectious agents were found. However, other tests to detect HHV-6 and HHV-7 in 
tissue samples might not be performed. In CMV and HHV-6 free patients no symptoms or 
significant laboratorial findings could be related to HHV-7.  
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Fig. 3. Venn diagrams illustrating the number of patients (n=29) or number of positive 
samples (n=198) that were positive nested-PCR for any combination of betaherpesviruses 
4. Discussion 
The high frequency of positive IgG test against CMV observed agrees with previously data 
indicating a prevalence of 90 to 100% anti-CMV antibodies in Brazilian population 
(Suassuna et al., 1995; Costa et al., 1999). Previously studies in Brazilian population have 
also demonstrated high prevalence of HHV-6 and HHV-7 (90 and 84%, respectively).  
CMV, HHV-6 and HHV-7 were frequently detected in patients after liver transplant (68.9%, 
44.8% and 48.2%, respectively). Ihira et al. (2001) and Feldstein et al. (2003) suggested that 
the detection of virus DNA in serum by PCR is a useful marker of HHV-6 and HHV-7 active 
infection. In adult liver transplant recipients, Griffths et al. (1999) found CMV DNA in 47%, 
HHV-6 DNA in 32% and HHV-7 DNA in 48% of the patients. Ihira et al. (2001) found HHV-
6 DNA in 38% and HHV-7 DNA in 40% of the patients until 8 weeks after liver 
transplantation. Humar et al. (2000) found CMV DNA in 63.6% and HHV-6 DNA in 54.5% 
of the liver transplant recipients.  
The rate difference in each report depends of the sensitivity of PCR, type of transplantation, 
immunosuppressive protocol, the size of samples used and differences among subjects. 
However, the rate found in this study was relatively similar with others reports. Interesting, 
6/29 (20.7%) patients had positive detectable HHV-7 DNA at the time of transplantation 
without symptoms. In addition, IgM against HHV-7 was found in all samples contributing 
to the hypothesis of true active infection had occurred. Since that this method did not detect 
latent infection in previously study (Thomasini et al., 2008) and blood was collected before 
surgery, it could be explained by reactivation caused by underlying liver disease or by 
transient viremia. Although some syndromes related to HHV-7 in immunocompetent 
patients have been described (Ward et al., 2005), studies in pre-transplant time should be 
performed to evaluate each hypothesis. 
Ten of twelve (50%) patients who had detectable CMV DNA developed symptomatic CMV 
infection. The remaining 10 patients without symptoms could be explained by the high 
sensibility of the PCR, that can detect lower viral load (Tokimatsu et al.,1995), and they were 
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not treated. However, the statistical analysis showed correlation between detection of CMV 
DNA and symptomatic CMV infection. Our symptomatic CMV incidence (34.4%) was 
higher (1.54-fold) than incidence reported by Humar et al. (2000) that reported symptomatic 
CMV infection in 21.6% of the patients. Similar to this study, Härmä et al. (2006) found 30% 
of symptomatic CMV infection during 3 first months after transplantation.  
We have considered that this higher incidence of CMV infection and symptomatic CMV 
infection due to high prevalence of CMV in Brazilian population, no routine or preemptive 
ganciclovir therapy and use of cyclosporine. Humar et al. (2000) have found an 
independently increasing risk factor for development of CMV disease when patient had 
D+/R+ CMV serostatus and all patients enrolled in this study were D+/R+. It is conflicting 
with most reports that suggest higher risk factor when CMV serostatus is D+/R-. Hoppe et 
al. (2004) had suggests a higher probability of CMV infection among patients treated with 
cyclosporine compared to tracolimus.  
Some cases of pneumonitis and encephalitis were related to HHV-6 active infection or with 
co-infections HHV-6/HHV-7. Previously reports had suggested association an increase risk 
of graft rejection associated with CMV (Lautenschlager et al., 1997). Although we have 
found that symptomatic CMV infection was present in most cases of liver dysfunction and 
graft rejection, CMV co-infection with HHV-6 or HHV-7 and HHV-6 alone were more likely 
related with graft rejection than CMV alone. Härmä et al. (2006) had suggested a role of 
HHV-6 in liver dysfunction and graft rejection (with HHV-6 antigens detected in liver 
biopsies in same patients). Griffiths et al. (1999) found also association between liver 
dysfunction and graft rejection with HHV-6 and dysfunction with HHV-7. HHV-6 could 
either be participating directly in the rejection process or potentially exacerbating the 
inflammatory response characteristic of rejection (Emery, 2001). However, the fact that the 
most of patients with HHV-6 active infection were asymptomatic in this study (probably 
due to transient viremia) turned difficult to establish a relation between liver 
dysfunction/graft rejections with HHV-6 active infection. In addition, all of the positive 
patients included in this study have betaherpesviruses reactivation/reinfection and not 
primary infection. Betaherpesviruses primary infections could have more significant clinical 
outcomes and this hypothesis should be considered in pediatric liver transplantation which 
primary infections could be more frequent.  
In CMV and HHV-6 free patients no symptoms or significant laboratorial findings could be 
related to HHV-7. However, the role of the HHV-7 in down regulation of CD4 expression in 
lymphocytes has been described (Secchiero et al., 1997; Secchiero et al., 1998) and a possible 
immnunomodulatory effects do not be discarded. Studies regarding CMV, HHV-6 and 
HHV-7 including determination of viral load with ‘cut-off’ values for clinical manifestation 
and detection of viral antigens in liver biopsies as well as evaluation of cellular and humoral 
immune response could be performed. In this study we have considered qualitative nested-
PCR which had limited value for clinical monitoring of the betaherpesvirus. 
5. Conclusion 
The results described above show that few patients remain free of betaherpesviruses after 
liver transplantation. Most of the patients with active infection with more than one virus 
were infected sequentially and not concurrently. Active infection with HHV-6, HHV-7 or 
CMV might develop independently of one another. Most patients with HHV-6 or HHV-7 
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active infections were asymptomatic. In few patients, HHV-6 could be associated with some 
clinical manifestations and episodes of graft dysfunction and rejection. Qualitative nested-
PCR was considered of limited value to clinical monitoring of betaherpesviruses.  
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1. Introduction  
Organ transplantation is now the treatment of choice for many end-stage diseases. 
However, the gap between organ demand and donor availability has progressively 
widened, and the severe shortage of organs for transplantation has resulted in the increasing 
use of expanded donor criteria, allowing the inclusion of older donors as well as donors 
with mild disease. Thus, organ donation may involve the risk of the transmittal of unwanted 
host factors, such as infections and malignancies. Infectious microbes and unexpected 
diseases that are present in an organ donor have the potential to be transmitted to the 
transplant recipient. Although the transmission of donor-derived infectious diseases was 
reported to occur in less than 1% of all donations from deceased donors, significant 
morbidity and mortality can occur following such disease transmissions. Infectious diseases 
remain a major complication in solid organ transplantation, and the study of donor-derived 
infections is an evolving field. Despite recent improvements in the microbiological screening 
of donors and detailed reviews of potential donors’ medical records, persistent clusters of 
donor-derived infections in transplant recipients remain. Bacterial, viral, fungal, parasitic, 
and other rare infections can be transmitted through organs and tissue allografts. However, 
the transmission of microorganisms from allografts is not likely to cause infectious 
complications in every transplant recipient. The risk of infection is mostly related to the 
recipient’s net state of immunosuppression. The balance between the recipient’s state of 
immunosuppression and epidemiological exposures contribute to the risk of infection 
(Fishman, 2007; Fishman & Rubin, 1998). Immunosuppression not only increases the risk of 
tissue invasion, dissemination, and superinfection, but also blunts the typical inflammatory 
responses that alert clinicians to the presence of infection after exposure. As a result, the 
recognition of infection is more difficult in transplant recipients than in individuals with 
normal immunities. The presentations of infections are often complicated by noninfectious 
events, such as allograft rejection. Specifically, 40% of infections in liver transplant recipients 
were not associated with fever (Chang et al., 1998). Thus, intervention treatments of 
infections may be delayed. The goals of patient care after organ transplantation are to 
prevent the transmission of donor-derived infections, to recognize the presence of infections 
in solid-organ transplant recipients, and to intervene early when such infections occur. In 
addition, malignancies that are transmitted from the donor due to direct transmission of 
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tumors or to tumors arising in cells of donor origin can also occur in organ transplantation. 
For example, melanoma, which is one of the most frequently reported and lethal donor-
derived malignancies, has a high transmission rate. Therefore, potential organ donors 
should be carefully screened for histories of malignancies. 
2. Potential infections of the donor 
Potential infections acquired from a donor can be classified into two categories: infections 
that already existed in the patient prior to becoming a potential donor and nosocomial 
exposures of the donor after hospitalization. Preexisting infections may be present in either 
living or deceased donors, and the majority of such infections are viral. Some of these 
infections, which might be detected by donor and recipient screening, involve infection from 
a seropositive donor to a seronegative recipient, including the transmission of 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), or toxoplasmosis, while others are 
unexpected despite routine donor screening. Unexpected clusters of donor-derived viral 
infections in transplant recipients have occurred, including rabies, West Nile virus (WNV), 
Human immunodeficiency virus (HIV), herpes simplex virus, hepatitis B virus (HBV), and 
hepatitis C virus (HCV) (Morris et al., 2010). Nosocomial donor infections are most 
commonly related to bacterial pathogens. These infections are usually caused by the same 
nosocomial pathogens that infect other patients with similar lengths of stay in the intensive 
care unit. Wu and colleagues have shown that several factors, including a longer stay in an 
intensive care unit, previous cardiopulmonary cerebral resuscitation, and the use of 
inotropic agents, contribute to the risk of infection of a potential donor (Wu et al., 2008). 
Additionally, infected donors may also transmit microorganisms that are resistant to formal 
antimicrobial treatments. The use of organs from deceased donors with potential infections 
is controversial, and there is a need for improved microbiological screening tools and 
therapies.  
Opportunistic infections are generally uncommon in the first 1–4 weeks after transplantation 
because the impact of immunosuppression depends on prolonged exposure to suppressive 
therapies. Unexplained early infections in this period are generally donor-derived or 
associated with surgery-related complications. Thus, a thorough investigation of infectious 
diseases in a potential donor is mandatory. The implementation of a preventive strategy of 
universal prophylaxis that provides antimicrobial therapy to all at-risk potential donors may 
alter the incidence and severity of organism transmission as well as post-transplant 
infections. However, routine antimicrobial prophylaxis should be adjusted based on the 
organ transplanted, individual exposures, and hospital epidemiology. Prophylaxis can also 
be adjusted according to known colonization patterns. All active infections in the donor 
should be eradicated or controlled prior to transplantation, as these may be transmitted and 
reactivated in the transplant recipient, which may lead to significant morbidity and 
mortality.  
3. Screening of the risks of infections of organ donors 
Benjamin Franklin said that an ounce of prevention is worth a pound of cure. The 
pretransplantation screening of potential organ donors is essential for the prevention of 
disease transmission, as well as the success of solid organ transplantation. Pretransplantation 
infectious disease screenings of potential donors are helpful in: (1) identifying conditions  
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that may disqualify the donor, (2) identifying and treating active infections prior to 
transplantation, (3) identifying the risk of infection and determining strategies for 
preventing and mitigating infection after transplantation, and (4) implementing preventive 
interventions, such as updating the recipient’s vaccination status. Although there is general 
consensus on the major infections for which screening should be performed, there is some 
variation in the types of screening used in different transplantation centers. A number of 
publications have discussed guidelines for the pretransplant screening of organ donors 
(Avery, 2004; Delmonico & Snydman, 1998; Fischer & Avery, 2009). Some documented 
infections preclude organ donation under specific infectious conditions, including 
uncontrolled sepsis, HIV or human T-cell lymphotropic virus (HTLV) infection, rabies, 
WNV infection, and lymphocytic choriomeningitis virus (LCMV) infection. Therefore, organ 
donors should be screened for the risk of infection on the basis of organ-procurement 
standards. The screening should include the donor’s medical history as well as laboratory 
serologic testing.  
3.1 Screening the donor’s medical/behavioral history 
A thorough medical history and physical examination are the first steps in donor screening. 
An accurate medical and social history, as well as the donor’s recent and remote exposures, 
is important in the assessment of donor eligibility. This initial evaluation may address 
current or active infections prior to organ procurement. Each potential donor should be 
screened for medical conditions that may affect the function of the donated organ, for the 
presence of transmissible disease or malignancies that are treated or untreated, or for any 
other known condition that may be transmitted by the donor organ that may reasonably 
affect the recipient. This history should also be used to identify whether the potential donor 
has factors associated with an increased risk of transmission of infection, including the 
blood-borne pathogens HIV, HBV, and HCV. The data that should be collected when 
assessing donor eligibility are summarized in Table 1.  
 
Medical history 
Previous infection  
Vaccinations 
Occupational exposures  
Travel history 
History of transfusions with blood or blood products 
Any contact with people with human immunodeficiency virus (HIV), hepatitis B 
virus (HBV), hepatitis C virus (HCV), or other transmissible diseases 
Tattooing, ear or body piercing 
Use of illicit drugs 
Sexual behavior 
Incarceration 
Contact with animals, including pets, bats, stray dogs, or rodents 
Physical examination 
Table 1. Suggested data to be collected for determining eligibility prior to organ donation 
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However, due to the limited pool of donors, it has become increasingly important to 
consider marginal donors, including those with infections at the time of donation. The 
decision to use organs from an infected donor reflects the urgency of transplantation for the 
recipient and the availability of alternative organs. 
3.1.1 Exclusion of high-risk donors 
The transmission of HIV through liver transplantation has been reported sporadically (Ahn 
& Cohen, 2008; Samuel et al., 1988). The Centers for Disease Control and Prevention of the 
United States (US) has issued guidelines for the classification of donors possessing a high 
risk for HIV infection (CDC, 1994). Potential donors who meet any of the criteria listed 
below should be excluded from the donation of organs or tissues and may be considered 
only if the risk to the recipient of not performing the transplant is deemed greater than the 
risk of HIV transmission and disease. In such a circumstance, it is recommended to inform 
the recipient and discuss the possibility of HIV transmission. 
Behavior/history exclusionary criteria 
1. Men who have had sex with another man in the preceding 5 years. 
2. Persons who report nonmedical intravenous, intramuscular, or subcutaneous injection 
of drugs in the preceding 5 years. 
3. Persons with hemophilia or related clotting disorders who have received human-
derived clotting factor concentrates. 
4. Men and women who have engaged in sex in exchange for money or drugs in the 
preceding 5 years. 
5. Persons who have had sex in the preceding 12 months with any person described in 
items 1-4 above or with a person known or suspected to have HIV infection. 
6. Persons who have been exposed in the preceding 12 months to known or suspected 
HIV-infected blood through percutaneous inoculation or through contact with an open 
wound, non-intact skin, or mucous membrane. 
7. Inmates of correctional systems. (This exclusion is to address issues such as difficulties 
with informed consent and the increased prevalence of HIV in this population.) 
Specific exclusionary criteria for pediatric donors 
• Children meeting any of the exclusionary criteria listed above for adults should not be 
accepted as donors. 
• Children born to mothers with HIV infections or mothers who meet the behavioral or 
laboratory exclusionary criteria for adult donors (regardless of their HIV status) should 
not be accepted as donors unless HIV infection can be definitely excluded in the child as 
follows: 
• Children greater than 18 months of age who are born to mothers with, or at risk for, 
HIV infection, who have not been breast fed within the last 12 months, and whose 
HIV antibody tests, physical examination, and review of medical records do not 
indicate evidence of HIV infection can be accepted as donors. 
• However, children less than or equal to 18 months of age who are born to mothers 
with, or at risk for, HIV infection should not be accepted as donors regardless of 
their HIV test results. 
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3.2 Laboratory screening tests 
In the US, all laboratory testing of donors must be performed in an appropriately accredited 
laboratory utilizing nationally licensed, approved, or cleared serological screening tests. 
Laboratory screening of potential donors is generally performed for HIV, HBV, HCV, and 
syphilis. The serological tests most frequently used for donor screening are listed in Table 2.  
 
Human immunodeficiency virus (HIV) antibody 
Hepatitis B (HBV) serologic tests: 
HBV surface antigen (HBsAg) 
HBV core antibody (HBcAb IgM and IgG) 
HBV surface antibody (HBsAb) 
Hepatitis C (HCV) antibody  
Venereal Disease Research Laboratory (VDRL) test or Rapid Plasma Reagin (RPR) 
Cytomegalovirus (CMV) antibody IgM and IgG 
Epstein-Barr virus (EBV) antibody panel  
Herpes simplex virus antibody 
Varicella-Zoster virus antibody 
Human T cell lymphotrophic virus (HTLV-I/II) antibody (for donors originating from 
high-incidence areas) 
Toxoplasma antibody (optional, not routinely performed for noncardiac donors) 
Blood and urine cultures 
Table 2. Common screening tests for potential organ donors 
Serology for HTLV-I/II is routinely performed in the US, but in Europe and other areas, this 
assay is restricted to donors living in, or originating from, high-incidence areas. However, 
the risk of infection may be difficult to assess, especially if HTLV has been transmitted 
vertically or sexually. Toxoplasmosis is a major concern, particularly in heart 
transplantation, but it is rarely transmitted to liver recipients (Mayes et al., 1995). Thus, 
toxoplasmosis screening is not routinely performed for noncardiac donors. Donor screening 
for toxoplasmosis is also not advocated based on the small amount of information gained 
and the high rate of false-positive results. In addition, a seropositive result for toxoplasma 
does not contraindicate organ donation, but does provide information that determines 
appropriate prophylaxis and treatment options following transplantation.  
3.2.1 Donors with identified infections 
The use of organs from deceased donors who had fevers or viral infections remains 
controversial, indicating the need for improved microbiological screening tests. However, 
the urgent demand for organs has led to the use of organs from donors with identified 
infections for specific recipients based on the urgency of the need for transplantation and the 
availability of antimicrobial therapies. Ideally, all active bacterial or fungal infections in the 
donor should be treated and resolved prior to transplantation. Currently, no 
recommendations are available regarding the optimal duration of therapy before 
transplantation or the interval required between resolution of the infection and 
transplantation. It may not be possible to document clearance of the infection in an 
emergent situation of life-saving transplantation. Common infections in donors that have 
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3.2 Laboratory screening tests 
In the US, all laboratory testing of donors must be performed in an appropriately accredited 
laboratory utilizing nationally licensed, approved, or cleared serological screening tests. 
Laboratory screening of potential donors is generally performed for HIV, HBV, HCV, and 
syphilis. The serological tests most frequently used for donor screening are listed in Table 2.  
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transplantation. It may not be possible to document clearance of the infection in an 
emergent situation of life-saving transplantation. Common infections in donors that have 
 
Liver Transplantation – Technical Issues and Complications 
 
416 
been treated adequately should not preclude the use of organs, and decisions must be 
flexible and individualized to the recipient.  
Additionally, livers from donors with HBV infection (HBcAb- or HBsAg-positive) may be 
used in recipients who have previously been infected or are in life-threatening situations, 
with appropriate treatment with specific anti-HBV antiviral agents (Seehofer & Berg, 2005; 
Trautwein, 2004). Similarly, the use of HCV-infected organs is generally reserved for HCV-
infected recipients or for selected HCV-negative recipients (Ghobrial et al., 2001; Vargas et 
al., 1999; Velidedeoglu et al., 2002). Suggested organ donation strategies that are based on 
donor screening data are summarized in Table 3 (Grossi & Fishman, 2009).  
 
Serologic finding Action 
Antibody to human 
immunodeficiency virus (HIV) 
Exclude from organ donation 
Antibody to human T-cell 
lymphotropic virus (HTLV) I/II 
Generally exclude from organ donation (may be used 
in life-threatening situations with informed consent) 
Antibody to hepatitis C virus 
(HCV) 
If used, organs are usually reserved for recipients 
with antibodies to HCV or severely ill recipients 
Antibody to cytomegalovirus 
(CMV) 
Use information to determine prophylaxis (in 
conjunction with recipient serology) 
Antibody to Epstein-Barr virus 
(EBV) 
Consider PCR monitoring if donor is seropositive 
and recipient is seronegative 
Hepatitis B virus (HBV) surface 
antigen (HBsAg) + or HBV core 
antibody (HBcAb IgM) +  
Exclude from organ donation (possible use in life-
threatening situations with intensive prophylaxis) 
HBV surface antibody (HBsAb) + Generally safe for organ donation 
HBV core antibody (HBcAb) IgG 
+ 
High-risk for transmission if liver is used for 
donation, but used at some centers with intensive 
prophylaxis; nonhepatic organs carry a small risk of 
transmission of HBV and are used for vaccinated 
recipients or with prophylaxis  
Rapid Plasma Reagin (RPR) + Not a contraindication to donation. Recipient should 
receive benzathine penicillin 
Antibody to Toxoplasma Not a contraindication to donation. Sulfa-allergic, 
seronegative heart transplant recipients with a 
seropositive donor should receive pyrimethamine 
prophylaxis 
Table 3. Suggested strategies based on donor screening results 
3.3 Additional considerations for donor screening  
Despite the use of highly sensitive assays and the development of new policies, the 
transmission of infections to organ transplant recipients remains uncommon. However, it 
does occur with sufficient frequency to suggest that the current approaches to donor 
screening are inadequate. Many potential exposures are too nonspecific to allow appropriate 
decision-making regarding the risk of transmission.  
 
Donor-Derived Infectious Complications and Disease Transmission 
 
417 
3.3.1 Hemodilution of donor blood samples 
All blood samples obtained and used for screening tests must be assessed for hemodilution, 
which is defined as the dilution of plasma that is sufficient to affect the results of 
communicable disease testing. Blood samples from a deceased organ donor who underwent 
blood loss and transfusion of blood products or infusion of colloids and crystalloids are 
likely to be hemodiluted, which might lead to false-negative test results. The Food and Drug 
Administration (FDA) of the US has published regulations to test specimens from donors 
who have undergone transfusion or infusion (FDA, 2007). Test results from donors who 
have suffered blood loss that was sufficient to require fluid replacement, certain volumes of 
transfusion, and/or infusions should be interpreted with caution. The donor might be 
ineligible unless a pretransfusion sample was available for testing or an appropriate 
algorithm was used to determine if plasma dilution is sufficient to affect test results.  
3.3.2 The window period 
The window period is the time between initial infection and when a test can reliably detect 
that infection, and the poor sensitivity of antibody-based tests within this period increases 
the risk of infection transmission through organ transplantation. As seroconversion may not 
occur during an acute infection, some active infections remain undetectable. For example, 
the period from initial HIV exposure to the development of HIV antibodies is approximately 
22 days, but it can be up to 3–6 months. On average, it takes 2–8 weeks from the time of 
possible exposure for the development of detectable levels of HIV antibodies, leading to 
accurate test results. Therefore, the donor may be seronegative while potentially infected. 
However, recent improvements in the sensitivity of virus-detection assays using nucleic acid 
testing (NAT) have resulted in a significant shortening of the window period (Busch et al., 
2005; Fiebig et al., 2003). The use of NAT may also detect viral replication in HBV core 
antigen (HBcAg)-positive donors who are HBV surface antigen (HBsAg)-negative, in 
addition to reducing the window period of HBV infection (Biswas et al., 2003; Kleinman & 
Busch, 2006). The window period of HCV infection can be reduced by the use of NAT as 
well (Kolk et al., 2002; Schreiber et al., 1996), suggesting the routine use of NAT in the 
screening of potential organ donors for HIV, HBV, and HCV.  
3.3.3 Living donors versus deceased donors 
The screening of living and deceased donors is largely different based on the period during 
which the evaluation is performed. The screening of a prospective living donor is conducted 
at the transplantation center, and the time between screening and transplantation is 
variable. The screening of living donors should include a thorough medical and behavioral 
history, physical examination, laboratory serological tests, radiographic imaging studies, 
and tests for any untreated underlying infectious diseases as needed. Repeat screening tests 
should be considered in the presence of newly developing clinical symptoms and signs in 
living donors between the time of initial screening and transplantation.  
In contrast, the period for deceased donor screening is very short, typically on the order of 
hours. The laboratories associated with organ procurement organizations (OPOs) should 
operate on a 24-hour basis in order to generate the information needed to determine donor 
eligibility (Delmonico & Snydman, 1998; Schaffner, 2001). Because of time constraints,  
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been treated adequately should not preclude the use of organs, and decisions must be 
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infected recipients or for selected HCV-negative recipients (Ghobrial et al., 2001; Vargas et 
al., 1999; Velidedeoglu et al., 2002). Suggested organ donation strategies that are based on 
donor screening data are summarized in Table 3 (Grossi & Fishman, 2009).  
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transmission of infections to organ transplant recipients remains uncommon. However, it 
does occur with sufficient frequency to suggest that the current approaches to donor 
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serologic tests are often limited to routinely available and rapid methods. In addition, the 
quality of testing may not be identical in each OPO, and some infections that require more 
sensitive testing may be difficult to detect at an early stage. Therefore, a detailed medical 
history of the potential deceased donor is required to identify potential infections that might 
not be reflected in serologic tests. If a deceased donor with a potential infection risk is to be 
used, the recipient should be informed of the risk of infection transmission. In the future, the 
development of more sensitive and rapid molecular serologic tests may allow immediate 
detection of viral infections, such as HBV, HCV, and HIV.  
4. Transmission of specific pathogens 
A variety of pathogens, including bacteria, fungi, parasites, and viruses, may be transmitted 
through organ transplantation (Table 4) (Gottesdiener, 1989; Ison et al., 2009).  
 
Bacteria Mycobacteria 
Staphylococcus aureus  Mycobacterium tuberculosis 
Klebsiella species Nontuberculous mycobacteria 
Bacteroides fragilis  
Pseudomonas aeruginosa Parasites/Protozoa 
Escherichia coli Toxoplasma gondii 
Salmonella species Strongyloides stercoralis 
Yersinia enterocolitica Plasmodium species 
Treponema pallidum Trypanosoma cruzi 
Brucella species  
Bartonella species Viruses 
Enterobacter species Cytomegalovirus 
Acinetobacter species Epstein-Barr virus 
 Herpes simplex virus 
Fungi Varicella-zoster virus 
Aspergillus species Human herpesvirus-6, 7, 8 
Candida species Hepatitis B, C 
Histoplasma capsulatum Human immunodeficiency virus 
Cryptococcus neoformans Human T cell lymphotrophic virus (HTLV) 
Cocciodioides immitis Parvovirus B19 
Scedosporium apiospermum Rabies 
Prototheca species Lymphocytic choriomeningitis virus 
(LCMV) 
 BK virus 
 West Nile virus 
Table 4. Pathogens that are transmitted with solid organ transplantation 
4.1 Bacteria 
Bacteria are the most common cause of infections in liver transplant recipients, with a 
reported incidence of 35–70%. Numerous factors may be associated with recipient infection, 
and bacterial transmission from the donor is one of the possible sources. Deceased donors 
may harbor known or unsuspected bacterial infections, which should be rapidly evaluated 
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by review of medical records, temperature charts, radiography, and cultures when available. 
It is desirable to obtain blood cultures prior to transplantation since occult donor bacteremia 
may occur. If an illness might have involved bacteremia, a thorough investigation should be 
performed to make sure that the target organ has not been infected. Previous studies, 
conducted on a small scale, have documented severely compromised initial allograft 
function when organs from infected donors were used for desperate recipients (Bull et al., 
1995; Nery et al., 1997). Therefore, transplantation programs have been reluctant to use 
organs from donors known to have active bacterial infections. Occasionally, however, a 
bacterial or fungal blood culture taken before organ recovery is reported as positive only 
after life-saving organs have been transplanted into a needy recipient. A retrospective 
review of bacteremic donors has found no evidence that transmitting bacterial infection 
results in poorer outcomes after organ transplantation (Freeman et al., 1999). Moreover, 
organs have been successfully transplanted from donors with bacterial meningitis with no 
evidence of infectious complications in the recipients, who were given appropriate 
antimicrobial therapy (Lopez-Navidad et al., 1997; Satoi et al., 2001). Therefore, potential 
donors with positive blood cultures should not be totally excluded as possible donors. This 
may increase organ availability and help improve the organ shortage.  
4.1.1 Syphilis 
Syphilis is a sexually transmitted infection with a worldwide incidence that is caused by the 
spirochete Treponema pallidum. Although the transmission of syphilis by means other than 
sexual routes is infrequent, it can be transmitted through blood transfusion and organ 
transplantation. Serologic testing of potential organ donors for syphilis is recommended, but 
evidence of syphilis infection is not considered a contraindication to organ donation if 
appropriate prophylactic antibiotics, such as benzathine penicillin, are administered to the 
recipient (Caballero et al., 1998; Ko et al., 1998). Therefore, current guidance suggests that 
organ transplantation from a donor with serologic evidence of a syphilis infection is safe as 
long as there is appropriate treatment of recipients in the posttransplantation phase. 
Recommended regimens of 2–3 doses weekly of 2.4 million units of intramuscular 
benzathine penicillin or an equivalent early syphilis therapeutic regimen should be given as 
soon as possible after transplantation for appropriate prophylaxis and treatment of early 
syphilis acquired from transplantation. 
4.2 Fungi  
Any known active and invasive fungal infection in the potential donor is a contraindication 
to transplantation. However, endemic mycoses may be present in dormant forms and 
transmitted to recipients by organ transplantation. For example, histoplasmosis that was 
transmitted by transplantation has been described, but most cases appeared to involve the 
reactivation of a past infection in the recipient (Limaye et al., 2000). Nonetheless, 
radiographic signs of suspected previous histoplasmosis have not been considered a 
contraindication to donation, and a consensus regarding recommendations for donor 
screening for endemic mycoses has not emerged yet.  
4.2.1 Candida species 
The incidence of fungal infections in liver transplant recipients is higher than in recipients of 
other types of solid organ transplants. The reasons for this high rate of fungal infection are  
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not completely understood, but specific risk factors, including retransplantation, prolonged 
or repeat surgeries, high transfusion requirements, renal failure, fungal colonization, and 
predisposition to fungal infections in liver transplant recipients, have been identified 
(Castaldo et al., 1991; Collins et al., 1994). The incidence of invasive fungal infections 
following liver transplantation ranges between 14% and 42%, and these infections are 
associated with high overall mortality rates (Briegel et al., 1995; Paya, 2002). Most fungal 
infections generally occur within the first 3 months following liver transplantation and are 
viewed as classic nosocomial infections instead of donor-derived transmissions. Infections 
due to Candida species are the most common invasive fungal infections among solid organ 
transplant recipients, accounting for over half of all fungal infections. However, the 
occurrence of invasive candidiasis, especially among liver and small bowel transplant 
recipients, is often substantially higher.  
The diagnosis of invasive candidiasis is dependent on the recovery of the organism from a 
sterile body site, such as the bloodstream, intraabdominal fluid, pleural fluid, or abscess 
material. Unfortunately, cultures, especially blood cultures, are not sensitive enough to 
identify patients with invasive candidiasis. Even with newer blood culture techniques, the 
overall sensitivity of blood cultures for identifying Candida species is estimated to be 70% 
(Berenguer et al., 1993). Thus, the development of nonculture-based diagnostic 
methodologies is especially important. Presently, the 1-3, beta-d-glucan assay is probably 
the most reliable, with a sensitivity and specificity of 70% and 87%, respectively, among 
patients who have proven invasive candidiasis (Obayashi et al., 2008; Ostrosky-Zeichner et 
al., 2005). The treatment of invasive candidiasis in organ transplant recipients, which is 
similar to treatment in most other patients, is based on updated clinical practice guidelines 
for the management of candidiasis (Pappas et al., 2009).  
4.2.2 Aspergillus species 
Aspergillosis accounts for 1–9.2% of invasive fungal infections in liver transplant recipients 
(Brown et al., 1996; Gavalda et al., 2005; Kusne et al., 1992). It is similar to other fungal 
infections in that aspergillosis is likely to be a nosocomial infection after transplantation and 
not due to donor-derived transmission. A number of well-characterized risk factors have 
been shown to portend a high risk of invasive aspergillosis following liver transplantation, 
of which retransplantation and renal failure are among the most significant (Fortun et al., 
2002; Gavalda et al., 2005; Singh et al., 2001). Historically, invasive aspergillosis in liver 
transplant recipients has predominantly occurred in the early posttransplant period. The 
mortality rate of liver transplant recipients with invasive aspergillosis has ranged from  
83–88% (Denning, 1996; Singh et al., 1997; Singh et al., 2006), highlighting the need for 
aggressive diagnostic evaluation and treatment. A substantial delay in establishing an early 
diagnosis remains a major impediment to the successful treatment of invasive aspergillosis. 
Cultures of respiratory tract secretions are less sensitive, and fungus may only be detected 
in clinical samples from the late stages of the disease. However, a positive culture of 
Aspergillus from respiratory tract samples does not always indicate invasive disease, and 
the significance of a positive culture from an airway sample also varies with the type of 
organ transplant. 
The utility of the galactomannan test for the early diagnosis of invasive aspergillosis has 
been assessed in solid organ transplant recipients. However, false-positive galactomannan 
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tests have been documented in up to 13% of liver transplant recipients (Kwak et al., 2004), 
but the sensitivity of the assay for the diagnosis of invasive aspergillosis may be improved 
by testing bronchoalveolar lavage (Husain et al., 2007). The diagnosis of invasive 
aspergillosis using the 1-3, beta-d-glucan assay has not been fully defined, but one study has 
shown that the test was useful for the diagnosis of invasive aspergillosis in living-donor 
liver transplant recipients (Kawagishi et al., 2006).  
Currently, prophylaxis against invasive aspergillosis is not routinely recommended in all 
solid organ transplant recipients. A more rational approach is to provide antifungal 
prophylaxis to high-risk liver transplant recipients (Singh & Husain, 2009). The treatment of 
invasive aspergillosis in liver transplant recipients remains generally the same as in other 
patients. Prompt initiation of antifungal therapy is crucial for achieving optimal outcomes in 
recipients with invasive aspergillosis. Because of their lower potential of nephrotoxicity, 
lipid formulations of amphotericin B have been the mainstay for the treatment of invasive 
aspergillosis in solid organ transplantation since the early 1990s. The availability of newer 
triazole agents and echinocandins that have potent anti-Aspergillus activity and better 
tolerability profiles have led to an expanded arsenal of antifungal agents for the treatment of 
invasive aspergillosis. Voriconazole is now regarded as the drug of choice for the primary 
treatment of invasive aspergillosis in all hosts, including solid organ transplant recipients, 
based on the clinical guidelines of the Infectious Diseases Society of America (IDSA) for the 
treatment of invasive aspergillosis (Walsh et al., 2008). For the primary treatment of invasive 
pulmonary aspergillosis, intravenous or oral voriconazole is recommended for most 
patients, while the parenteral formulation is recommended for seriously ill patients. In 
patients developing toxicity to or with contraindications against voriconazole, liposomal 
amphotericin B is considered an alternative primary therapy according to the IDSA 
guidelines, but higher doses are not recommended. Amphotericin B lipid complex, 
itraconazole, caspofungin, posaconazole, or micafungin are other rational choices for 
alternative therapies for invasive aspergillosis (Walsh et al., 2008).  
Currently, caspofungin, which is the only echinocandin approved by the FDA for the 
treatment of invasive aspergillosis, has been used successfully as a single agent or in 
combination with other drugs for salvage therapy in invasive aspergillosis (Carby et al., 
2004; Forestier et al., 2005). However, the efficacy of combination antifungal therapy for 
invasive aspergillosis has not been fully defined. Thus, the routine administration of a 
combination regimen for primary therapy is not recommended. In the context of salvage 
therapy, an additional antifungal agent may be added to existing therapy, or combination 
antifungal drugs from different classes other than those in the initial regimen may be used 
(Walsh et al., 2008).  
4.2.3 Cryptococcus species 
Cryptococcosis, which is the third most common invasive fungal infection, accounts for 
approximately 8% of the invasive fungal infections in solid organ transplant recipients. The 
overall incidence of cryptococcal disease in solid organ transplant recipients ranges from 
0.3–5% (Singh & Forrest, 2009). As in most other hosts, cryptococcal disease in solid organ 
transplant recipients is considered a reactivation of a quiescent infection. However, rare 
cases of transmission from donor organ and tissue grafts have also been reported (Beyt & 
Waltman, 1978; Kanj et al., 1996; Ooi et al., 1971). Approximately 53–72% of solid organ  
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transplant recipients with cryptococcosis develop disseminated disease or central nervous 
system (CNS) involvement. Among solid organ transplant recipients, liver transplant 
recipients had a 6-fold higher risk for developing disseminated disease than recipients of 
other types of transplants. The overall mortality of solid organ transplant recipients with 
cryptococcosis in the current era is 14%, but it may be higher in those with CNS 
involvement (Singh et al., 2007).  
All patients with suspected cryptococcosis should undergo complete evaluations, including 
lumbar punctures, blood and urine cultures, chest X-rays, or bronchoalveolar lavages with 
biopsies when necessary, in order to determine the extent of the disease, as this will dictate 
management. Distinguishing between disseminated disease and localized pulmonary and 
asymptomatic disease is necessary prior to initiating therapy. In patients with neurologic 
and disseminated disease or severe pulmonary disease, the recommended treatment 
includes induction therapy with an amphotericin B product and flucytosine, followed by 
consolidation with fluconazole, and, finally, maintenance with fluconazole (200–400 
mg/day) for 6–12 months in order to complete the regimen. The recommended treatment 
for focal or incidentally detected pulmonary disease in otherwise asymptomatic patients is 
fluconazole (400 mg/day) for 6–12 months (Dromer et al., 2008; Saag et al., 2000). Currently, 
the use of extended-spectrum azoles, such as voriconazole, itraconazole, and posaconazole, 
have not shown any extra benefits over fluconazole (Singh & Forrest, 2009).  
4.3 Mycobacteria  
Mycobacterium tuberculosis (TB) is a serious opportunistic infection that may affect transplant 
recipients. The prevalence of active TB among solid organ transplant recipients is estimated 
to be 1.2–6.4% in most countries, and it has been reported to be up to 15% in highly endemic 
areas. The mortality rate in these populations is close to 30% (Munoz et al., 2005). The 
incidence of active TB in adult liver transplant recipients has been reported to be 0.47–2.3% 
(Munoz et al., 2005; Torre-Cisneros et al., 2009). The most frequent mode of acquisition is 
thought to be reactivation of dormant disease; however, transmission with an allograft has 
been documented to occur in liver transplant recipients (Aguado et al., 2009; Kiuchi et al., 
1997). Because of this risk, all potential living donors should be given a thorough history, 
documenting TB risk factors, exposures, and infections, and undergo a tuberculin skin test 
(TST) or interferon-γ release assay. If either test is positive, additional testing and a 
symptom review should be performed in order to rule out active infection. Prospective 
living donors with active TB should not be considered for transplantation, and those with 
latent TB infection should be given treatment (with isoniazid for 9 months or rifampin for 4 
months) prior to transplantation. However, one study demonstrated no benefit to treating 
prospective living donors with latent TB infections prior to transplantation (Hernandez-
Hernandez et al., 2006). The optimal length of therapy prior to liver donations remains 
unclear, and a shorter course of therapy might be feasible with the caveat that the recipients 
will be treated after liver transplantation. In the case of deceased donors, it is not possible to 
perform TSTs, but a history of previously active TB and any associated treatment should be 
obtained from the donor’s family or relatives. Organs from potential donors, whether living 
or deceased, with active TB or a high suspicion of active TB should not be used. Recipients 
of organs from donors with latent TB should consider preventive therapy with isoniazid for 
up to 9 months (Yehia & Blumberg, 2010).  
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The initiation of posttransplant preventive treatment should begin as soon as medically 
possible after the recipient is stabilized in order to prevent the development of reactivated 
diseases. Once therapy is started, transplant recipients should be routinely monitored for 
drug-related hepatotoxicity. A suggested approach is to monitor liver enzymes at 2-week 
intervals for 6 weeks and then monthly. If significant hepatotoxicity is observed, alternative 
regimens, such as ethambutol plus either levofloxacin or moxifloxacin, could be considered 
for high-risk individuals (Aguado et al., 2009). If no alternative treatment is possible, then 
careful clinical follow-up with prompt diagnostic attention to pulmonary symptoms is likely 
the best strategy.  
The standard treatment recommendation for active TB in the general population is to 
administer a 4-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for a 2-
month intensive phase, followed by a continuation phase of 4–7 months (Blumberg et al., 
2003). Other agents used in the treatment of TB are aminoglycosides and fluoroquinolones, 
which are primarily used in cases of multidrug resistance or intolerance of first-line 
medications. Treatment of active TB in liver transplant recipients should consider the 
known risks of drug-related hepatotoxicity and drug-drug interactions between 
antituberculosis medications and immunosuppressive agents. These considerations also 
have an impact on the suggested length of treatment. The ideal length of TB therapy in liver 
transplant recipients remains controversial, and it is affected by the extent of the disease, 
choice of regimen, response to therapy, and resistance profile of the organism.  
4.4 Protozoa/parasites 
Parasitic diseases may affect transplant recipients as a result of natural infection, 
recrudescence of a previous latent infection in the recipient, or transmission by organ 
transplantation. For the most part, only those organisms that can complete their life cycle 
within the human host lead to more severe infections in an immunocompromised host. The 
incidence of parasitic infection is expected to increase in solid organ transplant recipients 
due to the universal expansion of transplantation programs, and the increase in the numbers 
of donors or recipients who are originally from endemic areas but are currently spreading 
throughout the world.  
4.4.1 Toxoplasma gondii 
Toxoplasma gondii infection in transplant recipients can be caused by a primary infection 
transmitted by an allograft. Although recipients of heart transplantation have the highest 
incidence of this disease among solid organ transplant recipients, toxoplasmosis has been 
described in liver transplant recipients as well. Transplant recipients with active 
toxoplasmosis may present with brain abscess, chorioretinitis, pneumonitis, or disseminated 
disease. The diagnosis of toxoplasmosis requires the identification of tachyzoites in biopsy 
samples or clear seroconversion. The presence of multiple ring-enhancing lesions in a CNS 
imaging study, especially with the coexistence of anti-toxoplasma IgG antibodies, is 
suggestive of CNS toxoplasmosis and is sufficient to start presumptive treatment for CNS 
toxoplasmosis. Optimal treatment after solid organ transplantation has not been well-
defined. The recommendations of treatment for active toxoplasmosis generally includes a 
prolonged course (4–6 weeks or longer) of pyrimethamine and sulfadiazine with folinic 
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transplant recipients with cryptococcosis develop disseminated disease or central nervous 
system (CNS) involvement. Among solid organ transplant recipients, liver transplant 
recipients had a 6-fold higher risk for developing disseminated disease than recipients of 
other types of transplants. The overall mortality of solid organ transplant recipients with 
cryptococcosis in the current era is 14%, but it may be higher in those with CNS 
involvement (Singh et al., 2007).  
All patients with suspected cryptococcosis should undergo complete evaluations, including 
lumbar punctures, blood and urine cultures, chest X-rays, or bronchoalveolar lavages with 
biopsies when necessary, in order to determine the extent of the disease, as this will dictate 
management. Distinguishing between disseminated disease and localized pulmonary and 
asymptomatic disease is necessary prior to initiating therapy. In patients with neurologic 
and disseminated disease or severe pulmonary disease, the recommended treatment 
includes induction therapy with an amphotericin B product and flucytosine, followed by 
consolidation with fluconazole, and, finally, maintenance with fluconazole (200–400 
mg/day) for 6–12 months in order to complete the regimen. The recommended treatment 
for focal or incidentally detected pulmonary disease in otherwise asymptomatic patients is 
fluconazole (400 mg/day) for 6–12 months (Dromer et al., 2008; Saag et al., 2000). Currently, 
the use of extended-spectrum azoles, such as voriconazole, itraconazole, and posaconazole, 
have not shown any extra benefits over fluconazole (Singh & Forrest, 2009).  
4.3 Mycobacteria  
Mycobacterium tuberculosis (TB) is a serious opportunistic infection that may affect transplant 
recipients. The prevalence of active TB among solid organ transplant recipients is estimated 
to be 1.2–6.4% in most countries, and it has been reported to be up to 15% in highly endemic 
areas. The mortality rate in these populations is close to 30% (Munoz et al., 2005). The 
incidence of active TB in adult liver transplant recipients has been reported to be 0.47–2.3% 
(Munoz et al., 2005; Torre-Cisneros et al., 2009). The most frequent mode of acquisition is 
thought to be reactivation of dormant disease; however, transmission with an allograft has 
been documented to occur in liver transplant recipients (Aguado et al., 2009; Kiuchi et al., 
1997). Because of this risk, all potential living donors should be given a thorough history, 
documenting TB risk factors, exposures, and infections, and undergo a tuberculin skin test 
(TST) or interferon-γ release assay. If either test is positive, additional testing and a 
symptom review should be performed in order to rule out active infection. Prospective 
living donors with active TB should not be considered for transplantation, and those with 
latent TB infection should be given treatment (with isoniazid for 9 months or rifampin for 4 
months) prior to transplantation. However, one study demonstrated no benefit to treating 
prospective living donors with latent TB infections prior to transplantation (Hernandez-
Hernandez et al., 2006). The optimal length of therapy prior to liver donations remains 
unclear, and a shorter course of therapy might be feasible with the caveat that the recipients 
will be treated after liver transplantation. In the case of deceased donors, it is not possible to 
perform TSTs, but a history of previously active TB and any associated treatment should be 
obtained from the donor’s family or relatives. Organs from potential donors, whether living 
or deceased, with active TB or a high suspicion of active TB should not be used. Recipients 
of organs from donors with latent TB should consider preventive therapy with isoniazid for 
up to 9 months (Yehia & Blumberg, 2010).  
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The initiation of posttransplant preventive treatment should begin as soon as medically 
possible after the recipient is stabilized in order to prevent the development of reactivated 
diseases. Once therapy is started, transplant recipients should be routinely monitored for 
drug-related hepatotoxicity. A suggested approach is to monitor liver enzymes at 2-week 
intervals for 6 weeks and then monthly. If significant hepatotoxicity is observed, alternative 
regimens, such as ethambutol plus either levofloxacin or moxifloxacin, could be considered 
for high-risk individuals (Aguado et al., 2009). If no alternative treatment is possible, then 
careful clinical follow-up with prompt diagnostic attention to pulmonary symptoms is likely 
the best strategy.  
The standard treatment recommendation for active TB in the general population is to 
administer a 4-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for a 2-
month intensive phase, followed by a continuation phase of 4–7 months (Blumberg et al., 
2003). Other agents used in the treatment of TB are aminoglycosides and fluoroquinolones, 
which are primarily used in cases of multidrug resistance or intolerance of first-line 
medications. Treatment of active TB in liver transplant recipients should consider the 
known risks of drug-related hepatotoxicity and drug-drug interactions between 
antituberculosis medications and immunosuppressive agents. These considerations also 
have an impact on the suggested length of treatment. The ideal length of TB therapy in liver 
transplant recipients remains controversial, and it is affected by the extent of the disease, 
choice of regimen, response to therapy, and resistance profile of the organism.  
4.4 Protozoa/parasites 
Parasitic diseases may affect transplant recipients as a result of natural infection, 
recrudescence of a previous latent infection in the recipient, or transmission by organ 
transplantation. For the most part, only those organisms that can complete their life cycle 
within the human host lead to more severe infections in an immunocompromised host. The 
incidence of parasitic infection is expected to increase in solid organ transplant recipients 
due to the universal expansion of transplantation programs, and the increase in the numbers 
of donors or recipients who are originally from endemic areas but are currently spreading 
throughout the world.  
4.4.1 Toxoplasma gondii 
Toxoplasma gondii infection in transplant recipients can be caused by a primary infection 
transmitted by an allograft. Although recipients of heart transplantation have the highest 
incidence of this disease among solid organ transplant recipients, toxoplasmosis has been 
described in liver transplant recipients as well. Transplant recipients with active 
toxoplasmosis may present with brain abscess, chorioretinitis, pneumonitis, or disseminated 
disease. The diagnosis of toxoplasmosis requires the identification of tachyzoites in biopsy 
samples or clear seroconversion. The presence of multiple ring-enhancing lesions in a CNS 
imaging study, especially with the coexistence of anti-toxoplasma IgG antibodies, is 
suggestive of CNS toxoplasmosis and is sufficient to start presumptive treatment for CNS 
toxoplasmosis. Optimal treatment after solid organ transplantation has not been well-
defined. The recommendations of treatment for active toxoplasmosis generally includes a 
prolonged course (4–6 weeks or longer) of pyrimethamine and sulfadiazine with folinic 
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acid, followed by suppressive therapy, or trimethoprim-sulfamethoxazole treatment, 
followed by suppressive therapy (Kotton & Lattes, 2009).  
4.4.2 Trypanosoma cruzi 
Chagas disease, caused by the flagellate protozoan parasite Trypanosoma cruzi, has been 
transmitted by unscreened blood transfusion, from infected mother to fetus, by laboratory 
accidents, or even by organ transplantation (de Faria & Alves, 1993; Vazquez et al., 1993). 
Routine screening for Trypanosoma cruzi prior to transplantation is not yet mandatory. In 
countries where the disease is endemic, transplant teams do accept organs from infected 
donors provided no better donor is available in a reasonable life-saving situation and with 
informed consent. Diagnosis can be achieved by direct parasitological tests, including the 
examination of whole blood preparations, by a concentration method (Strout test) (Strout, 
1962) in the acute phase, and by serological tests in the intermediate and chronic stages. Two 
drugs, nifurtimox and benznidazole, are available for treatment. Parasitic cure is achieved in 
60–100% of acute cases when either drug is administered for 30–60 days (Bern et al., 2007).  
4.4.3 Strongyloides stercoralis 
Strongyloides stercoralis is endemic in tropical and subtropical regions. Strongyloidiasis, 
which has mainly been described in kidney transplant recipients, has been considered in 
most cases to be caused by reactivation of a latent infection (Hoy et al., 1981). More recently, 
a few cases have been documented in pancreatic and intestine transplant recipients and 
were attributed to transmission from the donated organs (Ben-Youssef et al., 2005; Patel et 
al., 2008). The clinical disease may present with pulmonary involvement, sepsis, meningitis 
with multiple gram-negative rods, and acute and severe abdominal disease, including ileus 
and intestinal obstruction, and gastrointestinal hemorrhage. These symptoms are caused by 
the damage inflicted by larvae that penetrate through the intestinal wall. A definitive 
diagnosis is based on the identification of larvae in clinical specimens, mainly in stool and 
duodenal aspirate. All recipients with confirmed diagnoses should be treated with 
ivermectin or albendazole. Thiabendazole is another agent that has been extensively used 
clinically, but it is probably the least satisfactory of all available drugs because of its high 
relapse rates and toxicities (Liu & Weller, 1993). Strongyloidiasis can be a devastating 
disease in transplant recipients despite therapy. The mortality rate approaches 50–70% in 
recipients with hyperinfection syndrome and disseminated infection (Patel et al., 2008).  
4.5 Viruses 
Solid organ transplant recipients are uniquely predisposed to develop severe clinical 
illnesses related to a variety of common and opportunistic viruses. Transplant recipients 
may acquire viral infections from the donor (donor-derived transmission), from reactivation 
of endogenous latent infection, or from the community. Herpes viruses, most notably CMV 
and EBV, are the most common opportunistic viral pathogens that cause infection after solid 
organ transplantation. HBV and HCV are unique challenges, particularly among liver 
transplant recipients. Infection by polyoma BK virus is an important cause of allograft 
dysfunction in kidney transplant recipients, but viremia is relatively uncommon in liver 
transplant recipients. Other less common viral infections, including adenoviruses, 
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parvovirus B19, and WNV, may affect liver transplant recipients as well. Treatment of virus 
infections with proven effective antiviral drug therapies should be weighed against the 
potential reduction of immunosuppression. For viruses without proven effective therapies, 
reduction in the degree of immunosuppression remains the sole effective strategy for 
management. Therefore, the prevention of viral infections is of the utmost importance, and 
this may be accomplished by pretransplant screening of the donor and recipient to 
determine prophylactic and preventive strategies to be utilized after transplantation or 
posttransplant vaccinations and effective antiviral treatments. 
4.5.1 Cytomegalovirus 
Cytomegalovirus (CMV) infections, which have been recognized in every human population, 
are widely distributed in the general population with seroprevalence ranging from 30–97% 
(Humar & Snydman, 2009; Paya, 2001). The patterns of CMV acquisition vary greatly based 
on geographic and socioeconomic backgrounds of each population, and seroprevalence 
increases generally with age. Importantly, CMV infection is a major cause of morbidity in 
patients receiving solid organ transplants. CMV disease usually occurs 1–4 months after 
liver transplantation, and those recipients who are seronegative for CMV and receive an 
allograft from a seropositive donor are at highest risk. Other risk factors for CMV disease 
include the recipient’s overall state of immunosuppression (e.g., type of drug, dose, timing, 
duration) and various host factors (e.g., age, comorbidity, neutropenia). The risk of CMV 
disease also varies with the type of transplant. This may be due to the degree of 
immunosuppression or the viral load present in the transplanted allograft. The lowest risk 
of disease occurs when both donor and recipient are seronegative for CMV. Thus, 
pretransplant CMV screening of donors and recipients should be performed to allow for risk 
stratification.  
The diagnosis of CMV infection and disease has evolved considerably. Historically, the 
histological detection of owl's eye inclusion bodies has been used for the diagnosis of CMV 
disease. However, this method is limited by its invasive approach and insensitivity for 
detecting CMV organ involvement. For years, culture-based methods, such as shell-vial 
centrifugation detection or culture of the organism from clinical specimens, were used for 
CMV diagnosis. However, tissue culture can take weeks and the shell-vial centrifugation 
assay is insensitive compared with molecular assays. Newer methods for diagnosing CMV 
disease include detection of the pp65 antigen and a molecular diagnostic test; both methods 
are performed on serum and are rapid, with reasonable sensitivity and specificity. The pp65 
antigen assay is a semiquantitative fluorescent assay that is based on the detection of 
infected cells in peripheral blood. This assay has a far higher sensitivity and specificity than 
culture-based methods (Mazzulli et al., 1999). Molecular diagnostic tests, which may detect 
CMV deoxyribonucleic acid (DNA), can be qualitative or quantitative. Quantitative 
measurements of CMV DNA levels have become popular at many transplantation centers. 
The viral loads measured are associated with the severity of CMV infection (Humar et al., 
1999). Generally, both the pp65 antigen assay and quantitative CMV viral load testing can be 
utilized in preemptive protocols for the diagnosis of CMV infection, as well as to guide the 
management of CMV disease (Caliendo et al., 2000; Emery et al., 2000).  
Currently, two strategies commonly used for CMV prevention include universal 
prophylaxis and preemptive therapy. Universal prophylaxis involves providing antiviral  
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acid, followed by suppressive therapy, or trimethoprim-sulfamethoxazole treatment, 
followed by suppressive therapy (Kotton & Lattes, 2009).  
4.4.2 Trypanosoma cruzi 
Chagas disease, caused by the flagellate protozoan parasite Trypanosoma cruzi, has been 
transmitted by unscreened blood transfusion, from infected mother to fetus, by laboratory 
accidents, or even by organ transplantation (de Faria & Alves, 1993; Vazquez et al., 1993). 
Routine screening for Trypanosoma cruzi prior to transplantation is not yet mandatory. In 
countries where the disease is endemic, transplant teams do accept organs from infected 
donors provided no better donor is available in a reasonable life-saving situation and with 
informed consent. Diagnosis can be achieved by direct parasitological tests, including the 
examination of whole blood preparations, by a concentration method (Strout test) (Strout, 
1962) in the acute phase, and by serological tests in the intermediate and chronic stages. Two 
drugs, nifurtimox and benznidazole, are available for treatment. Parasitic cure is achieved in 
60–100% of acute cases when either drug is administered for 30–60 days (Bern et al., 2007).  
4.4.3 Strongyloides stercoralis 
Strongyloides stercoralis is endemic in tropical and subtropical regions. Strongyloidiasis, 
which has mainly been described in kidney transplant recipients, has been considered in 
most cases to be caused by reactivation of a latent infection (Hoy et al., 1981). More recently, 
a few cases have been documented in pancreatic and intestine transplant recipients and 
were attributed to transmission from the donated organs (Ben-Youssef et al., 2005; Patel et 
al., 2008). The clinical disease may present with pulmonary involvement, sepsis, meningitis 
with multiple gram-negative rods, and acute and severe abdominal disease, including ileus 
and intestinal obstruction, and gastrointestinal hemorrhage. These symptoms are caused by 
the damage inflicted by larvae that penetrate through the intestinal wall. A definitive 
diagnosis is based on the identification of larvae in clinical specimens, mainly in stool and 
duodenal aspirate. All recipients with confirmed diagnoses should be treated with 
ivermectin or albendazole. Thiabendazole is another agent that has been extensively used 
clinically, but it is probably the least satisfactory of all available drugs because of its high 
relapse rates and toxicities (Liu & Weller, 1993). Strongyloidiasis can be a devastating 
disease in transplant recipients despite therapy. The mortality rate approaches 50–70% in 
recipients with hyperinfection syndrome and disseminated infection (Patel et al., 2008).  
4.5 Viruses 
Solid organ transplant recipients are uniquely predisposed to develop severe clinical 
illnesses related to a variety of common and opportunistic viruses. Transplant recipients 
may acquire viral infections from the donor (donor-derived transmission), from reactivation 
of endogenous latent infection, or from the community. Herpes viruses, most notably CMV 
and EBV, are the most common opportunistic viral pathogens that cause infection after solid 
organ transplantation. HBV and HCV are unique challenges, particularly among liver 
transplant recipients. Infection by polyoma BK virus is an important cause of allograft 
dysfunction in kidney transplant recipients, but viremia is relatively uncommon in liver 
transplant recipients. Other less common viral infections, including adenoviruses, 
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parvovirus B19, and WNV, may affect liver transplant recipients as well. Treatment of virus 
infections with proven effective antiviral drug therapies should be weighed against the 
potential reduction of immunosuppression. For viruses without proven effective therapies, 
reduction in the degree of immunosuppression remains the sole effective strategy for 
management. Therefore, the prevention of viral infections is of the utmost importance, and 
this may be accomplished by pretransplant screening of the donor and recipient to 
determine prophylactic and preventive strategies to be utilized after transplantation or 
posttransplant vaccinations and effective antiviral treatments. 
4.5.1 Cytomegalovirus 
Cytomegalovirus (CMV) infections, which have been recognized in every human population, 
are widely distributed in the general population with seroprevalence ranging from 30–97% 
(Humar & Snydman, 2009; Paya, 2001). The patterns of CMV acquisition vary greatly based 
on geographic and socioeconomic backgrounds of each population, and seroprevalence 
increases generally with age. Importantly, CMV infection is a major cause of morbidity in 
patients receiving solid organ transplants. CMV disease usually occurs 1–4 months after 
liver transplantation, and those recipients who are seronegative for CMV and receive an 
allograft from a seropositive donor are at highest risk. Other risk factors for CMV disease 
include the recipient’s overall state of immunosuppression (e.g., type of drug, dose, timing, 
duration) and various host factors (e.g., age, comorbidity, neutropenia). The risk of CMV 
disease also varies with the type of transplant. This may be due to the degree of 
immunosuppression or the viral load present in the transplanted allograft. The lowest risk 
of disease occurs when both donor and recipient are seronegative for CMV. Thus, 
pretransplant CMV screening of donors and recipients should be performed to allow for risk 
stratification.  
The diagnosis of CMV infection and disease has evolved considerably. Historically, the 
histological detection of owl's eye inclusion bodies has been used for the diagnosis of CMV 
disease. However, this method is limited by its invasive approach and insensitivity for 
detecting CMV organ involvement. For years, culture-based methods, such as shell-vial 
centrifugation detection or culture of the organism from clinical specimens, were used for 
CMV diagnosis. However, tissue culture can take weeks and the shell-vial centrifugation 
assay is insensitive compared with molecular assays. Newer methods for diagnosing CMV 
disease include detection of the pp65 antigen and a molecular diagnostic test; both methods 
are performed on serum and are rapid, with reasonable sensitivity and specificity. The pp65 
antigen assay is a semiquantitative fluorescent assay that is based on the detection of 
infected cells in peripheral blood. This assay has a far higher sensitivity and specificity than 
culture-based methods (Mazzulli et al., 1999). Molecular diagnostic tests, which may detect 
CMV deoxyribonucleic acid (DNA), can be qualitative or quantitative. Quantitative 
measurements of CMV DNA levels have become popular at many transplantation centers. 
The viral loads measured are associated with the severity of CMV infection (Humar et al., 
1999). Generally, both the pp65 antigen assay and quantitative CMV viral load testing can be 
utilized in preemptive protocols for the diagnosis of CMV infection, as well as to guide the 
management of CMV disease (Caliendo et al., 2000; Emery et al., 2000).  
Currently, two strategies commonly used for CMV prevention include universal 
prophylaxis and preemptive therapy. Universal prophylaxis involves providing antiviral  
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therapy to all at-risk patients beginning in the early posttransplant period for a defined 
duration of 3–6 months. Drugs that have been considered for universal prophylaxis include 
ganciclovir, valganciclovir, acyclovir, valacyclovir, and immunoglobulin preparations (Gane 
et al., 1997; Paya et al., 2004; Snydman et al., 1993). Valganciclovir, which is a valine ester 
prodrug of ganciclovir, has improved bioavailability over the oral form ganciclovir. In 
preemptive therapy, patients are monitored for early evidence of CMV replication at regular 
intervals (often weekly). Patients with early replication are then treated with antiviral 
therapy in order to prevent symptomatic disease. Each approach has advantages and 
disadvantages that must be considered in the context of the patient and the allograft. The 
major concern with CMV prophylaxis continues to be late-onset CMV disease, which is 
defined as disease occurring sometime after discontinuation of antiviral prophylaxis. In 
contrast, preemptive therapy has the potential advantage of targeting therapy to patients at 
highest risk and thereby decreasing drug costs and toxicity.  
No consensus exists regarding the optimal treatment of CMV disease. However, intravenous 
ganciclovir has been used successfully in numerous therapeutic trials to treat solid organ 
transplant recipients with CMV disease and has been considered the mainstay for therapy. 
The basic principle governing CMV treatment is the clearance of viremia. Therefore, patients 
with evidence of CMV viremia should be maintained on therapy until viremia has dropped 
below the negative threshold level for a given test. This helps prevent relapse and the 
development of resistance to ganciclovir. The incidence of ganciclovir-resistant CMV 
remains generally low in most cases after solid organ transplant. In a prospective 
multicenter study, the overall rate of resistance was 1.9% in those who received oral 
ganciclovir versus 0% among those receiving valganciclovir (Boivin et al., 2004). However, 
resistance should be suspected if the patient develops CMV disease after prolonged courses 
of antiviral prophylaxis or the viral load fails to respond to standard ganciclovir treatment. 
Genetic resistance testing may be very helpful in managing resistant CMV. Therapeutic 
options for resistant CMV include reduction or discontinuance of immunosuppression and 
increasing the dosage of intravenous ganciclovir or switching to foscarnet alone or foscarnet 
in combination with low dose ganciclovir. Other unproven or untested therapeutic options, 
including cidofovir, compassionate release maribavir, leflunomide, and artesunate, may be 
considered for refractory cases (Humar & Snydman, 2009).  
4.5.2 Epstein-Barr virus  
EBV is also a herpes virus, and humans are the only known hosts of EBV. This virus has a 
worldwide distribution with seropositive rates of 90% among adults, and its transmission 
depends on the socioeconomic background of the population. In most nonindustrialized 
communities, the vast majority of individuals are EBV-seropositive before the age of 5 years. 
However, in the more developed affluent counties, seropositivity can be delayed until the 
fourth decade of life (Allen, 2005). Although EBV infection may be acquired from the 
community, donor-derived transmission from an EBV-seropositive donor organ is an 
important source of infection among solid organ transplant recipients. EBV is associated 
with the majority of cases of posttransplantation lymphoproliferative disorder (PTLD), 
which is recognized as one of the most devastating complications of organ transplantation. 
The development of PTLD after solid organ transplantation usually occurs in the first year 
after transplantation. Prolonged or extensive immunosuppression and transplantation from 
an EBV-seropositive donor into a seronegative recipient are the two major risk factors for 
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the development of PTLD after solid organ transplantation. CMV infection, which may 
contribute to the net state of immunosuppression, is known to be another risk factor for the 
development of PTLD after transplantation. The incidence of PTLD also varies with the type 
of organ transplantation; the risk for the development of PTLD is highest after small bowel 
transplantation (up to 32%), followed by moderate risk (3–12%) following lung, heart, and 
liver transplantation, and relatively low risk (1–2%) for kidney transplantation (Gottschalk 
et al., 2005). The reasons for these differences are not completely understood, but the 
recipient’s net state of immunosuppression and the amount of lymphoid tissue present in 
the transplanted allografts may be important. 
PTLD may present with a diverse spectrum of nonspecific clinical symptoms and signs that 
involve other organs, including the CNS, bone marrow, kidneys, lungs, small intestine, and 
spleen. Because early diagnosis and treatment may result in better outcome, there is great 
interest in developing tests to predict the development of PTLD. Several investigations have 
indicated that monitoring EBV viral load and analysis of EBV-specific cytotoxic T 
lymphocyte responses may be helpful in assessing the risk of PTLD development in 
recipients (Qu et al., 2000; Rose et al., 2001; Smets et al., 2002). However, tissue biopsies with 
histological classifications remain the current mainstay of PTLD diagnosis.  
The treatment of PTLD remains controversial because of the lack of a unifying consensus 
dictating the specific treatment approaches that should be undertaken for all categories of 
patients. The general approach to therapy involves a stepwise strategy that starts with the 
reduction of immunosuppression; subsequent therapies depend on the clinical situation and 
should be based largely on the clinical response and histopathological characteristics of the 
disease. Additional therapies currently used in clinical practice include antiviral agents, 
intravenous immune globulin, cytokine and anticytokine therapies, surgery or radiation, 
anti-B cell antibodies, and T cell-based cellular immunotherapies (Allen & Preiksaitis, 2009; 
Gottschalk et al., 2005). However, the efficacy of individual therapies is difficult to assess 
because they are often combined. Additional future research is needed to address several 
unresolved issues and to enhance the diagnosis, prevention, and treatment of PTLD.  
4.5.3 Hepatitis B virus  
The transmission of HBV by organ transplantation is hazardous to allograft recipients. The 
acquisition of HBV infection has been associated with rapidly progressive liver disease, 
leading to high rates of liver failure and mortality. Therefore, all prospective donors and 
recipients should be tested for HBV prior to liver transplantation. Although the response to 
vaccination in patients with end-stage organ disease may be suboptimal, it is prudent to 
vaccinate all seronegative transplant candidates with HBV vaccine. Donor screening usually 
includes, at least, HBsAg and HBV core antibody (HBcAb) assays, and it is most useful to 
test for IgG and IgM in the HBcAb assay. HBsAg or HBcAb-IgM positivity usually indicates 
active HBV infection, and HBsAg-negative and HBcAb-IgM-positive individuals may 
represent infection in the window period. A HBsAg-negative and HBcAb-IgG-positive 
result may represent either a false-positive test or persistent HBV infection (Lok et al., 1988). 
Isolated HBsAb positivity, which usually indicates prior vaccination or resolved infection, is 
not generally considered a risk for HBV transmission. Historically, prospective organ 
donors with either HBsAg or HBcAb positivity were not utilized because of the significant 
risk of HBV transmission to a liver transplant recipient. However, it has now become more  
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therapy to all at-risk patients beginning in the early posttransplant period for a defined 
duration of 3–6 months. Drugs that have been considered for universal prophylaxis include 
ganciclovir, valganciclovir, acyclovir, valacyclovir, and immunoglobulin preparations (Gane 
et al., 1997; Paya et al., 2004; Snydman et al., 1993). Valganciclovir, which is a valine ester 
prodrug of ganciclovir, has improved bioavailability over the oral form ganciclovir. In 
preemptive therapy, patients are monitored for early evidence of CMV replication at regular 
intervals (often weekly). Patients with early replication are then treated with antiviral 
therapy in order to prevent symptomatic disease. Each approach has advantages and 
disadvantages that must be considered in the context of the patient and the allograft. The 
major concern with CMV prophylaxis continues to be late-onset CMV disease, which is 
defined as disease occurring sometime after discontinuation of antiviral prophylaxis. In 
contrast, preemptive therapy has the potential advantage of targeting therapy to patients at 
highest risk and thereby decreasing drug costs and toxicity.  
No consensus exists regarding the optimal treatment of CMV disease. However, intravenous 
ganciclovir has been used successfully in numerous therapeutic trials to treat solid organ 
transplant recipients with CMV disease and has been considered the mainstay for therapy. 
The basic principle governing CMV treatment is the clearance of viremia. Therefore, patients 
with evidence of CMV viremia should be maintained on therapy until viremia has dropped 
below the negative threshold level for a given test. This helps prevent relapse and the 
development of resistance to ganciclovir. The incidence of ganciclovir-resistant CMV 
remains generally low in most cases after solid organ transplant. In a prospective 
multicenter study, the overall rate of resistance was 1.9% in those who received oral 
ganciclovir versus 0% among those receiving valganciclovir (Boivin et al., 2004). However, 
resistance should be suspected if the patient develops CMV disease after prolonged courses 
of antiviral prophylaxis or the viral load fails to respond to standard ganciclovir treatment. 
Genetic resistance testing may be very helpful in managing resistant CMV. Therapeutic 
options for resistant CMV include reduction or discontinuance of immunosuppression and 
increasing the dosage of intravenous ganciclovir or switching to foscarnet alone or foscarnet 
in combination with low dose ganciclovir. Other unproven or untested therapeutic options, 
including cidofovir, compassionate release maribavir, leflunomide, and artesunate, may be 
considered for refractory cases (Humar & Snydman, 2009).  
4.5.2 Epstein-Barr virus  
EBV is also a herpes virus, and humans are the only known hosts of EBV. This virus has a 
worldwide distribution with seropositive rates of 90% among adults, and its transmission 
depends on the socioeconomic background of the population. In most nonindustrialized 
communities, the vast majority of individuals are EBV-seropositive before the age of 5 years. 
However, in the more developed affluent counties, seropositivity can be delayed until the 
fourth decade of life (Allen, 2005). Although EBV infection may be acquired from the 
community, donor-derived transmission from an EBV-seropositive donor organ is an 
important source of infection among solid organ transplant recipients. EBV is associated 
with the majority of cases of posttransplantation lymphoproliferative disorder (PTLD), 
which is recognized as one of the most devastating complications of organ transplantation. 
The development of PTLD after solid organ transplantation usually occurs in the first year 
after transplantation. Prolonged or extensive immunosuppression and transplantation from 
an EBV-seropositive donor into a seronegative recipient are the two major risk factors for 
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the development of PTLD after solid organ transplantation. CMV infection, which may 
contribute to the net state of immunosuppression, is known to be another risk factor for the 
development of PTLD after transplantation. The incidence of PTLD also varies with the type 
of organ transplantation; the risk for the development of PTLD is highest after small bowel 
transplantation (up to 32%), followed by moderate risk (3–12%) following lung, heart, and 
liver transplantation, and relatively low risk (1–2%) for kidney transplantation (Gottschalk 
et al., 2005). The reasons for these differences are not completely understood, but the 
recipient’s net state of immunosuppression and the amount of lymphoid tissue present in 
the transplanted allografts may be important. 
PTLD may present with a diverse spectrum of nonspecific clinical symptoms and signs that 
involve other organs, including the CNS, bone marrow, kidneys, lungs, small intestine, and 
spleen. Because early diagnosis and treatment may result in better outcome, there is great 
interest in developing tests to predict the development of PTLD. Several investigations have 
indicated that monitoring EBV viral load and analysis of EBV-specific cytotoxic T 
lymphocyte responses may be helpful in assessing the risk of PTLD development in 
recipients (Qu et al., 2000; Rose et al., 2001; Smets et al., 2002). However, tissue biopsies with 
histological classifications remain the current mainstay of PTLD diagnosis.  
The treatment of PTLD remains controversial because of the lack of a unifying consensus 
dictating the specific treatment approaches that should be undertaken for all categories of 
patients. The general approach to therapy involves a stepwise strategy that starts with the 
reduction of immunosuppression; subsequent therapies depend on the clinical situation and 
should be based largely on the clinical response and histopathological characteristics of the 
disease. Additional therapies currently used in clinical practice include antiviral agents, 
intravenous immune globulin, cytokine and anticytokine therapies, surgery or radiation, 
anti-B cell antibodies, and T cell-based cellular immunotherapies (Allen & Preiksaitis, 2009; 
Gottschalk et al., 2005). However, the efficacy of individual therapies is difficult to assess 
because they are often combined. Additional future research is needed to address several 
unresolved issues and to enhance the diagnosis, prevention, and treatment of PTLD.  
4.5.3 Hepatitis B virus  
The transmission of HBV by organ transplantation is hazardous to allograft recipients. The 
acquisition of HBV infection has been associated with rapidly progressive liver disease, 
leading to high rates of liver failure and mortality. Therefore, all prospective donors and 
recipients should be tested for HBV prior to liver transplantation. Although the response to 
vaccination in patients with end-stage organ disease may be suboptimal, it is prudent to 
vaccinate all seronegative transplant candidates with HBV vaccine. Donor screening usually 
includes, at least, HBsAg and HBV core antibody (HBcAb) assays, and it is most useful to 
test for IgG and IgM in the HBcAb assay. HBsAg or HBcAb-IgM positivity usually indicates 
active HBV infection, and HBsAg-negative and HBcAb-IgM-positive individuals may 
represent infection in the window period. A HBsAg-negative and HBcAb-IgG-positive 
result may represent either a false-positive test or persistent HBV infection (Lok et al., 1988). 
Isolated HBsAb positivity, which usually indicates prior vaccination or resolved infection, is 
not generally considered a risk for HBV transmission. Historically, prospective organ 
donors with either HBsAg or HBcAb positivity were not utilized because of the significant 
risk of HBV transmission to a liver transplant recipient. However, it has now become more  
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common to transplant livers from HBcAb+ or HBsAg-positive donors with intensive 
posttransplantation prophylaxis (Dodson et al., 1999; Wachs et al., 1995).  
The relative risk of HBV transmission and posttransplantation management based on the 
serologic test results of the donor is summarized in Table 5. A donor who is positive for 
HBsAg poses the greatest risk of HBV transmission after transplantation. The risk of HBV 
infection may be reduced in recipients who are positive for anti-HB antibodies; however, 
infection has been well documented after transplantation from a donor positive for HBsAg, 
irrespective of the recipient's immunization status. Therefore, all recipients receiving 
transplanted organs from HBsAg-positive donors should be prophylactically treated with 
hepatitis B immunoglobulin (HBIG) and antiviral therapy. The major drawback of HBIG 
therapy is the cost, and, therefore, diverse strategies of HBIG administration, in terms of 
dosage and duration, exist in different transplantation centers. However, frequent 
monitoring of liver function, HBsAg, anti-HB antibodies, and HBV DNA in the allograft 
recipient, as well as the maintenance of adequate anti-HB antibody levels, is recommended.  
Antibodies against the HBcAg are only present after HBV infection, and they cannot be the 
result of previous HBV vaccination. Therefore, organs from any donor testing positive for 
anti-HBc antibodies can transmit HBV to allograft recipients. A positive result for anti-HBc 
antibodies should be further defined by determining whether the antibodies are of the IgM 
or the IgG class in order to identify donors with either recent HBV exposure or current HBV 
infection. If the anti-HBc antibody is of the IgM class, indicating a recent or ongoing acute 
HBV infection, then recipients should be treated in a manner analogous to allograft 
recipients from an HBsAg-positive donor. If the anti-HBc antibody is of the IgG class, then 
there is high risk of HBV transmission with liver transplantation. The approach to liver 
transplantation from an anti-HBc IgG-positive donor should be as aggressive as that from 
an HBsAg-positive donor. Therefore, the same regimens of HBIG in combination with oral 
lamivudine are recommended. However, several centers have described the successful 
prevention of graft HBV using lamivudine therapy alone (Malkan et al., 2000; Mutimer et 
al., 2000). Additionally, HBsAg, anti-HB antibody levels, and HBV DNA should be closely 
monitored in recipients in order to detect active infection as well (Chung et al., 2001). 
 
Donor HBV serology Risk of HBV transmission Post-transplantation Prophylaxis 
HBsAg + High HBIG and lamivudine 
Anti-HBc IgM +, 
HBsAg -, 
Anti-HBs +/- 
High HBIG and lamivudine 
Anti-HBc IgG +, 
HBsAg -, 
Anti-HBs +/- 
High HBIG and lamivudine 




Rare Not recommended 
HBsAg, hepatitis B Surface antigen; Anti-HBc, antibody of hepatitis B core antigen; Anti-
HBs, antibody of hepatitis B surface antigen; HBIG, hepatitis B immunoglobulin.  
Table 5. Relative risk of HBV transmission and suggested post-transplantation management 
of liver transplant recipients according to donor serologic status 
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The lowest risk of HBV transmission occurs when the donor is negative for both HBsAg and 
anti-HBc antibodies, a situation that is considered evidence of no active infection. However, 
in rare cases, HBV transmission to liver allograft recipients has been reported, even when 
the donors are negative for all markers of HBV, including HBsAg, anti-HBc antibodies, and 
anti-HB antibodies (Chazouilleres et al., 1994) 
4.5.4 Hepatitis C virus  
Prospective organ donors with HCV infection have traditionally posed a dilemma because 
of the high risk of transmission of HCV through organ transplantation. A donor positive for 
HCV RNA, indicating active viral replication, has a much higher risk of transmission 
(Pereira et al., 1992). The risks of transmission from HCV RNA-negative and HCV antibody-
positive donors have not yet been fully defined. However, all recipients of organs from 
HCV-infected donors are indeed at risk of becoming HCV infected after liver 
transplantation. In recent years, the use of organs from HCV-seropositive donors for life-
saving transplantations in HCV-seronegative recipients has been studied, with acceptable 
results. There are no increases in the 1- and 5-year mortality and morbidity rates associated 
with liver transplantation from HCV-positive versus HCV-negative donors (Rosengard et 
al., 2002).  
The greatest concern of HCV infection after liver transplantation is that at least 25% of 
recipients progress to cirrhosis within 5 years, with a 42% annual risk of decompensation 
once cirrhosis has developed (Berenguer, 2002). The treatment of HCV in liver transplant 
recipients is complicated further by poor sustained viral response (SVR) rates and reports of 
progressive fibrosis with hepatic decompensation despite SVR. Combination therapy for 
HCV after liver transplantation is currently recommended, and the most widely used is 
pegylated-interferon (Peg-IFN) plus ribavirin. Treatment of HCV with Peg-IFN plus 
ribavirin after liver transplantation is generally only successful in achieving SVR in 20–45% 
of recipients and is associated with high rates (30–50%) of discontinuation due to 
intolerability (Ponziani et al., 2011; Wang et al., 2006). The inability to reach target RBV 
doses due to the high prevalence of renal insufficiency in recipients is a major limiting factor 
in achieving an acceptable SVR rate (Chalasani et al., 2005; Gane et al., 1998).  
In contrast to HBV, there is no HCV vaccine to prevent transmission. A general concept in 
managing liver transplant recipients at risk for HCV infection or recurrence is to avoid 
precipitating factors, such as acute rejection, the use of older or extended criteria donors, 
and CMV infection. Additionally, slow tapering of all immunosuppressive agents and 
avoiding over- or under-immunosuppression is theoretically more likely to lead to a lower 
incidence of HCV recurrence and acute rejection. 
4.5.5 Human immunodeficiency virus (HIV) 
HIV-seropositive donors have traditionally not been utilized in transplantation, due to the 
known risk of transmission to the recipient. However, despite routine screening, 
transmission of HIV, which can be an uncommon complication of organ transplantation, is a 
public health concern. Specifically, if the donor is in the window period after infection but 
prior to development of anti-HIV antibodies, the recipient is at risk of HIV infection (Ahn & 
Cohen, 2008).  
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common to transplant livers from HBcAb+ or HBsAg-positive donors with intensive 
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transplanted organs from HBsAg-positive donors should be prophylactically treated with 
hepatitis B immunoglobulin (HBIG) and antiviral therapy. The major drawback of HBIG 
therapy is the cost, and, therefore, diverse strategies of HBIG administration, in terms of 
dosage and duration, exist in different transplantation centers. However, frequent 
monitoring of liver function, HBsAg, anti-HB antibodies, and HBV DNA in the allograft 
recipient, as well as the maintenance of adequate anti-HB antibody levels, is recommended.  
Antibodies against the HBcAg are only present after HBV infection, and they cannot be the 
result of previous HBV vaccination. Therefore, organs from any donor testing positive for 
anti-HBc antibodies can transmit HBV to allograft recipients. A positive result for anti-HBc 
antibodies should be further defined by determining whether the antibodies are of the IgM 
or the IgG class in order to identify donors with either recent HBV exposure or current HBV 
infection. If the anti-HBc antibody is of the IgM class, indicating a recent or ongoing acute 
HBV infection, then recipients should be treated in a manner analogous to allograft 
recipients from an HBsAg-positive donor. If the anti-HBc antibody is of the IgG class, then 
there is high risk of HBV transmission with liver transplantation. The approach to liver 
transplantation from an anti-HBc IgG-positive donor should be as aggressive as that from 
an HBsAg-positive donor. Therefore, the same regimens of HBIG in combination with oral 
lamivudine are recommended. However, several centers have described the successful 
prevention of graft HBV using lamivudine therapy alone (Malkan et al., 2000; Mutimer et 
al., 2000). Additionally, HBsAg, anti-HB antibody levels, and HBV DNA should be closely 
monitored in recipients in order to detect active infection as well (Chung et al., 2001). 
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The lowest risk of HBV transmission occurs when the donor is negative for both HBsAg and 
anti-HBc antibodies, a situation that is considered evidence of no active infection. However, 
in rare cases, HBV transmission to liver allograft recipients has been reported, even when 
the donors are negative for all markers of HBV, including HBsAg, anti-HBc antibodies, and 
anti-HB antibodies (Chazouilleres et al., 1994) 
4.5.4 Hepatitis C virus  
Prospective organ donors with HCV infection have traditionally posed a dilemma because 
of the high risk of transmission of HCV through organ transplantation. A donor positive for 
HCV RNA, indicating active viral replication, has a much higher risk of transmission 
(Pereira et al., 1992). The risks of transmission from HCV RNA-negative and HCV antibody-
positive donors have not yet been fully defined. However, all recipients of organs from 
HCV-infected donors are indeed at risk of becoming HCV infected after liver 
transplantation. In recent years, the use of organs from HCV-seropositive donors for life-
saving transplantations in HCV-seronegative recipients has been studied, with acceptable 
results. There are no increases in the 1- and 5-year mortality and morbidity rates associated 
with liver transplantation from HCV-positive versus HCV-negative donors (Rosengard et 
al., 2002).  
The greatest concern of HCV infection after liver transplantation is that at least 25% of 
recipients progress to cirrhosis within 5 years, with a 42% annual risk of decompensation 
once cirrhosis has developed (Berenguer, 2002). The treatment of HCV in liver transplant 
recipients is complicated further by poor sustained viral response (SVR) rates and reports of 
progressive fibrosis with hepatic decompensation despite SVR. Combination therapy for 
HCV after liver transplantation is currently recommended, and the most widely used is 
pegylated-interferon (Peg-IFN) plus ribavirin. Treatment of HCV with Peg-IFN plus 
ribavirin after liver transplantation is generally only successful in achieving SVR in 20–45% 
of recipients and is associated with high rates (30–50%) of discontinuation due to 
intolerability (Ponziani et al., 2011; Wang et al., 2006). The inability to reach target RBV 
doses due to the high prevalence of renal insufficiency in recipients is a major limiting factor 
in achieving an acceptable SVR rate (Chalasani et al., 2005; Gane et al., 1998).  
In contrast to HBV, there is no HCV vaccine to prevent transmission. A general concept in 
managing liver transplant recipients at risk for HCV infection or recurrence is to avoid 
precipitating factors, such as acute rejection, the use of older or extended criteria donors, 
and CMV infection. Additionally, slow tapering of all immunosuppressive agents and 
avoiding over- or under-immunosuppression is theoretically more likely to lead to a lower 
incidence of HCV recurrence and acute rejection. 
4.5.5 Human immunodeficiency virus (HIV) 
HIV-seropositive donors have traditionally not been utilized in transplantation, due to the 
known risk of transmission to the recipient. However, despite routine screening, 
transmission of HIV, which can be an uncommon complication of organ transplantation, is a 
public health concern. Specifically, if the donor is in the window period after infection but 
prior to development of anti-HIV antibodies, the recipient is at risk of HIV infection (Ahn & 
Cohen, 2008).  
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The CDC guidelines address donor screening, testing, and exclusion for prevention of HIV 
transmission through organ transplantation. The guidelines note that prospective donors 
may be considered if “the risk to the recipient of not performing the transplant is deemed to 
be greater than the risk of HIV transmission and disease.” In this circumstance, informed 
consent is deemed essential. Posttransplant testing of all recipients of high-risk donors for 
HIV is suggested but not mandated. The treatment of recipients infected by donor-derived 
HIV transmission is similar to that of HIV-seropositive individuals who have undergone 
liver transplantation after HIV infection has been confirmed. To maintain virological control 
of HIV infection, it is recommended to regularly and quantitatively measure HIV RNA and 
CD4-positive T-cell counts. If patients have persistent HIV viremia, a phenotypic HIV drug 
resistance assay should be carried out to determine alternative treatment options (Blumberg 
& Stock, 2009).  
4.5.6 Other unusual viruses 
Respiratory viruses, including influenza, respiratory syncytial virus, parainfluenza virus, 
rhinovirus, human metapneumovirus, coronavirus, bocavirus, and polyomaviruses, have 
been identified as causes of significant morbidity and mortality among transplant recipients. 
All of these viruses cause a range of diseases, from mild congestion and rhinorrhea, to more 
severe tracheobronchitis, bronchiolitis, and pneumonia. Transplant recipients are at a higher 
risk of infectious complications than are immunocompetent hosts, and they often present 
with mild or atypical symptoms. Although respiratory viruses are increasingly recognized 
in transplant recipients, there is still much to be learned about their impact. Prospective 
studies are needed to define the optimal timing, duration, and treatment regimen of each of 
the viruses.  
Parvovirus B19, which is a nonenveloped single-stranded DNA virus, is a common human 
pathogen that causes erythema infectiosum in children. The virus is primarily spread 
person-to-person by infected respiratory droplets, but transmission through organ 
transplantation has been reported as well (Yango et al., 2002). Parvovirus B19 infection can 
be either symptomatic or asymptomatic, depending on the age and immunologic status of 
the host. In immunocompromised hosts, this infection can cause persistent anemia and 
occasionally pancytopenia. Therefore, parvovirus B19 infection should be specifically 
suspected in solid organ transplant recipients with otherwise unexplained anemia. 
Currently, there is no antiviral drug available for the treatment of parvovirus infection, but 
intravenous immunoglobulin has been shown to be beneficial in transplant recipients with 
parvovirus B19 infection (Eid et al., 2006). 
Adenovirus is an important viral infection in pediatric liver transplantation. The clinical 
presentations of infected patients range from self-limited fever, gastroenteritis, or cystitis, to 
devastating illness with necrotizing hepatitis or pneumonia. Symptomatic infections 
frequently occur early after transplantation, indicating the possibility of donor transmission 
(Ison, 2006). The diagnoses of adenovirus can be performed through antigen detection, 
culture, molecular diagnosis, or histopathology. Unfortunately, there is no definitive 
treatment for adenoviral infection at this time. The most important component of 
therapeutic strategy is supportive care along with a reduction of the degree of 
immunosuppression (Ison & Green, 2009). 
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Human T-lymphotropic virus (HTLV-I/II), which is endemic in certain areas including the 
Caribbean and Japan, is often asymptomatic. Infection with HTLV-I can progress to HTLV-I-
associated myelopathy/tropical spastic paraparesis or adult T-cell leukemia/lymphoma 
after years or decades. Serology for HTLV-I/II is routinely performed in the US but not in 
other areas. In Europe and other areas, this assay is restricted to donors living in, or 
originating from, high-incidence areas. HTLV-I-seropositive donors are often not utilized 
and are only considered in life-threatening situations with appropriate informed consent. 
However, the use of HTLV-I-seropositive donors should be conducted with caution because 
the donor-derived transmission of HTLV-I with rapid development of myelopathy in 
recipients has been reported (Toro et al., 2003). 
West Nile virus (WNV), a flavivirus that can cause meningoencephalitis has recently 
appeared in the United States. WNV transmission through blood transfusions and solid 
organ transplantation has been reported as well (Iwamoto et al., 2003). Organ recipients 
receiving immunosuppressive drugs may be at high risk for severe disease after WNV 
infection. The US Health Resources and Service Administration has issued a guidance 
statement regarding donors and WNV, which recommends testing all prospective live 
donors with nucleic acid amplification tests (NAAT) prior to transplant and suggests 
avoiding the use of organs from donors with any form of unexplained or confirmed WNV 
encephalitis.  
Lymphocytic choriomeningitis virus (LCMV), a rodent-associated arenavirus, has been 
reported with donor-derived transmission to organ recipients leading to fatal infection 
(Fischer et al., 2006). LCMV infection in humans with normal immune systems usually 
causes either asymptomatic or mild, self-limited illnesses. Aseptic meningitis can occur in 
some patients, but the infection is rarely fatal. However, LCMV can cause serious infection 
in persons with impaired immune systems. 
Rabies, a rhabdovirus, is another potentially fatal donor-derived infection (Srinivasan et al., 
2005). The virus spreads inward from nerve endings in muscle or skin to the CNS and then 
disseminates outward to other organs. The majority of infected individuals develop the 
furious or encephalitic form of the disease, while others develop the paralytic or dumb form, 
mimicking Guillain-Barre syndrome. The disease is highly lethal, leading to very few 
survivors following infection (Willoughby et al., 2005). Therefore, clinicians are encouraged 
to avoid donors who pose even a small risk of rabies infection. 
5. Transmission of malignancy 
Malignancy after transplantation can develop in three different ways: (1) de novo 
occurrence, (2) recurrence of malignancy, and (3) donor-related malignancy that can be due 
to either direct transmission of tumors or tumors arising in cells of donor origin. Despite all 
efforts to secure a safe organ for transplantation, there continues to be some risk of donor-
derived malignancy that can be transmitted to recipients (Ison et al., 2009). Such risks may 
specifically be overlooked in the emergent donation process. Therefore, the risk of 
unintended transmission of tumors from donors to recipients must be placed in perspective. 
Few reports on transmitted cancers have been published, and the risk has never been 
reliably quantified. One study quantified the risk using a population-based cancer registry, 
and they estimated a 1.3% risk of having a donor with an undetected malignancy and a 0.2% 
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The CDC guidelines address donor screening, testing, and exclusion for prevention of HIV 
transmission through organ transplantation. The guidelines note that prospective donors 
may be considered if “the risk to the recipient of not performing the transplant is deemed to 
be greater than the risk of HIV transmission and disease.” In this circumstance, informed 
consent is deemed essential. Posttransplant testing of all recipients of high-risk donors for 
HIV is suggested but not mandated. The treatment of recipients infected by donor-derived 
HIV transmission is similar to that of HIV-seropositive individuals who have undergone 
liver transplantation after HIV infection has been confirmed. To maintain virological control 
of HIV infection, it is recommended to regularly and quantitatively measure HIV RNA and 
CD4-positive T-cell counts. If patients have persistent HIV viremia, a phenotypic HIV drug 
resistance assay should be carried out to determine alternative treatment options (Blumberg 
& Stock, 2009).  
4.5.6 Other unusual viruses 
Respiratory viruses, including influenza, respiratory syncytial virus, parainfluenza virus, 
rhinovirus, human metapneumovirus, coronavirus, bocavirus, and polyomaviruses, have 
been identified as causes of significant morbidity and mortality among transplant recipients. 
All of these viruses cause a range of diseases, from mild congestion and rhinorrhea, to more 
severe tracheobronchitis, bronchiolitis, and pneumonia. Transplant recipients are at a higher 
risk of infectious complications than are immunocompetent hosts, and they often present 
with mild or atypical symptoms. Although respiratory viruses are increasingly recognized 
in transplant recipients, there is still much to be learned about their impact. Prospective 
studies are needed to define the optimal timing, duration, and treatment regimen of each of 
the viruses.  
Parvovirus B19, which is a nonenveloped single-stranded DNA virus, is a common human 
pathogen that causes erythema infectiosum in children. The virus is primarily spread 
person-to-person by infected respiratory droplets, but transmission through organ 
transplantation has been reported as well (Yango et al., 2002). Parvovirus B19 infection can 
be either symptomatic or asymptomatic, depending on the age and immunologic status of 
the host. In immunocompromised hosts, this infection can cause persistent anemia and 
occasionally pancytopenia. Therefore, parvovirus B19 infection should be specifically 
suspected in solid organ transplant recipients with otherwise unexplained anemia. 
Currently, there is no antiviral drug available for the treatment of parvovirus infection, but 
intravenous immunoglobulin has been shown to be beneficial in transplant recipients with 
parvovirus B19 infection (Eid et al., 2006). 
Adenovirus is an important viral infection in pediatric liver transplantation. The clinical 
presentations of infected patients range from self-limited fever, gastroenteritis, or cystitis, to 
devastating illness with necrotizing hepatitis or pneumonia. Symptomatic infections 
frequently occur early after transplantation, indicating the possibility of donor transmission 
(Ison, 2006). The diagnoses of adenovirus can be performed through antigen detection, 
culture, molecular diagnosis, or histopathology. Unfortunately, there is no definitive 
treatment for adenoviral infection at this time. The most important component of 
therapeutic strategy is supportive care along with a reduction of the degree of 
immunosuppression (Ison & Green, 2009). 
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Human T-lymphotropic virus (HTLV-I/II), which is endemic in certain areas including the 
Caribbean and Japan, is often asymptomatic. Infection with HTLV-I can progress to HTLV-I-
associated myelopathy/tropical spastic paraparesis or adult T-cell leukemia/lymphoma 
after years or decades. Serology for HTLV-I/II is routinely performed in the US but not in 
other areas. In Europe and other areas, this assay is restricted to donors living in, or 
originating from, high-incidence areas. HTLV-I-seropositive donors are often not utilized 
and are only considered in life-threatening situations with appropriate informed consent. 
However, the use of HTLV-I-seropositive donors should be conducted with caution because 
the donor-derived transmission of HTLV-I with rapid development of myelopathy in 
recipients has been reported (Toro et al., 2003). 
West Nile virus (WNV), a flavivirus that can cause meningoencephalitis has recently 
appeared in the United States. WNV transmission through blood transfusions and solid 
organ transplantation has been reported as well (Iwamoto et al., 2003). Organ recipients 
receiving immunosuppressive drugs may be at high risk for severe disease after WNV 
infection. The US Health Resources and Service Administration has issued a guidance 
statement regarding donors and WNV, which recommends testing all prospective live 
donors with nucleic acid amplification tests (NAAT) prior to transplant and suggests 
avoiding the use of organs from donors with any form of unexplained or confirmed WNV 
encephalitis.  
Lymphocytic choriomeningitis virus (LCMV), a rodent-associated arenavirus, has been 
reported with donor-derived transmission to organ recipients leading to fatal infection 
(Fischer et al., 2006). LCMV infection in humans with normal immune systems usually 
causes either asymptomatic or mild, self-limited illnesses. Aseptic meningitis can occur in 
some patients, but the infection is rarely fatal. However, LCMV can cause serious infection 
in persons with impaired immune systems. 
Rabies, a rhabdovirus, is another potentially fatal donor-derived infection (Srinivasan et al., 
2005). The virus spreads inward from nerve endings in muscle or skin to the CNS and then 
disseminates outward to other organs. The majority of infected individuals develop the 
furious or encephalitic form of the disease, while others develop the paralytic or dumb form, 
mimicking Guillain-Barre syndrome. The disease is highly lethal, leading to very few 
survivors following infection (Willoughby et al., 2005). Therefore, clinicians are encouraged 
to avoid donors who pose even a small risk of rabies infection. 
5. Transmission of malignancy 
Malignancy after transplantation can develop in three different ways: (1) de novo 
occurrence, (2) recurrence of malignancy, and (3) donor-related malignancy that can be due 
to either direct transmission of tumors or tumors arising in cells of donor origin. Despite all 
efforts to secure a safe organ for transplantation, there continues to be some risk of donor-
derived malignancy that can be transmitted to recipients (Ison et al., 2009). Such risks may 
specifically be overlooked in the emergent donation process. Therefore, the risk of 
unintended transmission of tumors from donors to recipients must be placed in perspective. 
Few reports on transmitted cancers have been published, and the risk has never been 
reliably quantified. One study quantified the risk using a population-based cancer registry, 
and they estimated a 1.3% risk of having a donor with an undetected malignancy and a 0.2% 
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risk of cancer transmission (Birkeland & Storm, 2002). These risks are small compared with 
the benefits of organ transplantation. 
Melanoma is one of the most frequently reported and lethal donor-derived malignancies 
with a high transmission rate (Strauss & Thomas, 2010). The transmission of melanoma 
might be related to the biological characteristics of melanoma, including tumor dormancy, 
late recurrence, circulating tumor cells, and the destiny of micrometastases. Melanoma cell 
dormancy explains the late recurrence that can occur long after the initial treatment of 
melanoma. The high incidence of circulating tumor cells should be considered in the context 
of melanoma transmission, even in organ donors with early melanoma who present 
apparently disease-free following removal of a primary melanoma up to several decades 
previously. This scenario suggests that melanoma cells can remain dormant at distant sites 
for decades and possibly forever in immunocompetent patients and reactivate only after 
transplantation into an immunosuppressed recipient. Therefore, prospective organ donors 
should be carefully screened for a history of melanoma. The current recommendation for the 
treatment of donor-related melanoma in renal transplant recipients includes withdrawal or 
discontinuation of immunosuppression leading to graft rejection, followed by explantation 
of the allograft after rejection (Penn, 1996). However, this approach is certainly not feasible 
for liver transplant recipients because of the lack of alternative organ support.  
Additionally, prospective organ donors with a past history of several malignancies, 
including choriocarcinoma, lung cancer, and advanced-stage breast or renal cancer, should 
be avoided, despite curative resections. Donors with an extended disease-free interval after 
curative breast, colon, or renal surgery may be used after a detailed review of pathology 
reports. The use of organs from donors with small, localized, low-grade renal cell carcinoma 
is acceptable, as demonstrated by the fact that kidneys with such locally excised tumors 
have been transplanted without evidence of malignancy transmission. Moreover, organs 
from donors with in situ cancers can be considered with minimal hesitation and with the 
recipient’s informed consent. Donors with cerebral malignancies rarely transmit these 
tumors to recipients. The risk of malignancy transmission utilizing organs from donors with 
benign or low-grade astrocytoma (grade I and II) is extremely low. In contrast, the use of 
organs from donors with high-grade astrocytoma (grade III-IV) tumors, malignant tumors 
with ventriculosystemic shunts, or histories of extensive cranial surgery that disrupts the 
blood-brain barrier, is associated with a higher donor malignancy transmission rate (Buell et 
al., 2003). 
Once a donor-transmitted malignancy is suspected, confirmation is essential in order to 
determine treatment approach. Confirmation can be made by the comparison of donor and 
recipient tumor histology, fluorescence in-situ hybridization (FISH), which has been utilized 
to identify the donor origin of tumor cells in sex-mismatched transplant recipients, or PCR-
based amplification of highly polymorphic regions in the DNA. Recent reports have relied 
upon FISH and PCR analysis to confirm tumor origins (Gandhi & Strong, 2007). The fact 
that tumors in transplant recipients arise from foreign DNA can be exploited. However, 
there is currently no consensus in the guidelines for the management of recipients with 
donor-transmitted malignancies. In some cases, the reduction or cessation of 
immunosuppression might lead to rejection of the donor-derived tumor, which is perceived 
as a foreign antigen by the recovering immune system of the recipients, similar to the 
rejection of a transplanted organ by a nonimmunosuppressed recipient. However, a 
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majority of the recipients also require a traditional approach to treating the malignancy, 
including specific antineoplastic chemotherapy, radiotherapy, or surgery.  
6. Conclusion 
Donor-derived disease transmission remains a rarely recognized complication of solid organ 
transplantation, although the reported number of potential donor-derived infections and 
malignancies has increased every year. This increase is most likely the result of the 
improved recognition and the development of a formalized reporting process. The true 
incidence rates are not well known but will be clarified over time through enhanced 
reporting systems and the improved evaluation of suspicious cases. Since there is 
substantial morbidity and mortality among affected recipients, a better understanding of the 
risk of disease transmission is important in order to better inform patients and to provide 
advice on how to minimize transmissions in the future.  
Additionally, thorough pretransplantation screening of the donor and recipient for potential 
diseases is essential to the success of transplantation as well as to determine prophylactic 
and preventive strategies to be utilized after transplantation. Future advances will likely 
include more rapid diagnostic testing to refine the assessment of the risks of transmission 
posed by a particular donor. Moreover, clinicians should be constantly aware of the possibility 
of the donor-derived transmission of diseases. Earlier identification of transmission events 
may decrease morbidity and mortality rates through earlier intervention. 
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Once a donor-transmitted malignancy is suspected, confirmation is essential in order to 
determine treatment approach. Confirmation can be made by the comparison of donor and 
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to identify the donor origin of tumor cells in sex-mismatched transplant recipients, or PCR-
based amplification of highly polymorphic regions in the DNA. Recent reports have relied 
upon FISH and PCR analysis to confirm tumor origins (Gandhi & Strong, 2007). The fact 
that tumors in transplant recipients arise from foreign DNA can be exploited. However, 
there is currently no consensus in the guidelines for the management of recipients with 
donor-transmitted malignancies. In some cases, the reduction or cessation of 
immunosuppression might lead to rejection of the donor-derived tumor, which is perceived 
as a foreign antigen by the recovering immune system of the recipients, similar to the 
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majority of the recipients also require a traditional approach to treating the malignancy, 
including specific antineoplastic chemotherapy, radiotherapy, or surgery.  
6. Conclusion 
Donor-derived disease transmission remains a rarely recognized complication of solid organ 
transplantation, although the reported number of potential donor-derived infections and 
malignancies has increased every year. This increase is most likely the result of the 
improved recognition and the development of a formalized reporting process. The true 
incidence rates are not well known but will be clarified over time through enhanced 
reporting systems and the improved evaluation of suspicious cases. Since there is 
substantial morbidity and mortality among affected recipients, a better understanding of the 
risk of disease transmission is important in order to better inform patients and to provide 
advice on how to minimize transmissions in the future.  
Additionally, thorough pretransplantation screening of the donor and recipient for potential 
diseases is essential to the success of transplantation as well as to determine prophylactic 
and preventive strategies to be utilized after transplantation. Future advances will likely 
include more rapid diagnostic testing to refine the assessment of the risks of transmission 
posed by a particular donor. Moreover, clinicians should be constantly aware of the possibility 
of the donor-derived transmission of diseases. Earlier identification of transmission events 
may decrease morbidity and mortality rates through earlier intervention. 
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1. Introduction 
Liver transplantation is the definite surgical treatment for patients with end-stage liver 
disease and acute liver failure that improves liver functions and survival. In recent years 
health-related quality of life has been accepted to be in relation with surgical success and 
has become to be used as an important assessment parameter not only after transplantation 
but also during the disease process.  
The most limited sub-group of quality of life is probably the physical activity level that is 
reduced due to low physical performance status both before and after liver transplantation. 
This limitation is multi-factorial depending on the stage of the disease and post-transplant 
period.  
Rehabilitative approaches may help patients with liver disease and transplant recipients to 
improve quality of life by increasing muscle strength, prevent excessive fatigue, enhance 
aerobic capacity and increase physical activity level. In accordance with this purpose, 
specific physiotherapeutic interventions structured according to patients’ needs in any 
phase of the disease process should be properly defined by the professions working in 
related fields.  
Physiotherapy in patients with liver disease and liver transplant recipients could mainly be 
divided into three periods: Pre-operative physiotherapy, early post-operative physiotherapy 
and late post-operative physiotherapy. A similar rehabilitation process including six 
different periods after orthotopic liver transplantation has been previously defined as 
follows: pre-operative period, early and late post-operative periods, early and late 
ambulatory care periods and motor rehabilitation (Rongies et al., 2005).  
In any period of physiotherapy, indications and contraindications for participation in this 
long rehabilitation process should be well-clarified. Any sign of acute rejection of the 
transplanted organ, acute hemorrhage, electrolyte imbalance, physiological instability, 
severe neurologic complications and severe cardiovascular co-morbidities may further effect 
the implementation of specific techniques and exercises. Therefore phase-dependent 
specialized assessment procedures should be carried out before planning the exercise 
programs. Physiotherapeutic evaluation should include the assessment of muscle strength 
and endurance, aerobic capacity, physical activity level, independency in daily life activities 
and health-related quality of life. Neurologic, metabolic or musculoskeletal co-morbidities, 
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programs. Physiotherapeutic evaluation should include the assessment of muscle strength 
and endurance, aerobic capacity, physical activity level, independency in daily life activities 
and health-related quality of life. Neurologic, metabolic or musculoskeletal co-morbidities, 
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level of pain and fatigue, smoking and alcohol habits should also be recorded within the 
context of the assessment procedure. 
2. Pre-operative physiotherapy 
Patients waiting on transplantation list with end-stage liver disease usually show loss of 
muscle mass, low bone mineral density, reduced muscle strength, increased levels of fatigue 
and decreased aerobic capacity. Malnutrition, cardiopulmonary dysfunction, altered 
metabolism and corticosteroid treatment are thought to be responsible for the factors that 
play a role in impaired physical performance.  
Diminished exercise capacity is correlated with disease severity in patients with end stage 
liver disease and is mainly the result of muscle wasting called “cirrhotic myopathy” and 
cardiac dysfunction called as “cirrhotic cardiomyopathy” (Scott et al., 1998).  
Malnutrition is another important factor affecting muscle mass and the activity level. 
Dysfunctions of glycogen storage and gluconeogenesis in end-stage liver disease lead to a 
break down of muscle protein and fat for energy usage resulting in weight loss and muscle 
weakness (Vintro et al., 2002). Poor dietary intake, loss of appetite and medical dietary 
restrictions may aggravate the secondary effects of malnutrition. In addition to decreased 
muscle strength and fatigue, severe edema and ascites accompanying the disease negatively 
affect the ambulation leading to decreases in physical activity and performance level.  
Stage dependent reduction in aerobic physical fitness, isokinetic muscle strength and 
health-related quality of life were found in patients with cirrhosis waiting on the 
transplantation list (Wiesinger et al., 2001). Similarly, two thirds of cirrhotics, without 
cardiopulmonary disease or other confounding factors displayed significantly reduced 
aerobic capacity measured by maximal cardiopulmonary exercise testing (Epstein et al., 
1998). 
All the data revealed from the published papers emphasize the reasonable needs for specific 
exercise and rehabilitation programs with the objectives of increasing muscle strength and 
endurance, aerobic capacity and optimizing daily life independency and health-related 
quality of life by improving physical functioning for the patients waiting on the liver 
transplantation list. Longer waiting times make the process more difficult. Therefore, 
strategies for avoiding prolonged bed rest and increasing activity level are recommended as 
the disease progresses. To start physiotherapeutic interventions before the transplantation 
will no doubtfully help the patient to overcome post-operative complications and further 
deconditioning due to inactivity.  
3. Early post-operative physiotherapy 
3.1 Physiotherapy in the Intensive Care Unit  
Bed rest is a common prescription in the intensive care unit (ICU) because of drainage tubes, 
arterial lines, urinary and naso-gastric catheters and sometimes as a result of prolonged 
mechanical ventilation. Although bed rest can be considered as a part of the treatment in the 
ICU, immobilization may further affect the overall health status as a consequence of muscle 
atrophy, diminished bronchial drainage and decreased lung expansion. Physiotherapy in 
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the ICU aims to avoid complications of immobilization, provide respiratory support in 
order to prevent post-operative pulmonary complications and restore functional 
independency (Stiller, 2000). Post-operative pulmonary complications are common in 
patients who have undergone open abdominal surgery (Pasquina et al., 2006; Browning et 
al., 2007). Decreased mucociliary activity due to anesthesia and relatively longer surgery 
durations and immobilization during the operation may lead to dysfunction of the 
respiratory system and an increase in bronchial secretion. Post-operative pain resulting from 
an extensive surgical incision on the upper abdominal region negatively affects coughing by 
inhibiting the required contraction of abdominal muscles. Pain may also inhibit the physical 
activities of the patient not only for mobilization but also in bed during supine position. 
Therefore, it is important to implement effective analgesic treatment in order to overcome 
post-operative pain and provide bronchial clearance by facilitating coughing mechanism 
and promoting activity. Diaphragmatic dysfunction is another important factor in the 
development of pulmonary complications resulting from both pain due to incision and 
phrenic nerve irritation or paralysis in rare cases.  
Early post-transplant physiotherapy including interventions of pulmonary physiotherapy 
and early mobilization starts on the first post-operative day as soon as the patient is 
physiologically stabilized and lasts till the patient is discharged from the ICU. Pulmonary 
physiotherapy including lung expansion and diaphragmatic breathing exercises, forced 
expiratory technique and coughing techniques and incentive spirometry aims to provide 
airway clearance, increase lung expansion, restore respiratory function and prevent post-
operative pulmonary complications (Clini & Ambrosino, 2005). Manual techniques 
including chest percussion and vibration may also be alternative treatment approaches if 
airway clearance is not accomplished enough although they are not much preferable after a 
major surgery in the presence of numerous drains. They may also cause the patient to 
experience more pain and anxiety. Pulmonary physiotherapy should start on the first post-
operative day if the patient is already extubated just after the surgery. Unless the patient is 
extubated in the ICU, a physiotherapist can help to speed the weaning period up as long as 
the patient is cooperative enough to follow the instructions and participate in the exercises.  
Activity after surgery should start as early as possible as the physiological and 
hemodynamic stabilities are provided. It is important to consider the cardiac and respiratory 
reserves of the patient and hemoglobin level as well before planning the mobilization 
session. Mobilization should be implemented gradually as follows in order to be well-
tolerated by the patient: Limb exercises in supine position, sitting in bed, sitting on the edge 
of the bed, standing, preparatory walking exercises and ambulation (Senduran et al., 2010). 
Active-assistive or active limb exercises performed in bed and in sitting position on the edge 
of the bed stimulate circulation and respiration and should be implemented under 
supervision during the ICU admission. Lower limb exercises should not cause abdominal 
pain by increasing the tension on the abdominal region. Therefore, hip movements, 
especially flexion, should be performed in limited angles. Avoiding abdominal tension 
during all the activities including sitting and ambulation is necessary to motivate the patient 
to be more active. In order to prepare the patient for mobilization in the ICU, the surgical 
area should be bandaged tightly and drains, urine catheter, naso-gastric catheter should be 
fixed to the body of the patient with a plaster. Additionally, oxygen tube and catheter lines 
should be lengthened, if necessary.  
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Mechanical ventilation and ICU admission are standard post-operative care after liver 
transplantation improving post-operative outcomes by reducing physiological stress 
triggered by awakening and spontaneous ventilation (Mandell et al., 2002). However, early 
extubation is the key element to reduce health care costs by decreasing ICU stay and speed 
up the patients’ recovery. The importance of early extubation, aggressive chest 
physiotherapy and early ambulation for shortening ICU stay and preventing septic 
complications and mortality after liver transplantation was highlighted (Mor et al., 2001). 
Similarly, the vitality of physiotherapy in the ICU after liver transplantation in order to 
recover muscle waste due to metabolic and nutritional deficits, peripheral neuropathies 
depending on postural components and respiratory complications was emphasized in 
another study (Faenza et al., 2005).  
The time of physiotherapy initiation after liver transplantation and affecting factors were 
studied before. A significant correlation between the time of physiotherapy initiation and 
primary cause of liver transplantation was revealed. Patients with acute liver failure were 
the latest group that was enrolled in early post-operative physiotherapy suggesting the 
influence of compensation theory for the healing process rather than a rapid disease 
progression. A strong relationship between the time of initiation and the ability to take fully 
upright position was also detected in the same study (Rongies et al., 2005). 
Hemodynamic instability is common early after liver transplantation due to cardiac 
abnormalities characterized by cirrhosis per se. It is well documented that end stage liver 
disease is characterized by hyperdynamic circulation leading to higher resting heart rate, 
increased cardiac output and decreased systemic vascular resistance (Wong et al., 2001). 
Therefore, ongoing monitoring of vital signs, especially arterial pressures, heart rate, 
respiratory rate and peripheral oxygen saturation is recommended during the 
physiotherapy interventions in the ICU in order to observe physiological responses in case 
of any adverse effects.  
3.2 Physiotherapy in the clinical setting 
Similar interventions should also continue after discharge from the ICU ward and progress 
according to the patient’s health and physical status. Inpatient rehabilitation after liver 
transplantation also includes chest physiotherapy and active-assisted and active limb 
exercises in order to overcome post-surgical fatigue and improve physical performance level. 
Pulmonary physiotherapy including lung expansion and diaphragmatic breathing exercises, 
forced expiratory technique and coughing techniques and incentive spirometry should 
continue until the discharge from the hospital whether significant pulmonary complications 
exist or not.  
Muscular strengthening exercises, stretching exercises and posture exercises should be 
included in the inpatient exercise program. Strengthening exercises using elastic bands or 
free weights for upper and lower limbs help to prevent muscle loss and restore decreased 
muscle strength and endurance. Intensity of the exercises can be set according to 1 maximum 
repetition protocol. Stretching exercises are used to provide normal muscle elongation, 
especially in patients suffering from prolonged immobilization that may further affect daily 
activities and even ambulation. Stretching and posture exercises also help to prepare the 
patient for the exercise session and may stimulate relaxation and anxiety reduction.  
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It is important to increase the independency of self-care activities during the hospital stay. 
Fatigue is one of the major problems in patients with liver diseases which may be 
exacerbated in the early post-operative period. Exercises should progress gradually by 
increasing the number of repetitions, frequency during the day or the intensity according to 
the patient’s general condition.  
Studies related to inpatient physiotherapy after liver transplantation is limited in the 
literature. In a retrospective study, significant functional gains were achieved by acute 
inpatient rehabilitation in 55 liver transplant recipients. Nevertheless, the details and the 
content of inpatient rehabilitation that the patients participated in during their hospital stay 
were not mentioned (Cortazzo et al., 2005). 
In another study indicating the long rehabilitation process after liver transplantation early 
mobilization and exercises with graded intensity were implemented to 38 liver transplant 
recipients during post-operative three weeks and progressed to strengthening, balance, 
flexibility and aerobic exercises after the third post-transplant week. Exercise treatment 
continued as one hour in two weeks after the discharge and lasted for 8-24 weeks. As a 
result of the rehabilitation process significant improvements in aerobic capacity, muscle 
strength and physical performance were reported (Beyer et al., 1999).  
Patient education is another important part of inpatient rehabilitation especially during the 
first six weeks. Patients should be warned about not driving, not lifting, pushing or pullling 
heavy objects and not attempting sit-ups, push-ups or pull-ups. 
Inpatient physiotherapy should continue until the patient is discharged from the hospital. 
Structured, systematic and individualized home exercise programs should be well-planned 
according to the patients’ needs and be followed by regular controls. If there is a possibility 
for the patients to continue rehabilitation process in a clinical setting, they can enroll in an 
outpatient rehabilitation process under the supervision of physiotherapists. If outpatient 
rehabilitation service is not available telerehabilitation may be an alternative choice which is 
popular in recent days in the rehabilitation field. A simple connection from the patient’s 
house to the clinical setting is required in order to be supervised by the professions. 
4. Late post-operative physiotherapy 
4.1 Early phase interventions 
Early phase interventions involve the first three months after the discharge from the 
hospital. A home exercise program which is tailored to the individual patient should be 
prescribed. A handbook containing simple instructions and illustrations for exercises, 
suggestions for a more active life style and dietary requirements may help the patient after 
discharge.  
The first aim of this period is to maintain the possible highest level of physical activity. 
Pedometers and accelerometers may be used for not only monitoring but also defining a 
target daily activity level and will help to motivate the patient to be more active. Patients 
may develop a fear of damaging the newly transplanted organ and the protective attitudes 
of the family members may lead to restriction of the activity. Patients should be encouraged 
to stay more active by the multidisciplinary team including physicians, physiotherapists, 
dieticians, psychologists, social workers and family members as well. 
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During this period the patient may experience anxiety and irritability, sleep disturbances, 
stress and depression. Optimum level of physical activity and continuing inpatient exercises 
early after the discharge period will also help the patient to overcome these symptoms.  
4.2 Late phase interventions 
The late post-operative period, that starts mainly three months after liver transplantation 
aims to provide maximum capacity for daily life independency and optimize health-related 
quality of life. Returning to job, social life and leisure activities and even returning to sports 
participation are the objectives of this life-long process. Flexibility, balance, resistance and 
aerobic exercises are paramount in this period. 
Although liver transplantation is the only definite treatment for end-stage liver disease in 
order to regulate liver functions and maintain survival, it is not a solution per se for 
restoring the overall health status which is impaired due to loss of muscle mass, excessive 
fatigue, reduced physical performance and diminished aerobic capacity. Supervised 
rehabilitation programs are required to improve functional capacity after liver 
transplantation as surgery alone has a very modest and inconsistent effect on aerobic 
capacity (Lemzye et al., 2010). Studies investigating the level of aerobic capacity by 
measuring maximal oxygen uptake after liver transplantation found significant 
improvements in the long term process. In a related study functional capacity improved 12 
months after transplantation compared to the pre-operative period whereas no significant 
difference existed on the 3rd month-measurements (Iscar et al., 2009). In another similar 
investigation no significant difference was found in terms of isokinetic muscle strength and 
aerobic capacity before and 1-2 months after orthotopic liver transplantation without any 
post-operative rehabilitative approaches (Pieber et al., 2006). 
Resistance exercises help to restore muscle strength and prevent osteoporosis which may 
occur due to immunosuppressant therapy. Osteoporosis has been reported as a common 
cause of morbidity after liver transplantation leading to bone fractures especially in the first 
six months after the surgery (Atamaz et al., 2006). Aerobic training consisted of walking; 
jogging or cycling should also be planned in accordance with cardiac and pulmonary 
reserve of each patient. Physical activity level, co-morbidities, level of fatigue, and any 
complication should be considered while planning the exercise regimens. Treadmill and 
cycle ergometers can be alternative training methods to increase aerobic capacity. It was 
documented that transplant recipients experienced a positive perception of self esteem, 
body image and well-being after an 8-week structured aerobic exercise program (Surgit et 
al., 2001). 
It is well-known that life-long immunosuppressive therapy has long-term consequences 
including not only muscle and bone loss but also cardiovascular risks due to hyperlipidemia 
and hypertension. Patients will benefit from regular exercise programs to delay the 
cardiovascular complications. Weight control is another problem during the late post-
operative phase as a result of corticosteroids. Combined aerobic and resistance exercise 
trainings will no doubtfully help the patient to control excessive weight gain. A home-based 
exercise and nutrition behavior modifications initiated early after transplantation including 
regular follow-ups resulted in significant gains in exercise capacity, quality of life and body 
composition (Krasnoff et al., 2006). 
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Post-transplant rehabilitation programs are also suggested for reducing the complaint of 
physical fatigue which remains as one of the most distressing symptoms even one year after 
the surgery leading to a sedentary lifestyle (Van der Ber-Emons et al., 2006). Muscle energy 
techniques and interval trainings will provide energy saving and avoid excessive fatigue. 
4.3 Sports participation  
Sports participation after solid organ transplantation is the final objection of the long term 
rehabilitation process for maximizing quality of life. It is recommended to encourage the 
patients to participate in a sports activity three months after the surgery. This time is 
required to achieve optimal flexibility, muscular strength, muscular endurance and aerobic 
capacity and to provide proper post-operative wound healing and graft stabilization so that 
the patient can do sports without any deterioration. Patients should start with light activities 
such as walking, stair climbing, golf, bowling, darts, archery and fishing. Table tennis and 
volleyball can be suggested as medium intensity activities. Swimming, athletics, badminton, 
cycling, rowing, squashes, tennis, mini-marathon are recommended after getting used to 
light and moderate activities. However, swimming in community pools or lakes is not 
recommended because of high risk of infectious organisms. High impact and contact sports 
such as football, basketball, horse riding and bungee jumping are not preferable as they may 
cause a serious trauma and lead to organ damage. Patients usually have a fear of organ 
damage or severe pain avoiding them to participate in sports. Contact sports also have an 
additional fracture risk for weight bearing bones due to long term osteoporotic effects of 
corticosteroids. As liver transplantation surgery induces a denervation of the liver and 
intrahepatic vascular system strenuous exercises may carry a high risk for reduction in 
portal blood flow due to increased demands of contracting muscles (Ersoz&Ersoz, 2003). 
Besides, selected and well-prepared liver transplant recipients were able to participate in 
mountain trek and tolerate exposure to high altitude similar to healthy subjects after a 6-
month aerobic training and a hypercaloric diet including sugars, proteins and abundant 
hydration (Pirenne et al., 2004). 
Feeling of distress, muscle and joint pain, incisional pain and fatigue are the complaints of 
transplant recipients during or after exercises. Running, skiing, bike riding and tennis, shot-
put and body-building were reported as the most popular sports among a group of patients 
with liver and kidney transplantation (Pupkal et al., 2008). 
Patients may participate in a sport not only for a leisure time activity but also for 
professional competitions. The World Transplant Games Federation, officially recognized by 
the International Olympic Committee, is a world-wide organization staging international 
sporting events for transplant athletes for over 20 years in order to demonstrate the ability of 
sports participation after organ transplantation and to raise awareness of the vitality of 
organ donation. 
5. Conclusion 
In summary structured, specific and well-planned physiotherapeutic interventions tailored 
to individual needs of each patient are required before and after liver transplantation in 
order to prevent muscle and bone loss, delay cardiovascular complications and compete 
with excessive physical fatigue. Specific exercise programs will increase muscle strength and 
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order to regulate liver functions and maintain survival, it is not a solution per se for 
restoring the overall health status which is impaired due to loss of muscle mass, excessive 
fatigue, reduced physical performance and diminished aerobic capacity. Supervised 
rehabilitation programs are required to improve functional capacity after liver 
transplantation as surgery alone has a very modest and inconsistent effect on aerobic 
capacity (Lemzye et al., 2010). Studies investigating the level of aerobic capacity by 
measuring maximal oxygen uptake after liver transplantation found significant 
improvements in the long term process. In a related study functional capacity improved 12 
months after transplantation compared to the pre-operative period whereas no significant 
difference existed on the 3rd month-measurements (Iscar et al., 2009). In another similar 
investigation no significant difference was found in terms of isokinetic muscle strength and 
aerobic capacity before and 1-2 months after orthotopic liver transplantation without any 
post-operative rehabilitative approaches (Pieber et al., 2006). 
Resistance exercises help to restore muscle strength and prevent osteoporosis which may 
occur due to immunosuppressant therapy. Osteoporosis has been reported as a common 
cause of morbidity after liver transplantation leading to bone fractures especially in the first 
six months after the surgery (Atamaz et al., 2006). Aerobic training consisted of walking; 
jogging or cycling should also be planned in accordance with cardiac and pulmonary 
reserve of each patient. Physical activity level, co-morbidities, level of fatigue, and any 
complication should be considered while planning the exercise regimens. Treadmill and 
cycle ergometers can be alternative training methods to increase aerobic capacity. It was 
documented that transplant recipients experienced a positive perception of self esteem, 
body image and well-being after an 8-week structured aerobic exercise program (Surgit et 
al., 2001). 
It is well-known that life-long immunosuppressive therapy has long-term consequences 
including not only muscle and bone loss but also cardiovascular risks due to hyperlipidemia 
and hypertension. Patients will benefit from regular exercise programs to delay the 
cardiovascular complications. Weight control is another problem during the late post-
operative phase as a result of corticosteroids. Combined aerobic and resistance exercise 
trainings will no doubtfully help the patient to control excessive weight gain. A home-based 
exercise and nutrition behavior modifications initiated early after transplantation including 
regular follow-ups resulted in significant gains in exercise capacity, quality of life and body 
composition (Krasnoff et al., 2006). 
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Post-transplant rehabilitation programs are also suggested for reducing the complaint of 
physical fatigue which remains as one of the most distressing symptoms even one year after 
the surgery leading to a sedentary lifestyle (Van der Ber-Emons et al., 2006). Muscle energy 
techniques and interval trainings will provide energy saving and avoid excessive fatigue. 
4.3 Sports participation  
Sports participation after solid organ transplantation is the final objection of the long term 
rehabilitation process for maximizing quality of life. It is recommended to encourage the 
patients to participate in a sports activity three months after the surgery. This time is 
required to achieve optimal flexibility, muscular strength, muscular endurance and aerobic 
capacity and to provide proper post-operative wound healing and graft stabilization so that 
the patient can do sports without any deterioration. Patients should start with light activities 
such as walking, stair climbing, golf, bowling, darts, archery and fishing. Table tennis and 
volleyball can be suggested as medium intensity activities. Swimming, athletics, badminton, 
cycling, rowing, squashes, tennis, mini-marathon are recommended after getting used to 
light and moderate activities. However, swimming in community pools or lakes is not 
recommended because of high risk of infectious organisms. High impact and contact sports 
such as football, basketball, horse riding and bungee jumping are not preferable as they may 
cause a serious trauma and lead to organ damage. Patients usually have a fear of organ 
damage or severe pain avoiding them to participate in sports. Contact sports also have an 
additional fracture risk for weight bearing bones due to long term osteoporotic effects of 
corticosteroids. As liver transplantation surgery induces a denervation of the liver and 
intrahepatic vascular system strenuous exercises may carry a high risk for reduction in 
portal blood flow due to increased demands of contracting muscles (Ersoz&Ersoz, 2003). 
Besides, selected and well-prepared liver transplant recipients were able to participate in 
mountain trek and tolerate exposure to high altitude similar to healthy subjects after a 6-
month aerobic training and a hypercaloric diet including sugars, proteins and abundant 
hydration (Pirenne et al., 2004). 
Feeling of distress, muscle and joint pain, incisional pain and fatigue are the complaints of 
transplant recipients during or after exercises. Running, skiing, bike riding and tennis, shot-
put and body-building were reported as the most popular sports among a group of patients 
with liver and kidney transplantation (Pupkal et al., 2008). 
Patients may participate in a sport not only for a leisure time activity but also for 
professional competitions. The World Transplant Games Federation, officially recognized by 
the International Olympic Committee, is a world-wide organization staging international 
sporting events for transplant athletes for over 20 years in order to demonstrate the ability of 
sports participation after organ transplantation and to raise awareness of the vitality of 
organ donation. 
5. Conclusion 
In summary structured, specific and well-planned physiotherapeutic interventions tailored 
to individual needs of each patient are required before and after liver transplantation in 
order to prevent muscle and bone loss, delay cardiovascular complications and compete 
with excessive physical fatigue. Specific exercise programs will increase muscle strength and 
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endurance, enhance aerobic capacity, maximize physical activity level and optimize health-
related quality of life. Exercise programs accompanying dietary counseling will also help the 
patient to control excessive weight gain. Secondary positive effects of regular exercise on 
sleep disturbances, depression and anxiety may also be beneficial for liver transplant 
recipients. 
It is possible to divide physiotherapeutic interventions mainly into three periods: pre-
operative, early post-operative and late post-operative periods. These interventions should 
be initiated according to individual functional status while the patient is on the waiting list 
in order to speed up the patient’s recovery during the post-transplant period. 
An active style should be promoted during the whole life of the transplant recipient. 
Patients should also be encouraged to participate in sports activity, even on a professional 
level. 
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